Clustering O 0 0.0002455946523696184
of O 0 6.463450517912861e-06
missense O 0 0.38360604643821716
mutations O 0 0.00645474111661315
in O 0 2.2977021671977127e-06
the O 0 1.3647918422066141e-05
ataxia B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999016523361206
telangiectasia I-Disease 1 0.9999716281890869
gene O 0 5.008726930100238e-06
in O 0 1.05595077570797e-07
a O 0 9.80781464932079e-07
sporadic B-Disease 0 0.0017005506670102477
T I-Disease 1 0.9605950713157654
- I-Disease 0 0.3474206030368805
cell I-Disease 1 0.8587461709976196
leukaemia I-Disease 1 0.9514972567558289
. O 0 5.682900336978491e-06

Ataxia B-Disease 1 0.9999933242797852
- I-Disease 1 0.999975323677063
telangiectasia I-Disease 1 0.9999935626983643
( O 0 0.006461698561906815
A B-Disease 1 0.9997816681861877
- I-Disease 1 0.9999536275863647
T I-Disease 1 0.9999935626983643
) O 0 1.1916704067971295e-07
is O 0 2.4200330628332267e-08
a O 0 4.0604143691780337e-07
recessive B-Disease 0 0.00021112992544658482
multi I-Disease 0 0.0007577502983622253
- I-Disease 1 0.8741068840026855
system I-Disease 0 0.007236332166939974
disorder I-Disease 1 0.929746687412262
caused O 0 1.5846191672608256e-05
by O 0 2.2798487009367818e-07
mutations O 0 2.0059044345543953e-06
in O 0 1.762857770870596e-08
the O 0 1.0051398824373337e-08
ATM O 0 8.00167015313491e-07
gene O 0 1.7631208493185113e-07
at O 0 7.858948691819023e-08
11q22 O 0 6.953484444238711e-06
- O 0 1.7793172446545213e-05
q23 O 0 3.975973231717944e-05
( O 0 1.3939772713911225e-07
ref O 0 2.4556144126108848e-05
. O 0 8.840942200549762e-08
3 O 0 2.9926889055786887e-07
) O 0 3.329904814108886e-07
. O 0 1.334181661150069e-06

The O 0 1.8994976926478557e-05
risk O 0 5.009750748286024e-05
of O 0 1.3534211120713735e-06
cancer B-Disease 0 0.306824654340744
, O 0 5.604262582892261e-07
especially O 0 4.205613493013516e-07
lymphoid B-Disease 0 5.616326961899176e-05
neoplasias I-Disease 0 0.0022091034334152937
, O 0 1.5388702934160392e-07
is O 0 8.033633491777437e-08
substantially O 0 2.3290206172532635e-06
elevated O 0 3.345920777064748e-05
in O 0 9.417010460310848e-07
A B-Disease 1 0.9998058676719666
- I-Disease 1 0.9999961853027344
T I-Disease 1 1.0
patients O 1 0.9858815670013428
and O 0 3.7855451751056535e-07
has O 0 1.0473202110006241e-06
long O 0 1.7735643496052944e-06
been O 0 5.868413381904247e-07
associated O 0 5.250519166111189e-07
with O 0 2.1894677502132254e-06
chromosomal O 1 0.9998300075531006
instability O 1 0.9815178513526917
. O 0 2.0199286154820584e-05

By O 0 1.0752207344921771e-05
analysing O 0 0.00018035736866295338
tumour B-Disease 1 0.9999381303787231
DNA O 0 0.00019350741058588028
from O 0 7.356512128353643e-07
patients O 0 1.8644899682840332e-05
with O 0 4.634936203729012e-07
sporadic B-Disease 0 0.005616482347249985
T I-Disease 1 0.9620550274848938
- I-Disease 0 0.02336210571229458
cell I-Disease 0 0.18164324760437012
prolymphocytic I-Disease 1 0.6402063965797424
leukaemia I-Disease 1 0.9919629096984863
( O 0 1.3206200719650951e-06
T B-Disease 0 0.007319427095353603
- I-Disease 0 0.0002755303867161274
PLL I-Disease 0 0.01350065041333437
) O 0 7.415172120772695e-08
, O 0 2.201599791362696e-08
a O 0 1.8295529002898547e-07
rare O 0 5.39932898391271e-06
clonal B-Disease 0 0.0007996548665687442
malignancy I-Disease 0 0.0681755468249321
with O 0 9.178406656928928e-08
similarities O 0 6.851728926449141e-07
to O 0 8.152785824222519e-08
a O 0 3.47060404237709e-06
mature B-Disease 0 0.00017940904945135117
T I-Disease 0 0.4832451343536377
- I-Disease 0 0.04956524819135666
cell I-Disease 0 0.3151146173477173
leukaemia I-Disease 1 0.6726117730140686
seen O 0 1.2995742508792318e-06
in O 0 9.331414219104772e-08
A B-Disease 1 0.8688645958900452
- I-Disease 1 0.9988391995429993
T I-Disease 1 0.9999781847000122
, O 0 5.6783445501196184e-08
we O 0 1.7960537945782562e-08
demonstrate O 0 5.328941554694211e-08
a O 0 5.5495782191883336e-08
high O 0 6.203720204212004e-08
frequency O 0 1.809323038060029e-07
of O 0 2.4742206505834474e-08
ATM O 0 3.421650399104692e-05
mutations O 0 1.7496182408649474e-05
in O 0 7.326594868573011e-07
T B-Disease 0 0.02123301289975643
- I-Disease 0 0.0010199355892837048
PLL I-Disease 0 0.045371074229478836
. O 0 6.635791123699164e-06

In O 0 1.0300126632500906e-05
marked O 0 1.1322243153699674e-05
contrast O 0 3.6550477489072364e-06
to O 0 8.328345302288653e-08
the O 0 4.1656804228296096e-08
ATM O 0 9.236673577106558e-06
mutation O 0 3.0232154131226707e-06
pattern O 0 1.0236143452857505e-06
in O 0 4.455734483599372e-07
A B-Disease 1 0.9982397556304932
- I-Disease 1 0.9999567270278931
T I-Disease 1 0.9999916553497314
, O 0 5.108086043037474e-08
the O 0 7.398893941967799e-09
most O 0 1.3975948398581295e-08
frequent O 0 2.7575308081395633e-07
nucleotide O 0 2.1185873322338011e-07
changes O 0 1.004174450258688e-07
in O 0 4.3258093995746094e-08
this O 0 3.802359174187586e-07
leukaemia B-Disease 1 0.9455060362815857
were O 0 7.32344187781564e-06
missense O 0 0.010452541522681713
mutations O 0 0.00016669520118739456
. O 0 5.606204922514735e-06

These O 0 6.3523007156618405e-06
clustered O 0 1.1891441317857243e-05
in O 0 1.8743939733667503e-07
the O 0 2.6028860844462542e-08
region O 0 6.325860368860958e-08
corresponding O 0 3.92755410416612e-08
to O 0 1.4895690014782303e-08
the O 0 1.3615840899205978e-08
kinase O 0 4.4056972114958626e-07
domain O 0 3.066323728262432e-08
, O 0 4.1765297886797725e-09
which O 0 2.5771620393300054e-09
is O 0 3.2547702311092053e-09
highly O 0 2.0696637292871856e-08
conserved O 0 3.7777549977136005e-08
in O 0 1.27232553381873e-08
ATM O 0 8.478735367134504e-07
- O 0 2.672320988494903e-06
related O 0 4.768894257267675e-08
proteins O 0 1.3557094113991752e-08
in O 0 1.498488266804543e-08
mouse O 0 1.8391708636045223e-06
, O 0 7.180276639928707e-08
yeast O 0 1.1630328344836016e-06
and O 0 2.7130349167237e-07
Drosophila O 0 3.326674914205796e-06
. O 0 1.3424265716821537e-06

The O 0 5.019634500058601e-06
resulting O 0 4.658503257815028e-06
amino O 0 7.330418725359777e-07
- O 0 3.2035370622907067e-06
acid O 0 1.246767169504892e-06
substitutions O 0 3.571836089122371e-07
are O 0 2.0326702099282556e-08
predicted O 0 2.999385912971775e-07
to O 0 4.020609267740838e-08
interfere O 0 5.480332561091927e-07
with O 0 1.8518642264098162e-07
ATP O 0 7.354294211836532e-05
binding O 0 2.671885113159078e-06
or O 0 1.963119444781114e-07
substrate O 0 5.956070253887447e-06
recognition O 0 2.5472440938756336e-06
. O 0 2.1363759969972307e-06

Two O 0 3.1084443889994873e-06
of O 0 2.8466166668295045e-07
seventeen O 0 1.2980684005015064e-05
mutated O 0 0.0001676965330261737
T B-Disease 0 0.007179216481745243
- I-Disease 0 9.30394817260094e-05
PLL I-Disease 0 0.002515962813049555
samples O 0 1.0895643072217354e-06
had O 0 1.8911084964656766e-07
a O 0 2.454592049616622e-07
previously O 0 2.1611529064102797e-06
reported O 0 1.1571024515433237e-05
A B-Disease 0 0.3368096351623535
- I-Disease 1 0.9990789890289307
T I-Disease 1 0.9999765157699585
allele O 0 0.00026529227034188807
. O 0 3.1110778309084708e-06

In O 0 2.1520709196920507e-05
contrast O 0 6.836117245256901e-05
, O 0 4.786573413184669e-07
no O 0 6.672067343060917e-07
mutations O 0 2.2683441329718335e-06
were O 0 6.09434493981098e-08
detected O 0 5.510667051566998e-07
in O 0 2.4935406628401324e-08
the O 0 1.9078896684732172e-08
p53 O 0 1.3835029903930263e-06
gene O 0 2.8092620141251246e-07
, O 0 2.8225027648431933e-08
suggesting O 0 2.084823194081764e-07
that O 0 3.721762098507497e-08
this O 0 1.4712330198562995e-07
tumour B-Disease 1 0.9998534917831421
suppressor O 0 0.000277072744211182
is O 0 1.6727025808904727e-07
not O 0 7.426920944908488e-08
frequently O 0 5.518639909496414e-07
altered O 0 2.1847267817065585e-06
in O 0 2.4099691131596046e-07
this O 0 2.7571309146878775e-06
leukaemia B-Disease 1 0.9790318012237549
. O 0 9.200382010021713e-06

Occasional O 0 0.002520075300708413
missense O 1 0.8507656455039978
mutations O 0 0.007081998512148857
in O 0 1.0796355809361557e-06
ATM O 0 9.75182956608478e-06
were O 0 3.0509110615639656e-07
also O 0 1.1585544257286529e-07
found O 0 3.016082814610854e-07
in O 0 8.59589363244595e-07
tumour B-Disease 1 0.9999932050704956
DNA O 0 0.00047244984307326376
from O 0 5.671395229001064e-07
patients O 0 1.705276190477889e-05
with O 0 2.5836214945229585e-07
B B-Disease 0 1.8514951079851016e-05
- I-Disease 0 0.00036879468825645745
cell I-Disease 0 0.0007427523960359395
non I-Disease 0 6.6408360908098985e-06
- I-Disease 0 0.1764407902956009
Hodgkins I-Disease 1 0.99765944480896
lymphomas I-Disease 1 0.9902799725532532
( O 0 3.9504018900515803e-07
B B-Disease 0 1.8439793620927958e-06
- I-Disease 0 3.758866569114616e-06
NHL I-Disease 0 1.454033395020815e-06
) O 0 1.7700207521897937e-08
and O 0 9.163185765714843e-09
a O 0 3.532280743456795e-07
B B-Disease 0 4.082697159901727e-06
- I-Disease 0 2.344690619793255e-05
NHL I-Disease 0 7.5438870226207655e-06
cell O 0 3.254099647165276e-05
line O 0 7.225761692097876e-06
. O 0 2.7913022222492145e-06

The O 0 5.0404587454977445e-06
evidence O 0 1.3134231267031282e-06
of O 0 3.040651463948052e-08
a O 0 2.8450369882193627e-07
significant O 0 1.0910527237228962e-07
proportion O 0 1.8721019046097354e-07
of O 0 1.7556098796944752e-08
loss O 0 4.552938207780244e-06
- O 0 1.999197365876171e-06
of O 0 2.3315527286627002e-08
- O 0 0.0001490802242187783
function O 0 4.7116091650423186e-07
mutations O 0 3.839944611172541e-07
and O 0 1.050582465467187e-08
a O 0 6.08745551744505e-08
complete O 0 3.3698700008244487e-07
absence O 0 1.299996625903077e-07
of O 0 2.719197533807005e-09
the O 0 4.616828697123765e-09
normal O 0 3.585832430985647e-08
copy O 0 5.624727705821897e-08
of O 0 4.098155148568594e-09
ATM O 0 3.535816119892843e-07
in O 0 2.289506895181148e-08
the O 0 2.2668983135076815e-08
majority O 0 3.7271331621013815e-07
of O 0 6.823077569606539e-08
mutated O 0 0.002715491456910968
tumours B-Disease 1 0.9991528987884521
establishes O 0 5.953707841399591e-06
somatic O 0 1.0094964636664372e-05
inactivation O 0 6.957774166949093e-05
of O 0 1.4703853246089693e-08
this O 0 1.9277926810445933e-08
gene O 0 9.303121828452277e-08
in O 0 2.0026991620625267e-08
the O 0 7.46031361131827e-08
pathogenesis O 0 6.557105734827928e-06
of O 0 1.4821952731836063e-07
sporadic B-Disease 0 0.001093281083740294
T I-Disease 0 0.41887545585632324
- I-Disease 0 0.0005845995037816465
PLL I-Disease 0 0.003070225240662694
and O 0 1.258896134004317e-07
suggests O 0 1.466794969928742e-07
that O 0 1.1308205927207382e-08
ATM O 0 3.988377841324109e-07
acts O 0 9.83775692020572e-08
as O 0 7.0655190143043e-08
a O 0 6.7931459852843545e-06
tumour B-Disease 1 0.9998971223831177
suppressor O 0 0.005180577747523785
. O 0 7.680163434997667e-06

As O 0 2.657440745679196e-06
constitutional O 0 5.363440777728101e-06
DNA O 0 1.0645799193298444e-05
was O 0 6.888208190503065e-07
not O 0 6.413870323740412e-08
available O 0 3.092637257395836e-08
, O 0 3.0737425049665035e-08
a O 0 7.231892595882528e-07
putative O 0 0.0019072662107646465
hereditary O 1 0.8711170554161072
predisposition O 0 0.019109444692730904
to O 0 1.3857668818673119e-05
T B-Disease 0 0.165842667222023
- I-Disease 0 0.0003312258922960609
PLL I-Disease 0 0.0019131108419969678
will O 0 1.303723706769233e-07
require O 0 7.257020939732683e-08
further O 0 4.435578304651244e-08
investigation O 0 4.6218707439038553e-07
. O 0 2.0174449844034825e-07
. O 0 7.192310818027181e-07

Myotonic B-Disease 1 0.9999938011169434
dystrophy I-Disease 1 0.9999984502792358
protein O 0 0.0026650396175682545
kinase O 0 0.00028067277162335813
is O 0 2.8528236839520105e-07
involved O 0 6.858397227915702e-08
in O 0 1.3160101453024708e-08
the O 0 7.3634307540260124e-09
modulation O 0 4.3574723918027303e-07
of O 0 8.69258975910725e-09
the O 0 7.617197184117686e-08
Ca2 O 0 0.00035448448034003377
+ O 0 8.497527232975699e-06
homeostasis O 0 1.1072239431086928e-05
in O 0 3.4151059935538797e-07
skeletal O 0 0.11897841840982437
muscle O 0 0.43647775053977966
cells O 0 0.00027510858490131795
. O 0 5.294028596836142e-06

Myotonic B-Disease 1 0.9999988079071045
dystrophy I-Disease 1 0.9999998807907104
( O 1 0.9810357093811035
DM B-Disease 1 0.9999997615814209
) O 0 8.657656508148648e-06
, O 0 1.029372995731137e-07
the O 0 2.412953392649797e-08
most O 0 9.795179778393504e-08
prevalent O 0 5.8652196457842365e-05
muscular B-Disease 1 0.9999923706054688
disorder I-Disease 1 0.9999803304672241
in O 0 3.540372199495323e-05
adults O 0 0.0017956182127818465
, O 0 1.471119475127125e-07
is O 0 2.0876025530469633e-07
caused O 0 3.0685491765325423e-06
by O 0 6.088023951633659e-08
( O 0 7.739084395552709e-08
CTG O 0 9.88945430435706e-06
) O 0 4.4264762522061574e-08
n O 0 4.0259891420646454e-07
- O 0 1.1872639333887491e-06
repeat O 0 8.71472877861379e-07
expansion O 0 9.5542873168597e-08
in O 0 1.120034198720532e-08
a O 0 7.443001948104211e-08
gene O 0 1.0384462001411521e-07
encoding O 0 5.626777266343197e-08
a O 0 6.440914290806177e-08
protein O 0 3.5056848446402e-07
kinase O 0 2.0603467874025228e-06
( O 0 1.335261856638681e-07
DM B-Disease 1 0.9999105930328369
protein O 0 1.763710656632611e-06
kinase O 0 1.8704045032791328e-06
; O 0 5.657026491689976e-08
DMPK O 0 6.632956228713738e-06
) O 0 1.0361328683927695e-08
and O 0 5.09905984102943e-09
involves O 0 3.3581788017045255e-08
changes O 0 7.359066955814342e-08
in O 0 4.7864450181123175e-08
cytoarchitecture O 0 5.115710519021377e-05
and O 0 4.4237799556867685e-07
ion O 0 0.00024679620401002467
homeostasis O 0 0.0010287072509527206
. O 0 4.597885435941862e-06

To O 0 8.654221346660051e-06
obtain O 0 4.21848199039232e-06
clues O 0 4.465357960725669e-06
to O 0 1.1367853858246235e-07
the O 0 3.865225295385244e-08
normal O 0 1.749840663478608e-07
biological O 0 6.703356802972849e-08
role O 0 3.053099462135833e-08
of O 0 1.4869915077042606e-08
DMPK O 0 8.969456393970177e-05
in O 0 1.1130897092925807e-07
cellular O 0 4.108303073735442e-06
ion O 0 1.9526591131580062e-05
homeostasis O 0 3.060458766412921e-05
, O 0 3.58350078499825e-08
we O 0 7.355752007498495e-09
have O 0 1.5740367231842356e-08
compared O 0 5.8448996753668325e-08
the O 0 1.4660447078540528e-08
resting O 0 8.547470315534156e-06
[ O 0 9.857494660536759e-07
Ca2 O 0 8.399097168876324e-06
+ O 0 1.1105848898296244e-06
] O 0 1.9168777498634881e-07
i O 0 4.243014828375635e-08
, O 0 5.162463345698143e-09
the O 0 3.631332345932492e-09
amplitude O 0 1.8707598314904317e-07
and O 0 1.1083606921147293e-08
shape O 0 1.4468292874880717e-07
of O 0 2.58631267513465e-08
depolarization O 0 6.676476186839864e-05
- O 0 0.002278562868013978
induced O 0 0.01957925409078598
Ca2 O 0 0.00012347579468041658
+ O 0 3.624508735811105e-06
transients O 0 5.3437174756254535e-06
, O 0 1.4953533522543694e-08
and O 0 3.835568307408721e-09
the O 0 3.023946648639253e-09
content O 0 1.1061516147492512e-08
of O 0 7.634255005939394e-09
ATP O 0 1.5091114846654818e-06
- O 0 2.408030695733032e-06
driven O 0 9.569431540512596e-07
ion O 0 2.040744448095211e-06
pumps O 0 3.4405527458147844e-06
in O 0 6.684193465389399e-08
cultured O 0 7.688701771257911e-06
skeletal O 0 0.026143742725253105
muscle O 0 0.00038327040965668857
cells O 0 1.2512530247477116e-06
of O 0 1.2917457326011572e-08
wild O 0 1.4658942859568924e-07
- O 0 9.009749192046002e-06
type O 0 9.454057590119191e-07
and O 0 2.4929897790570976e-07
DMPK O 0 0.0007143372786231339
[ O 0 2.4569628749304684e-06
- O 0 2.808969293255359e-05
/ O 0 2.5016208383021876e-05
- O 0 0.00012017291010124609
] O 0 8.224134035117459e-06
knockout O 0 0.0003951398830395192
mice O 0 0.0008345358655788004
. O 0 2.272553501825314e-06

In O 0 1.5379637261503376e-05
vitro O 0 0.00014283607015386224
- O 0 0.00014386371185537428
differentiated O 0 3.760555773624219e-05
DMPK O 0 0.00045823334949091077
[ O 0 2.319850182175287e-06
- O 0 1.031266674544895e-05
/ O 0 1.4201707017491572e-05
- O 0 4.1137282096315175e-05
] O 0 1.1934871508856304e-06
myotubes O 0 6.535162356158253e-06
exhibit O 0 6.321325258795696e-07
a O 0 1.6423297211076715e-07
higher O 0 1.8323274275644508e-07
resting O 0 5.942363259237027e-06
[ O 0 1.0454092489453615e-06
Ca2 O 0 8.901922228687909e-06
+ O 0 6.606855436075421e-07
] O 0 8.581857002809556e-08
i O 0 3.7375691874785844e-08
than O 0 1.6377823541802172e-08
do O 0 2.6890781157362653e-08
wild O 0 8.815986518584396e-08
- O 0 7.133126473490847e-06
type O 0 1.3215094440965913e-06
myotubes O 0 3.572316200006753e-05
because O 0 2.7378195710525688e-08
of O 0 3.892493882773351e-09
an O 0 2.39943300783807e-08
altered O 0 8.600878800280043e-07
open O 0 1.4064627862353518e-07
probability O 0 3.041382257151781e-08
of O 0 8.34244406888729e-09
voltage O 0 5.255551059235586e-06
- O 0 7.219597137009259e-06
dependent O 0 9.424269933333562e-07
l O 0 1.2148941095802002e-05
- O 0 4.0728582462179475e-06
type O 0 1.7251959434361197e-06
Ca2 O 0 9.36321430344833e-06
+ O 0 1.0297849257767666e-06
and O 0 5.689055271318466e-08
Na O 0 4.666525001084665e-06
+ O 0 2.0326060621300712e-06
channels O 0 1.1238258821322233e-06
. O 0 8.374937578992103e-07

The O 0 7.482667115255026e-06
mutant O 0 3.273253241786733e-05
myotubes O 0 7.954350439831614e-05
exhibit O 0 3.442144361542887e-06
smaller O 0 4.235810422414943e-07
and O 0 9.38600024369407e-08
slower O 0 3.4634158510016277e-06
Ca2 O 0 0.00012724028783850372
+ O 0 2.6028076263173716e-06
responses O 0 1.771426383356811e-07
upon O 0 3.0683011686960526e-08
triggering O 0 5.659443900185579e-07
by O 0 5.13445961303205e-08
acetylcholine O 0 1.4485068504654919e-06
or O 0 5.41895488481714e-08
high O 0 1.5372523876067135e-07
external O 0 7.903910045570228e-06
K O 0 2.9116574296494946e-05
+ O 0 8.222102223953698e-06
. O 0 1.1429647202021442e-06

In O 0 7.878804353822488e-06
addition O 0 9.340385531686479e-07
, O 0 7.951511094006491e-08
we O 0 2.180100544535435e-08
observed O 0 3.940047221817622e-08
that O 0 6.175160383037337e-09
these O 0 1.2403986282549795e-08
Ca2 O 0 2.1797051886096597e-05
+ O 0 4.422250640345737e-06
transients O 0 2.8764528906322084e-05
partially O 0 4.971981070411857e-06
result O 0 5.22985885709204e-08
from O 0 6.472772096088875e-09
an O 0 7.434004078987755e-09
influx O 0 5.972389516273324e-08
of O 0 1.3607974302942694e-08
extracellular O 0 4.3653042780533724e-07
Ca2 O 0 5.478485491039464e-06
+ O 0 2.411182720152283e-07
through O 0 4.7868624619695765e-09
the O 0 8.838172860237137e-09
l O 0 7.775081940053497e-06
- O 0 1.2951081771461759e-05
type O 0 3.235774101995048e-06
Ca2 O 0 3.307272709207609e-05
+ O 0 3.5857617604051484e-06
channel O 0 5.1443248594296165e-06
. O 0 6.157650886962074e-07

Neither O 0 3.935856875614263e-05
the O 0 3.523781799685821e-07
content O 0 1.4676525950108044e-07
nor O 0 7.313478533887974e-08
the O 0 4.166011535744474e-09
activity O 0 8.658238570546928e-09
of O 0 8.477244684002017e-09
Na O 0 4.689241450250847e-06
+ O 0 2.251271553177503e-06
/ O 0 1.1132186727991211e-06
K O 0 6.477183660535957e-07
+ O 0 3.9688447373009694e-07
ATPase O 0 1.3990984371048398e-06
and O 0 5.4379857061803705e-08
sarcoplasmic O 0 5.7440374803263694e-05
reticulum O 0 0.0005180429434403777
Ca2 O 0 8.331430581165478e-05
+ O 0 2.97544806926453e-06
- O 0 1.2529604873634526e-06
ATPase O 0 5.929954113526037e-06
are O 0 1.8588261596619304e-08
affected O 0 6.180830780522228e-08
by O 0 7.987033967538082e-08
DMPK O 0 0.0006946211215108633
absence O 0 1.8582999473437667e-05
. O 0 3.281104909547139e-06

In O 0 7.952851774462033e-06
conclusion O 0 2.7035296170652146e-06
, O 0 1.340117279369224e-07
our O 0 2.2131821708626376e-08
data O 0 4.687085564114568e-08
suggest O 0 9.20354565892012e-08
that O 0 3.537032711165011e-08
DMPK O 0 4.770875602844171e-05
is O 0 6.504568972331981e-08
involved O 0 3.64047458845107e-08
in O 0 2.74241873654546e-08
modulating O 0 3.2549010029470082e-06
the O 0 3.8455546302884613e-08
initial O 0 1.7447398192871333e-07
events O 0 9.912529463917963e-09
of O 0 4.460153579799453e-09
excitation O 0 7.225109470709867e-07
- O 0 5.645801138598472e-06
contraction O 0 1.0795555681397673e-05
coupling O 0 3.037234137082123e-06
in O 0 4.0667157463758485e-07
skeletal O 0 0.07310951501131058
muscle O 0 0.014843128621578217
. O 0 1.6372034679079661e-06
. O 0 1.994364538404625e-06

Constitutional O 0 0.004482793156057596
RB1 O 1 0.9606135487556458
- O 0 0.011158966459333897
gene O 0 0.00013963872333988547
mutations O 0 0.0002272118435939774
in O 0 1.6726594367355574e-06
patients O 0 9.691945888334885e-05
with O 0 8.24261917387048e-07
isolated O 0 3.507981455186382e-05
unilateral B-Disease 0 0.000995831796899438
retinoblastoma I-Disease 1 0.5127970576286316
. O 0 2.005433452723082e-05

In O 0 2.30776822718326e-05
most O 0 9.15398049983196e-06
patients O 0 0.0003073287953156978
with O 0 5.097282951282978e-07
isolated O 0 2.560271786933299e-05
unilateral B-Disease 0 0.0005205517518334091
retinoblastoma I-Disease 1 0.5403730869293213
, O 0 2.5521387669869e-06
tumor B-Disease 0 6.106910586822778e-05
development O 0 3.247739144285333e-08
is O 0 1.6460594665090866e-08
initiated O 0 1.440961767684712e-07
by O 0 2.872704030210116e-08
somatic O 0 2.054827064057463e-06
inactivation O 0 4.133988841203973e-05
of O 0 2.367226237254272e-08
both O 0 6.202797209198252e-08
alleles O 0 4.473399712878745e-07
of O 0 3.3445250124941595e-08
the O 0 5.586482529906789e-07
RB1 O 0 0.0024463171139359474
gene O 0 9.312695510743652e-06
. O 0 2.5511315016046865e-06

However O 0 2.4084663891699165e-05
, O 0 2.931815004103555e-07
some O 0 3.355182442987825e-08
of O 0 2.0504655751096834e-08
these O 0 2.042904725385597e-07
patients O 0 0.0005686726071871817
can O 0 1.970580342458561e-06
transmit O 0 0.004901857580989599
retinoblastoma B-Disease 0 0.309364914894104
predisposition O 0 0.000530890712980181
to O 0 4.416710623900144e-07
their O 0 7.798799401825818e-07
offspring O 0 5.440001405077055e-05
. O 0 4.542273927654605e-06

To O 0 3.998846295871772e-06
determine O 0 8.413867362833116e-07
the O 0 5.17966718405205e-08
frequency O 0 1.1243254220971721e-06
and O 0 2.7297218707644788e-08
nature O 0 6.258269991121779e-08
of O 0 2.302693324907068e-08
constitutional O 0 0.00013491477875504643
RB1 O 1 0.5190178155899048
- O 0 0.0012791630579158664
gene O 0 8.124236956064124e-06
mutations O 0 1.3068263797322288e-05
in O 0 4.7310061290772865e-07
patients O 0 0.00012390203482937068
with O 0 3.8014528058738506e-07
isolated O 0 1.5951369277900085e-05
unilateral B-Disease 0 0.0001399837783537805
retinoblastoma I-Disease 0 0.006753073073923588
, O 0 1.0053338428406278e-07
we O 0 2.4038534718329174e-08
analyzed O 0 2.286875826484902e-07
DNA O 0 3.0650170401713694e-07
from O 0 5.1112632348804254e-08
peripheral O 0 8.049919415498152e-06
blood O 0 8.46583498059772e-06
and O 0 3.4259326753272035e-07
from O 0 1.867187620518962e-06
tumor B-Disease 0 0.1123761385679245
tissue O 0 0.0011119403643533587
. O 0 6.738263437000569e-06

The O 0 3.1105735160963377e-06
analysis O 0 3.035684812857653e-06
of O 0 8.987171327135002e-07
tumors B-Disease 1 0.9997045397758484
from O 0 4.054358839766792e-07
54 O 0 2.939467776741367e-06
( O 0 5.306738515287179e-08
71 O 0 8.852480846144317e-07
% O 0 2.9741263674054608e-08
) O 0 4.638453621197414e-09
of O 0 5.6001252524140455e-09
76 O 0 1.9078270270256326e-05
informative O 0 7.771435775794089e-05
patients O 0 0.24098314344882965
showed O 0 0.00011564951273612678
loss O 0 3.416680101508973e-06
of O 0 5.7001340536544376e-08
constitutional O 0 0.00028602551901713014
heterozygosity O 1 0.7449662685394287
( O 0 3.61384377356444e-06
LOH O 1 0.999218225479126
) O 0 3.5738565884457785e-07
at O 0 3.09597822933938e-07
intragenic O 0 5.966953176539391e-05
loci O 0 2.568342097220011e-05
. O 0 4.557843112706905e-06

Three O 0 1.1058878953917883e-05
of O 0 6.105770467002003e-07
13 O 0 6.592991667275783e-06
uninformative O 0 0.11801731586456299
patients O 0 0.26564761996269226
had O 0 6.6251232055947185e-06
constitutional O 0 2.6210203941445798e-05
deletions O 0 0.00036331324372440577
. O 0 8.79727303981781e-06

For O 0 5.806297849630937e-06
39 O 0 1.0951410331472289e-05
randomly O 0 2.2597034785576398e-06
selected O 0 1.48607216488017e-06
tumors B-Disease 1 0.9899049401283264
, O 0 3.0884703505762445e-07
SSCP O 0 0.00013084900274407119
, O 0 1.7903255411511054e-07
hetero O 0 9.633418085286394e-05
- O 0 3.1659994419896975e-05
duplex O 0 0.0006979682366363704
analysis O 0 2.2728517024006578e-07
, O 0 1.3755255601211047e-08
sequencing O 0 7.043694694175429e-08
, O 0 1.302545182824133e-08
and O 0 1.450648845491287e-08
Southern O 0 7.622124087447446e-08
blot O 0 0.00013368207146413624
analysis O 0 1.9976830856194283e-07
were O 0 1.4942983739274496e-08
used O 0 3.921917368643335e-08
to O 0 1.6333640928678506e-07
identify O 0 5.781086656497791e-06
mutations O 0 2.0161951397312805e-05
. O 0 1.843042468863132e-06

Mutations O 1 0.5668012499809265
were O 0 1.503108342149062e-05
detected O 0 1.0459883014846127e-05
in O 0 2.901482503148145e-07
21 O 0 7.713338163739536e-07
( O 0 6.833053589616611e-08
91 O 0 2.0711072465928737e-06
% O 0 7.303024318616735e-08
) O 0 1.4639601531030166e-08
of O 0 6.106795069626969e-08
23 O 0 0.008427229709923267
tumors B-Disease 1 0.9999909400939941
with O 0 0.0003064527700189501
LOH O 1 0.999993085861206
. O 0 2.324329034308903e-05

In O 0 1.2968125702172983e-05
6 O 0 5.176811555429595e-06
( O 0 2.333898265760581e-07
38 O 0 9.920190677803475e-07
% O 0 4.039025469637636e-08
) O 0 7.51546735955344e-09
of O 0 2.871110105218122e-08
16 O 0 0.00013197274529375136
tumors B-Disease 1 0.999987006187439
without O 0 4.623727363650687e-05
LOH O 1 0.9999721050262451
, O 0 1.1527639287578495e-07
one O 0 3.348463550878478e-08
mutation O 0 3.641544310539757e-07
was O 0 7.035852434000844e-08
detected O 0 2.7206522190681426e-07
, O 0 1.0555012863733282e-08
and O 0 2.0844606041237057e-08
in O 0 4.46436843049014e-08
9 O 0 3.482316515146522e-07
( O 0 1.3578728363938808e-08
56 O 0 2.309049307314126e-07
% O 0 1.4924925295645153e-08
) O 0 2.303421453575538e-09
of O 0 3.4599825227132897e-09
the O 0 1.1028579365301994e-06
tumors B-Disease 1 0.9999986886978149
without O 0 0.00047892663860693574
LOH O 1 0.9999918937683105
, O 0 2.9152926117603783e-07
both O 0 1.289471640575357e-07
mutations O 0 2.28684598369e-06
were O 0 1.2509052282894118e-07
found O 0 8.037002885430411e-07
. O 0 1.4074895489102346e-06

Thus O 0 1.0274344276695047e-05
, O 0 1.2413067906891229e-07
a O 0 4.506185291575093e-08
total O 0 1.8760584197252683e-08
of O 0 1.3215842642466669e-08
45 O 0 8.896906251720793e-07
mutations O 0 2.1200478386163013e-06
were O 0 8.766538428517379e-08
identified O 0 7.49388448184618e-07
in O 0 4.818413117391174e-07
tumors B-Disease 1 0.9997797608375549
of O 0 5.649068839375104e-07
36 O 0 0.0006766633014194667
patients O 0 0.0038179964758455753
. O 0 7.0474557105626445e-06

Thirty O 0 0.00011997253022855148
- O 0 6.354963988997042e-05
nine O 0 7.545632456640305e-07
of O 0 3.3086575257357254e-08
the O 0 3.66481636149274e-08
mutations O 0 1.275906015507644e-06
- O 0 2.4088758436846547e-06
including O 0 1.329838141828077e-07
34 O 0 4.800726856046822e-07
small O 0 1.1049606740698437e-07
mutations O 0 1.6049372106863302e-06
, O 0 2.6984908529925633e-08
2 O 0 8.314172106338447e-08
large O 0 6.010971276282362e-08
structural O 0 1.3924076483817771e-05
alterations O 0 3.6592609831131995e-05
, O 0 1.1434254787445752e-07
and O 0 1.0037646092087016e-07
hypermethylation O 0 0.0011027292348444462
in O 0 6.831873520241061e-07
3 O 0 1.1625077604549006e-05
tumors O 1 0.9999262094497681
- O 0 0.00027553935069590807
were O 0 1.2298404783450678e-07
not O 0 2.1526517457459704e-08
detected O 0 1.603240633585301e-07
in O 0 1.1434697633205815e-08
the O 0 1.4838975381792352e-08
corresponding O 0 4.4730541048920713e-07
peripheral O 0 4.0851427911547944e-05
blood O 0 6.503337499452755e-05
DNA O 0 4.2173229303443804e-05
. O 0 3.7097536278452026e-06

In O 0 1.5725170669611543e-05
6 O 0 5.845941814186517e-06
( O 0 1.9143421070566546e-07
17 O 0 4.2984137849089166e-07
% O 0 2.2209841077369674e-08
) O 0 2.5373423362395897e-09
of O 0 1.717755715446856e-09
the O 0 9.19889515671457e-08
36 O 0 0.0002794732863549143
patients O 0 0.00031753358780406415
, O 0 4.058330915768238e-08
a O 0 6.104291969677433e-07
mutation O 0 2.4783166736597195e-06
was O 0 2.170425688063915e-07
detected O 0 5.602414034910908e-07
in O 0 3.441870433107397e-08
constitutional O 0 2.647178916959092e-06
DNA O 0 4.5228998715174384e-06
, O 0 1.3929720488192743e-08
and O 0 6.879553815508643e-09
1 O 0 1.1147103684550075e-08
of O 0 2.184857406106744e-09
these O 0 1.3702831758166667e-08
mutations O 0 9.053669032255129e-07
is O 0 2.5848038376352633e-08
known O 0 3.980184715146606e-08
to O 0 3.062314135604538e-08
be O 0 3.715407004278859e-08
associated O 0 1.0337605971244557e-07
with O 0 2.3578381558309047e-07
reduced O 0 2.3579383196192794e-05
expressivity O 0 0.13134989142417908
. O 0 1.037508172885282e-05

The O 0 2.7702512852556538e-06
presence O 0 8.356324201486132e-07
of O 0 4.158043864777028e-08
a O 0 3.525327940678835e-07
constitutional O 0 5.154543759999797e-05
mutation O 0 4.758975046570413e-05
was O 0 7.917201401141938e-07
not O 0 5.51522063574339e-08
associated O 0 4.1539848893989983e-08
with O 0 1.6029922278448794e-08
an O 0 6.216204440079309e-08
early O 0 1.6040190757848904e-06
age O 0 1.5991527106962167e-06
at O 0 9.560091029925388e-07
treatment O 0 0.0002089777117362246
. O 0 8.211875865526963e-06

In O 0 2.2822641767561436e-05
1 O 0 9.35481602937216e-06
patient O 0 4.064757013111375e-05
, O 0 2.538339174407156e-07
somatic O 0 2.2819964215159416e-05
mosaicism O 0 0.043941665440797806
was O 0 3.072200570386485e-06
demonstrated O 0 1.6047259805418435e-06
by O 0 3.661497771645372e-08
molecular O 0 4.869161216447537e-07
analysis O 0 4.3937472327115756e-08
of O 0 1.2170035645908683e-08
DNA O 0 8.767722761149344e-07
and O 0 7.671011559295948e-08
RNA O 0 6.902806717334897e-07
from O 0 1.403739844363372e-07
peripheral O 0 2.3327716917265207e-05
blood O 0 3.4428965591359884e-05
. O 0 4.3952904889010824e-06

In O 0 5.6123488320736215e-05
2 O 0 8.613993122708052e-05
patients O 0 0.00023817036708351225
without O 0 2.4871977188922756e-07
a O 0 1.6410551779699745e-06
detectable O 0 4.3331263441359624e-05
mutation O 0 3.3694052490318427e-06
in O 0 2.1123273086232075e-07
peripheral O 0 0.00026305843493901193
blood O 0 0.00012295950728002936
, O 0 4.870749990004697e-07
mosaicism O 0 0.004020956344902515
was O 0 2.048216174443951e-06
suggested O 0 6.34203672689182e-07
because O 0 2.7778327194027952e-08
1 O 0 1.598775334343827e-08
of O 0 6.574364164180224e-09
the O 0 3.519583628985856e-07
patients O 0 0.0474562793970108
showed O 1 0.5225172638893127
multifocal O 1 0.999994158744812
tumors B-Disease 1 0.9999995231628418
and O 0 4.531710828814539e-07
the O 0 3.324516129055155e-08
other O 0 1.5862429592061744e-08
later O 0 2.251498329997048e-07
developed O 0 5.195230983190413e-07
bilateral B-Disease 0 4.724712198367342e-06
retinoblastoma I-Disease 0 0.19194117188453674
. O 0 8.911682016332634e-06

In O 0 9.283628060074989e-06
conclusion O 0 2.738483544817427e-06
, O 0 1.1195220395165961e-07
our O 0 3.516066726660938e-08
results O 0 1.385016759058999e-07
emphasize O 0 2.786536299481668e-07
that O 0 1.699305762770109e-08
the O 0 1.2269230964534472e-08
manifestation O 0 6.387457460732548e-07
and O 0 9.482991458753531e-08
transmissibility O 0 3.2150419428944588e-06
of O 0 2.1200058597514726e-08
retinoblastoma B-Disease 0 4.805651769856922e-05
depend O 0 1.2326162845965882e-07
on O 0 2.7254246859342857e-08
the O 0 8.60269810942782e-09
nature O 0 9.831751413003076e-09
of O 0 1.8603079077195162e-09
the O 0 4.689425736614794e-09
first O 0 1.3693862399577483e-07
mutation O 0 2.4909459739319573e-07
, O 0 2.724383829644239e-09
its O 0 3.880899157593376e-09
time O 0 1.7333571022959404e-08
in O 0 9.26380927523951e-09
development O 0 9.014209823021702e-09
, O 0 1.509728342341532e-08
and O 0 7.846843175229878e-09
the O 0 6.503325877815769e-09
number O 0 1.3832501366550787e-08
and O 0 1.6733050500761237e-08
types O 0 2.375752394812025e-08
of O 0 9.708926107521165e-09
cells O 0 8.116415415315714e-07
that O 0 5.63172726231187e-08
are O 0 2.6206851799770448e-08
affected O 0 3.033662494544842e-07
. O 0 2.1729566412886925e-07
. O 0 1.0393770253358525e-06

Hereditary B-Disease 1 0.9999902248382568
deficiency I-Disease 1 0.9996417760848999
of I-Disease 0 3.901847094311961e-07
the I-Disease 0 1.3589901470822952e-07
fifth I-Disease 0 8.788073273535701e-07
component I-Disease 0 1.2039078001180314e-07
of I-Disease 0 1.9049807065130153e-08
complement I-Disease 0 3.2553742812524433e-07
in O 0 3.349929897922266e-07
man O 0 3.7634359614457935e-05
. O 0 2.849182692443719e-06

I O 0 0.0030659327749162912
. O 0 0.0001621022092876956

Clinical O 0 0.023947108536958694
, O 0 7.561158781754784e-06
immunochemical O 0 0.0005189026123844087
, O 0 8.108764291137049e-07
and O 0 4.665527626457333e-07
family O 0 3.4355721254542004e-06
studies O 0 2.4389332793361973e-06
. O 0 4.3584132072282955e-06

The O 0 3.059697974094888e-06
first O 0 8.015188086574199e-07
recognized O 0 4.3366154045543226e-07
human O 0 5.180472726351582e-07
kindred O 0 0.0006344830035232008
with O 0 0.001657571760006249
hereditary B-Disease 1 0.9999915361404419
deficiency I-Disease 1 0.8310798406600952
of I-Disease 0 1.2550177785897176e-08
the I-Disease 0 2.009747746001267e-08
fifth I-Disease 0 4.968579219166713e-07
component I-Disease 0 1.140257666065736e-07
of I-Disease 0 1.420245610006532e-08
complement I-Disease 0 4.659773651383148e-07
( O 0 1.7561248455422174e-07
C5 O 0 4.360073580755852e-05
) O 0 1.393748618738755e-07
is O 0 1.2845522689985955e-07
described O 0 5.25588666278054e-06
. O 0 2.0122024579904974e-06

The O 0 5.040535597800044e-06
proband O 0 0.00011299362813588232
, O 0 2.2679820688153995e-07
a O 0 3.1298446856453666e-07
20 O 0 2.7277135927761265e-07
- O 0 3.6460689898376586e-06
year O 0 4.601604643994506e-07
- O 0 1.0383911103417631e-05
old O 0 8.017352229217067e-06
black O 0 1.3978747119836044e-05
female O 0 4.022854773211293e-05
with O 0 0.0015196631429716945
systemic B-Disease 1 0.9999998807907104
lupus I-Disease 1 0.9999998807907104
erythematosus I-Disease 1 0.9999998807907104
since O 0 0.011948070488870144
age O 0 1.598572634975426e-05
11 O 0 4.694194046805933e-07
, O 0 7.815478397787956e-08
lacked O 0 1.5307981811929494e-05
serum O 0 0.00013262825086712837
hemolytic O 0 0.00034992615110240877
complement O 0 3.526740215420432e-07
activity O 0 8.829920972175387e-08
, O 0 3.197619591333023e-08
even O 0 1.9956132746301591e-07
during O 0 2.6143729883187916e-06
remission O 0 0.00045752371079288423
. O 0 3.032178028661292e-06

C5 O 0 0.06973874568939209
was O 0 3.03441356663825e-05
undetectable O 0 2.4782011678325944e-05
in O 0 2.9070608320580504e-07
her O 0 2.836562089214567e-06
serum O 0 6.260542249947321e-06
by O 0 7.206825358707647e-08
both O 0 4.9793371204032155e-08
immunodiffusion O 0 3.086942160734907e-05
and O 0 3.118783524769242e-06
hemolytic O 0 0.18366074562072754
assays O 0 0.00013892713468521833
. O 0 3.717548679560423e-06

Other O 0 3.0732262530364096e-06
complement O 0 1.2345567483862396e-06
components O 0 4.870963721259614e-07
were O 0 1.1603346194988262e-07
normal O 0 2.284055398149576e-07
during O 0 8.494338885611796e-07
remission O 0 0.0002376685879426077
of O 0 7.95012851995125e-07
lupus O 1 0.9896534085273743
, O 0 5.334107981980196e-07
but O 0 5.129869009579124e-07
C1 O 0 0.00014675922284368426
, O 0 1.8968920301176695e-07
C4 O 0 1.602657175681088e-05
, O 0 3.8303727478705696e-07
C2 O 0 7.93126382632181e-05
, O 0 9.906409559334861e-08
and O 0 1.1020960499763532e-07
C3 O 0 9.520469029666856e-05
levels O 0 7.672108495171415e-07
fell O 0 8.406957931583747e-06
during O 0 3.5556386137614027e-06
exacerbations O 1 0.6645308136940002
. O 0 1.2008204976154957e-05

A O 0 9.054463589563966e-05
younger O 0 8.600909495726228e-05
half O 0 2.5250481030525407e-06
- O 0 1.0995362572430167e-05
sister O 0 6.937785656191409e-06
, O 0 6.007486774706194e-08
who O 0 2.1484048318143323e-07
had O 0 8.037661700655008e-07
no O 0 2.0547033727780217e-06
underlying O 0 0.021404076367616653
disease O 0 0.002425901824608445
, O 0 2.4869012804629165e-07
was O 0 8.978895493783057e-07
also O 0 1.2298897900109296e-07
found O 0 4.6258573860313845e-08
to O 0 1.1920170095436333e-07
lack O 0 1.4027618817635812e-06
immunochemically O 0 0.036672379821538925
detectable O 0 0.00024326650600414723
C5 O 0 0.00032760552130639553
. O 0 5.20077082910575e-06

By O 0 5.5819305998738855e-05
hemolytic O 1 0.6143926382064819
assay O 0 8.523523865733296e-05
, O 0 7.999029776328825e-07
she O 0 1.0142470046048402e-06
exhibited O 0 1.0422625109640649e-06
1 O 0 8.592682831931597e-08
- O 0 2.79103051070706e-06
2 O 0 2.3998524056878523e-07
% O 0 1.1251923837107825e-08
of O 0 2.197504178624854e-09
the O 0 2.0142607581874472e-08
normal O 0 4.986903263670683e-07
serum O 0 4.7521598389721476e-06
C5 O 0 5.955565029580612e-06
level O 0 4.127747743609689e-08
and O 0 2.4830802303199562e-08
normal O 0 1.1799568966353036e-07
concentrations O 0 1.0203089573224133e-07
of O 0 6.913384975604231e-09
other O 0 1.5703903954999987e-08
complement O 0 3.374057087057736e-07
components O 0 1.8386289184491034e-06
. O 0 1.2443000514394953e-06

C5 O 0 0.08297494053840637
levels O 0 1.2889720892417245e-05
of O 0 1.7005255870117253e-07
other O 0 8.917899663174467e-08
family O 0 3.695223256272584e-07
members O 0 4.4996063763846905e-08
were O 0 4.188002833416249e-08
either O 0 3.076874932617102e-08
normal O 0 4.57248745533434e-08
or O 0 9.890244179189267e-09
approximately O 0 2.345281124860321e-08
half O 0 8.755625913181575e-08
- O 0 4.036132850160357e-06
normal O 0 3.2873680311240605e-07
, O 0 4.62486937635731e-08
consistent O 0 3.5002230447389593e-07
with O 0 6.89930573116726e-07
autosomal O 0 0.01794174313545227
codominant O 0 0.001837060903199017
inheritance O 0 2.7277446861262433e-06
of O 0 1.8121406597515488e-08
the O 0 1.0560152219341035e-07
gene O 0 8.470607099297922e-06
determining O 0 5.148706623003818e-05
C5 B-Disease 1 0.9999922513961792
deficiency I-Disease 1 0.9999730587005615
. O 0 2.2845941202831455e-05

Normal O 0 0.003956406377255917
hemolytic O 1 0.992472767829895
titers O 0 0.11251936107873917
were O 0 1.9834237718896475e-06
restored O 0 1.6715064248273848e-06
to O 0 1.4447265073158633e-07
both O 0 4.489991454192932e-07
homozygous O 0 0.002481491770595312
C5 B-Disease 1 0.9999244213104248
- I-Disease 1 0.999691367149353
deficient I-Disease 1 0.9999792575836182
( O 0 1.4536008166032843e-06
C5D B-Disease 1 0.9993602633476257
) O 0 2.4263840714411344e-07
sera O 0 1.8793763956637122e-05
by O 0 1.8675757829100803e-08
addition O 0 2.4526073616470967e-08
of O 0 1.5050938273475367e-08
highly O 0 3.819415326233866e-07
purified O 0 8.091799827525392e-06
human O 0 3.6337878555059433e-06
C5 O 0 0.00023426218831446022
. O 0 6.062605734769022e-06

In O 0 1.4977980754338205e-05
specific O 0 3.1228878469846677e-06
C5 O 0 0.00033775297924876213
titrations O 0 0.005749159026890993
, O 0 6.419157898562844e-07
however O 0 8.936970630202268e-08
, O 0 1.996516729718678e-08
it O 0 1.3379944263647303e-08
was O 0 8.068614931744378e-08
noted O 0 5.8432945593267505e-08
that O 0 9.163989567184672e-09
when O 0 1.514221459331111e-08
limited O 0 2.5865000807812066e-08
amounts O 0 2.978077162651971e-08
of O 0 6.241840821985534e-09
C5 O 0 2.6131890535907587e-06
were O 0 2.8040552990660217e-08
assayed O 0 4.1139426798508794e-07
in O 0 1.4412278481756857e-08
the O 0 5.169734862420228e-09
presence O 0 2.78718399471245e-08
of O 0 6.1491269853775066e-09
low O 0 2.1513881165446946e-07
dilutions O 0 3.7340780636441195e-06
of O 0 4.0561644709669054e-08
either O 0 7.52223854760814e-07
C5D B-Disease 1 0.9996833801269531
serum O 0 3.315375215606764e-05
, O 0 3.624552746828158e-08
curving O 0 5.716639179809135e-07
rather O 0 8.162868425642955e-08
than O 0 3.699172168580844e-08
linear O 0 7.514767617067264e-07
dose O 0 5.2113231504336e-05
- O 0 1.1733014616766013e-05
response O 0 8.597253895459289e-07
plots O 0 3.2392642879131017e-07
were O 0 7.579299676763185e-08
consistently O 0 6.813608592892706e-07
obtained O 0 1.7797763973703695e-07
, O 0 2.0457230576198526e-08
suggesting O 0 1.1438878999570079e-07
some O 0 4.162963662679431e-08
inhibitory O 0 4.2922051761706825e-06
effect O 0 3.714532795129344e-06
. O 0 1.6052493947427138e-06

Further O 0 3.49739239027258e-05
studies O 0 4.7052699301275425e-06
suggested O 0 8.523372230229143e-07
that O 0 8.230531989283918e-08
low O 0 8.476067137053178e-07
dilutions O 0 1.501536462455988e-05
of O 0 2.3782716596087994e-07
C5D B-Disease 1 0.9999442100524902
serum O 0 3.845852552331053e-05
contain O 0 1.6826271576064755e-07
a O 0 1.7982516453685093e-07
factor O 0 1.3042584612321662e-07
( O 0 1.390155990321773e-08
or O 0 1.1472840455439837e-08
factors O 0 1.306605934559002e-08
) O 0 9.696361047417668e-09
interfering O 0 9.226253894212277e-08
at O 0 3.160619499453787e-08
some O 0 1.3711407120808872e-08
step O 0 1.581360464797399e-07
in O 0 3.812172977291084e-08
the O 0 7.38615071327331e-08
hemolytic O 0 0.001876350725069642
assay O 0 3.2396985716331983e-06
of O 0 6.428309973216528e-08
C5 O 0 7.111414015525952e-05
, O 0 7.33839229383193e-08
rather O 0 4.6288580080044994e-08
than O 0 2.998276116272791e-08
a O 0 1.7897639281727606e-07
true O 0 1.066576260200236e-06
C5 O 0 9.122888877755031e-05
inhibitor O 0 3.352225394337438e-05
or O 0 1.981994273592136e-06
inactivator O 0 0.0003240840742364526
. O 0 6.280287834670162e-06

Of O 0 6.272249720495893e-06
clinical O 0 0.0006204805104061961
interest O 0 1.4481546486422303e-06
are O 0 8.981022148191187e-08
( O 0 3.408714377428623e-08
a O 0 1.2962034645624954e-07
) O 0 1.2254122161436953e-08
the O 0 1.1510496555899863e-08
documentation O 0 1.7829361809162947e-07
of O 0 1.9275836393717327e-07
membranous O 1 0.9985705614089966
glomerulonephritis B-Disease 1 0.9999994039535522
, O 0 0.010175390169024467
vasculitis B-Disease 1 0.9999922513961792
, O 0 6.282033427851275e-05
and O 0 0.008421899750828743
arthritis B-Disease 1 1.0
in O 0 3.924188149539987e-06
an O 0 3.449063683547138e-07
individual O 0 1.141236865009887e-07
lacking O 0 4.1038310882868245e-06
C5 O 0 0.0010143480030819774
( O 0 3.3140889144078756e-08
and O 0 1.504379021355362e-08
its O 0 4.463023373091346e-08
biologic O 0 2.929865786427399e-06
functions O 0 3.07221306172778e-08
) O 0 1.838586527469488e-08
, O 0 1.637341817684046e-08
and O 0 3.537599724268148e-08
( O 0 3.311618357315638e-08
b O 0 1.0298855812607144e-07
) O 0 4.764482142149973e-09
a O 0 3.296292661048028e-08
remarkable O 0 4.400863815590128e-07
propensity O 0 7.460750930476934e-05
to O 0 0.0002185777557315305
bacterial B-Disease 1 0.9999973773956299
infections I-Disease 1 0.9999995231628418
in O 0 1.217235535477812e-06
the O 0 1.5136171782614838e-07
proband O 0 0.00013987328566145152
, O 0 3.524809599753098e-08
even O 0 2.1602609479032253e-08
during O 0 3.8655642242702015e-08
periods O 0 1.080894946881017e-07
of O 0 1.3970590906353664e-08
low O 0 9.518905699223978e-07
- O 0 2.9273211112013087e-05
dose O 0 3.40465921908617e-05
or O 0 4.9838600801876964e-08
alternate O 0 3.575281652956619e-07
- O 0 8.53270375955617e-06
day O 0 2.435667511235806e-06
corticosteroid O 1 0.6906288266181946
therapy O 0 0.004141733516007662
. O 0 4.756036560138455e-06

Other O 0 5.86295391258318e-06
observations O 0 2.189473707403522e-05
indicate O 0 4.050639745400986e-06
that O 0 1.1029582225319245e-07
the O 0 1.176972972416479e-07
C5D B-Disease 1 0.9982592463493347
state O 0 1.1685256140481215e-07
is O 0 1.4331276609880206e-08
compatible O 0 3.805227777320397e-08
with O 0 2.0169364844946358e-08
normal O 0 1.9139753248964553e-07
coagulation O 0 1.2442964134606882e-06
function O 0 7.333313334356717e-08
and O 0 1.2167924445805056e-08
the O 0 1.1705505897907642e-08
capacity O 0 1.112228105171198e-07
to O 0 5.96407971897861e-08
mount O 0 2.667734861461213e-06
a O 0 7.68364316172665e-06
neutrophilic O 1 0.7493959069252014
leukocytosis O 1 0.5824596285820007
during O 0 0.00015422742580994964
pyogenic B-Disease 1 0.9928923845291138
infection I-Disease 0 0.49853038787841797
. O 0 1.902934400277445e-06
. O 0 4.244595402269624e-06

Susceptibility O 1 0.9969795942306519
to O 0 0.23871952295303345
ankylosing B-Disease 1 0.9999996423721313
spondylitis I-Disease 1 1.0
in O 0 0.005370512139052153
twins O 0 0.09067582339048386
: O 0 1.1294361002001096e-07
the O 0 1.107046543324941e-08
role O 0 2.8774966409628178e-08
of O 0 8.60873949903862e-09
genes O 0 1.518252190635394e-07
, O 0 1.365009154596919e-07
HLA O 0 0.00033126093330793083
, O 0 6.26006126935863e-08
and O 0 2.1336685307460357e-08
the O 0 7.60594645043966e-08
environment O 0 2.315378878847696e-06
. O 0 1.9513115603331244e-06

OBJECTIVE O 0 6.876641418784857e-05
To O 0 1.4896876336933929e-06
determine O 0 5.07448191910953e-07
the O 0 3.088499056502769e-08
relative O 0 3.076652319577988e-07
effects O 0 6.718140639350167e-07
of O 0 3.585319419130428e-08
genetic O 0 1.2396700412864448e-06
and O 0 1.0716205167682347e-07
environmental O 0 7.208378747236566e-07
factors O 0 1.6998461660477915e-07
in O 0 4.4337178906062036e-07
susceptibility O 1 0.7904672622680664
to O 1 0.7825977802276611
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 4.2977921111742035e-05
AS B-Disease 0 0.0004745309124700725
) O 0 8.071129400377686e-07
. O 0 1.963182967301691e-06

METHODS O 0 0.0004959862562827766
Twins O 0 0.010481917299330235
with O 0 2.057179699477274e-06
AS B-Disease 0 0.0003785913286264986
were O 0 3.2391528748121345e-07
identified O 0 2.4507374973836704e-07
from O 0 1.4717770113747974e-08
the O 0 3.243077983938747e-08
Royal O 0 8.935357072914485e-06
National O 0 5.024003257858567e-07
Hospital O 0 0.004415310453623533
for O 0 2.866965951398015e-05
Rheumatic B-Disease 1 0.9999957084655762
Diseases I-Disease 1 0.6889856457710266
database O 0 1.114155566028785e-05
. O 0 4.20600099459989e-06

Clinical O 0 0.018531203269958496
and O 0 9.65891194937285e-06
radiographic O 0 0.2951783239841461
examinations O 0 5.471425174619071e-05
were O 0 6.967503622945515e-07
performed O 0 9.921486707753502e-07
to O 0 1.1693671808643558e-07
establish O 0 4.646018624043791e-06
diagnoses O 1 0.9878758192062378
, O 0 2.920809947681846e-06
and O 0 0.00013079388008918613
disease O 0 0.367240309715271
severity O 0 0.21347369253635406
was O 0 1.3595798918686341e-05
assessed O 0 3.9280604369196226e-07
using O 0 3.9512830340981964e-08
a O 0 1.8514140265324386e-07
combination O 0 3.9289034248213284e-07
of O 0 3.1424658430978525e-08
validated O 0 2.1738487703260034e-06
scoring O 0 7.476323276023322e-07
systems O 0 3.230156380595872e-06
. O 0 1.2231258779138443e-06

HLA O 0 0.03838367760181427
typing O 0 0.00033008819445967674
for O 0 1.1866494787682313e-05
HLA O 0 0.001844938495196402
- O 0 0.0004006324743386358
B27 O 0 6.765479338355362e-05
, O 0 4.2356083440608927e-07
HLA O 0 3.217379708075896e-05
- O 0 2.2288269974524155e-05
B60 O 0 2.34933067986276e-05
, O 0 9.023415259434842e-08
and O 0 1.3674522847395565e-07
HLA O 0 0.0010490578133612871
- O 0 0.02193433791399002
DR1 O 1 0.9995386600494385
was O 0 7.706235578552878e-07
performed O 0 2.5831803895925987e-07
by O 0 1.334100652172765e-08
polymerase O 0 7.263959105330287e-07
chain O 0 8.505679147674527e-07
reaction O 0 1.4385011581907747e-07
with O 0 8.861603006948826e-09
sequence O 0 4.427210953394933e-08
- O 0 3.5817313914776605e-07
specific O 0 3.467555487191021e-08
primers O 0 2.538462922530016e-06
, O 0 5.61086288541901e-08
and O 0 5.5239588903077674e-08
zygosity O 0 2.1043333617853932e-05
was O 0 3.546944356003223e-07
assessed O 0 3.8413912761825486e-07
using O 0 5.681496304532629e-07
microsatellite O 0 0.00021193041175138205
markers O 0 3.198605190846138e-05
. O 0 7.115203516150359e-06

Genetic O 0 0.00707701500505209
and O 0 5.124644758325303e-06
environmental O 0 1.145257101597963e-06
variance O 0 3.888488890879671e-07
components O 0 2.879237968045345e-07
were O 0 6.216963299721101e-08
assessed O 0 2.1036626662862545e-07
with O 0 2.527384168615754e-08
the O 0 1.7859731471503437e-08
program O 0 4.3402064164865806e-08
Mx O 0 9.778937055671122e-07
, O 0 6.617100201111725e-09
using O 0 8.926846817303158e-09
data O 0 1.2575624985800005e-08
from O 0 3.582433016902087e-09
this O 0 4.8162056565104194e-09
and O 0 2.3888844680186594e-08
previous O 0 4.2920316900563193e-07
studies O 0 6.779813332968843e-08
of O 0 2.2845471292498587e-08
twins O 0 0.00039837899385020137
with O 0 5.195785774958495e-07
AS B-Disease 0 0.001361087430268526
. O 0 4.344026820035651e-06

RESULTS O 0 0.0003288236912339926
Six O 0 2.2768704184272792e-06
of O 0 1.265025559860078e-07
8 O 0 2.354546722926898e-06
monozygotic O 0 0.0010322772432118654
( O 0 9.702827128421632e-07
MZ O 1 0.9572899341583252
) O 0 5.127179178998631e-07
twin O 0 0.0012216373579576612
pairs O 0 3.818518507614499e-06
were O 0 1.6666818964949925e-06
disease O 0 2.6010506189777516e-05
concordant O 0 0.0017594684613868594
, O 0 8.02781073616643e-07
compared O 0 7.239649448820273e-07
with O 0 4.5802213577417206e-08
4 O 0 9.640414333489389e-08
of O 0 8.09589728589799e-09
15 O 0 2.0636001352158928e-07
B27 O 0 8.492203960486222e-06
- O 0 1.7067959561245516e-05
positive O 0 1.1457258324298891e-06
dizygotic O 0 2.6819210688699968e-05
( O 0 1.7223635495611234e-07
DZ O 0 7.561845995951444e-05
) O 0 1.3497330542122654e-07
twin O 0 6.711317109875381e-05
pairs O 0 4.23423529127831e-07
( O 0 2.6674644715285467e-08
27 O 0 2.801174616706703e-07
% O 0 2.1736772382041636e-08
) O 0 5.606409114733424e-09
and O 0 1.0805935701796443e-08
4 O 0 3.952420968289516e-08
of O 0 1.1022595280962832e-08
32 O 0 1.3149884807717171e-06
DZ O 0 0.021076969802379608
twin O 0 0.025215523317456245
pairs O 0 7.828098205209244e-07
overall O 0 5.068905011285096e-07
( O 0 4.819387200427627e-08
12 O 0 1.3204596882587794e-07
. O 0 3.984256125022512e-08
5 O 0 3.38517963882623e-07
% O 0 1.21917167916763e-07
) O 0 1.9222561320475506e-07
. O 0 1.1744820085368701e-06

Nonsignificant O 0 0.11507409065961838
increases O 0 0.00020023212709929794
in O 0 4.037035239434772e-07
similarity O 0 4.979974050911551e-07
with O 0 5.736015751267587e-08
regard O 0 2.120329725130432e-07
to O 0 4.6157572342053754e-07
age O 0 1.6160032828338444e-05
at O 0 7.448096312145935e-06
disease O 0 0.0035362772177904844
onset O 0 0.00017937157826963812
and O 0 6.566784804817871e-08
all O 0 2.8476949687217257e-09
of O 0 6.616986514274004e-09
the O 0 1.0671409427231993e-06
disease O 0 0.026094520464539528
severity O 0 0.0369378924369812
scores O 0 1.547109059174545e-05
assessed O 0 1.5472140830752323e-06
were O 0 1.0867970701156082e-07
noted O 0 5.874701969332818e-07
in O 0 1.8089484683514456e-06
disease O 0 0.0022483039647340775
- O 0 0.3054361343383789
concordant O 1 0.9925373196601868
MZ O 1 0.9999263286590576
twins O 0 0.22766992449760437
compared O 0 5.104144747747341e-06
with O 0 9.513143481854058e-07
concordant O 0 0.013427522964775562
DZ O 1 0.9773625731468201
twins O 0 0.01904735341668129
. O 0 7.412142622342799e-06

HLA O 1 0.5680005550384521
- O 0 0.004407229367643595
B27 O 0 0.0003909258812200278
and O 0 8.78811476923147e-07
B60 O 0 2.4318811483681202e-05
were O 0 1.3552212863032764e-07
associated O 0 8.200821355330845e-08
with O 0 5.482560183622809e-08
the O 0 1.69670715877146e-06
disease O 0 0.00016064503870438784
in O 0 2.819044198076881e-07
probands O 0 0.0011040536919608712
, O 0 5.4819743411371746e-08
and O 0 1.132681415327852e-08
the O 0 1.1371796837522652e-08
rate O 0 1.4208774246071698e-07
of O 0 4.4411489596996034e-08
disease O 0 2.6574292860459536e-05
concordance O 0 4.865580558544025e-05
was O 0 6.085057066229638e-06
significantly O 0 1.97153144654294e-06
increased O 0 3.451070824667113e-07
among O 0 1.1120074816517445e-07
DZ O 0 0.02799045480787754
twin O 0 0.18324711918830872
pairs O 0 9.409909580426756e-07
in O 0 4.039880607820123e-08
which O 0 2.626459938426251e-08
the O 0 3.30306448859119e-08
co O 0 5.2422310545807704e-06
- O 0 4.006216477137059e-05
twin O 0 0.004206118639558554
was O 0 2.121502831187172e-07
positive O 0 4.445318424473044e-08
for O 0 1.404162475182602e-08
both O 0 1.2888764899798844e-07
B27 O 0 5.911404514336027e-05
and O 0 2.957980086648604e-06
DR1 O 1 0.9972816705703735
. O 0 1.2452280316210818e-05

Additive O 0 0.0003973185957875103
genetic O 0 0.0004957903875038028
effects O 0 6.316368671832606e-05
were O 0 5.979787829346606e-07
estimated O 0 1.4706803597164253e-07
to O 0 6.051602241541332e-08
contribute O 0 2.2378920050414308e-07
97 O 0 8.185933779714105e-07
% O 0 4.3704527996624165e-08
of O 0 6.018196163637413e-09
the O 0 5.3243397246660606e-08
population O 0 2.6937064490084595e-07
variance O 0 1.6617808569208137e-06
. O 0 1.8374947785559925e-06

CONCLUSION O 0 0.001359445508569479
Susceptibility O 1 0.5013637542724609
to O 0 5.511331437446643e-06
AS B-Disease 0 0.00018186355009675026
is O 0 1.894579924055506e-07
largely O 0 3.9320184441749007e-07
genetically O 0 5.323659024725202e-07
determined O 0 6.935985652489762e-07
, O 0 1.828741247322796e-08
and O 0 5.513934642209506e-09
the O 0 6.562487886441204e-09
environmental O 0 1.5660150154417352e-07
trigger O 0 4.275570063327905e-06
for O 0 1.1805038724332917e-07
the O 0 1.985982862606761e-06
disease O 0 0.00025790827930904925
is O 0 1.5454340029918967e-07
probably O 0 1.4412656810236513e-06
ubiquitous O 0 9.839012818702031e-06
. O 0 1.7175360653709504e-06

HLA O 1 0.6779847741127014
- O 0 0.0027175352443009615
B27 O 0 0.0001562993275001645
accounts O 0 7.150945293687982e-07
for O 0 4.5810601534412854e-08
a O 0 3.483943942228507e-07
minority O 0 5.253213544165192e-07
of O 0 1.0621314494585476e-08
the O 0 4.8796394480632443e-08
overall O 0 9.807583410292864e-06
genetic O 0 8.046493894653395e-05
susceptibility O 0 0.005085018929094076
to O 0 2.452231910865521e-06
AS B-Disease 0 0.010923662222921848
. O 0 5.759317900810856e-06

Cell O 0 0.0020406681578606367
cycle O 0 8.548480400349945e-05
- O 0 5.622955723083578e-05
dependent O 0 2.3595998754899483e-06
colocalization O 0 7.832452865841333e-06
of O 0 3.568284512311948e-08
BARD1 O 0 0.00011120596172986552
and O 0 3.764014309126651e-07
BRCA1 O 0 9.207175935443956e-06
proteins O 0 1.1417158418680629e-07
in O 0 4.6527215857850024e-08
discrete O 0 8.525153134542052e-07
nuclear O 0 3.347510528328712e-06
domains O 0 3.4343272545811487e-06
. O 0 1.851832053034741e-06

Germ O 0 0.003758449573069811
- O 0 0.005157415755093098
line O 0 2.3362783394986764e-05
mutations O 0 2.556365188866039e-06
of O 0 2.8378334349099532e-08
the O 0 1.683145427477939e-07
BRCA1 O 0 0.00026049374719150364
gene O 0 2.9678078590222867e-06
predispose O 0 3.0861119739711285e-05
women O 0 5.526914037545794e-07
to O 0 1.0771411496079963e-07
early O 0 3.0366577448148746e-06
- O 1 0.535862386226654
onset O 1 0.9848889112472534
breast B-Disease 1 0.9999551773071289
and I-Disease 1 0.9986124038696289
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
by O 0 5.920230137235194e-07
compromising O 0 9.626734936318826e-06
the O 0 1.2269271110199043e-07
genes O 0 6.409217121472466e-07
presumptive O 0 0.0006685076514258981
function O 0 2.3380884783819056e-07
as O 0 1.0694765251173521e-07
a O 0 3.5765679058386013e-06
tumor B-Disease 0 0.0013918622862547636
suppressor O 0 0.0004711119399871677
. O 0 6.153803042252548e-06

Although O 0 1.0613207450660411e-05
the O 0 5.977518640065682e-07
biochemical O 0 8.342195542354602e-06
properties O 0 5.031373007113871e-07
of O 0 3.704255391312472e-08
BRCA1 O 0 7.895239104982466e-05
polypeptides O 0 5.799762675451348e-06
are O 0 3.527890157783986e-08
not O 0 2.5221254418283934e-08
understood O 0 1.127706568126996e-07
, O 0 1.2476094823909989e-08
their O 0 1.2221024192626828e-08
expression O 0 1.494561416848228e-07
pattern O 0 2.205303104574341e-07
and O 0 3.006866577948131e-08
subcellular O 0 1.1914403330592904e-06
localization O 0 7.25750510355283e-07
suggest O 0 1.8786192867992213e-07
a O 0 8.295322118101467e-08
role O 0 1.2201836341318995e-07
in O 0 8.233280368585838e-08
cell O 0 1.635930129850749e-05
- O 0 3.1167175620794296e-05
cycle O 0 6.436373041651677e-06
regulation O 0 4.553967755782651e-06
. O 0 2.1743339857493993e-06

When O 0 4.43591306975577e-05
resting O 0 0.00015888220514170825
cells O 0 1.0971564734063577e-05
are O 0 1.5567871969324187e-07
induced O 0 3.338679380249232e-05
to O 0 3.569244881873601e-07
proliferate O 0 3.048135567951249e-06
, O 0 2.6662032581725725e-08
the O 0 1.407130412189872e-08
steady O 0 7.681376246182481e-07
- O 0 1.433459146937821e-06
state O 0 6.103673655388775e-08
levels O 0 1.6109890310644914e-08
of O 0 7.326375950356123e-09
BRCA1 O 0 6.283031780185411e-06
increase O 0 1.4547974558354326e-07
in O 0 4.559111488333656e-08
late O 0 1.5019771808510995e-06
G1 O 0 0.00469563202932477
and O 0 5.904319166916139e-08
reach O 0 7.265760615382533e-08
a O 0 1.2566421503379388e-07
maximum O 0 1.2385237369016977e-06
during O 0 1.3361119499677443e-06
S O 0 0.00029219736461527646
phase O 0 1.1297768651274964e-05
. O 0 3.7798563425894827e-06

Moreover O 0 6.946253415662795e-05
, O 0 6.765990292478818e-07
in O 0 2.345232559264332e-07
S O 0 9.39736855798401e-05
phase O 0 5.9244202930131e-06
cells O 0 6.10597271588631e-06
, O 0 1.6377455835936416e-07
BRCA1 O 0 9.141626833297778e-06
polypeptides O 0 2.0084428342670435e-06
are O 0 5.83116985808374e-08
hyperphosphorylated O 0 5.886108283448266e-06
and O 0 1.036548482602484e-07
accumulate O 0 8.181181669897342e-07
into O 0 5.608615438745801e-08
discrete O 0 1.0636964589139097e-06
subnuclear O 0 3.884281250066124e-05
foci O 0 3.687914431793615e-05
termed O 0 1.0243106771667954e-05
" O 0 3.0049714041524567e-06
BRCA1 O 0 5.817137207486667e-05
nuclear O 0 1.1044060556741897e-05
dots O 0 9.80275945039466e-05
. O 0 8.12769303593086e-06

" O 0 0.0002791278820950538
BRCA1 O 1 0.8440569043159485
associates O 0 0.0006201843498274684
in O 0 1.2859364915129845e-06
vivo O 0 0.00020295966533012688
with O 0 2.1016353457525838e-07
a O 0 3.6661069771071197e-06
structurally O 0 0.00022709251788910478
related O 0 1.3518267678591656e-06
protein O 0 2.7525909445103025e-06
termed O 0 1.8281667507835664e-05
BARD1 O 0 0.0010024895891547203
. O 0 6.594400019821478e-06

Here O 0 1.1500452274049167e-05
we O 0 5.610926336885314e-07
show O 0 3.3003161092892697e-07
that O 0 1.4079438059866334e-08
the O 0 1.1185290915705082e-08
steady O 0 7.280055456249102e-07
- O 0 2.220420356024988e-06
state O 0 5.765191701812e-08
levels O 0 2.1796099147763925e-08
of O 0 6.5763714474087465e-09
BARD1 O 0 8.859483932610601e-05
, O 0 6.444330580279711e-08
unlike O 0 6.128533414084814e-08
those O 0 4.303735590127644e-09
of O 0 1.0033240016582567e-08
BRCA1 O 0 5.438439984573051e-05
, O 0 1.0463053712328474e-07
remain O 0 1.1805995825397986e-07
relatively O 0 1.4285760130405833e-07
constant O 0 9.84977987172897e-07
during O 0 8.881113444658695e-07
cell O 0 4.115187766728923e-05
cycle O 0 1.6877480447874404e-05
progression O 0 5.1535309466999024e-05
. O 0 3.957538865506649e-06

However O 0 5.185495319892652e-05
, O 0 2.997738420162932e-06
immunostaining O 0 9.912341920426115e-05
revealed O 0 8.750484084885102e-06
that O 0 2.5112080948019866e-07
BARD1 O 0 0.0002029168972512707
resides O 0 4.2044248402817175e-06
within O 0 6.242152750246532e-08
BRCA1 O 0 5.920093826716766e-06
nuclear O 0 1.6784566696514958e-06
dots O 0 7.045123766147299e-06
during O 0 6.800366350034892e-07
S O 0 3.578944961191155e-05
phase O 0 2.608159661576792e-07
of O 0 7.096444765153365e-09
the O 0 2.4240382145990225e-08
cell O 0 2.4925027446442982e-06
cycle O 0 4.419854064963147e-07
, O 0 9.399433231749299e-09
but O 0 9.579885329458193e-09
not O 0 1.346365507970404e-08
during O 0 5.1148226987152157e-08
the O 0 1.1271473709939528e-07
G1 O 0 0.000993579626083374
phase O 0 1.2616424100997392e-05
. O 0 1.9648705347208306e-06

Nevertheless O 0 0.00028626370476558805
, O 0 3.739915655387449e-06
BARD1 O 0 0.0001303744938923046
polypeptides O 0 1.2543123375508003e-05
are O 0 8.99072318816252e-08
found O 0 3.916326107855639e-08
exclusively O 0 2.9630850661988006e-08
in O 0 8.617051960868594e-09
the O 0 4.432937572573792e-09
nuclear O 0 4.144741083678127e-08
fractions O 0 3.6897649380307485e-08
of O 0 2.9331352902062235e-09
both O 0 3.424321448619594e-08
G1 O 0 0.00012827981845475733
- O 0 5.422054073278559e-06
and O 0 1.2927654324812465e-07
S O 0 0.00014342594658955932
- O 0 2.7479289201437496e-05
phase O 0 8.485800208291039e-06
cells O 0 1.0263170224789064e-05
. O 0 1.301633233197208e-06

Therefore O 0 2.928614048869349e-05
, O 0 1.0404114618722815e-06
progression O 0 5.04986473970348e-06
to O 0 2.88383830593375e-07
S O 0 0.00043002914753742516
phase O 0 1.2535269888758194e-06
is O 0 2.9332150930372336e-08
accompanied O 0 2.1841862007931923e-07
by O 0 1.3701054513148847e-08
the O 0 9.694954172800863e-09
aggregation O 0 1.6689422466242831e-07
of O 0 1.888433587282634e-08
nuclear O 0 1.0339671234760317e-06
BARD1 O 0 3.079609086853452e-05
polypeptides O 0 2.9234295197966276e-06
into O 0 3.625476097113278e-07
BRCA1 O 0 2.867627699743025e-05
nuclear O 0 4.577226718538441e-06
dots O 0 4.1564300772733986e-05
. O 0 2.9404914130282123e-06

This O 0 6.540436970681185e-06
cell O 0 3.326009027659893e-05
cycle O 0 4.4080393308831844e-06
- O 0 5.410302946984302e-06
dependent O 0 4.6329080305440584e-07
colocalization O 0 4.3564227780734655e-06
of O 0 4.8959353904365344e-08
BARD1 O 0 0.00024965990451164544
and O 0 8.598648264523945e-07
BRCA1 O 0 0.00010337826824979857
indicates O 0 2.389240307820728e-07
a O 0 7.3741432515817e-08
role O 0 7.65019052550997e-08
for O 0 7.512058886049999e-08
BARD1 O 0 0.0013544776011258364
in O 0 8.467583256788203e-07
BRCA1 O 0 0.0008839002694003284
- O 0 0.001258071861229837
mediated O 0 0.00731391366571188
tumor B-Disease 0 0.05669686198234558
suppression O 0 5.888988744118251e-05
. O 0 1.0964588000206277e-05

Ethnic O 0 9.718043293105438e-05
differences O 0 3.766340887523256e-05
in O 0 8.058400453592185e-07
the O 0 3.106362100879778e-07
HFE O 0 0.0001572334294905886
codon O 0 1.0816208487085532e-05
282 O 0 1.1863790859933943e-05
( O 0 2.2856991108710645e-06
Cys O 0 0.02405034936964512
/ O 0 0.0006217006011866033
Tyr O 0 0.0012672299053519964
) O 0 2.2951310256758006e-06
polymorphism O 0 7.862068014219403e-05
. O 0 3.9687115531705786e-06

Recent O 0 9.989982208935544e-05
studies O 0 5.202963620831724e-06
have O 0 6.177307341204141e-07
shown O 0 4.768712642544415e-06
that O 0 3.100957110291347e-05
hereditary B-Disease 1 0.9999997615814209
hemochromatosis I-Disease 1 1.0
( O 0 5.44637005077675e-05
HH B-Disease 1 0.982282817363739
) O 0 1.0728926724823395e-07
is O 0 2.2087458972919194e-08
likely O 0 1.2396434101447085e-07
to O 0 3.3219997419564606e-08
be O 0 4.58432900529715e-08
caused O 0 5.201328576731612e-07
by O 0 2.897576933946766e-08
homozygosity O 0 1.4774953342566732e-05
for O 0 3.0251595006802745e-08
a O 0 7.058628739287087e-07
Cys282Tyr O 0 0.0023748204112052917
mutation O 0 2.3900865926407278e-06
in O 0 3.201293097276903e-08
the O 0 3.8539031521622746e-08
HFE O 0 0.00035242331796325743
gene O 0 1.7596817087905947e-06
located O 0 4.508919175805204e-07
4 O 0 1.3799029829897336e-06
. O 0 1.4311057157101459e-06

5 O 0 9.900410805130377e-05
Mb O 0 0.0019869760144501925
telomeric O 0 0.0057120113633573055
to O 0 1.575729766045697e-05
HLA O 0 0.005396304652094841
- O 0 0.00014660843589808792
A O 0 1.954091749212239e-05
. O 0 6.650697741861222e-06

Population O 0 3.456456761341542e-05
studies O 0 1.0473072507011238e-06
of O 0 2.0859918237192687e-08
this O 0 3.6647254120225625e-08
polymorphism O 0 1.5580048057017848e-05
are O 0 1.733998544750648e-08
facilitated O 0 1.4455410735081387e-07
by O 0 1.6344307240956368e-08
the O 0 9.616610618934374e-09
fact O 0 1.8993533856814793e-08
that O 0 1.1593873416870792e-08
the O 0 2.3774660462549946e-08
Cys282Tyr O 0 4.5252509153215215e-05
mutation O 0 7.649204576409829e-07
creates O 0 3.017023857410095e-07
a O 0 3.552428609054914e-07
Rsal O 0 1.9106730178464204e-05
restriction O 0 1.5009761682449607e-06
site O 0 1.4369192058438784e-06
. O 0 9.50007859046309e-07

We O 0 5.671412054653047e-06
have O 0 2.2990340653450403e-07
studied O 0 1.1416330636393468e-07
the O 0 2.616819294587458e-08
codon O 0 6.118617648098734e-07
282 O 0 2.2580663880944485e-06
( O 0 3.6390656532603316e-07
Cys O 0 0.003304441226646304
/ O 0 6.503994518425316e-05
Tyr O 0 0.00013622819096781313
) O 0 1.037487962207706e-07
polymorphism O 0 2.546107452872093e-06
in O 0 5.183551365917083e-08
different O 0 2.535901799660678e-08
ethnic O 0 3.1403155276166217e-07
groups O 0 3.461813662397617e-07
. O 0 2.0306551959947683e-06

In O 0 1.2881168004241772e-05
agreement O 0 1.3810667951474898e-06
with O 0 9.1585761197166e-08
previous O 0 2.0166102387975116e-07
observations O 0 4.2618731299626234e-07
the O 0 2.6935492059010357e-08
Tyr O 0 4.2527331970632076e-05
allele O 0 4.489688762987498e-06
appeared O 0 6.837159389760927e-07
to O 0 2.8119282902139275e-08
be O 0 3.1739823214138596e-08
rare O 0 5.740666892961599e-07
or O 0 1.8454733208272955e-07
absent O 0 2.9775515031360555e-06
in O 0 2.985624689699762e-07
Asiatic O 0 4.829693352803588e-06
( O 0 2.6515365902923804e-08
Indian O 0 2.8196726731266608e-08
, O 0 1.749906530790213e-08
Chinese O 0 3.8938619439932154e-08
) O 0 9.904519515657739e-08
populations O 0 5.380630341278447e-07
. O 0 8.31114164157043e-07

The O 0 4.055973931826884e-06
highest O 0 7.227484729810385e-06
allele O 0 1.1037216609111056e-05
frequency O 0 3.162638677167706e-06
( O 0 7.229225218452484e-08
7 O 0 2.7983071504422696e-07
. O 0 2.71854041500319e-08
5 O 0 9.671982326153739e-08
% O 0 2.8522682882226036e-08
) O 0 7.532702461787721e-09
was O 0 6.254499851365836e-08
found O 0 8.356923331120925e-08
in O 0 1.250824084308988e-07
Swedes O 0 0.005184725392609835
. O 0 3.672097363960347e-06

Saamis O 0 0.002477659611031413
( O 0 4.071689545526169e-06
2 O 0 1.1076105010943138e-06
% O 0 8.715471011555564e-08
) O 0 1.5894533689220225e-08
and O 0 3.946153626088744e-08
Mordvinians O 0 2.5749388441909105e-05
( O 0 2.4979200929919898e-08
1 O 0 2.474588889356255e-08
. O 0 1.2258330350789493e-08
8 O 0 9.391158073412953e-08
% O 0 2.6199106883950662e-08
) O 0 8.759296399318828e-09
had O 0 1.8537267010287906e-07
significantly O 0 2.528165623516543e-07
lower O 0 8.794858530336569e-08
frequencies O 0 6.55358434187292e-08
of O 0 7.805434520946619e-09
the O 0 1.8841238613731548e-07
Tyr O 0 0.0011267156805843115
allele O 0 2.3218808564706706e-05
. O 0 1.818355826799234e-06

Comparisons O 0 0.00018837166135199368
with O 0 5.587214218394365e-06
allele O 0 4.9192381993634626e-05
frequencies O 0 3.954554813390132e-06
based O 0 2.3799302084626106e-07
on O 0 8.890536378203251e-07
prevalence O 0 0.0001340249291388318
estimates O 0 1.290741693082964e-06
of O 0 1.428202693887215e-07
HH B-Disease 1 0.9966425895690918
showed O 0 0.00037048369995318353
some O 0 4.364571282167162e-08
disagreements O 0 3.6938811831532803e-07
with O 0 2.4441455082069297e-08
the O 0 3.530932701778511e-08
RFLP O 0 0.0001916950714075938
data O 0 2.0152893398517335e-07
, O 0 7.599072660013917e-08
particularly O 0 1.4002554848957516e-07
in O 0 4.16814486925432e-07
Finns O 0 0.0006221036310307682
. O 0 4.207758138363715e-06

The O 0 6.287677479122067e-06
newly O 0 8.868275472195819e-06
described O 0 6.690406280540628e-06
HFE O 0 0.00034540597698651254
marker O 0 1.1332861504342873e-05
provides O 0 2.7250615630691755e-07
a O 0 8.142855278947536e-08
new O 0 5.4736162269364286e-08
approach O 0 9.927178012958393e-08
to O 0 2.1529556804011918e-08
the O 0 1.1661782650662644e-08
screening O 0 2.140145483053857e-07
of O 0 4.163099021070593e-08
HH B-Disease 0 0.45247429609298706
as O 0 1.1066332206155494e-07
well O 0 3.444944240982295e-08
as O 0 2.6791052931685044e-08
studies O 0 2.1494761526241746e-08
of O 0 3.3025209233983333e-09
the O 0 1.3281949762244949e-08
relationship O 0 1.5538725506303308e-07
between O 0 2.2638261043539387e-08
the O 0 1.584976416779682e-07
HFE O 0 0.004335995763540268
Tyr O 0 0.0009378657559864223
allele O 0 8.505902769684326e-06
and O 0 2.34043994851163e-07
different O 0 9.987160183300148e-07
disorders O 0 0.21432609856128693
including O 0 9.920938464347273e-05
cancer B-Disease 1 0.9965792298316956

Autosomal B-Disease 1 0.9994914531707764
dominant I-Disease 1 0.9942697286605835
neurohypophyseal I-Disease 1 0.9999393224716187
diabetes I-Disease 1 0.9999970197677612
insipidus I-Disease 1 0.9998449087142944
associated O 0 5.259035242488608e-05
with O 0 3.657383444988227e-07
a O 0 4.825835731026018e-06
missense O 0 0.0011126173194497824
mutation O 0 4.7182511480059475e-06
encoding O 0 8.795728376753686e-07
Gly23 O 0 2.1827316231792793e-05
- O 0 4.421570338308811e-05
- O 0 0.00016384513583034277
> O 0 1.056710425473284e-05
Val O 0 5.5732492910465226e-05
in O 0 3.364205554134969e-07
neurophysin O 0 0.00021293362078722566
II O 0 0.00017369346460327506
. O 0 2.5372212348884204e-06

Autosomal B-Disease 1 0.9994819760322571
dominant I-Disease 1 0.996917724609375
neurohypophyseal I-Disease 1 0.9999322891235352
diabetes I-Disease 1 0.9999970197677612
insipidus I-Disease 1 0.9998112320899963
( O 0 1.3414944987744093e-05
ADNDI B-Disease 0 0.019153540953993797
) O 0 5.391088393480459e-07
is O 0 2.2248177344863507e-07
an O 0 4.2411338654346764e-05
inherited B-Disease 1 0.9999988079071045
disease I-Disease 1 0.9999886751174927
caused O 0 0.0011720954207703471
by O 0 7.512259116992936e-07
progressive O 0 0.08166977018117905
degeneration O 0 0.10175170004367828
of O 0 5.871201480545096e-08
the O 0 2.871696835882176e-07
magnocellular O 0 0.00039077652036212385
neurons O 0 1.7028996808221564e-06
of O 0 6.87076751049176e-09
the O 0 1.771864965860459e-08
hypothalamus O 0 3.804651441896567e-06
leading O 0 4.0659284650246263e-07
to O 0 2.0187516724945453e-07
decreased O 0 1.3883244491808e-06
ability O 0 6.66359696310792e-08
to O 0 4.2830524904502454e-08
produce O 0 1.9866921263655968e-07
the O 0 1.4200794851149112e-07
hormone O 0 5.904830231884262e-06
arginine O 0 8.158755917975213e-06
vasopressin O 0 4.419601827976294e-05
( O 0 6.032610713191389e-07
AVP O 0 5.0915074098156765e-05
) O 0 1.4218617252481636e-06
. O 0 1.7083601733247633e-06

Affected O 0 0.00037048474769108
individuals O 0 2.8600748009921517e-06
are O 0 1.1442097758163072e-07
not O 0 1.9769247217027441e-07
symptomatic O 0 0.0005555953830480576
at O 0 1.5017766372693586e-06
birth O 0 2.6461304514668882e-05
, O 0 8.742409107753701e-08
but O 0 2.274899060239477e-07
usually O 0 1.5975614360286272e-06
develop O 0 0.0003516145225148648
diabetes B-Disease 1 0.9979249238967896
insipidus I-Disease 0 0.4013615846633911
at O 0 3.753310977572255e-07
1 O 0 2.9449660132740973e-07
- O 0 1.3730816135648638e-05
6 O 0 1.7345430478599155e-06
yr O 0 0.0003101045440416783
of O 0 1.4240002599308355e-07
age O 0 2.035888655882445e-06
. O 0 1.2264443967069383e-06

The O 0 5.819830221298616e-06
genetic O 0 2.2482707208837382e-05
locus O 0 1.6666846931912005e-05
of O 0 3.262914844981424e-07
the O 0 4.332157004682813e-06
disease O 0 0.0002442728728055954
is O 0 4.6752461457799654e-08
the O 0 4.5051624653069666e-08
AVP O 0 0.000199609188712202
- O 0 0.00797997321933508
neurophysin O 0 0.06509419530630112
II O 0 0.0004448298132047057
( O 0 8.9124242208527e-08
NPII O 0 2.0544293874991126e-05
) O 0 3.2529840154893463e-08
gene O 0 9.020232738521372e-08
, O 0 1.4040152152006158e-08
and O 0 5.5176826663227985e-08
mutations O 0 2.0079908154002624e-06
that O 0 5.919270762433371e-08
cause O 0 4.930411250825273e-06
ADNDI B-Disease 0 0.023962736129760742
have O 0 2.4574356416451337e-07
been O 0 5.984294659810985e-08
found O 0 3.278735150047396e-08
in O 0 9.25755649916482e-09
both O 0 4.631080852135483e-09
the O 0 4.039532264243917e-09
signal O 0 6.91647414896579e-08
peptide O 0 3.747205212789595e-08
of O 0 2.5443889217768856e-09
the O 0 1.8830778714118424e-08
prepro O 0 7.508072030759649e-06
- O 0 5.734599653806072e-06
AVP O 0 2.50917837547604e-05
- O 0 1.4688999726786278e-05
NPII O 0 2.4175744329113513e-05
precursor O 0 3.3555093637005484e-07
and O 0 4.023079469561708e-08
within O 0 5.2863722288520876e-08
NPII O 0 8.491769403917715e-05
itself O 0 4.13688576372806e-06
. O 0 1.5257330687745707e-06

An O 0 1.884097946458496e-05
affected O 0 8.592855920142028e-06
girl O 0 3.231684968341142e-05
who O 0 1.6976605365925934e-06
presented O 0 3.8122095702419756e-07
at O 0 2.0295361835565018e-08
9 O 0 7.772709409437084e-08
months O 0 1.1337657923604638e-07
of O 0 6.811930575167935e-09
age O 0 2.1654223303357867e-07
and O 0 2.6989283696821076e-08
her O 0 7.306127827177988e-06
similarly O 0 2.0445337213459425e-05
affected O 0 4.621712434982328e-07
younger O 0 7.385952471850032e-07
brother O 0 8.76654382864217e-07
and O 0 2.1886707557428053e-08
father O 0 7.031230779830366e-07
were O 0 2.494225626037405e-08
all O 0 4.937909636737459e-09
found O 0 2.5429105932062157e-08
to O 0 2.4222588379529952e-08
have O 0 2.8228422266352027e-08
a O 0 2.9753610419902543e-07
novel O 0 5.485062047227984e-06
missense O 0 9.499440056970343e-05
mutation O 0 2.3678508114244323e-06
( O 0 7.572031535119095e-08
G1758 O 0 7.813785487087443e-06
- O 0 6.438250420615077e-05
- O 0 0.0015307931462302804
> O 0 3.4208216675324365e-05
T O 0 4.862992136622779e-05
) O 0 8.490724567877805e-09
encoding O 0 1.845155850332958e-08
the O 0 6.0728750916894114e-09
amino O 0 2.5397161707019222e-08
acid O 0 4.9206128949208505e-08
substitution O 0 5.156364935032798e-08
Gly23 O 0 5.564815637626452e-06
- O 0 1.1647038263618015e-05
- O 0 7.760697189951316e-05
> O 0 1.2678660823439714e-05
Val O 0 0.00012321080430410802
within O 0 7.82005486144044e-07
NPII O 0 0.00013449836114887148
. O 0 3.6642404666054063e-06

The O 0 1.4789670785830822e-05
mutation O 0 0.0002719348995015025
was O 0 1.9564170088415267e-06
confirmed O 0 9.348316325485939e-07
by O 0 9.07116373127792e-08
restriction O 0 1.3345812703846605e-06
endonuclease O 0 0.0001531148300273344
analysis O 0 1.0431871487526223e-05
. O 0 3.982132511737291e-06

A O 0 9.846068860497326e-05
T1 O 0 0.0018879941198974848
- O 0 2.769673847069498e-05
weighted O 0 1.6732847143430263e-06
magnetic O 0 5.970994152448839e-06
resonance O 0 2.231149483122863e-05
imaging O 0 2.0363668227219023e-05
of O 0 4.5276372873104265e-08
the O 0 2.2740574934232427e-07
fathers O 0 1.5570571122225374e-05
pituitary O 0 0.0001022785872919485
gland O 0 2.0460804080357775e-05
demonstrates O 0 3.4414813399052946e-06
an O 0 6.100095788497129e-07
attenuated O 0 0.00027081670123152435
posterior O 0 0.0003369913320057094
pituitary O 0 0.0016070986166596413
bright O 0 0.00028897871379740536
spot O 0 4.6611636207671836e-05
. O 0 7.545584594481625e-06

This O 0 1.93791256606346e-05
mutation O 0 0.0010394495911896229
may O 0 2.6831100967683597e-06
be O 0 1.7878170055496412e-08
valuable O 0 4.533954012231334e-08
for O 0 2.0424325342105476e-08
developing O 0 1.5290045496385574e-07
models O 0 5.15108638410311e-07
of O 0 6.949745312567757e-08
dominantly B-Disease 1 0.7615037560462952
inherited I-Disease 1 0.9958814382553101
neurodegeneration I-Disease 1 0.999998927116394
, O 0 3.852162251405389e-07
as O 0 2.0002561385012996e-08
the O 0 7.569732396461859e-09
early O 0 1.5105155171113438e-07
age O 0 1.8589490480280801e-07
of O 0 2.0478703177673196e-08
onset O 0 0.00011481485125841573
of O 0 1.5220707609842066e-06
symptoms O 1 0.8184015154838562
suggests O 0 7.091568932082737e-07
that O 0 2.5638277278972055e-08
this O 0 5.024980609391605e-08
mutation O 0 4.2603833207977004e-06
may O 0 2.1224683166565228e-07
be O 0 1.2533146076521007e-08
particularly O 0 6.941545649397085e-08
deleterious O 0 4.933510808768915e-06
to O 0 2.402249776878307e-07
the O 0 2.8089860393265553e-07
magnocellular O 0 0.0009619205957278609
neuron O 0 0.0009510891977697611
. O 0 5.628805297419603e-07
. O 0 1.0611371408231207e-06

Frequent O 0 0.0006694531184621155
inactivation O 0 0.0016844260971993208
of O 0 4.472679393074941e-06
PTEN O 0 0.2281016856431961
/ O 0 0.00034194838372059166
MMAC1 O 0 0.0021276697516441345
in O 0 8.666784196975641e-06
primary O 1 0.6824472546577454
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999986886978149
. O 0 4.616995283868164e-05

Sporadic B-Disease 1 0.9995090961456299
prostate I-Disease 1 0.9999994039535522
carcinoma I-Disease 1 1.0
is O 0 9.667280210123863e-06
the O 0 2.6351241899646993e-07
most O 0 3.030814070825727e-07
common O 0 2.9398968308669282e-06
male B-Disease 0 0.2697244882583618
cancer I-Disease 0 0.1089550033211708
in O 0 5.1927049327105124e-08
the O 0 2.8638249105483737e-08
Western O 0 8.444102661542274e-08
world O 0 5.4048335584866436e-08
, O 0 1.596560039729411e-08
yet O 0 4.229391947774275e-08
many O 0 1.4421592808844252e-09
of O 0 7.054309358878186e-10
the O 0 4.090610961071661e-09
major O 0 3.8478439989830804e-08
genetic O 0 1.4219145327842853e-07
events O 0 8.076063373607667e-09
involved O 0 1.4990799712677472e-08
in O 0 1.0342000145158181e-08
the O 0 2.3122437298184195e-08
progression O 0 8.746894195610366e-07
of O 0 1.196055698926557e-08
this O 0 1.0320781029804493e-07
often O 0 3.125283546978608e-05
fatal O 1 0.9998921155929565
cancer B-Disease 1 0.9968474507331848
remain O 0 2.1937378278380493e-06
to O 0 3.491963980195578e-07
be O 0 4.3210104649915593e-07
elucidated O 0 0.0001427119132131338
. O 0 3.74566934624454e-06

Numerous O 0 7.378057489404455e-05
cytogenetic O 0 0.019734352827072144
and O 0 5.22026994076441e-06
allelotype O 0 0.0030017162207514048
studies O 0 2.779778242256725e-06
have O 0 3.114528510650416e-07
reported O 0 1.9654214611364296e-06
frequent O 0 3.888966602971777e-06
loss O 0 1.2435618373274338e-05
of O 0 8.001214268915646e-08
heterozygosity O 0 0.00011882693797815591
on O 0 2.07331640922348e-06
chromosomal O 0 0.00023861974477767944
arm O 0 0.00024977538851089776
10q O 0 0.00028417122666724026
in O 0 7.333631401706953e-06
sporadic B-Disease 1 0.9972302317619324
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999980926513672
. O 0 7.829336391296238e-05

Deletion O 0 0.0995234027504921
mapping O 0 0.00029358186293393373
studies O 0 1.1011701644747518e-05
have O 0 6.346574537019478e-07
unambiguously O 0 4.179431198281236e-05
identified O 0 9.849977686826605e-07
a O 0 2.9583253535747644e-07
region O 0 7.822905701004856e-08
of O 0 2.1671487715479998e-08
chromosome O 0 1.5918240023893304e-05
10q23 O 0 1.129802785726497e-05
to O 0 6.839847088713213e-08
be O 0 1.528337811862457e-08
the O 0 2.1774367198190703e-08
minimal O 0 6.540647632391483e-07
area O 0 1.2723356235255778e-07
of O 0 8.830745912291604e-08
loss O 0 0.0001454152661608532
. O 0 5.231912382441806e-06

A O 0 5.912932101637125e-05
new O 0 7.505623671022477e-06
tumor B-Disease 0 0.00024501181906089187
suppressor O 0 0.00011449636804172769
gene O 0 5.1193155741202645e-06
, O 0 5.248916750133503e-07
PTEN O 0 0.001695502083748579
/ O 0 7.22810800652951e-05
MMAC1 O 0 0.0014509173342958093
, O 0 1.3547818866754824e-07
was O 0 2.7493484822116443e-07
isolated O 0 3.5859829949913546e-07
recently O 0 5.338041546565364e-07
at O 0 9.526279320937192e-09
this O 0 6.132061969310598e-09
region O 0 1.410989813876995e-08
of O 0 9.933765809932993e-09
chromosome O 0 6.835999556642491e-06
10q23 O 0 2.3752692868583836e-05
and O 0 6.165817723058353e-08
found O 0 5.520956491977813e-08
to O 0 2.208808957959718e-08
be O 0 2.4865542513907712e-08
inactivated O 0 9.6383155323565e-07
by O 0 3.782217561365542e-08
mutation O 0 8.016472179406264e-07
in O 0 2.9268616685840243e-07
three O 0 0.01497700810432434
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
cell O 0 0.33979934453964233
lines O 0 9.282369865104556e-05
. O 0 2.727474111452466e-06

We O 0 2.569743082858622e-05
screened O 0 0.0007375329732894897
80 O 0 0.0010218097595497966
prostate B-Disease 1 0.999915361404419
tumors I-Disease 1 0.9999898672103882
by O 0 9.356906502944184e-07
microsatellite O 0 0.00044156951480545104
analysis O 0 1.5708388900748105e-06
and O 0 1.7098926718972507e-07
found O 0 4.406730624850752e-07
chromosome O 0 9.64419450610876e-06
10q23 O 0 1.1523780813149642e-05
to O 0 8.277351781771358e-08
be O 0 2.6744643832898873e-08
deleted O 0 1.0413912150397664e-06
in O 0 1.540200429417382e-07
23 O 0 4.4879334382130764e-06
cases O 0 2.200999006163329e-06
. O 0 3.416843128434266e-06

We O 0 3.2365207971452037e-06
then O 0 4.3007219119317597e-07
proceeded O 0 5.720740432479943e-07
with O 0 2.5337746123454963e-08
sequence O 0 7.56318385697341e-08
analysis O 0 3.530286107888969e-08
of O 0 3.499726286548821e-09
the O 0 2.9716993310557882e-08
entire O 0 8.435480367552373e-07
PTEN O 0 0.0011052354238927364
/ O 0 3.0871953640598804e-05
MMAC1 O 0 0.0009531856048852205
coding O 0 6.442760422942229e-06
region O 0 1.6386344725560775e-07
and O 0 4.7115641166328714e-08
tested O 0 3.344181038755778e-07
for O 0 2.5238483303269277e-08
homozygous O 0 5.425415565696312e-06
deletion O 0 3.575844857550692e-06
with O 0 3.626004740908684e-08
new O 0 1.1005037947597884e-07
intragenic O 0 0.000157620117533952
markers O 0 3.357972445883206e-06
in O 0 5.595142482661686e-08
these O 0 2.4376646479140618e-08
23 O 0 4.406041398397065e-07
cases O 0 7.215766117951716e-08
with O 0 2.7445520345281693e-07
10q23 O 0 0.0007905579986982048
loss O 0 3.251738962717354e-05
of O 0 7.047234475976438e-07
heterozygosity O 0 0.001543947495520115
. O 0 1.4229960470402148e-05

The O 0 1.4125415646049078e-06
identification O 0 3.5197379588680633e-07
of O 0 2.2618579009758832e-08
the O 0 2.7265217639182993e-08
second O 0 5.536637104341935e-07
mutational O 0 0.0004934925818815827
event O 0 1.2695592204181594e-06
in O 0 1.1246606845816132e-07
10 O 0 1.0262911587233248e-07
( O 0 5.5774016516352276e-08
43 O 0 1.7886700334202033e-06
% O 0 3.7442549682964454e-07
) O 0 8.437870064881281e-07
tumors B-Disease 1 0.9997401833534241
establishes O 0 0.0002574908430688083
PTEN O 0 0.30131837725639343
/ O 0 3.638341149780899e-05
MMAC1 O 0 5.46862866031006e-05
as O 0 4.580273582632799e-08
a O 0 1.319353373219201e-07
main O 0 1.7421609754819656e-07
inactivation O 0 2.580462933110539e-05
target O 0 1.7195407053804956e-07
of O 0 2.789609254705283e-08
10q O 0 2.374496943957638e-05
loss O 0 1.5780649846419692e-05
in O 0 1.6971343939076178e-06
sporadic B-Disease 1 0.9996459484100342
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 5.252343726169784e-06
. O 0 3.7524307572311955e-06

Risk O 0 0.0016166706336662173
reversals O 0 0.0008359318017028272
in O 0 8.48444142320659e-06
predictive O 0 7.559934601886198e-05
testing O 0 2.9554021239164285e-05
for O 0 7.147718861233443e-05
Huntington B-Disease 1 0.9999909400939941
disease I-Disease 1 0.9998629093170166
. O 0 1.7308437236351892e-05

The O 0 2.65366725216154e-06
first O 0 1.5106667206055135e-06
predictive O 0 1.1841681953228544e-05
testing O 0 9.539094207866583e-06
for O 0 2.943358413176611e-05
Huntington B-Disease 1 0.9999959468841553
disease I-Disease 1 0.9999743700027466
( O 0 1.3452997791318921e-06
HD B-Disease 0 0.0002769713173620403
) O 0 3.6584260953986814e-08
was O 0 6.059409685121864e-08
based O 0 1.4163338057926467e-08
on O 0 2.102464691233763e-08
analysis O 0 8.279025820456809e-08
of O 0 1.8145549063319777e-08
linked O 0 2.7399071313993772e-06
polymorphic O 0 4.80176713608671e-05
DNA O 0 1.2209105989313684e-05
markers O 0 7.187606456682261e-07
to O 0 6.340707159324666e-08
estimate O 0 1.4786290591928264e-07
the O 0 9.323795957527636e-09
likelihood O 0 8.468038004139089e-08
of O 0 1.2714739483499216e-08
inheriting O 0 1.4319139154395089e-06
the O 0 1.5248225793129677e-07
mutation O 0 3.1982897326088278e-06
for O 0 3.3700371204758994e-07
HD B-Disease 0 0.000753136002458632
. O 0 3.688249307742808e-06

Limits O 0 2.36375599342864e-05
to O 0 1.1035239140255726e-06
accuracy O 0 1.8878087075790972e-06
included O 0 1.9620993896296568e-07
recombination O 0 8.199270951081417e-07
between O 0 6.475170266639907e-08
the O 0 4.585361068620841e-08
DNA O 0 3.0039914236112963e-06
markers O 0 7.328943070206151e-07
and O 0 3.069096976560104e-08
the O 0 4.272877163202793e-08
mutation O 0 7.837464863769128e-07
, O 0 3.3347919980997176e-08
pedigree O 0 1.606643081686343e-06
structure O 0 1.6871889840786025e-07
, O 0 1.7210886937846226e-08
and O 0 1.5491902871644925e-08
whether O 0 4.9396454926409206e-08
DNA O 0 3.6937152003702067e-07
samples O 0 7.922943723315257e-08
were O 0 2.402803644940832e-08
available O 0 2.333131909892927e-08
from O 0 1.942430571943987e-08
family O 0 1.9999285427729774e-07
members O 0 1.317996236593899e-07
. O 0 7.922684517325251e-07

With O 0 1.9567976323742187e-06
direct O 0 1.1843756055895938e-06
tests O 0 7.253450462485489e-07
for O 0 2.0476123907542387e-08
the O 0 1.450317341777918e-07
HD B-Disease 0 0.0029478424694389105
mutation O 0 1.2290543054405134e-06
, O 0 1.383160430634689e-08
we O 0 8.703705312029797e-09
have O 0 1.585892128730393e-08
assessed O 0 5.602179342645286e-08
the O 0 6.478515057750656e-09
accuracy O 0 2.2323456505546346e-07
of O 0 1.87842861265608e-08
results O 0 1.539149138807261e-06
obtained O 0 1.0009408413225174e-07
by O 0 1.2642387581252024e-08
linkage O 0 4.6330802661032067e-07
approaches O 0 3.291279710992967e-07
when O 0 1.285027622088819e-07
requested O 0 1.3629110640067665e-07
to O 0 2.235596063826506e-08
do O 0 2.176365399009228e-08
so O 0 1.4625311628435611e-08
by O 0 9.377211007688402e-09
the O 0 3.2941677829967375e-08
test O 0 1.2409592500262079e-06
individuals O 0 2.8686639552688575e-07
. O 0 7.354871058851131e-07

For O 0 2.5725894374772906e-06
six O 0 1.1101992640760727e-06
such O 0 4.4546549560209314e-08
individuals O 0 3.376908352947794e-08
, O 0 2.383536568117961e-08
there O 0 2.1973209030079488e-08
was O 0 1.438627492689193e-07
significant O 0 8.956969566042972e-08
disparity O 0 8.617266757937614e-07
between O 0 6.795335849574258e-08
the O 0 1.2856882847245288e-07
tests O 0 3.412834075788851e-06
. O 0 2.199322580054286e-06

Three O 0 9.402317118656356e-06
went O 0 2.0493141619226662e-06
from O 0 7.55464881763146e-08
a O 0 6.106679393269587e-07
decreased O 0 1.3549718460126314e-05
risk O 0 2.7008448455489997e-07
to O 0 3.300142381590376e-08
an O 0 6.95026258767939e-08
increased O 0 1.7040287048075697e-06
risk O 0 6.391655915649608e-07
, O 0 2.0339887996101425e-08
while O 0 1.6451648932047647e-08
in O 0 7.568533355595264e-09
another O 0 6.116213313589469e-08
three O 0 4.1095539415891835e-08
the O 0 8.675847595895902e-08
risk O 0 1.0192871968683903e-06
was O 0 1.2292898645682726e-06
decreased O 0 9.38373887038324e-06
. O 0 1.2227737897774205e-06

Knowledge O 0 7.997954526217654e-06
of O 0 1.7965683696274937e-07
the O 0 5.472216813018349e-08
potential O 0 1.1387688658714978e-07
reasons O 0 7.587919981233426e-08
for O 0 9.142237189507796e-09
these O 0 5.570084393724528e-09
changes O 0 8.428815334582396e-08
in O 0 5.083117571302864e-08
results O 0 5.424000164566678e-07
and O 0 1.854725084626807e-08
impact O 0 7.23426012427808e-08
of O 0 6.803529295495991e-09
these O 0 1.7887140657535383e-08
risk O 0 1.745705162647937e-07
reversals O 0 2.7807043807115406e-05
on O 0 4.4156890908197965e-06
both O 0 1.950554178620223e-06
patients O 0 0.00021161882614251226
and O 0 2.4435767187469537e-08
the O 0 2.9121654421260246e-08
counseling O 0 3.5231565220783523e-07
team O 0 3.621083877192177e-08
can O 0 1.1422163659347007e-08
assist O 0 2.2942234778611237e-08
in O 0 1.082004263963654e-08
the O 0 6.568122934424991e-09
development O 0 6.623350756740365e-09
of O 0 5.947866643651878e-09
strategies O 0 1.3576222102074098e-07
for O 0 1.7360436643798494e-08
the O 0 8.190269795704808e-08
prevention O 0 2.5779261250136187e-06
and O 0 1.3825952294155286e-07
, O 0 3.339272680591421e-08
where O 0 2.8791054873522626e-08
necessary O 0 3.025886385898957e-08
, O 0 2.1801545457833527e-08
management O 0 1.3512251761937932e-08
of O 0 2.1554362739095723e-09
a O 0 7.942505249047827e-07
risk O 0 1.5354603419837076e-06
reversal O 0 1.6677038729540072e-05
in O 0 4.249526597277509e-08
any O 0 2.3200721344096564e-08
predictive O 0 6.45829061340919e-07
testing O 0 4.897597705166845e-07
program O 0 3.8071959806984523e-07
. O 0 3.110927764282678e-07
. O 0 1.727731500977825e-06

A O 0 0.0001282150042243302
novel O 0 6.320400279946625e-05
common O 0 5.250361027719919e-06
missense O 0 0.0010757558047771454
mutation O 0 2.5682515115477145e-05
G301C O 0 1.6636149666737765e-05
in O 0 8.88987727876156e-08
the O 0 3.45282487046461e-08
N O 0 7.684932825213764e-06
- O 0 2.4923649107222445e-05
acetylgalactosamine O 0 0.0001271487126359716
- O 0 2.423948717478197e-05
6 O 0 1.2280723922231118e-06
- O 0 0.00013621104881167412
sulfate O 0 0.0009495943086221814
sulfatase O 0 0.00010607971489662305
gene O 0 1.8982218534802087e-06
in O 0 5.92747255723225e-07
mucopolysaccharidosis B-Disease 0 0.00038838403997942805
IVA I-Disease 0 0.003417304949834943
. O 0 9.8568489192985e-06

Mucopolysaccharidosis B-Disease 1 0.9591901302337646
IVA I-Disease 1 0.9979941844940186
( O 0 0.00826595164835453
MPS B-Disease 1 0.9999703168869019
IVA I-Disease 1 0.9999133348464966
) O 0 2.7764110654970864e-06
is O 0 5.387320811678364e-07
an O 0 4.212070507492172e-06
autosomal B-Disease 1 0.988186240196228
recessive I-Disease 1 0.9948398470878601
lysosomal I-Disease 1 0.9925844073295593
storage I-Disease 1 0.9934505224227905
disorder I-Disease 1 0.999432384967804
caused O 0 3.175769961671904e-05
by O 0 2.9788790811835497e-07
a O 0 0.0023474141489714384
genetic B-Disease 1 0.9998353719711304
defect I-Disease 1 0.9996956586837769
in O 0 9.669580549598322e-07
N O 0 2.3730504835839383e-05
- O 0 2.6497667931835167e-05
acetylgalactosamine O 0 0.00015191490820143372
- O 0 0.00010365988418925554
6 O 0 2.551350235080463e-06
- O 0 0.00037623397656716406
sulfate O 0 0.01940092444419861
sulfatase O 0 0.0006086502107791603
( O 0 9.290936873185274e-07
GALNS O 0 7.194508361862972e-05
) O 0 5.96814288655878e-07
. O 0 1.4906723890817375e-06

In O 0 6.790996394556714e-06
previous O 0 1.7857008742794278e-06
studies O 0 2.1149052997770923e-07
, O 0 2.2458449322471097e-08
we O 0 1.2544099092792749e-08
have O 0 1.620097833665568e-08
found O 0 2.5001984482742046e-08
two O 0 2.4994069036665678e-08
common O 0 2.75200875421433e-07
mutations O 0 2.5726410513016162e-06
in O 0 6.998644153100031e-08
Caucasians O 0 2.660011887201108e-06
and O 0 1.759264449674447e-07
Japanese O 0 1.3519492085833917e-06
, O 0 4.115084664135793e-07
respectively O 0 2.9700418053835165e-06
. O 0 1.499476866229088e-06

To O 0 1.1440430171205662e-05
characterize O 0 3.7374309613369405e-05
the O 0 1.3534133813664084e-06
mutational O 0 0.0030887392349541187
spectrum O 0 4.910394272883423e-05
in O 0 6.621888104518803e-08
various O 0 1.2119538261856633e-08
ethnic O 0 1.7918867456501175e-07
groups O 0 7.423833636721611e-08
, O 0 1.0243922332620059e-07
mutations O 0 7.501591881009517e-07
in O 0 1.502036539591245e-08
the O 0 2.8683183828093206e-08
GALNS O 0 0.0002510378835722804
gene O 0 7.866353826102568e-07
in O 0 1.056256948572809e-07
Colombian O 0 3.672748789540492e-05
MPS B-Disease 1 0.9999884366989136
IVA I-Disease 1 0.999996542930603
patients O 1 0.9974429607391357
were O 0 1.1535363455550396e-06
investigated O 0 6.943630523892352e-06
, O 0 9.618080554218977e-08
and O 0 1.4885996790781064e-07
genetic O 0 2.0348463749542134e-06
backgrounds O 0 2.454662535456009e-07
were O 0 7.541115820686173e-08
extensively O 0 5.052283995610196e-07
analyzed O 0 5.594719709733909e-07
to O 0 4.2045869008688896e-08
identify O 0 1.5445323242602171e-07
racial O 0 1.2072291610820685e-07
origin O 0 6.218184722683873e-08
, O 0 3.25853548588384e-08
based O 0 5.692962901093779e-08
on O 0 2.894970805300545e-07
mitochondrial O 0 0.00011933758651139215
DNA O 0 1.3379581105255056e-05
( O 0 2.6052808266285865e-07
mtDNA O 0 2.2499709757539677e-06
) O 0 2.2119441211998492e-07
lineages O 0 2.3156039787863847e-06
. O 0 1.575856458657654e-06

Three O 0 2.902270898630377e-05
novel O 0 7.825969805708155e-05
missense O 0 0.03154268115758896
mutations O 0 0.0008147085318341851
never O 0 3.4831077755370643e-06
identified O 0 8.843166483529785e-07
previously O 0 1.457975287166846e-07
in O 0 2.2994806059273287e-08
other O 0 1.10524895902131e-08
populations O 0 3.523666691762628e-08
and O 0 3.529195780060945e-08
found O 0 6.302268218405516e-08
in O 0 1.2673869953516714e-08
16 O 0 2.6870836222769867e-08
out O 0 1.5964960908831927e-08
of O 0 1.5517423790356588e-08
19 O 0 1.3284833357829484e-06
Colombian O 0 1.2255066394573078e-05
MPS B-Disease 1 0.9996722936630249
IVA I-Disease 1 0.9992783665657043
unrelated O 0 6.627537368331105e-05
alleles O 0 6.555699201271636e-06
account O 0 9.90051262306224e-07
for O 0 3.2449102604914515e-07
84 O 0 1.6730882634874433e-05
. O 0 4.288645868655294e-06

2 O 0 2.294049772899598e-05
% O 0 3.7804224461979175e-07
of O 0 1.1410557831936785e-08
the O 0 4.720820712122986e-08
alleles O 0 1.0021612979471684e-06
in O 0 8.069415002864844e-08
this O 0 1.999331686874939e-07
study O 0 2.2364376945915865e-06
. O 0 2.0575037069647806e-06

The O 0 1.111468554881867e-05
G301C O 0 9.181896166410297e-05
and O 0 1.5804014310560888e-06
S162F O 0 0.00019300695566926152
mutations O 0 1.935310683620628e-05
account O 0 8.27472206310631e-07
for O 0 3.485858428575739e-07
68 O 0 2.3622935259481892e-05
. O 0 4.880021151620895e-06

4 O 0 0.00015788408927619457
% O 0 4.490613719099201e-06
and O 0 6.299365509221388e-07
10 O 0 2.1086509605083847e-06
. O 0 2.095540139634977e-06

5 O 0 3.567583917174488e-05
% O 0 1.2535018640846829e-06
of O 0 8.536243711887437e-08
mutations O 0 1.4091606317379046e-05
, O 0 1.3921093966473563e-07
respectively O 0 3.5536211839826137e-07
, O 0 2.4364746664673476e-08
whereas O 0 2.3317793917954077e-08
the O 0 6.179508460490979e-09
remaining O 0 5.1465590900079405e-08
F69V O 0 6.617773760808632e-05
is O 0 1.766438906258827e-08
limited O 0 3.763600986417259e-08
to O 0 2.020324707530108e-08
a O 0 1.5506098804962676e-07
single O 0 4.430169155966723e-06
allele O 0 1.8151287804357708e-05
. O 0 1.5715821746198344e-06

The O 0 7.272662514878903e-06
skewed O 0 0.00015856075333431363
prevalence O 0 5.823170067742467e-05
of O 0 1.1250553910713279e-07
G301C O 0 4.1565213905414566e-05
in O 0 1.6800919411252835e-07
only O 0 1.4079121513077553e-07
Colombian O 0 2.6223331587971188e-05
patients O 0 0.004178921226412058
and O 0 5.63615344617574e-07
haplotype O 0 0.004875815473496914
analysis O 0 1.1523736276330965e-07
by O 0 1.3874143611758427e-08
restriction O 0 1.3140116550403036e-07
fragment O 0 1.837894387790584e-06
length O 0 1.58834313879197e-06
polymorphisms O 0 1.5713333141320618e-06
in O 0 2.918437758125947e-08
the O 0 3.7513743222916673e-08
GALNS O 0 0.0002656932338140905
gene O 0 6.381594630511245e-07
suggest O 0 2.6087715809808287e-07
that O 0 5.248205425800734e-08
G301C O 0 4.724139671452576e-06
originated O 0 2.1940483918569953e-07
from O 0 2.7219648757181858e-08
a O 0 2.691793383746699e-07
common O 0 5.271139116302948e-07
ancestor O 0 3.97751000491553e-06
. O 0 2.3752509150654078e-06

Investigation O 0 6.347266753436998e-05
of O 0 5.949866022092465e-07
the O 0 3.1237050279742107e-07
genetic O 0 1.3328310615179362e-06
background O 0 4.997414748686424e-07
by O 0 3.373225965219717e-08
means O 0 2.186501113499162e-08
of O 0 8.7131732939838e-09
mtDNA O 0 1.2786516663254588e-06
lineages O 0 1.53002133629343e-07
indicate O 0 4.836460121282471e-08
that O 0 6.441354560848822e-09
all O 0 5.022601445858754e-09
our O 0 1.5247717044530873e-07
patients O 0 4.162805271334946e-05
are O 0 1.8542440471946975e-08
probably O 0 9.288635993698335e-08
of O 0 1.5574652678651546e-08
native O 0 2.959722280593269e-07
American O 0 2.935187922048499e-06
descent O 0 0.00016851129475980997

Low O 0 0.00017956682131625712
frequency O 0 3.3351563615724444e-05
of O 0 1.2806029872081126e-06
BRCA1 O 0 0.002474929438903928
germline O 0 0.002525849500671029
mutations O 0 0.00012450510985217988
in O 0 5.993158538331045e-07
45 O 0 1.916839937621262e-05
German O 1 0.9896676540374756
breast B-Disease 1 0.9999971389770508
/ I-Disease 1 0.9999990463256836
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 0.00018039243877865374
. O 0 9.788614988792688e-06

In O 0 1.542108293506317e-05
this O 0 4.277211189673835e-07
study O 0 3.377037671725702e-07
we O 0 7.565116533214677e-08
investigated O 0 1.7375944025843637e-06
45 O 0 5.7881475186150055e-06
German O 1 0.8421165347099304
breast B-Disease 1 0.9999924898147583
/ I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 6.947147539904108e-06
for O 0 7.288050483111874e-07
germline O 0 0.08162277936935425
mutations O 0 3.719280721270479e-05
in O 0 1.658230104339964e-07
the O 0 7.103082566572994e-07
BRCA1 O 0 0.000836662482470274
gene O 0 1.017487738863565e-05
. O 0 2.0031632175232517e-06

We O 0 4.370325768832117e-06
identified O 0 1.858977043411869e-06
four O 0 2.838484078893089e-07
germline O 0 8.925906149670482e-05
mutations O 0 8.498247552779503e-06
in O 0 3.003771382736886e-07
three O 0 0.0001972980535356328
breast B-Disease 1 0.9999872446060181
cancer I-Disease 1 0.999817430973053
families O 0 2.118079237334314e-06
and O 0 8.492671810245156e-08
in O 0 2.0316359439220832e-07
one O 0 2.5172166715492494e-05
breast B-Disease 1 0.9999600648880005
- I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 4.257497494108975e-05
. O 0 7.768336729441216e-08
among O 0 1.9919713878380207e-08
these O 0 5.397372326854111e-09
were O 0 2.7859828222176475e-08
one O 0 2.1433643837553973e-07
frameshift O 0 0.35848259925842285
mutation O 0 3.5266432405478554e-06
, O 0 3.554339045308552e-08
one O 0 6.465075585992963e-08
nonsense O 0 1.7730228137224913e-05
mutation O 0 2.2577432901016437e-06
, O 0 2.043204005985899e-08
one O 0 2.4224714678666714e-08
novel O 0 3.572779974092555e-07
splice O 0 6.853154445707332e-06
site O 0 1.555653398099821e-06
mutation O 0 1.5394808769997326e-06
, O 0 2.7634166954726425e-08
and O 0 5.630889177155041e-08
one O 0 8.543082685719128e-07
missense O 0 0.0008312167483381927
mutation O 0 3.720749373314902e-05
. O 0 2.655832076925435e-06

The O 0 3.90490131394472e-05
missense O 0 0.05214281752705574
mutation O 0 0.0005171452648937702
was O 0 2.076815007967525e-06
also O 0 3.057732840261451e-07
found O 0 3.347276162912749e-07
in O 0 1.838813261656469e-07
2 O 0 3.022304554178845e-06
. O 0 2.738394641710329e-06

8 O 0 3.805197775363922e-05
% O 0 1.0927402627203264e-06
of O 0 1.9129691608554822e-08
the O 0 2.723231773416046e-08
general O 0 1.452482223385232e-07
population O 0 7.651503608485655e-08
, O 0 3.5505376416722356e-08
suggesting O 0 2.170388313516014e-07
that O 0 2.275705490717428e-08
it O 0 3.8187227602293206e-08
is O 0 1.9509452897636947e-07
not O 0 2.669725290616043e-06
disease O 0 0.00020867625426035374
associated O 0 3.528688239384792e-06
. O 0 3.4039048841805197e-06

The O 0 2.713862386372057e-06
average O 0 6.201162705110619e-06
age O 0 1.0079679668706376e-06
of O 0 4.4393959797162097e-07
disease O 0 0.021656669676303864
onset O 0 0.026457814499735832
in O 0 3.2793780064821476e-06
those O 0 3.009230624684278e-07
families O 0 7.511027320106223e-07
harbouring O 0 0.0004854778235312551
causative O 0 0.0007142699905671179
mutations O 0 3.510210081003606e-05
was O 0 7.007593580965477e-07
between O 0 2.673697565569455e-07
32 O 0 4.1078642425418366e-06
. O 0 2.382692400715314e-06

3 O 0 6.685739936074242e-05
and O 0 5.191518994251965e-06
37 O 0 3.348628160892986e-05
. O 0 7.884117621870246e-06

4 O 0 9.589205728843808e-05
years O 0 7.728234777459875e-06
, O 0 2.1033918073953828e-07
whereas O 0 1.7195883117437916e-07
the O 0 2.7924519585553753e-08
family O 0 2.496939544016641e-07
harbouring O 0 5.310142569214804e-06
the O 0 2.5601804054531385e-07
missense O 0 0.0007016268791630864
mutation O 0 7.066784746712074e-06
had O 0 1.2950667382938263e-07
an O 0 3.8035736338315473e-08
average O 0 4.0092609765451925e-07
age O 0 9.523267863187357e-08
of O 0 2.235391427518607e-08
onset O 0 1.8775581338559277e-05
of O 0 3.910668908702064e-07
51 O 0 5.568920460063964e-05
. O 0 4.834799710806692e-06

2 O 0 0.00031048821983858943
years O 0 4.8349789722124115e-05
. O 0 1.5245740542013664e-05

These O 0 9.80158984020818e-06
findings O 0 2.7496802431414835e-05
show O 0 2.7682017389452085e-06
that O 0 2.926574325101683e-07
BRCA1 O 0 0.00010474544251337647
is O 0 3.2445203146380663e-07
implicated O 0 1.966568788702716e-06
in O 0 4.0395335076937045e-08
a O 0 1.0309468478908457e-07
small O 0 6.851376355143657e-08
fraction O 0 4.598761904617277e-07
of O 0 1.4721582601850969e-06
breast B-Disease 1 0.9999921321868896
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 5.9632320699165575e-06
suggesting O 0 9.429781471226306e-07
the O 0 3.7737002855919854e-08
involvement O 0 2.790056896628812e-07
of O 0 3.468600695555324e-08
another O 0 3.889010713464813e-06
susceptibility O 0 0.023190723732113838
gene O 0 1.0864051546377596e-05
( O 0 8.792507628641033e-07
s O 0 0.0001269234053324908
) O 0 3.698216687553213e-06

Paternal O 1 0.9268045425415039
transmission O 1 0.8279707431793213
of O 0 0.0005220455932430923
congenital B-Disease 1 0.9999988079071045
myotonic I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.012801747769117355

We O 0 1.135983802669216e-05
report O 0 2.1492421637958614e-06
a O 0 6.935377427907952e-07
rare O 0 3.9924675547808874e-06
case O 0 3.944087893614778e-06
of O 0 9.84180815066793e-07
paternally O 1 0.9564679861068726
transmitted O 1 0.9998615980148315
congenital B-Disease 1 0.9999995231628418
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.14984188973903656
DM B-Disease 1 0.9999991655349731
) O 0 1.845939550548792e-05
. O 0 5.727068582928041e-06

The O 0 4.1549228626536205e-06
proband O 0 7.438813190674409e-05
is O 0 2.2618327477630373e-07
a O 0 5.104774913888832e-07
23 O 0 8.111463216664561e-07
year O 0 2.2569071234102012e-07
old O 0 4.552734480967047e-06
, O 0 1.1398960850783624e-06
mentally B-Disease 1 0.9996067881584167
retarded I-Disease 1 0.9999145269393921
male O 0 0.025668201968073845
who O 0 0.0047636027447879314
suffers O 1 0.9999208450317383
severe O 1 0.9997997879981995
muscular B-Disease 1 0.9999440908432007
weakness I-Disease 1 0.9944724440574646
. O 0 3.1261271942639723e-05

He O 0 6.91809254931286e-05
presented O 0 2.1171474145376123e-05
with O 0 1.317245278187329e-05
respiratory O 1 0.9920845031738281
and O 0 4.300375167076709e-06
feeding O 0 5.498498649103567e-05
difficulties O 0 3.1358162232209e-05
at O 0 1.4331584452520474e-06
birth O 0 3.130879485979676e-05
. O 0 2.4038592982833507e-06

His O 0 5.4672003898303956e-05
two O 0 1.522969705547439e-05
sibs O 1 0.9610937833786011
suffer O 1 0.8404184579849243
from O 0 9.262244930141605e-06
childhood O 0 0.06088895723223686
onset O 1 0.9917765855789185
DM B-Disease 1 0.9999971389770508
. O 0 0.00032451999140903354

Their O 0 7.957858542795293e-06
late O 0 6.2082576732791495e-06
father O 0 5.590774890151806e-06
had O 0 2.5854404839265044e-07
the O 0 2.5494422573046904e-08
adult O 0 6.761984536751697e-07
type O 0 6.03757200678956e-07
of O 0 2.629917048579955e-07
DM B-Disease 1 0.9999997615814209
, O 0 2.3044433419272536e-06
with O 0 3.2828910434545833e-07
onset O 0 4.38661954831332e-05
around O 0 3.542901083619654e-07
30 O 0 9.342318776361935e-07
years O 0 9.921988066707854e-07
. O 0 1.6751178009144496e-06

Only O 0 1.0163375009142328e-05
six O 0 1.962840315172798e-06
other O 0 5.710973383088458e-08
cases O 0 1.1956922207900789e-07
of O 0 4.7976143946470984e-08
paternal O 0 0.01135479100048542
transmission O 0 0.017251893877983093
of O 0 5.9773479733848944e-05
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 1.0
have O 0 0.00023365102242678404
been O 0 2.657790673765703e-06
reported O 0 1.5992876797099598e-05
recently O 0 6.234874490473885e-06
. O 0 3.312431772428681e-06

We O 0 3.591737367969472e-06
review O 0 2.696031970117474e-06
the O 0 1.3111700525314518e-07
sex O 0 1.7275237951253075e-06
related O 0 4.0984158999890496e-07
effects O 0 3.7219867863313993e-06
on O 0 8.737508323974907e-06
transmission O 0 0.01974412240087986
of O 0 3.738482701010071e-05
congenital B-Disease 1 0.9999982118606567
DM I-Disease 1 0.9999997615814209
. O 0 0.0007560350350104272

Decreased O 0 0.005756309721618891
fertility O 0 0.00011274930147919804
of O 0 2.6820765697266324e-07
males O 0 2.3659183625568403e-06
with O 0 5.950915920038824e-07
adult O 0 0.0005398142384365201
onset O 0 0.2597637474536896
DM B-Disease 1 0.9999994039535522
and O 0 2.9873158382542897e-06
contraction O 0 9.345212674816139e-06
of O 0 1.5218073912137697e-08
the O 0 2.8595074752502114e-08
repeat O 0 2.4875632789189694e-06
upon O 0 5.914569669585035e-07
male O 0 1.0809421837620903e-05
transmission O 0 6.10584447713336e-06
contribute O 0 1.2718456332549977e-07
to O 0 2.5048093377222358e-08
the O 0 2.7561103621565053e-08
almost O 0 1.1743549066522974e-07
absent O 0 5.787612167296174e-07
occurrence O 0 2.7348585263098357e-07
of O 0 6.49586482381892e-08
paternal O 0 0.0007208046736195683
transmission O 0 0.002630863105878234
of O 0 2.2440402972279117e-05
congenital B-Disease 1 0.9999980926513672
DM I-Disease 1 0.9999997615814209
. O 0 0.0016576790949329734

Also O 0 5.117192358738976e-06
the O 0 1.2535623739040602e-07
fathers O 0 2.817748736561043e-07
of O 0 1.277034922253506e-08
the O 0 2.0829094182772678e-07
reported O 0 5.693858111044392e-05
congenitally O 0 0.15745504200458527
affected O 0 2.2045724108465947e-06
children O 0 1.4170507256494602e-06
showed O 0 3.4111030799977016e-06
, O 0 2.1019754825601922e-08
on O 0 6.137857155863458e-08
average O 0 3.8614567188233195e-07
, O 0 7.97360897308863e-08
shorter O 0 4.503316176851513e-06
CTG O 0 7.948662823764607e-05
repeat O 0 1.571287793922238e-05
lengths O 0 1.4699425264552701e-05
and O 0 5.422573678970366e-08
hence O 0 1.2331830134826305e-07
less O 0 6.392302793756244e-07
severe O 1 0.8255547285079956
clinical O 1 0.9912585616111755
symptoms O 1 0.999795138835907
than O 0 1.1699634114847868e-06
the O 0 2.5367251055286033e-07
mothers O 0 2.4756218408583663e-05
of O 0 1.2116352365865168e-07
children O 0 3.421075962251052e-05
with O 0 0.002161388285458088
congenital B-Disease 1 0.9999982118606567
DM I-Disease 1 0.9999997615814209
. O 0 0.0008570901700295508

We O 0 1.133917521656258e-05
conclude O 0 1.840653749241028e-05
that O 0 1.3799043472317862e-06
paternal O 0 0.0003467388160061091
transmission O 0 0.001249617664143443
of O 0 6.827009201515466e-05
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 1.0
is O 0 0.0009417043766006827
rare O 0 2.132806184818037e-05
and O 0 3.882016130773991e-07
preferentially O 0 1.564005833643023e-05
occurs O 0 1.4405742376766284e-07
with O 0 4.1636070591266616e-08
onset O 0 1.8539823940955102e-05
of O 0 4.871678811468882e-07
DM B-Disease 1 0.9999979734420776
past O 0 1.0843153177120257e-05
30 O 0 4.6066364234320645e-07
years O 0 1.9182053279109823e-07
in O 0 2.8914653782408095e-08
the O 0 5.0256129924264314e-08
father O 0 4.61164790976909e-06
. O 0 2.0363650321542082e-07
. O 0 6.606332476621901e-07

The O 0 5.181659071240574e-05
RB1 O 0 0.09748300164937973
gene O 0 4.8271009291056544e-05
mutation O 0 2.5995208488893695e-05
in O 0 1.801122948563716e-07
a O 0 8.938314977058326e-07
child O 0 5.084161239210516e-05
with O 0 4.162630284554325e-05
ectopic B-Disease 1 0.9999527931213379
intracranial I-Disease 1 0.9999569654464722
retinoblastoma I-Disease 1 0.9653605818748474
. O 0 1.594647255842574e-05

The O 0 5.447403964353725e-05
RB1 O 0 0.18840433657169342
gene O 0 8.317236643051729e-05
mutation O 0 5.0935614126501605e-05
was O 0 6.484507366621983e-07
investigated O 0 1.343224425909284e-06
in O 0 6.610277836216483e-08
a O 0 2.1215566903265426e-06
child O 0 9.37919394345954e-05
with O 0 1.916317160066683e-05
ectopic B-Disease 1 0.9999771118164062
intracranial I-Disease 1 0.9999604225158691
retinoblastoma I-Disease 0 0.056450095027685165
using O 0 6.776489840376598e-07
DNA O 0 1.8857539316741168e-06
obtained O 0 1.353161422912308e-07
from O 0 1.1296910074065636e-08
both O 0 1.1149463574611218e-08
the O 0 3.7611684433613846e-08
pineal B-Disease 0 0.00019549251010175794
and I-Disease 0 4.205623554298654e-05
retinal I-Disease 1 0.9997451901435852
tumours I-Disease 1 0.9999849796295166
of O 0 5.122223001308157e-07
the O 0 2.2035339952708455e-06
patient O 0 0.006062119733542204
. O 0 1.1203203939658124e-05

A O 0 0.0001798855810193345
nonsense O 0 0.0007940093637444079
mutation O 0 0.000252594385528937
in O 0 1.123207766795531e-06
exon O 0 2.4575283532612957e-05
17 O 0 1.2915925253764726e-06
( O 0 4.5115339020185274e-08
codon O 0 2.1884292777940573e-07
556 O 0 4.333986112214916e-07
) O 0 1.3128587106336909e-08
of O 0 4.879934234480743e-09
the O 0 5.752603726705274e-08
RB1 O 0 0.0001488675770815462
gene O 0 1.9957938945935894e-07
was O 0 5.84334998166014e-08
found O 0 2.210992455786709e-08
to O 0 1.802028037900527e-08
be O 0 1.8948304258969983e-08
present O 0 6.751114511871492e-08
homozygously O 0 2.1901378204347566e-05
in O 0 4.144425247432082e-08
both O 0 1.6618990628103347e-08
the O 0 4.385776009030451e-08
retinal B-Disease 0 0.008265799842774868
and I-Disease 0 1.1339684533595573e-06
the I-Disease 0 2.9248878945509205e-06
pineal I-Disease 1 0.8963521122932434
tumours I-Disease 1 0.9999731779098511
. O 0 1.716616316116415e-05

The O 0 4.173874913249165e-06
same O 0 1.7040335933415918e-06
mutation O 0 4.9263035180047154e-06
was O 0 2.516206620839512e-07
present O 0 6.709663580295455e-08
heterozygously O 0 1.4978179933677893e-05
in O 0 3.856079899833276e-08
the O 0 1.748185241012834e-08
DNA O 0 3.405602342354541e-07
from O 0 1.1144446254718332e-08
the O 0 9.468871908779875e-09
constitutional O 0 8.534654512004636e-07
cells O 0 1.8942529322885093e-07
of O 0 3.4543643501194765e-09
the O 0 2.979747470988059e-08
patient O 0 1.6937883628997952e-05
, O 0 7.050657302443142e-08
proving O 0 7.5035387681055e-07
it O 0 2.2535342480978215e-08
to O 0 1.4273497939143454e-08
be O 0 8.910720161736663e-09
of O 0 2.8165336729557566e-08
germline O 0 3.553038914105855e-05
origin O 0 1.2182645150460303e-06
. O 0 1.8964086621053866e-06

The O 0 3.7240777146507753e-06
initial O 0 1.0209419997408986e-05
mutation O 0 1.4008171092427801e-05
was O 0 3.621858013502788e-07
shown O 0 1.9537492335075513e-07
to O 0 5.0529678219390917e-08
have O 0 4.559685251592782e-08
occurred O 0 1.1927254206511861e-07
in O 0 3.650584190495465e-08
the O 0 2.1382234649536258e-07
paternally O 0 7.451507553923875e-05
derived O 0 7.99879398982739e-06
RB1 O 0 0.0006106725777499378
allele O 0 3.8105936255306005e-05
. O 0 5.255285032035317e-06

The O 0 9.138096174865495e-06
mutation O 0 8.944029832491651e-05
is O 0 1.5474662973247177e-07
in O 0 2.647574603997782e-08
an O 0 3.055365382920172e-08
area O 0 2.203137228207197e-08
of O 0 2.2383084274935072e-09
the O 0 1.0472554379248322e-08
gene O 0 5.341091124932973e-08
that O 0 5.248893764076001e-09
encodes O 0 2.8247326255836924e-08
the O 0 6.962294296641858e-09
protein O 0 5.958736082334326e-08
- O 0 8.229258696701436e-07
binding O 0 3.120900089470524e-07
region O 0 3.2937091276608044e-08
known O 0 1.5767621874829274e-08
as O 0 7.441920413242542e-09
the O 0 1.4600533226882817e-08
pocket O 0 0.002198598813265562
region O 0 1.3236949314432422e-07
and O 0 4.0878521900822307e-08
has O 0 8.274541585251427e-08
been O 0 7.105712285238042e-08
detected O 0 7.612359809172631e-07
in O 0 2.7133289393077575e-08
other O 0 2.0651921062153633e-08
cases O 0 2.4921126851040754e-07
of O 0 1.2640632007787644e-07
retinoblastoma B-Disease 0 0.07729345560073853
. O 0 1.1579970760067226e-06
. O 0 1.7410677628504345e-06

Low O 0 0.0002431500906823203
levels O 0 1.918818043122883e-06
of O 0 3.656542801877549e-08
beta O 0 3.606722884796909e-07
hexosaminidase O 0 7.78115736466134e-06
A O 0 7.678271458644303e-07
in O 0 1.751705696051431e-07
healthy O 0 3.5494044823281e-06
individuals O 0 6.535508845217919e-08
with O 0 9.728538543640752e-07
apparent O 1 0.9985509514808655
deficiency O 1 0.8466795682907104
of O 0 5.1797464095670875e-08
this O 0 2.563909049513313e-07
enzyme O 0 4.137074938626029e-06
. O 0 1.8152491065848153e-06

Appreciable O 0 0.002134001348167658
beta O 0 9.036833216669038e-05
hexosaminidase O 0 0.0003418955602683127
A O 0 5.081943527329713e-06
( O 0 1.883935141222537e-07
hex O 0 3.6333376556285657e-06
A O 0 2.4815540200506803e-07
) O 0 1.8468179874275847e-08
activity O 0 1.7989577827393077e-08
has O 0 3.4405054805120017e-08
been O 0 5.296151783795722e-08
detected O 0 5.215624128140917e-07
in O 0 1.1316571857378221e-07
cultured O 0 0.000632462848443538
skin O 1 0.9983112812042236
fibroblasts O 0 0.03982274606823921
and O 0 0.0033573152031749487
melanoma B-Disease 1 0.9999837875366211
tissue O 0 0.013135949149727821
from O 0 7.162671522564779e-07
healthy O 0 2.3563332433695905e-05
individuals O 0 2.2302943136764952e-07
previously O 0 1.6601113657088717e-06
reported O 0 7.667736099392641e-06
as O 0 2.829157779160596e-07
having O 0 2.8463435228331946e-05
deficiency B-Disease 0 0.0001849895779741928
of I-Disease 0 9.637653342053909e-09
hex I-Disease 0 2.994069973283331e-06
A I-Disease 0 2.0131551536906045e-07
activity O 0 2.925554731803004e-08
indistinguishable O 0 1.2012631600555324e-07
from O 0 9.452073790328086e-09
that O 0 1.8325575723565635e-08
of O 0 1.0885583634490104e-07
patients O 0 0.011799217201769352
with O 0 0.14105159044265747
Tay B-Disease 1 1.0
- I-Disease 1 0.9999984502792358
Sachs I-Disease 1 0.9999988079071045
disease I-Disease 0 0.31985482573509216
( O 0 1.3727103578276e-06
TSD B-Disease 0 0.0037988130934536457
) O 0 2.2583335521630943e-06
. O 0 2.5504405130050145e-06

Identification O 0 4.40798066847492e-05
and O 0 1.1504711210363894e-06
quantitation O 0 4.9331294576404616e-05
of O 0 1.889186904691087e-07
hex O 0 1.205889475386357e-05
A O 0 1.2864147720392793e-06
, O 0 1.1190203252908759e-07
amounting O 0 8.628540513200278e-07
to O 0 1.4497615552500065e-07
3 O 0 1.5344430721597746e-06
. O 0 1.1963817314608605e-06

5 O 0 0.00011536521924426779
% O 0 1.461299052607501e-05
- O 0 0.00010718886915128678
6 O 0 3.541216574376449e-05
. O 0 6.757775736332405e-06

9 O 0 4.351733150542714e-05
% O 0 5.349319280867348e-07
of O 0 1.0266627548105589e-08
total O 0 3.745304510971437e-08
beta O 0 1.8528977818732528e-07
hexosaminidase O 0 2.8009874313283945e-06
activity O 0 3.2593934662372703e-08
, O 0 1.926043147193468e-08
has O 0 2.9096836939856985e-08
been O 0 2.107161911624189e-08
obtained O 0 2.6155419163842453e-08
by O 0 1.3084265226837033e-08
cellulose O 0 2.838353339029709e-06
acetate O 0 2.8177590138511732e-05
gel O 0 0.0024585602805018425
electrophoresis O 0 2.630272319947835e-05
, O 0 1.1042423153639902e-07
DEAE O 0 8.462920959573239e-06
- O 0 2.430695076327538e-06
cellulose O 0 3.1716724606667412e-06
ion O 0 3.5758755529968766e-06
- O 0 2.827320031428826e-06
exchange O 0 1.8208721996870736e-07
chromatography O 0 1.8132733430320513e-06
, O 0 9.065144723763296e-08
radial O 0 6.224638127605431e-06
immunodiffusion O 0 4.762093522003852e-05
, O 0 2.6737305347523943e-07
and O 0 3.2234433433586673e-07
radioimmunoassay O 0 0.00030287980916909873
. O 0 7.225527042464819e-06

Previous O 0 0.0003345718723721802
family O 0 3.796274177148007e-05
studies O 0 1.2109506997148856e-06
suggested O 0 9.602460977475857e-07
that O 0 4.964108057947669e-08
these O 0 2.0381829557436504e-08
individuals O 0 2.2968636770315243e-08
may O 0 1.8751215691281686e-07
be O 0 2.3959893624692086e-08
compound O 0 1.292018737331091e-06
heterozygotes O 0 5.182655058888486e-06
for O 0 2.1269478622798488e-08
the O 0 1.739115873533592e-08
common O 0 2.3308996333071264e-07
mutant O 0 2.825578485499136e-05
TSD B-Disease 0 0.0005937296082265675
gene O 0 6.080557000132103e-07
and O 0 5.653984658238187e-08
a O 0 8.2586154803721e-07
rare O 0 1.0541257324803155e-05
( O 0 3.2879384548323287e-07
allelic O 0 1.1203000212844927e-05
) O 0 2.750492171799124e-07
mutant O 0 1.3473667422658764e-05
gene O 0 4.534401341516059e-06
. O 0 1.8408361484034685e-06

Thus O 0 2.8604117687791586e-05
, O 0 2.761957773600443e-07
the O 0 4.069912051818392e-08
postulated O 0 2.253982756883488e-06
rate O 0 1.5771870209846384e-07
mutant O 0 6.760533324268181e-07
gene O 0 1.85956778864238e-07
appears O 0 1.599601233692738e-07
to O 0 7.839422444533284e-09
code O 0 1.3206821414257774e-08
for O 0 6.2448060056397026e-09
the O 0 9.90708581838362e-09
expression O 0 7.284423730880007e-08
of O 0 9.260240574349154e-09
low O 0 2.6186222612523125e-07
amounts O 0 8.070923485092862e-08
of O 0 2.6298586419670755e-08
hex O 0 9.86728809948545e-06
A O 0 3.5742389172810363e-06
. O 0 2.2129092940303963e-06

Heterozygotes O 0 0.07502815127372742
for O 0 2.5585432013031095e-06
the O 0 5.333807848728611e-07
rare O 0 3.389958919797209e-06
mutant O 0 6.077489524614066e-05
may O 0 1.2932982826896477e-06
be O 0 6.744794944779642e-08
indistinguishable O 0 5.302221666170226e-07
from O 0 8.2730110761986e-08
heterozygotes O 0 4.1160833461617585e-06
for O 0 5.571660111058918e-08
the O 0 1.4411266135994083e-07
common O 0 2.166704234696226e-06
TSD B-Disease 0 0.030786102637648582
mutant O 0 0.0007232111529447138
. O 0 5.831208454765147e-06

However O 0 1.7498685338068753e-05
, O 0 2.0575789960730617e-07
direct O 0 2.137098249477276e-07
visualization O 0 8.890104368219909e-07
and O 0 8.404863649502659e-08
quantitation O 0 8.216764399548993e-06
of O 0 1.874563260173545e-08
hex O 0 6.029842552379705e-06
A O 0 3.3329197890452633e-07
by O 0 2.6660606167183687e-08
the O 0 1.4301130057958744e-08
methods O 0 1.5198168057395378e-07
described O 0 1.6602409232291393e-05
may O 0 8.660073831379123e-07
prevent O 0 2.6680910991672135e-07
false O 0 1.3065008488410967e-06
- O 0 0.00029932509642094374
positive O 0 7.143494258343708e-06
prenatal O 1 0.6390514969825745
diagnosis O 0 0.4888760447502136
of O 0 4.7378603085235227e-07
TSD B-Disease 1 0.6209524273872375
in O 0 3.11226494886796e-06
fetuses O 0 0.008527549915015697
having O 0 2.0585994775501604e-07
the O 0 1.7237431038097384e-08
incomplete O 0 7.52958101202239e-07
hex B-Disease 0 0.0001166440561064519
A I-Disease 0 0.00020393540035001934
deficiency I-Disease 0 0.0003578319738153368
of O 0 8.305229393101854e-09
the O 0 3.2505159452966836e-08
type O 0 3.2088116768136388e-06
described O 0 2.044952680080314e-06
in O 0 4.484937221604923e-08
the O 0 4.73790535693297e-08
four O 0 1.2199946013424778e-06
healthy O 0 1.710119795461651e-05
individuals O 0 3.198158537998097e-06

The O 0 2.426633727736771e-05
tumor B-Disease 0 0.0006464037578552961
suppressor O 0 0.00021926697809249163
gene O 0 1.5213540791592095e-05
Smad4 O 0 0.00010484326776349917
/ O 0 1.1597407137742266e-05
Dpc4 O 0 1.2600647096405737e-05
is O 0 5.7479535797710923e-08
required O 0 3.2509252179124815e-08
for O 0 2.578363123006966e-08
gastrulation O 0 6.693252998957178e-06
and O 0 1.1617895978588422e-07
later O 0 1.5812683784588444e-07
for O 0 2.621075267938977e-08
anterior O 0 4.731890840048436e-06
development O 0 1.7760063641958368e-08
of O 0 9.951382828887745e-09
the O 0 9.247324328498507e-08
mouse O 0 2.0120731278439052e-05
embryo O 0 5.517628596862778e-05
. O 0 4.7165685828076676e-06

Mutations O 0 0.4753287732601166
in O 0 7.980020200193394e-06
the O 0 2.7290247999189887e-06
SMAD4 O 0 0.04428348317742348
/ O 0 0.0007987965364009142
DPC4 O 0 0.025183606892824173
tumor B-Disease 0 0.003276386298239231
suppressor O 0 9.305155253969133e-05
gene O 0 1.1927304512937553e-06
, O 0 1.3513567154177508e-08
a O 0 3.7947909703461846e-08
key O 0 5.097652433505573e-08
signal O 0 5.290937110657978e-07
transducer O 0 5.923453954892466e-06
in O 0 7.123950496179532e-08
most O 0 6.271187658057897e-08
TGFbeta O 0 4.9807400500867516e-05
- O 0 4.349077426013537e-05
related O 0 5.690150715054187e-07
pathways O 0 3.7970394828334975e-07
, O 0 2.167334933744769e-08
are O 0 3.525870040377299e-09
involved O 0 8.231172188288838e-09
in O 0 1.992332343547787e-08
50 O 0 1.4934899184027017e-07
% O 0 1.1276151212769037e-07
of O 0 4.778268021254917e-07
pancreatic B-Disease 1 0.9999500513076782
cancers I-Disease 1 0.9990311861038208
. O 0 1.1776485735026654e-05

Homozygous O 0 0.007013482041656971
Smad4 O 0 0.006139119155704975
mutant O 0 0.008789381012320518
mice O 0 0.35448941588401794
die O 0 0.002469163155183196
before O 0 6.441615028052183e-07
day O 0 1.160624037765956e-06
7 O 0 4.473549779504538e-06
. O 0 1.9017369368157233e-06

5 O 0 0.0001213157520396635
of O 0 6.2754625105299056e-06
embryogenesis O 0 0.0007647656020708382
. O 0 4.465844904188998e-05

Mutant O 0 0.0005318464245647192
embryos O 0 0.00013481795031111687
have O 0 1.4612340919484268e-06
reduced O 0 9.850316473603016e-07
size O 0 4.2690038526416174e-07
, O 0 1.0722011012376242e-07
fail O 0 2.405838586128084e-06
to O 0 1.3632113393668988e-07
gastrulate O 0 7.167056173784658e-05
or O 0 5.994873220060981e-08
express O 0 2.332669879478999e-07
a O 0 1.287827302576261e-07
mesodermal O 0 2.7408808819018304e-05
marker O 0 6.74387592880521e-06
, O 0 4.962157618138008e-08
and O 0 4.094633609952325e-08
show O 0 1.2998358442928293e-06
abnormal O 0 1.1535777048266027e-05
visceral O 0 0.0004393036069814116
endoderm O 0 0.0008675295393913984
development O 0 2.7777909963333514e-06
. O 0 3.694994575198507e-06

Growth B-Disease 1 0.9979798197746277
retardation I-Disease 1 0.9999010562896729
of O 0 1.1661092003123485e-06
the O 0 6.716269922435458e-07
Smad4 O 0 0.0019498326582834125
- O 0 0.03242587298154831
deficient O 0 0.0003686983836814761
embryos O 0 1.9861950022459496e-06
results O 0 2.3012405847566697e-07
from O 0 1.4577299367601881e-08
reduced O 0 2.447883105105575e-07
cell O 0 1.5093936553967069e-06
proliferation O 0 1.6544073844215745e-07
rather O 0 6.342460778796521e-08
than O 0 9.721511418092632e-08
increased O 0 1.4037307209946448e-06
apoptosis O 0 7.749944052193314e-05
. O 0 4.365160293673398e-06

Aggregation O 0 6.233993190107867e-05
of O 0 1.5713153516117018e-06
mutant O 0 7.368424849119037e-05
Smad4 O 0 0.000728099956177175
ES O 0 5.573037196882069e-05
cells O 0 3.2782586458779406e-06
with O 0 1.2730954779271997e-07
wild O 0 4.466464247343538e-07
- O 0 1.5642610378563404e-05
type O 0 4.178159997536568e-06
tetraploid O 0 4.1918370698112994e-05
morulae O 0 0.00015128077939152718
rescues O 0 2.5422774342587218e-05
the O 0 7.236135957100487e-07
gastrulation B-Disease 0 0.00047145559801720083
defect I-Disease 0 0.0008665815112181008
. O 0 5.181345386517933e-06

These O 0 1.2314534615143202e-05
results O 0 7.042779543553479e-06
indicate O 0 6.202661211318627e-07
that O 0 5.4793712678247175e-08
Smad4 O 0 6.669002686976455e-06
is O 0 4.639535688966134e-08
initially O 0 2.1638575731230958e-07
required O 0 1.6155802029516053e-08
for O 0 2.5125117542046382e-09
the O 0 2.325795112056994e-09
differentiation O 0 1.9481966262446804e-08
of O 0 5.122825719183766e-09
the O 0 2.554348732530798e-08
visceral O 0 8.750675624469295e-05
endoderm O 0 0.00010306947660865262
and O 0 7.030727999790543e-08
that O 0 1.406277227999908e-08
the O 0 3.524620950656754e-08
gastrulation B-Disease 0 3.4906119253719226e-05
defect I-Disease 0 3.140817352687009e-05
in O 0 5.2526818450360224e-08
the O 0 5.458061735907904e-08
epiblast O 0 9.780675463844091e-05
is O 0 5.685128456889288e-08
secondary O 0 5.692245963473397e-08
and O 0 4.4151352796006904e-08
non O 0 4.061107574671041e-07
- O 0 6.803528231102973e-05
cell O 0 0.00024184260109905154
autonomous O 0 4.739527867059223e-06
. O 0 1.9825727122224635e-06

Rescued O 0 0.0025452792178839445
embryos O 0 0.0002454125205986202
show O 0 0.00011760982306441292
severe O 0 0.08921734243631363
anterior O 0 0.020080165937542915
truncations O 0 0.00762514490634203
, O 0 7.567381317130639e-07
indicating O 0 3.584882222185115e-07
a O 0 7.591553696784104e-08
second O 0 1.0822896001627669e-07
important O 0 9.965039460269054e-09
role O 0 6.783551498301676e-08
for O 0 6.359395143817892e-08
Smad4 O 0 6.185240636114031e-05
in O 0 3.687809453367663e-07
anterior O 0 0.00016849651001393795
patterning O 0 0.0006474097026512027
during O 0 6.404777650459437e-06
embryogenesis O 0 0.00013116518675815314
. O 0 7.928708328108769e-06

Prevalence O 0 0.01381149422377348
of O 0 2.1769856175524183e-06
p16 O 0 0.00021149881649762392
and O 0 3.086396418439108e-06
CDK4 O 0 0.04324404522776604
germline O 0 0.00851759035140276
mutations O 0 7.959517097333446e-05
in O 0 8.360381684724416e-07
48 O 0 0.0005494797369465232
melanoma B-Disease 1 0.9996633529663086
- O 0 0.1297830045223236
prone O 0 0.06570449471473694
families O 0 4.197781890979968e-06
in O 0 1.097146878237254e-06
France O 0 0.00010052594006992877
. O 0 7.23610537534114e-06

The O 0 3.442151137278415e-05
French O 0 0.000942368118558079
Familial B-Disease 1 0.9937024116516113
Melanoma I-Disease 1 0.9999750852584839
Study O 0 0.00014974984514992684
Group O 0 2.294240221090149e-05
. O 0 4.22858784077107e-06

Germline O 1 0.9886077046394348
mutations O 1 0.8393968343734741
in O 0 2.544454218877945e-06
the O 0 3.472923992831056e-07
p16 O 0 1.5557019651168957e-05
and O 0 3.738817042631126e-07
CDK4 O 0 0.0015935881529003382
genes O 0 1.0901514997385675e-06
have O 0 1.1262878274465038e-07
been O 0 1.0965583641109333e-07
reported O 0 4.476305832668004e-07
in O 0 7.915312849604561e-09
a O 0 9.127413846954369e-08
subset O 0 2.8817268571401655e-07
of O 0 2.2234199548165634e-07
melanoma B-Disease 1 0.9994611144065857
pedigrees O 0 6.451697845477611e-05
, O 0 1.397179545392646e-07
but O 0 5.4384834413667704e-08
their O 0 8.555903008300447e-08
prevalence O 0 1.926673940033652e-05
is O 0 3.5844305301679924e-08
not O 0 2.7460984597382776e-08
well O 0 8.494956205140625e-08
known O 0 4.48080783144178e-07
. O 0 1.1562358395167394e-06

We O 0 4.5730903366347775e-06
searched O 0 3.697081410791725e-06
for O 0 8.323692668454896e-08
such O 0 1.2867825205375993e-07
germline O 0 0.0003272883768659085
mutations O 0 4.2756109905894846e-05
in O 0 3.168635487327265e-07
48 O 0 2.1109603039803915e-05
French O 0 0.0077044777572155
melanoma B-Disease 1 0.9999349117279053
- O 1 0.7410231828689575
prone O 0 0.07397738844156265
families O 0 5.197064751882863e-07
selected O 0 3.7123044194231625e-08
according O 0 1.9902927306247875e-08
to O 0 1.3821846778228064e-08
two O 0 2.3562213513628194e-08
major O 0 3.183203389767186e-08
criteria O 0 1.7443289834773168e-07
families O 0 3.565596884413935e-08
with O 0 1.3478660854104874e-08
at O 0 5.2095096236826066e-08
least O 0 8.885402991154479e-08
three O 0 4.754562255016026e-08
affected O 0 4.516993001857372e-08
members O 0 1.4639544687611306e-08
( O 0 1.7002783181396808e-08
n O 0 8.579022505728062e-07
= O 0 6.791888154111803e-07
20 O 0 2.143936406184821e-08
) O 0 5.187276830298515e-09
or O 0 1.4391456915063827e-08
families O 0 2.1547714723624267e-08
with O 0 1.2609683075481826e-08
two O 0 8.674309981415718e-08
affected O 0 1.0819345419577076e-07
members O 0 9.021571045764176e-09
, O 0 5.973435523998205e-09
one O 0 2.832878376324288e-09
of O 0 1.6558422410994922e-09
them O 0 1.868951216010828e-08
affected O 0 2.5358922073337453e-08
before O 0 8.704071241538713e-09
the O 0 7.648888633582374e-09
age O 0 3.243133761543504e-08
of O 0 4.686189214453407e-09
50 O 0 1.1301386138029557e-07
( O 0 4.446132351176857e-08
n O 0 1.6673799336786033e-06
= O 0 1.0386398798800656e-06
28 O 0 1.2971952401130693e-07
) O 0 7.191539808104608e-09
, O 0 7.071893293186804e-09
and O 0 1.0943702832832969e-08
one O 0 3.966581374470479e-08
additional O 0 3.0099423042884155e-07
minor O 0 2.4055218545981916e-06
criterion O 0 1.653173785598483e-05
. O 0 2.7570652036956744e-06

Sixteen O 0 7.982586248544976e-05
different O 0 3.151498958686716e-06
p16 O 0 0.00014674566045869142
germline O 0 0.004140365403145552
mutations O 0 0.0003767960879486054
were O 0 6.055459493836679e-07
found O 0 2.5587135610294354e-07
in O 0 1.7208219560416183e-07
21 O 0 1.7015328239722294e-06
families O 0 8.320930078298261e-08
, O 0 2.5671159420426193e-08
while O 0 3.4404529003495554e-08
one O 0 7.307259863864601e-08
germline O 0 2.8328795451670885e-05
mutation O 0 1.689028749751742e-06
, O 0 2.578608970793539e-08
Arg24His O 0 4.39043105870951e-06
, O 0 3.1987053006332644e-08
was O 0 1.1893394713524685e-07
detected O 0 4.3030811980315775e-07
in O 0 2.5507459255891263e-08
the O 0 1.7595765200439928e-07
CDK4 O 0 0.0012990438845008612
gene O 0 7.300207926164148e-06
. O 0 1.452057290407538e-06

The O 0 2.109250317516853e-06
frequency O 0 3.671341119115823e-06
of O 0 7.432787185734924e-08
p16 O 0 1.3295935787027702e-05
gene O 0 1.5133429087654804e-06
mutation O 0 1.4392425100595574e-06
in O 0 2.374529373128098e-08
our O 0 1.670081495319664e-08
sample O 0 9.271715128988944e-08
( O 0 2.5713056572840287e-08
44 O 0 1.8951635638586595e-07
% O 0 2.4076527438410267e-08
) O 0 4.542599629786537e-09
is O 0 4.453429180983903e-09
among O 0 5.333443464650145e-09
the O 0 1.3426522116333217e-08
highest O 0 4.997491487301886e-07
rates O 0 4.6171922463145165e-07
yet O 0 6.229652171896305e-07
reported O 0 8.999762144412671e-07
and O 0 1.5061074165600985e-08
the O 0 3.549867244601046e-08
CDK4 O 0 0.03933529555797577
mutation O 0 2.9144578093109885e-06
is O 0 8.276385798922092e-09
the O 0 7.536367085947404e-09
second O 0 5.408153924690851e-07
mutation O 0 3.525156898831483e-06
detected O 0 8.897118846107333e-07
in O 0 5.0304464593864395e-08
this O 0 8.461256584268995e-08
gene O 0 1.3939974223831086e-06
worldwide O 0 3.001978257088922e-06
. O 0 2.1270852812449448e-06

In O 0 2.301372842339333e-05
summary O 0 1.705425893305801e-05
, O 0 2.5999869990300795e-07
our O 0 6.719730549775704e-08
results O 0 3.448067218414508e-07
show O 0 1.9959082919740467e-07
frequent O 0 6.035062369846855e-07
involvement O 0 2.6167825240008824e-07
of O 0 1.7497262305710137e-08
the O 0 3.594617936641953e-08
p16 O 0 6.277976353885606e-06
gene O 0 9.261195259568922e-07
in O 0 3.540482680364221e-07
familial B-Disease 1 0.9685810208320618
melanoma I-Disease 1 0.9999949932098389
and O 0 2.4648225007695146e-06
confirm O 0 4.4310859266261104e-06
the O 0 1.6412409209465295e-08
role O 0 4.733858460781448e-08
of O 0 7.969803483831583e-09
the O 0 4.9931657031265786e-08
CDK4 O 0 0.00019477767636999488
gene O 0 5.648362844112853e-07
as O 0 5.2604118394583566e-08
a O 0 8.986196007754188e-06
melanoma B-Disease 1 0.9994188547134399
- O 0 0.01865508407354355
predisposing O 0 0.00021157527226023376
gene O 0 4.170230567979161e-06
. O 0 3.579160363642586e-07
. O 0 1.0426880407976569e-06

Progression O 0 0.0005480021936818957
of O 0 2.674878260222613e-06
somatic O 0 0.00015020403952803463
CTG O 0 0.0037388165947049856
repeat O 0 0.00020693779515568167
length O 0 2.493353713362012e-05
heterogeneity O 0 2.0000550648546778e-05
in O 0 2.024332985683941e-07
the O 0 1.9223149649860716e-07
blood O 0 8.19082106318092e-06
cells O 0 6.412778475350933e-06
of O 0 4.773422006110195e-06
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 1.0
patients O 1 0.9999572038650513
. O 0 9.024691098602489e-05

The O 0 1.3115620276948903e-05
genetic O 0 2.1759540686616674e-05
basis O 0 1.3866387007510639e-06
of O 0 1.6951473298831843e-05
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 0 0.02380410023033619
DM B-Disease 1 0.9999997615814209
) O 0 3.9134931739681633e-07
is O 0 1.0715179854514645e-08
the O 0 2.337464666268829e-09
expansion O 0 2.1030503560837133e-08
of O 0 5.575505390709168e-09
an O 0 1.260586373064143e-07
unstable O 0 3.0361503377207555e-05
CTG O 0 0.0003022942109964788
repeat O 0 7.784245099173859e-06
in O 0 6.414384046138366e-08
the O 0 4.943302656101878e-08
34 O 0 6.83933080836141e-07
UTR O 0 6.169757398311049e-06
of O 0 2.002905397091581e-08
the O 0 1.5465043645690457e-07
DM B-Disease 1 0.9999891519546509
protein O 0 2.375851181568578e-06
kinase O 0 1.5304868838939e-06
gene O 0 1.5555924903765117e-07
on O 0 9.032128645003468e-08
chromosome O 0 4.462771539692767e-05
19 O 0 4.0608583731227554e-06
. O 0 1.1024972081941087e-06

One O 0 2.31657372751215e-06
of O 0 5.3842555303162953e-08
the O 0 3.381484248166089e-08
principal O 0 7.61079306244028e-08
features O 0 8.38929636870489e-08
of O 0 2.6377758644002824e-08
the O 0 7.900833907115157e-07
DM B-Disease 1 0.9999998807907104
mutation O 0 0.0008247658261097968
is O 0 5.266556257765842e-08
an O 0 3.0557909980188924e-08
extraordinarily O 0 4.011978944618022e-06
high O 0 1.9171849885424308e-07
level O 0 1.845993757854103e-08
of O 0 1.9055729438832714e-08
somatic O 0 2.3272681573871523e-05
mosaicism O 0 0.0666227787733078
, O 0 2.0336518957719818e-07
due O 0 1.3421725952866836e-07
to O 0 3.8012743175386277e-08
an O 0 5.075938602772112e-08
extremely O 0 6.60839930333168e-07
high O 0 1.1236036101536229e-07
degree O 0 7.466904605735181e-08
of O 0 6.553856568558558e-09
somatic O 0 6.5254589571850374e-06
instability O 0 2.8848828605987364e-06
both O 0 3.365629908103074e-08
within O 0 9.631000885690355e-09
and O 0 4.502078709833768e-08
between O 0 9.012356372295471e-08
different O 0 3.3302097790510743e-07
tissues O 0 4.222860297886655e-05
. O 0 4.342452484706882e-06

This O 0 8.22978290671017e-06
instability O 0 2.6716643333202228e-05
appears O 0 3.833058599411743e-06
to O 0 1.2292940709812683e-07
be O 0 3.440072049443188e-08
biased O 0 2.3808314608686487e-07
towards O 0 3.6928273772218745e-08
further O 0 2.1069407551976838e-08
expansion O 0 5.30741708359983e-08
and O 0 1.9480182800180046e-08
continuous O 0 2.108255756638755e-07
throughout O 0 2.2718241510233383e-08
the O 0 7.74800135161513e-09
life O 0 3.475501131333658e-08
of O 0 3.6209024667499534e-09
an O 0 3.064499409788368e-08
individual O 0 1.3225625927759666e-08
, O 0 1.5473062831006246e-08
features O 0 1.5252413732014247e-07
that O 0 3.649547153372623e-08
could O 0 1.8857974737329641e-07
be O 0 2.554899225515328e-08
associated O 0 2.2003572297535356e-08
with O 0 1.3754233307849972e-08
the O 0 2.8784960193206643e-08
progressive O 0 2.21061818592716e-05
nature O 0 1.6432588267889514e-07
of O 0 4.979346712730148e-08
the O 0 3.656599346868461e-06
disease O 0 0.0025237423833459616
. O 0 7.013048161752522e-06

Although O 0 1.4503076272376347e-05
increasing O 0 1.4388733688974753e-06
measured O 0 3.5978600863018073e-06
allele O 0 5.173395948077086e-06
size O 0 4.7636987687837973e-07
between O 0 4.1566727304598317e-07
patients O 0 0.0004865989612881094
clearly O 0 1.0245548764942214e-06
correlates O 0 2.899744913520408e-06
with O 0 5.3157243939949694e-08
an O 0 1.33892541498426e-07
increased O 0 4.062810603500111e-06
severity O 0 0.0023036364000290632
of O 0 1.2089844858564902e-06
symptoms O 1 0.9605263471603394
and O 0 2.2746820604879758e-07
an O 0 1.3630241824102995e-07
earlier O 0 5.532600880542304e-06
age O 0 1.5968393540788384e-07
of O 0 1.2616803601872562e-08
onset O 0 4.2327137634856626e-05
, O 0 7.21605530884517e-08
this O 0 1.2071896371423918e-08
correlation O 0 6.659810480869055e-08
is O 0 1.4792236768812472e-08
not O 0 1.175562402977448e-08
precise O 0 2.4153300159923674e-07
and O 0 1.23897919479532e-07
measured O 0 7.809032467775978e-06
allele O 0 4.291215191187803e-06
length O 0 1.747637156768178e-06
cannot O 0 2.6204284608866146e-07
be O 0 9.245734844398612e-09
used O 0 1.3520064179317615e-08
as O 0 4.768719197301152e-09
an O 0 9.477961526727086e-09
accurate O 0 2.657136803918547e-07
predictor O 0 2.152331262550433e-06
of O 0 3.049421337664171e-08
age O 0 4.4270254306866264e-07
of O 0 2.0587036431152228e-07
onset O 0 0.0006475984118878841
. O 0 9.365795449411962e-06

In O 0 5.152076937520178e-06
order O 0 4.540462157365255e-07
to O 0 1.3508598328826338e-07
further O 0 1.0660631488690342e-07
characterize O 0 1.4022134564584121e-06
the O 0 6.717397837974204e-08
dynamics O 0 3.304676283732988e-06
of O 0 1.37499370111982e-07
DM B-Disease 1 0.9999899864196777
CTG O 0 0.007677774410694838
repeat O 0 4.707523112301715e-05
somatic O 0 3.214159733033739e-05
instability O 0 5.696640073438175e-06
, O 0 6.792096485241927e-08
we O 0 1.8077942698369043e-08
have O 0 1.4244967871945846e-08
studied O 0 1.2612129296485364e-07
repeat O 0 2.8227075290487846e-06
length O 0 1.4582353742298437e-06
changes O 0 7.066543616929266e-08
over O 0 6.053841872244448e-08
time O 0 1.2197975252092874e-07
in O 0 5.515651082532713e-07
111 O 0 0.13040611147880554
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
patients O 1 0.9998929500579834
with O 0 6.5707586145435926e-06
varying O 0 0.00014349624689202756
clinical O 0 0.028233883902430534
severity O 0 0.0508953258395195
and O 0 5.117555588185496e-07
CTG O 0 4.1942923417082056e-05
repeat O 0 2.082777427858673e-06
size O 0 1.5143189102673205e-07
over O 0 3.347881971649258e-08
time O 0 3.2675352201749774e-08
intervals O 0 6.77088323186581e-08
of O 0 1.2268856153241359e-08
1 O 0 2.2925860321265645e-07
- O 0 2.1783127522212453e-05
7 O 0 1.982134335776209e-06
years O 0 7.097855245774554e-07
. O 0 7.899206480033172e-07

We O 0 5.251507445791503e-06
have O 0 4.601455430019996e-07
found O 0 6.280583875195589e-08
a O 0 9.545926360488011e-08
direct O 0 1.7970927501664846e-07
progression O 0 8.658364549773978e-07
of O 0 8.035606846590326e-09
the O 0 1.7033359611673404e-08
size O 0 1.5550378407169774e-07
heterogeneity O 0 8.977123684417165e-07
over O 0 9.145711032942927e-08
time O 0 5.454460705323072e-08
related O 0 3.706092854827148e-08
to O 0 4.0264033884795936e-08
initial O 0 8.787151273281779e-07
CTG O 0 4.668057954404503e-05
repeat O 0 1.9359783891559346e-06
size O 0 7.76525581613896e-08
and O 0 1.1900685770172004e-08
the O 0 4.981101753287476e-09
time O 0 2.198469317704621e-08
interval O 0 1.1175038139299431e-07
and O 0 1.9033862486139697e-08
always O 0 1.0688769691569178e-07
biased O 0 3.4068432341882726e-07
towards O 0 6.40191686329672e-08
further O 0 1.4521124569455424e-07
expansion O 0 1.995643060581642e-06
. O 0 2.3418626824422972e-06

Attempts O 0 6.573557766387239e-05
to O 0 2.651152954058489e-06
mathematically O 0 2.1025682144681923e-05
model O 0 2.53087273449637e-06
the O 0 5.991649487668838e-08
dynamics O 0 5.175705155124888e-06
have O 0 5.6382617685812875e-08
proved O 0 3.6906732248098706e-07
only O 0 3.62123593333763e-08
partially O 0 8.863235052558593e-07
successful O 0 3.405423854019318e-07
suggesting O 0 5.412214250100078e-07
that O 0 1.9853070298836428e-08
individual O 0 1.2655656078663924e-08
specific O 0 1.7834199894650737e-08
genetic O 0 4.2788062160070695e-07
and O 0 1.3724783798352291e-07
/ O 0 3.102773553109728e-05
or O 0 1.0079124024287012e-07
environmental O 0 6.655022843915503e-07
factors O 0 7.57106377591299e-08
also O 0 3.4541422166967095e-08
play O 0 3.134360682111037e-08
a O 0 1.192419603057715e-07
role O 0 3.5407123277764185e-07
in O 0 3.7166728361626156e-07
somatic O 0 8.353370503755286e-05
mosaicism O 0 0.013602165505290031
. O 0 1.2595244243129855e-06
. O 0 2.4737285002629505e-06

Aspartylglucosaminuria B-Disease 1 0.9928227066993713
among O 0 9.525046334601939e-05
Palestinian O 0 0.0002857458312064409
Arabs O 0 0.00019031111150979996
. O 0 1.3790129742119461e-05

Aspartylglucosaminuria B-Disease 1 0.9999426603317261
( O 0 0.015286795794963837
AGU B-Disease 1 0.9999436140060425
) O 0 2.8972542622796027e-06
is O 0 2.210756804288394e-07
a O 0 5.766544745711144e-06
rare O 0 0.006016132887452841
disorder B-Disease 1 0.5948624610900879
of I-Disease 0 2.1807124994666083e-07
glycoprotein I-Disease 0 0.0010415567085146904
metabolism I-Disease 0 0.0001081715090549551
caused O 0 1.6373693142668344e-05
by O 0 2.646805228323501e-07
the O 0 2.0410479919519275e-06
deficiency B-Disease 0 0.001281999982893467
of I-Disease 0 1.8639386922814083e-08
the I-Disease 0 9.251241550600753e-08
lysosomal I-Disease 0 0.00014774163719266653
enzyme I-Disease 0 2.771836989268195e-06
aspartylglucosaminidase I-Disease 0 3.129816832370125e-05
( O 0 3.344203491906228e-07
AGA O 0 3.5662778827827424e-05
) O 0 5.150536139808537e-07
. O 0 6.638770173594821e-07

AGU B-Disease 1 0.9999717473983765
is O 0 0.0004427611129358411
inherited O 0 0.012085886672139168
as O 0 1.4387306919161347e-06
an O 0 7.678809197386727e-06
autosomal O 1 0.9875818490982056
recessive O 1 0.9953807592391968
trait O 0 0.0053703924641013145
and O 0 7.513921786994615e-07
occurs O 0 1.55193106365914e-07
with O 0 2.0176136317218152e-08
a O 0 3.1672882983002637e-07
high O 0 4.101884201190842e-07
frequency O 0 1.8335841787120444e-06
in O 0 5.0047407995634785e-08
Finland O 0 1.1652415196294896e-05
because O 0 2.405655763482173e-08
of O 0 3.392516934042078e-09
a O 0 2.699487708923698e-07
founder O 0 9.241042789653875e-06
effect O 0 3.128533990093274e-06
. O 0 1.2569482805702137e-06

While O 0 1.6324063835782e-05
very O 0 3.195911631337367e-06
few O 0 7.6033579716749955e-06
patients O 0 0.0010042814537882805
with O 0 2.1874471713090315e-05
AGU B-Disease 1 0.9999979734420776
have O 0 3.932036179321585e-06
been O 0 3.549367022515071e-07
reported O 0 4.3974065988550137e-07
from O 0 1.5472028991325715e-08
non O 0 9.839445880288622e-08
- O 0 1.191241608466953e-05
Finnish O 0 0.0030563094187527895
origin O 0 3.836631776721333e-07
, O 0 1.423564270908173e-07
we O 0 6.649084980381303e-07
diagnosed O 0 0.23807743191719055
the O 0 1.1732068969649845e-06
disorder O 0 0.4549916386604309
in O 0 7.860369919399091e-07
8 O 0 4.636908124666661e-05
patients O 0 0.000138673436595127
originating O 0 9.936175615621323e-08
from O 0 6.77762841405638e-08
3 O 0 3.8856492778904794e-07
unrelated O 0 2.662184442669968e-06
families O 0 1.3716748981096316e-07
, O 0 1.0840121689170701e-08
all O 0 3.850594509913208e-09
Palestinian O 0 5.708619710276253e-07
Arabs O 0 3.8972950733295875e-07
from O 0 1.2398570170546463e-08
the O 0 1.699344664984892e-08
region O 0 9.011049684204409e-08
of O 0 7.141282765132928e-08
Jerusalem O 0 4.0032522520050406e-05
. O 0 1.6683469539202633e-06

The O 0 6.359413237078115e-05
clinical O 0 0.17120468616485596
diagnosis O 1 0.993984043598175
of O 0 1.1749821169360075e-05
AGU B-Disease 1 0.9999972581863403
is O 0 6.36564845990506e-06
often O 0 1.111487563321134e-06
difficult O 0 5.584192308560887e-07
, O 0 4.5352344102411735e-08
in O 0 1.8804326984422914e-08
particular O 0 1.754558809352602e-08
early O 0 5.7232188765965475e-08
in O 0 9.90833282088488e-09
the O 0 1.4445550533537244e-08
course O 0 5.0694655584493375e-08
of O 0 8.799317718910515e-09
the O 0 1.1080774129368365e-06
disease O 0 0.0008121448918245733
, O 0 6.960264897770685e-08
and O 0 3.850707130936826e-08
most O 0 7.883611097270204e-09
of O 0 6.648081196658495e-09
the O 0 6.854747880424839e-07
patients O 0 0.10212302953004837
are O 0 1.2433640677045332e-06
diagnosed O 1 0.8475791811943054
after O 0 3.0105454129625286e-07
the O 0 3.8882582487076434e-08
age O 0 1.0987671572593172e-07
of O 0 1.7920093853263097e-08
5 O 0 8.178685106940975e-07
years O 0 9.707945309855859e-07
. O 0 1.2779213420799351e-06

However O 0 2.7191681510885246e-05
, O 0 5.292642981657991e-07
since O 0 2.666671718998259e-07
these O 0 5.319842699691435e-08
patients O 0 9.528628652333282e-06
excrete O 0 3.0354995033121668e-06
early O 0 2.501964218026842e-07
large O 0 3.1314328907683375e-08
amounts O 0 4.153929467065609e-08
of O 0 1.0454831667061626e-08
aspartylglucosamine O 0 2.6671787054510787e-05
in O 0 1.7055768353202438e-07
urine O 0 5.659515409206506e-06
, O 0 6.13301196494831e-08
biochemical O 0 9.155080533673754e-07
screening O 0 4.90379079565173e-07
is O 0 4.563130673318483e-08
easy O 0 2.507902934212325e-07
by O 0 2.20577419440815e-07
urine O 0 1.611653897271026e-05
chromatography O 0 1.626861558179371e-05
. O 0 2.5342538378936297e-07
. O 0 1.0434509931656066e-06

Detection O 0 0.00022767962946090847
of O 0 3.0966950816946337e-06
heterozygous O 0 9.179269545711577e-05
carriers O 0 3.3742994673957583e-06
of O 0 1.3214120997417922e-07
the O 0 8.857270586304367e-06
ataxia B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999383687973022
telangiectasia I-Disease 1 0.9999431371688843
( O 0 3.4921606584248366e-07
ATM O 0 1.179907826553972e-06
) O 0 2.700040369063572e-08
gene O 0 5.8721308704434705e-08
by O 0 2.2347860451077395e-08
G2 O 0 3.7683781556552276e-05
phase O 0 5.1379165597609244e-06
chromosomal O 0 4.440653356141411e-05
radiosensitivity O 0 2.894663884944748e-05
of O 0 3.0433903930315864e-07
peripheral O 0 0.0005007800064049661
blood O 0 0.0018820891855284572
lymphocytes O 0 0.0005395940388552845
. O 0 9.338131349068135e-06

In O 0 0.00943062175065279
ataxia B-Disease 1 0.9999955892562866
- I-Disease 1 0.999967098236084
telangiectasia I-Disease 1 0.9999896287918091
( O 0 0.0002757119946181774
A B-Disease 1 0.999657392501831
- I-Disease 1 0.9999610185623169
T I-Disease 1 0.9999985694885254
) O 0 1.2352726116660051e-05
patients O 0 0.0014420176157727838
, O 0 1.9134222384309396e-07
mutations O 0 1.0718285921029747e-06
in O 0 1.848389707959086e-08
a O 0 9.276154600001973e-08
single O 0 3.542803028722119e-07
gene O 0 1.4629851818881434e-07
, O 0 1.2433193141703214e-08
ATM O 0 4.937629682899569e-07
, O 0 3.654025704236119e-08
result O 0 9.220377705787541e-08
in O 0 2.981626892051281e-07
an O 0 0.038082994520664215
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.701140149634739e-06
embraces O 0 5.97440612182254e-06
a O 0 5.259479394226219e-07
variety O 0 7.345198582697776e-08
of O 0 4.886251758762228e-08
clinical O 0 9.958626833395101e-06
features O 0 3.7396162042568903e-06
and O 0 2.301354982137127e-07
manifests O 0 4.314135367167182e-05
extreme O 0 0.00018953281687572598
radiosensitivity O 0 0.00016645471623633057
and O 0 5.188823593016423e-08
a O 0 1.1631099994247052e-07
strong O 0 2.2324839221710135e-07
pre O 0 4.991607511328766e-06
- O 0 0.00010035526065621525
disposition O 0 5.4159212595550343e-05
to O 0 5.693717412214028e-06
malignancy B-Disease 0 0.010204545222222805
. O 0 9.704209332994651e-06

Heterozygotes O 0 0.007091588340699673
for O 0 1.1231402368139243e-06
the O 0 1.2463422649489075e-07
ATM O 0 2.719487383728847e-06
gene O 0 4.288872901270224e-07
have O 0 4.833140110349632e-08
no O 0 1.2538242799564614e-07
clinical O 0 5.649711056321394e-06
expression O 0 9.24960602333158e-07
of O 0 9.058058481059561e-08
A B-Disease 1 0.9961997866630554
- I-Disease 1 0.9999748468399048
T I-Disease 1 0.9999980926513672
but O 0 7.231235485960497e-06
may O 0 2.998701802425785e-06
be O 0 7.204172902675055e-07
cancer B-Disease 0 0.008548282086849213
prone O 0 2.524852243368514e-05
with O 0 1.7217722358964238e-07
a O 0 1.8586296164357918e-06
moderate O 0 0.002235432155430317
increase O 0 8.143008471961366e-07
in O 0 1.1881469674790424e-07
in O 0 6.00520763782697e-07
vitro O 0 0.0006937518483027816
radiosensitivity O 0 0.0032010783907026052
. O 0 5.46339106222149e-06

We O 0 4.733470632345416e-06
performed O 0 3.4786196465574903e-06
a O 0 1.138885522777855e-06
blind O 0 3.828803528449498e-05
chromosomal O 0 0.0001381718466291204
analysis O 0 8.820971970635583e-07
on O 0 1.3277690413815435e-06
G2 O 0 0.008586731739342213
- O 0 0.0002561048313509673
phase O 0 2.0297729861340486e-05
lymphocytes O 0 1.1875710697495379e-05
from O 0 5.651892820424109e-08
7 O 0 6.834825398982503e-07
unrelated O 0 6.980319085414521e-06
A B-Disease 1 0.9989942908287048
- I-Disease 1 0.9999957084655762
T I-Disease 1 1.0
patients O 1 0.9708957076072693
, O 0 1.6891613086045254e-07
13 O 0 2.056176242604124e-07
obligate O 0 1.2125939292673138e-06
A B-Disease 1 0.973612368106842
- I-Disease 1 0.9998384714126587
T I-Disease 1 0.9999963045120239
heterozygotes O 0 0.0036463746801018715
( O 0 6.27098444283547e-08
parents O 0 4.920631724303348e-08
of O 0 6.568798838202383e-09
the O 0 3.065025850901293e-07
patients O 0 0.007383767515420914
) O 0 3.4245566382651305e-08
, O 0 2.0973580205918552e-08
and O 0 1.6127538415844356e-08
14 O 0 7.491983922136569e-08
normal O 0 8.24965979973058e-08
controls O 0 8.317898050336225e-07
following O 0 1.8352812958255527e-07
X O 0 9.937377399182878e-06
- O 0 2.9598086257465184e-06
irradiation O 0 2.5424508294236148e-06
with O 0 1.0101102532189543e-07
1 O 0 2.4967252443275356e-07
Gy O 0 7.106675911927596e-05
in O 0 1.889366529894687e-08
order O 0 1.601595656097743e-08
to O 0 2.6947464704107915e-08
evaluate O 0 2.819326709868619e-07
this O 0 2.3000684024054863e-08
cytogenetic O 0 1.7206466509378515e-05
method O 0 1.308778934117072e-07
as O 0 1.562449014613776e-08
a O 0 3.978150786565493e-08
tool O 0 1.8683920188777847e-07
for O 0 3.868249009997271e-08
detection O 0 4.430704336755298e-07
of O 0 1.3380395103013143e-07
ATM O 0 3.1832831155043095e-05
carriers O 0 7.312233719858341e-06
. O 0 2.223738874818082e-06

Both O 0 2.3534297724836506e-05
A B-Disease 0 0.4653329849243164
- I-Disease 1 0.9983709454536438
T I-Disease 1 0.9999610185623169
homozygotes O 0 0.0009890415240079165
and O 0 3.5402936759965087e-07
heterozygotes O 0 5.484976281877607e-05
showed O 0 1.529716610093601e-05
significantly O 0 7.774923460601713e-07
increased O 0 1.321762539419069e-07
levels O 0 2.8798137208241315e-08
of O 0 3.137375159667499e-08
radiation O 0 0.14922396838665009
- O 0 0.018099475651979446
induced O 1 0.7360601425170898
chromatid O 1 0.9648240804672241
damage O 0 0.00021437386749312282
relative O 0 7.183015213740873e-07
to O 0 4.318142998727126e-08
that O 0 1.3402982723675905e-08
of O 0 3.3526877274425715e-08
normal O 0 9.932809916790575e-07
controls O 0 1.8650964193511754e-05
. O 0 3.940621809306322e-06

These O 0 8.446899300906807e-06
results O 0 3.5258158277429175e-06
show O 0 6.876859970361693e-07
that O 0 3.5259930086795066e-08
the O 0 4.1309295539804225e-08
G2 O 0 0.0003293761983513832
- O 0 9.815920202527195e-05
phase O 0 3.6244571219867794e-06
chromosomal O 0 3.6917881516274065e-05
radiosensitivity O 0 5.0931434088852257e-05
assay O 0 3.2104398997034878e-06
can O 0 3.320257846439745e-08
be O 0 4.926019148143723e-09
used O 0 1.434713858827763e-08
for O 0 5.662766699998656e-09
the O 0 1.1712876890612733e-08
detection O 0 3.342765637626144e-07
of O 0 9.007062828914059e-08
A B-Disease 1 0.9930481314659119
- I-Disease 1 0.999893307685852
T I-Disease 1 0.9999914169311523
heterozygotes O 0 0.009031791239976883
. O 0 6.093007414165186e-06

In O 0 1.928721940203104e-05
combination O 0 2.142356606782414e-05
with O 0 9.834565162236686e-07
molecular O 0 6.78855722071603e-05
genetic O 0 1.567118670209311e-05
analyses O 0 1.9499943846312817e-06
, O 0 5.536162461794447e-08
this O 0 2.1491890933589275e-08
test O 0 5.252953201306809e-07
may O 0 1.3728356407227693e-07
be O 0 2.847863278532259e-09
of O 0 1.1082587070276873e-09
value O 0 5.082969600778142e-09
in O 0 1.1484970308117681e-08
studies O 0 2.936086573868124e-08
of O 0 9.293080083239147e-09
familial B-Disease 0 5.4480791732203215e-05
and I-Disease 0 3.1720931019663112e-06
sporadic I-Disease 0 0.03053842857480049
cancers I-Disease 0 0.13835446536540985
aimed O 0 6.7849873630621e-07
at O 0 7.853808625668535e-08
determination O 0 3.2602738997411507e-07
of O 0 4.692405575212888e-09
the O 0 1.0305649666975114e-08
potential O 0 3.838951556645043e-08
involvement O 0 1.0468244937555937e-07
of O 0 2.0831846470059645e-08
ATM O 0 7.725609611952677e-05
mutations O 0 3.175960591761395e-05
in O 0 5.781935215054546e-07
tumor B-Disease 0 0.02694382518529892
risk O 0 3.834835297311656e-06
or O 0 1.11572759919909e-07
development O 0 1.846327108978585e-07
. O 0 3.73371477735418e-07
. O 0 1.6311753370246151e-06

Ataxia B-Disease 1 0.9999921321868896
- I-Disease 1 0.9998283386230469
telangiectasia I-Disease 1 0.9998639822006226
: O 0 8.780686584941577e-06
identification O 0 7.811378850419715e-07
and O 0 8.270187379366689e-08
detection O 0 2.983060483074951e-07
of O 0 2.5178957585580974e-08
founder O 0 1.2016853361274116e-05
- O 0 0.0002265708608319983
effect O 0 3.0557030186173506e-06
mutations O 0 1.0327382824470988e-06
in O 0 1.1883176220806035e-08
the O 0 1.8776049159896502e-08
ATM O 0 1.3386232922130148e-06
gene O 0 3.009431566169951e-07
in O 0 9.768872644144722e-08
ethnic O 0 7.84585608926136e-07
populations O 0 1.8754860775516136e-06
. O 0 1.9264712136646267e-06

To O 0 4.133005404582946e-06
facilitate O 0 8.301905154439737e-07
the O 0 8.512927962556205e-08
evaluation O 0 1.082444427424889e-07
of O 0 2.386743780391498e-08
ATM O 0 4.745036221720511e-06
heterozygotes O 0 2.7255779059487395e-05
for O 0 1.8590785089145356e-07
susceptibility O 0 0.0003357976966071874
to O 0 8.27055657737219e-07
other O 0 5.095707820146345e-07
diseases O 0 0.0003164323861710727
, O 0 4.982339163461802e-08
such O 0 4.403126041552241e-08
as O 0 0.0007532117306254804
breast B-Disease 1 0.9999810457229614
cancer I-Disease 1 0.9802327156066895
, O 0 1.5743452763672394e-07
we O 0 1.6893972443199345e-08
have O 0 9.712834980746266e-09
attempted O 0 4.667147379677772e-07
to O 0 3.931848979732422e-08
define O 0 1.5543321296718204e-07
the O 0 2.1113137904649193e-08
most O 0 3.801542547421377e-08
common O 0 1.5616274140484165e-07
mutations O 0 6.797772584832273e-07
and O 0 2.2110262065666575e-08
their O 0 4.152194676976251e-08
frequencies O 0 5.21529364050366e-06
in O 0 4.2798451431735884e-06
ataxia B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999794960021973
telangiectasia I-Disease 1 0.9999951124191284
( O 0 3.338172973599285e-06
A B-Disease 1 0.9637203216552734
- I-Disease 1 0.999017596244812
T I-Disease 1 0.9999604225158691
) O 0 3.667740031687572e-07
homozygotes O 0 8.354647434316576e-06
from O 0 4.755532856393074e-08
10 O 0 9.098056352740969e-08
ethnic O 0 4.837511369260028e-07
populations O 0 1.1507903536767117e-06
. O 0 1.671528821134416e-06

Both O 0 1.3523332199838478e-05
genomic O 0 7.552490569651127e-05
mutations O 0 0.00019299148698337376
and O 0 1.846887158762911e-07
their O 0 5.620094967184741e-08
effects O 0 8.145182732732792e-07
on O 0 2.9933337941656646e-07
cDNA O 0 3.646545337687712e-06
were O 0 5.596485834757914e-07
characterized O 0 8.91486070031533e-06
. O 0 3.193885277141817e-06

Protein O 0 2.5775310859899037e-05
- O 0 2.739229421422351e-05
truncation O 0 1.5408970284624957e-05
testing O 0 1.0211942935711704e-06
of O 0 1.730387388931831e-08
the O 0 1.954870754161675e-08
entire O 0 1.273782856969774e-07
ATM O 0 4.7310334139183396e-07
cDNA O 0 1.2315392723394325e-06
detected O 0 1.4405113688553683e-06
92 O 0 9.802420208870899e-07
( O 0 7.098762466739572e-08
66 O 0 1.8250689208798576e-06
% O 0 8.503856463448756e-08
) O 0 3.833098105587851e-08
truncating O 0 8.139459168887697e-06
mutations O 0 4.737317794933915e-06
in O 0 5.28803596466787e-08
140 O 0 8.380641247640597e-07
mutant O 0 4.098890713066794e-05
alleles O 0 1.1095516128989402e-05
screened O 0 2.9949957024655305e-05
. O 0 3.377747589183855e-06

The O 0 1.177383637696039e-05
haplotyping O 0 0.0006938794394955039
of O 0 1.7461328525314457e-06
patients O 0 0.0013309998903423548
with O 0 8.339318924299732e-07
identical O 0 0.021153192967176437
mutations O 0 8.931125921662897e-05
indicates O 0 2.912877619110077e-07
that O 0 1.261627513571284e-08
almost O 0 1.2705624996556253e-08
all O 0 1.1556864354389518e-09
of O 0 1.929976845005399e-09
these O 0 4.373460704698573e-09
represent O 0 2.5911417012025595e-08
common O 0 9.2387921313275e-08
ancestry O 0 7.388940161945357e-07
and O 0 3.021099814759509e-08
that O 0 2.9195902584433497e-08
very O 0 5.632393396126645e-08
few O 0 1.69785181469706e-07
spontaneously O 0 3.3518199415993877e-06
recurring O 0 8.854070074448828e-06
ATM O 0 4.7010988055262715e-05
mutations O 0 1.6613434127066284e-05
exist O 0 8.824454766909184e-07
. O 0 1.3290485867401003e-06

Assays O 0 0.0011044787243008614
requiring O 0 5.7422246754867956e-05
minimal O 0 1.599345705471933e-05
amounts O 0 9.520476282887103e-07
of O 0 5.039733608214192e-08
genomic O 0 2.3072493604558986e-06
DNA O 0 3.4886963931057835e-06
were O 0 4.217727322952669e-08
designed O 0 1.6836865768254938e-07
to O 0 2.2130260290964543e-08
allow O 0 6.233277360934153e-08
rapid O 0 1.243608380718797e-06
screening O 0 1.646160512791539e-06
for O 0 2.915954269155918e-07
common O 0 9.498810413788306e-07
ethnic O 0 7.751500561425928e-06
mutations O 0 0.00013299626880325377
. O 0 4.502972842601594e-06

These O 0 8.672737749293447e-06
rapid O 0 1.4290285434981342e-05
assays O 0 3.206102337571792e-05
detected O 0 3.210557042621076e-05
mutations O 0 8.174340109690093e-06
in O 0 1.3005993082515488e-07
76 O 0 8.430860361841042e-06
% O 0 6.611349334662009e-08
of O 0 2.438780910551941e-08
Costa O 0 4.7279481805162504e-06
Rican O 0 0.0036023308057338
patients O 0 0.2638075649738312
( O 0 5.3487781315197935e-08
3 O 0 8.112208149668731e-08
) O 0 9.701780712134678e-09
, O 0 1.000846960863555e-08
50 O 0 1.9203501011588742e-08
% O 0 6.231444693582944e-09
of O 0 4.8420325526876695e-09
Norwegian O 1 0.5034993886947632
patients O 0 0.056732188910245895
( O 0 2.970123880174924e-08
1 O 0 3.7607954084251105e-08
) O 0 1.4445633134130276e-08
, O 0 9.818070800804435e-09
25 O 0 3.550097460447432e-08
% O 0 8.875980839206932e-09
of O 0 1.1759391682630849e-08
Polish O 0 0.49423980712890625
patients O 0 0.09987135976552963
( O 0 2.565265866394384e-08
4 O 0 4.826682342695676e-08
) O 0 4.93352247943335e-09
, O 0 4.172158618587218e-09
and O 0 6.382431916307496e-09
14 O 0 6.019025278192203e-08
% O 0 5.539190883752099e-09
of O 0 4.652284335548984e-09
Italian O 0 0.052667416632175446
patients O 0 0.1983002871274948
( O 0 3.871652154430194e-08
1 O 0 3.482315946712333e-08
) O 0 1.0214476375836057e-08
, O 0 9.742483264574275e-09
as O 0 8.575161025703437e-09
well O 0 2.995115266912762e-08
as O 0 6.958287457337065e-08
in O 0 4.241797171289363e-07
patients O 0 1.413971676811343e-05
of O 0 4.9280142633278956e-08
Amish O 0 4.1108261939371005e-05
/ O 0 8.596618499723263e-06
Mennonite O 0 5.838810011482565e-06
and O 0 3.10937934955291e-07
Irish O 0 1.4038271274330327e-06
English O 0 7.570687330371584e-07
backgrounds O 0 2.8369947813189356e-06
. O 0 2.502112465663231e-06

Additional O 0 0.00011031706526409835
mutations O 0 0.0010205615544691682
were O 0 1.3277715424919734e-06
observed O 0 8.102278457045031e-07
in O 0 5.320491780480552e-08
Japanese O 0 2.934295935119735e-07
, O 0 3.631542000448462e-08
Utah O 0 2.331749016093454e-07
Mormon O 0 2.4463543013553135e-07
, O 0 1.721170761470603e-08
and O 0 3.406186266374789e-08
African O 0 1.6560949234190048e-07
American O 0 1.922123828990152e-06
patients O 0 0.0004057625192217529
. O 0 2.4059143015620066e-06

These O 0 3.3913979677890893e-06
assays O 0 1.0400759492767975e-05
should O 0 1.7864985579763015e-07
facilitate O 0 1.400584039856767e-07
screening O 0 8.738822430132132e-07
for O 0 3.0916234550204535e-07
A B-Disease 1 0.9947831034660339
- I-Disease 1 0.9998900890350342
T I-Disease 1 0.9999966621398926
heterozygotes O 0 0.0007617151131853461
in O 0 9.300300973791309e-08
the O 0 7.07721312664944e-08
populations O 0 4.240503130858997e-07
studied O 0 5.893910497434263e-07
. O 0 2.009815460723985e-07
. O 0 1.094904860110546e-06

The O 0 4.241558781359345e-05
von B-Disease 1 0.7108725905418396
Hippel I-Disease 1 0.9774262309074402
- I-Disease 1 0.6631879806518555
Lindau I-Disease 1 0.9698002338409424
tumor I-Disease 0 0.030627967789769173
suppressor O 0 0.0001730893418425694
gene O 0 3.03488309327804e-06
is O 0 6.755532666602448e-08
required O 0 5.219495236019611e-08
for O 0 2.6530948105119023e-08
cell O 0 5.947312729404075e-06
cycle O 0 1.5260313830367522e-06
exit O 0 2.360392272748868e-06
upon O 0 4.6950174237281317e-07
serum O 0 1.251542562386021e-05
withdrawal O 0 2.037767626461573e-05
. O 0 3.3021874514815863e-06

The O 0 5.3635480981029104e-06
inactivation O 0 0.00010238787945127115
of O 0 2.837360852936399e-07
the O 0 5.884508595954685e-07
von B-Disease 0 0.2924010157585144
Hippel I-Disease 1 0.9919474720954895
- I-Disease 1 0.8757848739624023
Lindau I-Disease 1 0.9698534607887268
( I-Disease 0 1.4534801948684617e-06
VHL I-Disease 0 0.0005090158083476126
) I-Disease 0 4.3430222262941243e-07
tumor I-Disease 0 5.040178803028539e-05
suppressor O 0 8.25582246761769e-05
gene O 0 4.7962148528313264e-06
predisposes O 0 0.00031601390219293535
affected O 0 6.630898496950977e-07
individuals O 0 2.7032971416929286e-08
to O 0 3.59832199592347e-08
the O 0 4.5879022536610137e-07
human O 0 0.004982877057045698
VHL B-Disease 1 0.9999995231628418
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
and O 0 3.1912882150209043e-06
is O 0 4.799133535016153e-07
associated O 0 5.604102284451074e-07
with O 0 1.0937693559753825e-06
sporadic B-Disease 1 0.9958876967430115
renal I-Disease 1 0.9999997615814209
cell I-Disease 1 0.9999966621398926
carcinomas I-Disease 1 0.9999997615814209
( O 0 5.0036054744850844e-05
RCC B-Disease 0 0.19771498441696167
) O 0 3.6120925983595953e-07
and O 0 6.228452207324153e-07
brain B-Disease 0 0.0027772036846727133
hemangioblastomas I-Disease 0 0.0007703526644036174
. O 0 4.017389073851518e-06

VHL O 0 0.4467284679412842
- O 0 0.01589604839682579
negative O 0 0.00038327957736328244
786 O 0 0.0012627310352399945
- O 0 0.10505624115467072
0 O 0 0.00012215723108965904
RCC B-Disease 0 0.020711952820420265
cells O 0 5.1516985877242405e-06
are O 0 1.0174347409019902e-07
tumorigenic O 0 5.687346128979698e-05
in O 0 6.414886115635454e-07
nude O 0 0.2565849721431732
mice O 0 0.008726658299565315
which O 0 1.57249502308332e-07
is O 0 3.740221998782545e-08
suppressed O 0 3.920325184481044e-07
by O 0 1.9406309448299908e-08
the O 0 3.3192574022677945e-08
reintroduction O 0 4.448102572496282e-06
of O 0 6.712915023854293e-07
VHL B-Disease 0 0.002503852592781186
. O 0 7.872712558310013e-06

Remarkably O 0 0.009990321472287178
, O 0 2.7178459731658222e-06
this O 0 1.4688610860957851e-07
occurs O 0 1.6818233916637837e-07
without O 0 5.494871402333956e-08
affecting O 0 9.418135960004292e-08
the O 0 2.0123138710914645e-08
growth O 0 1.2448752784166572e-07
rate O 0 1.334149430931575e-07
and O 0 2.9462629669296803e-08
cell O 0 2.701207449717913e-06
cycle O 0 5.907405125071818e-07
profile O 0 9.643354133004323e-07
of O 0 9.53917034252072e-09
these O 0 1.8642730026385834e-08
cells O 0 2.8821830255765235e-07
in O 0 4.171579703893258e-08
culture O 0 5.30206477833417e-07
. O 0 2.0910306375299115e-06

The O 0 1.476227589591872e-05
786 O 0 0.0003236409684177488
- O 0 0.0005421550013124943
0 O 0 4.762935532198753e-06
cell O 0 7.94924926594831e-06
line O 0 8.046865218602761e-07
, O 0 5.406628034165806e-08
like O 0 1.4933830527752434e-07
many O 0 4.5776053525514726e-07
cancer B-Disease 0 0.0336688794195652
cells O 0 3.054164835702977e-06
, O 0 6.343065450664653e-08
fails O 0 2.5223503143934067e-06
to O 0 3.841764240064549e-08
exit O 0 5.136854497322929e-07
the O 0 4.5378733659617865e-08
cell O 0 5.728641554014757e-06
cycle O 0 1.1453707884356845e-06
upon O 0 4.944443503518414e-07
serum O 0 2.165584737667814e-05
withdrawal O 0 2.3087432055035606e-05
. O 0 3.8802381823188625e-06

Here O 0 1.922854244185146e-05
, O 0 5.240434006736905e-07
it O 0 6.76892071282964e-08
is O 0 2.4449661850667326e-08
shown O 0 8.266623297004116e-08
that O 0 9.36679001029006e-09
reintroduction O 0 2.4101299800349807e-07
of O 0 8.115191185709136e-09
the O 0 1.3928392661455291e-08
wild O 0 1.4068491793750582e-07
- O 0 4.7894649469526485e-05
type O 0 6.432917871279642e-06
VHL B-Disease 0 0.000112197820271831
gene O 0 4.2972536107299675e-07
restores O 0 8.72936084306275e-07
the O 0 2.0653811105830755e-08
ability O 0 7.620030828547897e-08
of O 0 3.2249616310764395e-08
VHL O 0 0.004987908527255058
- O 0 0.24854327738285065
negative O 0 0.008954925462603569
RCC B-Disease 1 0.9996063113212585
cancer I-Disease 1 0.8636700510978699
cells O 0 1.2516361493908335e-06
to O 0 3.6924895141510206e-08
exit O 0 4.7540228820253105e-07
the O 0 3.0639149883882055e-08
cell O 0 1.4162063735057018e-06
cycle O 0 2.1806873462537624e-07
and O 0 3.7619503956420886e-08
enter O 0 3.702264166349778e-07
G0 O 0 0.00019791604427155107
/ O 0 1.3897252756578382e-05
quiescence O 0 5.795183824375272e-05
in O 0 1.0688927432056516e-06
low O 0 2.1333493350539356e-05
serum O 0 0.00014774742885492742
. O 0 6.452894012909383e-06

Both O 0 5.5869466450531036e-05
VHL O 0 0.0054282452911138535
- O 0 0.000494501437060535
positive O 0 3.1676522667112295e-06
and O 0 4.1114600435321336e-07
VHL O 0 0.00024111643142532557
- O 0 0.00044265136239118874
negative O 0 2.4707609554752707e-05
RCC B-Disease 0 0.014261970296502113
cells O 0 2.42690771301568e-06
exit O 0 9.23207835512585e-07
the O 0 5.6795467884285245e-08
cell O 0 5.311748282110784e-06
cycle O 0 8.838460985316487e-07
by O 0 1.3583745328560326e-07
contact O 0 9.478069955548563e-07
inhibition O 0 7.798094884492457e-06
. O 0 3.7783102015964687e-06

The O 0 1.3813743862556294e-05
cyclin O 0 0.000275696482276544
- O 0 2.176707494072616e-05
dependent O 0 2.1843143258593045e-06
kinase O 0 5.124772087583551e-06
inhibitor O 0 2.8720960472128354e-06
, O 0 2.059915260588241e-07
p27 O 0 1.0650876902218442e-05
, O 0 8.558873076935924e-08
accumulates O 0 1.4340922689370927e-06
upon O 0 1.5364726380084903e-07
serum O 0 2.314215407750453e-06
withdrawal O 0 1.066998493115534e-06
, O 0 2.5939206338421172e-08
only O 0 6.210999270450657e-09
in O 0 4.878054848944657e-09
the O 0 5.218457221900508e-09
presence O 0 2.4928320740968957e-08
of O 0 1.4305440387829549e-08
VHL B-Disease 0 0.0004589197051245719
, O 0 4.524443042441817e-08
as O 0 1.0048830212383564e-08
a O 0 8.544780172314859e-08
result O 0 3.0135492323779545e-08
of O 0 2.5627995281496396e-09
the O 0 8.470505186153332e-09
stabilization O 0 1.4052615426862758e-07
of O 0 1.6134892533159473e-08
the O 0 1.0911276859815189e-07
protein O 0 3.104279358012718e-06
. O 0 1.5137009086174658e-06

We O 0 8.97413701750338e-06
propose O 0 1.0773578651424032e-05
that O 0 1.6874851382908673e-07
the O 0 8.396499850960026e-08
loss O 0 1.3886265151086263e-06
of O 0 2.169940671592485e-08
wild O 0 5.828400730933936e-07
- O 0 0.0004775583220180124
type O 0 1.0517459486436564e-05
VHL B-Disease 0 0.0008788903360255063
gene O 0 1.3084347756375792e-06
results O 0 1.9501713666159048e-07
in O 0 1.1948312561571584e-08
a O 0 1.3639851204061415e-07
specific O 0 6.727835000219784e-08
cellular O 0 3.6939083656761795e-05
defect O 0 9.15626878850162e-05
in O 0 3.1693912205810193e-07
serum O 0 1.6197636796277948e-05
- O 0 1.4117743376118597e-05
dependent O 0 4.980914241059509e-07
growth O 0 1.0513044657045612e-07
control O 0 2.2753783923690207e-07
, O 0 3.447067342676746e-08
which O 0 7.274024937942158e-08
may O 0 4.574472427520959e-07
initiate O 0 7.278491011675214e-06
tumor B-Disease 0 0.0028843251056969166
formation O 0 3.5328807825862896e-06
. O 0 2.021261252593831e-06

This O 0 9.630619388190098e-06
is O 0 1.1723803936547483e-06
corrected O 0 5.58973533770768e-06
by O 0 3.294456973890192e-08
the O 0 2.153834621765327e-08
reintroduction O 0 5.421528044280421e-07
of O 0 1.9354631675128076e-08
wild O 0 7.898038916209771e-07
- O 0 0.0014936106745153666
type O 0 5.549627894652076e-05
VHL B-Disease 0 0.006404855754226446
, O 0 4.004682807590143e-07
implicating O 0 6.640987703576684e-05
VHL B-Disease 0 0.0003335438668727875
as O 0 4.673873021943109e-08
the O 0 1.2298987606129685e-08
first O 0 1.220132617163472e-07
tumor B-Disease 0 8.124833584588487e-06
suppressor O 0 6.905125246703392e-06
involved O 0 6.327912416281833e-08
in O 0 1.1940065824944668e-08
the O 0 8.242860616292091e-09
regulation O 0 5.926466783989781e-08
of O 0 1.2238753122062462e-08
cell O 0 5.593179594143294e-06
cycle O 0 9.552608162266552e-07
exit O 0 3.839142209471902e-06
, O 0 4.001345743631646e-08
which O 0 2.0729665095586824e-08
is O 0 9.072025797252081e-09
consistent O 0 4.35547349297849e-08
with O 0 1.3108245155990517e-08
its O 0 4.672268616445763e-08
gatekeeper O 0 1.0202646080870181e-05
function O 0 8.893778868923619e-08
in O 0 3.744954568674075e-08
the O 0 2.907105169924762e-07
kidney O 0 0.047477688640356064
. O 0 1.3940506278231624e-06
. O 0 1.932702161866473e-06

Piebaldism B-Disease 1 0.9998518228530884
with O 0 0.23497270047664642
deafness B-Disease 1 0.9999996423721313
: O 0 2.6443140086485073e-05
molecular O 0 1.745232475514058e-05
evidence O 0 1.0780038337543374e-06
for O 0 1.8744566432360443e-07
an O 0 2.9531743166444357e-06
expanded O 0 0.012534533627331257
syndrome O 1 0.9999057054519653
. O 0 4.681591690314235e-06

In O 0 6.3330830926133785e-06
a O 0 1.7871643649414182e-06
South O 0 3.3727152981555264e-07
African O 0 1.8612463748013397e-07
girl O 0 2.102245844071149e-06
of O 0 5.2350888068986023e-08
Xhosa O 0 0.0001089411525754258
stock O 0 6.727617005708453e-07
with O 0 1.599405976548951e-07
severe O 0 0.026522507891058922
piebaldism B-Disease 0 0.4834653437137604
and O 0 2.581575245130807e-05
profound O 1 0.988381028175354
congenital O 1 0.9999998807907104
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 9.05426568351686e-05
identified O 0 3.4443576168996515e-06
a O 0 2.8734061174873204e-07
novel O 0 1.3671774468093645e-06
missense O 0 3.4746410619845847e-06
substitution O 0 1.1158914503539563e-07
at O 0 2.2754580442096994e-08
a O 0 7.351014374989973e-08
highly O 0 5.25733270251294e-08
conserved O 0 6.461808510493938e-08
residue O 0 7.577391158974933e-08
in O 0 8.400756534854281e-09
the O 0 6.917183714705288e-09
intracellular O 0 2.5533628900120675e-07
kinase O 0 1.8504341880998254e-07
domain O 0 2.0094795161185175e-08
of O 0 2.3642241497867644e-09
the O 0 1.4370199252766724e-08
KIT O 0 1.2422082363627851e-05
proto O 0 0.009612697176635265
- O 0 0.00020537020463962108
oncogene O 0 0.0002207538636866957
, O 0 8.737472967368376e-07
R796G O 0 5.0580907554831356e-05
. O 0 3.14749195240438e-06

Though O 0 0.0002932853240054101
auditory B-Disease 0 0.006380356382578611
anomalies I-Disease 0 0.2695041298866272
have O 0 3.5302030028105946e-06
been O 0 4.3363178292565863e-07
observed O 0 7.768972523081175e-07
in O 0 1.536229348175766e-07
mice O 0 8.805972902337089e-05
with O 0 1.7370579996622837e-07
dominant O 0 1.2191652785986662e-05
white O 0 1.36281469167443e-05
spotting O 0 0.0003427068004384637
( O 0 1.3301618082550704e-06
W O 0 0.027652231976389885
) O 0 6.242473915563096e-08
due O 0 1.7101095295402047e-07
to O 0 4.0091919117912767e-07
KIT O 0 0.43419548869132996
mutations O 0 0.004720707889646292
, O 0 1.4795314200455323e-05
deafness B-Disease 1 0.9999992847442627
is O 0 8.587961133343924e-07
not O 0 1.5432631528256024e-07
typical O 0 1.2853136013291078e-06
in O 0 3.5711718737729825e-07
human O 0 1.853885351010831e-06
piebaldism B-Disease 0 0.0015958886360749602
. O 0 4.392625669424888e-06

Thus O 0 3.838377961074002e-05
, O 0 5.853182756254682e-07
the O 0 1.510731522103015e-07
occurrence O 0 1.7764047015589313e-06
of O 0 6.31551642982231e-07
sensorineural B-Disease 1 0.9999954700469971
deafness I-Disease 1 1.0
in O 0 9.566134394844994e-05
this O 0 1.6196702290471876e-06
patient O 0 0.0002975380339194089
extends O 0 1.1058394193241838e-05
considerably O 0 2.1556754745688522e-06
the O 0 3.009735394243762e-08
phenotypic O 0 2.1655680484400364e-06
range O 0 5.6481752608306124e-08
of O 0 1.003569050084252e-08
piebaldism B-Disease 0 2.8704185751848854e-05
due O 0 3.8598255969191086e-07
to O 0 1.2697393003691104e-07
KIT O 0 8.293903374578804e-05
gene O 0 2.100772690027952e-06
mutation O 0 1.006116235657828e-06
in O 0 5.6705303563830967e-08
humans O 0 1.1232586416554113e-07
and O 0 4.9452168582320155e-08
tightens O 0 0.08540742844343185
the O 0 3.999743967142422e-07
clinical O 0 3.431603909120895e-05
similarity O 0 1.2580611610246706e-06
between O 0 6.070121827406183e-08
piebaldism B-Disease 0 3.513009141897783e-05
and O 0 2.6225054128303782e-08
the O 0 1.922130898890373e-08
various O 0 2.289506895181148e-08
forms O 0 4.948207674715377e-07
of O 0 1.051777053362457e-05
Waardenburg B-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.999996542930603
. O 0 2.4786900212347973e-06
. O 0 2.5391070721525466e-06

Cycloheximide O 0 0.000700921518728137
facilitates O 0 2.6466173949302174e-05
the O 0 5.183887878956739e-07
identification O 0 3.995009194568411e-07
of O 0 8.484576596856641e-08
aberrant O 0 1.3606629181595054e-05
transcripts O 0 1.938417335622944e-05
resulting O 0 1.0038753543994972e-06
from O 0 2.6823213872262386e-08
a O 0 1.8745745933301805e-07
novel O 0 6.086155508455704e-07
splice O 0 7.209051091194851e-06
- O 0 3.194266901118681e-05
site O 0 6.571827952939202e-07
mutation O 0 6.714535061291826e-07
in O 0 3.186088903817108e-08
COL17A1 O 0 7.992822793312371e-05
in O 0 1.011386459026653e-07
a O 0 2.9509528758353554e-06
patient O 0 0.00020550597400870174
with O 0 5.554795279749669e-06
generalized O 0 0.10671436786651611
atrophic B-Disease 1 0.9998743534088135
benign I-Disease 1 0.9985079169273376
epidermolysis I-Disease 1 0.9995318651199341
bullosa I-Disease 1 0.9982007741928101
. O 0 0.00011147882469231263

Patients O 1 0.9949764013290405
with O 0 4.5513559598475695e-05
generalized O 0 0.04606969654560089
atrophic B-Disease 1 0.999659538269043
benign I-Disease 1 0.998046875
epidermolysis I-Disease 1 0.9994623064994812
bullosa I-Disease 1 0.9980661273002625
often O 0 6.589190888917074e-05
show O 0 8.330175660375971e-06
decreased O 0 2.6690659069572575e-06
expression O 0 2.846396682798513e-07
of O 0 5.0607226853571774e-08
type O 0 4.063931100972695e-06
XVII O 0 0.27624139189720154
collagen O 0 0.0003057520661968738
, O 0 1.286224176055839e-07
a O 0 5.204018407312105e-07
transmembrane O 0 6.689896054012934e-06
hemidesmosomal O 0 7.196068509074394e-06
protein O 0 1.6948621350820758e-07
encoded O 0 1.4913749168954382e-07
by O 0 1.0612995282599513e-07
COL17A1 O 0 0.00010264674347126856
. O 0 2.5337201350339456e-06

This O 0 1.1766540410462767e-05
report O 0 4.528968929662369e-06
documents O 0 7.2224781888508e-07
a O 0 3.1247301990333654e-07
novel O 0 7.725639648015203e-07
splice O 0 1.2318387234699912e-05
- O 0 4.2284696974093094e-05
site O 0 8.164548148670292e-07
mutation O 0 6.503960889858718e-07
in O 0 4.356071769962e-08
COL17A1 O 0 0.00013437015877570957
in O 0 2.2306984703845956e-07
a O 0 2.5808412829064764e-06
patient O 0 0.00041244507883675396
with O 0 5.110164693178376e-06
generalized O 0 0.029067756608128548
atrophic B-Disease 1 0.9999024868011475
benign I-Disease 1 0.9950749278068542
epidermolysis I-Disease 1 0.9995552897453308
bullosa I-Disease 1 0.9991939663887024
, O 0 2.323109129065415e-06
and O 0 1.1059516680234083e-07
applies O 0 1.5884567972079822e-07
a O 0 6.894872939255947e-08
new O 0 4.2112723974696564e-08
methodology O 0 1.1231515628651323e-07
to O 0 5.072222464264087e-08
define O 0 3.994209407665039e-07
and O 0 8.677056939632166e-08
characterize O 0 1.2495048622440663e-06
the O 0 3.6121853952408856e-08
resulting O 0 5.692180593541707e-07
mRNA O 0 9.417746582585096e-07
splice O 0 2.3506328943767585e-05
variants O 0 6.092466719564982e-06
. O 0 3.6631433886213927e-06

Mutational O 1 0.6219361424446106
analysis O 0 0.00012422264262568206
of O 0 2.8548427053465275e-06
COL17A1 O 0 0.009419439360499382
identified O 0 5.6415487961203326e-06
a O 0 1.9504927877278533e-06
maternally O 0 0.00022181932581588626
inherited O 0 0.0001745594636304304
G O 0 0.00020205526379868388
- O 0 1.6125612091855146e-05
to O 0 4.7305417183451937e-07
- O 0 0.00025157604250125587
T O 0 0.0007674071821384132
transversion O 0 7.486000413337024e-06
at O 0 2.244902574943808e-08
the O 0 9.810583456726363e-09
- O 0 1.429526037100004e-06
1 O 0 9.166091530232734e-08
position O 0 8.435361564806954e-08
of O 0 4.5632177148036135e-08
exon O 0 1.2055386832798831e-05
32 O 0 7.1196359385794494e-06
. O 0 9.996679182222579e-07

This O 0 6.2604226513940375e-06
acceptor O 0 3.5651426060212543e-06
splice O 0 2.611213130876422e-05
- O 0 4.498518683249131e-05
site O 0 7.713059062552929e-07
mutation O 0 4.6608448656115797e-07
led O 0 5.246954515314428e-08
to O 0 1.940079563667041e-08
the O 0 1.2023136264360801e-08
formation O 0 4.075924664448394e-08
of O 0 8.98338292643075e-09
aberrant O 0 2.1129831111466046e-06
transcripts O 0 2.4933656277426053e-06
present O 0 7.640785071316714e-08
at O 0 5.366651478766471e-08
extremely O 0 7.920780831227603e-07
low O 0 3.86327246815199e-06
levels O 0 8.517538958585646e-07
. O 0 6.824325851084723e-07

Based O 0 2.302244320162572e-05
on O 0 6.115467385825468e-07
our O 0 1.498833483992712e-07
recent O 0 2.0789383370356518e-07
finding O 0 1.308619204110073e-07
that O 0 9.262593891889992e-08
cycloheximide O 0 5.139082713867538e-05
stabilized O 0 5.0634185754461214e-05
mutant O 0 7.675865163037088e-06
COL17A1 O 0 5.236655488261022e-05
transcripts O 0 4.409927441884065e-06
in O 0 1.3322689085271122e-07
keratinocytes O 0 5.779779894510284e-05
homozygous O 0 6.52651715427055e-06
for O 0 4.9071541496914506e-08
a O 0 2.9897041713411454e-06
frameshift O 1 0.952528178691864
mutation O 0 1.374638122797478e-05
, O 0 2.4104787499368285e-08
the O 0 1.1847011371912686e-08
effects O 0 2.4497234107911936e-07
of O 0 6.00481531165542e-09
the O 0 1.9276198415241197e-08
splice O 0 6.084146207285812e-06
- O 0 2.6365260055172257e-05
site O 0 4.809690494766983e-07
mutation O 0 1.5043968915051664e-07
on O 0 1.5854807244863878e-08
splicing O 0 1.7888287118239532e-07
of O 0 1.7883523995010364e-08
COL17A1 O 0 0.00014272618864197284
transcripts O 0 1.6589181086601457e-06
were O 0 4.7465160690762787e-08
determined O 0 4.4547313393650256e-08
using O 0 2.6085769988526408e-08
reverse O 0 1.0601366966511705e-06
transcriptase O 0 3.1878691970632644e-06
polymerase O 0 1.1123952390335035e-06
chain O 0 5.603770887319115e-07
reaction O 0 8.086548319852227e-08
of O 0 4.156852195791316e-09
total O 0 3.554176331022063e-08
RNA O 0 4.1866692868097743e-07
from O 0 1.2151311068464565e-07
keratinocytes O 0 2.7257703550276347e-05
incubated O 0 1.340862854704028e-05
for O 0 6.434468104998814e-07
2 O 0 2.9246482426970033e-06
. O 0 2.559961330916849e-06

5 O 0 8.316840103361756e-05
h O 0 6.943928019609302e-05
in O 0 1.5453206003712694e-07
the O 0 2.6468173430771458e-08
presence O 0 8.43969090169594e-08
or O 0 2.973082757762313e-08
absence O 0 1.5625360560989066e-07
of O 0 3.437448725662762e-08
10 O 0 3.900024125869095e-07
microg O 0 6.839599518571049e-05
cycloheximide O 0 0.00013120660150889307
per O 0 3.069535523536615e-06
ml O 0 6.192482396727428e-05
. O 0 5.10877134729526e-06

Using O 0 5.122016318637179e-06
this O 0 2.408636419204413e-07
approach O 0 8.282372050416598e-07
, O 0 6.327863388833066e-08
an O 0 8.11909615094919e-08
abnormally O 0 4.087153502041474e-05
spliced O 0 0.002764244796708226
transcript O 0 0.00029759365133941174
was O 0 3.5156185163032205e-07
identified O 0 5.7887824311819713e-08
that O 0 3.890504807202433e-09
contains O 0 5.388557156038587e-09
an O 0 5.5832103385000664e-09
extra O 0 8.023602759976711e-08
264 O 0 2.11165655628065e-07
bases O 0 4.3325144361006096e-08
upstream O 0 6.234716209974067e-08
from O 0 1.253281034507836e-08
exon O 0 6.458912480411527e-07
32 O 0 2.720439624681603e-07
, O 0 2.4748816329633883e-08
resulting O 0 1.8091505182837864e-07
in O 0 5.6604694265161015e-08
a O 0 1.8172567024521413e-06
premature O 0 0.00138590217102319
termination O 0 8.767708095547277e-06
codon O 0 1.4227720157578005e-06
27 O 0 1.3067999589111423e-06
bp O 0 6.158053565741284e-06
downstream O 0 3.6887766441395797e-07
from O 0 2.03615861948947e-08
the O 0 6.08242984867502e-08
cryptic O 0 1.586993494129274e-05
splice O 0 3.6427052691578865e-05
site O 0 6.236456556507619e-06
. O 0 1.5715640984126367e-06

Three O 0 3.7457803045981564e-06
other O 0 1.7178918199078907e-07
splice O 0 7.243010259117e-06
variants O 0 1.464166189180105e-06
, O 0 4.671698405900315e-08
including O 0 2.7029981808368575e-08
one O 0 3.629374489833026e-08
derived O 0 2.5484311549917038e-08
from O 0 3.844401241792639e-09
the O 0 4.779618478778502e-09
skipping O 0 2.1553699980358942e-07
of O 0 1.7707669996980258e-08
exon O 0 2.7762337140302407e-06
32 O 0 3.8430766835517716e-07
, O 0 2.378146213288801e-08
were O 0 4.0045982530045876e-08
also O 0 5.779019147666986e-07
identified O 0 2.136938292096602e-06
. O 0 8.381984457628278e-07

These O 0 1.217427143274108e-05
results O 0 7.112923867680365e-06
indicate O 0 4.813319947061245e-07
the O 0 1.500833768375287e-08
usefulness O 0 2.485293748577533e-07
of O 0 2.9251586042278177e-08
cycloheximide O 0 0.047331154346466064
treatment O 0 0.00030274587334133685
in O 0 3.242082513565947e-08
evaluating O 0 1.8871342888360232e-07
the O 0 2.3776109969730896e-08
abnormal O 0 1.9799566075562325e-07
processing O 0 1.835538121497393e-08
of O 0 3.0765152647660443e-09
mRNA O 0 6.621079506885508e-08
due O 0 3.646805524226693e-08
to O 0 1.8609050300710805e-08
splice O 0 2.289674057465163e-06
- O 0 4.878738764091395e-05
site O 0 1.0600386985970545e-06
mutations O 0 1.789401949281455e-06
, O 0 3.6810270387377386e-08
because O 0 3.4957917449673914e-08
( O 0 1.1575136404928799e-08
i O 0 4.0216676211457525e-08
) O 0 1.0886036072577099e-08
aberrant O 0 3.3925871889550763e-07
splicing O 0 1.128911208070349e-06
often O 0 1.5084036419921176e-07
generates O 0 4.089720846423006e-07
a O 0 6.754900709893263e-07
premature O 0 0.00018026780162472278
termination O 0 8.260307367891073e-06
codon O 0 1.0455248684593244e-06
, O 0 6.967836441162945e-08
( O 0 2.7572669480946388e-08
ii O 0 1.236446564689686e-06
) O 0 2.521812625388975e-08
transcripts O 0 3.3194606885444955e-07
with O 0 1.8016676506249496e-07
premature O 0 0.00043717684457078576
termination O 0 7.89923797128722e-06
codons O 0 1.1511680213516229e-06
can O 0 1.2709435281976766e-07
occur O 0 4.9100002286195377e-08
at O 0 2.633814233377052e-08
low O 0 6.679318289570801e-07
or O 0 1.4148062632557412e-07
undetectable O 0 5.17516264153528e-06
levels O 0 1.117791583737926e-07
due O 0 5.5386021102776795e-08
to O 0 4.6901082129124916e-08
nonsense O 0 2.491758777978248e-06
- O 0 1.849622321969946e-06
mediated O 0 1.2927977195431595e-06
mRNA O 0 2.1285352147515368e-07
decay O 0 1.9608854984198842e-07
, O 0 1.3891780170638413e-08
and O 0 1.365321100621486e-08
( O 0 2.731430015501246e-08
iii O 0 1.179087803393486e-06
) O 0 4.3743448863153844e-09
the O 0 2.5803836845028627e-09
levels O 0 6.625877180255202e-09
of O 0 1.2758607503826624e-09
these O 0 4.492280325507636e-09
transcripts O 0 2.472240225870337e-07
can O 0 1.99743475093328e-08
be O 0 8.889279534685102e-09
increased O 0 5.192823593347384e-08
by O 0 1.1344395289825115e-07
cycloheximide O 0 0.00025840941816568375
. O 0 1.586217877047602e-06

A O 0 0.0003468611685093492
deletion O 0 0.028811240568757057
mutation O 0 0.0004072222800459713
in O 0 1.471330051572295e-06
COL17A1 O 0 0.000616779609117657
in O 0 3.841002751414635e-07
five O 0 5.614244855678407e-07
Austrian O 0 0.0022777640260756016
families O 0 1.0941178061329992e-06
with O 0 1.3568368331107195e-06
generalized O 0 0.011156242340803146
atrophic B-Disease 1 0.9999285936355591
benign I-Disease 1 0.999625563621521
epidermolysis I-Disease 1 0.9998626708984375
bullosa I-Disease 1 0.9987136125564575
represents O 0 1.06151510408381e-05
propagation O 0 2.2384265321306884e-06
of O 0 1.1912636210809069e-07
an O 0 6.353315029627993e-07
ancestral O 0 3.598754483391531e-05
allele O 0 5.853496986674145e-05
. O 0 3.007577561220387e-06

Patients O 1 0.9962320923805237
with O 0 4.3529154936550185e-05
generalized O 0 0.10903918743133545
atrophic B-Disease 1 0.9999086856842041
benign I-Disease 1 0.999559223651886
epidermolysis I-Disease 1 0.9998538494110107
bullosa I-Disease 1 0.9991727471351624
, O 0 3.6677786283689784e-06
a O 0 1.371087932966475e-06
usually O 0 4.289948662972165e-07
nonlethal O 0 3.308801296952879e-06
form O 0 2.850860028047464e-07
of O 0 2.1843464992343797e-07
junctional B-Disease 1 0.9803180694580078
epidermolysis I-Disease 1 0.9996731281280518
bullosa I-Disease 1 0.9984879493713379
, O 0 1.7727053318594699e-06
have O 0 1.733711627593948e-07
generalized O 0 4.214432919980027e-06
blistering B-Disease 0 0.3066241145133972
, O 0 1.0355043741583358e-05
nail B-Disease 1 0.9998736381530762
dystrophy I-Disease 1 0.9999455213546753
, O 0 4.9913003749679774e-05
patchy B-Disease 1 0.9914694428443909
alopecia I-Disease 1 0.9999973773956299
, O 0 1.3966794540465344e-05
and O 0 3.783783540711738e-05
dental B-Disease 1 0.9995005130767822
abnormalities I-Disease 1 0.9993908405303955
. O 0 1.9492505089147016e-05

Skin B-Disease 1 0.9998138546943665
fragility I-Disease 1 0.9883939027786255
in O 0 2.8635096896323375e-05
most O 0 1.3738051620748593e-06
cases O 0 1.7364033055855543e-06
is O 0 1.1169306191050055e-07
due O 0 5.722770879401651e-07
to O 0 5.329810619514319e-07
mutations O 0 3.6922576782671968e-06
in O 0 1.6592734297660172e-08
the O 0 2.0333526862259532e-08
gene O 0 3.7151843912397453e-07
encoding O 0 1.159637008640857e-06
type O 0 9.052253517438658e-06
XVII O 0 0.09434552490711212
collagen O 0 0.0025240748655050993
( O 0 1.4421498235606123e-06
COL17A1 O 0 0.00019441843323875219
) O 0 1.5019485317679937e-06
. O 0 2.52743325290794e-06

Recently O 0 6.365055742207915e-05
, O 0 8.119147878460353e-07
we O 0 1.6489919119067054e-07
reported O 0 8.666947337587771e-07
five O 0 1.5918871554276848e-07
Austrian O 0 0.0004880231572315097
families O 0 1.5275908253897796e-06
with O 0 1.4087706858845195e-06
generalized O 0 0.005154353566467762
atrophic B-Disease 1 0.9997884631156921
benign I-Disease 1 0.9966991543769836
epidermolysis I-Disease 1 0.9995633959770203
bullosa I-Disease 1 0.9980734586715698
who O 0 1.4851774722046684e-05
share O 0 3.808216320067004e-07
the O 0 4.903374062337207e-08
same O 0 4.864339189225575e-07
COL17A1 O 0 0.019426750019192696
mutation O 0 5.439031156129204e-05
. O 0 2.2993722268438432e-06

Affected O 0 0.00042895443039014935
individuals O 0 4.448174422577722e-06
in O 0 3.2609113986836746e-07
three O 0 2.3697067774719471e-07
families O 0 1.6784120759893995e-07
are O 0 1.6033744998367183e-08
homozygous O 0 8.832916478240804e-07
for O 0 5.357579624387654e-08
4003delTC O 0 1.1558892765606288e-05
, O 0 7.012608449485924e-08
whereas O 0 7.536830537446804e-08
those O 0 5.3619730877585425e-09
in O 0 1.0360499125283695e-08
two O 0 4.5668574699675446e-08
others O 0 2.679162207641639e-07
are O 0 4.728083524696558e-08
compound O 0 1.531059569970239e-05
heterozygotes O 0 0.0002005558053497225
. O 0 4.5166070776758716e-06

To O 0 7.372128493443597e-06
determine O 0 1.9551971490727738e-06
if O 0 7.933392964787345e-08
the O 0 3.103142987015417e-08
occurrence O 0 1.4932120961930195e-07
of O 0 8.81968276189582e-09
4003delTC O 0 6.286736152105732e-06
in O 0 4.1146364537780755e-08
these O 0 1.0615987200424115e-08
unrelated O 0 4.493020071549836e-07
families O 0 1.1464511118219889e-07
signifies O 0 2.9613599394906487e-07
propagation O 0 2.697578054267069e-07
of O 0 1.3040813762188463e-08
an O 0 1.2549655536986393e-07
ancestral O 0 1.940910578923649e-06
allele O 0 1.5662988062103977e-06
or O 0 1.1755401096991136e-08
a O 0 6.411534059225232e-08
mutational O 0 6.712104368489236e-05
hot O 0 3.720852328115143e-05
spot O 0 6.23399455434992e-06
, O 0 1.642043230276613e-07
haplotypes O 0 9.461594345339108e-06
were O 0 6.509719696623506e-08
determined O 0 3.432159019212122e-07
for O 0 5.945952707975266e-08
polymorphisms O 0 4.278543656255351e-06
both O 0 5.7806072817356835e-08
within O 0 3.2063347532584885e-08
and O 0 1.3758646844053146e-07
flanking O 0 0.00019071913266088814
COL17A1 O 0 0.0813596248626709
. O 0 6.16768056715955e-06

Five O 0 3.5519347875379026e-05
intragenic O 0 0.00043448799988254905
polymorphisms O 0 7.806984649505466e-05
were O 0 6.128335030552989e-07
chosen O 0 1.422663160610682e-07
based O 0 6.6364783890549e-08
on O 0 9.137864509511928e-08
their O 0 5.080835308035603e-07
informativeness O 0 0.0005638835718855262
. O 0 4.683860424847808e-06

One O 0 3.875726179103367e-06
of O 0 1.0575209330454527e-07
these O 0 2.673612620185395e-08
, O 0 3.891263133937173e-08
not O 0 4.684591914383418e-08
previously O 0 5.70418990264443e-07
reported O 0 9.31826718897355e-07
, O 0 2.1601126221071354e-08
was O 0 1.1672747746160894e-07
2988 O 0 1.7353587509205681e-06
A O 0 1.0137401886822772e-06
or O 0 1.1431278323925653e-07
C O 0 2.5617706000957696e-07
that O 0 9.339209405823112e-09
introduces O 0 1.631923964851012e-07
a O 0 6.108053440812e-08
new O 0 4.054818347754008e-08
restriction O 0 1.1006171263261422e-07
site O 0 5.7104173833977256e-08
for O 0 3.4817379201967924e-08
Eco0109 O 0 1.7088643289753236e-05
I O 0 2.75686284112453e-06
. O 0 1.3842077351000626e-06

All O 0 1.9457199869066244e-06
the O 0 3.5555399335862603e-07
4003delTC O 0 1.8620823539095e-05
alleles O 0 3.9726610339130275e-06
showed O 0 1.5844489098526537e-06
the O 0 2.436242496628438e-08
same O 0 1.5102935435606923e-07
haplotype O 0 8.104604057734832e-05
for O 0 5.370081268551985e-08
these O 0 3.252128166764123e-08
five O 0 3.6902861211274285e-07
polymorphic O 0 8.818131755106151e-05
markers O 0 2.9985334549564868e-05
. O 0 3.0184619390638545e-06

Fourteen O 0 0.0005423433613032103
microsatellite O 0 0.008510859683156013
polymorphisms O 0 0.0019139159703627229
were O 0 3.528247589201783e-06
selected O 0 4.824243546863727e-07
based O 0 9.987001448052979e-08
on O 0 6.594184753794252e-08
their O 0 5.7353922500169574e-08
high O 0 4.68573148282303e-07
heterozygosity O 0 3.1586052500642836e-05
and O 0 4.710054568590749e-08
their O 0 2.884150873683211e-08
location O 0 8.932198625188903e-08
within O 0 3.58332314931431e-08
10q23 O 0 9.667233825894073e-06
- O 0 1.9736064132303e-05
q25 O 0 2.834168481058441e-05
near O 0 2.638727892190218e-06
COL17A1 O 0 0.0001712092343950644
. O 0 4.585021088132635e-06

Three O 0 5.5473530665040016e-05
families O 0 1.2329247510933783e-05
shared O 0 2.5708800421853084e-06
microsatellite O 0 0.00034974634763784707
polymorphisms O 0 0.00011066445586038753
covering O 0 4.668278961617034e-06
at O 0 1.5805281350367295e-07
most O 0 7.703092563815517e-08
19 O 0 6.099252800595423e-07
cM O 0 1.3101818694849499e-05
, O 0 7.22539326147853e-08
whereas O 0 6.825459308856807e-08
the O 0 1.337269761592097e-08
others O 0 6.252710704757192e-08
shared O 0 5.357549071050016e-08
smaller O 0 6.193363333295565e-08
regions O 0 2.7072601938016305e-08
consistent O 0 1.4003195758505171e-07
with O 0 2.7839430316589642e-08
cross O 0 1.55301634663374e-07
- O 0 9.572275303071365e-06
over O 0 1.408661631785435e-07
events O 0 4.014877319491461e-08
during O 0 6.569854349436355e-08
passage O 0 6.850422096249531e-08
of O 0 8.117591043799166e-09
this O 0 2.673908383599155e-08
mutation O 0 5.430802048067562e-07
through O 0 4.489747240654651e-08
several O 0 1.6646440315071231e-07
generations O 0 2.0307461454649456e-06
. O 0 1.7402394405507948e-06

These O 0 7.467255727533484e-06
results O 0 6.796691195631865e-06
indicate O 0 1.4856386769679375e-06
that O 0 1.2972223828455753e-07
4003delTC O 0 1.6953947124420665e-05
occurs O 0 8.988254052155753e-08
on O 0 3.190637798411444e-08
a O 0 1.3579834501342702e-07
single O 0 6.613455525439349e-07
ancestral O 0 2.882776243495755e-06
allele O 0 4.779726623382885e-06
. O 0 2.0035670900142577e-07
. O 0 9.800111229196773e-07

The O 0 1.7753307474777102e-05
haptoglobin O 0 0.0010897248284891248
- O 0 0.0002528034965507686
gene O 0 1.1694385648297612e-05
deletion O 0 2.191205567214638e-05
responsible O 0 1.9275407794339117e-06
for O 0 5.880424396309536e-07
anhaptoglobinemia B-Disease 0 0.0005786303081549704
. O 0 7.787221875332762e-06

We O 0 4.6853033381921705e-06
have O 0 3.9967204656932154e-07
found O 0 7.265400370215502e-08
an O 0 3.902970391322924e-08
allelic O 0 6.21346998741501e-06
deletion O 0 7.793143595336005e-06
of O 0 3.220781863433331e-08
the O 0 8.877068324864013e-08
haptoglobin O 0 9.597603639122099e-05
( O 0 5.944954395431523e-08
Hp O 0 4.724716404780338e-07
) O 0 1.4478127141615005e-08
gene O 0 3.022575612021683e-08
from O 0 4.062635117207947e-09
an O 0 1.1862567816933733e-08
individual O 0 3.2362255097950765e-08
with O 0 3.2264694027617224e-07
anhaptoglobinemia B-Disease 0 0.005117417778819799
. O 0 4.6896570893295575e-06

The O 0 3.3927015010704054e-06
Hp O 0 1.5515106497332454e-05
gene O 0 2.3731768123980146e-06
cluster O 0 6.014084874550463e-07
consists O 0 8.480823510126356e-08
of O 0 2.0739790329571406e-08
coding O 0 1.327062705058779e-06
regions O 0 5.469838271210392e-08
of O 0 2.607202675974918e-09
the O 0 7.798425905036765e-09
alpha O 0 1.489623713268884e-07
chain O 0 3.727339219494752e-07
and O 0 1.8050103633981962e-08
beta O 0 5.567984473486831e-08
chain O 0 1.0298717967316406e-07
of O 0 2.6076003578623386e-09
the O 0 2.945161448053568e-08
haptoglobin O 0 1.2200272067275364e-05
gene O 0 2.9895196007601044e-07
( O 0 2.4621689576065364e-08
Hp O 0 3.0374692983059504e-07
) O 0 9.586246463300085e-09
and O 0 3.024257955175358e-09
of O 0 2.57301668860066e-09
the O 0 1.5023633892496946e-08
alpha O 0 1.482404456965014e-07
chain O 0 2.15924828239622e-07
and O 0 8.765146830569392e-09
beta O 0 5.0861142852909325e-08
chain O 0 6.215493186800813e-08
of O 0 3.282819793781755e-09
the O 0 2.3953404593157757e-08
haptoglobin O 0 2.270446202601306e-05
- O 0 2.8767930416506715e-05
related O 0 5.607171260635369e-07
gene O 0 3.9821713926357916e-07
( O 0 5.7788209772979826e-08
Hpr O 0 8.432155482296366e-06
) O 0 2.3355317679829568e-08
, O 0 9.197505868030476e-09
in O 0 1.5958903532009572e-08
tandem O 0 3.646559207481914e-06
from O 0 2.8810939411982872e-08
the O 0 3.8737866248084174e-08
5 O 0 1.066715526576445e-06
side O 0 3.6983508380217245e-06
. O 0 2.1629714410664747e-06

Southern O 0 0.00011482623813208193
blot O 0 0.0009783098939806223
and O 0 1.4580268725694623e-06
PCR O 0 4.493210508371703e-05
analyses O 0 5.892893113923492e-06
have O 0 2.3628511769402394e-07
indicated O 0 5.547281034523621e-07
that O 0 1.2137767235742558e-08
the O 0 8.748026303351253e-09
individual O 0 1.0391570270940065e-08
with O 0 3.2858597620588625e-08
anhaptoglobinemia B-Disease 0 0.00023998686810955405
was O 0 8.261593507086218e-07
homozygous O 0 5.13133670665411e-07
for O 0 6.514275341373832e-09
the O 0 8.151086916541317e-09
gene O 0 1.8050917560685775e-07
deletion O 0 4.679528956330614e-06
and O 0 3.414955429548172e-08
that O 0 1.561349627365871e-08
the O 0 1.0141850914635597e-08
gene O 0 8.540576601490102e-08
deletion O 0 1.1128566939078155e-06
was O 0 7.479861352521766e-08
included O 0 1.9133887363409485e-08
at O 0 1.80307999642082e-08
least O 0 1.9922069327549252e-08
from O 0 6.558183329730127e-09
the O 0 1.4325482133870082e-08
promoter O 0 1.034462343341147e-06
region O 0 4.24068460347371e-08
of O 0 6.843223765429229e-09
Hp O 0 8.147001153702149e-07
to O 0 1.3750513971899636e-07
Hpr O 0 5.421603873401182e-06
alpha O 0 1.5527511720847542e-07
but O 0 2.1999376542680693e-08
not O 0 1.330167354041123e-08
to O 0 9.15703921577915e-08
Hpr O 0 3.1424886401509866e-05
beta O 0 7.800696266713203e-07
( O 0 6.584858169844665e-08
Hpdel O 0 5.341806627257029e-06
) O 0 3.018313066149858e-07
. O 0 8.464272696073749e-07

In O 0 6.431292604247574e-06
addition O 0 5.409185064308986e-07
, O 0 4.551881715997297e-08
we O 0 1.2976352437021887e-08
found O 0 1.8067773055463476e-08
seven O 0 3.4939517945531406e-08
individuals O 0 6.8059695657041175e-09
with O 0 1.4809738324572663e-08
hypohaptoglobinemia B-Disease 0 0.00017810903955250978
in O 0 7.694061565644006e-08
three O 0 7.470536900200386e-08
families O 0 4.852352475381849e-08
, O 0 1.0034560737892662e-08
and O 0 7.87965781512412e-09
the O 0 6.749219405577378e-09
genotypes O 0 6.65554296119808e-07
of O 0 3.571571260962969e-09
six O 0 2.2562909762768868e-08
of O 0 2.233182749833418e-09
the O 0 8.139839025034235e-09
seven O 0 4.927186836312103e-08
individuals O 0 5.656721757674177e-09
were O 0 1.426065399101617e-08
found O 0 3.821112315449682e-08
to O 0 9.366506503738492e-08
be O 0 2.429489143196406e-07
Hp2 O 0 0.000357185082975775
/ O 0 0.0001025264136842452
Hpdel O 0 0.0002095459494739771
. O 0 3.7188110582064837e-06

The O 0 1.1499005267978646e-05
phenotypes O 0 0.0015920215519145131
and O 0 9.775533271749737e-07
genotypes O 0 5.56414233869873e-05
in O 0 6.550285291950786e-08
one O 0 1.8177626515125667e-08
of O 0 5.588068674455826e-09
these O 0 1.1203887595456763e-08
three O 0 6.005699759725758e-08
families O 0 1.0665920058272604e-07
showed O 0 7.955088676681044e-07
the O 0 1.7673489338676518e-08
father O 0 6.66324069698021e-07
to O 0 2.8393658979553038e-08
be O 0 4.392498453853477e-08
hypohaptoglobinemic B-Disease 0 9.710847734822892e-06
( O 0 4.1834521624650733e-08
Hp2 O 0 1.3601663795270724e-06
) O 0 1.7699260723702537e-08
and O 0 4.642297568580034e-08
Hp2 O 0 5.576083276537247e-05
/ O 0 1.0389952876721509e-05
Hpdel O 0 2.125620267179329e-05
, O 0 2.7514724720845152e-08
the O 0 1.4578967366674078e-08
mother O 0 7.100691732375708e-07
to O 0 1.68042468828844e-08
be O 0 1.7191201351351992e-08
Hp2 O 0 1.7483822603026056e-06
- O 0 1.434423325008538e-06
1 O 0 8.204169432701747e-08
and O 0 4.4077982153112316e-08
Hp1 O 0 1.231098849530099e-05
/ O 0 2.7824357857753057e-06
Hp2 O 0 7.22911863704212e-06
, O 0 1.1258170395933575e-08
one O 0 3.510563617581397e-09
of O 0 1.030157736892079e-09
the O 0 7.226300002827202e-09
two O 0 4.240838435976002e-08
children O 0 1.2640438740163518e-07
to O 0 3.234917045347174e-08
be O 0 4.030175659863744e-08
hypohaptoglobinemic B-Disease 0 1.2719194273813628e-05
( O 0 2.57611176834871e-08
Hp2 O 0 7.806463031556632e-07
) O 0 9.906178988217107e-09
and O 0 2.6810631936768914e-08
Hp2 O 0 1.603111195436213e-05
/ O 0 3.5796253996522864e-06
Hpdel O 0 8.850312951835804e-06
, O 0 2.4824267086387408e-08
and O 0 7.956392877872531e-09
the O 0 1.1107331054915903e-08
other O 0 6.967395549395405e-09
child O 0 3.881508519043564e-07
to O 0 4.5700030426587546e-08
be O 0 2.9537519097289078e-08
Hp1 O 0 2.243052904304932e-06
and O 0 6.449052136758837e-08
Hp1 O 0 3.669811485451646e-05
/ O 0 5.004253125662217e-06
Hpdel O 0 9.673763997852802e-06
, O 0 3.608728249560045e-08
showing O 0 2.532548251110711e-07
an O 0 9.790380062213444e-08
anomalous O 0 2.0321243937360123e-05
inheritance O 0 4.813315626961412e-06
of O 0 7.537132518109502e-08
Hp O 0 0.00019121075456496328
phenotypes O 0 0.00027011221391148865
in O 0 9.076114082517961e-08
the O 0 1.0801551297845435e-07
child O 0 5.461713044496719e-06
with O 0 1.3488338481693063e-06
Hp1 O 0 0.0013965937541797757
. O 0 5.823856099596014e-06

The O 0 1.2587267519847956e-05
Hp2 O 0 0.0009567613597027957
/ O 0 0.00012018139386782423
Hpdel O 0 0.00019547292322386056
individuals O 0 2.1510187764306465e-07
had O 0 1.7248538597414154e-07
an O 0 5.610723619042801e-08
extremely O 0 4.855222641708679e-07
low O 0 2.4112907226481184e-07
level O 0 2.7090989007660937e-08
of O 0 1.1525149723468076e-08
Hp O 0 2.6076174890476977e-06
( O 0 1.0114038673236792e-07
mean O 0 2.7465705443319166e-07
+ O 0 4.958548629474535e-07
/ O 0 9.195769621328509e-07
- O 0 9.07032244867878e-06
SD O 0 6.847456825198606e-05
= O 0 3.966335498262197e-06
0 O 0 2.8866944035144115e-07
. O 0 5.450935347539598e-08
049 O 0 7.5731736615125556e-06
+ O 0 1.0571754955890356e-06
/ O 0 5.480583240569104e-07
- O 0 1.6924310557442368e-06
0 O 0 5.202469992582337e-07
. O 0 5.823444837460556e-08
043 O 0 4.5791825868946034e-06
mg O 0 5.809221329400316e-05
/ O 0 7.05631282471586e-06
ml O 0 1.547097235743422e-05
; O 0 1.8246132071908505e-07
n O 0 6.643849701504223e-07
= O 0 5.359460146792117e-07
6 O 0 6.847901090623054e-08
) O 0 5.540184311314533e-09
, O 0 8.73458816386119e-09
compared O 0 4.9751221808946866e-08
with O 0 5.869351227261177e-09
the O 0 1.2815832839407904e-08
level O 0 1.7780841687908833e-08
( O 0 4.327350477950631e-09
1 O 0 1.1952324463493369e-08
. O 0 8.539399409812631e-09
64 O 0 1.8875877572099853e-07
+ O 0 3.3510963248772896e-07
/ O 0 2.3103466162410768e-07
- O 0 9.142952421825612e-07
1 O 0 1.1240538100310005e-07
. O 0 3.0526102534622623e-08
07 O 0 8.740531143303087e-07
mg O 0 4.5724249503109604e-05
/ O 0 2.889922143367585e-06
ml O 0 5.811644314235309e-06
) O 0 1.8893125286467694e-08
obtained O 0 4.096266081887734e-08
from O 0 1.465055099458823e-08
52 O 0 8.256945989160158e-07
healthy O 0 3.1294331392928143e-07
volunteers O 0 1.663699720211298e-07
having O 0 2.8912157290506e-07
phenotype O 0 0.00011140209244331345
Hp2 O 0 1.353468542220071e-05
, O 0 3.421886063392776e-08
whereas O 0 5.4433197504977215e-08
the O 0 1.9841825960043025e-08
serum O 0 9.364521247334778e-07
Hp O 0 4.663027937112929e-07
level O 0 9.188861227471534e-09
of O 0 1.9121766392515838e-09
an O 0 1.3667906806347219e-08
individual O 0 1.6383353340643225e-08
with O 0 8.716402533082146e-08
Hp1 O 0 0.00046408711932599545
/ O 0 4.7790123062441126e-05
Hpdel O 0 5.298466203385033e-05
was O 0 1.2374894140521064e-06
0 O 0 1.9605222405516542e-06
. O 0 1.2951991266163532e-06

50 O 0 0.00010822051990544423
mg O 0 0.003979968838393688
/ O 0 8.190971857402474e-05
ml O 0 7.371685933321714e-05
, O 0 1.411709007470563e-07
which O 0 3.9144289587511594e-08
was O 0 6.278811071069867e-08
approximately O 0 1.6409028802399916e-08
half O 0 1.4958326133296396e-08
the O 0 4.544228549008267e-09
level O 0 5.677789349789464e-09
of O 0 4.464689951078071e-09
Hp O 0 1.7000405705402954e-06
in O 0 7.842297122806485e-08
control O 0 1.2604028825080604e-06
sera O 0 1.93170035345247e-05
from O 0 2.631193218860517e-08
the O 0 5.3247759979058173e-08
Hp1 O 0 0.0003378662222530693
phenotype O 0 0.00011170654761372134
( O 0 3.106483248416225e-08
1 O 0 3.102610435234965e-08
. O 0 2.422194178564041e-08
26 O 0 2.70862443585429e-07
+ O 0 4.544126852579211e-07
/ O 0 6.626043500546075e-07
- O 0 3.653416797533282e-06
0 O 0 4.854750272897945e-07
. O 0 2.2897994611525974e-08
33 O 0 5.946088208474976e-07
mg O 0 4.8403304390376434e-05
/ O 0 1.7048096196958795e-05
ml O 0 9.878325363388285e-05
; O 0 1.0248255648548366e-06
n O 0 2.871909600798972e-06
= O 0 1.4197249811331858e-06
9 O 0 1.3201889714764548e-07
) O 0 1.914228420218933e-08
, O 0 1.0475690537248283e-08
showing O 0 1.5253475282861473e-07
a O 0 4.664139510168752e-07
gene O 0 2.114607923431322e-06
- O 0 9.260833030566573e-05
dosage O 0 0.00014579249545931816
effect O 0 4.635166988009587e-06
. O 0 1.8676204263101681e-06

The O 0 6.207677870406769e-06
other O 0 5.57172313619958e-07
allele O 0 8.37967854749877e-06
( O 0 1.9259260852777516e-07
Hp2 O 0 4.707329935627058e-06
) O 0 1.8004545410121864e-08
of O 0 8.072336576958605e-09
individuals O 0 1.719369357999767e-08
with O 0 8.254853867128986e-08
Hp2 O 0 0.0010397626319900155
/ O 0 3.300265234429389e-05
Hpdel O 0 2.6212404918624088e-05
was O 0 1.6648408518449287e-07
found O 0 2.5197644859531465e-08
to O 0 1.5684983978303535e-08
have O 0 2.964520895432088e-08
, O 0 1.0886783918806486e-08
in O 0 9.515129129056277e-09
all O 0 6.294168741760586e-09
exons O 0 9.233874607161852e-07
, O 0 2.5980702034189562e-08
no O 0 5.4523802361927665e-08
mutation O 0 2.1236832026261254e-07
, O 0 1.3509597884819868e-08
by O 0 3.9530089424033577e-08
DNA O 0 1.5108596471691271e-06
sequencing O 0 4.3900754462811165e-06
. O 0 2.6744241949927527e-06

On O 0 6.2311596593644936e-06
the O 0 1.3329780301774008e-07
basis O 0 3.010573479400591e-08
of O 0 7.082895159271629e-09
the O 0 2.19684306301815e-08
present O 0 1.141964176554211e-07
study O 0 1.0340879441628203e-07
, O 0 1.522132642151064e-08
the O 0 3.5153810973298505e-09
mechanism O 0 9.981151016802414e-09
of O 0 3.915129109799409e-09
anhaptoglobinemia B-Disease 0 1.7190244761877693e-05
and O 0 1.3156712164175133e-08
the O 0 5.916581002907151e-09
mechanism O 0 3.494265143899611e-08
of O 0 2.1067199540425463e-08
anomalous O 0 2.226863944088109e-05
inheritance O 0 7.356571586569771e-06
of O 0 1.6323488694069965e-07
Hp O 0 0.00031514206784777343
phenotypes O 0 0.0005375785985961556
were O 0 2.0972706238353567e-07
well O 0 3.159800030516635e-07
explained O 0 5.206427886150777e-06
. O 0 2.320642124686856e-06

However O 0 1.849894215411041e-05
, O 0 2.515853623208386e-07
the O 0 3.1406202083417156e-08
mechanism O 0 1.476795574717471e-07
of O 0 1.0060915656140423e-07
hypohaptoglobinemia B-Disease 0 0.0008368626004084945
remains O 0 2.2644650016445667e-05
unknown O 0 2.3417567717842758e-05

ATM O 0 0.011455819010734558
mutations O 1 0.6260550618171692
and O 0 3.8673271774314344e-05
phenotypes O 1 0.5036066174507141
in O 0 0.0001205702792503871
ataxia B-Disease 1 0.9999986886978149
- I-Disease 1 0.999971866607666
telangiectasia I-Disease 1 0.9999904632568359
families O 0 2.807799137372058e-05
in O 0 9.636517006583745e-08
the O 0 5.553326687390836e-08
British O 0 6.974456937314244e-06
Isles O 0 1.2859327398473397e-06
: O 0 2.545933952546875e-08
expression O 0 3.369894940874474e-08
of O 0 3.957186578418259e-09
mutant O 0 4.603878380748938e-07
ATM O 0 3.092897316037124e-07
and O 0 1.4752507659920866e-08
the O 0 3.444063878532688e-08
risk O 0 4.493088567869563e-07
of O 0 3.364988572229777e-07
leukemia B-Disease 1 0.9999456405639648
, O 0 0.023773230612277985
lymphoma B-Disease 1 0.9999997615814209
, O 0 2.5226501747965813e-05
and O 0 0.001194881508126855
breast B-Disease 1 0.9999645948410034
cancer I-Disease 1 0.9978137016296387
. O 0 1.498730944149429e-05

We O 0 6.465854312409647e-06
report O 0 9.396637210556946e-07
the O 0 5.7409305753708395e-08
spectrum O 0 4.5539229631685885e-07
of O 0 2.490565087498453e-08
59 O 0 5.1797596825053915e-06
ATM O 0 5.65653208468575e-05
mutations O 0 3.119334360235371e-05
observed O 0 3.010510226886254e-06
in O 0 7.663978976779617e-06
ataxia B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999781847000122
telangiectasia I-Disease 1 0.9999946355819702
( O 0 1.4645233022747561e-05
A B-Disease 1 0.9976154565811157
- I-Disease 1 0.9999645948410034
T I-Disease 1 0.9999983310699463
) O 0 2.225909383923863e-06
patients O 0 2.3476330170524307e-05
in O 0 2.8240162208703623e-08
the O 0 1.109321345893477e-07
British O 0 1.7725900761433877e-05
Isles O 0 1.6163037798833102e-05
. O 0 2.6412280931253918e-06

Of O 0 3.0883336421538843e-06
51 O 0 3.274274058640003e-05
ATM O 0 7.294715032912791e-05
mutations O 0 6.988376844674349e-05
identified O 0 8.588166338086012e-07
in O 0 7.628174358842443e-08
families O 0 2.0688712254468555e-07
native O 0 4.4660549036734665e-08
to O 0 4.694467037325012e-08
the O 0 7.743026486650706e-08
British O 0 9.206622962665278e-06
Isles O 0 2.4273706458188826e-06
, O 0 8.03240780555825e-08
11 O 0 7.18672978905488e-08
were O 0 3.785119062627018e-08
founder O 0 4.068743237439776e-06
mutations O 0 1.5970830418154947e-06
, O 0 1.1212075712307978e-08
and O 0 1.0192951371834624e-08
2 O 0 2.8339822932821335e-08
of O 0 2.989275271758629e-09
these O 0 1.0217321211314356e-08
11 O 0 1.4856794905426796e-07
conferred O 0 5.518829198081221e-07
a O 0 4.056438228872139e-06
milder O 1 0.8226802945137024
clinical O 1 0.8334593176841736
phenotype O 1 0.8172308802604675
with O 0 1.1705287050745028e-07
respect O 0 6.340960112538596e-08
to O 0 2.297022092534462e-07
both O 0 5.206023843129515e-07
cerebellar B-Disease 1 0.9155808091163635
degeneration I-Disease 1 0.9985159039497375
and O 0 5.87633803661447e-06
cellular O 0 0.00019417222938500345
features O 0 2.5363951863255352e-05
. O 0 4.27228451371775e-06

We O 0 9.137233973888215e-06
report O 0 1.157180122390855e-06
, O 0 2.5950191329116024e-08
in O 0 1.6498784560781132e-08
two O 0 1.8184705652402045e-07
A B-Disease 1 0.9824009537696838
- I-Disease 1 0.9999310970306396
T I-Disease 1 0.9999982118606567
families O 0 3.856757189169002e-07
, O 0 1.1337924377130548e-08
an O 0 1.7015370445960798e-08
ATM O 0 2.7781138669524807e-06
mutation O 0 9.772010116648744e-07
( O 0 2.3647125146908365e-08
7271T O 0 3.2404000194219407e-06
- O 0 1.6969766875263304e-05
- O 0 0.0008750610868446529
> O 0 8.430450543528423e-05
G O 0 0.0004965511034242809
) O 0 2.6626661764339588e-08
that O 0 3.841178042307547e-08
may O 0 5.679784180756542e-07
be O 0 1.3977733637204892e-08
associated O 0 1.1932074883702626e-08
with O 0 6.6780865282112245e-09
an O 0 9.218971541713472e-08
increased O 0 1.3389284276854596e-06
risk O 0 7.020677230684669e-07
of O 0 3.2401848670815525e-07
breast B-Disease 1 0.9999783039093018
cancer I-Disease 1 0.9993610978126526
in O 0 2.915234347256046e-07
both O 0 2.496191768841527e-07
homozygotes O 0 0.0005428108852356672
and O 0 9.261513582714542e-07
heterozygotes O 0 0.00011276737495791167
( O 0 8.198365719636058e-08
relative O 0 9.965050367100048e-07
risk O 0 9.455662279833632e-07
12 O 0 2.389796520674281e-07
. O 0 6.136697550118697e-08
7 O 0 4.90649426865275e-07
; O 0 3.0261816164056654e-07
P O 0 4.684598752646707e-05
= O 0 1.1915992672584252e-06
. O 0 2.4970292500370306e-08
0025 O 0 8.755726412346121e-06
) O 0 2.541295884839201e-08
, O 0 1.6769281074857645e-08
although O 0 1.1499349916732626e-08
there O 0 7.329953977119885e-09
is O 0 6.2704557102222225e-09
a O 0 1.6463960150758794e-07
less O 0 3.8854891499795485e-06
severe O 1 0.8838817477226257
A B-Disease 1 0.9999452829360962
- I-Disease 1 0.9999877214431763
T I-Disease 1 0.9999995231628418
phenotype O 0 0.3180607557296753
in O 0 6.073236846759755e-08
terms O 0 3.155360772666427e-08
of O 0 7.852531958008058e-09
the O 0 4.258695440739757e-08
degree O 0 1.031708620757854e-06
of O 0 1.3325412737685838e-06
cerebellar B-Disease 1 0.9974347949028015
degeneration I-Disease 1 0.9996258020401001
. O 0 3.674381150631234e-05

This O 0 1.2671844160649925e-05
mutation O 0 4.218992035021074e-05
( O 0 4.877908850176027e-07
7271T O 0 1.532207170384936e-05
- O 0 5.8381665439810604e-05
- O 0 0.00030005170265212655
> O 0 8.013170372578315e-06
G O 0 9.794151992537081e-06
) O 0 8.405068641081925e-09
also O 0 5.4076152444793024e-09
allows O 0 1.468182553310271e-08
expression O 0 1.9940506135185387e-08
of O 0 1.6675311131919557e-09
full O 0 8.495539560726684e-08
- O 0 2.211268110841047e-06
length O 0 4.543485658814461e-07
ATM O 0 2.2552353584615048e-07
protein O 0 2.8104484073310232e-08
at O 0 4.610123838233449e-09
a O 0 2.2612153927070722e-08
level O 0 1.576247932177921e-08
comparable O 0 5.240863387712125e-08
with O 0 1.5474185488528747e-08
that O 0 5.736092489883049e-08
in O 0 2.7560875537346874e-07
unaffected O 0 0.00016051351849455386
individuals O 0 4.2967002400473575e-07
. O 0 1.2432193443601136e-06

In O 0 8.752695066505112e-06
addition O 0 1.0379645800639992e-06
, O 0 9.793461686058436e-08
we O 0 2.1675168326851235e-08
have O 0 2.481205463311653e-08
studied O 0 4.385245233606838e-07
18 O 0 2.769144430203596e-06
A B-Disease 1 0.9923596978187561
- I-Disease 1 0.999995231628418
T I-Disease 1 1.0
patients O 1 0.9194889664649963
, O 0 1.429557272558668e-07
in O 0 6.453876011391912e-08
15 O 0 4.1307731635242817e-07
families O 0 8.592240163807219e-08
, O 0 1.1156105017562368e-07
who O 0 6.680141723336419e-06
developed O 0 0.00025481637567281723
leukemia B-Disease 1 0.9999207258224487
, O 0 0.01379313413053751
lymphoma B-Disease 1 0.9999996423721313
, O 0 5.059920113126282e-06
preleukemic O 0 0.028544707223773003
T O 0 0.01610204391181469
- O 0 5.240196696831845e-05
cell O 0 2.6994106519850902e-05
proliferation O 0 6.083045605009829e-07
, O 0 4.840013048124092e-07
or O 0 8.053410419961438e-05
Hodgkin B-Disease 1 0.9999996423721313
lymphoma I-Disease 1 0.9999998807907104
, O 0 3.173321601934731e-06
mostly O 0 9.130422995440313e-07
in O 0 9.308106996286369e-07
childhood O 0 0.0001102673340938054
. O 0 5.558536486205412e-06

A O 0 5.554949166253209e-05
wide O 0 6.3735692492628004e-06
variety O 0 4.111954012842034e-07
of O 0 5.265551905608845e-08
ATM O 0 1.4754506992176175e-05
mutation O 0 7.756440936645959e-06
types O 0 1.3838787538134056e-07
, O 0 3.9818250030521085e-08
including O 0 1.7445601940835331e-07
missense O 0 0.007234386634081602
mutations O 0 1.0627275514707435e-05
and O 0 3.821345728738379e-08
in O 0 8.632172665556936e-08
- O 0 7.330760126933455e-05
frame O 0 0.004163780249655247
deletions O 0 1.2692235031863675e-05
, O 0 8.816642349529502e-08
were O 0 2.752390848570485e-08
seen O 0 2.2186434023296897e-07
in O 0 6.087397252940718e-08
these O 0 2.2760903561902524e-07
patients O 0 0.0001767973881214857
. O 0 5.091539151180768e-06

We O 0 3.76859748030256e-06
also O 0 2.218237113993382e-07
show O 0 1.7106656002852105e-07
that O 0 2.6400055475050976e-08
25 O 0 4.021100252771248e-08
% O 0 5.0960067277117105e-09
of O 0 3.1480313911202984e-09
all O 0 3.538983150974673e-08
A B-Disease 1 0.996202290058136
- I-Disease 1 0.9999949932098389
T I-Disease 1 0.9999998807907104
patients O 0 0.2497439831495285
carried O 0 1.9061529883401818e-06
in O 0 6.820995679390762e-08
- O 0 4.424182407092303e-06
frame O 0 0.00014156880206428468
deletions O 0 8.000320121936966e-06
or O 0 4.2228145957778906e-07
missense O 0 0.00058676180196926
mutations O 0 8.310591510962695e-06
, O 0 2.7389841505964796e-08
many O 0 4.631310890346185e-09
of O 0 3.746674526183824e-09
which O 0 7.858423600737297e-08
were O 0 7.32626759258892e-08
also O 0 1.0247575943367337e-07
associated O 0 2.5480325405169424e-08
with O 0 1.0402080086180376e-08
expression O 0 1.327700260844722e-07
of O 0 1.820184358791721e-08
mutant O 0 5.710074219678063e-06
ATM O 0 9.315582246927079e-06
protein O 0 2.841684818122303e-06
. O 0 1.505471914242662e-06

The O 0 2.271721859870013e-05
DMPK O 0 0.0005702396156266332
gene O 0 1.4387950614036527e-05
of O 0 8.78648108937341e-07
severely O 0 0.033508073538541794
affected O 0 0.007964876480400562
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999483823776245
is O 0 1.6073142887762515e-06
hypermethylated O 0 0.0006689719157293439
proximal O 0 0.0001275759859709069
to O 0 4.191786899809813e-07
the O 0 1.3243666785456298e-07
largely O 0 7.531146479777817e-07
expanded O 0 3.6600008570530917e-06
CTG O 0 0.0002909769827965647
repeat O 0 7.487035327358171e-05
. O 0 8.834366781229619e-06

Using O 0 1.5974250345607288e-05
methylation O 0 2.8677317459369078e-05
- O 0 2.2737047402188182e-05
sensitive O 0 2.4144258077285485e-06
restriction O 0 6.688733265036717e-07
enzymes O 0 4.060639184899628e-07
, O 0 2.97664612958215e-08
we O 0 1.2315090280878849e-08
characterized O 0 8.946127394438008e-08
the O 0 1.0774201086860558e-08
methylation O 0 2.7870331109625113e-07
pattern O 0 2.1403208450010425e-07
on O 0 5.176407924523119e-08
the O 0 1.4074418075438189e-08
5 O 0 8.57374189422444e-08
side O 0 5.065077957056019e-08
of O 0 5.836886085575088e-09
the O 0 3.7448046441568295e-08
CTG O 0 5.8588688261806965e-05
repeat O 0 3.894299879902974e-06
in O 0 3.5379976282001735e-08
the O 0 1.7045385547476144e-08
DMPK O 0 2.8196940547786653e-05
gene O 0 9.451716209696315e-08
of O 0 4.174140588730779e-09
normal O 0 9.258372557496841e-08
individuals O 0 8.648270544142633e-09
and O 0 1.8321243189234337e-08
of O 0 9.103940357135798e-08
patients O 0 0.020153334364295006
affected O 0 3.086357992287958e-06
with O 0 0.001427378854714334
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
, O 0 4.12702638641349e-06
showing O 0 2.176715724999667e-06
expansions O 0 7.433892506014672e-07
of O 0 2.8979254551586564e-08
the O 0 1.3493739459136123e-07
repetitive O 0 0.00010330356599297374
sequence O 0 6.710694833600428e-06
. O 0 4.219170023134211e-06

The O 0 2.0705622318928363e-06
gene O 0 5.353097549232189e-06
segment O 0 2.2312863166007446e-06
analyzed O 0 6.257781137719576e-07
corresponds O 0 1.3194312487030402e-07
to O 0 2.9015978952884325e-08
the O 0 1.6839539540569604e-08
genomic O 0 1.020625632008887e-06
SacI O 0 1.9703400539583527e-05
- O 0 4.582201654557139e-06
HindIII O 0 5.652869731420651e-06
fragment O 0 1.6523796375622624e-06
carrying O 0 5.213724421082588e-07
exons O 0 2.9283294225024292e-06
11 O 0 6.692619081150042e-07
- O 0 7.175263363023987e-06
15 O 0 2.4829582798702177e-06
. O 0 1.8102703052136349e-06

There O 0 6.4259588725690264e-06
is O 0 6.282537015067646e-07
constitutive O 0 2.7690625756804366e-06
methylation O 0 1.964461944226059e-06
in O 0 9.593274086228121e-08
intron O 0 2.0102470443816856e-05
12 O 0 1.47155034824209e-07
at O 0 1.7680097386119087e-08
restriction O 0 2.537179000228207e-08
sites O 0 1.023585127768456e-08
of O 0 3.511869683947566e-09
SacII O 0 1.7839017800724832e-06
and O 0 4.576256884547547e-08
HhaI O 0 2.5892256871884456e-06
, O 0 2.7478694875071596e-08
localized O 0 2.8335941237855877e-07
1 O 0 4.578587819992208e-08
, O 0 1.4914908419427775e-08
159 O 0 4.6377925855267677e-07
- O 0 5.62549621463404e-06
1 O 0 7.271819413290359e-08
, O 0 1.7000933993926992e-08
232 O 0 2.701264634197287e-07
bp O 0 4.985028226656141e-06
upstream O 0 3.689982719379259e-08
of O 0 3.006830340268607e-09
the O 0 1.4069049925069521e-08
CTG O 0 2.481524097674992e-05
repeat O 0 4.3845398067787755e-06
, O 0 4.038732726030503e-08
whereas O 0 4.40645280264107e-08
most O 0 7.528063505901628e-09
, O 0 3.9934828777177245e-09
if O 0 4.3774250890749045e-09
not O 0 3.317686125825503e-09
all O 0 8.302121212722113e-10
, O 0 2.437900770146939e-09
of O 0 7.266710011499811e-10
the O 0 1.977433994326816e-09
other O 0 9.104367260093227e-10
sites O 0 4.9882227237674215e-09
of O 0 5.139669578824169e-09
SacII O 0 1.3197123735153582e-05
, O 0 5.1279414492455544e-08
HhaI O 0 3.7926383811281994e-06
, O 0 1.5737786185354707e-08
and O 0 1.6992927953651815e-08
HpaII O 0 9.068065992323682e-06
in O 0 2.7902210320007725e-08
this O 0 1.4740695775117274e-08
region O 0 5.293626870184198e-08
are O 0 1.990839493259955e-08
unmethylated O 0 2.6312109184800647e-05
, O 0 4.780131845905089e-08
in O 0 3.09590113545255e-08
normal O 0 1.6208525721594924e-07
individuals O 0 7.538049295874316e-09
and O 0 1.034040231218114e-08
most O 0 1.7430743071145116e-08
of O 0 4.3196422438995796e-08
the O 0 3.1281786050385563e-06
patients O 0 0.03280671313405037
. O 0 6.8803296926489566e-06

In O 0 3.2176335480471607e-06
a O 0 8.954020813689567e-07
number O 0 5.838492711518484e-08
of O 0 1.6699445382073463e-08
young O 0 8.99569499779318e-07
and O 0 9.794709967536619e-07
severely O 0 0.1596514731645584
affected O 0 9.7494907095097e-05
patients O 0 0.025490637868642807
, O 0 1.7880836367112352e-07
however O 0 7.995264184046391e-08
, O 0 1.2683591066320332e-08
complete O 0 3.090160660690344e-08
methylation O 0 7.507060217903927e-08
of O 0 2.086571804227333e-09
these O 0 3.0139444273658e-09
restriction O 0 2.6646578277222943e-08
sites O 0 8.357733172204007e-09
was O 0 4.0942353507489315e-08
found O 0 3.482016808220578e-08
in O 0 2.0067753681018985e-08
the O 0 1.931414601585857e-07
mutated O 0 0.00010255868983222172
allele O 0 3.2955951610347256e-05
. O 0 2.146278347936459e-06

In O 0 5.205455181567231e-06
most O 0 2.879150144963205e-07
of O 0 4.879397508261718e-08
these O 0 3.5776926665676e-07
patients O 0 0.00023035774938762188
, O 0 6.950806152872246e-08
the O 0 5.263373026309637e-08
onset O 0 1.863583383965306e-05
of O 0 1.5058812152801693e-07
the O 0 1.2099800187570509e-05
disease O 0 0.3677600920200348
was O 0 0.00961559358984232
congenital O 1 0.9999344348907471
. O 0 4.013045327155851e-05

Preliminary O 0 0.00023632928787264973
in O 0 9.01842304301681e-06
vivo O 0 0.004889362491667271
footprinting O 0 0.10341223329305649
data O 0 1.5937874877636204e-06
gave O 0 7.67198400808411e-07
evidence O 0 2.1049248744020588e-07
for O 0 1.7151899456280262e-08
protein O 0 1.4050095842321753e-07
- O 0 8.088914000836667e-06
DNA O 0 1.8651888922249782e-06
contact O 0 9.164062930722139e-08
in O 0 1.7556065046164804e-08
normal O 0 1.0159531882436568e-07
genes O 0 3.5381194862793564e-08
at O 0 8.353302050068123e-09
an O 0 2.0597083150164508e-08
Sp1 O 0 1.3404921901383204e-06
consensus O 0 6.386915885059352e-08
binding O 0 8.535707252121938e-08
site O 0 3.095588141377448e-08
upstream O 0 2.6810427655732383e-08
of O 0 3.290197669869599e-09
the O 0 1.0298085051374528e-08
CTG O 0 1.4287315025285352e-05
repeat O 0 2.229882511528558e-06
and O 0 1.586001019404648e-08
for O 0 7.693339298953106e-09
a O 0 8.031243936557075e-08
significant O 0 5.7230767680493955e-08
reduction O 0 9.319603577750968e-08
of O 0 3.145162796869272e-09
this O 0 5.204004782655147e-09
interaction O 0 1.5234162376032145e-08
in O 0 2.985197156135655e-08
cells O 0 2.5283682703047816e-07
with O 0 4.280038723436519e-08
a O 0 1.1153566674693138e-06
hypermethylated O 0 0.000654097821097821
DMPK O 0 0.00040355711826123297
gene O 0 2.940474360002554e-06
. O 0 3.423535304136749e-07
. O 0 9.377434366797388e-07

The O 0 7.827155786799267e-05
hemochromatosis B-Disease 1 0.999723494052887
gene O 0 2.3193868400994688e-05
product O 0 1.2159129028077587e-06
complexes O 0 6.333605142572196e-07
with O 0 3.430021777717229e-08
the O 0 5.898510835322668e-08
transferrin O 0 1.722646084090229e-05
receptor O 0 1.2216489722050028e-06
and O 0 4.400749986643859e-08
lowers O 0 4.458328930923017e-06
its O 0 4.571598211100536e-08
affinity O 0 1.6850921724653745e-07
for O 0 6.106981231823738e-08
ligand O 0 8.196454473363701e-06
binding O 0 1.1261067811574321e-05
. O 0 3.730515118149924e-06

We O 0 1.4628983990405686e-05
recently O 0 1.8763841580948792e-05
reported O 0 1.3593676158052403e-06
the O 0 3.533917336540071e-08
positional O 0 2.208899104516604e-06
cloning O 0 6.66812923100224e-07
of O 0 2.0164863556715318e-08
a O 0 6.153975959932723e-07
candidate O 0 6.0437628235376906e-06
gene O 0 3.54902226717968e-06
for O 0 1.1333445399941411e-05
hereditary B-Disease 1 0.9999988079071045
hemochromatosis I-Disease 1 1.0
called O 0 0.06814165413379669
HFE O 1 0.5949245691299438
. O 0 2.3821017748559825e-05

The O 0 3.1390807180287084e-06
gene O 0 5.262522336124675e-06
product O 0 5.227271344665496e-07
, O 0 5.34365902638001e-08
a O 0 7.455079042983925e-08
member O 0 2.9408898427618624e-08
of O 0 3.0497626646308618e-09
the O 0 9.72718439129494e-09
major O 0 1.0450170151443672e-07
histocompatibility O 0 3.141718843835406e-05
complex O 0 2.7182196049579943e-07
class O 0 1.6769658373050333e-07
I O 0 2.0872580819286668e-07
- O 0 1.2270703564354335e-06
like O 0 1.0348890810973899e-07
family O 0 1.3389063724389416e-07
, O 0 1.7070437507982206e-08
was O 0 5.939537217614088e-08
found O 0 2.4398415732207468e-08
to O 0 1.963214479872022e-08
have O 0 2.6963814292457755e-08
a O 0 2.72659519851004e-07
mutation O 0 1.0571251323199249e-06
, O 0 5.277053816143962e-08
Cys O 0 3.970358375227079e-05
- O 0 9.036219125846401e-06
282 O 0 2.389901965216268e-06
- O 0 4.074392927577719e-05
- O 0 0.00010230609768768772
> O 0 3.742866283573676e-06
Tyr O 0 2.030487303272821e-05
( O 0 3.6962806149176686e-08
C282Y O 0 9.513188388154958e-07
) O 0 1.1271146682645394e-08
, O 0 8.964555320289946e-09
in O 0 1.1817086864596149e-08
85 O 0 5.142663326296315e-07
% O 0 4.177631041102359e-08
of O 0 2.904593543462397e-08
patient O 0 0.00045946025056764483
chromosomes O 0 7.874154835008085e-05
. O 0 5.205196885071928e-06

This O 0 1.063481886376394e-05
mutation O 0 4.518941568676382e-05
eliminates O 0 5.302901627146639e-06
the O 0 1.2248214886767528e-07
ability O 0 1.6952840553585702e-07
of O 0 3.180345231612591e-08
HFE O 0 0.000214485073229298
to O 0 2.353713171032723e-07
associate O 0 3.4380917668386246e-07
with O 0 2.7039632755077037e-07
beta2 O 0 0.001789394300431013
- O 0 0.0005586835904978216
microglobulin O 0 0.0003050972300115973
( O 0 1.1618116957379243e-07
beta2m O 0 6.102700808696682e-06
) O 0 2.2527519405457497e-08
and O 0 1.9219953628635267e-08
prevents O 0 5.201418389333412e-07
cell O 0 4.3259671656414866e-05
- O 0 0.0001551975292386487
surface O 0 3.961107722716406e-05
expression O 0 8.063957466220018e-06
. O 0 2.0435334135981975e-06

A O 0 6.66171545162797e-05
second O 0 1.4416573321796022e-05
mutation O 0 2.2505186279886402e-05
that O 0 9.789577148922035e-08
has O 0 7.925240907979969e-08
no O 0 5.769833677504721e-08
effect O 0 1.0591559629347103e-07
on O 0 1.7896188353461184e-07
beta2m O 0 0.0012342400150373578
association O 0 1.506108020521424e-07
, O 0 3.258510972159456e-08
H63D O 0 6.654833123320714e-05
, O 0 3.3555664913365035e-08
was O 0 4.088959570935913e-08
found O 0 1.82125372560904e-08
in O 0 5.247842604916286e-09
eight O 0 2.6971994415703193e-08
out O 0 1.3143870880583108e-08
of O 0 1.1991599713212509e-08
nine O 0 7.397214176307898e-06
patients O 0 0.00010046402894658968
heterozygous O 0 2.507733370293863e-06
for O 0 4.4010604938193865e-08
the O 0 1.4373316048477136e-07
C282Y O 0 5.291507477522828e-05
mutant O 0 3.2789834222057834e-05
. O 0 1.8784681969918893e-06

In O 0 4.977157004759647e-06
this O 0 4.6152862864801136e-07
report O 0 6.632631084357854e-07
, O 0 1.533087967686697e-08
we O 0 2.119714714865495e-08
demonstrate O 0 2.4551189881094615e-07
in O 0 9.305002635073834e-08
cultured O 0 7.718276719970163e-06
293 O 0 2.152497836505063e-05
cells O 0 7.663635187782347e-06
overexpressing O 0 3.151296914438717e-05
wild O 0 3.983815872743435e-07
- O 0 5.1289962357259355e-06
type O 0 9.88338115348597e-07
or O 0 7.4247672898764e-08
mutant O 0 6.646906058449531e-06
HFE O 0 5.332010914571583e-05
proteins O 0 4.258654939803819e-08
that O 0 9.169776937767438e-09
both O 0 6.1651923566330424e-09
the O 0 5.849234874233389e-09
wild O 0 6.570856925236512e-08
- O 0 1.2130324648751412e-05
type O 0 6.642176799687149e-07
and O 0 8.415755559099125e-08
H63D O 0 0.0054575069807469845
HFE O 0 0.0002535431121941656
proteins O 0 8.784815719309336e-08
form O 0 8.13807332633587e-08
stable O 0 4.504359480961284e-07
complexes O 0 1.0970624941819551e-07
with O 0 2.6668338648505596e-08
the O 0 1.041985768779341e-07
transferrin O 0 0.00015786002040840685
receptor O 0 9.520135790808126e-06
( O 0 4.3095781165902736e-07
TfR O 0 4.0957176679512486e-05
) O 0 4.358149681138457e-07
. O 0 1.182903702101612e-06

The O 0 9.26962366065709e-06
C282Y O 0 0.00034227975993417203
mutation O 0 5.971695281914435e-05
nearly O 0 1.1311506113997893e-06
completely O 0 6.064660169613489e-07
prevents O 0 2.3007842742117646e-07
the O 0 2.1517815085303482e-08
association O 0 1.4193491715275286e-08
of O 0 4.907582340507588e-09
the O 0 5.2365667357889834e-08
mutant O 0 9.92493278317852e-06
HFE O 0 8.610806980868801e-05
protein O 0 5.246689624982537e-07
with O 0 1.8467514451003808e-07
the O 0 1.0635695844030124e-06
TfR O 0 0.0020411605946719646
. O 0 6.717578344250796e-06

Studies O 0 3.2726413337513804e-05
on O 0 2.617985728647909e-06
cell O 0 1.9752935259020887e-05
- O 0 3.091287726419978e-05
associated O 0 6.079078502807533e-07
transferrin O 0 4.52354697699775e-06
at O 0 6.162102295093064e-08
37 O 0 5.06999811022979e-07
degrees O 0 1.4363424725161167e-06
C O 0 1.592918238202401e-06
suggest O 0 1.8092056564000814e-07
that O 0 1.4096555034370795e-08
the O 0 2.209458038748835e-08
overexpressed O 0 9.344286809209734e-06
wild O 0 2.300470498539653e-07
- O 0 4.2815149754460435e-06
type O 0 1.0577452940196963e-06
HFE O 0 3.3857639209600165e-05
protein O 0 2.7117516765429173e-07
decreases O 0 2.652969044447673e-07
the O 0 6.717702394354319e-09
affinity O 0 3.4601161047476126e-08
of O 0 9.039622383966162e-09
the O 0 8.376280646871237e-08
TfR O 0 0.00012965765199624002
for O 0 6.388584665728558e-07
transferrin O 0 0.000807123607955873
. O 0 7.598566753586056e-06

The O 0 2.426842002023477e-05
overexpressed O 0 0.00044465894461609423
H63D O 0 0.0003142264031339437
protein O 0 1.5966917317200569e-06
does O 0 1.5205111481009226e-07
not O 0 9.327033367867443e-09
have O 0 5.3610729189301765e-09
this O 0 4.284471444293558e-09
effect O 0 6.11938730799011e-08
, O 0 6.752927994568836e-09
providing O 0 4.9868811302644644e-09
the O 0 3.4851115326972604e-09
first O 0 1.3210247118422558e-08
direct O 0 2.9350953667517388e-08
evidence O 0 6.211724468130342e-08
for O 0 7.832785975381285e-09
a O 0 1.1746774930543324e-07
functional O 0 5.419067861112126e-07
consequence O 0 2.069415785399542e-07
of O 0 1.6993672247167524e-08
the O 0 2.2609074790125305e-07
H63D O 0 0.04488934576511383
mutation O 0 6.641887739533558e-05
. O 0 4.744864327221876e-06

Addition O 0 1.220342528540641e-05
of O 0 5.9332182900107e-07
soluble O 0 9.255109944206197e-06
wild O 0 1.2348994005151326e-06
- O 0 6.34205061942339e-05
type O 0 5.421391506388318e-06
HFE O 0 0.000839752668980509
/ O 0 1.8992443074239418e-05
beta2m O 0 4.7653098590672016e-05
heterodimers O 0 2.3164622689364478e-05
to O 0 1.802502822556562e-07
cultured O 0 7.457690571754938e-06
cells O 0 3.2424247820017627e-06
also O 0 9.06293209368414e-08
decreased O 0 2.1869395538942626e-07
the O 0 1.2117133962874505e-08
apparent O 0 8.871446652847226e-07
affinity O 0 1.3450235769596475e-07
of O 0 7.991632244852553e-09
the O 0 2.2484336170691677e-08
TfR O 0 2.0017703718622215e-05
for O 0 1.6129076740867276e-08
its O 0 1.8937248214001556e-08
ligand O 0 5.42693953775597e-07
under O 0 1.2287044626191346e-07
steady O 0 1.5721457202744205e-06
- O 0 1.1921564691874664e-05
state O 0 3.15820955165691e-07
conditions O 0 7.393704777314269e-07
, O 0 1.4316468011088546e-08
both O 0 7.465150275720589e-09
in O 0 4.157203292720624e-08
293 O 0 3.130840923404321e-06
cells O 0 1.0493167792446911e-06
and O 0 1.1771334840204872e-07
in O 0 4.342227271081356e-07
HeLa O 0 0.005800941959023476
cells O 0 4.0152197470888495e-05
. O 0 1.999803771468578e-06

Furthermore O 0 8.662832988193259e-05
, O 0 7.916241884231567e-07
at O 0 1.0913898762510144e-07
4 O 0 2.9087274810990493e-07
degrees O 0 1.1997545925623854e-06
C O 0 1.6517132053195382e-06
, O 0 3.131611947537749e-08
the O 0 1.9618594748749274e-08
added O 0 1.0983816167708937e-07
soluble O 0 4.512110933774238e-07
complex O 0 7.306758220693155e-08
of O 0 3.5899862638189006e-08
HFE O 0 0.0012929202057421207
/ O 0 1.6810432498459704e-05
beta2m O 0 2.048646092589479e-05
inhibited O 0 9.319378477812279e-07
binding O 0 1.5314884649342275e-07
of O 0 1.1969502722308789e-08
transferrin O 0 4.203831394988811e-06
to O 0 4.2070294625773386e-07
HeLa O 0 0.00017854227917268872
cell O 0 0.00013010523980483413
TfR O 0 3.4529610275058076e-05
in O 0 8.320263589212118e-08
a O 0 5.921167485212209e-07
concentration O 0 2.302097163919825e-05
- O 0 3.269858643761836e-05
dependent O 0 4.506835466600023e-06
manner O 0 6.842881248303456e-06
. O 0 2.9596167223644443e-06

Scatchard O 0 0.0004938807687722147
plots O 0 1.616168265172746e-05
of O 0 2.2817779665729176e-07
these O 0 3.2271152861085284e-08
data O 0 6.46892388544984e-08
indicate O 0 7.052620532022047e-08
that O 0 5.9507940797232095e-09
the O 0 1.0342414036301761e-08
added O 0 9.690669600104229e-08
heterodimer O 0 2.099374614772387e-05
substantially O 0 2.3182974473456852e-06
reduced O 0 1.1067724869917583e-07
the O 0 6.82388190398342e-09
affinity O 0 5.945068082269245e-08
of O 0 3.561960326692315e-08
TfR O 0 4.772987085743807e-05
for O 0 5.347737896954641e-07
transferrin O 0 0.00040628461283631623
. O 0 2.82389783023973e-06

These O 0 7.857373930164613e-06
results O 0 7.494158126064576e-06
establish O 0 8.524657459929585e-07
a O 0 1.0312747917851084e-06
molecular O 0 5.874046564713353e-06
link O 0 3.2642299174767686e-06
between O 0 1.3486869931966794e-07
HFE O 0 0.0003720278909895569
and O 0 8.84669404399574e-08
a O 0 1.1872645444555019e-07
key O 0 3.2145951678330675e-08
protein O 0 3.0153202601468365e-08
involved O 0 1.2224194989585158e-08
in O 0 1.335006682978701e-08
iron O 0 3.084681884502061e-05
transport O 0 2.442934317059553e-07
, O 0 1.491448209378632e-08
the O 0 3.2184725995421104e-08
TfR O 0 7.99146801000461e-05
, O 0 2.648428143459114e-08
and O 0 1.3633460582695989e-08
raise O 0 9.297799863361433e-08
the O 0 9.314375049029877e-09
possibility O 0 4.586235746728562e-08
that O 0 1.6137322589315772e-08
alterations O 0 9.69592633737193e-07
in O 0 1.4597053343834432e-08
this O 0 9.503467346405614e-09
regulatory O 0 1.649479628440531e-07
mechanism O 0 1.4741235077053716e-07
may O 0 1.554412136783867e-07
play O 0 9.485991547819594e-09
a O 0 3.0179151622178324e-08
role O 0 4.407461773325849e-08
in O 0 3.908162682364491e-08
the O 0 1.1576521075085111e-07
pathogenesis O 0 0.0001083384413504973
of O 0 1.1509459909575526e-05
hereditary B-Disease 1 0.9999996423721313
hemochromatosis I-Disease 1 1.0
. O 0 5.988975681248121e-05
. O 0 5.519942078535678e-06

Genomic O 0 0.0005071976338513196
organization O 0 6.9440343395399395e-06
of O 0 4.1918352167158446e-07
the O 0 7.2112112547984e-07
UBE3A O 0 0.04422617331147194
/ O 0 0.000533750862814486
E6 O 0 0.0038675093092024326
- O 0 0.03990386426448822
AP O 0 0.0001974023034563288
gene O 0 1.1096382195319165e-06
and O 0 1.3691003175608785e-07
related O 0 1.3214012142270803e-06
pseudogenes O 0 9.660611249273643e-05
. O 0 5.8910723055305425e-06

The O 0 1.4278134585765656e-05
UBE3A O 0 0.0007479049381799996
gene O 0 9.170895282295533e-06
encodes O 0 3.766139570871019e-06
the O 0 3.0482007673526823e-07
E6 O 0 3.0361361496034078e-05
- O 0 6.041680171620101e-05
AP O 0 6.782879154343391e-06
ubiquitin O 0 7.654685418856388e-07
- O 0 6.065030220270273e-07
protein O 0 6.695881893392652e-08
ligase O 0 1.0607592315636794e-07
and O 0 1.4055478558816503e-08
has O 0 9.525810185095906e-08
recently O 0 4.2478896489228646e-07
been O 0 3.532151993113075e-08
shown O 0 1.0016016460667743e-07
to O 0 3.9379131067107664e-08
be O 0 1.3497137274498527e-07
mutated O 0 0.0012529708910733461
in O 0 0.2132762223482132
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9995511174201965
who O 0 1.0148226465389598e-05
lack O 0 1.4415983287108247e-06
15q11 O 0 0.000196943583432585
- O 0 0.0001224199659191072
q13 O 0 6.0772112192353234e-05
deletions O 0 1.3053913789917715e-05
or O 0 8.163489155776915e-07
chromosome O 0 6.920922169229016e-05
15 O 0 5.4859665397088975e-06
paternal O 0 0.00022960390197113156
uniparental B-Disease 0 0.13263842463493347
disomy I-Disease 0 0.010275228880345821
. O 0 1.6474861695314758e-05

Previous O 0 0.00013516639592126012
UBE3A O 0 0.0009880689904093742
cDNA O 0 9.114314889302477e-05
analysis O 0 1.3867094821762294e-05
has O 0 1.3131926834830665e-06
shown O 0 5.577879278462206e-07
a O 0 3.3049272474272584e-07
coding O 0 2.5511315016046865e-06
region O 0 1.6826624005261692e-07
of O 0 4.723702673459229e-08
approximately O 0 5.363725108509243e-07
2 O 0 1.8618619606058928e-06
. O 0 1.610648496352951e-06

6 O 0 9.264198888558894e-05
kb O 0 0.00011279049795120955
and O 0 2.876921314509673e-07
a O 0 4.1356173596796e-07
3 O 0 7.146596203710942e-07
- O 0 0.0001329002989223227
untranslated O 0 0.003848641412332654
region O 0 5.417259103523975e-07
( O 0 6.078231251649413e-08
UTR O 0 4.733885816676775e-06
) O 0 1.1638184638229632e-08
of O 0 7.773342858286014e-09
< O 0 7.260426286848087e-07
50 O 0 1.2715472053059784e-07
bp O 0 8.181624252756592e-06
, O 0 2.846127244993113e-08
whereas O 0 6.460551560394379e-08
Northern O 0 4.174827594738417e-08
analysis O 0 5.632372079844572e-08
has O 0 3.827195271810524e-08
indicated O 0 7.796911916102545e-08
mRNA O 0 2.8822096709291145e-08
sizes O 0 3.957867633630485e-08
of O 0 3.852240304524912e-09
5 O 0 1.285570618847487e-07
- O 0 8.798255294095725e-06
8 O 0 2.7029986995330546e-06
kb O 0 0.00010144112457055598
. O 0 1.4641830148320878e-06

We O 0 6.72941496304702e-06
have O 0 3.6860157592855103e-07
analyzed O 0 4.740137740100181e-07
additional O 0 1.3583706959252595e-07
cDNA O 0 1.0175351690122625e-06
clones O 0 9.497469477537379e-07
and O 0 3.344091226153978e-08
provide O 0 5.336488939633455e-08
evidence O 0 5.0661988382216805e-08
for O 0 2.0722115579019373e-08
an O 0 1.0907032077511758e-07
additional O 0 8.666939379509131e-07
0 O 0 6.5021636146411765e-06
. O 0 2.581673243184923e-06

5 O 0 2.6675475965021178e-05
kb O 0 6.12847798038274e-05
of O 0 2.48841502070718e-07
5 O 0 8.015929893190332e-07
- O 0 1.5022226762084756e-05
UTR O 0 8.948900358518586e-05
and O 0 1.560415512358304e-07
> O 0 6.011791242599429e-07
2 O 0 1.219367078419964e-07
kb O 0 2.874277015507687e-06
of O 0 5.180121576131569e-08
3 O 0 1.002717681330978e-06
- O 0 0.0002312337892362848
UTR O 0 0.005092435050755739
. O 0 5.198107828618959e-06

We O 0 5.720823082810966e-06
have O 0 3.022354349013767e-07
established O 0 5.4934250925953165e-08
the O 0 1.3262533293811885e-08
genomic O 0 3.232382539408718e-07
organization O 0 2.9648148824890086e-08
of O 0 1.1048232551047477e-08
UBE3A O 0 2.4009950720937923e-05
and O 0 4.907659345576576e-08
the O 0 9.256126531909104e-09
sequence O 0 5.837624073024017e-08
of O 0 2.3129274495659047e-08
intron O 0 0.00010758566349977627
- O 0 0.00010388391820015386
exon O 0 5.224678898230195e-05
borders O 0 5.746381248172838e-06
. O 0 2.4899914023990277e-06

We O 0 6.991278041823534e-06
have O 0 5.033052730141208e-07
also O 0 8.475082324821415e-08
mapped O 0 1.0978910722769797e-06
two O 0 7.992078110419243e-08
highly O 0 1.131792117803343e-07
homologous O 0 3.8216265352275514e-07
processed O 0 7.902220318101172e-07
pseudogenes O 0 6.024025879014516e-06
, O 0 1.184871081250094e-07
UBE3AP1 O 0 1.4814218047831673e-05
and O 0 7.889120468007604e-08
UBE3AP2 O 0 3.437139457673766e-05
, O 0 2.4509425600172108e-08
to O 0 2.788226183270126e-08
chromosomes O 0 1.7919586525749764e-07
2 O 0 4.185319824046019e-08
and O 0 1.6791430468288127e-08
21 O 0 2.2437903623995226e-07
, O 0 1.8491618902771734e-08
respectively O 0 7.751049935222909e-08
, O 0 8.661674044674328e-09
and O 0 1.1675047595360866e-08
determined O 0 1.7300961019373062e-07
their O 0 3.1092692864831406e-08
genomic O 0 1.5406793636429938e-06
organization O 0 4.148372170220682e-07
. O 0 7.315417178688222e-07

These O 0 1.5905738109722733e-05
results O 0 5.520505055756075e-06
will O 0 1.3618105754176213e-07
form O 0 4.208582282672069e-08
the O 0 1.0392065874498257e-08
basis O 0 2.048956559974613e-08
for O 0 1.0899748659198849e-08
studies O 0 4.4141753363646785e-08
of O 0 1.687799766614262e-08
mutation O 0 1.1517258826643229e-06
and O 0 1.1526462628808076e-07
imprinting O 0 1.4413136341318022e-05
of O 0 6.36085076166637e-07
UBE3A O 0 0.001809451263397932
. O 0 8.550779966753908e-06

Mutation O 0 0.4492814540863037
spectrum O 0 0.0024627961684018373
and O 0 1.0659493455023039e-05
genotype O 0 0.032083023339509964
- O 0 0.0476314015686512
phenotype O 0 0.12836292386054993
analyses O 0 1.5410132618853822e-05
in O 0 6.50514084554743e-06
Cowden B-Disease 1 0.9996951818466187
disease I-Disease 0 0.13697898387908936
and O 0 3.1844415389059577e-06
Bannayan B-Disease 1 0.9758648872375488
- I-Disease 1 0.9998811483383179
Zonana I-Disease 1 0.9999945163726807
syndrome I-Disease 1 0.9999946355819702
, O 0 6.621735906264803e-07
two O 0 5.454727670439752e-06
hamartoma B-Disease 1 0.999609649181366
syndromes I-Disease 1 0.9976690411567688
with O 0 3.010530417668633e-05
germline O 1 0.5316696763038635
PTEN O 1 0.9395000338554382
mutation O 0 0.00038265451439656317
. O 0 8.068003808148205e-06

The O 0 8.8560875155963e-05
tumour B-Disease 1 0.9995108842849731
suppressor O 0 0.006717422045767307
gene O 0 0.0001014528315863572
PTEN O 0 0.0024025775492191315
, O 0 2.8950617547707225e-07
which O 0 3.97340365054788e-08
maps O 0 3.94988944663055e-07
to O 0 3.8316076711453206e-07
10q23 O 0 0.0001085717449313961
. O 0 4.2776537156896666e-06

3 O 0 1.9033526768907905e-05
and O 0 3.4107020496776386e-07
encodes O 0 7.956416538945632e-07
a O 0 1.953045085656413e-07
403 O 0 6.442284643526364e-07
amino O 0 2.3419559624926478e-07
acid O 0 4.354149041319033e-07
dual O 0 9.905566002998967e-07
specificity O 0 1.3368027111937408e-06
phosphatase O 0 7.791960524627939e-05
( O 0 3.755519273340724e-08
protein O 0 6.606320113178299e-08
tyrosine O 0 4.90591446578037e-07
phosphatase O 0 1.3248042705527041e-05
; O 0 6.257673845766476e-08
PTPase O 0 1.2276742609174107e-06
) O 0 1.1979140346340955e-08
, O 0 8.026201037125702e-09
was O 0 4.805343678526697e-08
shown O 0 8.1446110300476e-08
recently O 0 9.66056958873196e-08
to O 0 1.1190839366292948e-08
play O 0 1.9914470072990298e-08
a O 0 6.963252729974556e-08
broad O 0 2.569169055277598e-07
role O 0 3.9719154187878303e-07
in O 0 6.069693654353614e-07
human O 0 6.154354650789173e-06
malignancy B-Disease 0 0.11497960984706879
. O 0 1.210082700708881e-05

Somatic O 0 0.011628657579421997
PTEN O 1 0.9061059355735779
deletions O 0 0.028322827070951462
and O 0 1.9658409655676223e-05
mutations O 0 0.00011305129737593234
were O 0 2.65762565732075e-07
observed O 0 8.673744105180958e-07
in O 0 2.7392124479774793e-07
sporadic B-Disease 0 0.02737320214509964
breast I-Disease 1 0.9997634291648865
, I-Disease 0 4.8824942496139556e-05
brain I-Disease 1 0.5829640626907349
, I-Disease 0 9.587266504240688e-06
prostate I-Disease 1 0.994951605796814
and I-Disease 0 0.017217593267560005
kidney I-Disease 1 0.9999783039093018
cancer I-Disease 1 0.996938943862915
cell O 0 0.002900121035054326
lines O 0 5.595714355877135e-06
and O 0 9.726074523541683e-08
in O 0 4.5934495318533664e-08
several O 0 7.305447979888413e-08
primary O 0 1.1737928616639692e-05
tumours B-Disease 1 0.999830961227417
such O 0 2.8462500267778523e-07
as O 0 4.718556738225743e-05
endometrial B-Disease 1 0.9999358654022217
carcinomas I-Disease 1 0.9999996423721313
, O 1 0.9804893732070923
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9559973478317261
thyroid B-Disease 1 0.9999679327011108
tumours I-Disease 1 0.9999885559082031
. O 0 5.7835019106278196e-05

In O 0 1.1941101547563449e-05
addition O 0 1.951337480932125e-06
, O 0 3.412442879380251e-07
PTEN O 0 0.0006548008532263339
was O 0 8.447306640846364e-07
identified O 0 1.12937470930774e-07
as O 0 7.0548105135515016e-09
the O 0 3.5703198619785326e-08
susceptibility O 0 3.100241519859992e-05
gene O 0 5.186577709537232e-07
for O 0 2.3364836465589178e-07
two O 0 3.047588688787073e-05
hamartoma B-Disease 1 0.9999721050262451
syndromes I-Disease 1 0.999992847442627
Cowden B-Disease 1 0.9999926090240479
disease I-Disease 1 0.9962577819824219
( O 0 7.387615141851711e-07
CD B-Disease 0 4.322874156059697e-05
; O 0 1.2559141850942979e-06
MIM O 0 4.0595190512249246e-05
158350 O 0 9.021347977977712e-06
) O 0 8.662735950792921e-08
and O 0 1.3394988229720184e-07
Bannayan B-Disease 0 0.00012032531230943277
- I-Disease 0 0.0009522524778731167
Zonana I-Disease 0 0.036120399832725525
( I-Disease 0 1.5130875397062482e-07
BZS I-Disease 0 6.09939615969779e-06
) I-Disease 0 6.831385235273046e-08
or I-Disease 0 1.4799030623180442e-07
Ruvalcaba I-Disease 0 0.00040738453390076756
- I-Disease 0 0.0003113911661785096
Riley I-Disease 0 0.0002553129743319005
- I-Disease 1 0.7621510624885559
Smith I-Disease 1 0.6607181429862976
syndrome I-Disease 1 0.9995630383491516
( O 0 9.528370128464303e-07
MIM O 0 9.120540198637173e-05
153480 O 0 5.391192462411709e-05
) O 0 9.919679087033728e-07
. O 0 1.1125437140435679e-06

Constitutive O 0 0.0019266089657321572
DNA O 0 0.00021445871971081942
from O 0 1.1087497568951221e-06
37 O 0 1.4333594435811392e-06
CD B-Disease 0 5.242510724201566e-06
families O 0 2.1858718923795095e-07
and O 0 7.849689609429333e-08
seven O 0 3.2428005170004326e-07
BZS B-Disease 0 0.00010745054896688089
families O 0 4.85358839341643e-07
was O 0 3.8475178598673665e-07
screened O 0 6.2197368606575765e-06
for O 0 1.2555393595903297e-06
germline O 0 0.03592706099152565
PTEN O 1 0.9248499274253845
mutations O 0 0.0001957189233507961
. O 0 3.971797468693694e-06

PTEN O 1 0.9974453449249268
mutations O 1 0.902529776096344
were O 0 5.175177193450509e-06
identified O 0 9.063041375156899e-07
in O 0 4.3550333117536866e-08
30 O 0 5.446694828492582e-08
of O 0 1.1738102934089056e-08
37 O 0 9.67611185842543e-07
( O 0 6.434725463577706e-08
81 O 0 4.176996753813e-06
% O 0 5.565754435110648e-08
) O 0 2.1499026559013146e-08
CD B-Disease 0 6.880868113512406e-06
families O 0 1.071091233484367e-07
, O 0 1.376685787590759e-08
including O 0 4.40163141490757e-08
missense O 0 8.174043614417315e-06
and O 0 6.623668724614618e-08
nonsense O 0 3.296589966339525e-06
point O 0 3.5371010653761914e-07
mutations O 0 8.557515798202076e-07
, O 0 2.1852462950278095e-08
deletions O 0 5.929621238465188e-07
, O 0 5.594128538177756e-08
insertions O 0 3.0339685963554075e-06
, O 0 1.2819872097225016e-07
a O 0 6.762055022591085e-07
deletion O 0 0.00012732780305668712
/ O 0 1.1366957551217638e-05
insertion O 0 3.3588339647394605e-06
and O 0 3.9181870192805945e-07
splice O 0 4.950661241309717e-05
site O 0 2.1856938474229537e-05
mutations O 0 1.8489225112716667e-05
. O 0 2.585410811661859e-06

These O 0 9.937216418620665e-06
mutations O 0 9.27118890103884e-05
were O 0 2.826016043400159e-07
scattered O 0 2.6736847758002114e-07
over O 0 9.547238022378224e-08
the O 0 2.4116696195619625e-08
entire O 0 7.396470635967489e-08
length O 0 2.6020109089586185e-07
of O 0 1.1915154196628919e-08
PTEN O 0 0.0007740791770629585
, O 0 2.2702126400986344e-08
with O 0 6.518824591239536e-09
the O 0 8.737754519927421e-09
exception O 0 2.909655982819004e-08
of O 0 2.7093713939052577e-09
the O 0 4.960641231122054e-09
first O 0 9.37159967406842e-08
, O 0 3.517388336149452e-08
fourth O 0 4.888722173745919e-07
and O 0 1.5454280344329163e-07
last O 0 4.09153744840296e-06
exons O 0 4.0216233173850924e-05
. O 0 3.595088855945505e-06

A O 0 3.351403938722797e-05
hot O 0 2.8114618544350378e-05
spot O 0 5.9867311392736156e-06
for O 0 3.0319299071379646e-07
PTEN O 0 0.007434725295752287
mutation O 0 6.695359388686484e-06
in O 0 4.9681617042551807e-08
CD B-Disease 0 1.2566230907395948e-05
was O 0 2.411049990769243e-06
identified O 0 2.54112677566809e-07
in O 0 2.9883473473546474e-08
exon O 0 1.363171463708568e-06
5 O 0 6.343451985912907e-08
that O 0 6.018953779829417e-09
contains O 0 9.067631090431405e-09
the O 0 8.586059863091577e-09
PTPase O 0 1.4891479622747283e-06
core O 0 2.287968641212501e-07
motif O 0 2.4700719336578913e-07
, O 0 1.2828744289095084e-08
with O 0 1.2173472008214503e-08
13 O 0 2.7131271451708017e-08
of O 0 5.487600152065397e-09
30 O 0 7.591886941327175e-08
( O 0 2.096642148785577e-08
43 O 0 2.8701305154754664e-07
% O 0 2.4873273218872782e-08
) O 0 1.3596843650987012e-08
CD B-Disease 0 8.303226059069857e-05
mutations O 0 8.135812095133588e-06
identified O 0 2.1154357909836108e-07
in O 0 2.2626132079039962e-08
this O 0 8.245097404824264e-08
exon O 0 1.5337336662923917e-05
. O 0 2.006541535592987e-06

Seven O 0 7.538033514720155e-06
of O 0 3.1764477625984e-07
30 O 0 5.762585715274327e-07
( O 0 6.258699869476914e-08
23 O 0 2.895257864565792e-07
% O 0 1.6323495444225955e-08
) O 0 6.887812098455015e-09
were O 0 8.185362609935964e-09
within O 0 2.0503549968964307e-09
the O 0 2.7231472632394116e-09
core O 0 1.059446930185004e-07
motif O 0 2.346024388089063e-07
, O 0 2.2800980659098968e-08
the O 0 1.746352218390257e-08
majority O 0 5.5387545216945e-07
( O 0 1.324142751002455e-08
five O 0 1.4136512405116264e-08
of O 0 3.836036377435903e-09
seven O 0 5.8966548976968625e-08
) O 0 7.448111460917062e-09
of O 0 2.8973712318247635e-09
which O 0 5.65745814640195e-08
were O 0 1.5719179202733358e-07
missense O 0 0.0002614446566440165
mutations O 0 5.923182470723987e-06
, O 0 6.327333323952189e-08
possibly O 0 1.618216032284181e-07
pointing O 0 2.6739448344414996e-07
to O 0 3.337489928867399e-08
the O 0 1.3579297686305836e-08
functional O 0 1.300197425280203e-07
significance O 0 5.691051896405952e-08
of O 0 1.0013968321231914e-08
this O 0 8.143010887806668e-08
region O 0 1.3447777291730745e-06
. O 0 2.221049271611264e-06

Germline O 1 0.9836995601654053
PTEN O 1 0.9976143836975098
mutations O 1 0.9556760191917419
were O 0 8.721607628103811e-06
identified O 0 1.8161963453167118e-06
in O 0 2.7899604404524325e-08
four O 0 3.762287548170207e-08
of O 0 2.5561423200315403e-08
seven O 0 3.288211587459955e-07
( O 0 7.018977044026542e-08
57 O 0 2.8339552500256104e-06
% O 0 2.3117748071399546e-07
) O 0 1.8984702876423398e-07
BZS B-Disease 0 0.00017011116142384708
families O 0 1.3947926618129713e-06
studied O 0 3.822155122179538e-06
. O 0 2.023647084570257e-06

Interestingly O 0 0.003452128730714321
, O 0 5.213369149714708e-06
none O 0 6.022982006470556e-07
of O 0 2.0681088841456585e-08
these O 0 2.834641676940919e-08
mutations O 0 2.156810523956665e-06
was O 0 2.075194629469479e-07
observed O 0 2.461622727878421e-07
in O 0 2.6495348137700603e-08
the O 0 6.352751569238535e-08
PTPase O 0 2.104799023072701e-05
core O 0 2.0910404145979555e-06
motif O 0 6.2637313931190874e-06
. O 0 1.4797718677073135e-06

It O 0 2.5282142814830877e-06
is O 0 2.168232668964265e-07
also O 0 9.251594690340426e-08
worthy O 0 1.4100957912432932e-07
of O 0 1.3066956405793917e-08
note O 0 2.7471313046589785e-07
that O 0 8.803632489673419e-09
a O 0 3.026446293574736e-08
single O 0 8.456384392729888e-08
nonsense O 0 9.798316114029149e-07
point O 0 1.2026718820834503e-07
mutation O 0 4.143418266266963e-07
, O 0 3.1117490806309434e-08
R233X O 0 3.589073457987979e-06
, O 0 4.7777255929304374e-08
was O 0 1.2893302425709408e-07
observed O 0 6.641923988581766e-08
in O 0 1.601305399390185e-08
the O 0 7.286717362831041e-08
germline O 0 5.090288686915301e-05
DNA O 0 1.956838787009474e-06
from O 0 1.8688904646069204e-08
two O 0 2.928463516127522e-08
unrelated O 0 6.491183626167185e-07
CD B-Disease 0 1.4009320693730842e-05
families O 0 3.1558610658066755e-07
and O 0 8.181744703961158e-08
one O 0 5.321455773810158e-07
BZS B-Disease 0 0.0009849844500422478
family O 0 6.957835466891993e-06
. O 0 1.4204794069883064e-06

Genotype O 1 0.99674391746521
- O 1 0.9974126219749451
phenotype O 1 0.9980525970458984
studies O 0 6.583422418771079e-06
were O 0 2.796524825043889e-07
not O 0 3.879006271745311e-08
performed O 0 2.789163033867226e-07
on O 0 7.742317365000417e-08
this O 0 2.6265352559562416e-08
small O 0 6.990999423805988e-08
group O 0 1.4920975388577062e-07
of O 0 5.840464467610218e-08
BZS B-Disease 0 0.000627816014457494
families O 0 6.827790457464289e-06
. O 0 3.3938408705580514e-06

However O 0 2.0708876036223955e-05
, O 0 2.5207702947227517e-06
genotype O 0 0.00025695524527691305
- O 0 0.0014921408146619797
phenotype O 0 0.005272428039461374
analysis O 0 9.063326729119581e-07
inthe O 0 1.1129225640615914e-05
group O 0 1.4788321323067066e-07
of O 0 8.50699954924039e-09
CD B-Disease 0 1.8443066437612288e-05
families O 0 2.3888165401331207e-07
revealed O 0 3.563191057764925e-07
two O 0 7.82326026183e-09
possible O 0 2.4684606358960082e-08
associations O 0 6.632680182860895e-09
worthy O 0 2.8505278137913592e-08
of O 0 4.16267553760008e-09
follow O 0 1.2705181973160506e-07
- O 0 3.115347453785944e-06
up O 0 2.249322079705962e-07
in O 0 9.168083892063805e-08
independent O 0 6.617164558520017e-07
analyses O 0 3.7615379824273987e-06
. O 0 1.7606922710911022e-06

The O 0 1.940921720233746e-06
first O 0 5.266606990517175e-07
was O 0 4.065761913807364e-07
an O 0 6.435560351292224e-08
association O 0 7.389814271618889e-08
noted O 0 1.429333735813998e-07
in O 0 1.6610814057571588e-08
the O 0 1.571070384898121e-08
group O 0 4.4418857925165867e-08
of O 0 1.1883039441329402e-08
CD B-Disease 0 3.805219603236765e-05
families O 0 1.6743606465752237e-06
with O 0 7.350598025368527e-05
breast B-Disease 1 0.9999735355377197
disease I-Disease 1 0.9156812429428101
. O 0 1.489932674303418e-05

A O 0 4.557962893159129e-05
correlation O 0 2.0365532691357657e-05
was O 0 1.2813799230571021e-06
observed O 0 2.4296119249811454e-07
between O 0 3.186180208558653e-08
the O 0 3.9430691600728096e-08
presence O 0 6.195655828378221e-07
/ O 0 1.4033697880222462e-05
absence O 0 3.730240791810502e-07
of O 0 2.47634517336337e-08
a O 0 3.917808953701751e-06
PTEN O 1 0.6337923407554626
mutation O 0 4.742552391689969e-06
and O 0 1.5663518482256222e-08
the O 0 2.4717113689121106e-08
type O 0 5.526350150830694e-07
of O 0 1.628168035949784e-07
breast O 1 0.8683652281761169
involvement O 0 7.219662074930966e-05
( O 0 1.0743430038928636e-06
unaffected O 0 0.00010076780017698184
versus O 0 0.0003372719220351428
benign O 0 0.47027114033699036
versus O 0 0.09665191173553467
malignant O 1 0.9959113597869873
) O 0 2.351795501454035e-06
. O 0 2.049028807959985e-06

Specifically O 0 1.8680228095036e-05
and O 0 3.7844625921934494e-07
more O 0 5.152736903824007e-08
directly O 0 4.699206002101164e-08
, O 0 1.9791556837844837e-08
an O 0 4.87781512958918e-08
association O 0 7.383165012697646e-08
was O 0 8.81198545243933e-08
also O 0 7.747679831027199e-08
observed O 0 4.975340317514565e-08
between O 0 2.7411990455306068e-09
the O 0 4.466597758323587e-09
presence O 0 2.075997329598067e-08
of O 0 1.2332390220137768e-08
a O 0 1.5385987808258506e-06
PTEN O 0 0.4267069399356842
mutation O 0 6.0743779613403603e-05
and O 0 3.8005739043001086e-05
malignant B-Disease 1 0.9999860525131226
breast I-Disease 1 0.9999947547912598
disease I-Disease 1 0.9250268936157227
. O 0 1.1056496077799238e-05

Secondly O 0 0.003773018252104521
, O 0 4.125365649088053e-06
there O 0 3.1497663144364196e-07
appeared O 0 2.254612581964466e-06
to O 0 3.516630187050396e-08
be O 0 1.2988981445971604e-08
an O 0 5.095717625636098e-08
interdependent O 0 1.0556699635344557e-05
association O 0 1.229725654638969e-07
between O 0 3.323755137785156e-08
mutations O 0 4.251602092608664e-07
upstream O 0 6.41570565562688e-08
and O 0 1.2076847966113746e-08
within O 0 4.267515674172273e-09
the O 0 7.039393956631557e-09
PTPase O 0 1.8125713268091204e-06
core O 0 1.9526466132901987e-07
motif O 0 2.4297233380821126e-07
, O 0 9.560354286008987e-09
the O 0 3.973038342763857e-09
core O 0 9.982525739360426e-08
motif O 0 1.6908776956370275e-07
containing O 0 4.088265370683075e-08
the O 0 1.0226952618097584e-08
majority O 0 1.403367804186928e-07
of O 0 3.480927901478026e-08
missense O 0 0.0039398581720888615
mutations O 0 1.377832541038515e-05
, O 0 2.367036522343824e-08
and O 0 1.5290055443983874e-08
the O 0 1.2089201639753355e-08
involvement O 0 7.636938192945308e-08
of O 0 8.380544258557165e-09
all O 0 1.090842172146722e-08
major O 0 1.2357517675809504e-07
organ O 0 3.5589935578173026e-05
systems O 0 4.475670721149072e-06
( O 0 5.435683547716508e-08
central O 0 8.382129834672014e-08
nervous O 0 5.51653192815138e-06
system O 0 1.7160887182399165e-06
, O 0 5.412955488282023e-06
thyroid O 1 0.6938776969909668
, O 0 1.2380829502944835e-05
breast O 1 0.9438371062278748
, O 0 6.87704814481549e-05
skin O 1 0.9996572732925415
and O 1 0.5352599024772644
gastrointestinal O 1 0.9999978542327881
tract O 1 0.9991528987884521
) O 0 5.686337772203842e-06
. O 0 3.1275046694645425e-06

However O 0 1.6179341400857083e-05
, O 0 1.5515966822476912e-07
these O 0 7.65644969646928e-09
observations O 0 2.309240869635687e-07
would O 0 4.231538497379006e-08
need O 0 3.199950171506316e-08
to O 0 5.308753614485795e-08
be O 0 6.602994062632206e-08
confirmed O 0 4.769776751345489e-07
by O 0 1.240675562286242e-08
studying O 0 4.276570919614642e-08
a O 0 4.7255589663564024e-08
larger O 0 3.336789689001307e-08
number O 0 1.9733093381546496e-08
of O 0 2.1186636445236218e-08
CD B-Disease 0 5.642578253173269e-05
families O 0 3.4881106785178417e-06
. O 0 3.3786400308599696e-06

Molecular O 1 0.6749814748764038
defects O 1 0.9982913136482239
leading O 0 8.85836016095709e-06
to O 0 3.6683556459138345e-07
human O 0 3.059305129227141e-07
complement B-Disease 0 4.002883088105591e-06
component I-Disease 0 0.002735361224040389
C6 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999970197677612
in O 0 6.384370294654218e-07
an O 0 3.665331007596251e-07
African O 0 7.334942893066909e-07
- O 0 7.567738794023171e-05
American O 0 2.7614491955318954e-06
family O 0 5.080731625639601e-06
. O 0 1.8769480902847135e-06

Complement B-Disease 0 0.003119348781183362
component I-Disease 0 0.4596828520298004
C6 I-Disease 1 0.9999990463256836
deficiency I-Disease 1 0.9999984502792358
( O 0 1.459463601349853e-05
C6D B-Disease 0 0.005841286852955818
) O 0 8.629660328551836e-07
was O 0 2.9153221476008184e-05
diagnosed O 1 0.6251412630081177
in O 0 3.121432357033882e-08
a O 0 1.8413946634154854e-07
16 O 0 3.144181164316251e-07
- O 0 4.714580427389592e-06
year O 0 4.3691278506230447e-07
- O 0 3.3246544717258075e-06
old O 0 2.3409272671415238e-06
African O 0 7.930110257348133e-08
- O 0 1.5422052683788934e-06
American O 0 3.814297144799639e-07
male O 0 9.96050857793307e-06
with O 0 4.2138013668591157e-05
meningococcal B-Disease 1 0.9999884366989136
meningitis I-Disease 1 0.9999964237213135
. O 0 9.018882701639086e-05

The O 0 6.506252975668758e-05
patients O 0 0.08731189370155334
father O 0 1.782387880666647e-05
and O 0 3.258163303598849e-07
two O 0 2.0395407318574144e-07
brothers O 0 3.0691201118315803e-06
also O 0 8.74697931863011e-08
had O 0 2.3719972830349434e-07
C6D B-Disease 0 5.804281681776047e-05
, O 0 4.4167020263330414e-08
but O 0 2.0638847075815647e-08
gave O 0 1.473689223985275e-07
no O 0 5.252011092693465e-08
history O 0 5.8518715206901106e-08
of O 0 2.46721384655757e-07
meningitis B-Disease 1 0.9996210336685181
or O 0 9.5116195097944e-07
other O 0 4.753538007662428e-07
neisserial B-Disease 1 0.9734162092208862
infection I-Disease 0 0.20808985829353333
. O 0 8.457353942503687e-06

By O 0 5.7716006267583e-06
using O 0 1.4066495168663096e-06
exon O 0 8.706383596290834e-06
- O 0 2.1833227492606966e-06
specific O 0 6.680879494069814e-08
polymerase O 0 1.8301966520084534e-06
chain O 0 3.313550450911862e-06
reaction O 0 7.550455052296456e-07
( O 0 3.154187666609687e-08
PCR O 0 1.9806470845651347e-06
) O 0 4.734978276133006e-08
/ O 0 3.8605179497608333e-07
single O 0 1.5911024320303113e-07
- O 0 2.0276634131732862e-06
strand O 0 2.0547151962091448e-06
conformation O 0 1.016320879898558e-06
polymorphism O 0 2.0642823983507697e-06
as O 0 1.6802065516685616e-08
a O 0 6.9010177128348e-08
screening O 0 3.57915666882036e-07
step O 0 2.4157722577911045e-07
and O 0 1.7007746322406092e-08
nucleotide O 0 3.3674790955728895e-08
sequencing O 0 2.0691505397962828e-08
of O 0 3.19860005149053e-09
target O 0 5.8237674238625914e-08
exons O 0 5.105334253130422e-07
, O 0 1.462910592664457e-08
we O 0 5.816526371660302e-09
determined O 0 2.2292473644824895e-08
that O 0 3.6836100836268315e-09
the O 0 6.230374438587205e-09
proband O 0 5.5815530686231796e-06
was O 0 1.5420744148286758e-07
a O 0 1.1588991810640437e-07
compound O 0 1.0171063422603766e-06
heterozygote O 0 6.527077403006842e-06
for O 0 8.031978637745851e-08
two O 0 7.274634867826535e-07
C6 O 0 0.2893788516521454
gene O 0 4.109650035388768e-05
mutations O 0 1.8855862435884774e-05
. O 0 2.132370127583272e-06

The O 0 7.634208486706484e-06
first O 0 1.775090595401707e-06
, O 0 2.491858310804673e-07
1195delC O 0 2.9111495223332895e-06
located O 0 6.556309983807296e-08
in O 0 3.5439683188087656e-08
exon O 0 2.0587558537954465e-06
7 O 0 4.7178141926451644e-07
, O 0 2.830740797321596e-08
is O 0 1.296977103493191e-08
a O 0 1.4586441920982907e-07
novel O 0 2.1360033315431792e-06
mutation O 0 6.950116357984371e-07
, O 0 8.231470616237857e-09
while O 0 5.254432888790461e-09
the O 0 4.120241925420487e-09
second O 0 8.257342187789618e-08
, O 0 4.226658134598438e-08
1936delG O 0 1.761643034114968e-06
in O 0 3.764254330462791e-08
exon O 0 1.3225433121988317e-06
12 O 0 1.246064158522131e-07
, O 0 1.2489189238351628e-08
has O 0 3.916408175541619e-08
been O 0 3.080909394270748e-08
described O 0 2.3512521352131444e-07
before O 0 4.2404906253068475e-08
to O 0 1.1689848378182432e-07
cause O 0 2.77465346698591e-06
C6D B-Disease 0 0.0023010950535535812
in O 0 1.9065187473188416e-07
an O 0 1.264203035589162e-07
unrelated O 0 1.6586775473115267e-06
African O 0 2.5119865654232854e-07
- O 0 1.815388532122597e-05
American O 0 1.250338073077728e-06
individual O 0 7.943240234453697e-07
. O 0 2.7572073122428264e-06

Both O 0 7.11536267772317e-05
mutations O 0 0.0008759283227846026
result O 0 3.8622224565187935e-06
in O 0 1.1108899116152315e-06
premature O 0 0.010871308855712414
termination O 0 0.0002786564582493156
codons O 0 1.4837858543614857e-05
and O 0 2.1462967652041698e-06
C6 O 0 0.07383649051189423
null O 0 0.0005987937329337001
alleles O 0 3.820556594291702e-05
. O 0 5.546426109503955e-06

Allele O 0 0.008518903516232967
- O 0 0.00014083526912145317
specific O 0 9.611696896172361e-07
PCR O 0 5.2843424782622606e-05
indicated O 0 6.643021151830908e-06
that O 0 4.4795342546422035e-08
the O 0 3.264034731387255e-08
probands O 0 3.3649826946202666e-05
two O 0 2.1985560749726574e-07
brothers O 0 1.5223843092826428e-06
also O 0 8.47726511210567e-08
inherited O 0 9.773659712664085e-07
the O 0 3.0041721998941284e-08
1195delC O 0 3.9329155697487295e-05
mutation O 0 7.428357662320195e-07
from O 0 1.396861915026193e-08
their O 0 3.3374579544442895e-08
heterozygous O 0 9.461197805649135e-06
mother O 0 3.2132427350006765e-06
and O 0 1.0980376607960807e-08
the O 0 2.0065686001657923e-08
1936delG O 0 1.8427121176500805e-05
mutation O 0 7.203087193374813e-07
from O 0 1.4766639466756715e-08
their O 0 6.284047060489684e-08
homozygous O 0 1.04557138911332e-05
father O 0 3.5616219520306913e-06
. O 0 2.0186497806662373e-07
. O 0 9.149983384304505e-07

PAX6 O 1 0.99112868309021
mutations O 1 0.9867086410522461
reviewed O 0 0.003934377338737249
. O 0 0.00013956951443105936

Mutations O 1 0.7234907746315002
in O 0 2.1294668840710074e-05
PAX6 O 0 0.10145387053489685
are O 0 4.6809745413156634e-07
responsible O 0 3.6038244388691965e-07
for O 0 7.809413915538244e-08
human O 0 6.787097390770214e-07
aniridia B-Disease 1 0.9998905658721924
and O 0 1.3752863878835342e-06
have O 0 2.3390363423914096e-07
also O 0 1.951879511352672e-07
been O 0 1.6420275983364263e-07
found O 0 2.6051145596284186e-07
in O 0 1.3081839824735653e-06
patients O 0 0.0028468554373830557
with O 0 9.002224942378234e-06
Peters B-Disease 1 0.999967098236084
anomaly I-Disease 1 0.9999771118164062
, O 0 1.0828758604475297e-05
with O 0 0.007594076916575432
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.9999984502792358
, O 0 3.2905041734920815e-05
with O 0 3.711535464390181e-05
autosomal B-Disease 1 0.9394595623016357
dominant I-Disease 0 0.054956160485744476
keratitis I-Disease 1 0.9992508292198181
, O 0 1.5225120932882419e-06
and O 0 2.0603573602784309e-07
with O 0 1.7239327689821948e-06
isolated B-Disease 0 0.0012169313849881291
foveal I-Disease 1 0.9999728202819824
hypoplasia I-Disease 1 0.9999523162841797
. O 0 3.9858598029240966e-05

No O 0 1.9579270883696154e-05
locus O 0 3.6725316022057086e-05
other O 0 1.859947360571823e-07
than O 0 2.550617637098185e-07
chromosome O 0 1.0100587132910732e-05
11p13 O 0 4.345905836089514e-05
has O 0 4.740725785268296e-07
been O 0 1.2074710298293212e-07
implicated O 0 1.3553755024986458e-06
in O 0 3.8055443951634516e-07
aniridia B-Disease 1 0.9995269775390625
, O 0 3.151993155370292e-07
and O 0 1.8875626039971394e-07
PAX6 O 0 0.002375634852796793
is O 0 1.7676799757282424e-07
clearly O 0 1.0180112042235123e-07
the O 0 7.616162811530103e-09
major O 0 3.207160403917442e-08
, O 0 1.4684514049179143e-08
if O 0 1.8350899466668125e-08
not O 0 1.1114090980868241e-08
only O 0 2.6141254494405075e-08
, O 0 9.009382750946315e-08
gene O 0 5.278493517835159e-07
responsible O 0 1.1819722658401588e-06
. O 0 1.4707829905091785e-06

Twenty O 0 0.00011833337339339778
- O 0 0.00011344219819875434
eight O 0 3.092312681474141e-06
percent O 0 1.0516429256313131e-06
of O 0 5.3440366798440664e-08
identified O 0 3.716212404469843e-06
PAX6 O 0 0.08218082785606384
mutations O 0 7.854642171878368e-05
are O 0 1.3153406541732693e-07
C O 0 6.836293323431164e-06
- O 0 0.0006162304198369384
T O 0 0.0037057276349514723
changes O 0 1.861255043422716e-07
at O 0 3.821695671035741e-08
CpG O 0 1.4167858353175689e-06
dinucleotides O 0 2.212798790424131e-05
, O 0 4.875099435253105e-08
20 O 0 2.870524085096804e-08
% O 0 1.01788657502766e-08
are O 0 2.0391268673591867e-09
splicing O 0 4.476856645396765e-07
errors O 0 6.709707918162167e-07
, O 0 2.042833990856252e-08
and O 0 5.576377581917313e-09
more O 0 8.110935922900353e-09
than O 0 2.7243384437269924e-08
30 O 0 8.595420553092481e-08
% O 0 1.583537390104084e-08
are O 0 8.608542323429447e-09
deletion O 0 4.263480605004588e-06
or O 0 2.0506440989720431e-07
insertion O 0 7.901023309386801e-06
events O 0 1.500171947554918e-06
. O 0 3.0642415822512703e-06

There O 0 9.38412358664209e-06
is O 0 5.622410412797763e-07
a O 0 8.164843734448368e-07
noticeably O 0 8.007486030692235e-05
elevated O 0 4.22223201894667e-05
level O 0 5.16542080220006e-08
of O 0 1.12965432563783e-08
mutation O 0 1.1059796634071972e-06
in O 0 1.3494506845290744e-08
the O 0 1.0505283754014272e-08
paired O 0 3.632927985108836e-07
domain O 0 8.445938703971478e-08
compared O 0 8.874664558788936e-08
with O 0 4.117178153961731e-09
the O 0 9.498229758264642e-09
rest O 0 2.717871439017472e-08
of O 0 4.745517756532536e-09
the O 0 6.471675817465439e-08
gene O 0 2.844336449925322e-06
. O 0 8.183600357369869e-07

Increased O 0 0.00016148740542121232
mutation O 0 6.624909292440861e-05
in O 0 1.6232625910106435e-07
the O 0 7.771271270939906e-08
homeodomain O 0 1.1414601431170013e-05
is O 0 6.216180281626293e-08
accounted O 0 6.796878437853593e-08
for O 0 1.0382615656112648e-08
by O 0 4.155522503879183e-08
the O 0 8.631926107227628e-08
hypermutable O 0 0.00011276694567641243
CpG O 0 3.477746213320643e-05
dinucleotide O 0 3.507549990899861e-05
in O 0 5.734729597861588e-07
codon O 0 7.188661129475804e-06
240 O 0 1.4001629097037949e-05
. O 0 3.5236914754932513e-06

Very O 0 1.567187428008765e-05
nearly O 0 3.141302840958815e-06
all O 0 1.1145938572099112e-07
mutations O 0 3.5079262943327194e-06
appear O 0 1.0721025773818837e-06
to O 0 4.285953423277533e-07
cause O 0 5.150524157215841e-05
loss O 0 1.719539432087913e-05
of O 0 7.575017946237494e-09
function O 0 2.6184171275644985e-08
of O 0 2.447633651314618e-09
the O 0 1.3158720335582075e-08
mutant O 0 3.425616341701243e-06
allele O 0 8.80645529832691e-07
, O 0 1.1039870351226e-08
and O 0 9.905838815882362e-09
more O 0 1.70448650749222e-08
than O 0 3.469024179025837e-08
80 O 0 8.115102190231482e-08
% O 0 1.2876941291040112e-08
of O 0 6.524969897725441e-09
exonic O 0 1.1344226550136227e-05
substitutions O 0 1.8802246586346882e-06
result O 0 4.5779418655911286e-07
in O 0 1.523065407127433e-07
nonsense O 0 2.434319867461454e-05
codons O 0 1.2998943020647857e-05
. O 0 2.232244241895387e-06

In O 0 5.613765097223222e-06
a O 0 2.190911118304939e-06
gene O 0 6.021431318004034e-07
with O 0 4.066016856540955e-08
such O 0 3.037387941162706e-08
extraordinarily O 0 1.1222387001907919e-05
high O 0 5.509784273272089e-07
sequence O 0 1.0847861631191336e-07
conservation O 0 2.5375952006356783e-08
throughout O 0 2.34585364466966e-08
evolution O 0 6.483437431370476e-08
, O 0 2.0571093273247243e-08
there O 0 2.3408077254316595e-08
are O 0 2.472003757247876e-08
presumed O 0 3.334660505061038e-05
undiscovered O 0 0.00012316090578678995
missense O 0 0.0009487592033110559
mutations O 0 5.391085778683191e-06
, O 0 2.556386036189906e-08
these O 0 4.5882631027893694e-09
are O 0 8.61567084342596e-09
hypothesized O 0 8.204496566577291e-07
to O 0 5.009783521359168e-08
exist O 0 3.456185382333388e-08
in O 0 1.727277876284461e-08
as O 0 9.155118618764391e-08
- O 0 6.795876834075898e-05
yet O 0 6.87055398884695e-06
unidentified O 0 5.188839350012131e-05
phenotypes O 0 4.5852539187762886e-05
. O 0 3.3086863027165236e-07
. O 0 1.121105810852896e-06

Genetic O 0 0.025780120864510536
heterogeneity O 0 0.005155365914106369
and O 0 1.2290553058846854e-05
penetrance O 0 0.001012887223623693
analysis O 0 1.2898876775579993e-06
of O 0 3.5733584979880106e-08
the O 0 2.877661984257429e-07
BRCA1 O 0 0.0006297862273640931
and O 0 5.3083908824191894e-06
BRCA2 O 0 0.015152686275541782
genes O 0 9.832569958234672e-06
in O 0 0.0001034693923429586
breast B-Disease 1 0.9999854564666748
cancer I-Disease 1 0.9998795986175537
families O 0 3.5642038710648194e-05
. O 0 9.117004992731381e-06

The O 0 0.022011281922459602
Breast B-Disease 1 0.9999977350234985
Cancer I-Disease 1 0.9999840259552002
Linkage O 0 0.003036148613318801
Consortium O 0 0.00021647759422194213
. O 0 1.212418374052504e-05

The O 0 3.2148852824320784e-06
contribution O 0 1.3909033214076771e-06
of O 0 1.758789665018412e-07
BRCA1 O 0 0.0006812126375734806
and O 0 1.1369407729944214e-05
BRCA2 O 1 0.8689586520195007
to O 0 0.025164397433400154
inherited B-Disease 1 0.9999997615814209
breast I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999998807907104
was O 0 0.00035773954004980624
assessed O 0 2.536323790991446e-06
by O 0 3.860892761053947e-08
linkage O 0 1.9406070350669324e-06
and O 0 2.9905348242209584e-07
mutation O 0 1.5870772358539398e-06
analysis O 0 7.46190735867458e-08
in O 0 5.246263867775269e-08
237 O 0 4.890372565569123e-06
families O 0 2.97555686756823e-07
, O 0 1.9033572939974874e-08
each O 0 5.05389063931716e-09
with O 0 1.783161529544941e-08
at O 0 2.3025879869464916e-08
least O 0 4.7697582772343594e-08
four O 0 6.601231206104785e-08
cases O 0 1.6764525412327203e-07
of O 0 8.921725225263799e-07
breast B-Disease 1 0.9999862909317017
cancer I-Disease 1 0.995514452457428
, O 0 1.1621042972365103e-07
collected O 0 7.424441861303421e-08
by O 0 8.873293211308919e-08
the O 0 1.4164456842991058e-05
Breast B-Disease 1 0.9999988079071045
Cancer I-Disease 1 0.9999760389328003
Linkage O 0 0.00024063116870820522
Consortium O 0 2.815628977259621e-05
. O 0 3.409740202187095e-06

Families O 0 6.629295239690691e-05
were O 0 4.0596708572593343e-07
included O 0 1.3827428801960195e-07
without O 0 6.778959971143195e-08
regard O 0 4.024905919663979e-08
to O 0 6.015788756030815e-08
the O 0 2.6913975048614702e-08
occurrence O 0 7.239269734782283e-07
of O 0 2.470585513947299e-07
ovarian B-Disease 1 0.9671339988708496
or I-Disease 0 1.453570348530775e-06
other I-Disease 0 1.0931801170954714e-06
cancers I-Disease 0 0.11173202097415924
. O 0 7.0632004280923866e-06

Overall O 0 0.005966473370790482
, O 0 0.00021896196994930506
disease O 0 0.007354154717177153
was O 0 1.181056177301798e-06
linked O 0 1.2333376844253507e-06
to O 0 1.9228795622439065e-07
BRCA1 O 0 0.00010590516467345878
in O 0 6.354424186838514e-08
an O 0 7.982922056726238e-08
estimated O 0 1.8267704149366182e-07
52 O 0 6.460588224399544e-07
% O 0 1.8773935295257616e-08
of O 0 5.19789411512761e-09
families O 0 9.215964524855735e-08
, O 0 3.436910844811791e-08
to O 0 2.53404124350709e-07
BRCA2 O 0 0.0001115296472562477
in O 0 7.375367516715414e-08
32 O 0 3.6620289733946265e-07
% O 0 1.2885589484312732e-08
of O 0 3.560810757363697e-09
families O 0 6.352630776973456e-08
, O 0 2.262302523092785e-08
and O 0 3.035077256186014e-08
to O 0 7.565564175138206e-08
neither O 0 2.958020957066765e-07
gene O 0 7.226771003843169e-08
in O 0 2.0083682272797887e-08
16 O 0 1.3012009958401904e-07
% O 0 1.897941181994156e-08
( O 0 4.991201674187096e-09
95 O 0 6.877404246097285e-08
% O 0 4.768257255705066e-08
confidence O 0 2.759022379450471e-07
interval O 0 4.441674263944151e-07
[ O 0 5.224998744779441e-07
CI O 0 7.65562890592264e-06
] O 0 5.657716997120588e-07
6 O 0 1.7817140474107873e-07
% O 0 5.4167848873021285e-08
- O 0 2.818143229887937e-06
28 O 0 1.7592453787074191e-06
% O 0 2.4519806629541563e-08
) O 0 5.2015041163144815e-09
, O 0 1.1303548319574475e-08
suggesting O 0 2.449088185585424e-07
other O 0 5.005914971434322e-08
predisposition O 0 0.00011385347897885367
genes O 0 4.6048885451455135e-06
. O 0 1.6573903849348426e-06

The O 0 1.414740654581692e-05
majority O 0 2.5860448658932e-05
( O 0 3.797919703174557e-07
81 O 0 4.257950422470458e-06
% O 0 5.687861914793757e-08
) O 0 7.157698433957194e-09
of O 0 1.0541854500445424e-08
the O 0 3.819892299361527e-06
breast B-Disease 1 0.9999740123748779
- I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 5.0641783673199825e-06
were O 0 1.673910645649812e-07
due O 0 2.929654385752656e-07
to O 0 4.814986596102244e-07
BRCA1 O 0 0.0012125346111133695
, O 0 4.7693578864027586e-08
with O 0 2.913171037732809e-08
most O 0 5.256550394960868e-08
others O 0 2.971422645714483e-07
( O 0 2.348790850703608e-08
14 O 0 1.7086276216105034e-07
% O 0 2.7444333028370238e-08
) O 0 1.7035244326280008e-08
due O 0 4.24190659487067e-07
to O 0 3.5295165616844315e-06
BRCA2 O 0 0.010069350712001324
. O 0 6.788108294131234e-06

Conversely O 0 0.0012218853225931525
, O 0 1.4583133634005208e-06
the O 0 8.371712567623035e-08
majority O 0 2.6944721298605145e-07
of O 0 1.3279619182071656e-08
families O 0 1.1654616827172504e-07
with O 0 1.6650456302613748e-07
male B-Disease 0 7.936574547784403e-05
and I-Disease 0 9.297139513364527e-06
female I-Disease 1 0.9675849080085754
breast I-Disease 1 0.9999901056289673
cancer I-Disease 1 0.9971725344657898
were O 0 6.287997393883415e-07
due O 0 1.3189611536290613e-06
to O 0 4.576956143864663e-06
BRCA2 O 0 0.3091103434562683
( O 0 6.346568284243403e-07
76 O 0 4.2023719288408756e-05
% O 0 5.014855446461297e-07
) O 0 2.3580967933867214e-07
. O 0 1.440863115931279e-06

The O 0 6.323620254988782e-06
largest O 0 4.28499106419622e-06
proportion O 0 2.1214493699517334e-06
( O 0 1.7062941992662672e-07
67 O 0 3.414829734538216e-06
% O 0 8.18850480754918e-08
) O 0 8.33557223245407e-09
of O 0 8.416779273545671e-09
families O 0 1.7094197346523288e-07
due O 0 1.3508481799817673e-07
to O 0 5.1306809467632775e-08
other O 0 1.0288386143031403e-08
genes O 0 7.892235487361177e-08
was O 0 1.9957255403824092e-07
found O 0 7.100427978912194e-08
in O 0 1.747838318522099e-08
families O 0 2.6985372159060717e-08
with O 0 9.771104814149112e-09
four O 0 4.9136257729287536e-08
or O 0 1.6078640641126185e-08
five O 0 5.498813493431953e-08
cases O 0 1.2682023964316613e-07
of O 0 1.995668412746454e-07
female O 1 0.9946809411048889
breast B-Disease 1 0.9999902248382568
cancer I-Disease 1 0.999338686466217
only O 0 8.464042366540525e-06
. O 0 5.760531621490372e-06

These O 0 8.631128366687335e-06
estimates O 0 7.245407232403522e-06
were O 0 1.965455567187746e-07
not O 0 1.0614068202130511e-07
substantially O 0 1.3109865903970785e-06
affected O 0 7.402906732068004e-08
either O 0 1.5506625317129874e-08
by O 0 1.746968436577845e-08
changing O 0 9.153006175210976e-08
the O 0 2.3201872423328496e-08
assumed O 0 1.537435537102283e-06
penetrance O 0 1.1598933269851841e-05
model O 0 1.0878687817239552e-06
for O 0 1.9376541615656606e-07
BRCA1 O 0 0.00010302428563591093
or O 0 8.899802850237393e-08
by O 0 6.332331281555525e-08
including O 0 8.278978214093513e-08
or O 0 2.918218910963333e-07
excluding O 0 9.723514267534483e-06
BRCA1 O 0 0.008674870245158672
mutation O 0 2.063245301542338e-05
data O 0 2.0838263026234927e-06
. O 0 2.037726062553702e-06

Among O 0 2.0145074813626707e-05
those O 0 1.5640716810594313e-06
families O 0 1.2704191476586857e-06
with O 0 6.3709012465551496e-06
disease O 0 0.0034209752921015024
due O 0 2.8739125355059514e-06
to O 0 1.251701633009361e-06
BRCA1 O 0 0.00048279427574016154
that O 0 1.1858625015293e-07
were O 0 1.388342809605092e-07
tested O 0 3.073625975957839e-07
by O 0 8.869347034590191e-09
one O 0 6.528878770950541e-09
of O 0 2.0762340735558382e-09
the O 0 1.1436944724607656e-08
standard O 0 1.6569890703976853e-07
screening O 0 2.345129672676194e-07
methods O 0 1.4489363309166947e-07
, O 0 1.0258096949655737e-07
mutations O 0 1.0845104725376586e-06
were O 0 3.781337909458671e-08
detected O 0 2.452505043493147e-07
in O 0 7.28112903303213e-09
the O 0 8.877029777920598e-09
coding O 0 2.132367029616944e-07
sequence O 0 2.1959381868441596e-08
or O 0 4.755430715874809e-09
splice O 0 2.654482500474842e-07
sites O 0 1.6708174399582276e-08
in O 0 6.03233196727615e-09
an O 0 2.6078108561478075e-08
estimated O 0 2.253242570304792e-07
63 O 0 1.1934655503864633e-06
% O 0 2.6069553626939523e-08
( O 0 1.0949214868105628e-08
95 O 0 1.193075860328463e-07
% O 0 1.0360010094245808e-07
CI O 0 1.5513835023739375e-05
51 O 0 8.846119271765929e-06
% O 0 1.8414489488804975e-07
- O 0 2.264858085254673e-05
77 O 0 2.1113810362294316e-05
% O 0 2.2329673754484247e-07
) O 0 1.0218611379286813e-07
. O 0 5.661878503815387e-07

The O 0 6.286316420300864e-06
estimated O 0 7.211409865703899e-06
sensitivity O 0 1.1222472494409885e-05
was O 0 1.0049750471807783e-06
identical O 0 6.995387593633495e-07
for O 0 1.997145204768458e-08
direct O 0 5.716956152923558e-08
sequencing O 0 2.082404790826331e-07
and O 0 5.191179752728203e-08
other O 0 3.358242750550744e-08
techniques O 0 1.549155626889842e-06
. O 0 1.953791752384859e-06

The O 0 1.0011142876464874e-05
penetrance O 0 0.00027504144236445427
of O 0 1.021342313833884e-06
BRCA2 O 0 0.016241872683167458
was O 0 1.7542295154271415e-06
estimated O 0 1.6542007585940155e-07
by O 0 1.815638484004012e-08
maximizing O 0 2.1572434150129993e-07
the O 0 3.96177988193358e-08
LOD O 0 0.0017727374797686934
score O 0 4.723720792298991e-07
in O 0 5.206122750678333e-07
BRCA2 O 0 0.11056295037269592
- O 0 0.006439813878387213
mutation O 0 2.758434129646048e-05
families O 0 1.0133695127478859e-07
, O 0 8.93856810790794e-09
over O 0 1.7838623023180844e-08
all O 0 2.4925135733155912e-08
possible O 0 4.411768372847291e-07
penetrance O 0 4.9607271648710594e-05
functions O 0 1.27126270399458e-06
. O 0 1.8081377675116528e-06

The O 0 5.8816917771764565e-06
estimated O 0 4.507987341639819e-06
cumulative O 0 3.6150190680928063e-06
risk O 0 3.6310548239271156e-06
of O 0 1.0394910532340873e-06
breast B-Disease 1 0.9999512434005737
cancer I-Disease 1 0.998344898223877
reached O 0 8.979556696431246e-06
28 O 0 4.234378593537258e-06
% O 0 5.511413903036555e-08
( O 0 1.3829335010484556e-08
95 O 0 2.500628397683613e-07
% O 0 9.68708491200232e-08
CI O 0 1.0456532436364796e-05
9 O 0 7.243855293381785e-07
% O 0 5.730526453362472e-08
- O 0 4.710733719548443e-06
44 O 0 9.736550055094995e-07
% O 0 2.15799609293299e-08
) O 0 2.6751008075365235e-09
by O 0 4.345605209010728e-09
age O 0 5.058348762077003e-08
50 O 0 1.500747970339944e-08
years O 0 2.6949571463319444e-08
and O 0 2.291328549119953e-08
84 O 0 1.1122615433123428e-06
% O 0 2.3035982010810585e-08
( O 0 4.614047366402474e-09
95 O 0 7.795618017780725e-08
% O 0 7.997583395535912e-08
CI O 0 5.20091953148949e-06
43 O 0 9.491529908700613e-07
% O 0 5.7481070570020165e-08
- O 0 1.3285821296449285e-06
95 O 0 1.0695168839447433e-06
% O 0 4.601077918664487e-08
) O 0 8.930507888749162e-09
by O 0 2.7571934069214876e-08
age O 0 5.012067845200363e-07
70 O 0 4.4888224692840595e-07
years O 0 9.398985412190086e-07
. O 0 1.295789729738317e-06

The O 0 9.192873403662816e-05
corresponding O 1 0.7870638966560364
ovarian B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999990463256836
risks O 0 0.011600100435316563
were O 0 2.3540796973975375e-06
0 O 0 1.2299910849833395e-05
. O 0 1.8721640344665502e-06

4 O 0 6.034430771251209e-05
% O 0 2.6020159111794783e-06
( O 0 2.1182034970479435e-07
95 O 0 4.103343371752999e-07
% O 0 1.5920859652851505e-07
CI O 0 8.736891686567105e-06
0 O 0 1.1070645768995746e-06
% O 0 6.355296733318028e-08
- O 0 1.360959231533343e-06
1 O 0 1.1952943168580532e-07
% O 0 2.7128839619194878e-08
) O 0 3.6379181889145684e-09
by O 0 4.917926954561835e-09
age O 0 6.470614266618213e-08
50 O 0 1.869878119009627e-08
years O 0 2.257048414833207e-08
and O 0 3.055755826153472e-08
27 O 0 1.2886027889180696e-06
% O 0 2.9145770241711944e-08
( O 0 7.011053959615765e-09
95 O 0 1.4098536382789462e-07
% O 0 8.492413172689339e-08
CI O 0 7.013436061242828e-06
0 O 0 9.020539550874673e-07
% O 0 5.392415758365132e-08
- O 0 3.2721873139962554e-06
47 O 0 1.0685528650355991e-05
% O 0 5.6187019481512834e-08
) O 0 1.2799024950993498e-08
by O 0 4.8013493625376213e-08
age O 0 3.8082890796431457e-07
70 O 0 4.3388325821069884e-07
years O 0 1.1243705557717476e-06
. O 0 2.6274378797097597e-06

The O 0 1.1552654541446827e-05
lifetime O 0 0.00010861689952434972
risk O 0 1.390455690852832e-05
of O 0 3.398919261599076e-06
breast B-Disease 1 0.9999942779541016
cancer I-Disease 1 0.999884843826294
appears O 0 7.06776772858575e-05
similar O 0 3.6593095842363255e-07
to O 0 7.259873058274025e-08
the O 0 8.166949072574425e-08
risk O 0 5.758025736213312e-07
in O 0 1.1541322919583763e-07
BRCA1 O 0 0.0003236813936382532
carriers O 0 1.3890794434701093e-06
, O 0 3.385731162097727e-08
but O 0 1.9821627006422204e-08
there O 0 1.2855223552321604e-08
was O 0 2.283618982801272e-08
some O 0 2.8900966064782097e-09
suggestion O 0 3.7745209624517884e-08
of O 0 3.0858007260547993e-09
a O 0 1.3417328545983764e-06
lower O 0 3.846956678899005e-05
risk O 0 2.597312686702935e-06
in O 0 4.400314139729744e-07
BRCA2 O 0 0.0010604818817228079
carriers O 0 1.7950405890587717e-06
< O 0 1.2865706366937957e-06
50 O 0 1.4186962005169335e-07
years O 0 1.0128768224149098e-07
of O 0 5.456489660105035e-08
age O 0 5.457558017951669e-06
. O 0 3.5751968425756786e-06

Eye B-Disease 1 0.9980564117431641
movement I-Disease 0 0.01214988250285387
abnormalities I-Disease 1 0.9980332255363464
correlate O 0 0.00021980787278153002
with O 0 5.95486653764965e-06
genotype O 0 0.20359526574611664
in O 0 1.2704525943263434e-05
autosomal O 1 0.9599862098693848
dominant O 0 0.19747884571552277
cerebellar B-Disease 1 0.9991447925567627
ataxia I-Disease 1 0.99980229139328
type I-Disease 0 0.003925537224858999
I I-Disease 0 6.854172534076497e-05
. O 0 8.502252967446111e-06

We O 0 1.513302959210705e-05
compared O 0 1.2320501809881534e-05
horizontal O 0 9.111499093705788e-05
eye O 0 0.006949627306312323
movements O 0 2.646166876729694e-06
( O 0 2.0692164071078878e-07
visually O 0 3.4232357393193524e-06
guided O 0 3.970862053392921e-06
saccades O 0 0.0012112765107303858
, O 0 4.6781318019384344e-07
antisaccades O 0 2.234633211628534e-05
, O 0 5.8577338535314993e-08
and O 0 2.401511522975852e-08
smooth O 0 1.1189770248165587e-06
pursuit O 0 1.6029058542699204e-06
) O 0 5.564990246398338e-08
in O 0 2.9386804101250164e-08
control O 0 4.4852797032035596e-07
subjects O 0 8.871818977240764e-07
( O 0 5.12385476270083e-08
n O 0 3.5440332339931047e-06
= O 0 2.390184590694844e-06
14 O 0 1.121866901598878e-07
) O 0 3.226758238383809e-08
and O 0 4.1336576828143734e-07
patients O 0 0.0001621734700165689
with O 0 7.474898211512482e-08
three O 0 1.220902987597583e-07
forms O 0 1.209513271760443e-07
of O 0 1.4414098359338823e-07
autosomal O 0 0.046396177262067795
dominant O 0 0.0002039062383119017
cerebellar B-Disease 0 0.03579426184296608
ataxias I-Disease 0 0.011878709308803082
type I-Disease 0 1.1394068678782787e-05
I I-Disease 0 7.292636382771889e-06
spinocerebellar B-Disease 0 0.0010040134657174349
ataxias I-Disease 0 0.00017757352907210588
1 I-Disease 0 3.4497151091272826e-07
and I-Disease 0 6.841608524155163e-08
2 I-Disease 0 2.420407270165015e-07
( O 0 4.991413860011562e-08
SCA1 B-Disease 0 2.7413383577368222e-05
, O 0 1.6450948692181555e-07
n O 0 1.66968538906076e-06
= O 0 8.428572755292407e-07
11 O 0 1.1490749329823302e-07
; O 0 6.721537459952742e-08
SCA2 B-Disease 0 3.638788984972052e-05
, O 0 1.7989583511734963e-07
n O 0 9.03653699424467e-07
= O 0 7.715088941040449e-07
10 O 0 4.59747262482324e-08
) O 0 2.3699142204236523e-08
and O 0 1.8274430146902887e-07
SCA3 B-Disease 1 0.9996354579925537
/ O 0 0.0002952452632598579
Machado B-Disease 0 5.1014121709158644e-05
- I-Disease 0 0.038134049624204636
Joseph I-Disease 0 0.013557684607803822
disease I-Disease 0 0.0010701214196160436
( O 0 4.301940350615041e-07
MJD B-Disease 1 0.9995680451393127
) O 0 3.195297040292644e-07
( O 0 9.426241120991108e-08
n O 0 2.210637603639043e-06
= O 0 3.38875634042779e-06
16 O 0 4.151498842475121e-07
) O 0 2.975565394081059e-07
. O 0 1.3945466434961418e-06

In O 0 8.86157158674905e-06
SCA1 B-Disease 0 0.00018212349095847458
, O 0 3.167309330365242e-07
saccade O 0 1.0876108717639e-05
amplitude O 0 3.4651336591196014e-06
was O 0 5.803728981845779e-07
significantly O 0 7.54907318878395e-07
increased O 0 2.3658003556192853e-07
, O 0 9.862989713838033e-08
resulting O 0 1.0200807309956872e-06
in O 0 9.990779972213204e-07
hypermetria B-Disease 0 0.0023797601461410522
. O 0 6.406506599887507e-06

The O 0 4.712625468528131e-06
smooth O 0 3.7417001294670627e-05
pursuit O 0 2.545360621297732e-05
gain O 0 2.6569859983283095e-05
was O 0 1.2902818525617477e-05
decreased O 0 2.1572364858002402e-05
. O 0 3.104693860223051e-06

In O 0 1.3247234164737165e-05
SCA2 B-Disease 0 0.0002638252335600555
, O 0 9.311444841841876e-07
saccade O 0 4.395559517433867e-05
velocity O 0 1.4563644072040915e-05
was O 0 3.910145551344613e-06
markedly O 0 5.370625513023697e-05
decreased O 0 1.3444326214084867e-05
. O 0 1.9127157884213375e-06

The O 0 2.9046877898508683e-06
percentage O 0 3.190834604538395e-06
of O 0 5.050327800404375e-08
errors O 0 1.4140025541564682e-06
in O 0 2.5692889948913944e-07
antisaccades O 0 0.0007341376040130854
was O 0 9.032478942572197e-07
greatly O 0 1.78295138653084e-07
increased O 0 6.928807039230378e-08
and O 0 3.86011969055744e-08
was O 0 8.759757861298567e-07
significantly O 0 1.0707149158406537e-06
correlated O 0 4.057004332480574e-07
with O 0 8.514876981280395e-08
age O 0 5.225963377597509e-06
at O 0 2.8746881071128882e-06
disease O 0 0.0064896526746451855
onset O 0 0.04086567088961601
. O 0 3.02148619084619e-05

In O 0 1.2856868124799803e-05
addition O 0 9.8592340691539e-07
, O 0 7.19273600680026e-08
a O 0 1.6813679337701615e-07
correlation O 0 3.0006850693098386e-07
between O 0 4.2509697095738375e-08
smooth O 0 3.0767453154112445e-06
pursuit O 0 3.07180812342267e-06
gain O 0 3.541472551660263e-06
and O 0 1.9564634357038813e-08
the O 0 1.0341111966738481e-08
number O 0 1.5824625165805628e-08
of O 0 1.935980087353073e-08
trinucleotide O 0 0.0003908744838554412
repeats O 0 1.0766809282358736e-05
was O 0 8.930543913265865e-07
found O 0 6.807854333601426e-07
. O 0 1.094749222829705e-06

In O 0 6.972706614760682e-05
SCA3 B-Disease 1 0.9953800439834595
, O 0 5.560651516134385e-06
gaze B-Disease 0 0.0006218819180503488
- I-Disease 0 0.001454137614928186
evoked I-Disease 0 0.025406913831830025
nystagmus I-Disease 0 0.19766181707382202
was O 0 1.567026401971816e-06
often O 0 7.913474320275782e-08
present O 0 3.0954169005781296e-08
as O 0 2.1231459257364804e-08
was O 0 1.0150873919201331e-07
saccade O 0 4.6223744902818e-06
hypometria O 0 1.044188320520334e-05
and O 0 5.118639023748983e-08
smooth O 0 9.309899837717239e-07
pursuit O 0 3.014644562426838e-06
gain O 0 9.390758350491524e-06
was O 0 4.1116977627098095e-06
markedly O 0 0.00012886709009762853
decreased O 0 2.0022192984470166e-05
. O 0 4.155192527832696e-06

Three O 0 1.0555531844147481e-05
major O 0 1.7741733699949691e-06
criteria O 0 4.355357532404014e-07
, O 0 1.1363366070327174e-07
saccade O 0 8.975781383924186e-06
amplitude O 0 1.350812567579851e-06
, O 0 4.5534971349070474e-08
saccade O 0 3.406714085940621e-06
velocity O 0 7.246163136187533e-07
, O 0 3.33399050589378e-08
and O 0 1.5196523150962093e-08
presence O 0 3.1705820191518796e-08
of O 0 1.739232047270889e-08
gaze B-Disease 0 9.466768096899614e-05
- I-Disease 0 0.00020357327593956143
evoked I-Disease 0 0.0007882899371907115
nystagmus I-Disease 0 0.002032486954703927
, O 0 7.617546060600944e-08
permitted O 0 3.279448179682731e-08
the O 0 7.458375250735116e-09
correct O 0 1.8861913986256695e-07
assignment O 0 9.281924207016345e-08
of O 0 8.640421711447743e-09
90 O 0 8.167712195472632e-08
% O 0 8.425565134473345e-09
of O 0 1.400291660402786e-09
the O 0 1.0342729339640755e-08
SCA1 B-Disease 0 9.073575347429141e-05
, O 0 5.1666425804342e-08
90 O 0 6.286121134735367e-08
% O 0 6.1153828667670496e-09
of O 0 1.4135157488937011e-09
the O 0 2.7482677467105532e-08
SCA2 B-Disease 0 0.0009663265664130449
, O 0 7.445500926905879e-08
and O 0 4.1240017623067615e-08
93 O 0 5.064546826361038e-07
% O 0 1.2366073498526475e-08
of O 0 2.2478705563599988e-09
the O 0 4.4155987666272267e-07
patients O 0 0.005698877386748791
with O 0 1.6617998426227132e-06
SCA3 B-Disease 1 0.9999737739562988
to O 0 3.361954270530987e-07
their O 0 5.278694459320832e-08
genetically O 0 9.019335038829013e-07
confirmed O 0 8.586179319536313e-06
patient O 0 2.3212433006847277e-05
group O 0 1.270483096504904e-07
and O 0 4.0672890833093334e-08
, O 0 5.0834955800382886e-08
therefore O 0 6.06019625593035e-08
, O 0 3.6240063394643585e-08
may O 0 1.4314645113699953e-07
help O 0 1.897357151392498e-07
orient O 0 4.181157783023082e-05
diagnoses O 0 0.006259203888475895
of O 0 7.642577770639036e-08
SCA1 B-Disease 0 0.002604397479444742
, O 0 3.238770034386107e-07
SCA2 B-Disease 0 7.78066023485735e-05
, O 0 7.77394006945542e-08
and O 0 7.557545700365154e-08
SCA3 B-Disease 1 0.9753457307815552
at O 0 1.2574130892062385e-07
early O 0 4.252989356245962e-07
clinical O 0 6.091769591876073e-06
stages O 0 1.6398754496549373e-06
of O 0 1.116881591656238e-07
the O 0 3.977745109295938e-06
diseases O 0 0.0055252863094210625
. O 0 6.908523459969729e-07
. O 0 1.561835915708798e-06

Genetic O 0 0.0018309742445126176
basis O 0 4.048079517815495e-06
and O 0 7.92738546806504e-07
molecular O 0 1.127825271396432e-05
mechanism O 0 5.875503120478243e-06
for O 0 0.00013500537897925824
idiopathic B-Disease 1 0.9999997615814209
ventricular I-Disease 1 0.9999985694885254
fibrillation I-Disease 1 0.9999997615814209
. O 0 0.0007750422810204327

Ventricular B-Disease 1 0.9998220801353455
fibrillation I-Disease 1 0.9999746084213257
causes O 0 0.10047115385532379
more O 0 1.6891657423911965e-06
than O 0 3.115592051017302e-07
300 O 0 3.584684122870385e-07
, O 0 1.8677185664728313e-07
000 O 0 1.209186279993446e-06
sudden O 0 0.0005236251745373011
deaths O 0 9.335595677839592e-05
each O 0 4.198848557734891e-08
year O 0 1.6732738572500239e-07
in O 0 4.234533790281603e-08
the O 0 1.0961485230609469e-07
USA O 0 6.067348294891417e-06
alone O 0 4.653264113585465e-06
. O 0 2.2360027287504636e-06

In O 0 6.5320591602358036e-06
approximately O 0 9.39685207868024e-07
5 O 0 3.6707635331367783e-07
- O 0 2.8558526992128463e-06
12 O 0 2.9579814508906566e-07
% O 0 9.325094474377238e-09
of O 0 1.7735614088465468e-09
these O 0 1.5871661318556107e-08
cases O 0 3.4006305327238806e-07
, O 0 7.223643194720353e-08
there O 0 2.646888042079354e-08
are O 0 7.36358529707104e-09
no O 0 1.81199951043709e-07
demonstrable O 0 0.01858779415488243
cardiac O 1 0.9988325238227844
or O 0 8.399637181355502e-07
non O 0 5.0045632633555215e-06
- O 1 0.9678497314453125
cardiac O 1 0.9999769926071167
causes O 0 9.849393245531246e-05
to O 0 1.915748271130724e-07
account O 0 1.378660954287625e-07
for O 0 1.3230218698367935e-08
the O 0 3.6152869142824784e-08
episode O 0 4.046407866553636e-06
, O 0 4.7544805426014136e-08
which O 0 4.9055255857410884e-08
is O 0 5.070055664191386e-08
therefore O 0 1.3066114945559093e-07
classified O 0 5.357063628252945e-07
as O 0 1.0697121069824789e-05
idiopathic B-Disease 1 0.9999995231628418
ventricular I-Disease 1 0.9999996423721313
fibrillation I-Disease 1 1.0
( O 0 0.0011956864036619663
IVF B-Disease 1 0.9999325275421143
) O 0 8.76282592798816e-06
. O 0 3.05582830151252e-06

A O 0 0.0001171776166302152
distinct O 0 2.1030735297244973e-05
group O 0 3.7453623917826917e-06
of O 0 6.051752734492766e-07
IVF B-Disease 1 0.9999995231628418
patients O 1 0.9992156028747559
has O 0 1.83034501333168e-06
been O 0 1.0113633663877408e-07
found O 0 2.5876843778860348e-08
to O 0 1.8582342775630423e-08
present O 0 2.147804067931247e-08
with O 0 3.3910048102825385e-08
a O 0 1.9727576727746055e-06
characteristic O 0 1.204960517497966e-05
electrocardiographic O 0 0.0008959911065176129
pattern O 0 2.2087320758146234e-05
. O 0 3.3283884022239363e-06

Because O 0 5.808884452562779e-06
of O 0 6.770225269292496e-08
the O 0 2.871471416199256e-08
small O 0 2.5060758801487282e-08
size O 0 4.4752898276101405e-08
of O 0 5.750933507187028e-09
most O 0 2.7128582047453165e-08
pedigrees O 0 1.2662532071772148e-06
and O 0 4.443673873311127e-08
the O 0 2.3686940409106683e-08
high O 0 1.130189843934204e-06
incidence O 0 8.74139295774512e-05
of O 0 6.955951903364621e-08
sudden B-Disease 1 0.8987971544265747
death I-Disease 0 0.12651202082633972
, O 0 2.4515276209058356e-07
however O 0 1.6246130485342292e-07
, O 0 5.55572086113898e-08
molecular O 0 1.3704971024708357e-06
genetic O 0 5.301579335537099e-07
studies O 0 6.111024930532949e-08
of O 0 6.136803420986325e-08
IVF B-Disease 1 0.9999732971191406
have O 0 4.661285402107751e-06
not O 0 1.2368224133751937e-07
yet O 0 3.609007421800925e-07
been O 0 1.9999514222490689e-07
done O 0 7.662748657821794e-07
. O 0 1.4342263057187665e-06

Because O 0 0.0009133857092820108
IVF B-Disease 1 0.9999157190322876
causes O 1 0.720355749130249
cardiac O 1 0.9992332458496094
rhythm O 0 0.08911169320344925
disturbance O 0 0.0001478786434745416
, O 0 1.5089057114892057e-07
we O 0 2.1509936942720742e-08
investigated O 0 3.2981293429656944e-07
whether O 0 8.930904016324348e-08
malfunction O 0 2.9116854420863092e-05
of O 0 1.5170343203863013e-08
ion O 0 1.913316737045534e-05
channels O 0 1.4600138911191607e-06
could O 0 7.891390509939811e-07
cause O 0 2.833407052094117e-06
the O 0 1.2197269825264812e-06
disorder O 0 0.4104291498661041
by O 0 8.871279533195775e-08
studying O 0 6.572441861862899e-07
mutations O 0 4.239522240823135e-06
in O 0 3.5986378321695156e-08
the O 0 2.1991786525177304e-07
cardiac O 1 0.918834924697876
sodium O 0 0.018326548859477043
channel O 0 7.111549348337576e-05
gene O 0 5.04354966324172e-06
SCN5A O 0 0.0001127587747760117
. O 0 4.5972101361257955e-06

We O 0 1.731578231556341e-05
have O 0 7.305489475584181e-07
now O 0 2.873230755540135e-07
identified O 0 2.138729371381487e-07
a O 0 5.02609282193589e-07
missense O 0 0.0014069947646930814
mutation O 0 3.2408759125246434e-06
, O 0 2.0950992052348738e-08
a O 0 7.887179265253508e-08
splice O 0 2.2707623429596424e-05
- O 0 0.0002213372354162857
donor O 0 7.910387466836255e-06
mutation O 0 4.796786470251391e-06
, O 0 1.2833933915601392e-08
and O 0 1.9589279531828652e-08
a O 0 5.2215791583876126e-06
frameshift O 1 0.9800258874893188
mutation O 0 4.954619271302363e-06
in O 0 2.0472375794611253e-08
the O 0 1.8088359254875286e-08
coding O 0 9.903100135488785e-07
region O 0 3.534510639724431e-08
of O 0 1.1627334650654575e-08
SCN5A O 0 0.00025200407253578305
in O 0 3.707783378104068e-07
three O 0 2.0459435745578958e-06
IVF B-Disease 1 0.9995163679122925
families O 0 1.576843533257488e-05
. O 0 3.210743216186529e-06

We O 0 3.2102868772199145e-06
show O 0 1.1225683920201845e-06
that O 0 5.054876339727343e-08
sodium O 0 8.419020787187037e-07
channels O 0 1.0429899077735172e-07
with O 0 1.995370801921581e-08
the O 0 4.015574006643874e-08
missense O 0 4.453485962585546e-05
mutation O 0 2.664477960934164e-06
recover O 0 2.773365167740849e-06
from O 0 4.021698529754758e-08
inactivation O 0 0.0001712125085759908
more O 0 7.198445928224828e-08
rapidly O 0 1.4273163628786278e-07
than O 0 2.5865594110996426e-08
normal O 0 6.008644248822748e-08
and O 0 1.4479645926712692e-08
that O 0 2.5509940826395905e-08
the O 0 1.7370446414588514e-07
frameshift O 1 0.9140548706054688
mutation O 0 1.633384272281546e-05
causes O 0 4.985661803402763e-07
the O 0 1.527443060922451e-08
sodium O 0 6.020218279445544e-06
channel O 0 1.088137537408329e-06
to O 0 2.3842229524007053e-08
be O 0 1.540738914229678e-08
non O 0 1.5936416275508236e-07
- O 0 8.611634257249534e-06
functional O 0 8.452870133623946e-06
. O 0 1.9010298046850949e-06

Our O 0 3.5025357647100464e-05
results O 0 1.2720140148303472e-05
indicate O 0 1.5851954913159716e-06
that O 0 3.0175647225405555e-07
mutations O 0 4.793187599716475e-06
in O 0 1.9895456659924093e-07
cardiac O 0 0.05052565410733223
ion O 0 0.00012385621084831655
- O 0 0.00010397213191026822
channel O 0 4.691003596235532e-06
genes O 0 9.185271920841842e-08
contribute O 0 2.2095253626730482e-08
to O 0 1.0979099407393278e-08
the O 0 3.088882039037344e-08
risk O 0 2.1710260966756323e-07
of O 0 3.410015025906432e-08
developing O 0 6.098954145272728e-06
IVF B-Disease 1 0.9998956918716431
. O 0 3.0113719731161837e-06
. O 0 3.0968042210588465e-06

Molecular O 0 0.0010741578880697489
heterogeneity O 0 0.0012937429128214717
in O 0 1.0843433301488403e-05
mucopolysaccharidosis B-Disease 0 0.0036134852562099695
IVA I-Disease 0 0.003026189748197794
in O 0 8.501243655700819e-07
Australia O 0 1.9481377933061594e-07
and O 0 3.864606057391029e-08
Northern O 0 8.216400004812385e-08
Ireland O 0 1.8354056408043107e-07
: O 0 4.6483581428446996e-08
nine O 0 1.6806752967113425e-07
novel O 0 1.3280615576150012e-06
mutations O 0 1.2454065654310398e-06
including O 0 4.3423096229844305e-08
T312S O 0 1.6717454855097458e-05
, O 0 4.0773556975182146e-08
a O 0 2.5408701276319334e-07
common O 0 2.2812383804193814e-07
allele O 0 2.4363760076084873e-06
that O 0 6.633796090227406e-08
confers O 0 1.3974427929497324e-05
a O 0 5.5394975788658485e-05
mild O 1 0.9970582723617554
phenotype O 1 0.9856433868408203
. O 0 1.3030842637817841e-05

Mucopolysaccharidosis B-Disease 1 0.9720670580863953
IVA I-Disease 1 0.9970966577529907
( O 0 0.011972233653068542
MPS B-Disease 1 0.999971866607666
IVA I-Disease 1 0.9999042749404907
) O 0 1.5748167925266898e-06
is O 0 2.804061125516455e-07
an O 0 3.625013505370589e-06
autosomal B-Disease 1 0.9686089754104614
recessive I-Disease 1 0.9924302697181702
lysosomal I-Disease 1 0.98111891746521
storage I-Disease 1 0.897874116897583
disorder I-Disease 1 0.9972195625305176
caused O 0 2.611399941088166e-05
by O 0 2.6343249714955164e-07
a O 0 0.0005771096330136061
genetic B-Disease 1 0.9994515776634216
defect I-Disease 1 0.9997373223304749
in O 0 7.703487767685147e-07
N O 0 3.3647840609773993e-05
- O 0 2.7625459551927634e-05
acetylgalactosamine O 0 0.00036243387148715556
- O 0 6.010236029396765e-05
6 O 0 5.273781425785273e-06
- O 0 0.001792917842976749
sulfate O 0 0.14529907703399658
sulfatase O 0 0.003098659683018923
( O 0 8.002998015399498e-07
GALNS O 0 5.645856072078459e-05
) O 0 1.3720821243623504e-06
. O 0 1.8970310975419125e-06

Previous O 0 4.922696825815365e-05
studies O 0 2.6390071070636623e-06
of O 0 4.968256916981773e-07
patients O 0 0.00035737649886868894
from O 0 5.607182274047773e-08
a O 0 1.448131115466822e-06
British O 0 4.1255731048295274e-05
- O 0 0.0001510135771241039
Irish O 0 5.668605808750726e-06
population O 0 5.5022756129119443e-08
showed O 0 3.9302301502175396e-07
that O 0 1.3378463670221663e-08
the O 0 3.347218324734058e-08
I113F O 0 0.0002852757752407342
mutation O 0 2.396539002802456e-06
is O 0 1.5065067415775957e-08
the O 0 1.219252698803075e-08
most O 0 2.5891655042187267e-08
common O 0 1.0859309185207167e-07
single O 0 5.0793023547157645e-06
mutation O 0 3.428613854339346e-05
among O 0 2.8455058327381266e-06
MPS B-Disease 1 0.9999886751174927
IVA I-Disease 1 0.9999990463256836
patients O 1 0.9935185313224792
and O 0 1.2083874025847763e-06
produces O 0 2.0935623979312368e-05
a O 0 0.00024036059039644897
severe O 1 0.9993343949317932
clinical O 1 0.9907682538032532
phenotype O 1 0.9960773587226868
. O 0 1.688266456767451e-05

We O 0 9.37085223995382e-06
studied O 0 1.6155456250999123e-05
mutations O 0 1.7938642486114986e-05
in O 0 1.1173759162375063e-07
the O 0 6.414677500288235e-08
GALNS O 0 0.00016953566228039563
gene O 0 5.30514000729454e-07
from O 0 3.568440831713815e-08
23 O 0 5.724648417526623e-07
additional O 0 9.519187074147339e-07
MPS B-Disease 1 0.9999632835388184
IVA I-Disease 1 0.9999966621398926
patients O 1 0.9634064435958862
( O 0 1.3208287441557331e-07
15 O 0 7.716620586961653e-08
from O 0 1.4735746844962705e-08
Australia O 0 7.278563174395458e-08
, O 0 2.3678403238136525e-08
8 O 0 4.376442319653506e-08
from O 0 1.0670575534277305e-08
Northern O 0 9.513354370938032e-08
Ireland O 0 1.2185208220216737e-07
) O 0 6.6686807187466e-09
, O 0 5.98683813635148e-09
with O 0 1.200510180154879e-08
various O 0 5.377050982247056e-08
clinical O 0 0.017971888184547424
phenotypes O 1 0.682115375995636
( O 0 9.13848964501085e-07
severe O 0 0.09708341211080551
, O 0 9.793570825422648e-07
16 O 0 1.7768113593774615e-06
cases O 0 5.59415980205813e-07
; O 0 1.398608731051354e-07
intermediate O 0 4.327596627717867e-07
, O 0 6.265771190783198e-08
4 O 0 6.670094876426447e-07
cases O 0 1.3477036873155157e-06
; O 0 2.9607176657009404e-06
mild O 0 0.33744025230407715
, O 0 1.4157404848447186e-06
3 O 0 5.557243184739491e-06
cases O 0 1.3589243508249638e-06
) O 0 4.302867750993755e-07
. O 0 2.1251773887343006e-06

We O 0 9.936619790096302e-06
found O 0 1.6492592749273172e-06
two O 0 3.3182641345774755e-07
common O 0 8.068150805229379e-07
mutations O 0 3.0895475902070757e-06
that O 0 2.3450217767617687e-08
together O 0 3.730902520260315e-08
accounted O 0 1.0556547636042524e-07
for O 0 1.507325997351927e-08
32 O 0 2.619316603613697e-07
% O 0 1.1589938786471521e-08
of O 0 2.5626822885982392e-09
the O 0 2.7914028422060255e-08
44 O 0 1.2386666412567138e-06
unrelated O 0 2.403724010946462e-06
alleles O 0 2.201903953391593e-06
in O 0 3.35759352765308e-07
these O 0 8.203838888221071e-07
patients O 0 0.001350347651168704
. O 0 5.204075478104642e-06

One O 0 4.0073750824376475e-06
is O 0 1.8957527458951517e-07
the O 0 1.3127302622706338e-07
T312S O 0 0.00012182442878838629
mutation O 0 6.433832368202275e-06
, O 0 3.980663265679141e-08
a O 0 9.683500934443146e-08
novel O 0 2.911182718889904e-06
mutation O 0 1.2709692782664206e-06
found O 0 1.043666486566508e-07
exclusively O 0 3.5988719560009486e-07
in O 0 1.5564190789518761e-06
milder O 1 0.9752072691917419
patients O 1 0.5945686101913452
. O 0 1.3029673937126063e-05

The O 0 3.29714657709701e-06
other O 0 1.2182465525256703e-07
is O 0 2.2761264872883658e-08
the O 0 1.734051302548778e-08
previously O 0 4.396303836529114e-07
described O 0 1.2433166602932033e-06
I113F O 0 5.65105847272207e-06
that O 0 5.239363787268303e-08
produces O 0 9.673141221355763e-07
a O 0 1.8118395018973388e-05
severe O 1 0.9970404505729675
phenotype O 1 0.9903078675270081
. O 0 1.3265717825561296e-05

The O 0 4.965574589732569e-06
I113F O 0 4.7949903091648594e-05
and O 0 4.731330989216076e-07
T312S O 0 3.552141060936265e-05
mutations O 0 4.491915660764789e-06
accounted O 0 2.7306938932269986e-07
for O 0 2.7977831607017833e-08
8 O 0 3.051536623388529e-07
( O 0 4.344446935533597e-08
18 O 0 1.2042740138440422e-07
% O 0 2.0187146176908755e-08
) O 0 9.725996896747802e-09
and O 0 2.9094561426745713e-08
6 O 0 2.443022992792976e-07
( O 0 2.0898786701195604e-08
14 O 0 9.164448044884921e-08
% O 0 1.3508310026111303e-08
) O 0 2.6997610813594974e-09
of O 0 5.837776928530047e-09
44 O 0 8.037109751057869e-07
unrelated O 0 2.7234427761868574e-06
alleles O 0 3.3766300475690514e-06
, O 0 4.4296101009422273e-07
respectively O 0 3.6382398320711218e-06
. O 0 1.697919628895761e-06

The O 0 3.6115143302595243e-06
relatively O 0 2.621836074467865e-06
high O 0 6.620131784984551e-07
residual O 0 7.79315087129362e-06
GALNS O 0 8.576111576985568e-05
activity O 0 2.2872443139476673e-07
seen O 0 2.1896607904636767e-07
when O 0 3.0415620244639285e-08
the O 0 1.3970937295937347e-08
T312S O 0 1.1753145372495055e-06
mutant O 0 6.609748197661247e-07
cDNA O 0 5.529961413230922e-07
is O 0 3.342930554595114e-08
overexpressed O 0 1.2804613334083115e-06
in O 0 4.911180084832267e-08
mutant O 0 7.857133823563345e-06
cells O 0 9.659636361902812e-07
provides O 0 7.929338607937098e-08
an O 0 3.0857670196837717e-08
explanation O 0 3.205081782198249e-07
for O 0 3.2000968985812506e-08
the O 0 5.381780283642001e-07
mild O 1 0.9988515377044678
phenotype O 1 0.9996009469032288
in O 0 2.5563344024703838e-05
patients O 0 0.0012734198244288564
with O 0 1.9545898055639555e-07
this O 0 1.0287267286912538e-06
mutation O 0 1.709679600025993e-05
. O 0 1.7158333776023937e-06

The O 0 1.2907933069072897e-06
distribution O 0 1.7726263479289628e-07
and O 0 3.0576565279716306e-08
relative O 0 1.2550397343602526e-07
frequencies O 0 1.2041306263199658e-07
of O 0 7.042160188319713e-09
the O 0 2.231531937013642e-08
I113F O 0 7.967177225509658e-06
and O 0 1.399039604166319e-07
T312S O 0 3.3355765481246635e-05
mutations O 0 2.4063549517450156e-06
in O 0 2.960960543418878e-08
Australia O 0 5.684369597247496e-08
corresponded O 0 2.619593999497738e-07
to O 0 2.1963236562783095e-08
those O 0 8.13105671682024e-09
observed O 0 7.131087897960242e-08
in O 0 2.0178445581109372e-08
Northern O 0 9.551117585715474e-08
Ireland O 0 7.274690716485566e-08
and O 0 1.1251622744623546e-08
are O 0 3.1623905716315903e-09
unique O 0 8.251654470825542e-09
to O 0 1.9655223226777707e-08
these O 0 5.179209505712379e-09
two O 0 2.666711651500009e-08
populations O 0 3.8557782744419455e-08
, O 0 1.2035410890121057e-08
suggesting O 0 1.179992850097733e-07
that O 0 1.9268000528427365e-08
both O 0 2.2514546671459357e-08
mutations O 0 4.836957714360324e-07
were O 0 2.5632262534713846e-08
probably O 0 6.03226482098762e-08
introduced O 0 6.802572016795239e-08
to O 0 2.67366875306152e-08
Australia O 0 4.8300254462674275e-08
by O 0 1.5183832857701418e-08
Irish O 0 1.5963109945005272e-07
migrants O 0 7.810412228081987e-08
during O 0 7.426623227502205e-08
the O 0 3.842306739443302e-08
19th O 0 8.261963557743002e-07
century O 0 2.355085825911374e-06
. O 0 4.284533588361228e-06

Haplotype O 1 0.9808639883995056
analysis O 0 3.356486195116304e-05
using O 0 2.5448305223108036e-06
6 O 0 2.7720959678845247e-06
RFLPs O 0 1.4062809896131512e-05
provides O 0 2.0102564235457976e-07
additional O 0 4.2657518406485906e-08
data O 0 2.7511628530874077e-08
that O 0 9.938162293110508e-09
the O 0 3.20544799592426e-08
I113F O 0 6.0506517911562696e-05
mutation O 0 1.5719538168923464e-06
originated O 0 7.882668029424167e-08
from O 0 1.889499934293326e-08
a O 0 5.161008971299452e-07
common O 0 1.2386466323732748e-06
ancestor O 0 6.999785000516567e-06
. O 0 4.0592399273009505e-06

The O 0 2.695813464015373e-06
other O 0 3.5620053040474886e-07
9 O 0 1.735866817398346e-06
novel O 0 8.405762855545618e-06
mutations O 0 2.403909275017213e-05
identified O 0 5.482967253556126e-07
in O 0 2.9082244168421312e-08
these O 0 3.555816974198933e-08
23 O 0 1.1926625120395329e-05
patients O 0 4.1747432987904176e-05
were O 0 2.678538102429684e-08
each O 0 1.0380675874444023e-08
limited O 0 3.149546401459702e-08
to O 0 2.1140296624366783e-08
a O 0 2.649126145115588e-07
single O 0 2.107537284246064e-06
family O 0 2.9008067485847278e-06
. O 0 2.0940938156854827e-06

These O 0 4.5415722524921875e-06
data O 0 6.606256874874816e-07
provide O 0 2.407295198736392e-07
further O 0 8.769029591348954e-08
evidence O 0 1.207167059646963e-07
for O 0 5.039771977521923e-08
extensive O 0 1.3238733345133369e-06
allelic O 0 8.130590140353888e-05
heterogeneity O 0 0.00010330484656151384
in O 0 6.5827384787553456e-06
MPS B-Disease 1 0.999887228012085
IVA I-Disease 1 0.9998040795326233
in O 0 1.0372864380769897e-05
British O 0 0.00025492257555015385
- O 0 0.1299344152212143
Irish O 0 0.00443699536845088
patients O 0 0.0014236557763069868
and O 0 6.279002917608523e-08
provide O 0 8.851807820065005e-08
evidence O 0 5.899950750176686e-08
for O 0 9.292691061091318e-09
their O 0 2.4080522464942078e-08
transmission O 0 1.1085425057899556e-06
to O 0 4.947037623992401e-08
Australia O 0 4.9947562530405776e-08
by O 0 3.048798902227645e-08
British O 0 1.255564598068304e-06
- O 0 7.737379746686202e-06
Irish O 0 1.2678603980020853e-06
migrants O 0 6.94834000114497e-07
. O 0 3.345198820170481e-07
. O 0 1.555104518047301e-06

Identification O 0 4.744908801512793e-05
of O 0 1.5028482494017226e-06
constitutional O 0 8.230606908909976e-05
WT1 O 1 0.9837914705276489
mutations O 0 0.002536710351705551
, O 0 6.813738764321897e-07
in O 0 1.2253606200829381e-06
patients O 0 0.0002975346287712455
with O 0 1.2385261243252899e-06
isolated O 0 0.003602943615987897
diffuse B-Disease 1 0.9999324083328247
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 0.9999998807907104
, O 0 1.3213293641456403e-06
and O 0 7.999169326922129e-08
analysis O 0 1.1166110169824606e-07
of O 0 9.738009509874246e-08
genotype O 0 0.23563212156295776
/ O 0 0.08256978541612625
phenotype O 0 0.06757482141256332
correlations O 0 2.1129367269168142e-06
by O 0 2.076021132779715e-08
use O 0 2.1626355817261356e-08
of O 0 1.2423472917078016e-08
a O 0 9.35456000661361e-07
computerized O 0 0.0013916481984779239
mutation O 0 5.397802669904195e-05
database O 0 2.9188915959821315e-06
. O 0 1.8698623307500384e-06

Constitutional O 0 0.0006230720318853855
mutations O 0 0.0006478450959548354
of O 0 2.7616573561317637e-07
the O 0 3.695685109050828e-07
WT1 O 0 0.0006133783026598394
gene O 0 1.2891018741356675e-06
, O 0 3.8727080209355336e-08
encoding O 0 1.2943048943725444e-07
a O 0 2.355900647899034e-07
zinc O 0 1.9134005924570374e-05
- O 0 1.1500378604978323e-06
finger O 0 1.1669191053442773e-06
transcription O 0 2.242318544176669e-07
factor O 0 1.0021060603548904e-07
involved O 0 4.411111476088081e-08
in O 0 2.596017338873935e-07
renal O 1 0.9960649609565735
and O 0 2.8812314667447936e-06
gonadal O 0 0.0003074333944823593
development O 0 8.305391219209923e-08
, O 0 4.45417924765934e-08
are O 0 1.3355721861785241e-08
found O 0 5.993157969896856e-08
in O 0 3.6660257052290035e-08
most O 0 4.312875603318389e-07
patients O 0 0.0003310904430691153
with O 0 7.472912329831161e-06
Denys B-Disease 1 0.9996852874755859
- I-Disease 1 0.9999740123748779
Drash I-Disease 1 0.9999961853027344
syndrome I-Disease 1 0.9999980926513672
( O 0 3.285125330876326e-06
DDS B-Disease 1 0.9999693632125854
) O 0 6.999898687354289e-07
, O 0 3.762223457215441e-07
or O 0 2.539811703172745e-06
diffuse B-Disease 1 0.9996082186698914
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 3.9133825339376926e-05
DMS B-Disease 1 0.8499335050582886
) O 0 3.267947192853171e-07
associated O 0 1.1332685545539789e-07
with O 0 1.3604346804640954e-07
pseudohermaphroditism B-Disease 1 0.9991851449012756
and O 0 4.499255737755448e-06
/ O 0 0.00036609102971851826
or O 0 3.678171651699813e-06
Wilms B-Disease 1 0.9979894161224365
tumor I-Disease 1 0.5853027105331421
( O 0 1.859801614045864e-06
WT B-Disease 1 0.9985811710357666
) O 0 1.1997957471976406e-06
. O 0 1.310950437982683e-06

Most O 0 9.728530130814761e-05
mutations O 0 0.014431457035243511
in O 0 6.996024603722617e-05
DDS B-Disease 1 0.9999996423721313
patients O 1 0.9997864365577698
lie O 0 0.00020774478616658598
in O 0 4.1320927834931354e-07
exon O 0 6.918803137523355e-06
8 O 0 4.7303115024988074e-07
or O 0 5.2754131729670917e-08
exon O 0 1.6456597222713754e-06
9 O 0 3.2234370905825926e-07
, O 0 3.269480330914121e-08
encoding O 0 2.9411373247967276e-07
zinc O 0 2.7533300453796983e-05
finger O 0 1.0009205652750097e-05
2 O 0 6.286576876846084e-07
or O 0 1.1915556541453043e-07
zinc O 0 7.542622915934771e-05
finger O 0 6.037182538420893e-05
3 O 0 4.820132062377525e-07
, O 0 4.938383213470843e-08
respectively O 0 1.2824004613776196e-07
, O 0 4.894961325163649e-09
with O 0 6.124826867903721e-09
a O 0 2.199321329499071e-07
hot O 0 1.1319856639602222e-05
spot O 0 6.416246833396144e-06
( O 0 1.0519283222265585e-07
R394W O 0 3.3326159609714523e-06
) O 0 4.0050107230626963e-08
in O 0 4.610644666058761e-08
exon O 0 6.425609626603546e-06
9 O 0 4.597543465933995e-06
. O 0 1.1568148465812556e-06

We O 0 5.987034001009306e-06
analyzed O 0 4.600323791237315e-06
a O 0 2.574172128788632e-07
series O 0 3.527725596086384e-07
of O 0 9.509345488822873e-08
24 O 0 0.00034965036320500076
patients O 0 0.0004939410137012601
, O 0 8.635219472807876e-08
10 O 0 1.0928437887969267e-07
with O 0 2.2530447552071564e-07
isolated B-Disease 0 0.00010391671094112098
DMS I-Disease 1 0.9723284244537354
( O 0 6.865333261885098e-07
IDMS B-Disease 0 0.003077483270317316
) O 0 6.851689704490127e-08
, O 0 2.594276971024101e-08
10 O 0 4.5467800191545393e-08
with O 0 3.5313408375259314e-07
DDS B-Disease 1 0.9999969005584717
, O 0 6.323236902971985e-07
and O 0 6.963013987615341e-08
4 O 0 4.161360891430377e-07
with O 0 5.4260698334474e-07
urogenital B-Disease 1 0.9975806474685669
abnormalities I-Disease 1 0.9998763799667358
and O 0 2.5341973014292307e-05
/ O 0 0.047892507165670395
or O 0 2.2190160962054506e-05
WT B-Disease 1 0.9999371767044067
. O 0 1.3181249414628837e-05

We O 0 1.9137638446409255e-05
report O 0 1.2869232705270406e-05
WT1 O 0 0.000750317529309541
heterozygous O 0 0.0003968851233366877
mutations O 0 4.7000768972793594e-05
in O 0 6.01573162839486e-07
16 O 0 3.282668694737367e-05
patients O 0 0.002658360404893756
, O 0 1.7690764764211053e-07
4 O 0 2.606881537303707e-07
of O 0 4.402571818218348e-08
whom O 0 2.4714765913813608e-06
presented O 0 2.2440478915086715e-06
with O 0 2.2985525447438704e-06
IDMS B-Disease 0 0.4749901592731476
. O 0 1.0896778803726193e-05

One O 0 1.4615847248933278e-05
male O 0 2.0235764168319292e-05
and O 0 2.9360734288275125e-07
two O 0 8.017573236429598e-07
female O 0 0.0023679614532738924
IDMS B-Disease 1 0.9996021389961243
patients O 1 0.8257678151130676
with O 0 1.1267426998529118e-05
WT1 O 1 0.9964374303817749
mutations O 0 0.01354699395596981
underwent O 0 0.19238001108169556
normal O 0 2.4680737624294125e-05
puberty O 0 0.00011311394337099046
. O 0 6.569755896634888e-06

Two O 0 0.00011383696983102709
mutations O 0 0.003894963301718235
associated O 0 3.3103506211773492e-06
with O 0 3.841453519726201e-07
IDMS B-Disease 0 0.3771618902683258
are O 0 8.399062068065177e-08
different O 0 9.734069550404456e-09
from O 0 1.7064904156427474e-08
those O 0 6.619728054602092e-08
described O 0 1.7450427549192682e-05
in O 0 2.3257349312189035e-05
DDS B-Disease 1 0.9999997615814209
patients O 1 0.9992499947547913
. O 0 1.4821524018771015e-05

No O 0 0.0001099725704989396
WT1 O 1 0.6484370231628418
mutations O 0 0.004315593279898167
were O 0 1.5579724959025043e-06
detected O 0 2.154662297471077e-06
in O 0 4.558041766244969e-08
the O 0 3.348648647261143e-08
six O 0 5.041675876782392e-07
other O 0 4.268405291441013e-07
IDMS B-Disease 1 0.9995946288108826
patients O 1 0.9394991993904114
, O 0 5.414940460468642e-07
suggesting O 0 7.620519227202749e-06
genetic O 0 2.6855368560063653e-06
heterogeneity O 0 9.525549103273079e-06
of O 0 4.466021152893518e-07
this O 0 8.528108082828112e-06
disease O 0 0.006486247293651104
. O 0 5.679504283762071e-06

We O 0 1.2980411156604532e-05
analyzed O 0 8.56251353980042e-05
genotype O 0 0.02568569965660572
/ O 0 0.003280097618699074
phenotype O 0 0.01627781242132187
correlations O 0 8.11016343504889e-06
, O 0 1.0313165432762617e-07
on O 0 5.60431701046582e-08
the O 0 1.3180775582100068e-08
basis O 0 7.969378046368547e-09
of O 0 4.2553884860296876e-09
the O 0 1.8575219584704428e-08
constitution O 0 8.169207887931407e-08
of O 0 5.697804894566616e-09
a O 0 6.427814014386968e-07
WT1 O 0 0.0038123871199786663
mutation O 0 1.1955650052186684e-06
database O 0 4.210316717490059e-08
of O 0 1.0287720009216628e-08
84 O 0 8.41238318116666e-07
germ O 0 1.3978093193145469e-05
- O 0 0.0001249007327714935
line O 0 1.1406286830606405e-05
mutations O 0 1.6631888684059959e-06
, O 0 1.8758365527560272e-08
to O 0 1.6316928252990692e-08
compare O 0 9.247572307913288e-08
the O 0 7.557066084018516e-09
distribution O 0 2.1137473993348976e-08
and O 0 2.7169333449705846e-08
type O 0 1.114897898446543e-07
of O 0 3.8784961020610353e-08
mutations O 0 1.28059264170588e-05
, O 0 4.1557441932127404e-08
according O 0 1.993776876929587e-08
to O 0 2.3080314548451497e-08
the O 0 6.599217527991641e-08
different O 0 7.521313136749086e-07
symptoms O 0 0.04689156636595726
. O 0 6.356184712785762e-06

This O 0 9.663307537266519e-06
demonstrated O 0 2.4314333131769672e-05
( O 0 3.1515060072706547e-07
1 O 0 1.2376955282888957e-07
) O 0 2.3046002439741642e-08
the O 0 1.858131426502041e-08
association O 0 4.642315332148428e-08
between O 0 3.936967019058102e-08
mutations O 0 1.5959747088345466e-06
in O 0 3.8304964533608654e-08
exons O 0 2.581084800112876e-06
8 O 0 1.7459966272781458e-07
and O 0 4.844131851200473e-08
9 O 0 3.937410895105131e-07
and O 0 4.1815138729361934e-07
DMS B-Disease 1 0.9489730000495911
; O 0 9.038649295689538e-07
( O 0 1.978491326326548e-08
2 O 0 9.704097436724624e-08
) O 0 3.392997527384978e-08
among O 0 1.7973636090573564e-07
patients O 0 0.0002023988781729713
with O 0 1.2446311075109406e-06
DMS B-Disease 1 0.9928062558174133
, O 0 1.0120541560354468e-07
a O 0 1.798462534452483e-07
higher O 0 5.975250161327494e-08
frequency O 0 1.423867104222154e-07
of O 0 7.825887493595474e-09
exon O 0 3.1757981560076587e-06
8 O 0 8.028805495996494e-07
mutations O 0 1.36480002765893e-06
among O 0 3.607379639447572e-08
46 O 0 1.0860154588954174e-06
, O 0 1.287653162762581e-06
XY O 1 0.9988777041435242
patients O 1 0.6578252911567688
with O 0 1.7381380530423485e-06
female O 0 0.048093851655721664
phenotype O 0 0.11185194551944733
than O 0 1.8091505182837864e-07
among O 0 5.784930579011416e-08
46 O 0 2.4533499072276754e-06
, O 0 1.318948648076912e-06
XY O 1 0.9971147775650024
patients O 0 0.04159526154398918
with O 0 2.7370737143428414e-07
sexual O 0 1.2878313100372907e-06
ambiguity O 0 7.349847237492213e-06
or O 0 4.577122126647737e-06
male O 0 0.032688748091459274
phenotype O 1 0.914138674736023
; O 0 6.681656259388546e-07
and O 0 1.0648276571600945e-07
( O 0 2.920910269210708e-08
3 O 0 4.319312907341555e-08
) O 0 8.958128461244996e-09
statistically O 0 5.845244999136412e-08
significant O 0 2.1551988638179864e-08
evidence O 0 8.538914642031159e-08
that O 0 7.01587197227127e-08
mutations O 0 8.907306323635567e-07
in O 0 2.209348437531844e-08
exons O 0 1.7517385231258231e-06
8 O 0 1.0396114902277986e-07
and O 0 3.279573235204225e-08
9 O 0 2.503224152405892e-07
preferentially O 0 1.0846378017959069e-06
affect O 0 1.7857983891644835e-07
amino O 0 6.03601719717517e-08
acids O 0 2.3866071785505483e-08
with O 0 7.324503670247395e-09
different O 0 7.962070114331254e-09
functions O 0 4.621236016078001e-08
. O 0 1.3482933525210683e-07
. O 0 7.028126560726378e-07

The O 0 1.0956528967653867e-05
185delAG O 0 0.0008809171849861741
BRCA1 O 0 0.006859581917524338
mutation O 0 2.9891292797401547e-05
originated O 0 4.423092434535647e-07
before O 0 3.146226390526863e-08
the O 0 6.4402483346270856e-09
dispersion O 0 3.218166284568724e-07
of O 0 2.0074452322660363e-08
Jews O 0 1.9196255607312196e-07
in O 0 2.3387146441677942e-08
the O 0 2.565686685329638e-08
diaspora O 0 4.026576618798572e-07
and O 0 4.9634262921927075e-08
is O 0 3.969676853898818e-08
not O 0 3.676115767348165e-08
limited O 0 1.9022634489829215e-07
to O 0 5.306142156769056e-07
Ashkenazim O 0 3.203871165169403e-05
. O 0 4.468306087801466e-06

The O 0 1.619097929506097e-05
185delAG O 0 0.00047740357695147395
mutation O 0 0.00012822919234167784
in O 0 7.629839728906518e-07
BRCA1 O 0 0.00030994846019893885
is O 0 4.3678528527379967e-07
detected O 0 4.005804385087686e-06
in O 0 1.1698502078161255e-07
Ashkenazi O 0 3.142719288007356e-05
Jews O 0 1.7737896484959492e-07
both O 0 3.4846813434796786e-08
in O 0 2.5107507894972514e-07
familial B-Disease 1 0.625541627407074
breast I-Disease 1 0.9999945163726807
and I-Disease 1 0.9999383687973022
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
and O 0 1.3799069620290538e-06
in O 0 9.910472442697937e-08
the O 0 4.070144754564353e-08
general O 0 6.354047741297109e-07
population O 0 8.892130836102297e-07
. O 0 2.4708922410354717e-06

All O 0 1.3423800737655256e-05
tested O 0 6.972759729251266e-05
Ashkenazi O 0 0.0002691025147214532
mutation O 0 1.3007822417421266e-05
carriers O 0 1.3007099823880708e-06
share O 0 1.1703546221042416e-07
the O 0 1.7947696662190538e-08
same O 0 9.606969797459897e-08
allelic O 0 7.2378725235466845e-06
pattern O 0 1.9439225980022456e-06
at O 0 9.802282363580161e-08
the O 0 3.210870147540845e-07
BRCA1 O 0 0.0003687795833684504
locus O 0 5.867776781087741e-05
. O 0 8.012490980036091e-06

Our O 0 1.5977435396052897e-05
previous O 0 5.587011855823221e-06
study O 0 8.219516871577071e-07
showed O 0 1.235816057487682e-06
that O 0 2.2158221923973542e-08
this O 0 3.41534622805284e-08
Ashkenazi O 0 5.2979710744693875e-05
mutation O 0 2.593228828118299e-06
also O 0 1.6386579204663576e-07
occurs O 0 4.3960017848121424e-08
in O 0 1.8342641183721753e-08
Iraqi O 0 7.860970185902261e-07
Jews O 0 1.0222841950735528e-07
with O 0 2.334186888219847e-08
a O 0 5.792283559458156e-07
similar O 0 1.7252600628125947e-06
allelic O 0 8.875430648913607e-05
pattern O 0 3.253227987443097e-05
. O 0 6.284601568040671e-06

We O 0 2.249893668704317e-06
extended O 0 6.604443001378968e-07
our O 0 4.681385235016933e-08
analysis O 0 4.1584005572303795e-08
to O 0 1.7857482603744756e-08
other O 0 8.057538636307982e-09
non O 0 6.214995096343046e-08
- O 0 2.1823152565048076e-06
Ashkenazi O 0 2.268279331474332e-06
subsets O 0 2.889553343266016e-07
354 O 0 3.85711757644458e-07
of O 0 1.371606295208494e-08
Moroccan O 0 4.2974643292836845e-06
origin O 0 1.203411983397018e-07
, O 0 2.0468158723474517e-08
200 O 0 7.188265271906857e-08
Yemenites O 0 3.130112418148201e-06
and O 0 5.674338510175403e-08
150 O 0 2.0816086987451854e-07
Iranian O 0 1.607961394256563e-06
Jews O 0 1.5268509514498874e-06
. O 0 1.248065018444322e-06

Heteroduplex O 0 0.005263155791908503
analysis O 0 1.9724571757251397e-05
complemented O 0 1.0272648978570942e-05
by O 0 1.1858161741429285e-07
direct O 0 1.6552549197967892e-07
DNA O 0 5.17134594701929e-07
sequencing O 0 2.7020402626476425e-07
of O 0 6.250588313605476e-08
abnormally O 0 4.388828074297635e-06
migrating O 0 4.2725187654468755e-07
bands O 0 4.1754248059078236e-07
were O 0 1.88697228509227e-07
employed O 0 2.0852655779890483e-06
. O 0 1.952780166902812e-06

Four O 0 1.1293449460936245e-05
of O 0 4.084852491814672e-07
Moroccan O 0 2.298028084624093e-05
origin O 0 4.6832565203658305e-07
( O 0 3.476999665963376e-08
1 O 0 3.461007125338256e-08
. O 0 1.2636070856331116e-08
1 O 0 4.26276720588703e-08
% O 0 1.6821113391074505e-08
) O 0 7.74764696842567e-09
and O 0 1.5714510581688046e-08
none O 0 4.012748888726492e-08
of O 0 4.004726328332708e-09
the O 0 4.689151111847423e-08
Yemenites O 0 1.216369855683297e-05
or O 0 2.4235621509660632e-08
Iranians O 0 1.1216829420845897e-07
was O 0 4.134831854685217e-08
a O 0 1.1278419975724319e-07
carrier O 0 7.049822556837171e-07
of O 0 2.400490295428881e-08
the O 0 2.0841712000674306e-07
185delAG O 0 0.0002212330000475049
mutation O 0 3.455820478848182e-05
. O 0 2.3124371182348114e-06

BRCA1 O 1 0.9474884271621704
allelic O 0 0.023782340809702873
patterns O 0 0.0012069568037986755
were O 0 4.8726683417044114e-06
determined O 0 1.445279394829413e-06
for O 0 4.654710039631027e-08
four O 0 3.454366392929842e-08
of O 0 5.171588934871352e-09
these O 0 1.1252953235896257e-08
individuals O 0 5.177116069177146e-09
and O 0 1.1918540820943235e-08
for O 0 1.6469167363197812e-08
12 O 0 8.64192557514798e-08
additional O 0 5.780628953289124e-08
non O 0 1.5593801094837545e-07
- O 0 1.5017098121461459e-05
Ashkenazi O 0 2.1081255908939056e-05
185delAG O 0 1.0017571185017005e-05
mutation O 0 2.258869471916114e-06
carriers O 0 1.2492487257986795e-06
who O 0 3.7992560919519747e-06
had O 0 0.0011354624293744564
breast B-Disease 1 0.9999626874923706
/ I-Disease 1 0.9999955892562866
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 0 3.345340155647136e-05

Six O 0 6.92775720381178e-05
non O 0 1.2461710866773501e-05
- O 0 0.0008537942194379866
Ashkenazi O 0 0.0007595648639835417
individuals O 0 1.4349826926718379e-07
shared O 0 9.206706153008781e-08
the O 0 3.4229763912208e-08
common O 0 6.787705046917836e-07
Ashkenazi O 0 0.006625133100897074
haplotype O 0 0.09428451210260391
, O 0 4.591574764845063e-08
four O 0 3.1768109920449206e-08
had O 0 6.356411574870435e-08
a O 0 4.7153310589465036e-08
closely O 0 1.1507307817737455e-07
related O 0 9.072912376950626e-08
pattern O 0 8.393503208026232e-07
, O 0 5.155538929102477e-08
and O 0 2.4159099609732948e-08
the O 0 1.739696564584392e-08
rest O 0 1.2691339179582428e-07
( O 0 2.6398998542731533e-08
n O 0 8.497409567098657e-07
= O 0 9.95071900433686e-07
6 O 0 6.043838851610417e-08
) O 0 8.537543116915458e-09
displayed O 0 5.830257876482392e-08
a O 0 2.403679957296845e-07
distinct O 0 1.6219951248785947e-06
BRCA1 O 0 0.00022138786152936518
allelic O 0 0.0001174017452285625
pattern O 0 4.349023583927192e-05
. O 0 6.50978336125263e-06

We O 0 1.149416948464932e-05
conclude O 0 7.80900245445082e-06
that O 0 1.8923751099464425e-07
the O 0 1.942523795150919e-07
185delAG O 0 0.0002827170828823
BRCA1 O 0 0.0038640040438622236
mutation O 0 2.723702164075803e-05
occurs O 0 2.2812297117980052e-07
in O 0 3.3020818079876335e-08
some O 0 2.55801513304732e-08
non O 0 4.230606407418236e-07
- O 0 0.0002245809737360105
Ashkenazi O 0 0.0004779525042977184
populations O 0 2.0727873106807237e-07
at O 0 3.073092003091915e-08
rates O 0 7.655343381429702e-08
comparable O 0 4.5253059965943976e-08
with O 0 1.783045888714696e-08
that O 0 5.9318498557558996e-08
of O 0 2.2099222007909702e-07
Ashkenazim O 0 3.381136411917396e-05
. O 0 2.9203201847849414e-06

The O 0 5.40823430128512e-06
majority O 0 3.310638248876785e-06
of O 0 5.478723252849704e-08
Jewish O 0 5.304679575601767e-07
185delAG O 0 4.9890397349372506e-05
mutation O 0 4.445150807441678e-06
carriers O 0 4.22592478344086e-07
have O 0 3.2150428097565964e-08
a O 0 1.9823750108116656e-07
common O 0 2.743110201208765e-07
allelic O 0 4.084737884113565e-05
pattern O 0 7.163011559896404e-06
, O 0 5.301538763546887e-08
supporting O 0 4.539085551868993e-08
the O 0 1.806494864808883e-08
founder O 0 5.321400067259674e-07
effect O 0 6.760365778291089e-08
notion O 0 7.890128728149648e-08
, O 0 2.4198531178853955e-08
but O 0 2.702987877967189e-08
dating O 0 1.0424966490063525e-07
the O 0 2.987327363257464e-08
mutations O 0 4.43683120465721e-07
origin O 0 1.569791407973753e-08
to O 0 1.5948526055353796e-08
an O 0 3.192543118757385e-08
earlier O 0 8.216194373744656e-07
date O 0 2.66413735516835e-07
than O 0 1.3219377592577075e-07
currently O 0 8.77808076893416e-07
estimated O 0 1.208931507790112e-06
. O 0 1.4043507690075785e-06

However O 0 2.7325062546879053e-05
, O 0 2.2792943354943418e-07
the O 0 2.6593669488761407e-08
different O 0 2.018722256025285e-08
allelic O 0 2.603879920570762e-06
pattern O 0 1.1864149200846441e-06
at O 0 6.314071043789227e-08
the O 0 7.350566022523708e-08
BRCA1 O 0 6.556966400239617e-05
locus O 0 4.6582194954680745e-06
even O 0 1.3184778424601973e-07
in O 0 2.0545606105315528e-08
some O 0 2.4989779134898527e-08
Jewish O 0 2.690353824164049e-07
mutation O 0 1.3532701359508792e-06
carriers O 0 3.3661569887044607e-07
, O 0 5.68067370920744e-08
might O 0 1.2758557943470805e-07
suggest O 0 1.3500033446689486e-07
that O 0 2.211447913680331e-08
the O 0 4.666337360959005e-08
mutation O 0 2.248542386951158e-06
arose O 0 4.679323239997757e-07
independently O 0 5.567372909354162e-07
. O 0 1.5427805521994742e-07
. O 0 5.428491931525059e-07

Crystal O 0 0.0019364329054951668
structure O 0 4.548793640424265e-06
of O 0 2.0907204145714786e-07
the O 0 1.0197792335020495e-06
hemochromatosis B-Disease 1 0.9999608993530273
protein O 0 4.339513452578103e-06
HFE O 0 9.358503302792087e-05
and O 0 9.343452944676756e-08
characterization O 0 4.101477486528893e-07
of O 0 8.714968302570014e-09
its O 0 2.4809972742900754e-08
interaction O 0 9.267524347933431e-08
with O 0 3.022824159870652e-07
transferrin O 0 0.0003443400200922042
receptor O 0 2.3852910089772195e-05
. O 0 2.4577313979534665e-06

HFE O 1 0.5312893986701965
is O 0 1.0644875146681443e-05
an O 0 2.316061227247701e-06
MHC O 0 0.0010131032904610038
- O 0 0.00023221010633278638
related O 0 3.748195922526065e-07
protein O 0 8.310207988415641e-08
that O 0 1.1845294523027405e-08
is O 0 8.434794196432449e-09
mutated O 0 7.353938258347625e-07
in O 0 3.137818183063246e-08
the O 0 1.1517924747295183e-07
iron B-Disease 0 0.22237174212932587
- I-Disease 1 0.9978321194648743
overload I-Disease 1 0.9998664855957031
disease I-Disease 1 0.9998263716697693
hereditary B-Disease 1 0.9999992847442627
hemochromatosis I-Disease 1 1.0
. O 0 0.0005220443708822131

HFE O 0 0.00736865634098649
binds O 0 6.45354448352009e-05
to O 0 3.1824802135815844e-06
transferrin O 0 6.585063965758309e-05
receptor O 0 6.9165139393589925e-06
( O 0 1.8066073437239538e-07
TfR O 0 9.266795132134575e-06
) O 0 2.804697096792097e-08
and O 0 1.3777575524898111e-08
reduces O 0 3.2859730936252163e-07
its O 0 2.4488352678986303e-08
affinity O 0 1.0084239221441749e-07
for O 0 2.9434037429609816e-08
iron O 0 2.1870491764275357e-05
- O 0 4.0391055335931014e-06
loaded O 0 1.8822573792931507e-06
transferrin O 0 3.3602267649257556e-05
, O 0 1.6601097740931436e-07
implicating O 0 9.923380275722593e-06
HFE O 0 0.0003910515224561095
in O 0 1.5686202914366731e-06
iron O 0 0.001750841736793518
metabolism O 0 7.728807395324111e-05
. O 0 5.723082722397521e-06

The O 0 3.0284094464150257e-05
2 O 0 2.3563850845675915e-05
. O 0 1.5148913007578813e-05

6 O 0 0.0001289501815335825
A O 0 1.2329529454291333e-05
crystal O 0 7.142378308344632e-05
structure O 0 3.4038555440929485e-07
of O 0 7.09271290588731e-08
HFE O 0 0.0004935720353387296
reveals O 0 1.1429634469095618e-05
the O 0 7.620670317010081e-08
locations O 0 3.005940811817709e-07
of O 0 3.3006057265083655e-07
hemochromatosis B-Disease 1 0.999998927116394
mutations O 0 0.00196922873146832
and O 0 9.350423368914562e-08
a O 0 1.5710635352661484e-06
patch O 0 0.001977444626390934
of O 0 4.5893944644603835e-08
histidines O 0 0.00029619818087667227
that O 0 4.4433349444261694e-08
could O 0 3.2354169121617815e-08
be O 0 5.4977200569794604e-09
involved O 0 2.4483586713586192e-08
in O 0 2.060418324845159e-07
pH O 0 8.829895523376763e-05
- O 0 1.8832966816262342e-05
dependent O 0 2.1475518678926164e-06
interactions O 0 1.9402998532314086e-06
. O 0 1.850267949521367e-06

We O 0 6.302163001237204e-06
also O 0 9.728446457302198e-07
demonstrate O 0 1.8671929638003348e-06
that O 0 4.1439042774982227e-07
soluble O 0 1.4537418792315293e-05
TfR O 0 6.566915544681251e-05
and O 0 1.0732630784104913e-07
HFE O 0 9.594474249752238e-05
bind O 0 1.1179946568518062e-06
tightly O 0 7.539101716247387e-07
at O 0 2.9459030770340178e-08
the O 0 1.594238341340315e-08
basic O 0 1.4603909903598833e-07
pH O 0 8.609955557403737e-07
of O 0 3.516051894081329e-09
the O 0 1.3301090007189487e-08
cell O 0 6.0821098486485425e-06
surface O 0 2.4599967218819074e-06
, O 0 2.1947741402073007e-08
but O 0 1.8427678938337522e-08
not O 0 6.940496621865577e-09
at O 0 8.361272563206512e-09
the O 0 4.148767018818944e-08
acidic O 0 4.4127373257651925e-05
pH O 0 7.556516266049584e-06
of O 0 1.4455079622166522e-07
intracellular O 0 1.2831927961087786e-05
vesicles O 0 8.81241649040021e-05
. O 0 4.194769189780345e-06

TfR O 1 0.9693078398704529
HFE O 1 0.9180959463119507
stoichiometry O 0 0.005112016573548317
( O 0 7.737173291388899e-06
2 O 0 1.3995295375934802e-06
1 O 0 2.0077214912816999e-07
) O 0 3.7011055553648475e-08
differs O 0 2.447005442718364e-07
from O 0 4.115186058584186e-08
TfR O 0 1.7922482584253885e-05
transferrin O 0 1.7114343791035935e-05
stoichiometry O 0 3.7640752452716697e-06
( O 0 3.0061094946631783e-08
2 O 0 4.935953867857279e-08
2 O 0 2.8170171972874414e-08
) O 0 6.841944788504861e-09
, O 0 6.799481866437418e-09
implying O 0 1.3320530456439883e-07
a O 0 4.626572192023559e-08
different O 0 4.641595552357103e-09
mode O 0 3.290839600822437e-08
of O 0 4.007591591914661e-09
binding O 0 6.212363956592526e-08
for O 0 3.0221144697861746e-08
HFE O 0 4.715358227258548e-05
and O 0 1.3058514980457403e-07
transferrin O 0 2.3502045223722234e-05
to O 0 7.675972142351384e-07
TfR O 0 0.00015228852862492204
, O 0 6.854304501757724e-08
consistent O 0 1.74382336126655e-07
with O 0 2.6633772520767707e-08
our O 0 4.219481297695893e-08
demonstration O 0 5.997744096930546e-07
that O 0 1.0399267580396554e-07
HFE O 0 4.140961027587764e-05
, O 0 1.1842463010225401e-07
transferrin O 0 8.111780516628642e-06
, O 0 7.814077207513037e-08
and O 0 1.325596201695589e-07
TfR O 0 0.0001628557947697118
form O 0 1.6855324247444514e-07
a O 0 3.694687791266915e-07
ternary O 0 1.0657409802661277e-05
complex O 0 5.27031716046622e-06
. O 0 4.073192485520849e-06

Identification O 0 2.0632707673939876e-05
of O 0 6.352181571855908e-07
three O 0 4.0102398202179756e-07
novel O 0 6.485134690592531e-06
mutations O 0 5.7335550991410855e-06
and O 0 4.5306350671125983e-08
a O 0 1.2132240101436764e-07
high O 0 1.9699987774401961e-07
frequency O 0 3.3132172916339186e-07
of O 0 8.320482081103364e-09
the O 0 9.28126979715671e-08
Arg778Leu O 0 0.00022141636873129755
mutation O 0 5.161465196579229e-06
in O 0 2.6586778290038637e-07
Korean O 0 1.9842713300022297e-05
patients O 0 0.001838708994910121
with O 0 9.923380275722593e-06
Wilson B-Disease 0 0.1778828203678131
disease I-Disease 0 0.01731128618121147
. O 0 7.066771559038898e-06

Four O 0 3.0731840524822474e-05
mutations O 0 0.0001384633214911446
- O 0 3.982523412560113e-05
- O 0 6.042849781806581e-05
R778L O 0 2.442828736093361e-05
, O 0 1.0947172768283053e-07
A874V O 0 3.0529881769325584e-06
, O 0 5.548477943762009e-08
L1083F O 0 1.368770313092682e-06
, O 0 1.705950047892202e-08
and O 0 1.3683087551896733e-08
2304delC O 0 2.0407910596986767e-06
- O 0 5.659995622409042e-06
- O 0 8.615264960099012e-06
in O 0 3.727103958794942e-08
the O 0 1.6665461899378897e-08
copper O 0 6.956362312848796e-07
- O 0 4.939759037370095e-07
transporting O 0 6.972089749979204e-07
enzyme O 0 2.477503358022659e-07
, O 0 4.218982496695389e-08
P O 0 1.4503701777357492e-06
- O 0 1.1424089052525233e-06
type O 0 5.435925913843676e-07
ATPase O 0 6.188213319546776e-06
( O 0 3.8247144118486176e-08
ATP7B O 0 9.804142791836057e-06
) O 0 3.0326468447583466e-08
, O 0 1.2495051215921649e-08
were O 0 1.4784056645567034e-08
identified O 0 8.065384093924877e-08
in O 0 4.782101825639984e-08
Korean O 0 2.2969172277953476e-05
Patients O 0 0.00375739810988307
with O 0 8.395557415497024e-06
Wilson B-Disease 0 0.19924837350845337
disease I-Disease 0 0.004855849780142307
. O 0 7.071268555591814e-06

Arg778Leu O 0 0.007417888846248388
, O 0 2.2688202534482116e-06
the O 0 1.35184052396653e-07
most O 0 9.762986508121685e-08
frequently O 0 1.5247381952576688e-06
reported O 0 3.353392912686104e-06
mutation O 0 1.8040178417777497e-07
of O 0 4.3396499727066384e-09
this O 0 1.9984902621672518e-08
enzyme O 0 9.522540267425939e-08
, O 0 1.212647493531449e-08
was O 0 7.621862607720686e-08
found O 0 3.021710881512263e-08
in O 0 1.4430845851620688e-08
six O 0 4.195182157218369e-08
of O 0 1.4641584833441357e-08
eight O 0 1.2127027275710134e-06
unrelated O 0 0.0013166136341169477
patients O 0 0.08886535465717316
studied O 0 1.9426959170232294e-06
, O 0 5.4000118154817756e-08
an O 0 4.766293315583425e-08
allele O 0 6.923627893229423e-07
frequency O 0 2.614445122617326e-07
of O 0 3.5106655360550576e-08
37 O 0 2.598125320218969e-06
. O 0 1.4390654996532248e-06

5 O 0 0.0001225721644004807
% O 0 4.481915311771445e-06
, O 0 9.034954473463586e-08
which O 0 3.507841128680411e-08
is O 0 2.9069433082895557e-08
considerably O 0 6.272371706472768e-07
higher O 0 3.484674238052321e-08
than O 0 1.2627638490414483e-08
those O 0 6.510685324201404e-09
in O 0 9.564457670308002e-09
other O 0 2.4849565960494147e-08
Asian O 0 3.583562886433356e-07
populations O 0 1.2972759577678517e-06
. O 0 1.4994953971836367e-06

The O 0 3.945389835280366e-06
novel O 0 3.2323966934200143e-06
single O 0 5.074912792224495e-07
nucleotide O 0 9.752673122420674e-07
deletion O 0 4.43406634076382e-06
, O 0 2.0183225046821462e-07
2304delC O 0 6.8371082306839526e-06
, O 0 7.713001082265691e-08
was O 0 7.55431699417386e-08
found O 0 4.003956632914196e-08
in O 0 5.7029396316465863e-08
one O 0 3.605708513987338e-07
patient O 0 0.00017177025438286364
. O 0 4.119142431591172e-06

Since O 0 2.0573645088006742e-05
a O 0 4.331120180722792e-06
mutation O 0 5.110998245072551e-06
at O 0 1.662053534801089e-07
cDNA O 0 2.560032044129912e-06
nucleotide O 0 2.071950802928768e-06
2302 O 0 2.3518681700807065e-05
( O 0 1.1222307705338608e-07
2302insC O 0 2.0732888970087515e-06
) O 0 3.2452497578105977e-08
had O 0 7.84882203674897e-08
been O 0 4.3484430278795116e-08
previously O 0 3.2771788482932607e-07
described O 0 4.293054871595814e-07
, O 0 1.0205829070741856e-08
this O 0 3.1029403491089624e-09
region O 0 5.633228106205479e-09
of O 0 2.7226798593460444e-09
the O 0 4.482619431200874e-08
ATP7B O 0 0.0458342507481575
gene O 0 1.4668385119875893e-06
may O 0 2.5944680714928836e-07
be O 0 2.3010599647932395e-08
susceptible O 0 1.5571584981444175e-06
to O 0 2.3697475626249798e-07
gene O 0 2.0627612684620544e-06
rearrangements O 0 0.0005347983096726239
causing O 0 0.0015647761756554246
Wilson B-Disease 0 0.007451115641742945
disease I-Disease 0 0.011691839434206486
. O 0 7.191554686869495e-06

Disruption O 0 0.0002989759959746152
of O 0 1.6448658470835653e-06
splicing O 0 2.3125863663153723e-05
regulated O 0 1.7412687611795263e-06
by O 0 7.904905885425251e-08
a O 0 7.124316994122637e-07
CUG O 0 0.00031790736829862
- O 0 3.0146444260026328e-05
binding O 0 3.865561211569002e-06
protein O 0 3.1901531656330917e-06
in O 0 5.614594556391239e-06
myotonic B-Disease 1 0.9999964237213135
dystrophy I-Disease 1 0.9999986886978149
. O 0 0.00017588336777407676

Myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999998807907104
( O 1 0.9949719905853271
DM B-Disease 1 0.9999997615814209
) O 0 1.7193558960570954e-05
is O 0 7.974587106218678e-07
caused O 0 2.0091306396352593e-06
by O 0 3.735858555842242e-08
a O 0 2.7729262797038245e-07
CTG O 0 3.971570185967721e-05
expansion O 0 6.007928732287837e-07
in O 0 3.397232362090108e-08
the O 0 1.513528502528061e-08
3 O 0 2.633983342548163e-07
untranslated O 0 2.044030770775862e-05
region O 0 1.04379786591835e-07
of O 0 4.286697574684695e-08
the O 0 1.64716391282127e-06
DM B-Disease 1 0.9999977350234985
gene O 0 7.684631418669596e-05
. O 0 2.476242343618651e-06

One O 0 1.1987528523604851e-05
model O 0 9.694145774119534e-06
of O 0 1.6396925275330432e-06
DM B-Disease 1 0.9999996423721313
pathogenesis O 0 0.490966796875
suggests O 0 8.45404701976804e-06
that O 0 7.454467265688436e-08
RNAs O 0 3.714607146321214e-07
from O 0 6.521573059359298e-09
the O 0 5.070342812274475e-09
expanded O 0 7.845663674288517e-08
allele O 0 3.901832315023057e-07
create O 0 3.6852984663937605e-08
a O 0 1.0645534587183647e-07
gain O 0 6.194302955009334e-07
- O 0 7.604653546877671e-07
of O 0 1.6272174718778842e-08
- O 0 3.325098805362359e-05
function O 0 1.9979344756393402e-07
mutation O 0 1.5803908581801807e-07
by O 0 3.6470471087568512e-09
the O 0 6.87260248710686e-09
inappropriate O 0 2.1484520118519868e-07
binding O 0 1.0345515732979038e-07
of O 0 9.354077512568892e-09
proteins O 0 2.66339750254474e-08
to O 0 3.640418810846313e-08
the O 0 1.988149591625188e-07
CUG O 0 0.0021347629372030497
repeats O 0 6.259614747250453e-05
. O 0 2.8847398425568826e-06

Data O 0 3.7060635804664344e-05
presented O 0 1.02807844086783e-05
here O 0 3.4770468460010306e-07
indicate O 0 3.666757493192563e-07
that O 0 1.810102645549705e-08
the O 0 1.6398454150134967e-08
conserved O 0 1.575905912432063e-07
heterogeneous O 0 5.623381298391905e-07
nuclear O 0 5.709338211090653e-07
ribonucleoprotein O 0 7.085295237629907e-06
, O 0 7.970172077875759e-08
CUG O 0 9.208738447341602e-06
- O 0 2.4730375116632786e-06
binding O 0 2.947258508356754e-07
protein O 0 8.619110047902723e-08
( O 0 1.4705086925914657e-08
CUG O 0 1.4787160580453929e-05
- O 0 0.00014828742132522166
BP O 0 0.008439973928034306
) O 0 4.559389310543338e-08
, O 0 2.907004414964831e-08
may O 0 1.4272985993102338e-07
mediate O 0 3.862495304929325e-06
the O 0 5.98504783511089e-08
trans O 0 2.537373802624643e-06
- O 0 2.2544712919625454e-05
dominant O 0 1.9584965684771305e-06
effect O 0 2.463320356582699e-07
of O 0 2.9676550994395257e-08
the O 0 1.6645137179693847e-07
RNA O 0 6.075779310776852e-06
. O 0 2.6867101041716523e-06

CUG O 0 0.3544522821903229
- O 0 0.13070048391819
BP O 0 0.014034987427294254
was O 0 5.680710728483973e-07
found O 0 5.443039086117096e-08
to O 0 1.8965515380386933e-08
bind O 0 1.5263822206179611e-07
to O 0 4.303048228848638e-08
the O 0 5.987742213164893e-08
human O 0 2.468758339091437e-06
cardiac O 1 0.9976027607917786
troponin O 1 0.993899941444397
T O 0 0.03570333495736122
( O 0 1.0252541926547565e-07
cTNT O 0 1.9043251313632936e-06
) O 0 1.958703776949733e-08
pre O 0 3.965780024373089e-07
- O 0 1.4925600453352672e-06
messenger O 0 5.061215233581606e-07
RNA O 0 8.019426900318649e-08
and O 0 8.426625619506467e-09
regulate O 0 1.320476172850249e-07
its O 0 8.391024408638259e-08
alternative O 0 1.120890942729602e-06
splicing O 0 1.3391082575253677e-05
. O 0 3.15075976686785e-06

Splicing O 0 0.00016180615057237446
of O 0 4.335641733632656e-06
cTNT O 0 0.0001269122731173411
was O 0 3.0693336157128215e-06
disrupted O 0 1.3035902156843804e-05
in O 0 1.4637711274190224e-06
DM B-Disease 1 0.9999980926513672
striated O 1 0.9708189964294434
muscle O 0 0.11947594583034515
and O 0 7.490897360185045e-07
in O 0 2.4394375941483304e-07
normal O 0 2.0821896669076523e-06
cells O 0 3.7262768728396622e-06
expressing O 0 2.819904239004245e-06
transcripts O 0 3.22429946209013e-06
that O 0 3.382246234195918e-07
contain O 0 2.015298150581657e-06
CUG O 0 0.0005225841305218637
repeats O 0 9.957285510608926e-05
. O 0 6.321358796412824e-06

Altered O 0 0.0005342060467228293
expression O 0 1.1627206731645856e-05
of O 0 1.5620085491718783e-07
genes O 0 6.260789859879878e-07
regulated O 0 4.039769692099071e-07
posttranscriptionally O 0 9.958076589100529e-06
by O 0 2.4733225245654467e-07
CUG O 0 0.00013937294716015458
- O 0 0.00016277875693049282
BP O 0 0.0009031021036207676
therefore O 0 2.887398977691191e-07
may O 0 2.1834094354744593e-07
contribute O 0 1.6029532901029597e-07
to O 0 3.4718286769930273e-06
DM B-Disease 1 0.9999996423721313
pathogenesis O 0 0.496807724237442
. O 0 1.8502114471630193e-06
. O 0 2.127748757629888e-06

Identification O 0 2.8994491003686562e-05
of O 0 5.773989641966182e-07
a O 0 1.5619565374436206e-06
novel O 0 5.746589067712193e-06
nonsense O 0 4.952380186296068e-05
mutation O 0 3.401445155759575e-06
and O 0 3.345367360907403e-08
a O 0 2.395500757756963e-07
missense O 0 4.262045877112541e-06
substitution O 0 1.3722480218802957e-07
in O 0 2.6681158615815548e-08
the O 0 3.6530082070385106e-08
vasopressin O 0 1.5837367755011655e-05
- O 0 0.00011176983389304951
neurophysin O 0 0.0004626341979019344
II O 0 1.6869596947799437e-05
gene O 0 1.6085918730368576e-07
in O 0 1.6402456282094136e-08
two O 0 4.732179448296847e-08
Spanish O 0 6.676719408460485e-07
kindreds O 0 9.526656867819838e-06
with O 0 1.5767253671583603e-06
familial B-Disease 0 0.410946249961853
neurohypophyseal I-Disease 1 0.9998289346694946
diabetes I-Disease 1 0.9999639987945557
insipidus I-Disease 1 0.9924492835998535
. O 0 2.2445603462983854e-05

Familial B-Disease 1 0.9996358156204224
neurohypophyseal I-Disease 1 0.9999792575836182
diabetes I-Disease 1 0.9999994039535522
insipidus I-Disease 1 0.9999748468399048
( O 0 0.0007009927066974342
FNDI B-Disease 1 0.9999696016311646
) O 0 9.71271447269828e-07
is O 0 2.008238482176239e-07
an O 0 1.3758111663264572e-06
autosomal B-Disease 1 0.9710516929626465
dominant I-Disease 1 0.9931580424308777
disease I-Disease 1 0.9650334119796753
caused O 0 0.007846267893910408
by O 0 7.25728168617934e-05
deficiency O 0 0.476077675819397
in O 0 8.735409551263729e-08
the O 0 1.5514028461893759e-07
antidiuretic O 0 0.00030603265622630715
hormone O 0 2.6433459424879402e-05
arginine O 0 5.042876637162408e-06
vasopressin O 0 1.6144660548889078e-05
( O 0 8.814002683266153e-08
AVP O 0 3.7076101762067992e-06
) O 0 2.4036838297547547e-08
encoded O 0 4.968294575746768e-08
by O 0 1.5573553113767957e-08
the O 0 4.403512221529127e-08
AVP O 0 3.901417585439049e-05
- O 0 0.00022742728469893336
neurophysin O 0 0.002268437761813402
II O 0 4.010390330222435e-05
( O 0 1.1472079819441205e-07
AVP O 0 8.34525144455256e-06
- O 0 4.520549555309117e-05
NPII O 0 0.000416879600379616
) O 0 1.3123897701916576e-07
gene O 0 3.101891934420564e-07
on O 0 2.6502354444346565e-07
chromosome O 0 6.264456897042692e-05
20p13 O 0 0.00013654628128279
. O 0 3.896859652741114e-06

In O 0 9.13611802388914e-06
this O 0 2.9554070124504506e-07
study O 0 4.5505800017053843e-07
, O 0 5.416495341137306e-08
we O 0 2.4691951594491002e-08
analyzed O 0 3.247498341352184e-07
two O 0 4.164980893506254e-08
families O 0 4.407242926163235e-08
with O 0 7.152446812597191e-08
FNDI B-Disease 1 0.9412072896957397
using O 0 1.0904535940881033e-07
direct O 0 4.745637838254879e-08
automated O 0 3.6751629295395105e-07
fluorescent O 0 4.898003680864349e-06
, O 0 3.143304994068785e-08
solid O 0 3.042020750854135e-07
phase O 0 5.485707674779405e-07
, O 0 2.8163672283199048e-08
single O 0 1.687375572601013e-07
- O 0 2.154292360501131e-06
stranded O 0 6.566697265952826e-07
DNA O 0 1.4598590780678933e-07
sequencing O 0 5.268605818287142e-08
of O 0 1.0789542592704038e-08
PCR O 0 4.784328211826505e-06
- O 0 1.03731226772652e-05
amplified O 0 3.385344098205678e-05
AVP O 0 0.00015006359899416566
- O 0 9.449071512790397e-05
NPII O 0 0.00045598455471917987
DNA O 0 3.6033081414643675e-05
. O 0 2.4904190922825364e-06

In O 0 2.4717642190807965e-06
one O 0 1.9753548485823558e-07
of O 0 1.800481896907513e-08
the O 0 6.36291304090264e-08
families O 0 2.542581398756738e-07
, O 0 1.4420174920815043e-07
affected O 0 3.2168622965400573e-07
individuals O 0 2.0649714826959098e-08
presented O 0 1.5387573171210533e-07
a O 0 3.8421643466790556e-07
novel O 0 2.0020554529764922e-06
nonsense O 0 2.2063846699893475e-05
mutation O 0 1.6114058780658524e-06
in O 0 2.8280695119065058e-08
exon O 0 7.163641839724733e-07
3 O 0 4.3119868564645e-08
of O 0 3.4432867668243716e-09
the O 0 1.1553167311717516e-08
gene O 0 8.728197542495764e-08
, O 0 1.7157427478764475e-08
consisting O 0 4.859169067117364e-08
in O 0 3.019003358417649e-08
a O 0 6.324792707346205e-07
G O 0 0.0012897986453026533
to O 0 5.922364607613417e-07
T O 0 9.04584230738692e-05
transition O 0 4.396794395233883e-07
at O 0 7.680850444558018e-08
nucleotide O 0 3.133390009679715e-07
2101 O 0 4.440405518835178e-06
, O 0 3.010108784451404e-08
which O 0 9.694066882559582e-09
produces O 0 4.9481606367862696e-08
a O 0 2.7875563191059882e-08
stop O 0 1.3343301930035523e-07
signal O 0 2.4914828600230976e-07
in O 0 4.287588595275338e-08
codon O 0 1.0893429589486914e-06
82 O 0 3.1889912861515768e-06
( O 0 1.3928716668942798e-07
Glu O 0 0.0001718841231195256
) O 0 1.10364005934116e-07
of O 0 1.0761964830408033e-07
NPII O 0 0.000751368934288621
. O 0 5.004586910217768e-06

The O 0 1.2139189493609592e-05
premature O 0 0.0010911187855526805
termination O 0 1.9123737729387358e-05
eliminates O 0 2.530191977712093e-06
part O 0 1.0124190197302596e-07
of O 0 1.6586565010356935e-08
the O 0 6.654681072859603e-08
C O 0 2.064304226223612e-06
- O 0 1.1758441360143479e-05
terminal O 0 2.02131718651799e-06
domain O 0 3.08172012353225e-08
of O 0 6.9120535961531004e-09
NPII O 0 4.057797559653409e-05
, O 0 1.6845868699988387e-08
including O 0 4.709863610230514e-09
a O 0 2.5046469787071146e-08
cysteine O 0 3.3405978427936134e-08
residue O 0 1.0567082853185639e-07
in O 0 8.531650053100748e-09
position O 0 1.0872096112279905e-07
85 O 0 1.5137383968522045e-07
, O 0 1.090457235619624e-08
which O 0 1.6146497472391275e-08
could O 0 8.738675205677282e-08
be O 0 1.0161737229452683e-08
involved O 0 1.5583745849312436e-08
in O 0 1.4124383440616839e-08
the O 0 2.0971381076151374e-08
correct O 0 8.114310503515298e-07
folding O 0 3.5690850381797645e-06
of O 0 3.6389192104024914e-08
the O 0 4.3318868847563863e-07
prohormone O 0 0.002033249009400606
. O 0 6.525708158733323e-06

In O 0 6.934868906682823e-06
the O 0 2.3971190898919303e-07
second O 0 8.396057182835648e-07
family O 0 3.84269554842831e-07
, O 0 1.5094865801756896e-08
a O 0 7.313953176435462e-08
G279A O 0 1.2030910738758394e-06
substitution O 0 7.450898920069449e-08
at O 0 3.566971074064895e-08
position O 0 1.0926145677103705e-07
- O 0 1.1371663504178287e-06
1 O 0 4.195454295086165e-08
of O 0 2.1139880956866364e-09
the O 0 1.1547373723885812e-08
signal O 0 4.0144414015230723e-07
peptide O 0 2.240999492642004e-07
was O 0 5.462247898435635e-08
observed O 0 5.359255439429944e-08
in O 0 1.2652856540285029e-08
all O 0 2.530123666133477e-08
affected O 0 3.405550614843378e-07
individuals O 0 1.8749625496639055e-07
. O 0 1.200029146275483e-06

This O 0 9.448483979213051e-06
missense O 0 0.012101714499294758
mutation O 0 0.00018423126311972737
, O 0 2.916093251315033e-07
which O 0 8.704937926040657e-08
replaces O 0 1.0809566447278485e-05
Ala O 0 2.908693568315357e-05
with O 0 5.921551178289519e-07
Thr O 0 0.0002796124026644975
, O 0 1.484101943560745e-07
is O 0 6.183802270243177e-08
frequent O 0 4.100615569768706e-06
among O 0 5.155138751433697e-06
FNDI B-Disease 1 0.9999995231628418
patients O 1 0.9766653776168823
and O 0 2.1583566933713882e-07
is O 0 2.8908589300158383e-08
thought O 0 3.150333682810924e-08
to O 0 7.909351396051534e-09
reduce O 0 5.7544038867263225e-08
the O 0 9.390652699892144e-09
efficiency O 0 1.0318282051002825e-07
of O 0 8.662599526587655e-09
cleavage O 0 1.5069527989908238e-06
by O 0 9.659667199457544e-08
signal O 0 1.6114274785650196e-06
peptidases O 0 1.3768068129138555e-05
. O 0 3.481589203602198e-07
. O 0 8.795024086794001e-07

Genetic O 0 0.0010646376758813858
heterogeneity O 0 0.00020199938444420695
of O 0 3.941204340662807e-06
Saethre B-Disease 1 0.8989251852035522
- I-Disease 1 0.999582827091217
Chotzen I-Disease 1 0.9999722242355347
syndrome I-Disease 1 0.9999971389770508
, O 0 2.9984880711708684e-07
due O 0 1.5598472202782432e-07
to O 0 1.8120063316473534e-07
TWIST O 0 0.0003502104664221406
and O 0 3.7461948068084894e-06
FGFR O 0 0.35425588488578796
mutations O 0 5.667298682965338e-05
. O 0 1.8140464135285583e-06

Thirty O 0 0.0002173748071072623
- O 0 0.000675036630127579
two O 0 4.15231670558569e-06
unrelated O 0 0.0003037542919628322
patients O 0 0.0005095992819406092
with O 0 5.155381188615138e-08
features O 0 4.366657719856448e-07
of O 0 8.92225457960194e-08
Saethre B-Disease 0 0.15020015835762024
- I-Disease 1 0.998565137386322
Chotzen I-Disease 1 0.9999269247055054
syndrome I-Disease 1 0.9999874830245972
, O 0 2.2483720840682508e-07
a O 0 3.230076345062116e-06
common O 0 3.7745176086900756e-05
autosomal B-Disease 1 0.9443705081939697
dominant I-Disease 0 0.05281807854771614
condition I-Disease 0 0.0008307939860969782
of O 0 2.605797533306031e-07
craniosynostosis B-Disease 1 0.9886093139648438
and O 0 5.9656569646904245e-05
limb B-Disease 1 0.9802875518798828
anomalies I-Disease 0 0.09606850147247314
, O 0 1.99469610606684e-07
were O 0 7.240872434977064e-08
screened O 0 1.731807515170658e-06
for O 0 1.2479955557864741e-07
mutations O 0 3.469650891929632e-06
in O 0 7.921659062049002e-08
TWIST O 0 0.0005589461652562022
, O 0 7.615031449859089e-07
FGFR2 O 0 0.00019411409448366612
, O 0 1.7467627344558423e-07
and O 0 3.392972303117858e-07
FGFR3 O 0 0.0005542923463508487
. O 0 2.6797652026289143e-06

Nine O 0 7.300010474864393e-05
novel O 0 1.767605499480851e-05
and O 0 3.5462610981085163e-07
three O 0 5.975010708425543e-07
recurrent O 0 0.001546489424072206
TWIST O 1 0.8860238790512085
mutations O 0 0.0008048874442465603
were O 0 2.0315835058681841e-07
found O 0 1.5742385528483283e-07
in O 0 1.1810061550932005e-07
12 O 0 1.2167898830739432e-06
families O 0 8.853105555317597e-07
. O 0 1.525228185528249e-06

Seven O 0 3.979478424298577e-05
families O 0 3.625255658334936e-06
were O 0 1.243556937424728e-07
found O 0 6.983869127452635e-08
to O 0 1.8410780455724307e-08
have O 0 1.2845616126355708e-08
the O 0 9.14764441972693e-09
FGFR3 O 0 0.0019198659574612975
P250R O 0 0.0003278760996181518
mutation O 0 1.4735192053194623e-06
, O 0 7.97689114762079e-09
and O 0 5.1938804368489855e-09
one O 0 1.9309499776909433e-08
individual O 0 7.473584417994061e-09
was O 0 9.996949756896356e-08
found O 0 4.2212121798002045e-08
to O 0 2.9895730335738335e-08
have O 0 4.7205414688278324e-08
an O 0 1.125765933807088e-07
FGFR2 O 0 0.00032713799737393856
VV269 O 0 2.325155946891755e-05
- O 0 1.0999505320796743e-05
270 O 0 1.3009311260248069e-05
deletion O 0 0.00015416038513649255
. O 0 3.850645043712575e-06

To O 0 4.833416824112646e-06
date O 0 1.0044452665169956e-06
, O 0 6.1318772281993e-08
our O 0 1.8019763459165006e-08
detection O 0 2.0191157545923488e-07
rate O 0 7.525683543008199e-08
for O 0 1.4652451696406388e-08
TWIST O 0 9.970663813874125e-05
or O 0 8.888790716810036e-07
FGFR O 0 0.06123169884085655
mutations O 0 1.2216700270073488e-05
is O 0 6.800691210173682e-08
68 O 0 1.327270183537621e-06
% O 0 4.067941006269393e-08
in O 0 1.6420049320231556e-08
our O 0 8.787647942654075e-08
Saethre B-Disease 0 0.006708681117743254
- I-Disease 1 0.9969022274017334
Chotzen I-Disease 1 0.999984860420227
syndrome I-Disease 1 0.9999997615814209
patients O 0 0.49674856662750244
, O 0 6.522632389760474e-08
including O 0 4.023762301130773e-08
our O 0 7.436162263729784e-08
five O 0 2.8419260615919484e-06
patients O 0 0.0007308268104679883
elsewhere O 0 1.089278612198541e-06
reported O 0 1.5195645346466335e-06
with O 0 3.687439971145068e-07
TWIST O 0 0.34740766882896423
mutations O 0 0.00033556119888089597
. O 0 3.50434856954962e-06

More O 0 8.236276698880829e-06
than O 0 7.108151294232812e-07
35 O 0 3.3229511586796434e-07
different O 0 3.353301636366268e-08
TWIST O 0 0.00022496908786706626
mutations O 0 2.3205127945402637e-05
are O 0 2.0606632844533124e-08
now O 0 6.518180128978202e-08
known O 0 3.8649599076734376e-08
in O 0 2.402409648993853e-08
the O 0 6.539374197700454e-08
literature O 0 5.892954959563212e-07
. O 0 9.607801985112019e-07

The O 0 3.795315933530219e-06
most O 0 4.902977366327832e-07
common O 0 2.5313818241556874e-07
phenotypic O 0 1.0234601177216973e-05
features O 0 3.085134039793047e-06
, O 0 6.697683119227804e-08
present O 0 3.725554620359617e-08
in O 0 1.3735645509882488e-08
more O 0 1.161425799978133e-08
than O 0 1.6978413341917076e-08
a O 0 8.577356425121252e-08
third O 0 1.1622628193208584e-07
of O 0 1.1160399715492986e-08
our O 0 2.6379930773146043e-07
patients O 0 1.790736314433161e-05
with O 0 1.5459144719898177e-07
TWIST O 0 0.36030879616737366
mutations O 0 4.3264128180453554e-05
, O 0 3.936366255175017e-08
are O 0 1.2472383126294062e-08
coronal B-Disease 0 3.9408449083566666e-05
synostosis I-Disease 0 9.32499096961692e-05
, O 0 1.1398717703059447e-07
brachycephaly B-Disease 0 1.4156812540022656e-05
, O 0 1.257313613223232e-07
low B-Disease 0 3.0715532375324983e-06
frontal I-Disease 1 0.8722780346870422
hairline I-Disease 1 0.9999771118164062
, O 0 1.6446712834294885e-05
facial B-Disease 1 0.9524078965187073
asymmetry I-Disease 0 0.004157972987741232
, O 0 4.862219157075742e-06
ptosis B-Disease 1 0.7330812811851501
, O 0 3.1155998385656858e-06
hypertelorism B-Disease 0 0.16156327724456787
, O 0 3.430529602610477e-07
broad B-Disease 0 5.254540837995592e-07
great I-Disease 0 6.816182462898723e-07
toes I-Disease 0 7.766790076857433e-05
, O 0 2.0401596145802614e-07
and O 0 4.171373859662708e-07
clinodactyly B-Disease 0 0.0003892053500749171
. O 0 2.6480652195459697e-06

Significant O 0 5.682537448592484e-05
intra O 0 5.549162233364768e-05
- O 0 0.00012616944150067866
and O 0 1.5575535599055002e-06
interfamilial O 0 0.000310203293338418
phenotypic O 0 0.0006962694460526109
variability O 0 4.4293356040725484e-05
is O 0 1.2038424301863415e-07
present O 0 5.871907404753074e-08
for O 0 4.526359020928794e-08
either O 0 5.022959044254094e-07
TWIST O 0 0.01815117336809635
mutations O 0 0.00013208430027589202
or O 0 1.2611566262421547e-06
FGFR O 0 0.21267130970954895
mutations O 0 0.0002919211401604116
. O 0 3.834967174043413e-06

The O 0 2.4590021894255187e-06
overlap O 0 5.6102594498952385e-06
in O 0 9.54389406615519e-07
clinical O 0 1.4402173292182852e-05
features O 0 1.6017261259548832e-06
and O 0 7.376000610292976e-08
the O 0 1.8397125600699837e-08
presence O 0 6.678025243900265e-08
, O 0 9.66445501404678e-09
in O 0 5.7817950427363485e-09
the O 0 6.715166200876865e-09
same O 0 2.4090951455946197e-08
genes O 0 2.2291878565283696e-08
, O 0 4.058483771274268e-09
of O 0 3.9360115167141885e-09
mutations O 0 3.505534493797313e-07
for O 0 8.381695337789097e-09
more O 0 1.4495950217963127e-08
than O 0 1.8595921247310798e-08
one O 0 1.1538835309465867e-07
craniosynostotic B-Disease 0 0.018891118466854095
condition I-Disease 0 2.091152055072598e-05
- O 0 1.4316517535917228e-06
such O 0 1.4777149281997026e-08
as O 0 1.0212688295041517e-07
Saethre B-Disease 0 1.4708947674080264e-05
- I-Disease 0 6.9382426772790495e-06
Chotzen I-Disease 0 9.57180054683704e-06
, I-Disease 0 7.092929621421717e-08
Crouzon I-Disease 0 3.838270913547603e-06
, I-Disease 0 7.303107452116819e-08
and I-Disease 0 2.9389897804321663e-07
Pfeiffer I-Disease 0 0.047336988151073456
syndromes I-Disease 0 0.08962002396583557
- O 0 9.809791663428769e-06
support O 0 1.1533048649425837e-07
the O 0 3.0077384138849084e-08
hypothesis O 0 3.4570692264423997e-07
that O 0 1.1441001923628846e-08
TWIST O 0 2.116478299285518e-06
and O 0 7.861632411731989e-08
FGFRs O 0 3.5860284697264433e-06
are O 0 4.061860181536758e-09
components O 0 1.1827143708842414e-08
of O 0 1.5023510213652003e-09
the O 0 7.765844856066906e-09
same O 0 4.4078316108198123e-08
molecular O 0 5.147845172359666e-07
pathway O 0 7.954650982355815e-08
involved O 0 1.8287691361251746e-08
in O 0 1.3103146123683018e-08
the O 0 2.0554775659320512e-08
modulation O 0 8.816405170364305e-06
of O 0 2.838714294739475e-07
craniofacial O 1 0.9977526068687439
and O 0 4.2153766116825864e-05
limb O 0 0.3284842371940613
development O 0 1.970173428844646e-07
in O 0 3.420624352656887e-07
humans O 0 9.14764541448676e-07
. O 0 4.16874513575749e-07
. O 0 1.5395484069813392e-06

Mutation O 0 0.003700094996020198
analysis O 0 2.5568635464878753e-05
of O 0 6.895924798300257e-06
UBE3A O 1 0.9916353225708008
in O 1 0.9785973429679871
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9996986389160156
. O 0 6.130500696599483e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.17079894244670868
AS B-Disease 0 0.23433558642864227
) O 0 3.575254368115566e-07
is O 0 1.5181667833985557e-07
caused O 0 2.1327095964807086e-06
by O 0 8.78240342672143e-08
chromosome O 0 1.0281774848408531e-05
15q11 O 0 1.6489289919263683e-05
- O 0 1.292167235078523e-05
q13 O 0 1.4061066394788213e-05
deletions O 0 1.649213572818553e-06
of O 0 7.048559780287178e-08
maternal O 0 4.373737465357408e-05
origin O 0 2.7043446948482597e-07
, O 0 7.944552748995193e-08
by O 0 1.4476850651590212e-07
paternal O 0 0.00017266205395571887
uniparental B-Disease 0 0.40716519951820374
disomy I-Disease 0 0.1698625385761261
( O 0 1.6037039358707261e-06
UPD B-Disease 1 0.9993937015533447
) O 0 1.7067026192307821e-07
15 O 0 7.390406864260513e-08
, O 0 3.212707255784153e-08
by O 0 8.845580623528804e-08
imprinting O 0 0.0546705387532711
defects O 1 0.9690229892730713
, O 0 5.533016533831869e-08
and O 0 4.494862793080756e-08
by O 0 1.433450762533539e-07
mutations O 0 1.8622384914124268e-06
in O 0 2.8542382679574985e-08
the O 0 1.4265324921325373e-07
UBE3A O 0 0.0015128590166568756
gene O 0 7.0456612775160465e-06
. O 0 1.683782670625078e-06

UBE3A O 0 0.010425346903502941
encodes O 0 0.00011230218660784885
a O 0 7.229166385513963e-06
ubiquitin O 0 1.8033428204944357e-05
- O 0 9.382137250213418e-06
protein O 0 7.758310971439641e-07
ligase O 0 9.862393426374183e-07
and O 0 6.613127823129616e-08
shows O 0 4.4717316427522746e-07
brain O 0 4.044503657496534e-05
- O 0 7.607027782796649e-06
specific O 0 4.287564081550954e-07
imprinting O 0 8.06250172900036e-05
. O 0 3.733070343514555e-06

Here O 0 2.0196628611302003e-05
we O 0 1.1985285937043955e-06
describe O 0 6.027496510796482e-06
UBE3A O 0 0.0006642250227741897
coding O 0 3.697506690514274e-05
- O 0 6.80953889968805e-05
region O 0 1.789308043953497e-06
mutations O 0 2.66207257482165e-06
detected O 0 5.352901553123957e-07
by O 0 4.0338822060448365e-08
SSCP O 0 0.0002229496749350801
analysis O 0 4.1424974028814177e-07
in O 0 1.2324539966357406e-07
13 O 0 8.527536010660697e-07
AS B-Disease 0 0.000453067768830806
individuals O 0 1.6001001768017886e-07
or O 0 2.6247704454362975e-07
families O 0 1.2832314268962364e-06
. O 0 1.4913463246557512e-06

Two O 0 1.4618692148360424e-05
identical O 0 1.8621514755068347e-05
de O 0 2.711585921133519e-06
novo O 0 1.0951357580779586e-05
5 O 0 9.23523089113587e-07
- O 0 5.134228103997884e-06
bp O 0 2.6246374545735307e-05
duplications O 0 2.4066739570116624e-06
in O 0 1.3789411923426087e-07
exon O 0 7.431960966641782e-06
16 O 0 6.168924642224738e-07
were O 0 2.2353216877490922e-07
found O 0 1.0279480875396985e-06
. O 0 1.34570655063726e-06

Among O 0 1.022607375489315e-05
the O 0 3.0436052611548803e-07
other O 0 6.549272768552328e-08
11 O 0 3.3686779943309375e-07
unique O 0 4.5489571220969083e-07
mutations O 0 7.216135145426961e-06
, O 0 7.512088018302165e-08
8 O 0 1.332438017698223e-07
were O 0 2.737782978101677e-08
small O 0 4.987302659742454e-08
deletions O 0 1.4426078678297927e-06
or O 0 6.595315937829582e-08
insertions O 0 6.470481366704917e-06
predicted O 0 1.9539762433851138e-05
to O 0 4.04790313268677e-07
cause O 0 9.563360436004587e-06
frameshifts O 0 0.0042739021591842175
, O 0 2.12823067613499e-07
1 O 0 1.1473348848767273e-07
was O 0 1.087199308358322e-07
a O 0 2.2415274258946738e-07
mutation O 0 6.09846154020488e-07
to O 0 2.1255042170764682e-08
a O 0 8.106067639346293e-08
stop O 0 4.1945983753066685e-07
codon O 0 2.9538372814386094e-07
, O 0 3.850854213283128e-08
1 O 0 3.331790665583867e-08
was O 0 5.420050541715682e-08
a O 0 4.2513428866186587e-07
missense O 0 0.0002521208953112364
mutation O 0 3.567775138435536e-06
, O 0 1.8373174981434204e-08
and O 0 2.477101190834219e-08
1 O 0 7.116616274061016e-08
was O 0 3.2423983498119924e-07
predicted O 0 1.1604967085077078e-06
to O 0 5.1020489166830885e-08
cause O 0 2.3769996460032417e-07
insertion O 0 4.620355014139932e-07
of O 0 1.6095087929102192e-08
an O 0 1.5797159846897557e-07
isoleucine O 0 0.00016919475456234068
in O 0 6.71565558718612e-08
the O 0 2.2605252780749652e-08
hect O 0 1.6389046777476324e-06
domain O 0 2.8273738905681967e-08
of O 0 3.0362337088973845e-09
the O 0 1.9952871355144453e-08
UBE3A O 0 3.28565038216766e-05
protein O 0 2.471129789682891e-07
, O 0 2.0533226674501748e-08
which O 0 1.0079235224225158e-08
functions O 0 9.85176207279892e-09
in O 0 3.5040226720184364e-08
E2 O 0 1.2786681509169284e-05
binding O 0 7.31550755972421e-07
and O 0 1.386807753078756e-07
ubiquitin O 0 2.801409436870017e-06
transfer O 0 1.7456849263908225e-06
. O 0 1.3694415201825905e-06

Eight O 0 1.019684896164108e-05
of O 0 2.3078604272086523e-07
the O 0 1.9401764461690618e-07
cases O 0 1.3548803963203682e-06
were O 0 7.962055974530813e-07
familial O 0 0.0013992171734571457
, O 0 4.348007962562406e-07
and O 0 8.785519867160474e-08
five O 0 1.22515444900273e-07
were O 0 2.881561727008375e-07
sporadic O 0 1.7219892470166087e-05
. O 0 4.305677521188045e-06

In O 0 1.3638133168569766e-05
two O 0 2.666272393980762e-06
familial O 0 0.040448788553476334
cases O 0 2.0370020138216205e-05
and O 0 3.160535584356694e-07
one O 0 2.4943309995251184e-07
sporadic O 0 4.0495669964002445e-05
case O 0 1.6052177670644596e-05
, O 0 2.537874479457969e-07
mosaicism O 0 9.130669059231877e-05
for O 0 3.057753303892241e-07
UBE3A O 0 0.11806416511535645
mutations O 0 2.5434657800360583e-05
was O 0 3.755849604658579e-07
detected O 0 8.525412908966246e-07
in O 0 2.6094875593685174e-08
the O 0 2.02510470614925e-08
mother O 0 1.7773198806025903e-06
of O 0 9.6482839495593e-09
three O 0 1.7382826911216398e-07
AS B-Disease 0 0.006852559745311737
sons O 0 0.00010498072515474632
, O 0 1.6221260779047952e-08
in O 0 5.878101116962853e-09
the O 0 1.1620307382997908e-08
maternal O 0 6.0962206589465495e-06
grandfather O 0 9.166035965790797e-07
of O 0 6.431177368426688e-09
two O 0 2.7874603958366606e-08
AS B-Disease 0 2.009329000429716e-05
first O 0 3.6082124665881565e-07
cousins O 0 2.2199185423232848e-06
, O 0 2.2502998575646416e-08
and O 0 1.7332908441858308e-08
in O 0 1.3565164103113148e-08
the O 0 3.411439664091631e-08
mother O 0 3.989319793618051e-06
of O 0 2.506233443000383e-08
an O 0 5.333263288775925e-07
AS B-Disease 0 0.03674929216504097
daughter O 0 0.020742516964673996
. O 0 3.29277850141807e-06

The O 0 1.8670398276299238e-06
frequencies O 0 2.5113090487138834e-06
with O 0 7.317692762853767e-08
which O 0 6.566572352539879e-08
we O 0 4.252786567349176e-08
detected O 0 1.1639403965091333e-06
mutations O 0 8.140236218423524e-07
were O 0 3.212229415794354e-08
5 O 0 9.452094928974475e-08
( O 0 1.9181866761641686e-08
14 O 0 5.459581586819695e-08
% O 0 9.573930981332524e-09
) O 0 1.4192158559467316e-09
of O 0 2.561714840254581e-09
35 O 0 6.34408152677679e-08
in O 0 2.5162632866226886e-08
sporadic O 0 9.915982082020491e-05
cases O 0 3.207734607713064e-06
and O 0 9.909073384051226e-08
8 O 0 2.575061159859615e-07
( O 0 2.21638014608061e-08
80 O 0 7.283993852524873e-08
% O 0 1.3990750780124017e-08
) O 0 2.515806230007911e-09
of O 0 2.959479994402159e-09
10 O 0 6.707782773673898e-08
in O 0 1.9034213494251162e-07
familial O 0 0.04904763028025627
cases O 0 7.448437827406451e-05
. O 0 1.4673030364065198e-06
. O 0 2.836786734405905e-06

The O 0 0.00022680059191770852
hemochromatosis B-Disease 1 0.9998834133148193
845 O 0 0.10949418693780899
G O 0 0.3066778779029846
- O 0 0.0024751247838139534
- O 0 0.00036458068643696606
> O 0 3.133852032988216e-06
A O 0 1.577608230718397e-07
and O 0 7.402906732068004e-08
187 O 0 1.5421890111610992e-06
C O 0 6.195760306582088e-06
- O 0 0.00010954096069326624
- O 0 0.00176003307569772
> O 0 8.002906542969868e-05
G O 0 0.020587200298905373
mutations O 0 1.2635399798455182e-05
: O 0 2.9310740501387045e-07
prevalence O 0 7.764448128000367e-06
in O 0 1.1598611138197157e-07
non O 0 1.0868463959923247e-06
- O 0 0.001492125098593533
Caucasian O 0 0.001715517370030284
populations O 0 5.567385414906312e-06
. O 0 2.6283478291588835e-06

Hemochromatosis B-Disease 1 0.9987950325012207
, O 0 9.484097245149314e-05
the O 0 6.55968688079156e-05
inherited B-Disease 1 0.9999899864196777
disorder I-Disease 1 0.9999823570251465
of I-Disease 0 7.734921609880985e-07
iron I-Disease 1 0.6149027347564697
metabolism I-Disease 0 5.394719846663065e-05
, O 0 2.1638967950821097e-07
leads O 0 2.294214027642738e-06
, O 0 1.4985603513650858e-07
if O 0 3.7999811297595443e-07
untreated O 0 0.00477224588394165
, O 0 5.114208434520151e-08
to O 0 1.1260043208949355e-07
progressive O 0 8.66003247210756e-05
iron B-Disease 0 0.09085389226675034
overload I-Disease 0 0.022271478548645973
and O 0 5.3569992815027945e-06
premature B-Disease 0 0.10595855116844177
death I-Disease 0 0.018967216834425926
. O 0 1.2065060218446888e-05

The O 0 6.800071423640475e-05
hemochromatosis B-Disease 1 0.9998844861984253
gene O 0 9.027057967614383e-05
, O 0 2.8002768885926344e-06
HFE O 0 0.0010513890301808715
, O 0 8.751082418712031e-07
recently O 0 1.4639651908510132e-06
has O 0 1.293211795427851e-07
been O 0 6.989679235402946e-08
identified O 0 1.4599301323414693e-07
, O 0 1.0057055632728407e-08
and O 0 1.514932179702555e-08
characterization O 0 6.114791517575213e-07
of O 0 7.585920336339314e-09
this O 0 1.8985494065759667e-08
gene O 0 1.8828090730949043e-07
has O 0 1.063674588408503e-07
shown O 0 1.1072919647858726e-07
that O 0 6.6338694537648735e-09
it O 0 7.753471642502063e-09
contains O 0 1.7689609776994075e-08
two O 0 3.067142628765396e-08
mutations O 0 3.781547377457173e-07
that O 0 1.6485635967455892e-08
result O 0 5.2651596860187055e-08
in O 0 1.9460722811004416e-08
amino O 0 4.8010377895479905e-08
acid O 0 1.2419273787145357e-07
substitutions O 0 9.45869516044695e-08
- O 0 2.729368588916259e-07
cDNA O 0 7.016728318376408e-07
nucleotides O 0 7.739437819509476e-07
845 O 0 4.625355359166861e-06
G O 0 3.456914782873355e-05
- O 0 2.9377890314208344e-05
- O 0 5.2241703087929636e-05
> O 0 1.4265299341786886e-06
A O 0 3.8622522424702765e-07
( O 0 4.15771843620405e-08
C282Y O 0 1.2969692306796787e-06
) O 0 1.695731199902184e-08
and O 0 1.552455941578046e-08
187 O 0 3.0710006626577524e-07
C O 0 1.438486378901871e-06
- O 0 5.7734287111088634e-05
- O 0 0.013438010588288307
> O 0 3.4617249184520915e-05
G O 0 0.0003027054772246629
( O 0 2.2066114979679696e-07
H63D O 0 5.70758456888143e-05
) O 0 5.368165716390649e-07
. O 0 1.2899823786938214e-06

Although O 0 0.005480002611875534
hemochromatosis B-Disease 1 0.9999669790267944
is O 0 3.128348680547788e-06
common O 0 5.278895969240693e-07
in O 0 2.0604085193554056e-07
Caucasians O 0 2.9757471565972082e-05
, O 0 4.0403205048278323e-07
affecting O 0 9.94487550087797e-07
> O 0 5.014070211473154e-06
= O 0 3.5541231682145735e-06
1 O 0 1.846490818024904e-07
/ O 0 1.3022702205489622e-06
300 O 0 7.78111939325754e-08
individuals O 0 7.627210862892753e-09
of O 0 2.874922522266843e-09
northern O 0 1.230315547218197e-07
European O 0 9.793013333592171e-08
origin O 0 3.305623152982662e-08
, O 0 9.786175425574584e-09
it O 0 2.082001060443872e-08
has O 0 6.340017222328242e-08
not O 0 1.6319821938282075e-08
been O 0 4.152875732188477e-08
recognized O 0 3.637961398794687e-08
in O 0 3.985259411365405e-08
other O 0 8.258790273885097e-08
populations O 0 1.0740878906290163e-06
. O 0 1.3303953210197506e-06

The O 0 2.3527329631178873e-06
present O 0 1.3378931953411666e-06
study O 0 3.4671791127038887e-07
used O 0 9.122452837573292e-08
PCR O 0 1.4004067452333402e-06
and O 0 2.3082250777406443e-08
restriction O 0 1.1089173312939238e-07
- O 0 9.014003694574058e-07
enzyme O 0 1.2835077711770282e-07
digestion O 0 2.8791609452127886e-07
to O 0 2.564859791220897e-08
analyze O 0 5.6200523346205955e-08
the O 0 6.64667432204169e-09
frequency O 0 5.923562085285994e-08
of O 0 3.072674115145446e-09
the O 0 2.3052333375517264e-08
845 O 0 3.5407469113124534e-05
G O 0 0.005539741367101669
- O 0 0.00023454402980860323
- O 0 0.00016861029143910855
> O 0 6.182552851896617e-07
A O 0 9.654012700366366e-08
and O 0 1.593770093677449e-08
187 O 0 3.285061325186689e-07
C O 0 8.458350180262642e-07
- O 0 3.5059580113738775e-05
- O 0 0.0032005400862544775
> O 0 1.7039334125001915e-05
G O 0 0.00041206172318197787
mutations O 0 1.8361810134592815e-06
in O 0 8.754474123406908e-08
HLA O 0 0.00011488811287563294
- O 0 3.3470409107394516e-05
typed O 0 3.891118467436172e-06
samples O 0 2.1406556527381326e-07
from O 0 3.430695727502098e-08
non O 0 1.0378640524777438e-07
- O 0 9.695365406514611e-06
Caucasian O 0 7.698310218984261e-05
populations O 0 2.6960040599988133e-07
, O 0 3.324566932860762e-08
comprising O 0 6.02561840423732e-08
Australian O 0 2.5479019427621097e-07
Aboriginal O 0 1.920857926052122e-07
, O 0 2.0715237525337216e-08
Chinese O 0 3.2589337450872335e-08
, O 0 6.103767447029895e-08
and O 0 8.119715744214773e-08
Pacific O 0 5.70292797874572e-07
Islanders O 0 1.2941649401909672e-05
. O 0 1.953529135789722e-06

Results O 0 0.0004585366405081004
showed O 0 1.4155070857668761e-05
that O 0 7.705355642428913e-08
the O 0 8.070754375921751e-08
845 O 0 4.352699761511758e-05
G O 0 0.006618871819227934
- O 0 0.0002733190485741943
- O 0 0.00033834081841632724
> O 0 3.643566287792055e-06
A O 0 2.564985152275767e-06
mutation O 0 3.500353841445758e-06
was O 0 1.398574056565849e-07
present O 0 4.594465607965503e-08
in O 0 1.446854724918012e-08
these O 0 1.3915327556901502e-08
populations O 0 2.7803080726584994e-08
( O 0 1.3030942547231916e-08
allele O 0 3.245962432174565e-07
frequency O 0 2.8739597723870247e-07
0 O 0 9.596622874141758e-08
. O 0 1.0418720108873458e-08
32 O 0 1.5735302838493226e-07
% O 0 2.0987465987332143e-08
) O 0 7.072068708424695e-09
, O 0 1.0638852465660875e-08
and O 0 1.3930731235234362e-08
, O 0 3.6589355545402213e-08
furthermore O 0 1.312911734885347e-07
, O 0 1.1833235724623137e-08
it O 0 9.77833902737757e-09
was O 0 5.199126462684944e-08
always O 0 5.534515423732955e-08
seen O 0 1.2139183525050612e-07
in O 0 2.1366169278280722e-08
conjunction O 0 2.5220973043360573e-07
with O 0 8.62784133914829e-07
HLA O 1 0.6397379040718079
haplotypes O 0 0.007110230159014463
common O 0 8.254623935499694e-07
in O 0 2.239441982965218e-07
Caucasians O 0 1.1569767593755387e-05
, O 0 1.4311504514807893e-07
suggesting O 0 3.881690133766824e-07
that O 0 5.50888081818357e-08
845 O 0 1.923730997077655e-05
G O 0 0.026962274685502052
- O 0 0.005096473731100559
- O 0 0.020934587344527245
> O 0 5.787469035567483e-06
A O 0 2.8531114821817027e-06
may O 0 1.0000017027778085e-06
have O 0 1.4195360442670335e-08
been O 0 1.9066854761717877e-08
introduced O 0 3.525118685843154e-08
into O 0 1.7246870598341957e-08
these O 0 1.2533790894053709e-08
populations O 0 6.483993786332576e-08
by O 0 1.2957573858329852e-07
Caucasian O 0 2.941705497505609e-05
admixture O 0 0.0001465530804125592
. O 0 1.0032505088020116e-05

187 O 0 0.00039225074579007924
C O 0 0.0001449017581762746
- O 0 0.0003216508193872869
- O 0 0.0027596529107540846
> O 0 4.2227879021083936e-05
G O 0 6.519233284052461e-05
was O 0 1.569956822322638e-07
present O 0 1.867319276982471e-08
at O 0 8.269064544208504e-09
an O 0 3.409358129147222e-08
allele O 0 1.1077361250499962e-06
frequency O 0 3.4195022635685746e-07
of O 0 3.757282129868145e-08
2 O 0 1.178134652946028e-06
. O 0 1.5179045931290602e-06

68 O 0 0.006573273800313473
% O 0 8.584247552789748e-06
in O 0 1.200025252501291e-07
the O 0 5.092210386692386e-08
two O 0 1.5604170755523228e-07
populations O 0 2.5072574771911604e-07
analyzed O 0 1.104899183701491e-06
( O 0 4.181154622528993e-08
Australian O 0 2.0591316740592447e-07
Aboriginal O 0 2.1235109670669772e-07
and O 0 3.531141601342824e-08
Chinese O 0 2.0801044797735813e-07
) O 0 5.201060844228778e-07
. O 0 1.2841239822591888e-06

In O 0 6.4565751927148085e-06
the O 0 7.845526965866156e-07
Australian O 0 1.6034057352953823e-06
Aboriginal O 0 1.0839562492037658e-06
samples O 0 2.7517279477251577e-07
, O 0 4.9938797985760175e-08
187 O 0 6.009934168105246e-07
C O 0 1.998377683776198e-06
- O 0 1.707767842162866e-05
- O 0 0.00087290711235255
> O 0 1.4299174836196471e-05
G O 0 6.542364280903712e-05
was O 0 1.518666294941795e-07
found O 0 2.4287123423505363e-08
to O 0 2.3529159065560634e-08
be O 0 2.728951464803231e-08
associated O 0 1.057845651075695e-07
with O 0 4.3673861682691495e-07
HLA O 1 0.7255905866622925
haplotypes O 0 0.006311450619250536
common O 0 7.141009632505302e-07
in O 0 2.417325504211476e-07
Caucasians O 0 1.7829419448389672e-05
, O 0 1.698433180763459e-07
suggesting O 0 8.709088206160231e-07
that O 0 2.372817853313336e-08
it O 0 2.584769198676895e-08
was O 0 5.435745720205887e-08
introduced O 0 1.0762334312630628e-07
by O 0 6.581718992038077e-08
recent O 0 1.3939894643044681e-06
admixture O 0 8.228314982261509e-05
. O 0 8.704838364792522e-06

In O 0 3.410787257962511e-06
the O 0 1.4187111219143844e-07
Chinese O 0 1.3551010624723858e-07
samples O 0 3.8602601648562995e-07
analyzed O 0 6.237249863261241e-07
, O 0 5.163490257587e-08
187 O 0 3.7772076666442445e-07
C O 0 1.0682090305635938e-06
- O 0 1.9324521417729557e-05
- O 0 0.00648874556645751
> O 0 1.5194025763776153e-05
G O 0 8.201007585739717e-05
was O 0 1.8132908508050605e-07
present O 0 3.382671565077544e-08
in O 0 3.08426066908396e-08
association O 0 3.293413897154096e-08
with O 0 1.555680917419977e-08
a O 0 1.8148877245494077e-07
wide O 0 3.100008143519517e-07
variety O 0 9.668588774047748e-08
of O 0 4.9073410224309555e-08
HLA O 0 0.14514999091625214
haplotypes O 0 0.0026760813780128956
, O 0 1.2012000638605969e-07
showing O 0 4.2566009028632834e-07
this O 0 2.1389858773090964e-08
mutation O 0 3.307156362097885e-07
to O 0 3.579361163019712e-08
be O 0 1.6672997205091633e-08
widespread O 0 2.4786518793007417e-07
and O 0 2.925101227901905e-07
likely O 0 2.352118372073164e-06
to O 0 1.0769541347599443e-07
predate O 0 1.559244765303447e-06
the O 0 3.4982264196514734e-08
more O 0 5.029698257885684e-08
genetically O 0 3.5882888482774433e-07
restricted O 0 3.0826379315840313e-07
845 O 0 3.449584619374946e-05
G O 0 0.010923672467470169
- O 0 0.0006002839654684067
- O 0 0.0012596918968483806
> O 0 1.2363531823211815e-05
A O 0 6.16691613686271e-06
mutation O 0 2.352119372517336e-05
. O 0 1.5721096815468627e-06

Genotype O 1 0.9947593808174133
- O 1 0.9819340109825134
phenotype O 1 0.9799694418907166
correlations O 0 0.0021928695496171713
in O 0 0.00021261775691527873
attenuated B-Disease 1 0.9973419308662415
adenomatous I-Disease 1 0.9999849796295166
polyposis I-Disease 1 0.9999710321426392
coli I-Disease 1 0.9996461868286133
. O 0 0.00018270652799401432

Germ O 0 0.0039406027644872665
- O 0 0.008968561887741089
line O 0 3.267645661253482e-05
mutations O 0 4.222273673804011e-06
of O 0 3.44874422353314e-08
the O 0 2.0167063041753863e-07
tumor B-Disease 0 0.00016816200513858348
suppressor O 0 0.0001276051625609398
APC O 0 1.959740802703891e-05
are O 0 1.6272413461138058e-07
implicated O 0 9.958779628504999e-06
in O 0 1.042558596964227e-05
attenuated B-Disease 1 0.9996362924575806
adenomatous I-Disease 1 0.9999992847442627
polyposis I-Disease 1 0.9999982118606567
coli I-Disease 1 0.9999837875366211
( O 0 0.0001803131599444896
AAPC B-Disease 1 0.9999232292175293
) O 0 5.095552637612855e-07
, O 0 6.352593828751196e-08
a O 0 4.883191309090762e-07
variant O 0 9.302557009505108e-05
of O 0 5.0231878958584275e-06
familial B-Disease 1 0.9999971389770508
adenomatous I-Disease 1 0.9999982118606567
polyposis I-Disease 1 0.9999995231628418
( O 0 0.00010030684643425047
FAP B-Disease 0 0.009361207485198975
) O 0 5.2355258048919495e-06
. O 0 4.699654709838796e-06

AAPC B-Disease 1 0.9998979568481445
is O 0 3.9995360566535965e-05
recognized O 0 2.022269654844422e-06
by O 0 1.0638856196010238e-07
the O 0 5.0690303510236845e-08
occurrence O 0 2.563006944455992e-07
of O 0 3.027202666316953e-08
< O 0 2.7265896278549917e-06
100 O 0 3.469712908099609e-07
colonic B-Disease 0 0.004747114144265652
adenomas I-Disease 0 0.004606625996530056
and O 0 1.54814230768352e-07
a O 0 3.4155488037868054e-07
later O 0 3.0698342925461475e-06
onset O 0 0.00025023517082445323
of O 0 0.00044419843470677733
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
( O 0 3.0569681257475168e-06
age O 0 3.7012580378359416e-06
> O 0 3.7218376292003086e-06
40 O 0 4.3776697111752583e-07
years O 0 4.607418588875589e-07
) O 0 4.1772690906327625e-07
. O 0 9.461886634198891e-07

The O 0 2.561047949711792e-06
aim O 0 1.3269740293253562e-06
of O 0 2.7886622788741988e-08
this O 0 4.21445420784039e-08
study O 0 2.601906601285009e-07
was O 0 1.7971441934605537e-07
to O 0 1.3866146275631763e-07
assess O 0 3.033444590982981e-05
genotype O 0 0.0025254555512219667
- O 0 0.0026794099248945713
phenotype O 0 0.006096400320529938
correlations O 0 1.928008350660093e-05
in O 0 7.766462658764794e-06
AAPC B-Disease 1 0.9999092817306519
families O 0 4.6431869122898206e-05
. O 0 4.560617071547313e-06

By O 0 3.877692961395951e-06
protein O 0 2.0542174752335995e-06
- O 0 3.0824076020508073e-06
truncation O 0 6.249936177482596e-06
test O 0 1.0626723678797134e-06
( O 0 5.6255434088825496e-08
PTT O 0 1.8991995602846146e-06
) O 0 2.247636032848277e-08
assay O 0 2.63981007719849e-07
, O 0 1.0203960343346807e-08
the O 0 4.089721894473541e-09
entire O 0 3.3745905625437445e-08
coding O 0 3.062603752823634e-07
region O 0 1.5884287662970564e-08
of O 0 2.9571554094331987e-09
the O 0 1.5008625453560853e-08
APC B-Disease 0 1.893318653856113e-06
gene O 0 2.0779155818217987e-07
was O 0 1.2561389439724735e-07
screened O 0 1.4995640640336205e-06
in O 0 1.537179059596383e-07
affected O 0 3.332862661409308e-07
individuals O 0 3.666920989076061e-08
from O 0 9.4401855221804e-08
11 O 0 7.601479865115834e-06
AAPC B-Disease 1 0.9999473094940186
kindreds O 0 0.003547066356986761
, O 0 1.072626645282071e-07
and O 0 2.8961240516878206e-08
their O 0 5.6993730623844385e-08
phenotypic O 0 4.331920717959292e-05
differences O 0 7.422929684253177e-06
were O 0 1.2038416343784775e-06
examined O 0 7.564873521914706e-05
. O 0 5.511105428013252e-06

Five O 0 3.675762127386406e-05
novel O 0 2.422351826680824e-05
germ O 0 8.872630132827908e-05
- O 0 0.00012220500502735376
line O 0 1.4045882380742114e-05
APC B-Disease 0 6.0441409004852176e-05
mutations O 0 1.7231915990123525e-05
were O 0 2.5864613917292445e-07
identified O 0 6.955427238608536e-07
in O 0 1.730259384657984e-07
seven O 0 2.1084881609567674e-06
kindreds O 0 0.00023899930238258094
. O 0 6.966607088543242e-06

Mutations O 0 0.2712435722351074
were O 0 3.983177066402277e-06
located O 0 2.515745904929645e-07
in O 0 4.3934452520488776e-08
three O 0 2.7643970668123075e-08
different O 0 6.299020860467408e-09
regions O 0 8.309760879399164e-09
of O 0 3.1421287793875763e-09
the O 0 2.0689652657779334e-08
APC B-Disease 0 4.936989171255846e-06
gene O 0 2.17331503904461e-07
( O 0 9.566482717104918e-09
1 O 0 1.0086658619457012e-08
) O 0 5.135181613269424e-09
at O 0 3.492884426137266e-09
the O 0 6.1148113239539725e-09
5 O 0 4.161074329545045e-08
end O 0 1.0300603747737114e-07
spanning O 0 3.389828577837761e-07
exons O 0 1.0776718681881903e-06
4 O 0 8.521489291979378e-08
and O 0 2.241368690647505e-08
5 O 0 5.0822158925711847e-08
, O 0 2.096182249999856e-08
( O 0 1.1652399933836932e-08
2 O 0 3.0486766888770944e-08
) O 0 6.629606641439523e-09
within O 0 7.402789936605814e-09
exon O 0 2.593914132376085e-07
9 O 0 1.108318841147593e-07
, O 0 1.0570606612247957e-08
and O 0 1.94808524867085e-08
( O 0 1.706900398801281e-08
3 O 0 4.366194872318374e-08
) O 0 9.69676694495547e-09
at O 0 7.049362871214271e-09
the O 0 7.699739512645465e-09
3 O 0 2.016860207731952e-07
distal O 0 4.704242019215599e-05
end O 0 2.5735684516803303e-07
of O 0 2.1281003625972517e-08
the O 0 1.600559471626184e-07
gene O 0 3.0094711291894782e-06
. O 0 1.2588808431246434e-06

Variability O 0 0.041583262383937836
in O 0 2.2317760794976493e-06
the O 0 1.496184154348157e-07
number O 0 2.598561081867956e-07
of O 0 4.281372184777865e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999991655349731
was O 0 0.0005530326161533594
most O 0 1.4658075997431297e-07
apparent O 0 1.9827844880637713e-05
in O 0 1.3760471517798578e-07
individuals O 0 2.3934861204111257e-08
with O 0 1.1865797233667763e-07
mutations O 0 1.1688788617902901e-05
in O 0 4.708671141884224e-08
region O 0 1.31300438965809e-07
1 O 0 1.5036380318633746e-07
, O 0 4.8608281844053636e-08
and O 0 1.1506089236945627e-07
upper O 0 0.0009628278203308582
- O 1 0.9869918823242188
gastrointestinal O 1 0.9998869895935059
manifestations O 0 0.0005728784599341452
were O 0 7.591994517497369e-07
more O 0 5.952976493972528e-07
severe O 0 0.04451702535152435
in O 0 6.287739893195976e-07
them O 0 8.583883754909039e-07
. O 0 2.442392315060715e-06

In O 0 1.3394965208135545e-05
individuals O 0 7.58690589464095e-07
with O 0 4.42189474370025e-07
mutations O 0 1.4004646800458431e-05
in O 0 6.868411617233505e-08
either O 0 1.8786623456890084e-07
region O 0 1.4399341807802557e-07
2 O 0 2.2133727384243684e-07
or O 0 4.7687304771670824e-08
region O 0 5.022747728844479e-08
3 O 0 8.243776505878486e-08
, O 0 6.3917635628740754e-09
the O 0 4.704315159642647e-09
average O 0 6.45040572067046e-08
number O 0 6.695624055197413e-09
of O 0 9.318515736822519e-09
adenomas B-Disease 0 0.00044171311310492456
tended O 0 4.071060538990423e-05
to O 0 1.805556735234859e-07
be O 0 4.108785844891827e-08
lower O 0 3.6169601003166463e-07
than O 0 2.6653793838704587e-08
those O 0 1.3743952642641943e-08
in O 0 3.9473430746284066e-08
individuals O 0 2.038385282787658e-08
with O 0 1.201708812459401e-07
mutations O 0 1.042864823830314e-05
in O 0 9.377321674719497e-08
region O 0 2.335017939003592e-07
1 O 0 1.2044958452861465e-07
, O 0 2.7021837212259925e-08
although O 0 1.1711227188015982e-07
age O 0 3.6789077739740605e-07
at O 0 2.607055478165421e-07
diagnosis O 0 0.055587589740753174
was O 0 4.5070546548231505e-06
similar O 0 3.926370482076891e-06
. O 0 2.087167558784131e-06

In O 0 2.3681490347371437e-05
all O 0 2.908396481871023e-06
AAPC B-Disease 1 0.9992352724075317
kindreds O 0 0.0018389461329206824
, O 0 2.2806814570230927e-07
a O 0 1.1956420564729342e-07
predominance O 0 2.5157316940749297e-06
of O 0 1.808986525020373e-07
right O 0 0.0005754938465543091
- O 1 0.9980331063270569
sided O 1 0.9999969005584717
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999891519546509
and O 0 0.0008756291354075074
rectal B-Disease 1 0.9999148845672607
polyp I-Disease 1 0.9986352324485779
sparing O 0 0.0007235624361783266
was O 0 2.611230593174696e-05
observed O 0 1.528835855424404e-05
. O 0 4.627733687811997e-06

No O 0 0.00043734483188018203
desmoid B-Disease 1 0.9832538962364197
tumors I-Disease 1 0.9999643564224243
were O 0 2.374534915361437e-06
found O 0 4.6943057441239944e-07
in O 0 1.4192252706379804e-07
these O 0 3.0807748885308683e-07
kindreds O 0 0.00018425531743559986
. O 0 5.685134510713397e-06

Our O 0 1.1380472642485984e-05
data O 0 1.86091403975297e-06
suggest O 0 1.1572375342439045e-06
that O 0 7.75053194956854e-08
, O 0 8.92429738996725e-08
in O 0 4.4394724341145775e-07
AAPC B-Disease 1 0.9999822378158569
families O 0 1.2336175814198214e-06
, O 0 1.1630684859653684e-08
the O 0 3.841381435165658e-09
location O 0 1.8074977958804084e-08
of O 0 6.562287158118352e-09
the O 0 1.5612447157309362e-07
APC B-Disease 0 0.0004966969136148691
mutation O 0 4.9668426072457805e-05
may O 0 1.4395993730431655e-06
partially O 0 5.0486414693295956e-06
predict O 0 3.583960051400936e-06
specific O 0 2.1818877371515555e-07
phenotypic O 0 5.754388257628307e-05
expression O 0 1.9841671019094065e-05
. O 0 4.702550995716592e-06

This O 0 2.3081054223439423e-06
should O 0 3.760548281661613e-07
help O 0 1.1281196066192933e-07
in O 0 1.9905774806261434e-08
the O 0 1.578353980846714e-08
design O 0 3.040657645669853e-07
of O 0 5.0392429784551496e-08
tailored O 0 0.003407559124752879
clinical O 0 0.08285605907440186
- O 0 0.18825992941856384
management O 0 1.2200632681924617e-06
protocols O 0 6.001016572554363e-07
in O 0 4.4072095306546544e-08
this O 0 2.377565699873685e-08
subset O 0 3.0700752517986984e-07
of O 0 4.462534377580596e-07
FAP B-Disease 1 0.9979544878005981
patients O 1 0.9993495345115662
. O 0 3.1356457839137875e-06
. O 0 5.608900210063439e-06

Wilms B-Disease 1 0.9916980266571045
' I-Disease 0 0.016546960920095444
tumor I-Disease 0 0.0009435339015908539
1 O 0 1.0267380048389896e-06
and O 0 1.776452620561031e-07
Dax O 0 6.179552292451262e-05
- O 0 2.2297412215266377e-05
1 O 0 2.315658207407978e-07
modulate O 0 1.112961854232708e-06
the O 0 3.245838087195807e-08
orphan O 0 2.365498630751972e-06
nuclear O 0 5.448392812468228e-07
receptor O 0 8.449401320831385e-07
SF O 0 0.004038576502352953
- O 0 1.2489289474615362e-05
1 O 0 2.3395226378397638e-07
in O 0 4.867703395916578e-08
sex O 0 5.179815616429551e-07
- O 0 3.131032144665369e-06
specific O 0 1.5299279709779512e-07
gene O 0 1.4704686464028782e-06
expression O 0 4.279429049347527e-06
. O 0 2.818017037498066e-06

Products O 0 1.1795842510764487e-05
of O 0 6.089708790568693e-07
steroidogenic O 0 0.00015292121679522097
factor O 0 2.276312670801417e-06
1 O 0 8.422007908848173e-07
( O 0 3.361588767347712e-07
SF O 0 0.3197596073150635
- O 0 0.00011836632620543242
1 O 0 2.56906616868946e-07
) O 0 3.325689235111895e-08
and O 0 1.590894527225828e-07
Wilms B-Disease 1 0.5511713624000549
tumor I-Disease 0 0.0004692457150667906
1 O 0 1.8171495241858793e-07
( O 0 4.4791754305606446e-08
WT1 O 0 1.6932939615799114e-05
) O 0 2.8663277973350887e-08
genes O 0 3.2794858384477266e-08
are O 0 2.211581806577101e-09
essential O 0 7.618328190517332e-09
for O 0 1.1622701023839e-08
mammalian O 0 1.0801453527164995e-06
gonadogenesis O 0 4.593885023496114e-05
prior O 0 2.2012392264514347e-07
to O 0 1.1325748516810563e-07
sexual O 0 1.4390818705578567e-06
differentiation O 0 4.003909907623893e-06
. O 0 4.417790478328243e-06

In O 0 2.2868785890750587e-05
males O 0 4.747276034322567e-05
, O 0 1.7966966652238625e-06
SF O 1 0.5764193534851074
- O 0 0.00014651732635684311
1 O 0 3.517744460168615e-07
participates O 0 1.095715802534869e-07
in O 0 2.1267611671760278e-08
sexual O 0 6.431682209040446e-08
development O 0 1.0198085043100491e-08
by O 0 7.087625153445742e-09
regulating O 0 1.5590322277603264e-07
expression O 0 1.2017466133329435e-07
of O 0 8.159268816143594e-09
the O 0 7.204653940107164e-08
polypeptide O 0 1.758641519700177e-05
hormone O 0 9.67629148362903e-06
Mullerian O 0 2.7705429602065124e-05
inhibiting O 0 1.2998249076190405e-05
substance O 0 1.14646118163364e-05
( O 0 7.367134458036162e-07
MIS O 0 8.564587187720463e-05
) O 0 3.0461885671684286e-06
. O 0 2.8002236831525806e-06

Here O 0 1.5502386304433458e-05
, O 0 5.348192075871339e-07
we O 0 4.617218962721381e-08
show O 0 1.5158518351654493e-07
that O 0 7.56898401732542e-08
WT1 O 0 9.700350346975029e-05
- O 0 9.35274874791503e-05
KTS O 0 0.0011248784139752388
isoforms O 0 3.2952225410554092e-06
associate O 0 3.8776903465986834e-07
and O 0 5.0919577887498235e-08
synergize O 0 1.832617817854043e-05
with O 0 9.361145885122824e-07
SF O 1 0.9937949180603027
- O 0 0.00021663386723957956
1 O 0 3.908248800144065e-07
to O 0 1.0321824817083325e-07
promote O 0 7.633536824869225e-07
MIS O 0 0.0003937305882573128
expression O 0 2.0944367861375213e-05
. O 0 2.8118320187786594e-06

In O 0 1.8385413568466902e-05
contrast O 0 4.391487527755089e-05
, O 0 1.1488035625006887e-06
WT1 O 0 0.0197630375623703
missense O 0 0.09432829171419144
mutations O 0 0.0001138109146268107
, O 0 9.310364390557879e-08
associated O 0 8.167945253489961e-08
with O 0 1.74045723611016e-07
male B-Disease 0 0.00032425648532807827
pseudohermaphroditism I-Disease 1 0.9999014139175415
in O 0 2.0456685888348147e-05
Denys B-Disease 1 0.980748176574707
- I-Disease 1 0.9995549321174622
Drash I-Disease 1 0.9999710321426392
syndrome I-Disease 1 0.99998939037323
, O 0 4.967195650351641e-07
fail O 0 3.74157821170229e-06
to O 0 1.318057911703363e-07
synergize O 0 8.098052785499021e-05
with O 0 3.7906063425907632e-06
SF O 1 0.9988897442817688
- O 0 0.008412333205342293
1 O 0 3.93937443732284e-06
. O 0 1.7591464711586013e-06

Additionally O 0 9.507314825896174e-05
, O 0 1.2285304364922922e-06
the O 0 1.8128049816823477e-07
X O 0 0.00025578029453754425
- O 0 0.00038012253935448825
linked O 0 6.693303930660477e-06
, O 0 4.90985065937366e-08
candidate O 0 2.754009074124042e-07
dosage O 0 4.868199994234601e-06
- O 0 4.16435659644776e-06
sensitive O 0 9.774656746230903e-07
sex O 0 9.54818233367405e-07
- O 0 9.45226929616183e-06
reversal O 0 1.4381227629201021e-05
gene O 0 5.740710662394122e-07
, O 0 5.5665612563871036e-08
Dax O 0 6.9731408984807786e-06
- O 0 4.442981207830599e-06
1 O 0 6.049986467360213e-08
, O 0 1.8726764139387342e-08
antagonizes O 0 1.6340353568011778e-06
synergy O 0 6.185914571688045e-07
between O 0 1.8691012826366205e-07
SF O 1 0.9543355107307434
- O 0 0.0010916449828073382
1 O 0 3.2151172035810305e-07
and O 0 9.860976746267625e-08
WT1 O 0 8.678419544594362e-05
, O 0 3.833281070342309e-08
most O 0 1.0302014352703281e-08
likely O 0 5.035649408569043e-08
through O 0 6.460425527876623e-09
a O 0 3.330215392338687e-08
direct O 0 5.986098017274344e-08
interaction O 0 7.128844004000712e-08
with O 0 5.110069309921528e-07
SF O 1 0.9985926747322083
- O 0 0.00681996438652277
1 O 0 4.98620784128434e-06
. O 0 1.8637042558111716e-06

We O 0 4.921828349324642e-06
propose O 0 9.14277734409552e-06
that O 0 3.5250218388682697e-07
WT1 O 0 4.0568611439084634e-05
and O 0 3.1675085665483493e-07
Dax O 0 0.00013475431478582323
- O 0 6.113260315032676e-05
1 O 0 5.318001399245986e-07
functionally O 0 1.1618686812653323e-06
oppose O 0 1.6029808591611072e-07
each O 0 9.966940162087212e-09
other O 0 5.1470565587408146e-09
in O 0 1.9143122642617527e-08
testis O 0 2.155196671083104e-05
development O 0 4.299225153658881e-08
by O 0 1.2280567318612157e-07
modulating O 0 0.00013363748439587653
SF O 1 0.9490850567817688
- O 0 0.00011393688328098506
1 O 0 6.248561703614541e-07
- O 0 1.8660197383724153e-05
mediated O 0 1.9628476366051473e-05
transactivation O 0 9.099014278035611e-05
. O 0 5.417920760919515e-07
. O 0 1.045204840011138e-06

A O 0 7.550028385594487e-05
mouse O 0 0.0001322493772022426
model O 0 4.313403042033315e-05
for O 0 1.4270947758632246e-05
Prader B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999974966049194
Willi I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999945163726807
imprinting O 0 0.003744201734662056
- O 0 0.06422409415245056
centre O 0 0.00019381099264137447
mutations O 0 0.00010419275349704549
. O 0 4.353465556050651e-06

Imprinting O 0 0.0016464578220620751
in O 0 6.396366643457441e-06
the O 0 5.259619797470805e-07
15q11 O 0 2.357295306865126e-05
- O 0 1.2928611795359757e-05
q13 O 0 8.0898544183583e-06
region O 0 8.328138534352547e-08
involves O 0 4.066854586426416e-08
an O 0 3.478578136650867e-08
imprinting O 0 8.112275281746406e-06
centre O 0 1.3451125369101646e-06
( O 0 2.6187965573853944e-08
IC O 0 1.4563912600351614e-06
) O 0 1.4563903860675964e-08
, O 0 5.390777602087837e-09
mapping O 0 8.303458542968656e-08
in O 0 8.699356790486945e-09
part O 0 9.854204563453095e-09
to O 0 1.6644051470393606e-08
the O 0 1.9977244747337863e-08
promoter O 0 9.022397762237233e-07
and O 0 3.7808472796996284e-08
first O 0 1.4141345161533536e-07
exon O 0 1.9025641222469858e-06
of O 0 2.7812953362627013e-07
SNRPN O 0 0.0013025138759985566
. O 0 5.329970463208156e-06

Deletion O 0 0.002219884190708399
of O 0 1.1854344847961329e-06
this O 0 8.653568102090503e-07
IC O 0 5.8697354688774794e-05
abolishes O 0 0.00024183082859963179
local O 0 6.934101293154527e-07
paternally O 0 1.5794486898812465e-05
derived O 0 5.801388169857091e-07
gene O 0 4.724387281385134e-07
expression O 0 4.6560023747588275e-07
and O 0 1.626143131261415e-07
results O 0 8.926031114242505e-06
in O 0 0.00012360431719571352
Prader B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 8.79863728187047e-05
PWS B-Disease 1 0.9996849298477173
) O 0 1.2352985322650056e-05
. O 0 6.159574695629999e-06

We O 0 5.5185737437568605e-06
have O 0 1.8677863522498228e-07
created O 0 1.1754026019161756e-07
two O 0 8.95881484552774e-08
deletion O 0 0.00026589087792672217
mutations O 0 3.365451630088501e-05
in O 0 2.675737960089464e-07
mice O 0 0.0002405825216555968
to O 0 8.203213042179414e-07
understand O 0 1.4384136193257291e-05
PWS B-Disease 1 0.9997913241386414
and O 0 3.4050827935061534e-07
the O 0 2.6283341725275022e-08
mechanism O 0 6.249550921211267e-08
of O 0 2.4690066879884398e-08
this O 0 1.790694454939512e-07
IC O 0 0.00016025152581278235
. O 0 5.707744548999472e-06

Mice O 0 0.37303751707077026
harbouring O 0 0.0011544042499735951
an O 0 6.116650183685124e-06
intragenic O 0 0.001089793280698359
deletion O 0 0.00031538429902866483
in O 0 4.803666797670303e-07
Snrpn O 0 8.088389586191624e-05
are O 0 2.0795491195713112e-07
phenotypically O 0 0.0001258330448763445
normal O 0 7.455575428139127e-07
, O 0 4.634918582269165e-08
suggesting O 0 4.1852720755741757e-07
that O 0 4.2272628064665696e-08
mutations O 0 3.492646953873191e-07
of O 0 1.0700230035354252e-08
SNRPN O 0 0.0004726615734398365
are O 0 3.183355445912639e-08
not O 0 4.3850398867562035e-08
sufficient O 0 3.8871542074048193e-07
to O 0 1.6629255696898326e-06
induce O 0 0.0005730182165279984
PWS B-Disease 1 0.999769389629364
. O 0 3.119851680821739e-05

Mice O 0 0.15301565825939178
with O 0 9.188248668579035e-07
a O 0 7.000419373071054e-07
larger O 0 4.1963588159887877e-07
deletion O 0 7.39023334972444e-06
involving O 0 3.868209148549795e-07
both O 0 1.0342970568899545e-07
Snrpn O 0 1.2864422387792729e-05
and O 0 9.277110990524307e-08
the O 0 7.678096380914212e-08
putative O 0 0.0004002839559689164
PWS O 1 0.9996979236602783
- O 0 0.0013705140445381403
IC O 0 0.00016132860037032515
lack O 0 1.2755057241520262e-06
expression O 0 2.1053044463315018e-07
of O 0 1.1484488027235784e-08
the O 0 6.170982658204593e-08
imprinted O 0 4.861211345996708e-05
genes O 0 8.202430876735889e-07
Zfp127 O 0 8.300358786073048e-06
( O 0 5.381052048392121e-08
mouse O 0 5.047703552918392e-07
homologue O 0 2.393229806330055e-06
of O 0 5.7120406182775696e-08
ZNF127 O 0 0.00023768378014210612
) O 0 1.0750476064913528e-07
, O 0 6.10150934221565e-08
Ndn O 0 6.779523118893849e-06
and O 0 7.167045623646118e-08
Ipw O 0 1.3929919987276662e-05
, O 0 5.1943487733296934e-08
and O 0 3.711129181738215e-08
manifest O 0 4.216647994326195e-06
several O 0 4.848952812608331e-07
phenotypes O 0 0.00027564523043110967
common O 0 2.1407895474112593e-06
to O 0 3.516733704600483e-05
PWS B-Disease 1 0.9999948740005493
infants O 1 0.9994503855705261
. O 0 9.178035725199152e-06

These O 0 3.8835628402011935e-06
data O 0 1.8198269344793516e-06
demonstrate O 0 1.3730834780290024e-06
that O 0 3.1674751710397686e-08
both O 0 1.1282697442993594e-08
the O 0 7.2855463884025085e-09
position O 0 7.459744466586926e-08
of O 0 5.466706198831162e-09
the O 0 2.286595979228423e-08
IC O 0 3.6104952414461877e-06
and O 0 1.8863060446960844e-08
its O 0 9.442739923315457e-09
role O 0 2.91330994883765e-08
in O 0 7.1180399352499535e-09
the O 0 5.742493591753828e-09
coordinate O 0 2.01202269067835e-07
expression O 0 2.632398832247418e-07
of O 0 8.575896437434949e-09
genes O 0 7.195027507123086e-08
is O 0 1.555621587101541e-08
conserved O 0 3.100303302971952e-08
between O 0 1.2598336596170157e-08
mouse O 0 1.3189988976591849e-06
and O 0 7.641076393838375e-08
human O 0 7.217197861564273e-08
, O 0 4.778454609777327e-08
and O 0 2.864327264262556e-08
indicate O 0 1.6210162812058115e-07
that O 0 1.040126740292635e-08
the O 0 1.0515607939964866e-08
mouse O 0 5.496075914379617e-07
is O 0 9.317608906656005e-09
a O 0 2.7524068357820397e-08
suitable O 0 9.140148193864661e-08
model O 0 6.504054113065649e-07
system O 0 4.9416808423075054e-08
in O 0 1.3192369863190834e-08
which O 0 1.6924870394063873e-08
to O 0 1.9732528500071567e-08
investigate O 0 1.8497603093692305e-07
the O 0 1.6668895597149458e-08
molecular O 0 1.894476895358821e-07
mechanisms O 0 2.4805146381368104e-08
of O 0 4.788305307812379e-09
imprinting O 0 6.889719770697411e-06
in O 0 4.96232814839459e-08
this O 0 1.7770059201893673e-08
region O 0 2.5600163766625883e-08
of O 0 5.496084476419583e-09
the O 0 2.7881517539185552e-08
genome O 0 6.112936716817785e-07
. O 0 1.7064992618998076e-07
. O 0 8.007280598576472e-07

Mutations O 0 0.005414213053882122
of O 0 4.832660920328635e-07
the O 0 1.5869154879055714e-07
ATM O 0 4.253636234352598e-06
gene O 0 9.183973475046514e-07
detected O 0 6.940108505659737e-07
in O 0 7.845409299989115e-08
Japanese O 0 0.0001727519993437454
ataxia B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999988079071045
telangiectasia I-Disease 1 0.9999998807907104
patients O 1 0.9996022582054138
: O 0 2.3295464757211448e-07
possible O 0 6.99167941320411e-08
preponderance O 0 1.5414112795042456e-06
of O 0 7.333758045291461e-09
the O 0 2.3883423239112744e-08
two O 0 1.56963636754881e-07
founder O 0 1.0194971764576621e-05
mutations O 0 3.2823943456605775e-06
4612del165 O 0 5.938754384260392e-06
and O 0 4.464002927306865e-07
7883del5 O 0 9.023158781928942e-05
. O 0 2.7828605198010337e-06

The O 0 8.335610800713766e-06
ATM O 0 9.580868936609477e-05
( O 0 3.082848706981167e-06
A O 1 0.5414544939994812
- O 1 0.9984918832778931
T O 1 0.999976634979248
, O 0 2.822390854362311e-07
mutated O 0 2.323035914741922e-06
) O 0 2.4647626162277447e-08
gene O 0 7.655444989040916e-08
on O 0 1.4122664993010403e-07
human O 0 1.052052198247111e-06
chromosome O 0 0.00010749440116342157
11q22 O 0 0.00016284614684991539
. O 0 3.4760296330205165e-06

3 O 0 6.172607390908524e-05
has O 0 2.6218035600322764e-06
recently O 0 1.930141706907307e-06
been O 0 5.468127284302682e-08
identified O 0 6.719986345160578e-08
as O 0 3.4800167192372555e-09
the O 0 4.5118420111123214e-09
gene O 0 3.65459698059567e-08
responsible O 0 2.6500250882577348e-08
for O 0 1.8030249293587985e-08
the O 0 3.068483067636407e-07
human O 0 0.0001965627452591434
recessive B-Disease 1 0.9999381303787231
disease I-Disease 1 0.9999346733093262
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999955892562866
telangiectasia I-Disease 1 0.9999974966049194
( O 0 1.8164742868975736e-05
A B-Disease 1 0.9956788420677185
- I-Disease 1 0.9996168613433838
T I-Disease 1 0.9999555349349976
) O 0 2.5416120479349047e-06
. O 0 1.0904209375439677e-06

In O 0 4.170373358647339e-06
order O 0 5.316135229804786e-07
to O 0 9.326876693194208e-08
define O 0 2.433955614833394e-07
the O 0 3.20845110479695e-08
types O 0 1.410242305155407e-07
of O 0 1.708650501086595e-07
disease O 0 0.0004896354512311518
- O 0 0.0024434393271803856
causing O 0 3.140320040984079e-05
ATM O 0 2.3099060854292475e-05
mutations O 0 3.170208856317913e-06
in O 0 3.2290731866169153e-08
Japanese O 0 1.7925617612490896e-06
A B-Disease 1 0.9982824325561523
- I-Disease 1 0.9999916553497314
T I-Disease 1 0.9999998807907104
patients O 0 0.11674154549837112
as O 0 1.816327710457699e-08
well O 0 5.7541371667468866e-09
as O 0 5.540226499789469e-09
to O 0 8.860756572914852e-09
look O 0 8.306025023330221e-08
for O 0 1.536841232052666e-08
possible O 0 1.4683638482893002e-07
mutational O 0 0.0001261513098143041
hotspots O 0 7.4930076152668335e-06
, O 0 1.5742266157303675e-07
reverse O 0 5.410354333434952e-06
- O 0 1.3579574442701414e-05
transcribed O 0 1.4773718248761725e-06
RNA O 0 2.3038603558234172e-07
derived O 0 3.175932050680785e-08
from O 0 1.1840821656505796e-08
ten O 0 1.9916414828458073e-07
patients O 0 4.804720902029658e-06
belonging O 0 1.143430878869367e-07
to O 0 6.000112762194476e-08
eight O 0 3.089451183768688e-07
unrelated O 0 1.2919066421090974e-06
Japanese O 0 8.279013854917139e-06
A B-Disease 1 0.9936489462852478
- I-Disease 1 0.9998656511306763
T I-Disease 1 0.9999973773956299
families O 0 1.3327471606316976e-06
was O 0 1.9028223618988704e-07
analyzed O 0 5.443853297038004e-07
for O 0 3.168453943658278e-08
mutations O 0 4.816722594114253e-07
by O 0 6.99309055107733e-09
the O 0 2.1935521843374772e-08
restriction O 0 6.257745326365693e-07
endonuclease O 0 2.9718874429818243e-05
fingerprinting O 0 1.9504072042764165e-05
method O 0 4.997251835447969e-06
. O 0 2.7804412638943177e-06

As O 0 5.775554200226907e-06
has O 0 8.048001518545789e-07
been O 0 2.6222360816063883e-07
reported O 0 1.1070887921960093e-06
by O 0 3.678879423318904e-08
others O 0 2.02480407551775e-07
, O 0 1.5281372611752886e-07
mutations O 0 9.18424461815448e-07
that O 0 1.9695717057288675e-08
lead O 0 2.7421711479291844e-07
to O 0 8.56720276942724e-08
exon O 0 1.3855998304279638e-06
skipping O 0 1.2837284657507553e-06
or O 0 1.330850523117988e-07
premature O 0 1.4036414540896658e-05
protein O 0 1.9574083864881686e-07
truncation O 0 1.1804075938925962e-06
were O 0 7.616645092412e-08
also O 0 9.132011058454736e-08
predominant O 0 5.54749817638367e-07
in O 0 1.2130388427067373e-07
our O 0 3.4688792993620154e-07
mutants O 0 2.213389780081343e-05
. O 0 2.480615194144775e-06

Six O 0 1.8565799109637737e-05
different O 0 1.2918437732878374e-06
mutations O 0 1.5416848327731714e-05
were O 0 2.2435463620240625e-07
identified O 0 1.6967737792583648e-07
on O 0 6.307908506641979e-08
12 O 0 5.6049795915669165e-08
of O 0 6.368787719424063e-09
the O 0 7.242059751888519e-08
16 O 0 3.625207000368391e-06
alleles O 0 5.732204954256304e-06
examined O 0 4.8965532187139615e-05
. O 0 3.936174380214652e-06

Four O 0 1.246437295776559e-05
were O 0 6.067870685910748e-07
deletions O 0 6.1072596508893184e-06
involving O 0 9.574825980962487e-07
a O 0 2.996600642291014e-06
loss O 0 1.62345477292547e-05
of O 0 2.144267696735369e-08
a O 0 6.468775382018066e-07
single O 0 1.1615940138653968e-06
exon O 0 6.933387339813635e-06
exon O 0 4.135560175200226e-06
7 O 0 4.1675366446725093e-07
, O 0 3.779707924422837e-08
exon O 0 7.011657885414024e-07
16 O 0 1.242589462435717e-07
, O 0 2.25689795740891e-08
exon O 0 1.0295569836671348e-06
33 O 0 4.796983148480649e-07
or O 0 8.386319905184791e-08
exon O 0 7.766981070744805e-06
35 O 0 5.650007551594172e-06
. O 0 2.4239054710051278e-06

The O 0 8.033278390939813e-06
others O 0 1.8643193016032455e-06
were O 0 8.64393641109018e-08
minute O 0 1.5383977824967587e-07
deletions O 0 2.1913981527177384e-06
, O 0 9.889361507475769e-08
4649delA O 0 2.233021405118052e-06
in O 0 4.6827160815610114e-08
exon O 0 1.2578030919030425e-06
33 O 0 2.507809711005393e-07
and O 0 4.50268835550105e-08
7883del5 O 0 8.913517376640812e-06
in O 0 3.0840112685837084e-07
exon O 0 1.974308725039009e-05
55 O 0 8.023295777093153e-06
. O 0 1.5974821963027352e-06

The O 0 1.0618766282277647e-05
mutations O 0 8.43937013996765e-05
4612del165 O 0 2.887655318772886e-05
and O 0 2.8200150836710236e-07
7883del5 O 0 9.262942512577865e-06
were O 0 8.020405317665791e-08
found O 0 2.718374325638706e-08
in O 0 5.373849365497563e-09
more O 0 7.537632740195477e-09
than O 0 1.743413591270837e-08
two O 0 2.81645853306145e-08
unrelated O 0 6.76070101235382e-07
families O 0 1.657542298971748e-07
; O 0 6.008999520190628e-08
44 O 0 3.267956572017283e-07
% O 0 2.567679224796393e-08
( O 0 5.294856109117063e-09
7 O 0 3.106998747171019e-08
of O 0 4.911739903690204e-09
16 O 0 4.8299330757117787e-08
) O 0 2.4683086685683975e-09
of O 0 1.6963320748075716e-09
the O 0 7.975993199238474e-09
mutant O 0 3.83539145332179e-06
alleles O 0 3.0794646477261267e-07
had O 0 4.296257927194347e-08
one O 0 7.224590703458489e-09
of O 0 3.4262928050310393e-09
the O 0 5.3344635375651706e-08
two O 0 9.553409654472489e-07
mutations O 0 1.8518023352953605e-05
. O 0 3.2546154216106515e-06

The O 0 1.0835163266165182e-05
4612del165 O 0 0.0004438920004758984
mutations O 0 6.688782013952732e-05
in O 0 8.09262772349939e-08
three O 0 4.5616772581524856e-08
different O 0 1.2672902727217661e-08
families O 0 4.24303081558719e-08
were O 0 1.178231467946489e-08
all O 0 2.2061383830873638e-09
ascribed O 0 1.6913921285777178e-07
to O 0 3.309976648324664e-08
the O 0 1.5994737978530793e-08
same O 0 8.327153722120784e-08
T O 0 7.967391866259277e-05
- O 0 8.955533303378616e-06
- O 0 1.4119897059572395e-05
> O 0 3.206763494745246e-07
A O 0 4.9765265686119164e-08
substitution O 0 2.8001963414681086e-08
at O 0 1.5034869349506153e-08
the O 0 9.665634514988142e-09
splice O 0 2.8722520255541895e-06
donor O 0 7.707544114055054e-07
site O 0 5.368513598114077e-07
in O 0 1.809039957834102e-07
intron O 0 0.0002567608025856316
33 O 0 1.691375109658111e-05
. O 0 1.940255515364697e-06

Microsatellite O 0 0.022208336740732193
genotyping O 0 0.0042328136041760445
around O 0 1.0495476090000011e-05
the O 0 6.051071750334813e-07
ATM O 0 1.2975412573723588e-05
locus O 0 1.8743952750810422e-05
also O 0 5.707694299417199e-07
indicated O 0 8.791049026513065e-07
that O 0 3.225017053409829e-08
a O 0 7.283179570549692e-07
common O 0 3.4661916288314387e-06
haplotype O 0 0.0720924511551857
was O 0 8.777318498687237e-07
shared O 0 7.75170008182613e-08
by O 0 1.6398484348201237e-08
the O 0 1.707492991442905e-08
mutant O 0 6.951733666937798e-06
alleles O 0 9.513769327895716e-07
in O 0 6.778688543818134e-08
both O 0 3.511935631195229e-07
mutations O 0 1.3382593351707328e-05
. O 0 1.4815976783211227e-06

This O 0 4.449324023880763e-06
suggests O 0 3.992353413195815e-06
that O 0 8.568869702685333e-08
these O 0 1.4904159684192564e-08
two O 0 5.5000089815848696e-08
founder O 0 4.463529330678284e-05
mutations O 0 1.3068077350908425e-05
may O 0 1.5717034784756834e-07
be O 0 1.5202408221171027e-08
predominant O 0 2.760388326805696e-07
among O 0 2.0350364948740207e-08
Japanese O 0 5.502694762071769e-07
ATM O 0 1.1032850125047844e-05
mutant O 0 5.396541746449657e-05
alleles O 0 1.4096110135142226e-05
. O 0 2.4399967060162453e-06

W474C O 0 0.0009273284231312573
amino O 0 2.4645434677950107e-05
acid O 0 9.937719369190745e-06
substitution O 0 1.0584083156572888e-06
affects O 0 1.1119975624751532e-06
early O 0 1.2177750363662199e-07
processing O 0 5.240663369932008e-08
of O 0 7.540018387430791e-09
the O 0 8.719523769684656e-09
alpha O 0 9.900156783260172e-08
- O 0 1.0351812562703344e-07
subunit O 0 6.473231195514018e-08
of O 0 5.728272078897589e-09
beta O 0 1.2876037658315909e-07
- O 0 1.5748257737868698e-06
hexosaminidase O 0 1.5465484466403723e-05
A O 0 5.911406333325431e-07
and O 0 6.460687274056909e-08
is O 0 3.968034079093741e-08
associated O 0 1.8790152012115868e-07
with O 0 7.11390214291896e-07
subacute O 1 0.9993345141410828
G B-Disease 1 0.840421199798584
( I-Disease 0 8.78158061823342e-07
M2 I-Disease 0 1.648419492994435e-05
) I-Disease 0 8.667261681694072e-07
gangliosidosis I-Disease 0 8.877376967575401e-05
. O 0 2.803143843266298e-06

Mutations O 0 0.18554086983203888
in O 0 2.735413772825268e-06
the O 0 5.911502398703306e-07
HEXA O 0 0.004105356987565756
gene O 0 9.533214324619621e-07
, O 0 2.851582614482595e-08
encoding O 0 3.1856878024427715e-08
the O 0 5.417567283672042e-09
alpha O 0 4.759697702638732e-08
- O 0 6.915155381648219e-08
subunit O 0 3.9700250198393405e-08
of O 0 4.465396941100153e-09
beta O 0 7.227666998232962e-08
- O 0 1.1422051784393261e-06
hexosaminidase O 0 8.21216690383153e-06
A O 0 5.465389563141798e-07
( O 0 3.2547962547369025e-08
Hex O 0 8.378819984500296e-07
A O 0 2.506994292161835e-07
) O 0 1.3691755285094587e-08
, O 0 7.339523211413734e-09
that O 0 7.4429706842238375e-09
abolish O 0 3.2180281550608925e-07
Hex O 0 8.189682034753787e-07
A O 0 1.330761705276018e-07
enzyme O 0 3.477468055734789e-07
activity O 0 3.3029641599569004e-07
cause O 0 0.0005377436755225062
Tay B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999953508377075
Sachs I-Disease 1 0.999998927116394
disease I-Disease 0 0.32860833406448364
( O 0 2.9812599677825347e-07
TSD B-Disease 0 0.0013891163980588317
) O 0 8.404285978258486e-08
, O 0 3.256559821807059e-08
the O 0 9.213222540438437e-08
fatal O 0 0.4295275807380676
infantile B-Disease 1 0.6457937955856323
form I-Disease 0 1.5670742641304969e-06
of I-Disease 0 1.826681454986101e-07
G I-Disease 0 0.0027400751132518053
( I-Disease 0 1.354513159412818e-07
M2 I-Disease 0 1.9127101040794514e-06
) I-Disease 0 5.3493295126827434e-08
gangliosidosis I-Disease 0 9.861718353931792e-06
, I-Disease 0 1.1084626549973109e-07
Type I-Disease 0 9.079348615159688e-07
1 I-Disease 0 9.851405593508389e-07
. O 0 1.3513613339455333e-06

Less O 0 0.004042189102619886
severe O 1 0.9884372353553772
, O 0 5.314055670169182e-05
subacute O 1 0.9955434203147888
( O 0 1.2388790310069453e-05
juvenile O 0 0.01269108708947897
- O 0 0.28135088086128235
onset O 0 0.026364605873823166
) O 0 1.4272156931838254e-06
and O 0 1.5927351341815665e-05
chronic O 1 0.9995595812797546
( O 0 8.686989758643904e-07
adult O 0 5.080637856735848e-05
- O 0 0.012499920092523098
onset O 0 0.0017018369399011135
) O 0 8.756361324913087e-08
variants O 0 2.9137027013348415e-07
are O 0 1.2237491908706488e-08
characterized O 0 4.723792983440944e-07
by O 0 5.298232963468763e-08
a O 0 8.672768672113307e-07
broad O 0 2.135390104740509e-06
spectrum O 0 1.1584009371290449e-05
of O 0 8.600373035960729e-08
clinical O 0 0.0002017006918322295
manifestations O 0 0.0002889379393309355
and O 0 5.4729889598093e-07
are O 0 3.126908865169753e-08
associated O 0 3.714974639024149e-08
with O 0 2.363017337358997e-08
residual O 0 1.3339727956918068e-05
levels O 0 3.608315424230568e-08
of O 0 5.268542935255027e-09
Hex O 0 2.1928760816081194e-06
A O 0 3.446088214786869e-07
enzyme O 0 4.978231231689279e-07
activity O 0 1.8564068682280777e-07
. O 0 6.50533195312164e-07

We O 0 1.0848201782209799e-05
identified O 0 2.5271583581343293e-06
a O 0 8.095466341728752e-07
1422 O 0 0.0002523173170629889
G O 0 0.0005725056398659945
- O 0 0.00015522979083471
- O 0 0.0003516564320307225
> O 0 9.073445653484669e-06
C O 0 4.136090581141616e-07
( O 0 7.137194835138416e-09
amino O 0 2.101286078470821e-08
acid O 0 9.441878745519716e-08
W474C O 0 2.514704817713209e-07
) O 0 3.3285818545891743e-09
substitution O 0 7.4565260632653e-09
in O 0 6.320008960614132e-09
the O 0 4.907301232037753e-09
first O 0 3.7417059672861797e-08
position O 0 8.455513267335846e-08
of O 0 6.834562693569524e-09
exon O 0 1.0682517768145772e-06
13 O 0 5.303025574221465e-08
of O 0 6.861089918430707e-09
HEXA O 0 7.30168103473261e-05
of O 0 1.7227241855266584e-08
a O 0 2.063885347070027e-07
non O 0 2.224923747462526e-07
- O 0 5.335411970008863e-06
Jewish O 0 5.880951903236564e-07
proband O 0 0.00010480589844519272
who O 0 8.436670668743318e-07
manifested O 0 1.4726706467627082e-06
a O 0 1.3374377658692538e-06
subacute O 0 0.34506943821907043
variant O 0 9.200055501423776e-05
of O 0 2.8688117481578956e-07
G B-Disease 0 0.007878703996539116
( I-Disease 0 2.3733436194106616e-07
M2 I-Disease 0 7.135956821002765e-06
) I-Disease 0 4.5720776142843533e-07
gangliosidosis I-Disease 0 7.342080061789602e-05
. O 0 2.4606958959338954e-06

On O 0 5.62290551897604e-06
the O 0 3.0660959282613476e-07
second O 0 1.7474404785389197e-06
maternally O 0 0.000437634444097057
inherited O 0 0.0003413502126932144
allele O 0 6.461534212576225e-06
, O 0 4.164417077845428e-08
we O 0 2.7758412457501436e-08
identified O 0 1.359874204354128e-07
the O 0 4.74850843090735e-08
common O 0 5.951233106316067e-06
infantile O 1 0.9998868703842163
disease O 1 0.7429653406143188
- O 0 0.020258145406842232
causing O 0 2.9264756449265406e-05
4 O 0 4.0486983721166325e-07
- O 0 4.629901013686322e-06
bp O 0 2.148285784642212e-05
insertion O 0 2.8660135740210535e-06
, O 0 3.436695408254309e-07
+ O 0 2.003807139772107e-06
TATC O 0 3.097165244980715e-05
1278 O 0 3.7163732486078516e-05
, O 0 1.5481556658869522e-07
in O 0 1.967049456652603e-07
exon O 0 1.6240526747424155e-05
11 O 0 3.8400248740799725e-06
. O 0 2.1725161332142306e-06

Pulse O 0 0.0019167416030541062
- O 0 0.0002469176542945206
chase O 0 6.225938250281615e-06
analysis O 0 3.0736669032194186e-07
using O 0 1.6681688919106819e-07
proband O 0 1.5521263776463456e-05
fibroblasts O 0 5.849243279953953e-06
revealed O 0 2.385277412031428e-06
that O 0 1.707291197305949e-08
the O 0 1.7251311490440457e-08
W474C O 0 2.902724418163416e-06
- O 0 4.6399426878451777e-07
containing O 0 5.114110734893984e-08
alpha O 0 6.271151420378374e-08
- O 0 1.339974176062242e-07
subunit O 0 7.999078377451951e-08
precursor O 0 8.40550526959305e-08
was O 0 3.8306204430682556e-08
normally O 0 4.239625184254692e-08
synthesized O 0 3.572411912955431e-07
, O 0 1.5780891260419594e-08
but O 0 6.753107850698825e-09
not O 0 3.830662453907507e-09
phosphorylated O 0 7.60902167940003e-08
or O 0 1.2940958526996837e-08
secreted O 0 1.4183336816131487e-07
, O 0 1.5172020084719406e-08
and O 0 1.4341694942743288e-08
the O 0 2.853280101078326e-08
mature O 0 6.976965210014896e-07
lysosomal O 0 3.223297198928776e-06
alpha O 0 3.3697287449285795e-07
- O 0 4.841841132474656e-07
subunit O 0 3.2616890166536905e-07
was O 0 1.7070541957764362e-07
not O 0 8.80313208995176e-08
detected O 0 2.871811147997505e-06
. O 0 1.9886060727003496e-06

When O 0 1.2667445844272152e-05
the O 0 5.986555038361985e-07
W474C O 0 1.303254521189956e-05
- O 0 1.740926677484822e-06
containing O 0 1.3705685830700531e-07
alpha O 0 1.2228946388859185e-07
- O 0 2.845986841748527e-07
subunit O 0 1.9679876572809007e-07
was O 0 2.3478732202875108e-07
transiently O 0 9.189473530568648e-06
co O 0 2.706111672523548e-06
- O 0 4.386166438052896e-06
expressed O 0 1.0839299591225426e-07
with O 0 8.774764026497905e-09
the O 0 5.569978256403374e-09
beta O 0 3.5519533980732376e-08
- O 0 1.065172980929674e-07
subunit O 0 5.1667708333980045e-08
to O 0 1.2777171320976777e-08
produce O 0 3.559834382826921e-08
Hex O 0 8.011023169274267e-07
A O 0 1.8962572312375414e-07
( O 0 2.4365538919823848e-08
alphabeta O 0 3.1307185963669326e-06
) O 0 3.0418405572163465e-08
in O 0 5.139633074691119e-08
COS O 0 2.8788701456505805e-05
- O 0 5.162797970115207e-05
7 O 0 9.340884616904077e-07
cells O 0 1.7222879478140385e-07
, O 0 6.861063273078116e-09
the O 0 5.110597278701334e-09
mature O 0 6.730992652137502e-08
alpha O 0 5.610969822100742e-08
- O 0 1.550000803263174e-07
subunit O 0 1.4711854134930036e-07
was O 0 6.509917938046783e-08
present O 0 1.0762124524887895e-08
, O 0 5.620124365890433e-09
but O 0 5.348224974000004e-09
its O 0 8.102570170365198e-09
level O 0 1.294471108082007e-08
was O 0 2.8159320208942518e-08
much O 0 2.642589969070741e-08
lower O 0 1.5136113518110506e-07
than O 0 1.623107159787196e-08
that O 0 1.099890667433101e-08
from O 0 8.89443629858988e-09
normal O 0 2.660716624802717e-08
alpha O 0 6.772485505734949e-08
- O 0 2.703733628095506e-07
subunit O 0 1.3551941435707704e-07
transfections O 0 2.0939219211868476e-06
, O 0 1.843523733668917e-08
although O 0 1.5035386269346418e-08
higher O 0 2.5041979156981142e-08
than O 0 2.109252861259847e-08
in O 0 4.426222943720859e-08
those O 0 5.3361429053211396e-08
cells O 0 5.295192408993898e-07
transfected O 0 1.2358935236989055e-05
with O 0 1.647290481798791e-08
an O 0 1.5073545966970414e-08
alpha O 0 2.4376933538405865e-07
- O 0 1.1143063147756038e-06
subunit O 0 9.639951485951315e-07
associated O 0 4.368665429410612e-07
with O 0 5.427550036074535e-07
infantile O 0 0.35002246499061584
TSD B-Disease 1 0.8968015313148499
. O 0 1.9605484339990653e-05

Furthermore O 0 0.00013754377141594887
, O 0 6.179381557558372e-07
the O 0 5.7402402831030486e-08
precursor O 0 1.3688078581708396e-07
level O 0 8.931683836976845e-09
of O 0 1.9358905589683673e-09
the O 0 1.0995298005411769e-08
W474C O 0 1.5303394320653751e-06
alpha O 0 1.6978454198124382e-07
- O 0 2.0027131597544212e-07
subunit O 0 1.1915818021179803e-07
was O 0 5.819514470317699e-08
found O 0 1.9990888944221297e-08
to O 0 3.5784736951427476e-08
accumulate O 0 8.000608886504779e-07
in O 0 2.2754669259938964e-08
comparison O 0 6.34810035649025e-08
to O 0 1.0843844044927664e-08
the O 0 7.734064055853196e-09
normal O 0 3.468111131610385e-08
alpha O 0 1.3766627660061204e-07
- O 0 2.934906149221206e-07
subunit O 0 4.336458516718267e-07
precursor O 0 7.957160050864331e-07
levels O 0 5.461768637360365e-07
. O 0 9.105710319090576e-07

We O 0 6.2879475990484934e-06
conclude O 0 5.266965672490187e-06
that O 0 1.5127181995922e-07
the O 0 1.4562132832907082e-07
1422 O 0 0.0002709992986638099
G O 0 0.005022817756980658
- O 0 0.0019288090988993645
- O 0 0.04106411337852478
> O 0 9.218049672199413e-05
C O 0 6.325652975647245e-06
mutation O 0 4.101082140550716e-07
is O 0 8.073999246960284e-09
the O 0 1.336718913336199e-08
cause O 0 2.0877796202967147e-07
of O 0 2.080345851140919e-08
Hex B-Disease 0 0.0001128620351664722
A I-Disease 0 0.0013491571880877018
enzyme I-Disease 1 0.9957243204116821
deficiency I-Disease 1 0.9993833303451538
in O 0 3.3499492246846785e-07
the O 0 7.180645411608566e-07
proband O 0 0.0010887628886848688
. O 0 4.393480139697203e-06

The O 0 9.115457942243665e-06
resulting O 0 1.1267082300037146e-05
W474C O 0 2.2380858354154043e-05
substitution O 0 1.3382951919993502e-06
clearly O 0 1.1878086070282734e-06
interferes O 0 1.7319628113909857e-06
with O 0 3.945807591776429e-08
alpha O 0 1.40873822829235e-07
- O 0 2.3591383069287986e-07
subunit O 0 7.671743418313781e-08
processing O 0 2.6444455514251786e-08
, O 0 6.466984281416899e-09
but O 0 6.425990850544849e-09
because O 0 3.7285530218866825e-09
the O 0 4.1067549361173405e-09
base O 0 3.1620785989616707e-08
substitution O 0 6.070561653359619e-08
falls O 0 9.998281029766076e-07
at O 0 7.987425831856854e-09
the O 0 4.960886812455101e-09
first O 0 2.2104316599325102e-08
position O 0 5.04001214096661e-08
of O 0 1.1818010570152637e-08
exon O 0 2.0035377019667067e-06
13 O 0 1.2438415808446734e-07
, O 0 2.2294132762112895e-08
aberrant O 0 5.250558956504392e-07
splicing O 0 8.192789209715556e-06
may O 0 1.1939880550926318e-06
also O 0 3.5969911493793916e-08
contribute O 0 4.3724373455233945e-08
to O 0 6.356581394584282e-08
Hex B-Disease 0 0.00044848595280200243
A I-Disease 0 0.032851070165634155
deficiency I-Disease 0 0.04594757780432701
in O 0 5.5894357586794285e-08
this O 0 8.26225701189287e-08
proband O 0 0.0002707340754568577
. O 0 6.579070941370446e-07
. O 0 1.1072112329202355e-06

Two O 0 4.4142023398308083e-05
frequent O 0 0.00034880571183748543
missense O 1 0.5442726612091064
mutations O 0 0.21379713714122772
in O 0 0.0005546036409214139
Pendred B-Disease 1 0.9999983310699463
syndrome I-Disease 1 0.9999998807907104
. O 0 6.42952581983991e-05

Pendred B-Disease 1 0.9999982118606567
syndrome I-Disease 1 1.0
is O 0 0.0021258662454783916
an O 1 0.5440406203269958
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.37731263041496277
by O 0 7.71842405811185e-06
early O 0 0.0005264607025310397
childhood O 1 0.9858174920082092
deafness B-Disease 1 0.9999998807907104
and O 1 0.8109337091445923
goiter B-Disease 1 0.9999997615814209
. O 0 0.0001792529074009508

A O 0 2.698239404708147e-05
century O 0 4.122117388760671e-06
after O 0 8.063904601840477e-07
its O 0 7.165965598687762e-08
recognition O 0 1.978624055709588e-07
as O 0 4.1093903746514115e-07
a O 0 0.006564117968082428
syndrome O 1 0.9999387264251709
by O 0 4.265020265847852e-07
Vaughan O 0 2.2127227566670626e-05
Pendred O 0 6.515180575661361e-05
, O 0 2.392615101598494e-07
the O 0 4.558385171549162e-07
disease O 0 0.00022851495305076241
gene O 0 1.0706332886911696e-06
( O 0 1.7214472336490871e-07
PDS O 0 0.0004904345842078328
) O 0 9.166056003095946e-08
was O 0 1.8409065205560182e-07
mapped O 0 1.841887979026069e-06
to O 0 2.613846845633816e-07
chromosome O 0 2.4129863959387876e-05
7q22 O 0 5.220260936766863e-05
- O 0 8.267190423794091e-05
q31 O 0 0.0002409757871646434
. O 0 3.457020511632436e-06

1 O 0 2.364660394960083e-05
and O 0 9.071507633962028e-07
, O 0 1.9538946105512878e-07
recently O 0 1.2156949651398463e-06
, O 0 3.90454140131169e-08
found O 0 1.568067631296799e-08
to O 0 1.5956407750650214e-08
encode O 0 4.1850486809380527e-07
a O 0 8.786992111708969e-07
putative O 0 0.00010724806634243578
sulfate O 0 0.001815127208828926
transporter O 0 0.0005948454490862787
. O 0 3.5243970160081517e-06

We O 0 1.003974011837272e-05
performed O 0 1.0356900929764379e-05
mutation O 0 4.244299816491548e-06
analysis O 0 1.0008224649027397e-07
of O 0 1.676979444198423e-08
the O 0 8.211668500734959e-08
PDS B-Disease 0 0.010594758205115795
gene O 0 1.694427169240953e-06
in O 0 4.773963269144588e-07
patients O 0 3.476492565823719e-05
from O 0 4.031344502664069e-08
14 O 0 3.70043579778212e-07
Pendred B-Disease 0 2.234402927570045e-05
families O 0 1.1632719321141849e-07
originating O 0 3.708935736312924e-08
from O 0 8.135415896504128e-09
seven O 0 4.037346457153035e-08
countries O 0 4.949998633207997e-09
and O 0 2.689031930458441e-08
identified O 0 2.8495827564256615e-07
all O 0 3.6117441482019785e-08
mutations O 0 5.282066467771074e-06
. O 0 7.001026460784487e-07

The O 0 1.2746503671223763e-05
mutations O 0 0.00014833154273219407
include O 0 1.7834989307630167e-07
three O 0 9.78132774775986e-08
single O 0 2.582286242613918e-07
base O 0 2.6116666163034097e-07
deletions O 0 1.2402517768350663e-06
, O 0 2.5403071646223907e-08
one O 0 1.9094221315185678e-08
splice O 0 2.84670272776566e-06
site O 0 8.679131155986397e-07
mutation O 0 1.4365451761477743e-06
and O 0 1.5381674245418253e-07
10 O 0 1.9833180431305664e-06
missense O 0 0.001371795660816133
mutations O 0 0.00010451755952090025
. O 0 4.205712230032077e-06

One O 0 4.578979132929817e-05
missense O 0 0.026595231145620346
mutation O 0 0.0004807300283573568
( O 0 1.3069857232039794e-06
L236P O 0 2.7683294320013374e-05
) O 0 1.0833738883775368e-07
was O 0 2.666776026671869e-07
found O 0 6.23355091988742e-08
in O 0 1.167912344612887e-08
a O 0 2.9001685675211775e-07
homozygous O 0 1.2781041505149915e-06
state O 0 1.897340240475387e-08
in O 0 7.959230607923473e-09
two O 0 3.6923061941251945e-08
consanguineous O 0 0.0001007308965199627
families O 0 2.0430137226412626e-07
and O 0 2.5631823774574514e-08
in O 0 2.159610090757269e-08
a O 0 8.371263788831129e-07
heterozygous O 0 8.079437975538895e-06
state O 0 3.7375691874785844e-08
in O 0 1.9477138124557314e-08
five O 0 3.1692639623770447e-08
additional O 0 1.4464222886090283e-07
non O 0 5.027185352446395e-07
- O 0 0.00011766266106860712
consanguineous O 0 0.001353711006231606
families O 0 7.497067599615548e-06
. O 0 3.7005381727794884e-06

Another O 0 0.00014664969057776034
missense O 0 0.34546148777008057
mutation O 0 0.0021228750701993704
( O 0 1.6425519788754173e-06
T416P O 0 3.207245754310861e-05
) O 0 1.759199079742757e-07
was O 0 2.493660247182561e-07
found O 0 5.1154568581068816e-08
in O 0 9.212780760492478e-09
a O 0 3.9326258161054284e-07
homozygous O 0 3.851166638924042e-06
state O 0 2.3242442637183558e-08
in O 0 1.1014651413177035e-08
one O 0 3.814231064325213e-08
family O 0 1.1588670645323873e-07
and O 0 1.5367591643666856e-08
in O 0 1.886579426013668e-08
a O 0 4.173136005647393e-07
heterozygous O 0 3.3122107652161503e-06
state O 0 3.2186324716576564e-08
in O 0 3.322880814948803e-08
four O 0 3.0700022080054623e-07
families O 0 7.256952017087315e-07
. O 0 1.4385124131877092e-06

Pendred B-Disease 1 0.9956681728363037
patients O 1 0.9928838014602661
in O 0 1.4292124888015678e-06
three O 0 1.8794058576077077e-07
non O 0 3.432934931879572e-07
- O 0 3.5128956369590014e-05
consanguineous O 0 0.0010407868539914489
families O 0 8.495117072016001e-07
were O 0 1.1245340658661007e-07
shown O 0 1.2537478255580936e-07
to O 0 5.3671119104592435e-08
be O 0 7.329817464096777e-08
compound O 0 2.084828338411171e-06
heterozygotes O 0 6.4311334426747635e-06
for O 0 1.5932752717162657e-07
L236P O 0 1.3629552086058538e-05
and O 0 5.917159455748333e-07
T416P O 0 9.582587517797947e-05
. O 0 3.70416069017665e-06

In O 0 5.9154485825274605e-06
total O 0 4.605125525358744e-07
, O 0 5.28192742876854e-08
one O 0 1.2378532865398029e-08
or O 0 7.53214202120489e-09
both O 0 3.0409452733692888e-09
of O 0 2.762772011166703e-09
these O 0 1.3009113786210946e-08
mutations O 0 6.774681082788447e-07
were O 0 1.8094674203439354e-08
found O 0 2.0358013941290665e-08
in O 0 7.984350069989432e-09
nine O 0 2.915144214910015e-08
of O 0 4.569538525345251e-09
the O 0 5.3397776866859203e-08
14 O 0 6.961246867831505e-07
families O 0 3.559441665856866e-07
analyzed O 0 4.329137937020278e-06
. O 0 1.7134852896560915e-06

The O 0 2.7688936370395822e-06
identification O 0 1.0618963415254257e-06
of O 0 9.298917547084784e-08
two O 0 3.087309892180201e-07
frequent O 0 4.109552173758857e-05
PDS B-Disease 1 0.8884260654449463
mutations O 0 2.003831286856439e-05
will O 0 8.04692916744898e-08
facilitate O 0 8.79329817848884e-08
the O 0 1.565014571269785e-07
molecular O 0 0.00021480311988852918
diagnosis O 1 0.9230873584747314
of O 0 7.004201324889436e-05
Pendred B-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
. O 0 4.823548442800529e-05

Insertional O 0 0.0168355330824852
mutation O 0 0.0012987717054784298
by O 0 1.8686500879994128e-06
transposable O 0 0.00019335048273205757
element O 0 2.612339130791952e-06
, O 0 3.103054666553362e-07
L1 O 0 6.121339538367465e-05
, O 0 1.1291830048776319e-07
in O 0 2.3043805086331304e-08
the O 0 1.1644961972478995e-07
DMD B-Disease 1 0.9999970197677612
gene O 0 9.979886272049043e-06
results O 0 1.9890042040060507e-06
in O 0 3.6264756886339455e-07
X B-Disease 1 0.9553391933441162
- I-Disease 1 0.9955403208732605
linked I-Disease 1 0.7813509702682495
dilated I-Disease 1 0.9983983635902405
cardiomyopathy I-Disease 1 0.9999920129776001
. O 0 8.053433703025803e-05

X B-Disease 1 0.9964780211448669
- I-Disease 1 0.998301088809967
linked I-Disease 1 0.946852445602417
dilated I-Disease 1 0.9995749592781067
cardiomyopathy I-Disease 1 0.9999985694885254
( O 0 8.083175998763181e-06
XLDCM B-Disease 0 0.0076225013472139835
) O 0 8.320263589212118e-08
is O 0 3.133051862391767e-08
a O 0 1.2562148867800715e-06
clinical O 0 0.0006868334603495896
phenotype O 0 0.007187225390225649
of O 0 3.367389211916816e-08
dystrophinopathy B-Disease 0 0.0017915008356794715
which O 0 2.0650864485105558e-07
is O 0 6.448215827958848e-08
characterized O 0 1.1382405773474602e-06
by O 0 2.7398942847867147e-07
preferential O 0 4.6699551603524014e-05
myocardial B-Disease 1 0.999868631362915
involvement I-Disease 0 8.120247912302148e-06
without O 0 1.2386153969146108e-07
any O 0 3.466331932600042e-08
overt O 0 4.145321327087004e-06
clinical O 0 0.00019777835404966027
signs O 0 0.00018378929235041142
of O 0 1.4088691386859864e-05
skeletal B-Disease 1 0.9999994039535522
myopathy I-Disease 1 1.0
. O 0 9.15791024453938e-05

To O 0 5.784604582004249e-06
date O 0 2.265421471747686e-06
, O 0 1.1693460066908301e-07
several O 0 6.68770070433311e-08
mutations O 0 1.1900775689355214e-06
in O 0 7.944809965465538e-08
the O 0 1.4965423815738177e-06
Duchenne B-Disease 1 0.9999109506607056
muscular I-Disease 1 0.9999929666519165
dystrophy I-Disease 1 0.9999915361404419
gene O 0 0.0005959850968793035
, O 0 7.450362318195403e-06
DMD O 1 0.9999942779541016
, O 0 2.0549289274640614e-06
have O 0 1.9457777966636058e-07
been O 0 1.2230880486185924e-07
identified O 0 8.612074680058868e-07
in O 0 4.945806608702696e-07
patients O 0 0.00020389883138705045
with O 0 2.079172247704264e-07
XLDCM B-Disease 0 0.4466981291770935
, O 0 5.1493966424231985e-08
but O 0 1.171730001914284e-08
a O 0 5.0913360638560334e-08
pathogenic O 0 2.331566690827458e-07
correlation O 0 7.807239654766818e-08
of O 0 5.310289985516192e-09
these O 0 3.163616923984591e-08
cardiospecific O 0 0.00472497520968318
mutations O 0 6.802101415814832e-05
in O 0 6.267283652050537e-07
DMD O 1 0.9999933242797852
with O 0 3.484792387098423e-06
the O 0 9.830936278376612e-07
XLDCM B-Disease 1 0.979430615901947
phenotype O 0 0.326273113489151
has O 0 5.826917117701669e-07
remained O 0 4.911152586828393e-07
to O 0 9.511993681599051e-08
be O 0 1.3318205560608476e-07
elucidated O 0 4.893383083981462e-05
. O 0 1.7303002550761448e-06

We O 0 1.145605438068742e-05
report O 0 1.401229724251607e-06
here O 0 4.064218117605378e-08
the O 0 9.32630417338487e-09
identification O 0 2.246744479350582e-08
of O 0 3.988040564451012e-09
a O 0 8.290735564742135e-08
unique O 0 1.029867888746594e-07
de O 0 1.6952921555457579e-07
novo O 0 1.0884375569730764e-06
L1 O 0 2.023600927714142e-06
insertion O 0 5.055773613094061e-07
in O 0 2.8884890923563944e-08
the O 0 2.7360915311192002e-08
muscle O 0 2.1083185856696218e-05
exon O 0 1.87658461072715e-05
1 O 0 7.412047011712275e-07
in O 0 6.237463594516157e-07
DMD O 1 0.9999938011169434
in O 0 2.8790479973395122e-06
three O 0 1.8156819123760215e-06
XLDCM B-Disease 1 0.9491510987281799
patients O 0 0.002226821845397353
from O 0 3.634805878505176e-08
two O 0 7.525712675260365e-08
unrelated O 0 1.964958528333227e-06
Japanese O 0 3.818256573140388e-06
families O 0 1.9480130504234694e-06
. O 0 1.624645392439561e-06

The O 0 2.2398146484192694e-06
insertion O 0 1.4327048120321706e-05
was O 0 6.294567356235348e-07
a O 0 2.0383897947340301e-07
5 O 0 2.9018644909228897e-07
- O 0 6.250299975363305e-06
truncated O 0 3.018191364390077e-06
form O 0 9.383422394648733e-08
of O 0 1.4135649095692315e-08
human O 0 5.8904944921778224e-08
L1 O 0 7.902252036728896e-06
inversely O 0 2.2494580207421677e-06
integrated O 0 5.385240910982247e-07
in O 0 3.7172856792722087e-08
the O 0 2.5175642903718654e-08
5 O 0 1.7959141018764058e-07
- O 0 1.2648516531044152e-05
untranslated O 0 0.00011250218813074753
region O 0 1.0846330411595773e-07
in O 0 1.2381130787275652e-08
the O 0 1.7891439441086732e-08
muscle O 0 1.5578147213091142e-05
exon O 0 6.052605840523029e-06
1 O 0 1.6217741460877733e-07
, O 0 2.7586663620127183e-08
which O 0 2.6441881573191495e-08
affected O 0 2.0976822057150457e-08
the O 0 3.677362414578056e-09
transcription O 0 5.517388146358826e-08
or O 0 7.650639233247603e-09
the O 0 5.7971107914056574e-09
stability O 0 3.634632506077651e-08
of O 0 4.0246352916994965e-09
the O 0 3.0815616725021755e-08
muscle O 0 1.902797339425888e-05
form O 0 8.897868042367918e-08
of O 0 1.5751600912494723e-08
dystrophin O 0 0.00015260731743182987
transcripts O 0 3.248661414545495e-06
but O 0 2.2271436250775878e-08
not O 0 4.209157911105876e-09
that O 0 1.8871288975930156e-09
of O 0 2.2085677731098485e-09
the O 0 4.8482824865914154e-08
brain O 0 0.0002751573920249939
or O 0 2.2032975266483845e-07
Purkinje O 0 0.0034275511279702187
cell O 0 0.00013581548410002142
form O 0 2.622130921281496e-07
, O 0 4.305445244767725e-08
probably O 0 1.9489164060360054e-07
due O 0 4.744181225646571e-08
to O 0 1.407704885991734e-08
its O 0 2.635120743832431e-08
unique O 0 7.735926033092255e-08
site O 0 1.0403613259768463e-07
of O 0 2.5777927348258345e-08
integration O 0 1.2230932497914182e-06
. O 0 2.3388361114484724e-06

We O 0 4.0687045839149505e-06
speculate O 0 6.972104074520757e-06
that O 0 5.047679607628197e-08
this O 0 1.6605429919991366e-08
insertion O 0 2.3723117692497908e-07
of O 0 7.344312713541967e-09
an O 0 6.34276275945922e-08
L1 O 0 4.5993467210792005e-05
sequence O 0 3.968670512222161e-07
in O 0 3.357443176810193e-07
DMD O 1 0.9999839067459106
is O 0 1.370603968098294e-07
responsible O 0 5.611162379182133e-08
for O 0 8.682317087504998e-09
some O 0 2.9658879796556903e-09
of O 0 1.7827560538918874e-09
the O 0 1.0463030442053878e-08
population O 0 1.8909997123728317e-08
of O 0 1.338155186658696e-08
Japanese O 0 1.4838368770142552e-05
patients O 0 0.0007021788042038679
with O 0 3.58653409193721e-07
XLDCM B-Disease 0 0.02944042906165123
. O 0 5.314147983881412e-07
. O 0 1.2505705626608687e-06

Severe O 1 0.9864864349365234
early O 0 0.0010256071109324694
- O 1 0.9795628786087036
onset O 1 0.9977591037750244
obesity B-Disease 1 0.9999855756759644
, O 0 0.0004506883560679853
adrenal B-Disease 1 0.999946117401123
insufficiency I-Disease 1 0.9999902248382568
and O 0 4.370293390820734e-05
red O 0 0.006923242472112179
hair O 1 0.9910548329353333
pigmentation O 1 0.9808722734451294
caused O 0 0.0038057302590459585
by O 0 3.3184837775479537e-06
POMC O 1 0.9889454245567322
mutations O 0 0.00016081056674011052
in O 0 5.57128203126922e-07
humans O 0 2.0300838059483794e-06
. O 0 1.3114167813910171e-06

Sequential O 0 0.00016288823098875582
cleavage O 0 0.0001224898878717795
of O 0 2.490128849785833e-07
the O 0 5.575019557113592e-08
precursor O 0 1.6646440315071231e-07
protein O 0 9.419968449719818e-08
pre O 0 9.306438073508616e-07
- O 0 6.458373263740214e-06
pro O 0 6.949373982934048e-06
- O 0 0.00012768075976055115
opiomelanocortin O 0 0.00020805995154660195
( O 0 1.6972317951058358e-07
POMC O 0 1.2549153325380757e-05
) O 0 3.557859074021508e-08
generates O 0 1.5080541970746708e-07
the O 0 3.1977659631365896e-08
melanocortin O 0 1.1339921911712736e-05
peptides O 0 3.898152954207035e-06
adrenocorticotrophin O 0 4.9679983931127936e-05
( O 0 1.0898235558443048e-07
ACTH O 0 1.1995019121968653e-05
) O 0 3.1794357369108184e-08
, O 0 3.5418867838643564e-08
melanocyte O 0 1.3621014659292996e-05
- O 0 1.1966216334258206e-05
stimulating O 0 5.431974386738148e-06
hormones O 0 8.565561074647121e-06
( O 0 1.5171043799000472e-07
MSH O 0 6.014707832946442e-05
) O 0 3.999209141625215e-08
alpha O 0 1.0668117056411575e-07
, O 0 9.960364977246172e-09
beta O 0 1.974122554315727e-08
and O 0 3.949683691217842e-09
gamma O 0 7.518696065744734e-08
as O 0 5.9722853329446934e-09
well O 0 1.081154366033843e-08
as O 0 8.856313904459512e-09
the O 0 2.0289245838966963e-08
opioid O 0 6.912623121024808e-06
- O 0 7.710125828452874e-06
receptor O 0 1.0888818451348925e-06
ligand O 0 1.6676135601301212e-06
beta O 0 1.270878442483081e-06
- O 0 1.3222760571807157e-05
endorphin O 0 0.00033933346276171505
. O 0 3.55702240995015e-06

While O 0 1.0694173397496343e-05
a O 0 1.9268240976089146e-06
few O 0 5.535264335776446e-07
cases O 0 3.380240798378509e-07
of O 0 2.94037477033271e-07
isolated O 0 0.0905114933848381
ACTH B-Disease 1 0.9999877214431763
deficiency I-Disease 1 0.9983571171760559
have O 0 7.890322422099416e-07
been O 0 1.049717070600309e-06
reported O 0 1.9782062736339867e-05
( O 0 3.250472673244076e-07
OMIM O 0 0.02368275634944439
201400 O 0 6.338018283713609e-05
) O 0 9.436585202138303e-08
, O 0 4.613714565948612e-08
an O 0 3.243790160922799e-07
inherited O 0 0.003954727668315172
POMC O 1 0.9379477500915527
defect O 0 0.001330086961388588
has O 0 2.552917237608199e-07
not O 0 3.033051498846362e-08
been O 0 7.104397781176885e-08
described O 0 6.29765395387949e-07
so O 0 1.857292346585382e-07
far O 0 7.542984690189769e-07
. O 0 1.1536034207892953e-06

Recent O 0 7.392719999188557e-05
studies O 0 5.623458037007367e-06
in O 0 3.277816631452879e-07
animal O 0 7.466974807357474e-07
models O 0 1.7978862842937815e-06
elucidated O 0 8.061566404649056e-06
a O 0 2.3926014591779676e-07
central O 0 5.1971831283026404e-08
role O 0 3.0961075481172884e-08
of O 0 7.613810026896317e-09
alpha O 0 4.668701194532332e-07
- O 0 8.469881322525907e-06
MSH O 0 0.00043538250611163676
in O 0 2.40887469971085e-08
the O 0 5.069859199124949e-09
regulation O 0 2.5938069470043956e-08
of O 0 7.293764259230784e-09
food O 0 6.432553334434488e-08
intake O 0 1.0440751339046983e-06
by O 0 1.2451228492693645e-08
activation O 0 4.2752656526090504e-08
of O 0 6.944521846463658e-09
the O 0 7.753030928370208e-08
brain O 0 6.210365972947329e-05
melanocortin O 0 1.7176544133690186e-05
- O 0 8.078491191554349e-06
4 O 0 5.456296321426635e-07
- O 0 3.54091184817662e-06
receptor O 0 1.0325906032448984e-06
( O 0 7.718166727954667e-08
MC4 O 0 4.27171507908497e-05
- O 0 1.9617771613411605e-05
R O 0 4.543459726846777e-05
; O 0 9.190459593355627e-08
refs O 0 1.918795987876365e-06
3 O 0 1.5588419444156898e-07
- O 0 1.6000833511498058e-06
5 O 0 1.1011841394292787e-07
) O 0 7.86425324861284e-09
and O 0 4.865677194487716e-09
the O 0 7.801832957454735e-09
linkage O 0 4.5275680804479634e-07
of O 0 4.563722555417371e-08
human O 0 8.776408321864437e-06
obesity B-Disease 1 0.9996663331985474
to O 0 3.6369597182783764e-06
chromosome O 0 4.227614772389643e-05
2 O 0 2.1491119639449607e-07
in O 0 3.2359416479721403e-08
close O 0 8.113538285670074e-08
proximity O 0 2.0323955141066108e-07
to O 0 1.3483834493399627e-07
the O 0 2.0066649142336246e-07
POMC O 0 0.002087906701490283
locus O 0 5.781907930213492e-06
, O 0 3.267186343691719e-08
led O 0 7.887450692578568e-08
to O 0 4.320219204601017e-08
the O 0 2.6672509534364508e-08
proposal O 0 3.510827184527443e-07
of O 0 8.009394925068136e-09
an O 0 8.703643317176102e-08
association O 0 6.734177304679179e-08
of O 0 4.059275582335431e-08
POMC O 0 0.024313421919941902
with O 0 4.053174507134827e-06
human O 0 4.8421916289953515e-05
obesity B-Disease 1 0.9994316697120667
. O 0 1.6481775674037635e-05

The O 0 2.3692011836828897e-06
dual O 0 4.901428837911226e-06
role O 0 1.793582811160377e-07
of O 0 2.914560504052588e-08
alpha O 0 8.28935014851595e-07
- O 0 2.8096765163354576e-05
MSH O 0 0.0005774774472229183
in O 0 6.254702356045527e-08
regulating O 0 2.212688912095473e-07
food O 0 2.3569209872675856e-07
intake O 0 2.1000696506234817e-06
and O 0 1.0141468465008074e-07
influencing O 0 2.8555480184877524e-06
hair O 1 0.8604999780654907
pigmentation O 1 0.961200475692749
predicts O 0 0.12321595102548599
that O 0 3.7610899994433566e-07
the O 0 4.0273064882967446e-07
phenotype O 0 0.20269005000591278
associated O 0 3.815308673438267e-07
with O 0 1.0064754718541735e-07
a O 0 1.0186761755903717e-05
defect O 0 0.01546055544167757
in O 0 1.0615884775688755e-06
POMC O 0 0.05766643211245537
function O 0 4.0681430846234434e-07
would O 0 1.6316094786361646e-07
include O 0 6.195561468302913e-07
obesity B-Disease 1 0.9993374943733215
, O 0 6.88920636093826e-07
alteration O 0 2.043865060841199e-05
in O 0 4.73681257062708e-06
pigmentation O 1 0.9708576202392578
and O 0 0.1297723948955536
ACTH B-Disease 1 0.9999769926071167
deficiency I-Disease 1 0.9985900521278381
. O 0 9.052512723428663e-06

The O 0 6.3994475567596965e-06
observation O 0 1.4783649930905085e-05
of O 0 2.7884848918802163e-07
these O 0 7.469096772183548e-07
symptoms O 0 0.022210365161299706
in O 0 1.0441522846349471e-07
two O 0 1.5486635618344735e-07
probands O 0 0.00029843096854165196
prompted O 0 4.2292494981666096e-06
us O 0 1.7719789013881382e-07
to O 0 3.753442712195465e-08
search O 0 1.3834235801368777e-07
for O 0 9.226412345242352e-08
mutations O 0 2.0872232653346146e-06
within O 0 5.831792648791634e-08
their O 0 3.5984120927423646e-07
POMC O 0 0.03544928878545761
genes O 0 1.0341907909605652e-05
. O 0 4.307837571104756e-06

Patient O 1 0.6972002983093262
1 O 0 1.4502508747682441e-05
was O 0 1.162896296591498e-06
found O 0 7.422530501344227e-08
to O 0 1.3538127063839056e-08
be O 0 4.7890544863093965e-09
a O 0 5.488125864872018e-08
compound O 0 7.023978696452104e-07
heterozygote O 0 4.08303230869933e-06
for O 0 2.137636023746836e-08
two O 0 1.066990762410569e-07
mutations O 0 1.1267997024333454e-06
in O 0 2.4318598690342697e-08
exon O 0 1.020139166030276e-06
3 O 0 1.495915995519681e-07
( O 0 1.2306730745592631e-08
G7013T O 0 1.272941631214053e-06
, O 0 2.9374309207241822e-08
C7133delta O 0 1.6217289839914883e-06
) O 0 5.056956631221965e-09
which O 0 5.8267644043041855e-09
interfere O 0 4.967706956904294e-08
with O 0 1.303812791064729e-08
appropriate O 0 3.525609315602196e-08
synthesis O 0 1.027864229286024e-07
of O 0 3.147852822849018e-08
ACTH O 0 6.199655763339251e-05
and O 0 1.792628552266251e-07
alpha O 0 4.370129317976534e-06
- O 0 9.17815777938813e-05
MSH O 0 0.005971627775579691
. O 0 5.807698926219018e-06

Patient O 1 0.8517667055130005
2 O 0 1.5409734260174446e-05
was O 0 9.460740670874657e-07
homozygous O 0 2.198703896283405e-06
for O 0 4.34104272528657e-08
a O 0 6.86194312038424e-07
mutation O 0 2.7895750918105477e-06
in O 0 1.3136946108716074e-07
exon O 0 4.812640781892696e-06
2 O 0 5.435501293504785e-07
( O 0 6.90911718947973e-08
C3804A O 0 5.208186394156655e-06
) O 0 6.636529548131875e-08
which O 0 2.3034121454656997e-07
abolishes O 0 0.0004185440484434366
POMC O 0 0.01044132187962532
translation O 0 1.022755623125704e-05
. O 0 2.147396116924938e-06

These O 0 1.5446572433575056e-05
findings O 0 2.2989423086983152e-05
represent O 0 1.5715700385499076e-07
the O 0 1.80153989504106e-08
first O 0 5.144576320503802e-08
examples O 0 3.7013457188095344e-08
of O 0 1.4665201497621183e-08
a O 0 0.00016638649685773998
genetic B-Disease 1 0.9992503523826599
defect I-Disease 1 0.9996753931045532
within O 0 9.3231946607375e-08
the O 0 1.1649460418539093e-07
POMC O 0 0.008637760765850544
gene O 0 6.300261361502635e-07
and O 0 2.922643460578911e-08
define O 0 3.38967993229744e-07
a O 0 5.578714876719459e-07
new O 0 3.910428858944215e-06
monogenic B-Disease 1 0.9837357401847839
endocrine I-Disease 1 0.9950442314147949
disorder I-Disease 1 0.9458397030830383
resulting O 0 5.89674982620636e-06
in O 0 4.6275516751848045e-07
early O 0 1.3692711036128458e-05
- O 1 0.9179732799530029
onset O 1 0.9984391331672668
obesity B-Disease 1 0.9999934434890747
, O 0 0.002377137541770935
adrenal B-Disease 1 0.9999563694000244
insufficiency I-Disease 1 0.9999860525131226
and O 0 2.7083373424829915e-05
red O 0 0.0009491374948993325
hair O 1 0.9525558948516846
pigmentation O 0 0.485481321811676
. O 0 1.8071448266709922e-06
. O 0 2.024656623689225e-06

A O 0 0.00010700167331378907
European O 0 2.1118625227245502e-05
multicenter O 1 0.5671555995941162
study O 0 9.981798939406872e-06
of O 0 2.2130022898636525e-06
phenylalanine B-Disease 1 0.9999822378158569
hydroxylase I-Disease 1 0.9999822378158569
deficiency I-Disease 1 0.999994158744812
: O 0 8.9985780959978e-07
classification O 0 3.781302382321883e-07
of O 0 1.6687216941591032e-08
105 O 0 1.3909696008340688e-06
mutations O 0 4.793471362063428e-06
and O 0 3.3828392531631835e-08
a O 0 1.7890897652250715e-07
general O 0 1.843531265421916e-07
system O 0 1.753964085082771e-07
for O 0 9.34138597585843e-08
genotype O 0 5.6992252211784944e-05
- O 0 1.1616844858508557e-05
based O 0 6.630443181165901e-07
prediction O 0 3.934215783374384e-06
of O 0 3.1645015496906126e-07
metabolic O 0 0.11046595871448517
phenotype O 0 0.17133808135986328
. O 0 5.14641988047515e-06

Phenylketonuria B-Disease 1 0.9991201758384705
( O 0 0.0006431051879189909
PKU B-Disease 1 0.9138732552528381
) O 0 6.851899797766237e-06
and O 0 1.345448436040897e-05
mild B-Disease 1 0.9994857311248779
hyperphenylalaninemia I-Disease 1 0.9999990463256836
( O 0 5.586781117017381e-05
MHP B-Disease 1 0.9999922513961792
) O 0 1.5292044963644003e-06
are O 0 6.224937010301801e-07
allelic B-Disease 1 0.9315058588981628
disorders I-Disease 1 0.999736487865448
caused O 0 0.0003886781050823629
by O 0 1.2571016441143001e-06
mutations O 0 1.611312836757861e-05
in O 0 4.016316879074111e-08
the O 0 6.254619222545443e-08
gene O 0 9.17313684567489e-07
encoding O 0 2.667406533873873e-06
phenylalanine O 0 0.0002871742472052574
hydroxylase O 0 0.0022571878507733345
( O 0 2.6563411665847525e-06
PAH O 0 0.0006713670445606112
) O 0 1.2625863519133418e-06
. O 0 2.019760131588555e-06

Previous O 0 0.00010375562851550058
studies O 0 9.325547580374405e-06
have O 0 3.8881330510776024e-07
suggested O 0 4.515162856932875e-07
that O 0 2.944661758874645e-08
the O 0 2.531088938440007e-08
highly O 0 4.209987594094855e-07
variable O 0 0.00011462548718554899
metabolic O 0 0.1896507292985916
phenotypes O 0 0.021286090835928917
of O 0 1.4012874999025371e-05
PAH B-Disease 1 0.9999886751174927
deficiency I-Disease 1 0.999367892742157
correlate O 0 0.0001348911173408851
with O 0 3.710456076078117e-05
PAH O 1 0.997904896736145
genotypes O 0 0.006455321796238422
. O 0 9.468960342928767e-06

We O 0 8.252385669038631e-06
identified O 0 5.930366569373291e-06
both O 0 4.683386123360833e-07
causative O 0 1.44289251693408e-05
mutations O 0 1.8596243535284884e-05
in O 0 6.877666010041139e-07
686 O 0 0.4028494954109192
patients O 0 0.20886188745498657
from O 0 2.0413231993643421e-07
seven O 0 7.173212566158327e-07
European O 0 6.812881565565476e-07
centers O 0 1.1789607015089132e-06
. O 0 2.387505446677096e-06

On O 0 3.695653731483617e-06
the O 0 1.1641319730415489e-07
basis O 0 3.0556158492345276e-08
of O 0 6.506502003844616e-09
the O 0 2.1697504237749854e-08
phenotypic O 0 5.203499767958419e-06
characteristics O 0 1.585441964380152e-07
of O 0 2.1715720777137903e-08
297 O 0 1.3323352504812647e-05
functionally O 0 0.0010775297414511442
hemizygous O 1 0.7331334352493286
patients O 0 0.003377424320206046
, O 0 2.4507368578952082e-08
105 O 0 3.5438532108855725e-08
of O 0 3.536956949545811e-09
the O 0 2.2778204211704178e-08
mutations O 0 9.072546163224615e-07
were O 0 2.560973477727657e-08
assigned O 0 4.4789359776586934e-08
to O 0 1.1151229273309582e-08
one O 0 9.691738078743128e-09
of O 0 8.623760372472589e-09
four O 0 1.253188202099409e-07
arbitrary O 0 1.2879079804406501e-05
phenotype O 0 0.07397235184907913
categories O 0 3.246047754146275e-06
. O 0 1.7308201449850458e-06

We O 0 4.058013018948259e-06
proposed O 0 1.7449642655265052e-06
and O 0 2.1110120940193156e-07
tested O 0 9.190579817186517e-07
a O 0 1.4154244354358525e-07
simple O 0 3.0200925493772957e-07
model O 0 4.5435851347974676e-07
for O 0 2.0701534708678082e-08
correlation O 0 2.3746838451188523e-07
between O 0 1.571036563063899e-07
genotype O 0 3.11765652440954e-05
and O 0 3.8811606373201357e-07
phenotypic O 0 6.426467007258907e-05
outcome O 0 9.763945854501799e-06
. O 0 7.114103937055916e-06

The O 0 1.5521292880293913e-05
observed O 0 9.18795631150715e-05
phenotype O 0 0.004176778253167868
matched O 0 5.676542059518397e-06
the O 0 2.67667473963229e-07
predicted O 0 6.521322939079255e-05
phenotype O 0 0.00048316881293430924
in O 0 1.631886590303111e-07
79 O 0 6.532719908136642e-06
% O 0 2.458414982697832e-08
of O 0 2.0334525174803275e-09
the O 0 3.169469664499047e-08
cases O 0 1.4748421790500288e-06
, O 0 7.445927252547335e-08
and O 0 3.0511198900740055e-08
in O 0 1.798587234702609e-08
only O 0 1.9521245064879622e-08
5 O 0 2.651890618210473e-08
of O 0 1.0632158264911595e-08
184 O 0 9.823738946579397e-05
patients O 0 0.022101646289229393
was O 0 3.839581665943115e-07
the O 0 3.7477484227110835e-08
observed O 0 1.4532348586726584e-06
phenotype O 0 4.444720616447739e-05
more O 0 1.379016900671104e-08
than O 0 1.0683669948718943e-08
one O 0 1.0904281921852998e-08
category O 0 2.775873042537569e-08
away O 0 3.9775894578042426e-08
from O 0 1.3369535700746837e-08
that O 0 1.301165042377761e-07
expected O 0 2.357063067393028e-06
. O 0 1.2437103578122333e-06

Among O 0 1.1304990039207041e-05
the O 0 4.929358397021133e-07
seven O 0 3.8586188111366937e-07
contributing O 0 3.090768530000787e-07
centers O 0 8.190254163764621e-08
, O 0 2.05580708012576e-08
the O 0 1.000438487608335e-08
proportion O 0 1.8402253942895186e-07
of O 0 5.103859379573805e-08
patients O 0 0.00037611922016367316
for O 0 9.559008873338826e-08
whom O 0 1.8708325342231547e-06
the O 0 5.4869953913794234e-08
observed O 0 2.1234552605164936e-06
phenotype O 0 5.970944039290771e-05
did O 0 8.683430507971934e-08
not O 0 7.507287236308002e-09
match O 0 4.969886902017606e-08
the O 0 2.7146802139554893e-08
predicted O 0 3.5760585888056085e-05
phenotype O 0 9.968248923541978e-05
was O 0 1.0148337281634667e-07
4 O 0 7.884276698177928e-08
% O 0 3.7654750428828265e-08
- O 0 6.0470956668723375e-06
23 O 0 7.0819378379383124e-06
% O 0 8.866356893122429e-08
( O 0 4.38667946411897e-08
P O 0 4.913897100777831e-06
< O 0 4.0601821638119873e-07
. O 0 2.6657556162490437e-08
0001 O 0 6.786100357203395e-07
) O 0 9.808750256468102e-09
, O 0 7.245331445915326e-09
suggesting O 0 7.251252043261047e-08
that O 0 8.617906388508345e-09
differences O 0 7.06890261881199e-08
in O 0 8.735904444279186e-09
methods O 0 2.0645147813525e-08
used O 0 4.597937319772427e-08
for O 0 5.270083036634787e-08
mutation O 0 2.2123922462924384e-06
detection O 0 3.12061638396699e-06
or O 0 6.336049409583211e-06
phenotype O 1 0.9813171625137329
classification O 0 0.00012021233123959973
may O 0 3.8089751797087956e-06
account O 0 8.543900520407988e-08
for O 0 1.257039716762165e-08
a O 0 2.266713039489332e-07
considerable O 0 9.836253411776852e-07
proportion O 0 4.0102361253957497e-07
of O 0 7.45195123386111e-08
genotype O 0 0.0018067591590806842
- O 0 0.075596883893013
phenotype O 0 0.12601590156555176
inconsistencies O 0 0.00011510666081449017
. O 0 1.0993978321494069e-05

Our O 0 1.8301043382962234e-05
data O 0 2.6900893317360897e-06
indicate O 0 1.4319302863441408e-06
that O 0 1.475440001286188e-07
the O 0 2.654522859302233e-07
PAH O 1 0.508388876914978
- O 0 0.03646848723292351
mutation O 0 8.453183545498177e-05
genotype O 0 1.034081378747942e-05
is O 0 1.2739039156883791e-08
the O 0 3.034774653798422e-09
main O 0 1.8677322799476315e-08
determinant O 0 2.1440104092107504e-07
of O 0 6.813869646293824e-08
metabolic O 0 0.04484042897820473
phenotype O 0 0.02957921475172043
in O 0 4.873714374298288e-07
most O 0 8.837164386932272e-06
patients O 1 0.7909691333770752
with O 0 0.3991163671016693
PAH B-Disease 1 0.9999982118606567
deficiency I-Disease 1 0.9995405673980713
. O 0 7.940763680380769e-06

In O 0 6.714740720781265e-06
the O 0 4.068515693234076e-07
present O 0 2.3424249206982495e-07
study O 0 2.0826452384881122e-07
, O 0 2.764454976045272e-08
the O 0 2.7451559247992918e-08
classification O 0 1.1439446723215951e-07
of O 0 1.938799698564253e-08
105 O 0 5.017199509893544e-05
PAH O 1 0.9997435212135315
mutations O 0 0.00015543420158792287
may O 0 1.713032986572216e-07
allow O 0 1.976462016273217e-08
the O 0 1.272109528827059e-08
prediction O 0 5.368288498175389e-07
of O 0 4.6800616715358956e-09
the O 0 6.803350771633632e-08
biochemical O 0 0.0001765899796737358
phenotype O 0 0.005234855227172375
in O 0 1.9490036606839567e-07
> O 0 2.397261368969339e-06
10 O 0 7.495170706306453e-08
, O 0 4.245653784096248e-08
000 O 0 2.984719174037309e-07
genotypes O 0 4.161581728112651e-06
, O 0 5.061031416175865e-08
which O 0 7.681479985421902e-08
may O 0 1.6848703410232702e-07
be O 0 5.752578857709523e-09
useful O 0 2.4018413924409288e-08
for O 0 6.187339529617475e-09
the O 0 2.319010405926747e-08
management O 0 1.4587958219181019e-07
of O 0 5.912928813245344e-08
hyperphenylalaninemia B-Disease 1 0.9997751116752625
in O 0 3.148437463096343e-05
newborns O 1 0.5318349599838257
. O 0 7.198141702247085e-06

Somatic O 0 0.004723311401903629
instability O 0 0.00044981492101214826
of O 0 1.2470096635297523e-06
the O 0 1.2921345842187293e-06
CTG O 0 0.0005932435160502791
repeat O 0 0.00010223373828921467
in O 0 5.659038606609101e-07
mice O 0 1.6076353858807124e-05
transgenic O 0 2.5978577014029725e-06
for O 0 2.0922662713473983e-07
the O 0 9.72483121586265e-06
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
region O 0 6.668058631476015e-05
is O 0 9.654801260694512e-07
age O 0 6.539767696267518e-07
dependent O 0 2.1902853575284098e-07
but O 0 2.440637736356166e-08
not O 0 1.3906386264750381e-08
correlated O 0 1.0319639898170863e-07
to O 0 8.930116202066074e-09
the O 0 8.69394956026781e-09
relative O 0 1.6908325051190332e-07
intertissue O 0 4.9393725021218415e-06
transcription O 0 5.672926022270985e-07
levels O 0 1.7697918508474686e-07
and O 0 3.9715592947686673e-07
proliferative O 0 0.2519966661930084
capacities O 0 5.254087227513082e-05
. O 0 4.06547769671306e-06

A O 0 0.00010932151781162247
( O 0 4.24885638494743e-06
CTG O 0 8.091908239293844e-05
) O 0 2.2302432967080676e-07
nexpansion O 0 9.869198947853874e-06
in O 0 4.4759300266150603e-08
the O 0 1.757405598823425e-08
3 O 0 4.652855238873599e-07
- O 0 0.00011484026617836207
untranslated O 0 0.0026303690392524004
region O 0 6.423701393032388e-07
( O 0 6.711839972695088e-08
UTR O 0 9.740842870087363e-06
) O 0 1.3344924276736947e-08
of O 0 6.409440977961367e-09
the O 0 1.947884982200776e-07
DM O 1 0.9999977350234985
protein O 0 5.835892807226628e-06
kinase O 0 2.767372961898218e-06
gene O 0 2.0887196683361253e-07
( O 0 3.3386868381057866e-08
DMPK O 0 7.156565970944939e-06
) O 0 2.0669652656124526e-08
is O 0 1.8607133611681093e-08
responsible O 0 2.9436657200676564e-07
for O 0 1.7923156292454223e-06
causing O 1 0.8526819348335266
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 0 0.029061824083328247
DM B-Disease 1 0.9999991655349731
) O 0 1.7014783225022256e-05
. O 0 4.630404419003753e-06

Major O 0 7.688934420002624e-05
instability O 0 0.00011995424574706703
, O 0 5.663071647177276e-07
with O 0 7.326379147798434e-08
very O 0 6.067401869813693e-08
large O 0 6.500822991029054e-08
expansions O 0 5.20195442277327e-07
between O 0 3.169336437736092e-08
generations O 0 1.1595956550536357e-07
and O 0 2.245545083212619e-08
high O 0 1.13608848550939e-07
levels O 0 3.5007559517907794e-08
of O 0 1.2462014531422483e-08
somatic O 0 5.98821588937426e-06
mosaicism O 0 0.005293527152389288
, O 0 1.597404519770862e-07
is O 0 5.6241809431867296e-08
observed O 0 6.672398171758687e-07
in O 0 1.6060702137110638e-06
patients O 0 0.003984952811151743
. O 0 4.701806574303191e-06

There O 0 6.532021870953031e-06
is O 0 2.184669369853509e-07
a O 0 3.0726292266081145e-07
good O 0 2.8319300326984376e-07
correlation O 0 2.153403926286046e-07
between O 0 3.447724594707324e-08
repeat O 0 2.9610141609737184e-06
size O 0 5.214778866502456e-07
( O 0 1.1346165784686946e-08
at O 0 1.3037977808494361e-08
least O 0 3.489410005386162e-08
in O 0 3.9496327985943935e-08
leucocytes O 0 7.973973697517067e-05
) O 0 8.871990075931535e-08
, O 0 1.6776967015630362e-07
clinical O 0 4.154215275775641e-05
severity O 0 0.005086827557533979
and O 0 8.710416636859009e-07
age O 0 1.1735393172784825e-06
of O 0 1.5762847738187702e-07
onset O 0 0.0010148149449378252
. O 0 7.868344255257398e-06

The O 0 1.8228567569167353e-05
trinucleotide O 0 0.0032847216352820396
repeat O 0 0.000523278140462935
instability O 0 4.581198300002143e-05
mechanisms O 0 5.3187332014204e-06
involved O 0 1.9341439383424586e-06
in O 0 4.5628967200173065e-06
DM B-Disease 1 0.9999996423721313
and O 0 6.561059308296535e-06
other O 0 3.3492369766463526e-07
human O 0 7.27722654119134e-05
genetic B-Disease 1 0.9999544620513916
diseases I-Disease 1 0.9999445676803589
are O 0 1.331296402895532e-06
unknown O 0 7.94414972915547e-06
. O 0 1.837883814914676e-06

We O 0 1.6267529645119794e-05
studied O 0 8.204635378206149e-06
somatic O 0 5.581164077739231e-05
instability O 0 9.19476860872237e-06
by O 0 1.0813961637268221e-07
measuring O 0 9.50549804201728e-07
the O 0 7.012246783233422e-08
CTG O 0 7.0272566517815e-05
repeat O 0 7.637630915269256e-06
length O 0 1.3990810430186684e-06
at O 0 2.7497305765677993e-08
several O 0 3.24089555192586e-08
ages O 0 2.470545439337002e-07
in O 0 7.868424134471752e-09
various O 0 8.270451878900076e-09
tissues O 0 3.118076961072802e-07
of O 0 9.658521094024763e-09
transgenic O 0 6.930042218300514e-06
mice O 0 4.8025092837633565e-05
carrying O 0 2.99262296721281e-07
a O 0 1.841471828356589e-07
( O 0 4.214582816075563e-08
CTG O 0 4.695170446211705e-06
) O 0 3.9835875043081614e-08
55expansion O 0 2.5429503693885636e-06
surrounded O 0 2.8395615458975954e-07
by O 0 3.725512343066839e-08
45 O 0 1.2455342357498012e-07
kb O 0 1.4861005865896004e-06
of O 0 1.165282270676471e-08
the O 0 8.280778018843193e-08
human O 0 2.870335265470203e-06
DM B-Disease 1 0.9999986886978149
region O 0 2.6778391202242346e-06
, O 0 5.677044967455913e-08
using O 0 3.343421539625524e-08
small O 0 7.684338498847865e-08
- O 0 9.197838153340854e-06
pool O 0 5.312345820129849e-06
PCR O 0 0.00011265720968367532
. O 0 3.254329840274295e-06

These O 0 2.0222376406309195e-05
mice O 0 0.0014333731960505247
have O 0 3.335317160235718e-07
been O 0 8.371473114721084e-08
shown O 0 1.7333196922209027e-07
to O 0 5.621864218596784e-08
reproduce O 0 2.599312210804783e-06
the O 0 2.9434431780828163e-08
intergenerational O 0 2.7677872367348755e-06
and O 0 9.957842195262856e-08
somatic O 0 3.799473233812023e-06
instability O 0 6.26806638592825e-07
of O 0 8.64197158279012e-09
the O 0 2.0113430920787323e-08
55 O 0 4.5084675548423547e-07
CTG O 0 1.5284611436072737e-05
repeat O 0 6.211645086295903e-06
suggesting O 0 8.991338518171688e-07
that O 0 3.727971531475305e-08
surrounding O 0 9.92047688441744e-08
sequences O 0 9.876600159941518e-08
and O 0 1.6965788773859458e-08
the O 0 1.696261797690113e-08
chromatin O 0 6.063098680897383e-07
environment O 0 4.249640142006683e-07
are O 0 1.7015045372659188e-08
involved O 0 9.520742594304465e-08
in O 0 2.651873671766225e-07
instability O 0 1.3314843272382859e-05
mechanisms O 0 1.3015590411669109e-05
. O 0 4.713888301921543e-06

As O 0 9.137224878941197e-06
observed O 0 3.6370222460391233e-06
in O 0 6.47335482995004e-08
some O 0 8.238616899802764e-09
of O 0 6.290508558493002e-09
the O 0 9.238686260459872e-08
tissues O 0 3.663838651846163e-05
of O 0 2.9917978281446267e-06
DM B-Disease 1 1.0
patients O 1 0.9999693632125854
, O 0 2.9469973128470883e-07
there O 0 1.8539823898322538e-08
is O 0 8.143380192393579e-09
a O 0 4.9757293396623936e-08
tendency O 0 4.357750640338054e-07
for O 0 4.1525119343077677e-08
repeat O 0 4.289865046303021e-06
length O 0 1.5219154647638788e-06
and O 0 6.027089227700344e-08
somatic O 0 3.392746975805494e-06
mosaicism O 0 0.0001555732887936756
to O 0 1.0706194331078223e-07
increase O 0 6.687101006264129e-08
with O 0 1.9753127133981252e-08
the O 0 2.59724757256663e-08
age O 0 7.45542010349709e-08
of O 0 6.157283571894823e-09
the O 0 8.085422109616047e-08
mouse O 0 1.901636460388545e-05
. O 0 2.03860486180929e-06

Furthermore O 0 6.4520922023803e-05
, O 0 7.021949386398774e-07
we O 0 9.689967583881298e-08
observed O 0 2.0535543399091694e-07
no O 0 3.006854853992991e-08
correlation O 0 3.786216140611032e-08
between O 0 9.2197067758093e-09
the O 0 1.867547183564966e-08
somatic O 0 3.4428601793479174e-05
mutation O 0 1.816006624721922e-05
rate O 0 3.394153509361786e-07
and O 0 9.460175220965539e-08
tissue O 0 1.8048946003546007e-05
proliferation O 0 2.2466047084890306e-06
capacity O 0 3.431145387366996e-06
. O 0 1.3283363387017744e-06

The O 0 1.1147931218147278e-05
somatic O 0 0.0004541154485195875
mutation O 0 0.0009495083359070122
rates O 0 2.1809316876897356e-06
in O 0 4.1523847471580666e-08
different O 0 3.410802307257654e-08
tissues O 0 2.68558801508334e-06
were O 0 7.2510722759489e-08
also O 0 7.742863772364217e-08
not O 0 2.0111167842173927e-08
correlated O 0 1.5028969357899769e-07
to O 0 1.020403939122616e-08
the O 0 1.0220127855120609e-08
relative O 0 2.1533298877329798e-07
inter O 0 5.21605159065075e-07
- O 0 7.61042902013287e-05
tissue O 0 3.3906686439877376e-05
difference O 0 1.255851458381585e-07
in O 0 1.0858621557474635e-08
transcriptional O 0 3.188302173384727e-07
levels O 0 5.218539911311382e-08
of O 0 2.4973043633025327e-09
the O 0 6.416902564865268e-09
three O 0 2.9925114830575694e-08
genes O 0 1.5724666013738897e-07
( O 0 4.4697276990746104e-08
DMAHP O 0 1.518410317657981e-05
, O 0 1.6923941359436867e-07
DMPK O 0 4.724144673673436e-05
and O 0 1.980179575866714e-07
59 O 0 1.6350377336493693e-06
) O 0 3.910056278755292e-08
surrounding O 0 1.3840582369084586e-07
the O 0 8.326136935465911e-08
repeat O 0 1.418482861481607e-05
. O 0 6.528631502078497e-07
. O 0 1.391909222547838e-06

A O 0 0.00028931224369443953
novel O 0 0.00037363424780778587
missense O 0 0.28210604190826416
mutation O 0 0.010539256036281586
in O 0 1.1663978511933237e-05
patients O 0 0.002063692081719637
from O 0 8.799673878456815e-08
a O 0 2.44361058321374e-06
retinoblastoma B-Disease 0 0.01608590967953205
pedigree O 0 7.508671114919707e-05
showing O 0 5.653203970723553e-06
only O 0 2.1444235187573213e-07
mild O 0 0.0006001204019412398
expression O 0 6.970720392018848e-07
of O 0 5.412292836126653e-08
the O 0 2.5026945422723657e-06
tumor B-Disease 1 0.6906933784484863
phenotype O 0 0.02382330410182476
. O 0 6.352343007165473e-06

We O 0 2.6723694190877723e-06
have O 0 2.415542041944718e-07
used O 0 9.992031380079425e-08
single O 0 2.819544420162856e-07
strand O 0 2.658515541043016e-06
conformation O 0 1.6110187743834103e-06
polymorphism O 0 1.0912751349678729e-05
analysis O 0 1.8197576423517603e-07
to O 0 5.68410918333484e-08
study O 0 1.0085335588883027e-07
the O 0 3.0780547888298315e-08
27 O 0 5.916606369282817e-07
exons O 0 5.235548314885818e-07
of O 0 1.1743702010846846e-08
the O 0 8.773664461614317e-08
RB1 O 0 0.00023394814343191683
gene O 0 4.5416314264912216e-07
in O 0 6.15604136555703e-08
individuals O 0 1.5009025133849718e-08
from O 0 2.0905565278894755e-08
a O 0 6.273328949646384e-07
family O 0 2.9752266073046485e-06
showing O 0 1.6132717064465396e-05
mild O 0 0.020159216597676277
expression O 0 1.5700226185799693e-06
of O 0 8.246292537705813e-08
the O 0 1.6918532992349355e-06
retinoblastoma B-Disease 1 0.9084811806678772
phenotype O 1 0.6640608310699463
. O 0 9.458779459237121e-06

In O 0 6.434293027268723e-06
this O 0 4.3615466438495787e-07
family O 0 7.503223855565011e-07
affected O 0 1.432832874570522e-07
individuals O 0 3.874540155379691e-08
developed O 0 1.5605806993335136e-06
unilateral B-Disease 0 0.36612942814826965
tumors I-Disease 1 0.9999995231628418
and O 0 1.092207867259276e-06
, O 0 4.828579136528788e-08
as O 0 1.1911472697079262e-08
a O 0 8.330378875598399e-08
result O 0 6.187767098708719e-08
of O 0 1.1079929862489735e-08
linkage O 0 3.361638164278702e-06
analysis O 0 1.0831874988070922e-06
, O 0 3.971438218286494e-07
unaffected O 0 3.531925176503137e-05
mutation O 0 5.800724920845823e-06
carriers O 0 5.480206937136245e-07
were O 0 4.708141787546083e-08
also O 0 6.618680004066846e-08
identified O 0 9.439860804150157e-08
within O 0 2.0293386526759605e-08
the O 0 1.2578028929510765e-07
pedigree O 0 4.561589230434038e-05
. O 0 5.180555035622092e-06

A O 0 2.551689431129489e-05
single O 0 2.9709058253502008e-06
band O 0 1.6146425423357869e-06
shift O 0 1.0086929478347884e-06
using O 0 3.2517408499188605e-07
SSCP O 0 9.572824637871236e-05
was O 0 9.479815048507589e-07
identified O 0 2.5198491471201123e-07
in O 0 4.3193374210659385e-08
exon O 0 3.0618989512731787e-06
21 O 0 3.257424054936564e-07
which O 0 3.0715739285369636e-08
resulted O 0 1.7758885917373846e-07
in O 0 3.369888545989852e-08
a O 0 8.271692308881029e-07
missense O 0 8.034610073082149e-05
mutation O 0 9.06812545053981e-07
converting O 0 1.8865780759824702e-07
a O 0 4.7644579126426834e-07
cys O 0 0.0003299831005278975
- O 0 4.294994141673669e-05
- O 0 6.282182584982365e-05
> O 0 2.3126951873564394e-06
arg O 0 3.5072973787464434e-06
at O 0 4.5932036840667934e-08
nucleotide O 0 1.5452998525233852e-07
position O 0 1.9705097997757548e-07
28 O 0 3.699729802519869e-07
in O 0 5.0253639471975475e-08
the O 0 1.7309426425526908e-07
exon O 0 3.3445205190218985e-05
. O 0 2.6001775950135197e-06

The O 0 1.2719910046143923e-05
mutation O 0 6.839873094577342e-05
destroyed O 0 3.0697403872181894e-06
an O 0 2.5514762569400773e-07
NdeI O 0 1.8112417819793336e-05
restriction O 0 2.770261744444724e-06
enzyme O 0 3.8092766772024333e-06
site O 0 4.225323209539056e-06
. O 0 2.091192072839476e-06

Analysis O 0 1.156246435130015e-05
of O 0 1.7511042926798837e-07
all O 0 4.587617752349615e-08
family O 0 2.8840909749305865e-07
members O 0 4.0691514158197606e-08
demonstrated O 0 3.7153685639168543e-07
that O 0 2.5888098775794788e-08
the O 0 8.478090052221887e-08
missense O 0 0.0002353157033212483
mutation O 0 7.43498139854637e-06
co O 0 4.59946431874414e-06
- O 0 2.678983764781151e-05
segregated O 0 4.965731022821274e-06
with O 0 1.7468490113969892e-05
patients O 0 0.16311834752559662
with O 0 0.00024257233599200845
tumors B-Disease 1 0.9999994039535522
or O 0 2.169907247662195e-06
who O 0 2.9543996333813993e-06
, O 0 2.7258510115757417e-08
as O 0 1.9316683363967968e-08
a O 0 2.3286955297407985e-07
result O 0 1.090967458594605e-07
of O 0 1.7472718383260144e-08
linkage O 0 3.5035932341997977e-06
analysis O 0 4.6427533106907504e-07
had O 0 3.15526506255992e-07
been O 0 3.9146978991766446e-08
predicted O 0 2.9176484872550645e-07
to O 0 3.095068734637607e-08
carry O 0 2.544774417856388e-07
the O 0 1.8930826684027124e-07
predisposing O 0 6.647227564826608e-05
mutation O 0 2.3627395421499386e-05
. O 0 1.865907734099892e-06

These O 0 3.9424971873813774e-06
observations O 0 5.4025636018195655e-06
point O 0 2.539818808600103e-07
to O 0 8.918817684389069e-08
another O 0 1.2933907100887154e-07
region O 0 1.0539968542389033e-07
of O 0 2.0203708928079323e-08
the O 0 2.090333737214678e-07
RB1 O 0 0.0015455834800377488
gene O 0 5.47673778328317e-07
where O 0 7.208571872752145e-08
mutations O 0 3.704828372974589e-07
only O 0 1.3502462259395998e-08
modify O 0 2.6188794777226576e-07
the O 0 9.061770889218224e-09
function O 0 9.444252491164207e-09
of O 0 1.4803998027446141e-09
the O 0 1.010867212158928e-08
gene O 0 8.050491118183345e-08
and O 0 1.7173832134176337e-08
raise O 0 7.055849948756077e-08
important O 0 8.71954064507463e-09
questions O 0 1.1117530362980688e-07
for O 0 5.841032546527458e-08
genetic O 0 5.140572739037452e-06
counseling O 0 4.657010777009418e-06
in O 0 2.8079736580366443e-07
families O 0 2.10166348324492e-07
with O 0 6.842196142997636e-08
these O 0 9.831248348746158e-08
distinctive O 0 9.400594717590138e-05
phenotypes O 0 0.0019090634305030107
. O 0 5.992883984617947e-07
. O 0 1.0005263675338938e-06

Maternal B-Disease 1 0.7235145568847656
disomy I-Disease 0 0.46730172634124756
and O 0 0.006966856308281422
Prader B-Disease 1 0.9999996423721313
- I-Disease 1 0.999998927116394
Willi I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999984502792358
consistent O 0 1.72050731634954e-05
with O 0 5.129492137712077e-07
gamete O 0 3.0379345844266936e-05
complementation O 0 0.0001730231597321108
in O 0 2.9533529755099153e-07
a O 0 8.150988151101046e-07
case O 0 1.1399275763324113e-06
of O 0 1.26545756984342e-07
familial O 0 0.0004783139447681606
translocation O 0 0.0002630519156809896
( O 0 2.397534899500897e-07
3 O 0 3.9614974411961157e-07
; O 0 1.8463499884546763e-07
15 O 0 1.0602211375498882e-07
) O 0 2.5107405932089932e-08
( O 0 3.4437878326798455e-08
p25 O 0 1.1902968253707513e-05
; O 0 3.294859993729915e-07
q11 O 0 1.3500613931682892e-05
. O 0 6.843122690725068e-08
2 O 0 2.6084879323207133e-07
) O 0 2.2337468408295535e-07
. O 0 4.644334694603458e-07

Maternal B-Disease 1 0.9771429300308228
uniparental I-Disease 1 0.9966686367988586
disomy I-Disease 1 0.9889243245124817
( I-Disease 0 0.00020323814533185214
UPD I-Disease 1 0.9999151229858398
) I-Disease 0 1.2820902384191868e-06
for I-Disease 0 2.7801894475487643e-07
chromosome I-Disease 0 3.726999420905486e-05
15 I-Disease 0 2.356451176410701e-07
is O 0 1.5788327090149323e-08
responsible O 0 4.517355023381242e-08
for O 0 9.448577031889727e-09
an O 0 5.0667495088418946e-08
estimated O 0 1.2958426509612764e-07
30 O 0 5.9247149408747646e-08
% O 0 1.2939255000787853e-08
of O 0 8.503381998536952e-09
cases O 0 6.752299555046193e-07
of O 0 2.0152954675722867e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 3.3466134482296184e-05
PWS B-Disease 1 0.9996122717857361
) O 0 6.08497612120118e-06
. O 0 3.5341104194230866e-06

We O 0 6.533879059134051e-06
report O 0 1.3663679965247866e-06
on O 0 8.9035722794506e-08
an O 0 9.03783288208615e-08
unusual O 0 1.2911269777760026e-06
case O 0 1.197393089569232e-06
of O 0 5.87170525534475e-08
maternal B-Disease 0 0.00011101525160484016
disomy I-Disease 0 0.0005461499677039683
15 I-Disease 0 8.127306045935256e-07
in O 0 2.652539023983991e-07
PWS B-Disease 1 0.9998385906219482
that O 0 1.598132826075016e-07
is O 0 2.477252181165568e-08
most O 0 9.043554349830174e-09
consistent O 0 8.498360415387651e-08
with O 0 2.689534817079675e-08
adjacent O 0 2.1819231221797963e-07
- O 0 2.0107943328184774e-06
1 O 0 5.295262894833286e-08
segregation O 0 8.215804569999818e-08
of O 0 9.597425076890431e-09
a O 0 7.452255772477656e-07
paternal O 0 0.0004605872672982514
t O 0 0.0005489944014698267
( O 0 5.1901302811074856e-08
3 O 0 9.223861496820973e-08
; O 0 3.494045586194261e-08
15 O 0 7.69896431052075e-08
) O 0 1.694748341662944e-08
( O 0 1.6211362918738814e-08
p25 O 0 6.488462986453669e-06
; O 0 2.5586257379472954e-07
q11 O 0 8.123253792291507e-06
. O 0 3.545563842521915e-08
2 O 0 2.8918570649238973e-08
) O 0 6.044459599507945e-09
with O 0 1.608342614645153e-08
simultaneous O 0 1.9167221125826472e-06
maternal O 0 1.8316603018320166e-05
meiotic O 0 4.913959128316492e-05
nondisjunction O 0 0.00023080006940290332
for O 0 5.413365329332009e-07
chromosome O 0 5.5584736401215196e-05
15 O 0 2.5984127205447294e-06
. O 0 1.7296567875746405e-06

The O 0 2.759578637778759e-05
patient O 0 0.0010354113765060902
( O 0 1.4216068393579917e-06
J O 0 0.0005565262981690466
. O 0 1.814686925172282e-07
B O 0 4.615294812992943e-07
. O 0 1.2861133491526289e-08
) O 0 5.739471120591588e-09
, O 0 7.4066881516898775e-09
a O 0 1.0845296571915242e-07
17 O 0 2.1561780272350006e-07
- O 0 5.2240347940823995e-06
year O 0 5.694243441212166e-07
- O 0 2.4162838599295355e-05
old O 0 2.4742717869230546e-05
white O 0 1.0982389540004078e-05
male O 0 1.771131792338565e-05
with O 0 1.6313136939061224e-06
PWS B-Disease 1 0.9999768733978271
, O 0 5.187185934119043e-07
was O 0 2.673876053904678e-07
found O 0 3.2909902358824183e-08
to O 0 2.1190356136457922e-08
have O 0 4.272412468253606e-08
47 O 0 4.3199020183237735e-07
chromosomes O 0 1.3135729659552453e-07
with O 0 2.016290245876462e-08
a O 0 5.461070031742565e-07
supernumerary O 0 0.0004652084317058325
, O 0 2.5022097815963207e-07
paternal O 0 2.0281127945054322e-05
der O 0 8.978236292023212e-05
( O 0 3.824728977974701e-08
15 O 0 2.2194090121274712e-08
) O 0 5.344288567243893e-09
consisting O 0 1.0646200365727054e-08
of O 0 2.266490772839802e-09
the O 0 1.2107916447234857e-08
short O 0 3.572179991806479e-07
arm O 0 4.225657448841957e-06
and O 0 1.6292329263478678e-08
the O 0 1.353921152968951e-08
proximal O 0 7.213070057332516e-05
long O 0 4.0307018025487196e-06
arm O 0 1.0915040547843091e-05
of O 0 6.599078972158168e-08
chromosome O 0 1.749785224092193e-05
15 O 0 4.138560427691118e-07
, O 0 6.807945851505792e-08
and O 0 2.444843119064899e-07
distal O 0 0.004539353772997856
chromosome O 0 0.023864490911364555
arm O 0 0.001515854150056839
3p O 0 0.0020585416350513697
. O 0 9.676236004452221e-06

The O 0 1.5888244888628833e-05
t O 0 0.0006250561564229429
( O 0 4.3028100549236115e-07
3 O 0 4.0686319380256464e-07
; O 0 1.6161786220436625e-07
15 O 0 1.1317229819951535e-07
) O 0 1.4698497530218901e-08
was O 0 7.105793287109918e-08
present O 0 1.9289327468641204e-08
in O 0 8.991748678965905e-09
the O 0 1.3553215438832922e-08
balanced O 0 1.8989447880812804e-07
state O 0 3.5000685016939315e-08
in O 0 4.117117313739982e-08
the O 0 2.1268996874823642e-07
patients O 0 0.0005561214056797326
father O 0 9.299648809246719e-06
and O 0 1.5236261674544949e-07
a O 0 2.355703600187553e-06
sister O 0 7.877272582845762e-05
. O 0 1.7208348026542808e-06

Fluorescent O 0 0.0018038960406556726
in O 0 6.286927600740455e-06
situ O 0 2.131395012838766e-05
hybridization O 0 4.764925506606232e-06
analysis O 0 2.101961172229494e-06
demonstrated O 0 1.8111614963345346e-06
that O 0 3.894218281175199e-08
the O 0 8.84860114069852e-08
PWS B-Disease 1 0.999581515789032
critical O 0 1.4095155165705364e-05
region O 0 3.644897219601262e-07
resided O 0 4.794769097316021e-07
on O 0 3.173534679490331e-08
the O 0 1.7778026162318383e-08
derivative O 0 7.277660074578307e-07
chromosome O 0 3.0467926990240812e-06
3 O 0 6.005264197028737e-08
and O 0 1.0741576517148133e-08
that O 0 1.232157487152108e-08
there O 0 1.5910638140326228e-08
was O 0 8.623813130270719e-08
no O 0 4.979584034003892e-08
deletion O 0 1.158016971203324e-06
of O 0 1.4249261326426677e-08
the O 0 2.493218005383824e-07
PWS B-Disease 1 0.999893069267273
region O 0 4.184625481684634e-07
on O 0 1.08259307296521e-07
the O 0 2.504379281731417e-08
normal O 0 9.670082334878316e-08
pair O 0 2.5008813508975436e-07
of O 0 2.7940236790868767e-08
15s O 0 1.3997557289258111e-05
present O 0 7.96605945652118e-07
in O 0 1.09790153146605e-06
J O 0 0.006817869376391172
. O 0 5.4618903959635645e-06

B O 0 0.004546016454696655
. O 0 8.71399388415739e-05

Methylation O 0 0.0002928243193309754
analysis O 0 1.3088405466987751e-05
at O 0 5.34318076006457e-07
exon O 0 1.3340161331143463e-06
alpha O 0 1.6060226926128962e-07
of O 0 1.0504521696930169e-08
the O 0 1.158618090357777e-08
small O 0 3.9122870276742105e-08
nuclear O 0 5.994404546072474e-07
ribonucleoprotein O 0 1.7882412066683173e-05
- O 0 2.968392254842911e-05
associated O 0 3.629232878665789e-07
polypeptide O 0 2.9011882816121215e-06
N O 0 2.1300795651768567e-06
( O 0 4.493585592513227e-08
SNRPN O 0 6.640962965320796e-06
) O 0 2.5417950411110724e-08
gene O 0 8.051166844325053e-08
showed O 0 3.191834423432738e-07
a O 0 1.9681377239066933e-07
pattern O 0 1.4701463442179374e-06
characteristic O 0 3.420412042487442e-07
of O 0 9.574551818047894e-09
only O 0 4.7454296492333015e-08
the O 0 6.764945226223062e-08
maternal O 0 0.0001860161719378084
chromosome O 0 5.3323259635362774e-05
15 O 0 9.802026852412382e-07
in O 0 5.513773544407741e-07
J O 0 0.008628248237073421
. O 0 5.579802291322267e-06

B O 0 0.005626488942652941
. O 0 0.00010454427683725953

Maternal B-Disease 1 0.606871485710144
disomy I-Disease 0 0.029672417789697647
was O 0 1.9752878870349377e-05
confirmed O 0 1.7104517837651656e-06
by O 0 3.3511533104046975e-08
polymerase O 0 1.1768679542001337e-06
chain O 0 1.4285857332652085e-06
reaction O 0 1.9961518660238653e-07
analysis O 0 3.6915032808337855e-08
of O 0 1.0044327147795684e-08
microsatellite O 0 1.3029475667281076e-05
repeats O 0 1.2695131772488821e-06
at O 0 1.2574329133485662e-08
the O 0 5.953870729769051e-09
gamma O 0 2.9354546882132126e-07
- O 0 1.4763323861188837e-06
aminobutyric O 0 1.2476908523240127e-05
acid O 0 1.2283981050131842e-06
receptor O 0 4.0924675204223604e-07
beta3 O 0 3.343548087286763e-06
subunit O 0 9.71730059973197e-07
( O 0 1.6878118458407698e-07
GABRB3 O 0 2.0128349206061102e-05
) O 0 2.8136133778389194e-07
locus O 0 1.105017145164311e-05
. O 0 1.9306407921249047e-06

A O 0 0.00012200041965115815
niece O 0 0.0117778480052948
( O 0 1.3658195712196175e-06
B O 0 1.4952984201954678e-06
. O 0 4.041768875140406e-08
B O 0 1.8268208634708571e-07
. O 0 5.38881428369109e-09
) O 0 2.06963912674496e-09
with O 0 6.2279505996798434e-09
45 O 0 6.241414496344078e-08
chromosomes O 0 1.204989814596047e-07
and O 0 7.969256365925048e-09
the O 0 7.018559511351441e-09
derivative O 0 1.6944386516115628e-07
3 O 0 5.912342615488342e-08
but O 0 2.5121966729102496e-08
without O 0 1.7811185415439468e-08
the O 0 2.5763672084622158e-08
der O 0 5.861646422999911e-05
( O 0 2.40260202843956e-08
15 O 0 3.646576018923042e-08
) O 0 1.4245267188073285e-08
demonstrated O 0 2.7524390588951064e-07
a O 0 4.232840183249209e-06
phenotype O 0 0.04123764485120773
consistent O 0 1.035841478369548e-06
with O 0 6.423211118544714e-08
that O 0 1.3451737856939872e-07
reported O 0 6.335483817565546e-07
for O 0 2.024467526950957e-08
haploinsufficiency O 0 1.391860769217601e-05
of O 0 7.746542252107247e-08
distal O 0 0.003595697693526745
3 O 0 2.0401748770382255e-05
p O 0 4.6311582991620526e-05
. O 0 1.3580174709204584e-06

Uniparental B-Disease 1 0.9998558759689331
disomy I-Disease 1 0.9995421171188354
associated O 0 0.0001596218644408509
with O 0 7.720955750301073e-07
unbalanced O 0 2.91770320473006e-05
segregation O 0 1.5979194358806126e-06
of O 0 3.1741397066298305e-08
non O 0 2.428981531465979e-07
- O 0 1.4627993550675455e-05
Robertsonian O 0 0.00026662222808226943
translocations O 0 0.0001546223647892475
has O 0 1.1587570725168916e-06
been O 0 2.0858415439306555e-07
reported O 0 8.225414376283879e-07
previously O 0 8.775119653137153e-08
but O 0 2.8600581458704255e-08
has O 0 4.874922865383269e-08
not O 0 1.324622722620461e-08
, O 0 5.587194262801631e-09
to O 0 5.946788839139572e-09
our O 0 6.381664974242085e-09
knowledge O 0 9.751890850395739e-09
, O 0 1.0528030891521212e-08
been O 0 1.8711197924403677e-08
observed O 0 6.978383737532567e-08
in O 0 1.1307127678605866e-08
a O 0 3.9035441545820504e-07
case O 0 2.156680920961662e-06
of O 0 7.215999744403234e-07
PWS B-Disease 1 0.9998980760574341
. O 0 2.3540313122794032e-05

Furthermore O 0 0.00014850348816253245
, O 0 9.826202358453884e-07
our O 0 1.782567267127888e-07
findings O 0 5.766862614109414e-07
are O 0 8.450736999066066e-09
best O 0 6.430467891505032e-08
interpreted O 0 2.546616997278761e-07
as O 0 3.466642795046937e-08
true O 0 1.4843313067558483e-07
gamete O 0 2.643841298777261e-06
complementation O 0 2.166836566175334e-05
resulting O 0 3.884818397636991e-06
in O 0 1.0949057696052478e-06
maternal B-Disease 0 0.1386130154132843
UPD I-Disease 1 0.9999781847000122
15 I-Disease 0 3.559068136382848e-05
and O 0 1.524620529380627e-05
PWS B-Disease 1 0.9992252588272095

Schwartz B-Disease 1 0.8875454068183899
- I-Disease 1 0.9976096153259277
Jampel I-Disease 1 0.9997537732124329
syndrome I-Disease 1 0.9999825954437256
type I-Disease 0 9.216163562086876e-06
2 I-Disease 0 1.1127771131214104e-06
and O 0 1.1207029047000105e-06
Stuve B-Disease 1 0.6196229457855225
- I-Disease 1 0.9997972846031189
Wiedemann I-Disease 1 0.9999960660934448
syndrome I-Disease 1 0.9999921321868896
: O 0 1.82752827981858e-07
a O 0 2.895384909606946e-07
case O 0 4.02869289928276e-07
for O 0 3.932704117914909e-08
" O 0 2.120228685953407e-07
lumping O 0 2.8380827643559314e-06
" O 0 1.1726666571121314e-06
. O 0 1.003817033051746e-06

Recent O 0 0.00028659767122007906
studies O 0 2.010076423175633e-05
demonstrated O 0 6.607003342651296e-06
the O 0 5.787789092437379e-08
existence O 0 6.888983961061967e-08
of O 0 9.953489588099274e-09
a O 0 5.883296694264573e-07
genetically O 0 1.114605993279838e-06
distinct O 0 1.7369617921758618e-07
, O 0 4.144582987919421e-08
usually O 0 1.1477397521275634e-07
lethal O 0 9.487313263889519e-07
form O 0 3.462704256662619e-08
of O 0 7.385133393711385e-09
the O 0 1.730983854031365e-07
Schwartz B-Disease 0 0.01473775040358305
- I-Disease 1 0.9919825196266174
Jampel I-Disease 1 0.9999463558197021
syndrome I-Disease 1 0.9999909400939941
( O 0 1.0987006362483953e-06
SJS B-Disease 0 0.0009575840667821467
) O 0 8.523520733660916e-08
of O 0 5.523105173210752e-08
myotonia B-Disease 1 0.88646399974823
and O 0 3.966350413975306e-05
skeletal B-Disease 1 0.9996335506439209
dysplasia I-Disease 1 0.9999656677246094
, O 0 1.4492239870378398e-06
which O 0 8.423784692013214e-08
we O 0 1.2038125873914396e-07
called O 0 1.5246030216076178e-06
SJS B-Disease 0 0.016724731773138046
type I-Disease 0 6.445328835980035e-06
2 I-Disease 0 2.756868070719065e-06
. O 0 2.3257512111740652e-06

This O 0 0.00024128913355525583
disorder O 1 0.9153111577033997
is O 0 3.240231194467924e-07
reminiscent O 0 4.547939170151949e-06
of O 0 8.320739652845077e-08
another O 0 6.412667971744668e-06
rare O 0 0.00013177984510548413
condition O 0 0.00019098154734820127
, O 0 7.119413680811704e-08
the O 0 1.639486413296254e-07
Stuve B-Disease 1 0.5244678854942322
- I-Disease 1 0.9999070167541504
Wiedemann I-Disease 1 0.9999978542327881
syndrome I-Disease 1 0.9999978542327881
( O 0 1.041196583173587e-06
SWS B-Disease 1 0.5174151062965393
) O 0 7.785766342749412e-08
, O 0 2.8012861363890806e-08
which O 0 1.8282808156300234e-08
comprises O 0 8.694036779388625e-08
campomelia B-Disease 0 3.266835483373143e-05
at O 0 2.366709708212511e-07
birth O 0 6.1803161770512816e-06
with O 0 1.861876171460608e-06
skeletal B-Disease 1 0.9988277554512024
dysplasia I-Disease 1 0.9999599456787109
, O 0 2.1725247279391624e-05
contractures B-Disease 1 0.8227358460426331
, O 0 5.068760060567001e-07
and O 0 3.779874475640099e-07
early B-Disease 0 5.9068975133413915e-06
death I-Disease 0 0.0005474761710502207
. O 0 4.411820555105805e-06

To O 0 8.486602382618003e-06
test O 0 1.7851900793175446e-06
for O 0 4.879024828596812e-08
possible O 0 2.0494945829341304e-07
nosologic O 0 0.00020525959553197026
identity O 0 8.490888490086945e-07
between O 0 1.0119826754362293e-07
these O 0 4.2098551489289093e-07
disorders O 0 0.046107541769742966
, O 0 7.256868883587231e-08
we O 0 2.649514563302091e-08
reviewed O 0 1.1997266824437247e-07
the O 0 1.0040553277690378e-08
literature O 0 2.4540860010802135e-08
and O 0 1.2494717260835841e-08
obtained O 0 4.372186879209039e-08
a O 0 3.221174793566206e-08
follow O 0 5.473469499861494e-08
- O 0 7.814813329787285e-07
up O 0 2.205533711219232e-08
of O 0 2.366479900928198e-09
the O 0 4.811412601668508e-09
only O 0 1.0425041274686464e-08
two O 0 8.796133244004523e-08
surviving O 0 0.005872427020221949
patients O 0 0.001119287102483213
, O 0 4.406158637948465e-08
one O 0 3.18024824252916e-08
with O 0 1.2386507819428516e-07
SJS B-Disease 0 0.002658844692632556
type I-Disease 0 3.7080661741129006e-07
2 I-Disease 0 5.330486985144489e-08
at O 0 1.865041276971624e-08
age O 0 1.0804807004660688e-07
10 O 0 1.610853850309013e-08
years O 0 3.7863028268247945e-08
and O 0 1.1747869343992079e-08
another O 0 8.10115281524304e-08
with O 0 3.520550251323584e-07
SWS B-Disease 1 0.8661274313926697
at O 0 5.494189281307627e-07
age O 0 1.1108062381026684e-06
7 O 0 1.1754030992960907e-06
years O 0 1.694423872322659e-06
. O 0 1.9836168121400988e-06

Patients O 1 0.9995729327201843
reported O 0 0.0003538500750437379
as O 0 5.276822321320651e-07
having O 0 7.328097808567691e-07
either O 0 3.3833605357358465e-06
neonatal O 1 0.9999748468399048
SJS B-Disease 1 0.9993283748626709
or O 0 2.7266753022558987e-05
SWS B-Disease 1 0.976442277431488
presented O 0 2.5675819870230043e-06
a O 0 2.8712747734971344e-07
combination O 0 4.217091884584079e-07
of O 0 2.2472674388041014e-08
a O 0 1.1789768905146047e-05
severe O 1 0.8898476362228394
, O 0 4.109375731786713e-05
prenatal O 1 0.993633508682251
- O 1 0.999643087387085
onset O 1 0.99991774559021
neuromuscular B-Disease 1 0.9999986886978149
disorder I-Disease 1 0.9999780654907227
( O 0 1.5634066130587598e-06
with O 0 2.7434043659013696e-05
congenital B-Disease 1 0.9999858140945435
joint I-Disease 1 0.9551610350608826
contractures I-Disease 1 0.9999922513961792
, O 0 0.184078648686409
respiratory O 1 0.9997033476829529
and O 0 1.021074513118947e-05
feeding O 0 3.5000350180780515e-05
difficulties O 0 1.1794390957220457e-05
, O 0 1.6093866861410788e-07
tendency O 0 1.1981811667283182e-06
to O 0 1.3944016927780467e-06
hyperthermia B-Disease 1 0.9966703057289124
, O 0 4.6957293875493633e-07
and O 0 1.4829390693194e-07
frequent O 0 0.00011511193588376045
death O 0 0.07703165709972382
in O 0 1.2582902400026796e-06
infancy O 0 0.0008376668556593359
) O 0 2.5736168751677724e-08
with O 0 1.9077258883726245e-08
a O 0 2.966546617244603e-07
distinct O 0 6.30947226909484e-07
campomelic B-Disease 0 0.0014463374391198158
- I-Disease 0 0.023243701085448265
metaphyseal I-Disease 1 0.6510801911354065
skeletal I-Disease 1 0.9944139719009399
dysplasia I-Disease 1 0.9992218017578125
. O 0 2.3359931219602004e-05

The O 0 2.3732038698653923e-06
similarity O 0 2.1462005861394573e-06
of O 0 3.9584943323234256e-08
the O 0 2.405509746949974e-07
clinical O 0 4.1250339563703164e-05
and O 0 3.5723203382076463e-06
radiographic O 1 0.9903788566589355
findings O 0 0.001707947812974453
is O 0 7.624886677604081e-08
so O 0 3.472982967878124e-08
extensive O 0 2.3889305111879366e-07
that O 0 1.7418587106021732e-07
these O 0 3.043744527531089e-07
disorders O 0 0.08486734330654144
appear O 0 2.1336741156119388e-06
to O 0 7.925860501245552e-08
be O 0 2.0862465532900387e-08
a O 0 1.488382395109511e-07
single O 0 1.3083088106213836e-06
entity O 0 2.965414296340896e-06
. O 0 1.197301571664866e-06

The O 0 2.740008994805976e-06
follow O 0 2.231431153632002e-06
- O 0 4.3950940380454995e-06
up O 0 1.5941203912461788e-07
observation O 0 4.280185805782821e-07
of O 0 8.795475459066893e-09
an O 0 3.93581096602702e-08
identical O 0 1.370016320834111e-06
and O 0 2.3066846210895164e-08
unique O 0 3.720278840546598e-08
pattern O 0 3.5723198266168765e-07
of O 0 3.909459778128621e-08
progressive O 1 0.6237218379974365
bone B-Disease 1 0.9990623593330383
dysplasia I-Disease 1 0.999966025352478
in O 0 1.6211755564654595e-06
the O 0 2.0077158069398138e-07
two O 0 1.103255544876447e-05
patients O 0 0.002312537282705307
( O 0 2.6734801039651757e-08
one O 0 6.048809808589795e-08
with O 0 3.89571965797586e-07
SJS B-Disease 0 0.3200647532939911
type I-Disease 0 5.175295427761739e-06
2 I-Disease 0 1.464037495679804e-07
, O 0 1.9806510209718908e-08
one O 0 2.1066314914719442e-08
with O 0 1.8458817407918104e-07
SWS B-Disease 1 0.6138156652450562
) O 0 1.5004594899892254e-07
surviving O 0 2.1827231648785528e-06
beyond O 0 3.1732838579046074e-07
infancy O 0 7.2356779128313065e-06
adds O 0 1.613318886484194e-06
to O 0 3.42342048043065e-08
the O 0 1.784624714673555e-08
evidence O 0 1.2390347592372564e-07
in O 0 2.468517124043501e-08
favor O 0 1.1697286339540369e-07
of O 0 6.559110943271662e-08
identity O 0 3.0701153264089953e-06
. O 0 2.079804062304902e-06

The O 0 8.541333954781294e-06
hypothesis O 0 5.605978367384523e-05
that O 0 6.467985826930089e-07
SWS B-Disease 0 0.10691139101982117
and O 0 1.176793944068777e-06
SJS B-Disease 0 0.020675215870141983
type I-Disease 0 2.143884785255068e-06
2 I-Disease 0 1.3715074942410865e-07
are O 0 1.1768951146962081e-08
the O 0 5.7194213809452776e-08
same O 0 7.382259354926646e-06
disorder O 0 0.035664211958646774
should O 0 8.297347164898383e-08
be O 0 1.476585165249844e-08
testable O 0 2.6697708221945504e-07
by O 0 3.759353717214253e-08
molecular O 0 6.56071279081516e-07
methods O 0 3.970465058955597e-07
. O 0 2.832664449670119e-07
. O 0 7.759028335385665e-07

A O 0 5.463531852001324e-05
mouse O 0 7.468573312507942e-05
model O 0 1.3459232832246926e-05
of O 0 3.2106481739901938e-06
severe O 1 0.9998602867126465
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999995231628418
disease I-Disease 1 0.9999992847442627
: O 0 0.0021264441311359406
defects O 1 0.988498866558075
in O 0 6.6909742599818856e-06
hemostasis O 1 0.7906164526939392
and O 0 0.0005359914503060281
thrombosis B-Disease 1 0.9992631077766418
. O 0 8.487851300742477e-05

von B-Disease 1 0.9930787682533264
Willebrand I-Disease 1 0.9915557503700256
factor I-Disease 0 0.0008269333629868925
( I-Disease 0 6.34032694506459e-05
vWf I-Disease 0 0.022921418771147728
) I-Disease 0 0.0006261070957407355
deficiency I-Disease 1 0.9944769740104675
causes O 0 0.2006898671388626
severe O 1 0.9999768733978271
von B-Disease 1 0.9999998807907104
Willebrand I-Disease 1 0.9999992847442627
disease I-Disease 1 0.9999986886978149
in O 0 5.4521595302503556e-05
humans O 0 1.6629110177746043e-05
. O 0 4.66953906652634e-06

We O 0 3.3186736345669487e-06
generated O 0 1.7563821756994002e-06
a O 0 6.554947162840108e-07
mouse O 0 5.866897481610067e-06
model O 0 1.9926951608795207e-06
for O 0 8.455061362155902e-08
this O 0 3.230065317438857e-07
disease O 0 7.475734946638113e-06
by O 0 3.584594310268585e-08
using O 0 2.45381073682438e-07
gene O 0 8.986502848529199e-07
targeting O 0 1.9332699139340548e-06
. O 0 1.9819867702608462e-06

vWf B-Disease 1 0.8153383731842041
- I-Disease 1 0.992435872554779
deficient I-Disease 1 0.8888658881187439
mice O 0 0.003861560020595789
appeared O 0 1.9595390767790377e-05
normal O 0 6.643051619903417e-07
at O 0 1.3179987945477478e-07
birth O 0 3.942531293432694e-06
; O 0 1.0255162408157048e-07
they O 0 2.592466685769068e-08
were O 0 3.518374569466687e-08
viable O 0 4.969939482180052e-07
and O 0 3.1173632919490046e-07
fertile O 0 1.1347592590027489e-05
. O 0 3.900049705407582e-06

Neither O 0 0.0009082559845410287
vWf O 0 0.0038957272190600634
nor O 0 0.00014829152496531606
vWf O 0 0.00041160787804983556
propolypeptide O 0 0.0012261489173397422
( O 0 4.8656424951332156e-06
von B-Disease 0 0.050955068320035934
Willebrand I-Disease 0 0.3376169204711914
antigen O 0 0.00056436937302351
II O 0 3.014978028659243e-05
) O 0 6.074464664607149e-08
were O 0 4.3379056791081894e-08
detectable O 0 4.844219461119792e-07
in O 0 2.233150020458652e-08
plasma O 0 1.4860600458632689e-05
, O 0 1.0189048538222778e-07
platelets O 0 4.874550995737081e-06
, O 0 4.7772331868145557e-08
or O 0 3.811024384958728e-08
endothelial O 0 1.2744460946123581e-05
cells O 0 3.5888638194592204e-07
of O 0 1.5669613162572205e-08
the O 0 1.0891108104260638e-07
homozygous O 0 3.5779110476141796e-05
mutant O 0 0.00015373423229902983
mice O 0 0.00023788167163729668
. O 0 2.4054966161202174e-06

The O 0 1.2714670447167009e-05
mutant O 0 0.003520916448906064
mice O 1 0.5473859906196594
exhibited O 0 0.017919206991791725
defects O 1 0.9562020897865295
in O 0 1.2879713722213637e-06
hemostasis O 0 0.012299947440624237
with O 0 2.2031925084320392e-07
a O 0 2.766726538538933e-06
highly O 0 2.333175643798313e-06
prolonged O 1 0.5760905146598816
bleeding O 1 0.9985595345497131
time O 0 5.848322643942083e-07
and O 0 2.0184592131045065e-07
spontaneous O 0 8.801343938102946e-06
bleeding O 1 0.8525641560554504
events O 0 1.894176904215783e-07
in O 0 1.457230212054128e-07
approximately O 0 9.823993707414047e-08
10 O 0 8.377974580753289e-08
% O 0 5.047236584232451e-08
of O 0 8.423367603427323e-08
neonates O 0 0.4357166290283203
. O 0 1.045146655087592e-05

As O 0 5.112002781970659e-06
in O 0 2.735361874783848e-07
the O 0 2.164823484918088e-07
human O 0 4.1874704947986174e-06
disease O 0 4.1641309508122504e-05
, O 0 1.825482875972284e-08
the O 0 1.3564412704170081e-08
factor O 0 1.0041782871894611e-07
VIII O 0 0.00014393463789019734
level O 0 4.516769180895608e-08
in O 0 2.1593711707623697e-08
these O 0 1.807253013907939e-08
mice O 0 2.4775088604656048e-05
was O 0 4.927896384288033e-07
reduced O 0 4.1251632865169086e-07
strongly O 0 2.749337966179155e-07
as O 0 1.3331695747353933e-08
a O 0 1.0914856574117948e-07
result O 0 4.650122420457592e-08
of O 0 2.6510802442203385e-09
the O 0 1.9827639974323574e-08
lack O 0 1.103435920413176e-07
of O 0 4.944839560039327e-08
protection O 0 1.0695739547372796e-06
provided O 0 7.059321660563e-07
by O 0 9.713112376630306e-07
vWf O 0 0.00010150266462005675
. O 0 5.445398073788965e-06

Defective O 1 0.9942571520805359
thrombosis B-Disease 1 0.9997733235359192
in O 0 2.1351630493882112e-05
mutant O 0 0.003369296668097377
mice O 0 0.0025592877063900232
was O 0 6.729015353812429e-07
also O 0 1.2511486602306832e-07
evident O 0 3.879114558458241e-07
in O 0 3.569236994849234e-08
an O 0 5.7942173725678003e-08
in O 0 1.5111797324607323e-07
vivo O 0 6.498335278593004e-05
model O 0 1.201561417474295e-06
of O 0 3.8025839899091807e-07
vascular B-Disease 1 0.9991274476051331
injury I-Disease 1 0.9796078205108643
. O 0 2.7288420824334025e-05

In O 0 7.805394488968886e-06
this O 0 2.2639045482719666e-07
model O 0 7.885259947215673e-07
, O 0 4.10792395655335e-08
the O 0 2.295475276525849e-08
exteriorized O 0 3.323656346765347e-05
mesentery O 0 5.849428634974174e-05
was O 0 4.1981039089478145e-07
superfused O 0 6.1288478718779515e-06
with O 0 1.2054185560828046e-07
ferric O 0 7.254520460264757e-05
chloride O 0 2.3806391254765913e-05
and O 0 6.50424567538721e-08
the O 0 5.029947658385936e-08
accumulation O 0 6.151734055492852e-07
of O 0 8.671563733742005e-08
fluorescently O 0 0.0005309595726430416
labeled O 0 4.993504626327194e-05
platelets O 0 5.2958293963456526e-05
was O 0 7.132515520424931e-07
observed O 0 4.291687503155117e-07
by O 0 1.5147796261771873e-07
intravital O 0 8.708445238880813e-05
microscopy O 0 6.435402610804886e-05
. O 0 6.034864782122895e-06

We O 0 9.377852620673366e-06
conclude O 0 1.090686328097945e-05
that O 0 1.909925515519717e-07
these O 0 7.059968964995278e-08
mice O 0 8.408826033701189e-06
very O 0 7.025272452665376e-08
closely O 0 7.620240580763493e-07
mimic O 0 0.00581654766574502
severe O 1 0.9972490668296814
human O 0 0.1949707716703415
von B-Disease 1 0.9999998807907104
Willebrand I-Disease 1 0.9999985694885254
disease I-Disease 1 0.999995231628418
and O 0 1.753575475049729e-06
will O 0 2.7712184191841516e-07
be O 0 2.680510924335522e-08
very O 0 1.9909078829982718e-08
useful O 0 1.6805977054445975e-08
for O 0 9.267679956792563e-09
investigating O 0 8.52095283221388e-08
the O 0 1.1503495045417367e-08
role O 0 3.26546683027118e-08
of O 0 1.8113665234409382e-08
vWf O 0 4.871604232903337e-06
in O 0 1.1501207808350955e-07
normal O 0 8.282956400762487e-07
physiology O 0 1.446358783141477e-05
and O 0 9.021115374707733e-07
in O 0 1.4233109141059685e-05
disease O 0 0.0026566372253000736
models O 0 1.6924866940826178e-05
. O 0 5.474659587889619e-07
. O 0 8.967086841948912e-07

Oral O 0 0.43570128083229065
contraceptives O 1 0.7611156702041626
and O 0 1.2632644939003512e-06
the O 0 4.525867325355648e-07
risk O 0 2.8954946174053475e-06
of O 0 4.032293418276822e-06
hereditary B-Disease 1 0.9999979734420776
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 6.21350554865785e-05

Hereditary B-Disease 1 0.9999896287918091
Ovarian I-Disease 1 0.999998927116394
Cancer I-Disease 1 0.9999821186065674
Clinical O 0 0.3310685157775879
Study O 0 4.027180693810806e-05
Group O 0 8.771822649578098e-06
. O 0 4.028491730423411e-06

BACKGROUND O 0 0.033096808940172195
Women O 0 0.0001047507394105196
with O 0 1.7825515215008636e-06
mutations O 0 4.390972389956005e-05
in O 0 8.826384600979509e-08
either O 0 8.290561481771874e-08
the O 0 1.1934353949527576e-07
BRCA1 O 0 0.00014242615725379437
or O 0 1.3704223533750337e-07
the O 0 3.3738896831891907e-07
BRCA2 O 0 0.0005084577132947743
gene O 0 5.746248348259542e-07
have O 0 6.232896510027786e-08
a O 0 3.169790261381422e-07
high O 0 2.432682322250912e-06
lifetime O 0 5.107044125907123e-05
risk O 0 1.3729702004638966e-05
of O 0 9.222365042660385e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
. O 0 4.397584780235775e-05

Oral O 0 0.05486510321497917
contraceptives O 1 0.962593674659729
protect O 0 0.0050683957524597645
against O 1 0.8917421102523804
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
in O 0 1.812854861782398e-06
general O 0 3.7052981838314736e-07
, O 0 8.799187867225555e-08
but O 0 4.134129838462286e-08
it O 0 1.254797510341632e-08
is O 0 1.1440543623564281e-08
not O 0 1.3432720713524304e-08
known O 0 1.0599396915722537e-08
whether O 0 2.9339258134086776e-08
they O 0 1.2680663630249e-08
also O 0 2.9308438342923182e-08
protect O 0 9.194246786137228e-08
against O 0 5.611418600892648e-07
hereditary B-Disease 0 0.02429203875362873
forms I-Disease 0 8.228667866205797e-06
of I-Disease 0 0.0003600400814320892
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999974966049194
. O 0 3.7888166843913496e-05

METHODS O 0 4.497900954447687e-05
We O 0 1.0320343335479265e-06
enrolled O 0 2.5833380732365185e-06
207 O 0 7.215853202069411e-06
women O 0 1.2453942872525658e-05
with O 0 0.0004640148254111409
hereditary B-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
and O 0 8.622511131761712e-07
161 O 0 1.0590787269393331e-06
of O 0 2.0244135257030393e-08
their O 0 4.9877780128326776e-08
sisters O 0 4.435883340647706e-07
as O 0 1.5080418691582054e-08
controls O 0 3.0960373464949953e-07
in O 0 1.5518164531158618e-08
a O 0 1.6705091354651813e-07
case O 0 2.2051822270441335e-06
- O 0 7.65772711019963e-05
control O 0 1.5212003745546099e-05
study O 0 4.799980615644017e-06
. O 0 1.996830633288482e-06

All O 0 2.657055574672995e-06
the O 0 1.4095271581027191e-06
patients O 0 8.756960596656427e-05
carried O 0 6.348415126922191e-07
a O 0 8.249185157183092e-07
pathogenic O 0 4.011068540421547e-06
mutation O 0 2.5500974061287707e-06
in O 0 4.7629491461975704e-08
either O 0 4.989957460566075e-07
BRCA1 O 0 0.00022119039203971624
( O 0 1.1775388486512384e-07
179 O 0 3.3837509363365825e-06
women O 0 1.8480125163478078e-06
) O 0 1.3359598938222916e-07
or O 0 6.25722009317542e-07
BRCA2 O 0 0.0037823962047696114
( O 0 3.8867983676027507e-07
28 O 0 4.299329702917021e-06
women O 0 1.5394044794447836e-06
) O 0 4.7497087507508695e-07
. O 0 1.025642973218055e-06

The O 0 7.950152394187171e-06
control O 0 1.5126665857678745e-05
women O 0 2.01609987016127e-06
were O 0 1.2213223499202286e-07
enrolled O 0 2.2923127573903912e-07
regardless O 0 4.872775249964434e-08
of O 0 5.94193627634354e-09
whether O 0 6.590197898503902e-08
or O 0 3.239511059405231e-08
not O 0 1.967405260927535e-08
they O 0 2.0507314957285416e-08
had O 0 3.094667704317544e-07
either O 0 5.744604436586087e-07
mutation O 0 6.133835540822474e-06
. O 0 1.8490613911126275e-06

Lifetime O 0 0.0027322552632540464
histories O 0 4.753840039484203e-05
of O 0 6.863932071610179e-07
oral O 0 5.407674325397238e-05
- O 0 0.0006681153317913413
contraceptive O 0 0.033334918320178986
use O 0 4.2220739260301343e-07
were O 0 8.371154081032728e-08
obtained O 0 1.4609565823775483e-07
by O 0 3.0601650991002316e-08
interview O 0 1.3664064681506716e-05
or O 0 2.3432599860484515e-08
by O 0 2.157658585133504e-08
written O 0 2.2377169273113395e-07
questionnaire O 0 5.8261498452338856e-06
and O 0 4.3885876266358537e-08
were O 0 7.644094068837148e-08
compared O 0 5.754611720476532e-07
between O 0 2.4931085818025167e-07
patients O 0 0.0008361831423826516
and O 0 4.6447109980363166e-07
control O 0 1.4663974070572294e-05
women O 0 2.3297670850297436e-06
, O 0 3.9469970403160914e-08
after O 0 8.166590248492867e-08
adjustment O 0 2.038683106775352e-07
for O 0 2.0629913777270303e-08
year O 0 5.6841525264417214e-08
of O 0 1.635484814244137e-08
birth O 0 2.7531107207323657e-06
and O 0 2.4821835609145637e-07
parity O 0 6.6797215367842e-06
. O 0 1.5714862229287974e-06

RESULTS O 0 0.0002983601007144898
The O 0 1.130339683186321e-06
adjusted O 0 3.320570249343291e-05
odds O 0 0.00011839782382594422
ratio O 0 7.415087020490319e-05
for O 0 0.01596108265221119
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
associated O 0 3.2106665912579047e-06
with O 0 1.888069611766241e-08
any O 0 6.632224547331589e-09
past O 0 1.6646337641645914e-08
use O 0 2.2995902071443197e-08
of O 0 2.1702387442701365e-08
oral O 0 0.000237316926359199
contraceptives O 1 0.9210711717605591
was O 0 8.505439836881123e-06
0 O 0 3.7538338801823556e-06
. O 0 1.4552653055943665e-06

5 O 0 2.4175744329113513e-05
( O 0 7.806470989635272e-07
95 O 0 5.62234617973445e-07
percent O 0 8.304787684210169e-07
confidence O 0 4.7391165480803465e-07
interval O 0 3.681947475797642e-07
, O 0 7.887600617095814e-08
0 O 0 1.4900101064085902e-07
. O 0 9.032453007762342e-09
3 O 0 3.069354548301817e-08
to O 0 2.9665118361776877e-08
0 O 0 5.061002639195067e-07
. O 0 8.543346297074095e-08
8 O 0 4.94752839585999e-07
) O 0 2.864158830107044e-07
. O 0 6.631588007621758e-07

The O 0 1.7183408999699168e-05
risk O 0 4.231761340633966e-05
decreased O 0 2.8663932880590437e-06
with O 0 7.599362561450107e-08
increasing O 0 1.8089814091126755e-07
duration O 0 7.022337626949593e-07
of O 0 2.1710089725957005e-08
use O 0 2.043044986521636e-07
( O 0 7.504770138666572e-08
P O 0 8.823083135212073e-07
for O 0 1.4123090252837756e-08
trend O 0 3.3653799391686334e-07
, O 0 6.710303779300375e-08
< O 0 1.0263944432153949e-06
0 O 0 2.63692896851353e-07
. O 0 2.4138371301773986e-08
001 O 0 1.6419710391346598e-06
) O 0 1.877146438289401e-08
; O 0 9.228010355855076e-09
use O 0 9.117857580065447e-09
for O 0 1.0735677236084484e-08
six O 0 7.641630617172268e-08
or O 0 1.439153951565686e-08
more O 0 1.8853672401064614e-08
years O 0 2.5098265155065747e-07
was O 0 4.769603947352152e-07
associated O 0 3.1585223325691913e-08
with O 0 1.0026850461031245e-08
a O 0 4.7547530357405776e-07
60 O 0 8.974392358140904e-07
percent O 0 1.6214165725614293e-06
reduction O 0 8.257938475253468e-07
in O 0 6.30355486919143e-07
risk O 0 1.2610240446520038e-05
. O 0 2.395917363173794e-06

Oral O 0 0.0021686935797333717
- O 0 0.0018408717587590218
contraceptive O 0 0.004551501013338566
use O 0 2.579470447017229e-06
protected O 0 1.1426996024965774e-05
against O 0 0.08832637220621109
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
both O 0 2.276303092685339e-07
for O 0 4.8023110821304726e-08
carriers O 0 1.199241665972295e-07
of O 0 9.497342468023362e-09
the O 0 1.4138379356154473e-07
BRCA1 O 0 0.004812972154468298
mutation O 0 8.327284376719035e-06
( O 0 9.515822796402063e-08
odds O 0 1.0755335097201169e-05
ratio O 0 1.8070379610435339e-06
, O 0 8.195145539957593e-08
0 O 0 2.179373552735342e-07
. O 0 9.627438402048938e-09
5 O 0 3.467555487191021e-08
; O 0 1.775599933750982e-08
95 O 0 1.0927980298447437e-07
percent O 0 2.530293272684503e-07
confidence O 0 1.9148589558426465e-07
interval O 0 2.3019387640488276e-07
, O 0 3.7762710292099655e-08
0 O 0 1.2334076870956778e-07
. O 0 8.612318858070012e-09
3 O 0 2.1274873418519746e-08
to O 0 2.013046973559085e-08
0 O 0 1.3508430640740698e-07
. O 0 1.0016872664664334e-08
9 O 0 4.4246277752790775e-08
) O 0 4.8062211988053605e-09
and O 0 4.2256487198244486e-09
for O 0 9.53445944418263e-09
carriers O 0 8.525602623876694e-08
of O 0 1.1201858107767748e-08
the O 0 4.837308438254695e-07
BRCA2 O 0 0.14823219180107117
mutation O 0 9.638733899919316e-06
( O 0 4.941586695395017e-08
odds O 0 9.28608096728567e-06
ratio O 0 9.444757438359375e-07
, O 0 5.75708227756877e-08
0 O 0 1.20680795134831e-07
. O 0 6.68467503572856e-09
4 O 0 5.5123599906892196e-08
; O 0 1.6901289257020835e-08
95 O 0 3.528441538946936e-08
percent O 0 1.581360464797399e-07
confidence O 0 8.848719090792656e-08
interval O 0 8.830560460637571e-08
, O 0 1.829351781168498e-08
0 O 0 8.021093833576742e-08
. O 0 6.017714326844725e-09
2 O 0 2.321240621938614e-08
to O 0 2.7508793465358394e-08
1 O 0 8.899684189600521e-08
. O 0 3.253350300269631e-08
1 O 0 1.6033645522384177e-07
) O 0 1.5365694139291008e-07
. O 0 8.802978754829383e-07

CONCLUSIONS O 0 0.0032216848339885473
Oral O 0 0.0017249885713681579
- O 0 0.021740417927503586
contraceptive O 0 0.14185531437397003
use O 0 1.2465602594602387e-06
may O 0 9.804410865399404e-07
reduce O 0 3.1894822427602776e-07
the O 0 8.441300280992436e-08
risk O 0 2.1422131339932093e-06
of O 0 1.7879616279969923e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
in O 0 1.0288787962053902e-05
women O 0 6.457381914515281e-06
with O 0 9.874505622065044e-07
pathogenic O 0 6.612097058678046e-05
mutations O 0 2.0792307623196393e-05
in O 0 1.488214991240966e-07
the O 0 6.288027520895412e-07
BRCA1 O 0 0.002390448935329914
or O 0 1.595839967194479e-05
BRCA2 O 0 0.007055709138512611
gene O 0 0.00012197565229143947

A O 0 3.530292087816633e-05
Japanese O 0 1.2843473086832091e-05
family O 0 3.6347687455418054e-06
with O 0 7.403315294141066e-07
adrenoleukodystrophy B-Disease 1 0.9999022483825684
with O 0 4.074254320585169e-07
a O 0 6.517670954053756e-07
codon O 0 3.123325541309896e-06
291 O 0 5.737318133469671e-06
deletion O 0 3.423602174734697e-05
: O 0 2.3406430216255103e-07
a O 0 6.98168435064872e-07
clinical O 0 3.9984264731174335e-05
, O 0 2.298886982998738e-07
biochemical O 0 8.163620805134997e-06
, O 0 1.8731770978774875e-07
pathological O 0 3.35230834025424e-05
, O 0 3.2692375384613115e-07
and O 0 6.676293082819029e-07
genetic O 0 1.4914581697667018e-05
report O 0 4.984030510968296e-06
. O 0 1.6042440620367415e-06

We O 0 9.92841614788631e-06
report O 0 1.4498543805530062e-06
a O 0 3.538548583037482e-07
Japanese O 0 1.8542283442002372e-06
family O 0 4.799692305823555e-06
with O 0 1.7632648450671695e-05
adrenoleukodystrophy B-Disease 1 0.999998927116394
( O 0 0.00019949539273511618
ALD B-Disease 1 0.9999949932098389
) O 0 2.2682353062464244e-07
with O 0 2.885922789630513e-08
a O 0 1.5435178113420989e-07
three O 0 4.480149229380004e-08
base O 0 1.5510906337112829e-07
pair O 0 1.2552748103189515e-06
deletion O 0 1.1495420039864257e-05
( O 0 1.1629202845142572e-07
delGAG O 0 1.0931646102108061e-05
291 O 0 1.917069312185049e-06
) O 0 7.278244140707102e-08
in O 0 8.369413961872851e-08
the O 0 1.1064787486247951e-06
ALD B-Disease 1 0.9999779462814331
gene O 0 0.00012792435882147402
. O 0 4.90225193061633e-06

A O 0 5.2666735427919775e-05
variety O 0 2.831508027156815e-06
of O 0 3.06648502146345e-07
phenotypes O 0 0.00035822519566863775
were O 0 2.638785474573524e-07
observed O 0 2.7400903945817845e-07
within O 0 3.6756460985998274e-08
this O 0 6.783371020446793e-08
family O 0 1.938372633958352e-06
. O 0 1.2815656873499393e-06

While O 0 2.3778122340445407e-05
the O 0 1.3950773336546263e-06
proband O 0 0.00045732574653811753
( O 0 1.101799171010498e-06
patient O 0 4.8960904678096995e-05
1 O 0 3.404257995498483e-07
) O 0 3.6635025679743194e-08
was O 0 1.2351580380709493e-07
classified O 0 1.2772460422638687e-07
as O 0 1.5490780214122424e-08
having O 0 3.235386358824144e-08
a O 0 1.416786972185946e-07
rare O 0 9.041494308803522e-07
intermediate O 0 4.5746512000732764e-07
type O 0 1.6564219151860016e-07
of O 0 2.292228984401845e-08
adult O 0 6.255174957914278e-05
cerebral O 0 0.4525461792945862
and O 0 1.5263706245605135e-06
cerebello O 0 0.18399544060230255
- O 0 0.15025216341018677
brain O 0 0.13605967164039612
stem O 0 4.22133962274529e-06
forms O 0 2.655226865044824e-07
, O 0 4.175098311520742e-08
his O 0 8.530821560270851e-07
younger O 0 9.37682398216566e-06
brother O 0 1.7155589375761338e-05
( O 0 7.258959300315837e-08
patient O 0 6.4024634411907755e-06
2 O 0 2.2743263627944543e-07
) O 0 3.399780013069176e-08
and O 0 1.1286103074326093e-07
nephew O 0 0.0073910546489059925
( O 0 2.982539797358186e-07
patient O 0 8.92548996489495e-05
3 O 0 7.87108206168341e-07
) O 0 6.523428908167261e-08
had O 0 6.866393960081041e-07
a O 0 1.586041798873339e-05
childhood O 0 0.16183701157569885
ALD B-Disease 1 0.9999963045120239
type O 0 0.0015599443577229977
. O 0 4.959720172337256e-06

Another O 0 0.00015446821635123342
nephew O 0 0.02580706775188446
( O 0 4.7725111471663695e-06
patient O 0 9.248406422557309e-05
4 O 0 6.818692099841428e-07
) O 0 7.492098319517027e-08
of O 0 6.016408349296398e-08
patient O 0 0.0004832051636185497
1 O 0 2.0744855646626092e-06
was O 0 1.4276378124122857e-06
classified O 0 1.8885492636400159e-07
as O 0 5.217564336135183e-08
having O 0 1.3113037766743219e-07
an O 0 3.662951257865643e-07
adolescent O 0 0.0013876454904675484
form O 0 9.622888683225028e-06
. O 0 6.28077941655647e-06

The O 0 3.5918162666348508e-06
tau O 0 4.370754595584003e-06
level O 0 2.6007927544924314e-07
in O 0 3.2918816117444294e-08
the O 0 7.915149780046704e-08
cerebrospinal O 0 0.048958588391542435
fluid O 0 0.1353105753660202
( O 0 1.5826487924641697e-06
CSF O 0 0.18664972484111786
) O 0 1.0034334962938374e-07
in O 0 1.3785454200387903e-07
patient O 0 8.893578342394903e-05
1 O 0 3.021210090992099e-07
was O 0 1.6263710733710468e-07
as O 0 1.1494700302705496e-08
high O 0 3.9646675276117094e-08
as O 0 7.2680861329388335e-09
that O 0 1.1816365663719353e-08
of O 0 9.085206897907483e-08
patients O 0 0.029849546030163765
with O 0 0.01765499636530876
Alzheimers B-Disease 1 0.9999988079071045
disease I-Disease 1 0.9286942481994629
( O 0 3.9319246525337803e-07
AD B-Disease 0 5.566626350628212e-05
) O 0 1.1088829978689319e-06
. O 0 1.2358394769762526e-06

His O 0 0.00010666854359442368
brain O 0 0.000916638586204499
magnetic O 0 7.631417975062504e-05
resonance O 0 0.0009310977184213698
image O 0 0.0006571919075213373
( O 0 1.209948777614045e-06
MRI O 0 0.40348488092422485
) O 0 4.570883334054088e-07
showed O 0 0.0017898778896778822
abnormalities B-Disease 0 0.09580101072788239
in I-Disease 0 6.169664601429758e-08
the I-Disease 0 3.31491101235315e-08
bilateral I-Disease 0 1.8260611795994919e-06
cerebellar I-Disease 1 0.8625777363777161
hemispheres I-Disease 0 0.38887810707092285
and O 0 5.491515821631765e-06
brain O 0 0.023511208593845367
stem O 0 8.937027814681642e-06
, O 0 9.426438651871649e-08
but O 0 2.8249159456095185e-08
not O 0 1.0865748301114309e-08
in O 0 2.2407871114182853e-08
the O 0 2.221713657490909e-07
cerebral O 1 0.7849164009094238
white O 0 1.122287994803628e-05
matter O 0 3.635596783624351e-07
, O 0 3.91224190821049e-08
where O 0 4.6576587919844314e-08
marked O 0 2.2801857824106264e-07
reductions O 0 2.9615094376822526e-07
of O 0 1.0017044971277755e-08
the O 0 1.5884720028225274e-07
cerebral O 0 0.2656804025173187
blood O 0 6.726848368998617e-06
flow O 0 4.2626780327736924e-07
and O 0 1.3040967417055072e-07
oxygen O 0 7.6208170867175795e-06
metabolism O 0 5.963966032140888e-07
were O 0 4.892519100963e-08
clearly O 0 1.9015723751181213e-07
demonstrated O 0 2.6710037559496413e-07
by O 0 3.923114633153091e-08
positron O 0 3.5813660360872746e-05
emission O 0 4.956084467266919e-06
tomography O 0 6.320677493931726e-05
( O 0 3.595201292228012e-07
PET O 0 1.5813355275895447e-05
) O 0 7.708661087235669e-07
. O 0 1.519780425951467e-06

In O 0 0.000711992266587913
patients O 0 0.20877985656261444
2 O 0 1.6677106486895354e-06
and O 0 1.874749813168819e-07
3 O 0 3.204580707460991e-07
, O 0 4.196334657535772e-08
the O 0 8.580595789453582e-08
autopsy O 1 0.8682644963264465
findings O 0 5.0508508138591424e-05
showed O 0 2.1478883354575373e-05
massive O 0 0.00015659394557587802
demyelination B-Disease 1 0.9998396635055542
of I-Disease 0 1.6010068293326185e-07
the I-Disease 0 7.169368814174959e-07
cerebral I-Disease 1 0.7983195781707764
white I-Disease 0 1.1397698472137563e-05
matter I-Disease 0 2.3310353469696565e-07
with O 0 2.9519158672997037e-08
sparing O 0 1.0180592653341591e-06
of O 0 2.2054706505514332e-08
the O 0 6.575871935865507e-08
U O 0 0.0007010902045294642
- O 0 0.0076162125915288925
fibers O 0 6.486108031822369e-05
, O 0 3.889942234991395e-08
compatible O 0 1.1789894927005662e-07
with O 0 2.5641602618975412e-08
the O 0 5.237895095433487e-08
findings O 0 2.081379534502048e-06
of O 0 4.992908770873328e-07
childhood O 0 0.0540553517639637
ALD B-Disease 1 0.9999912977218628
. O 0 4.858106331084855e-05

Oleic O 0 0.03752506896853447
and O 0 3.442725574132055e-05
erucic O 0 0.07421800494194031
acids O 0 4.875987542618532e-06
( O 0 1.5370544304005307e-07
Lorenzos O 0 2.236134832855896e-06
Oil O 0 1.7118685491368524e-07
) O 0 8.550025576425924e-09
were O 0 1.4118620050851405e-08
administered O 0 1.0977282016710888e-07
to O 0 2.911361320911965e-07
patients O 0 3.2741398172220215e-05
1 O 0 6.872421920434135e-08
and O 0 4.0171830306690026e-08
4 O 0 1.19511085472368e-07
, O 0 1.4317998342505689e-08
but O 0 2.1309027431470895e-08
sufficient O 0 6.55265921523096e-08
effectiveness O 0 3.3060968007703195e-07
was O 0 4.0206020912592066e-07
not O 0 1.1227660223767089e-07
obtained O 0 1.6591995972703444e-06
. O 0 1.6012403420972987e-06

The O 0 6.637708793277852e-06
findings O 0 1.3420831237453967e-05
in O 0 1.199042714006282e-07
this O 0 4.573534440055482e-08
family O 0 2.5824931526585715e-07
suggest O 0 2.1289126550527726e-07
that O 0 2.4462908143618733e-08
delGAG291 O 0 2.3478714865632355e-06
is O 0 1.4990543917292598e-08
part O 0 8.821129604541511e-09
of O 0 3.117896385518293e-09
the O 0 1.847628361417719e-08
cause O 0 5.277975105855148e-07
of O 0 4.0517566191056176e-08
Japanese O 0 4.6545854274882004e-05
ALD B-Disease 1 0.9999783039093018
with O 0 5.942363259237027e-06
phenotypic O 0 0.000636047450825572
variations O 0 2.75816837529419e-05
. O 0 2.4101052531477762e-06

Moreover O 0 0.00019701661949511617
, O 0 2.0380623482196825e-06
although O 0 1.6552216663967556e-07
the O 0 1.483003497781965e-08
scale O 0 1.2918447112042486e-07
of O 0 9.172803849821776e-09
the O 0 2.1345639922287774e-08
study O 0 2.779648866635398e-07
is O 0 4.322659208355617e-08
limited O 0 7.6159913930951e-08
, O 0 4.0834102321696264e-08
there O 0 8.031912912542793e-09
is O 0 1.109223557449468e-08
a O 0 5.651386203453512e-08
possibility O 0 1.3945064836207166e-07
that O 0 4.7147736381703e-08
PET O 0 5.869191681995289e-06
can O 0 1.1567923507982414e-07
detect O 0 3.2935981835180428e-06
an O 0 5.443594091047999e-07
insidious B-Disease 0 0.011553785763680935
lesion I-Disease 1 0.8568115830421448
which O 0 4.5020360062153486e-07
is O 0 5.150771542616894e-08
undetectable O 0 9.432443448531558e-07
by O 0 4.241218576339634e-08
computed O 0 1.0228044402538217e-06
tomogram O 0 4.441534110810608e-05
( O 0 2.1341858769119426e-07
CT O 0 0.003111931961029768
) O 0 5.288207560738556e-08
or O 0 4.506408401994122e-08
MRI O 0 0.05347345769405365
analysis O 0 5.039113375460147e-07
, O 0 2.1894557278301363e-08
and O 0 9.600317874003395e-09
that O 0 7.878936614247323e-09
the O 0 4.606722114885997e-09
higher O 0 1.6939143421268454e-08
level O 0 3.649162305663367e-09
of O 0 1.9013024488145902e-09
tau O 0 1.3761153638824908e-07
reflects O 0 7.446750771578081e-08
the O 0 5.1184603222509395e-09
process O 0 2.8142835617472883e-08
of O 0 6.32721253168711e-08
neuronal B-Disease 0 0.000631742354016751
degeneration I-Disease 1 0.9957160353660583
in O 0 0.0002413878683000803
ALD B-Disease 1 0.999988317489624
. O 0 5.452373079606332e-05

Lorenzos O 0 0.0011957529932260513
Oil O 0 1.3531420336221345e-05
should O 0 3.87506588594988e-07
be O 0 2.3193464926407614e-08
given O 0 1.6893649146254575e-08
in O 0 9.502542752670706e-09
the O 0 3.804516524041901e-08
early O 0 7.030164397292538e-07
stage O 0 1.0891666534007527e-05
. O 0 7.312948469007097e-07
. O 0 1.4349445791594917e-06

Nonsense O 0 0.0034061053302139044
mutation O 0 0.004076976329088211
in O 0 1.9761434941756306e-06
exon O 0 1.56750284077134e-05
4 O 0 4.522338201695675e-07
of O 0 3.4216512290186074e-08
human O 0 1.347247149396935e-07
complement O 0 9.356273267258075e-07
C9 O 0 0.0005691259284503758
gene O 0 5.953544359726948e-07
is O 0 2.600330795132777e-08
the O 0 1.0162978014705004e-08
major O 0 5.37613864537434e-08
cause O 0 3.562416281965852e-07
of O 0 3.919419810927138e-08
Japanese O 0 1.4440804989135358e-05
complement B-Disease 0 0.00017999863484874368
C9 I-Disease 1 0.9993695616722107
deficiency I-Disease 1 0.9875524044036865
. O 0 5.514606982615078e-06

Deficiency B-Disease 1 0.9989927411079407
of I-Disease 0 6.243569714570185e-07
the I-Disease 0 2.0755943808126176e-07
ninth I-Disease 0 1.662359409237979e-06
component I-Disease 0 1.8331385831515945e-07
of I-Disease 0 1.5611025361295106e-08
human I-Disease 0 7.474841368093621e-08
complement I-Disease 0 4.1946583451135666e-07
( O 0 1.147508896792715e-07
C9 O 0 0.00010026534437201917
) O 0 5.7451035928579586e-08
is O 0 7.942897894963608e-09
the O 0 1.2408387206619409e-08
most O 0 6.528283336137974e-08
common O 0 3.67019310942851e-06
complement B-Disease 1 0.9998106360435486
deficiency I-Disease 1 0.999992847442627
in O 0 1.322207481280202e-07
Japan O 0 3.817700076069741e-07
but O 0 6.42317488086519e-08
is O 0 3.313924779035915e-08
rare O 0 2.7346030151420564e-07
in O 0 4.7766320676601026e-08
other O 0 3.744982990383505e-08
countries O 0 1.282143671232916e-07
. O 0 1.786417897164938e-06

We O 0 7.014948096184526e-06
studied O 0 3.016896471308428e-06
the O 0 1.2434087182100484e-07
molecular O 0 1.2011133776468341e-06
basis O 0 1.0228439606407846e-07
of O 0 5.047121476309258e-07
C9 B-Disease 1 0.9999163150787354
deficiency I-Disease 1 0.9858074188232422
in O 0 1.6102003996820713e-07
four O 0 1.2937533711010474e-07
Japanese O 0 3.0881158181728097e-06
C9 B-Disease 0 0.38920360803604126
- I-Disease 1 0.959747314453125
deficient I-Disease 1 0.9237527251243591
patients O 0 0.1453736424446106
who O 0 1.2827681530325208e-05
had O 0 2.668944580364041e-05
suffered O 1 0.918274462223053
from O 0 0.00010613515769364312
meningococcal B-Disease 1 0.9999922513961792
meningitis I-Disease 1 0.999992847442627
. O 0 5.6545151892350987e-05

Direct O 0 2.3357481040875427e-05
sequencing O 0 9.506844435236417e-06
of O 0 4.659889043523435e-07
amplified O 0 2.127581501554232e-05
C9 O 0 9.195398160954937e-05
cDNA O 0 7.5105067480762955e-06
and O 0 3.256762397541024e-07
DNA O 0 1.5447370742549538e-06
revealed O 0 8.010259193724778e-07
a O 0 7.759214781799528e-08
nonsense O 0 8.384198508792906e-07
substitution O 0 1.4560131944563182e-07
( O 0 3.2265674576592573e-08
CGA O 0 1.912458628794411e-06
- O 0 1.5942730897222646e-05
- O 0 4.877603714703582e-05
> O 0 5.2377286010596436e-06
TGA O 0 3.613300577853806e-05
) O 0 3.062945097553893e-08
at O 0 1.5744992865052154e-08
codon O 0 1.5238644834880688e-07
95 O 0 6.519609740962551e-08
in O 0 1.7260758156112388e-08
exon O 0 7.541942181887862e-07
4 O 0 1.0472798095406688e-07
in O 0 1.5076709658501386e-08
the O 0 2.5578396289915872e-08
four O 0 5.228253598943411e-07
C9 B-Disease 0 0.040625717490911484
- I-Disease 0 0.24648714065551758
deficient I-Disease 0 0.004643972963094711
individuals O 0 6.650118393736193e-07
. O 0 1.5621859574821428e-06

An O 0 8.558416993764695e-06
allele O 0 4.814082058146596e-05
- O 0 4.225016709824558e-06
specific O 0 1.1311079362030796e-07
polymerase O 0 1.4237111827242188e-06
chain O 0 1.2510596434367471e-06
reaction O 0 2.11393739846244e-07
system O 0 3.012641514033021e-08
designed O 0 1.1497249374770036e-07
to O 0 3.647480184554297e-08
detect O 0 1.3129886156093562e-06
exclusively O 0 1.1108289044159392e-07
only O 0 1.4921452518024125e-08
one O 0 5.787399892653866e-09
of O 0 1.6982355521832915e-09
the O 0 1.0916060055876642e-08
normal O 0 6.50727400852702e-08
and O 0 2.9014151081696582e-08
mutant O 0 5.970840447844239e-06
alleles O 0 7.776777692924952e-07
indicated O 0 3.59679262373902e-07
that O 0 2.4714177371265578e-09
all O 0 9.29277543804119e-10
the O 0 5.091974397686272e-09
four O 0 5.429983502835967e-07
patients O 0 1.757676000124775e-05
were O 0 3.4539052506943335e-08
homozygous O 0 4.85317627862969e-07
for O 0 6.565692878268692e-09
the O 0 1.8142918278840625e-08
mutation O 0 3.3333105875499314e-07
in O 0 1.49159600226767e-08
exon O 0 1.2964695770278922e-06
4 O 0 9.11622564103709e-08
and O 0 1.1779550668222782e-08
that O 0 8.266272999435387e-09
the O 0 1.0056653287904282e-08
parents O 0 9.52315843960605e-08
of O 0 1.1044671843762899e-08
patient O 0 5.058606984675862e-05
2 O 0 1.0284755944667268e-06
were O 0 6.362658382386144e-07
heterozygous O 0 1.7958649550564587e-05
. O 0 1.3672073464476853e-06

The O 0 4.7108815124374814e-06
common O 0 2.146413407899672e-06
mutation O 0 2.953520606752136e-06
at O 0 3.947644700019737e-08
codon O 0 4.4820683342550183e-07
95 O 0 1.8956841074668773e-07
in O 0 4.619517568471565e-08
exon O 0 2.751609372353414e-06
4 O 0 3.96874639818634e-07
might O 0 1.2602558285834675e-07
be O 0 8.376469295967581e-09
responsible O 0 3.3173712665757193e-08
for O 0 2.6151527166007327e-08
most O 0 9.557805213944448e-08
Japanese O 0 0.0001557326759211719
C9 B-Disease 1 0.9998103976249695
deficiency I-Disease 1 0.9832887053489685
. O 0 8.890502840586123e-07
. O 0 1.026413997351483e-06

BRCA1 O 1 0.8529025316238403
required O 0 6.728336757078068e-06
for O 0 2.522511124425364e-07
transcription O 0 1.4891862747390405e-06
- O 0 2.0759298422490247e-05
coupled O 0 7.540491878899047e-06
repair O 0 2.090083398798015e-05
of O 0 1.668466325099871e-07
oxidative O 0 0.012551023624837399
DNA O 0 0.0006064163753762841
damage O 0 0.00035306476638652384
. O 0 7.5642742558557075e-06

The O 0 8.196034468710423e-05
breast B-Disease 1 0.9993745684623718
and I-Disease 1 0.9397851824760437
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
susceptibility O 1 0.9971174001693726
gene O 0 6.790280167479068e-05
BRCA1 O 0 0.00011031350732082501
encodes O 0 2.0417683117557317e-06
a O 0 1.2851027122451342e-06
zinc O 0 0.00018587186059448868
finger O 0 7.00636292094714e-06
protein O 0 3.5838056078318914e-07
of O 0 2.7912964384313455e-08
unknown O 0 8.042975991884305e-07
function O 0 7.804007395861845e-07
. O 0 1.2268690170458285e-06

Association O 0 3.7222751416265965e-05
of O 0 6.627130915148882e-07
the O 0 3.4433088558216696e-07
BRCA1 O 0 6.185741949593648e-05
protein O 0 2.756429182682041e-07
with O 0 2.2391466458770992e-08
the O 0 4.3230876656252804e-08
DNA O 0 1.698209530331951e-06
repair O 0 1.4697729966428597e-05
protein O 0 4.1006171613844344e-07
Rad51 O 0 1.316720499744406e-05
and O 0 2.2580302072583436e-08
changes O 0 1.7913020400328605e-08
in O 0 4.022893129729255e-09
the O 0 3.0009406071229705e-09
phosphorylation O 0 7.897445897242505e-08
and O 0 2.632362772203578e-08
cellular O 0 4.95532447075675e-07
localization O 0 1.0118166926531558e-07
of O 0 1.866353294133205e-09
the O 0 8.00802002487444e-09
protein O 0 6.514240169508412e-08
after O 0 2.2161438550938328e-07
exposure O 0 1.5933952681734809e-06
to O 0 9.837025061187887e-08
DNA O 0 2.5730432753334753e-06
- O 0 4.8264013457810506e-05
damaging O 0 9.079193659999873e-06
agents O 0 9.625954078273935e-08
are O 0 4.9389079492812016e-09
consistent O 0 2.4799753362003685e-08
with O 0 1.1654223364132577e-08
a O 0 1.4021397021224402e-07
role O 0 2.109635630631601e-07
for O 0 2.515673998004786e-07
BRCA1 O 0 0.00016682893328834325
in O 0 7.908341785878292e-07
DNA O 0 2.315419988008216e-05
repair O 0 0.0005191079108044505
. O 0 7.299038315977668e-06

Here O 0 2.0704452253994532e-05
, O 0 5.322450533640222e-07
it O 0 4.040982659603287e-08
is O 0 2.429282197624616e-08
shown O 0 8.461643830059984e-08
that O 0 2.6005093189951367e-08
mouse O 0 3.5022972042497713e-06
embryonic O 0 1.8124130292562768e-05
stem O 0 4.062842344865203e-05
cells O 0 7.659346738364547e-05
deficient B-Disease 0 8.220016752602533e-05
in I-Disease 0 2.7112733391732036e-07
BRCA1 I-Disease 0 0.00013290373317431659
are O 0 7.36134140311151e-08
defective O 0 9.969821803679224e-06
in O 0 3.8084809972360745e-08
the O 0 2.14717346125326e-08
ability O 0 4.707908018986018e-08
to O 0 7.680202251947321e-09
carry O 0 3.348904087374649e-08
out O 0 2.3734061826985453e-08
transcription O 0 1.3950385380212538e-07
- O 0 3.3555204481672263e-06
coupled O 0 2.337921841899515e-06
repair O 0 5.6138560466933995e-06
of O 0 3.8949757197315193e-08
oxidative O 0 0.0021980153396725655
DNA O 0 0.00019896846788469702
damage O 0 6.263059185585007e-05
, O 0 1.1210647699044785e-07
and O 0 7.351505360020383e-08
are O 0 4.2364000307770766e-08
hypersensitive O 0 0.00028008705703541636
to O 0 2.3003331079962663e-06
ionizing O 0 0.0029585198499262333
radiation O 0 0.0988067165017128
and O 0 5.486110694619128e-07
hydrogen O 0 1.3381432836467866e-05
peroxide O 0 0.0005028524319641292
. O 0 5.19971399626229e-06

These O 0 7.912122782727238e-06
results O 0 5.159422926226398e-06
suggest O 0 1.2226454373376328e-06
that O 0 2.327354593489872e-07
BRCA1 O 0 3.0214690923457965e-05
participates O 0 2.140067891787112e-07
, O 0 3.146016425148446e-08
directly O 0 3.8050249173693373e-08
or O 0 3.458598740735397e-08
indirectly O 0 4.3670570448739454e-07
, O 0 1.5853718338121325e-08
in O 0 1.1918722897519274e-08
transcription O 0 2.1347393897030997e-07
- O 0 1.1031619578716345e-05
coupled O 0 6.703556664433563e-06
repair O 0 2.1411513444036245e-05
of O 0 1.0213662449132244e-07
oxidative O 0 0.01578384079039097
DNA O 0 0.0007031122222542763
damage O 0 0.00010620451212162152
. O 0 7.111446507224173e-07
. O 0 1.2377137181829312e-06

Truncation O 0 0.012456884607672691
mutations O 0 0.1953003704547882
in O 0 2.2453709789260756e-06
the O 0 3.85719090445491e-07
transactivation O 0 7.278045086422935e-05
region O 0 7.137401212276018e-07
of O 0 9.504594800091581e-08
PAX6 O 0 0.005429939832538366
result O 0 1.123204469877237e-06
in O 0 1.4949233673178242e-07
dominant O 0 5.1760507631115615e-06
- O 0 6.453562673414126e-05
negative O 0 9.927526662067976e-06
mutants O 0 6.019964348524809e-05
. O 0 3.935521363018779e-06

PAX6 O 0 0.3346719741821289
is O 0 2.3944853637658525e-06
a O 0 5.815486474602949e-07
transcription O 0 4.2453953597032523e-07
factor O 0 7.870708884638589e-08
with O 0 1.6332434071841817e-08
two O 0 3.4942782889402224e-08
DNA O 0 9.021494520311535e-07
- O 0 9.764839887793642e-06
binding O 0 7.78897288000735e-07
domains O 0 2.456817185247928e-07
( O 0 2.12993569448372e-08
paired O 0 3.154521834858315e-07
box O 0 1.5990049178071786e-06
and O 0 1.7008565578180423e-07
homeobox O 0 1.1886396350746509e-05
) O 0 1.3901215289990887e-08
and O 0 7.3224923902159844e-09
a O 0 1.1739204808236536e-07
proline O 0 2.885961521315039e-06
- O 0 2.8603230930457357e-06
serine O 0 7.826471346561448e-07
- O 0 4.042905402457109e-06
threonine O 0 2.799478579618153e-06
( O 0 9.818093360536295e-08
PST O 0 1.209539459523512e-05
) O 0 1.2701619311883405e-07
- O 0 2.650243004609365e-06
rich O 0 9.791011734705535e-07
transactivation O 0 3.0453866202151403e-05
domain O 0 2.8285176085773855e-06
. O 0 1.5442892618011683e-06

PAX6 O 1 0.6422090530395508
regulates O 0 0.0009693852043710649
eye O 0 0.11301970481872559
development O 0 1.2862308267358458e-06
in O 0 4.2371357267256826e-07
animals O 0 2.2492385198802367e-07
ranging O 0 9.842802910497994e-07
from O 0 1.134132432412116e-07
jellyfish O 0 4.6862687668181024e-06
to O 0 1.5296288324861962e-07
Drosophila O 0 8.869593557392363e-07
to O 0 8.529357273800997e-07
humans O 0 1.9275078102509724e-06
. O 0 1.6708992234271136e-06

Heterozygous O 1 0.9336346387863159
mutations O 0 0.3514638841152191
in O 0 1.5323562365665566e-06
the O 0 1.9963287911650696e-07
human O 0 5.111736527396715e-07
PAX6 O 0 0.029011938720941544
gene O 0 3.923660642612958e-06
result O 0 3.2564736329732114e-07
in O 0 3.532886339030483e-08
various O 0 4.652846286035128e-08
phenotypes O 0 0.00024401821428909898
, O 0 1.1078918760176748e-07
including O 0 5.089967203275592e-07
aniridia B-Disease 1 0.9999626874923706
, O 0 2.859555206669029e-05
Peters B-Disease 1 0.9996389150619507
anomaly I-Disease 1 0.9999412298202515
, O 0 1.4059604836802464e-05
autosomal B-Disease 0 0.054436568170785904
dominant I-Disease 0 0.0012848005862906575
keratitis I-Disease 1 0.9909232258796692
, O 0 2.171909500248148e-06
and O 0 2.310111540282378e-06
familial B-Disease 0 0.4970152676105499
foveal I-Disease 1 0.9992890357971191
dysplasia I-Disease 1 0.9998511075973511
. O 0 4.273499143891968e-05

It O 0 1.1065410035371315e-05
is O 0 6.204104465723503e-07
believed O 0 2.819549820287648e-07
that O 0 1.3017304567597421e-08
the O 0 2.0924753485473957e-08
mutated O 0 4.373106548882788e-06
allele O 0 1.4241049939300865e-06
of O 0 3.98741875073938e-08
PAX6 O 0 0.0001737250859150663
produces O 0 1.839135848058504e-06
an O 0 7.816462499476984e-08
inactive O 0 3.618274320160708e-07
protein O 0 1.3230588535861898e-07
and O 0 7.398784163115124e-08
aniridia B-Disease 1 0.9944844841957092
is O 0 3.882482531025744e-07
caused O 0 5.1285560402902775e-06
due O 0 8.270043281299877e-07
to O 0 2.0642960407712962e-06
genetic O 0 3.7401518056867644e-05
haploinsufficiency O 0 0.0023662587627768517
. O 0 3.526656428221031e-06

However O 0 1.4431814634008333e-05
, O 0 2.3115123326533649e-07
several O 0 8.67745342247872e-08
truncation O 0 8.982399776868988e-06
mutations O 0 5.3551248129224405e-05
have O 0 1.155207058900487e-07
been O 0 7.258059042669629e-08
found O 0 2.662508613582304e-08
to O 0 4.990718949215989e-08
occur O 0 7.057168716073647e-08
in O 0 1.4942813209017913e-08
the O 0 4.479072757135327e-08
C O 0 1.9217427507101092e-06
- O 0 1.9757966583711095e-05
terminal O 0 9.53254675550852e-06
half O 0 9.767494191237347e-08
of O 0 1.585311437679593e-08
PAX6 O 0 0.0071625071577727795
in O 0 7.673595973756164e-06
patients O 0 0.0025506976526230574
with O 0 1.379104446641577e-06
Aniridia B-Disease 1 0.999669075012207
resulting O 0 6.373332325892989e-06
in O 0 5.3695284663035636e-08
mutant O 0 1.1709746559063205e-06
proteins O 0 2.880445570951906e-08
that O 0 9.64614876863834e-09
retain O 0 2.8556712550198426e-07
the O 0 2.0302058700849557e-08
DNA O 0 4.909929884888697e-07
- O 0 1.2775728919223184e-06
binding O 0 3.048380676773377e-07
domains O 0 6.860425827426297e-08
but O 0 2.102408558357638e-08
have O 0 1.891342371607152e-08
lost O 0 9.75863017060874e-08
most O 0 7.704999305246929e-09
of O 0 9.339387929685472e-09
the O 0 1.2925188741519378e-07
transactivation O 0 9.478266292717308e-05
domain O 0 4.110340796614764e-06
. O 0 2.4315088467119494e-06

It O 0 4.244352567184251e-06
is O 0 3.4512882507442555e-07
not O 0 5.31188319996545e-08
clear O 0 8.251154781646619e-08
whether O 0 2.5175499018814662e-08
such O 0 1.1473760608282646e-08
mutants O 0 2.8697604648186825e-06
really O 0 5.436797323454812e-07
behave O 0 4.1873761347233085e-07
as O 0 1.2800343895946753e-08
loss O 0 4.147612742144702e-07
- O 0 1.0924245543719735e-06
of O 0 2.225390005605732e-08
- O 0 1.1278122656221967e-05
function O 0 1.145313532902037e-07
mutants O 0 9.329347108177899e-07
as O 0 4.533755770808057e-08
predicted O 0 6.046976182005892e-07
by O 0 1.6371068056741933e-07
haploinsufficiency O 0 9.846828470472246e-05
. O 0 2.3423317543347366e-06

Contrary O 0 6.695086631225422e-05
to O 0 1.047828732225753e-06
this O 0 7.290122994163539e-08
theory O 0 1.2288556661133043e-07
, O 0 1.8491229880623905e-08
our O 0 8.706246390488559e-09
data O 0 3.047363250630042e-08
showed O 0 2.2664967502805666e-07
that O 0 4.033357647870162e-09
these O 0 2.966069168053309e-09
mutants O 0 3.0512893545164843e-07
are O 0 4.380707352424906e-09
dominant O 0 2.4737400394769793e-07
- O 0 4.524263204075396e-06
negative O 0 7.412591571664962e-07
in O 0 4.806829068115803e-08
transient O 0 5.057228463556385e-06
transfection O 0 8.550013444619253e-05
assays O 0 4.698552402260248e-06
when O 0 1.0072973566366272e-07
they O 0 1.5139153930476823e-08
are O 0 7.1845480675847284e-09
coexpressed O 0 3.916728928743396e-06
with O 0 9.820247015568384e-08
wild O 0 1.317980377280037e-06
- O 0 0.0001715429243631661
type O 0 3.534775532898493e-05
PAX6 O 0 0.005541018210351467
. O 0 8.82407675817376e-06

We O 0 5.140734629094368e-06
found O 0 3.081180182107346e-07
that O 0 1.0685993423464879e-08
the O 0 5.823953319605835e-09
dominant O 0 4.2000101529993117e-07
- O 0 2.293222860316746e-05
negative O 0 1.920489467011066e-06
effects O 0 1.6469659840367967e-06
result O 0 9.447714433008514e-08
from O 0 9.211480467286037e-09
the O 0 1.1118097553719508e-08
enhanced O 0 6.625342621191521e-07
DNA O 0 1.1008319233951624e-06
binding O 0 1.72426183553398e-07
ability O 0 5.005914971434322e-08
of O 0 8.309253729521515e-09
these O 0 2.4998932701691956e-08
mutants O 0 1.0404905879113358e-05
. O 0 1.3327839951671194e-06

Kinetic O 0 0.00017579687118995935
studies O 0 3.920230938092573e-06
of O 0 8.963874620349088e-08
binding O 0 1.3413464330369607e-06
and O 0 2.8156026132819534e-07
dissociation O 0 5.2553503337549046e-05
revealed O 0 1.1186867823198554e-06
that O 0 9.128298117389022e-09
various O 0 5.215233134236996e-09
truncation O 0 9.281159805141215e-07
mutants O 0 1.156297184934374e-05
have O 0 6.279254449736982e-08
3 O 0 4.583245072353748e-08
- O 0 1.912044581331429e-06
5 O 0 1.3726210568165698e-07
- O 0 2.025042931563803e-06
fold O 0 2.319263785466319e-06
higher O 0 3.2605004918195846e-08
affinity O 0 2.0173750669982837e-08
to O 0 9.533950517948142e-09
various O 0 5.813043824076658e-09
DNA O 0 3.198025808615057e-07
- O 0 1.2086248943887767e-06
binding O 0 1.8240650945244852e-07
sites O 0 1.980484931607407e-08
when O 0 1.9234953185787163e-08
compared O 0 6.685608866519033e-08
with O 0 7.47272910217589e-09
the O 0 2.798957332572627e-08
wild O 0 4.0619406149744464e-07
- O 0 7.078221824485809e-05
type O 0 1.3625250176119152e-05
PAX6 O 0 0.0019646401051431894
. O 0 5.293937647365965e-06

These O 0 8.037976840569172e-06
results O 0 5.656622761307517e-06
provide O 0 3.3099013307946734e-07
a O 0 2.4000263465495664e-07
new O 0 1.6960586890490958e-07
insight O 0 2.2908791663667216e-07
into O 0 9.019557545286716e-09
the O 0 3.715249441427204e-09
role O 0 2.09688213459458e-08
of O 0 1.4198582753977007e-08
mutant O 0 8.741475539864041e-06
PAX6 O 0 0.0001787732617231086
in O 0 8.069790169429325e-07
causing O 0 4.2041196138598025e-05
aniridia B-Disease 1 0.9987547397613525
. O 0 1.1709523732861271e-06
. O 0 1.6750044551372412e-06

Reversal O 0 0.004625843372195959
of O 0 2.775689063128084e-05
severe O 1 0.999737560749054
hypertrophic B-Disease 1 0.999971866607666
cardiomyopathy I-Disease 1 0.9999992847442627
and O 0 4.444776277523488e-05
excellent O 0 2.905677138187457e-05
neuropsychologic O 0 0.007761013228446245
outcome O 0 4.52070526080206e-06
in O 0 1.39943324484193e-07
very B-Disease 0 2.315658207407978e-07
- I-Disease 0 3.632035441114567e-05
long I-Disease 0 3.909418410330545e-06
- I-Disease 0 4.847869058721699e-05
chain I-Disease 0 1.6260457414318807e-05
acyl I-Disease 0 1.2551212421385571e-05
- I-Disease 0 3.177426697220653e-05
coenzyme I-Disease 0 1.649046862439718e-05
A I-Disease 0 0.00012341000547166914
dehydrogenase I-Disease 0 0.16517147421836853
deficiency I-Disease 0 0.014958246611058712
. O 0 2.3659138150833314e-06

Very B-Disease 0 2.829753066180274e-05
- I-Disease 0 0.00012098696606699377
long I-Disease 0 6.342693268379662e-06
- I-Disease 0 3.3137159334728494e-05
chain I-Disease 0 8.022576366784051e-06
acyl I-Disease 0 4.661498678615317e-06
- I-Disease 0 6.058120561647229e-06
coenzyme I-Disease 0 2.9091402211633977e-06
A I-Disease 0 1.6205756310228026e-06
dehydrogenase I-Disease 0 1.5770316167618148e-05
( I-Disease 0 2.2857136627862928e-07
VLCAD I-Disease 0 0.011704200878739357
) I-Disease 0 6.599270363949472e-06
deficiency I-Disease 0 0.02240011654794216
is O 0 8.861386646685787e-08
a O 0 3.4287710150238127e-05
disorder O 0 0.023113610222935677
of O 0 2.639779062008074e-08
fatty O 0 3.2042521524999756e-06
acid O 0 4.448012987268157e-06
beta O 0 3.31769456352049e-07
oxidation O 0 2.0671829759066895e-07
that O 0 2.1062215083134106e-08
reportedly O 0 1.4414898714676383e-06
has O 0 8.014319519134006e-08
high O 0 2.7600643193181895e-07
rates O 0 2.5630950517552265e-07
of O 0 1.0104397318855263e-07
morbidity O 1 0.9078413248062134
and O 0 3.506185385049321e-05
mortality O 0 0.0036409148015081882
. O 0 4.155521310167387e-06

We O 0 3.5496689179126406e-06
describe O 0 2.947409029729897e-06
the O 0 3.687801708451843e-08
outcome O 0 1.447305351121031e-07
of O 0 8.985267641037353e-09
a O 0 4.2522512444520544e-07
5 O 0 3.6643660905610886e-07
- O 0 1.4274553905124776e-05
year O 0 3.9261917095245735e-07
- O 0 8.678975973452907e-06
old O 0 1.4401677617570385e-05
girl O 0 0.00023848893761169165
with O 0 1.3391324500844348e-05
VLCAD B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999970197677612
who O 0 3.941779141314328e-06
was O 0 1.373934566117896e-07
first O 0 6.996682344606597e-08
seen O 0 2.218108079432568e-07
at O 0 1.50851953151232e-08
5 O 0 5.70828326829087e-08
months O 0 1.341181103953204e-07
of O 0 1.627565104911355e-08
age O 0 1.4343986549647525e-06
with O 0 8.562416951463092e-06
severe O 1 0.9998685121536255
hypertrophic B-Disease 1 0.9999938011169434
cardiomyopathy I-Disease 1 1.0
, O 1 0.6326165199279785
hepatomegaly B-Disease 1 0.9999985694885254
, O 0 0.0021742458920925856
encephalopathy B-Disease 0 0.039475809782743454
, O 0 6.056077381799696e-07
and O 0 1.9227672964916565e-06
hypotonia B-Disease 0 0.41902056336402893
. O 0 9.618403055355884e-06

Biochemical O 0 0.13839788734912872
studies O 0 0.0036321550142019987
indicated O 1 0.9982964396476746
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999994039535522
caused O 0 0.00039267915417440236
by O 0 2.457117034282419e-07
a O 0 1.9085030089627253e-06
stable O 0 7.326068953261711e-06
yet O 0 1.0368050880060764e-06
inactive O 0 4.668309884436894e-06
enzyme O 0 2.2026179067324847e-06
. O 0 1.014643657981651e-06

Molecular O 0 0.002289482159540057
genetic O 0 0.0005330857820808887
analysis O 0 3.912193278665654e-06
of O 0 1.1593679261068246e-07
her O 0 2.3179783966043033e-05
VLCAD O 0 0.12804359197616577
gene O 0 4.188125330983894e-06
revealed O 0 3.1464776384382276e-06
a O 0 8.215473599193501e-07
T1372C O 0 6.385324377333745e-05
( O 0 1.7580535427441646e-07
F458L O 0 6.767449576727813e-06
) O 0 1.2565584484036663e-07
missense O 0 2.543558002798818e-05
mutation O 0 3.83863334718626e-06
and O 0 1.9580058108203957e-07
a O 0 6.745078735548304e-06
1668 O 0 0.3136005997657776
ACAG O 0 0.08886630088090897
1669 O 0 0.0002437205839669332
splice O 0 7.185307185864076e-05
site O 0 9.205964488501195e-06
mutation O 0 1.543308826512657e-05
. O 0 1.7899191107062506e-06

After O 0 3.904000186594203e-05
initial O 0 4.793870175490156e-05
treatment O 0 4.803315096069127e-05
with O 0 3.545503659552196e-07
intravenous O 0 0.00037653392064385116
glucose O 0 7.725263276370242e-05
and O 0 5.411605457084079e-07
carnitine O 0 0.0001197771925944835
, O 0 1.0432226105194786e-07
the O 0 5.287461490866008e-08
patient O 0 2.7306878109811805e-05
has O 0 2.868912929443468e-07
thrived O 0 1.0885288475037669e-06
on O 0 6.255119444631418e-08
a O 0 2.479105774000345e-07
low O 0 6.546663371409522e-07
- O 0 8.315348168252967e-06
fat O 0 1.3239605323178694e-05
diet O 0 1.9010932419405435e-06
supplemented O 0 2.864830719317979e-07
with O 0 3.410541893344998e-08
medium O 0 3.952644078708545e-07
- O 0 5.7346924222656526e-06
chain O 0 2.060001179415849e-06
triglyceride O 0 2.248533746751491e-06
oil O 0 3.72006269344638e-07
and O 0 8.799153761174239e-08
carnitine O 0 1.846599843702279e-05
and O 0 2.8246554961697257e-07
avoidance O 0 8.385346518480219e-06
of O 0 5.889943395231967e-07
fasting O 0 0.00016716093523427844
. O 0 1.2239532225066796e-05

Her O 0 0.0009073970140889287
ventricular O 1 0.939314067363739
hypertrophy O 1 0.8411336541175842
resolved O 0 0.00012448565394151956
significantly O 0 6.438208856707206e-06
over O 0 3.4875378673859814e-07
1 O 0 1.6024213778109697e-07
year O 0 1.8426770509449852e-07
, O 0 4.599901970436804e-08
and O 0 1.723867200098539e-07
cognitively O 0 0.00016908120596781373
, O 0 7.544366553702275e-08
she O 0 1.6049509099502757e-07
is O 0 6.222845350123407e-09
in O 0 6.462200108359184e-09
the O 0 1.587244824463596e-08
superior O 0 6.78637206874555e-07
range O 0 2.555002254212013e-07
for O 0 1.9177848287199595e-07
age O 0 2.830568291756208e-06
. O 0 1.4491216688838904e-06

Clinical O 0 0.029217055067420006
recognition O 0 5.418410728452727e-05
of O 0 4.211053601466119e-05
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999995231628418
is O 0 4.591680067278503e-07
important O 0 2.7998330764944512e-08
because O 0 3.7801264340942e-08
it O 0 1.4023879835178832e-08
is O 0 5.784685175314053e-09
one O 0 2.7197732954675757e-09
of O 0 1.3557940325981122e-09
the O 0 1.0169493691591924e-08
few O 0 1.899241652836281e-07
directly O 0 2.8787926567019895e-06
treatable O 1 0.8840508460998535
causes O 0 2.091596797981765e-05
of O 0 2.0398415472300258e-06
cardiomyopathy B-Disease 1 0.9999994039535522
in O 0 0.00010216785449301824
children O 0 3.7784793676109985e-05
. O 0 8.185778597180615e-07
. O 0 2.7265248263574904e-06

Cloning O 0 8.42598092276603e-05
of O 0 8.536062523489818e-07
a O 0 2.0535633211693494e-06
novel O 0 2.0127552033955e-06
member O 0 4.409059073395838e-08
of O 0 4.618925242283467e-09
the O 0 2.027868362119989e-08
low O 0 1.5711084415670484e-06
- O 0 9.556105214869604e-05
density O 0 5.2867380873067304e-06
lipoprotein O 0 0.000193158644833602
receptor O 0 1.3009572285227478e-05
family O 0 3.4347858672845177e-06
. O 0 1.5777870885358425e-06

A O 0 9.230802970705554e-05
gene O 0 2.7480495191412047e-05
encoding O 0 5.5675868679827545e-06
a O 0 1.1997727824564208e-06
novel O 0 4.63324477095739e-06
transmembrane O 0 7.063362318149302e-06
protein O 0 4.234094035382441e-07
was O 0 1.335539536739816e-07
identified O 0 8.488574820830763e-08
by O 0 1.7252233419640106e-08
DNA O 0 3.3993657666542276e-07
sequence O 0 5.97475988683982e-08
analysis O 0 3.885271127046508e-08
within O 0 8.72200267565404e-09
the O 0 5.2527322935702614e-08
insulin B-Disease 0 0.0128636434674263
- I-Disease 1 0.6484999060630798
dependent I-Disease 1 0.6586646437644958
diabetes I-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999974966049194
( O 0 1.7161983123514801e-06
IDDM B-Disease 0 0.0013072758447378874
) O 0 2.1940778083262558e-07
locus O 0 2.9931848075648304e-06
IDDM4 O 0 5.5842683650553226e-05
on O 0 1.6840524494909914e-06
chromosome O 0 7.930855645099655e-05
11q13 O 0 0.000141046941280365
. O 0 3.611259671743028e-06

Based O 0 1.1891735994140618e-05
on O 0 5.925420509811374e-07
its O 0 1.9147327634527755e-07
chromosomal O 0 7.788514631101862e-05
position O 0 1.8667656149773393e-06
, O 0 3.2587969656106e-08
this O 0 8.023032904702632e-09
gene O 0 5.6981228624408686e-08
is O 0 5.733387542505852e-09
a O 0 6.210184011479214e-08
candidate O 0 2.8961471798538696e-07
for O 0 6.731121260372674e-08
conferring O 0 0.00011241242464166135
susceptibility O 1 0.6921272277832031
to O 0 0.0007548478315584362
diabetes B-Disease 1 0.9995356798171997
. O 0 3.4499200410209596e-05

The O 0 6.070688414183678e-06
gene O 0 7.766328963043634e-06
, O 0 2.602251640837494e-07
termed O 0 1.821445152927481e-06
low O 0 1.342792756986455e-06
- O 0 1.317639816988958e-05
density O 0 1.641640551497403e-06
lipoprotein O 0 1.972998506971635e-05
receptor O 0 1.390532133882516e-06
related O 0 2.3378277091978816e-07
protein O 0 1.618007701154056e-07
5 O 0 1.246256715603522e-07
( O 0 3.817921623294751e-08
LRP5 O 0 2.566606053733267e-05
) O 0 1.7521175621482143e-08
, O 0 7.296616644225651e-09
encodes O 0 4.38121112722456e-08
a O 0 4.63525466898318e-08
protein O 0 4.0259116929064476e-08
of O 0 9.742390894018627e-09
1615 O 0 8.476708899252117e-06
amino O 0 1.2247117808783514e-07
acids O 0 2.9484720442951584e-08
that O 0 4.932770192311864e-09
contains O 0 8.43849523590734e-09
conserved O 0 2.8433706944497317e-08
modules O 0 1.0969495889412428e-07
which O 0 1.760411549867058e-08
are O 0 2.7287989645685684e-09
characteristic O 0 2.4843403778618267e-08
of O 0 2.304748614179175e-09
the O 0 1.982631658847822e-08
low O 0 1.1959732546529267e-06
- O 0 0.00019608467118814588
density O 0 9.00197665032465e-06
lipoprotein O 0 0.0003019787836819887
( O 0 4.848180310546013e-07
LDL O 0 4.03418016503565e-05
) O 0 5.063624826107116e-07
receptor O 0 5.119188699609367e-06
family O 0 2.353567879254115e-06
. O 0 1.368770313092682e-06

These O 0 3.4267632145201787e-06
modules O 0 3.955286501877708e-06
include O 0 1.4711348228502175e-07
a O 0 3.60910746621812e-07
putative O 0 3.5211014619562775e-06
signal O 0 8.109406053335988e-07
peptide O 0 1.4431290651373274e-07
for O 0 5.508363098982727e-09
protein O 0 1.6049073181534368e-08
export O 0 1.271520133627746e-08
, O 0 1.1533615840164657e-08
four O 0 1.7146208008966823e-08
epidermal O 0 1.0812058235387667e-06
growth O 0 1.1838545788123156e-07
factor O 0 7.96897197119506e-08
( O 0 3.298153927744352e-08
EGF O 0 3.463931079750182e-06
) O 0 2.692162404116516e-08
repeats O 0 3.336707550261053e-07
with O 0 3.3435618718158366e-08
associated O 0 9.659667199457544e-08
spacer O 0 2.0296579350542743e-06
domains O 0 2.9671238621631346e-07
, O 0 3.331168230147341e-08
three O 0 6.042029099262436e-08
LDL O 0 6.230215149116702e-06
- O 0 4.803892443305813e-05
receptor O 0 3.045398216272588e-06
( O 0 6.564017240862086e-08
LDLR O 0 1.638126741454471e-05
) O 0 3.170691087461819e-08
repeats O 0 4.0006747781262675e-07
, O 0 9.44652178702654e-09
a O 0 4.080965609887244e-08
single O 0 1.561384692649881e-07
transmembrane O 0 1.1182014532096218e-06
spanning O 0 1.589017415426497e-07
domain O 0 6.271366714827309e-08
, O 0 1.0923058013645459e-08
and O 0 1.651836889493552e-08
a O 0 4.3524840975806e-07
cytoplasmic O 0 2.5684988941065967e-05
domain O 0 8.481762961309869e-06
. O 0 4.828993496630574e-06

The O 0 2.6946570415020688e-06
encoded O 0 1.567947379044199e-06
protein O 0 6.796437332923233e-07
has O 0 7.529847323439753e-08
a O 0 8.348447977368778e-08
unique O 0 4.336582293262836e-08
organization O 0 2.711580293635052e-08
of O 0 3.1665571498251666e-08
EGF O 0 1.7340207705274224e-05
and O 0 3.638517114268325e-07
LDLR O 0 0.004339896608144045
repeats O 0 3.3443542633904144e-05
; O 0 1.822710373744485e-07
therefore O 0 5.7196288594241196e-08
, O 0 2.326710379918495e-08
LRP5 O 0 7.37414593459107e-05
likely O 0 6.340246727631893e-07
represents O 0 4.7619135301602e-08
a O 0 3.822686878152126e-08
new O 0 5.774072420194898e-08
category O 0 3.647062740697038e-08
of O 0 6.760737747413259e-09
the O 0 1.1330220672789437e-07
LDLR O 0 0.04605107381939888
family O 0 6.428018423321191e-06
. O 0 1.509662752141594e-06

Both O 0 1.4013917279953603e-05
human O 0 2.0569896150846034e-06
and O 0 3.069448553105758e-07
mouse O 0 1.390567013004329e-05
LRP5 O 0 0.0012736334465444088
cDNAs O 0 7.30179890524596e-05
have O 0 1.2163984308699582e-07
been O 0 5.732887586873403e-08
isolated O 0 1.6515227230229357e-07
and O 0 1.1397137456015116e-08
the O 0 8.319529953837446e-09
encoded O 0 8.718879485059006e-08
mature O 0 1.279339301163418e-07
proteins O 0 1.1347096595670791e-08
are O 0 4.2763730334627326e-09
95 O 0 1.354473084802521e-07
% O 0 5.583234496953082e-08
identical O 0 4.7288861537708726e-07
, O 0 2.8163295695549095e-08
indicating O 0 1.8765814502330613e-07
a O 0 1.3372448393056402e-07
high O 0 1.3799962061966653e-07
degree O 0 1.1498565299916663e-07
of O 0 2.2976479385761195e-08
evolutionary O 0 1.4412313475986593e-06
conservation O 0 3.5684141153069504e-07
. O 0 1.0935257677147092e-07
. O 0 6.637237675022334e-07

The O 0 1.2654477359319571e-05
APC B-Disease 0 6.666939589194953e-05
variants O 0 1.0620832654240075e-05
I1307K O 0 3.22756968671456e-05
and O 0 2.393126123934053e-07
E1317Q O 0 2.8612930691451766e-05
are O 0 9.663703082196662e-08
associated O 0 1.1875039263031795e-06
with O 0 0.16730815172195435
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.7744065189617686e-05
but O 0 1.5519384533035918e-07
not O 0 1.2697968898578438e-08
always O 0 2.6320465806861648e-08
with O 0 2.1511905146098798e-08
a O 0 1.0417726343803224e-06
family O 0 1.2340952935119276e-06
history O 0 9.631296506995568e-07
. O 0 1.8863706827687565e-06

Classical O 0 0.38541704416275024
familial B-Disease 1 0.9999963045120239
adenomatous I-Disease 1 0.9999966621398926
polyposis I-Disease 1 0.9999996423721313
( O 0 0.007907239720225334
FAP B-Disease 1 0.8270257115364075
) O 0 2.3025563677947503e-06
is O 0 1.613803704003658e-07
a O 0 1.1121534271296696e-06
high O 0 2.2782412997912616e-05
- O 1 0.9316926002502441
penetrance O 1 0.9962471127510071
autosomal B-Disease 1 0.9988316893577576
dominant I-Disease 1 0.5300334095954895
disease I-Disease 0 0.0025269901379942894
that O 0 1.277495869089762e-07
predisposes O 0 5.706790034309961e-05
to O 0 1.7495102611064794e-07
hundreds O 0 3.2302872909895086e-07
or O 0 1.3997161829593097e-07
thousands O 0 1.0587191354716197e-06
of O 0 1.6088009942905046e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.9995775818824768
carcinoma I-Disease 1 1.0
and O 0 8.794555469648913e-06
that O 0 2.6644676154319313e-07
results O 0 6.584066909454123e-07
from O 0 8.034368903508948e-08
truncating O 0 6.10360293649137e-05
mutations O 0 1.683716254774481e-05
in O 0 9.399221312378359e-08
the O 0 2.0966388092347188e-07
APC B-Disease 0 8.865068957675248e-05
gene O 0 1.700292523310054e-05
. O 0 2.81912707578158e-06

A O 0 0.0001509482244728133
variant O 0 0.00024156284052878618
of O 0 6.171348445604963e-07
FAP B-Disease 0 0.014907518401741982
is O 0 0.00020723397028632462
attenuated B-Disease 1 0.9967865943908691
adenomatous I-Disease 1 0.9999974966049194
polyposis I-Disease 1 0.9999854564666748
coli I-Disease 1 0.9996762275695801
, O 0 1.5575326415273594e-06
which O 0 2.2673053479138616e-07
results O 0 1.662789230749695e-07
from O 0 3.0661599481618396e-08
germ O 0 7.5360203481977805e-06
- O 0 8.578874985687435e-05
line O 0 7.509017450502142e-06
mutations O 0 9.870514077192638e-07
in O 0 1.2263007498347633e-08
the O 0 1.1345452577415926e-08
5 O 0 8.613308466465242e-08
and O 0 2.800452847395718e-08
3 O 0 1.2727701914627687e-07
regions O 0 1.9911849946652183e-08
of O 0 1.1875969541108589e-08
the O 0 1.2866561860391812e-07
APC B-Disease 0 3.372158971615136e-05
gene O 0 4.301498847780749e-06
. O 0 1.8266899814989301e-06

Attenuated B-Disease 1 0.9983944296836853
adenomatous I-Disease 1 0.9999822378158569
polyposis I-Disease 1 0.9999933242797852
coli I-Disease 1 0.9999971389770508
patients O 1 0.999963641166687
have O 0 3.882970122504048e-05
" O 0 4.53206257589045e-06
multiple O 0 6.399235280696303e-05
" O 0 0.0954439789056778
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999948740005493
( O 0 1.4929928511264734e-06
typically O 0 3.763795461964037e-07
fewer O 0 2.380525074840989e-07
than O 0 4.0064318085342165e-08
100 O 0 3.0550914686955366e-08
) O 0 1.3876526594458483e-08
without O 0 3.289045125143275e-08
the O 0 5.3357965157374565e-08
florid O 0 0.02996663562953472
phenotype O 0 0.00108117435593158
of O 0 8.300386156179229e-08
classical O 0 1.0821469913935289e-05
FAP B-Disease 0 0.024893078953027725
. O 0 2.3387037799693644e-05

Another O 0 4.724369864561595e-05
group O 0 5.002974376111524e-06
of O 0 3.7406431374620297e-07
patients O 0 0.00021532211394514889
with O 0 1.1454296782176243e-06
multiple O 0 0.0003902865864802152
adenomas B-Disease 0 0.2505221366882324
has O 0 1.2469486136978958e-05
no O 0 2.0490249426075025e-06
mutations O 0 2.2529554826178355e-06
in O 0 2.1816353168446767e-08
the O 0 3.366926648595836e-08
APC B-Disease 0 6.033995759935351e-06
gene O 0 2.6921938456325734e-07
, O 0 1.629593349150582e-08
and O 0 1.4244261770102185e-08
their O 0 1.5685543530707946e-07
phenotype O 0 0.036973752081394196
probably O 0 1.2427487945387838e-06
results O 0 1.0192236032935398e-07
from O 0 6.6062293413438056e-09
variation O 0 9.845697945820575e-08
at O 0 1.3837805568073236e-08
a O 0 1.711657944269973e-07
locus O 0 2.09918653126806e-06
, O 0 3.961636352300957e-08
or O 0 2.3045606312166456e-08
loci O 0 2.620096211103373e-07
, O 0 1.0033703290446283e-07
elsewhere O 0 1.7379096561853657e-07
in O 0 3.171434670434792e-08
the O 0 1.1012807732413421e-07
genome O 0 3.177940016030334e-06
. O 0 2.2360325147019466e-06

Recently O 0 0.0002735270536504686
, O 0 1.5954130958562018e-06
however O 0 2.6505739469939726e-07
, O 0 4.292358823931863e-08
a O 0 4.719487947113521e-07
missense O 0 7.176569488365203e-05
variant O 0 5.964358024357352e-06
of O 0 1.0688443552453464e-07
APC B-Disease 0 3.1359777494799346e-05
( O 0 1.3350886263197026e-07
I1307K O 0 1.2788133062713314e-05
) O 0 4.548896370693001e-08
was O 0 1.0559869423332202e-07
described O 0 2.8338371294012177e-07
that O 0 2.388337705383492e-08
confers O 0 1.282095013266371e-06
an O 0 5.998636254389567e-08
increased O 0 4.450926951449219e-07
risk O 0 1.4916550981070031e-06
of O 0 4.81380702694878e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.723828275629785e-06
including O 0 5.951307571194775e-07
multiple O 0 3.4235272323712707e-05
adenomas B-Disease 0 0.004763158969581127
, O 0 8.246448146564944e-07
in O 0 6.067343747417908e-07
Ashkenazim O 0 5.0503502279752865e-05
. O 0 3.4995262012671446e-06

We O 0 1.0311125151929446e-05
have O 0 5.807920615552575e-07
studied O 0 3.035291911146487e-07
a O 0 9.295779079820932e-08
set O 0 6.66641923885436e-08
of O 0 1.8140287494361473e-08
164 O 0 3.5244349419372156e-05
patients O 0 0.0009182460489682853
with O 0 1.4379294952959754e-05
multiple O 1 0.9904282093048096
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999960660934448
and I-Disease 0 0.005481785163283348
/ I-Disease 1 0.9055122137069702
or I-Disease 0 0.004261658992618322
carcinoma I-Disease 1 1.0
and O 0 7.8623434092151e-06
analyzed O 0 1.1741566595446784e-05
codons O 0 4.3726558942580596e-06
1263 O 0 6.832864892203361e-05
- O 0 0.0001024974844767712
1377 O 0 0.00030772783793509007
( O 0 4.578317316372704e-07
exon O 0 5.080470145912841e-06
15G O 0 2.0506340661086142e-05
) O 0 4.7401016445292043e-08
of O 0 8.208501434125992e-09
the O 0 3.095889056226042e-08
APC B-Disease 0 4.9994737310044e-06
gene O 0 5.114686132401403e-07
for O 0 6.34783390296434e-08
germ O 0 1.9452525521046482e-05
- O 0 6.157785537652671e-05
line O 0 1.0142111932509579e-05
variants O 0 4.608570634445641e-06
. O 0 2.259319899167167e-06

Three O 0 0.0004191093903500587
patients O 0 0.0030213254503905773
with O 0 2.166322872199089e-07
the O 0 1.3867733628103451e-07
I1307K O 0 7.851900591049343e-05
allele O 0 6.644300810876302e-06
were O 0 8.219409153298329e-08
detected O 0 4.889216711490008e-07
, O 0 1.9627089287155286e-08
each O 0 1.332785704022399e-08
of O 0 6.682586928263845e-08
Ashkenazi O 0 6.635226600337774e-05
descent O 0 3.2146133889909834e-05
. O 0 2.5990991616708925e-06

Four O 0 0.0012386332964524627
patients O 0 0.033948641270399094
had O 0 7.806307280588953e-07
a O 0 4.4708275481752935e-07
germ O 0 1.9365770640433766e-05
- O 0 4.429808905115351e-05
line O 0 2.0271202174626524e-06
E1317Q O 0 7.868959983170498e-06
missense O 0 7.494707915611798e-06
variant O 0 9.931029580911854e-07
of O 0 1.3525944808634449e-08
APC O 0 2.3099948975868756e-06
that O 0 3.089459355010149e-08
was O 0 1.0365187819161292e-07
not O 0 1.754127154640628e-08
present O 0 2.143891464356784e-08
in O 0 2.5098165323811372e-08
controls O 0 4.883307610725751e-06
; O 0 3.607888743317744e-08
one O 0 5.938571412400506e-09
of O 0 2.6137552122662555e-09
these O 0 1.0029834740521437e-08
individuals O 0 9.563984271210302e-09
had O 0 6.750689607315508e-08
an O 0 5.3186855808462496e-08
unusually O 0 8.28321572043933e-06
large O 0 6.155278242658824e-08
number O 0 2.2655150644368405e-08
of O 0 2.0736585781833128e-08
metaplastic B-Disease 0 0.0039069997146725655
polyps I-Disease 0 0.0002372065355302766
of I-Disease 0 1.2698579610059824e-07
the I-Disease 0 8.800091677585442e-07
colorectum I-Disease 0 0.0004543748509604484
. O 0 4.934193384542596e-06

There O 0 9.549452443025075e-06
is O 0 5.928071686867042e-07
increasing O 0 2.0674569611855986e-07
evidence O 0 1.9515481142207136e-07
that O 0 3.427928874089048e-08
there O 0 2.975221313761267e-08
exist O 0 2.226651041326022e-08
germ O 0 8.79111610174732e-07
- O 0 6.057947757653892e-06
line O 0 5.634379931507283e-07
variants O 0 4.813912113377228e-08
of O 0 3.5270806275633504e-09
the O 0 1.8192887196732954e-08
APC B-Disease 0 2.9939385512989247e-06
gene O 0 1.5163811895035906e-07
that O 0 3.3528920084791025e-08
predispose O 0 8.923835252971912e-07
to O 0 4.6534673003861826e-08
the O 0 1.6917576672881296e-08
development O 0 3.726250952240662e-08
of O 0 2.718714995353366e-07
multiple O 1 0.9535601735115051
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.9993801116943359
carcinoma I-Disease 1 1.0
, O 0 6.334454155876301e-06
but O 0 2.7406886715652945e-07
without O 0 7.788499090111145e-08
the O 0 5.227086674608472e-08
florid O 0 0.16347116231918335
phenotype O 0 0.005331064574420452
of O 0 1.8561335579647675e-08
classical O 0 1.0529395240155281e-06
FAP B-Disease 0 0.0015215367311611772
, O 0 2.6887249759965925e-07
and O 0 4.348898841044502e-08
possibly O 0 1.7909061966747686e-07
with O 0 6.206679614706445e-08
importance O 0 1.0432499948365148e-06
for O 0 0.27933818101882935
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0005562391015700996
in O 0 1.223240957415328e-07
the O 0 8.201228496318436e-08
general O 0 7.512724664593406e-07
population O 0 5.277980221762846e-07
. O 0 3.237121006804955e-07
. O 0 1.6941783087531803e-06

Genomic O 0 0.0003114202991127968
structure O 0 1.4811350411036983e-05
of O 0 7.370633738901233e-07
the O 0 1.9574135876609944e-06
human O 0 0.001979661174118519
congenital B-Disease 1 0.9999992847442627
chloride I-Disease 1 0.9999985694885254
diarrhea I-Disease 1 1.0
( O 0 0.00046007122728042305
CLD B-Disease 1 0.9733954668045044
) O 0 1.5625405467289966e-06
gene O 0 3.856517651001923e-06
. O 0 1.4947110003049602e-06

Congenital B-Disease 1 0.9999994039535522
chloride I-Disease 1 0.9999990463256836
diarrhea I-Disease 1 1.0
( O 0 0.08607126027345657
CLD B-Disease 1 0.9993720650672913
) O 0 1.8446582998876693e-06
is O 0 2.405704719876667e-07
caused O 0 4.0217782952822745e-06
by O 0 2.0492365138125024e-07
mutations O 0 6.18504509475315e-06
in O 0 2.7888164666478588e-08
a O 0 4.2407700107105484e-07
gene O 0 4.5051882580082747e-07
which O 0 8.10994933431175e-08
encodes O 0 1.4848001228529029e-06
an O 0 2.2692270249535795e-06
intestinal O 1 0.9674561619758606
anion O 0 0.00418725935742259
transporter O 0 0.0004249682533554733
. O 0 5.605916157946922e-06

We O 0 1.5188927136478014e-05
report O 0 2.557484549470246e-06
here O 0 8.036300158664744e-08
the O 0 2.0468940320483853e-08
complete O 0 3.274917048656789e-07
genomic O 0 6.366961997628096e-07
organization O 0 2.5896694566540646e-08
of O 0 6.137865771194129e-09
the O 0 3.061835229800636e-08
human O 0 3.2773104408079234e-07
CLD B-Disease 0 0.02820175513625145
gene O 0 8.984789019450545e-07
which O 0 7.982480099144595e-08
spans O 0 8.887315630090598e-07
approximately O 0 8.705602994041328e-08
39kb O 0 5.706340289179934e-06
, O 0 3.652046842717027e-08
and O 0 5.326401009142501e-08
comprises O 0 3.3115335895672615e-07
21 O 0 1.890013663796708e-06
exons O 0 2.2573154637939297e-05
. O 0 2.6541733859630767e-06

All O 0 5.93080221733544e-06
exon O 0 5.474222780321725e-05
/ O 0 1.7960175682674162e-05
intron O 0 3.115475919912569e-05
boundaries O 0 3.177605094606406e-07
conform O 0 3.8224652598728426e-07
to O 0 6.07626091664315e-08
the O 0 1.8232631759929063e-07
GT O 0 0.0004447026294656098
/ O 0 0.10077709704637527
AG O 1 0.9879997372627258
rule O 0 1.3345404113351833e-05
. O 0 3.2414818633696996e-06

An O 0 5.872887413715944e-06
analysis O 0 2.190750137742725e-06
of O 0 4.243921480906465e-08
the O 0 5.871537567259111e-08
putative O 0 3.4140548450523056e-06
promoter O 0 2.9148275189072592e-06
region O 0 1.2514422564890992e-07
sequence O 0 1.219776493144309e-07
shows O 0 1.2812904515158152e-07
a O 0 1.6001963842882105e-07
putative O 0 8.943968168750871e-06
TATA O 0 0.00013498979387804866
box O 0 1.2872922070528148e-06
and O 0 3.7283840015334135e-08
predicts O 0 1.4005095181346405e-06
multiple O 0 1.1317575143721115e-07
transcription O 0 2.157169376459933e-07
factor O 0 1.6883285525182146e-07
binding O 0 4.2490404439377016e-07
sites O 0 4.903224635199877e-07
. O 0 1.078893433259509e-06

The O 0 4.834975243284134e-06
genomic O 0 1.86110773938708e-05
structure O 0 3.507866040308727e-06
was O 0 6.639859293500194e-07
determined O 0 3.302775155589188e-07
using O 0 1.3119104380621138e-07
DNA O 0 5.077352511762001e-07
from O 0 1.1135457889110967e-08
several O 0 1.3458930858689655e-08
sources O 0 3.759934585900737e-08
including O 0 1.6622191623127947e-08
multiple O 0 1.423410935785796e-07
large O 0 8.025118347632088e-08
- O 0 2.1230735001154244e-05
insert O 0 4.0748825995251536e-05
libaries O 0 2.5709834517329e-05
and O 0 9.670303313669137e-08
genomic O 0 1.265089622393134e-06
DNA O 0 1.720080035738647e-06
from O 0 2.1303995367816242e-07
Finnish O 0 0.37216755747795105
CLD B-Disease 1 0.9997404217720032
patients O 1 0.5935580134391785
and O 0 9.064701202987635e-07
controls O 0 5.315784437698312e-05
. O 0 4.613082182913786e-06

Exon O 0 0.0008520907140336931
- O 0 0.00015988510858733207
specific O 0 8.803650075606129e-07
primers O 0 3.186834146617912e-05
developed O 0 1.6178578334802296e-06
in O 0 4.522243202131904e-08
this O 0 3.5255219188456977e-08
study O 0 1.1222199702842772e-07
will O 0 4.3973518160100866e-08
facilitate O 0 2.1439429076508532e-07
mutation O 0 2.9851371436961927e-06
screening O 0 1.1495443459352828e-06
studies O 0 2.1684559214918409e-07
of O 0 1.2305984853355767e-07
patients O 0 0.0008852948085404932
with O 0 1.8535599792812718e-06
the O 0 6.238506466615945e-05
disease O 0 0.029235227033495903
. O 0 7.859539437049534e-06

Genomic O 0 8.419202640652657e-05
sequencing O 0 1.3951138498669025e-05
of O 0 7.940748218970839e-07
a O 0 9.075280104298145e-06
BAC O 0 0.0028817085549235344
clone O 0 0.0022977215703576803
H O 1 0.9972055554389954
_ O 0 1.0583386256257654e-06
RG364P16 O 0 6.635069439653307e-06
revealed O 0 4.564553819363937e-07
the O 0 8.197611478522049e-09
presence O 0 1.2995225340262095e-08
of O 0 5.662507795989313e-09
another O 0 1.5696183197633218e-07
, O 0 4.6357410354858075e-08
highly O 0 9.916239918084102e-08
homologous O 0 4.177974233243731e-07
gene O 0 2.184513192560189e-07
3 O 0 3.2710271824498705e-08
of O 0 5.464308561187181e-09
the O 0 7.100062759946013e-08
CLD B-Disease 0 0.3194390833377838
gene O 0 1.0932541272268281e-06
, O 0 1.7524818929359753e-08
with O 0 1.348308309445656e-08
a O 0 1.6622992404791148e-07
similar O 0 2.2917006958778074e-07
genomic O 0 1.8096731082550832e-06
structure O 0 4.4539925170283823e-07
, O 0 5.186607054952219e-08
recently O 0 6.035131150383677e-07
identified O 0 1.7736088864239719e-07
as O 0 7.331956908274151e-08
the O 0 3.7233851344353752e-06
Pendred B-Disease 1 0.9999996423721313
syndrome I-Disease 1 1.0
gene O 0 3.123913120361976e-05
( O 0 6.32347166629188e-07
PDS B-Disease 0 0.0005410214071162045
) O 0 4.86585634007497e-07
. O 0 1.548180676991251e-07
. O 0 1.4230678289095522e-06

The O 0 1.935587715706788e-05
APCI1307K O 0 0.018800929188728333
allele O 0 0.003218327183276415
and O 0 4.6111690608086064e-05
cancer B-Disease 1 0.7717886567115784
risk O 0 2.9438358524203068e-06
in O 0 9.527518329832674e-08
a O 0 5.979622414997721e-07
community O 0 1.2648337133214227e-07
- O 0 6.679937996523222e-06
based O 0 2.3022352024781867e-07
study O 0 1.6880163400401216e-07
of O 0 8.860153144496508e-08
Ashkenazi O 0 9.186739043798298e-05
Jews O 0 3.912809006578755e-06
. O 0 1.6179596968868282e-06

Mutations O 1 0.9609009623527527
in O 0 4.707047264673747e-05
APC O 0 0.000789584475569427
are O 0 1.5308532965718769e-06
classically O 0 0.39723488688468933
associated O 0 2.7620848413789645e-05
with O 0 0.0002372911258134991
familial B-Disease 1 0.9999990463256836
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.9999997615814209
( O 0 9.485816553933546e-05
FAP B-Disease 0 0.024799689650535583
) O 0 1.1884942523465725e-06
, O 0 2.389750761722098e-07
a O 0 3.1668396331951953e-06
highly O 0 4.5918262912891805e-05
penetrant O 1 0.9997738003730774
autosomal B-Disease 1 0.9999992847442627
dominant I-Disease 1 0.99994957447052
disorder I-Disease 1 0.9999996423721313
characterized O 0 0.006427548360079527
by O 0 3.795652446569875e-06
multiple O 0 0.0034520451445132494
intestinal O 1 0.9999731779098511
polyps B-Disease 1 0.6808363795280457
and O 0 4.323706264131033e-07
, O 0 9.151050051059428e-08
without O 0 1.2237987334628997e-07
surgical O 0 0.00042591849341988564
intervention O 0 1.6087451513158157e-06
, O 0 3.281125060539125e-08
the O 0 1.5885257553804877e-08
development O 0 1.9719969657217007e-07
of O 0 0.0009047967032529414
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.872347820608411e-05
CRC B-Disease 0 0.0010340609587728977
) O 0 1.9741166852327297e-06
. O 0 2.7504183890414424e-06

APC B-Disease 0 0.0017345596570521593
is O 0 7.063786597427679e-06
a O 0 1.3970550753583666e-05
tumour O 1 0.9995218515396118
- O 0 0.00025581123190931976
suppressor O 0 8.28863849164918e-05
gene O 0 9.116153592003684e-07
, O 0 2.4155228928179895e-08
and O 0 5.199126462684944e-08
somatic O 0 2.892538941523526e-05
loss O 0 0.0005053547210991383
occurs O 0 3.146933977404842e-06
in O 0 8.617171260993928e-06
tumours B-Disease 1 0.9999796152114868
. O 0 3.466785710770637e-05

The O 0 2.1143532649148256e-05
germline O 0 0.004203291144222021
T O 0 0.05032278224825859
- O 0 7.326860213652253e-05
to O 0 3.83195100539524e-07
- O 0 1.4646921954408754e-05
A O 0 2.216296934420825e-06
transversion O 0 3.786855086218566e-05
responsible O 0 2.271993650992954e-07
for O 0 1.3282202893094563e-08
the O 0 3.414818650071538e-08
APC O 0 3.0156393222569022e-06
I1307K O 0 9.455623512621969e-06
allele O 0 9.384403938383912e-07
converts O 0 2.532101461838465e-07
the O 0 9.764081987384543e-09
wild O 0 5.4449809994139287e-08
- O 0 1.6427916307293344e-06
type O 0 1.6252454315690557e-07
sequence O 0 3.045980179194885e-08
to O 0 2.556893008431871e-08
a O 0 2.020211013586959e-06
homopolymer O 1 0.9529827833175659
tract O 1 0.7431949973106384
( O 0 3.841010141059087e-07
A8 O 0 0.007462783716619015
) O 0 6.19463946804899e-08
that O 0 2.3712344088266946e-08
is O 0 7.685276415259068e-08
genetically O 0 6.190446697473817e-07
unstable O 0 1.3492942343873437e-05
and O 0 1.3277623622798274e-07
prone O 0 1.636705746932421e-05
to O 0 7.537936994594929e-07
somatic O 0 0.00026562201674096286
mutation O 0 6.812376523157582e-05
. O 0 3.1277281777875032e-06

The O 0 2.9411219657049514e-05
I1307K O 0 0.0004584907437674701
allele O 0 0.00015330051246564835
was O 0 3.3697715480229817e-06
found O 0 7.362070277849853e-07
in O 0 4.755374334308726e-07
6 O 0 7.136583008104935e-06
. O 0 2.8389220005919924e-06

1 O 0 1.888146834971849e-05
% O 0 1.254490939572861e-06
of O 0 1.2389804737722443e-07
unselected O 0 0.00256136991083622
Ashkenazi O 0 0.0006923667970113456
Jews O 0 1.6787126924100448e-06
and O 0 1.0859081811531723e-07
higher O 0 2.2929030762952607e-07
proportions O 0 1.1514754305608221e-06
of O 0 3.374674051315196e-08
Ashkenazim O 0 1.649935802561231e-05
with O 0 2.6125161411982845e-07
family O 0 9.083557870326331e-07
or O 0 4.098000871977092e-08
personal O 0 8.961401931628643e-07
histories O 0 6.506206773337908e-07
of O 0 8.998254941161576e-08
CRC B-Disease 0 0.00018192408606410027
( O 0 4.689593993134622e-07
ref O 0 0.0006509057711809874
. O 0 7.759954456787455e-08
2 O 0 2.217888237510124e-07
) O 0 2.540155321639759e-07
. O 0 6.296038463915465e-07

To O 0 6.108570232754573e-06
evaluate O 0 6.709997251164168e-06
the O 0 6.615234582341145e-08
role O 0 1.2839080909543554e-07
of O 0 5.6229904288329635e-08
I1307K O 0 0.00024286530970130116
in O 0 8.889079254004173e-06
cancer B-Disease 0 0.01341879554092884
, O 0 7.216371500362584e-08
we O 0 2.679192334653635e-08
genotyped O 0 6.955235221539624e-06
5 O 0 9.598343808647769e-08
, O 0 3.635783230038214e-08
081 O 0 4.6535507863154635e-05
Ashkenazi O 0 6.9364364208013285e-06
volunteers O 0 1.8964470882565365e-07
in O 0 2.223790218636168e-08
a O 0 3.1928297516969906e-07
community O 0 2.621930832447106e-07
survey O 0 4.389568402984878e-06
. O 0 1.9708022591657937e-06

Risk O 0 0.0004545177798718214
of O 0 3.4725342175079277e-06
developing O 0 0.000494867330417037
colorectal B-Disease 1 0.999998927116394
, I-Disease 0 0.005745278671383858
breast I-Disease 1 0.9853531718254089
and I-Disease 0 2.1783291686006123e-06
other I-Disease 0 6.897266189298534e-07
cancers I-Disease 0 0.059753287583589554
were O 0 3.5921169683206244e-07
compared O 0 1.7454651697335066e-06
between O 0 1.6916825984480965e-07
genotyped O 0 0.00028721257694996893
I1307K O 0 6.214412860572338e-05
carriers O 0 4.372779471850663e-07
and O 0 3.1419144619349026e-08
non O 0 1.2648710878693237e-07
- O 0 5.312882876751246e-06
carriers O 0 3.754531689992291e-07
and O 0 2.4011452381955678e-08
their O 0 2.1505343283934053e-08
first O 0 1.5204952319436416e-07
- O 0 3.885244223056361e-05
degree O 0 1.1116178939118981e-05
relatives O 0 2.1997708245180547e-05
. O 0 2.940760623459937e-06

Sperm O 0 0.0008070258772931993
DNA O 0 0.000219692854443565
analysis O 0 8.75520800036611e-06
in O 0 7.283770173671655e-07
a O 0 1.1815894140454475e-05
Friedreich B-Disease 1 0.9968793392181396
ataxia I-Disease 1 0.9958752989768982
premutation O 0 0.18704241514205933
carrier O 0 0.00011711013939930126
suggests O 0 8.361194545614126e-07
both O 0 5.439095573933628e-08
meiotic O 0 3.232045173717779e-06
and O 0 5.3054737492175263e-08
mitotic O 0 1.752159619172744e-06
expansion O 0 3.4328661513427505e-07
in O 0 9.361416886122242e-08
the O 0 1.1038189740020243e-07
FRDA B-Disease 0 0.0010320855071768165
gene O 0 6.994172508711927e-06
. O 0 2.0069837773917243e-06

Friedreich B-Disease 1 0.9997226595878601
ataxia I-Disease 1 0.9998823404312134
is O 0 0.0002678623131942004
usually O 0 4.101811646251008e-05
caused O 0 5.184192559681833e-06
by O 0 3.3295673773636736e-08
an O 0 2.0974260550588042e-08
expansion O 0 6.135913821481154e-08
of O 0 9.903420306045518e-09
a O 0 2.3022899142688402e-07
GAA O 0 1.6583089745836332e-06
trinucleotide O 0 5.829832298331894e-05
repeat O 0 6.257117092900444e-06
in O 0 1.0039484266144427e-07
intron O 0 1.4832200577075128e-05
1 O 0 9.120574162579942e-08
of O 0 2.213861804989392e-08
the O 0 1.9354104097146774e-07
FRDA B-Disease 0 0.001645617070607841
gene O 0 1.0194282367592677e-05
. O 0 2.161060137950699e-06

Occasionally O 0 0.00010621028195600957
, O 0 6.39789504930377e-07
a O 0 3.866944382480142e-07
fully O 0 5.197441055315721e-07
expanded O 0 2.3794446235569922e-07
allele O 0 1.479454340369557e-06
has O 0 6.91080472847716e-08
been O 0 3.114955759997429e-08
found O 0 5.4593940035374544e-08
to O 0 8.009810414932872e-08
arise O 0 2.0352932494915876e-07
from O 0 9.846088389053875e-09
a O 0 1.2069425281424628e-07
premutation O 0 9.647856131778099e-06
of O 0 1.6106726619113942e-08
100 O 0 7.458890394218542e-08
or O 0 7.569706639287688e-08
less O 0 9.148709523287835e-07
triplet O 0 0.005458226427435875
repeats O 0 0.00011252504191361368
. O 0 7.146308234950993e-06

We O 0 4.562426966003841e-06
have O 0 4.817273975277203e-07
examined O 0 1.5138712115003727e-06
the O 0 2.4454278602092927e-08
sperm O 0 7.528747687501891e-07
DNA O 0 4.498409396092029e-07
of O 0 2.3421787176403086e-08
a O 0 1.0962359056065907e-06
premutation O 0 0.0006672044401057065
carrier O 0 0.0001278521667700261
. O 0 2.900519120885292e-06

This O 0 9.57710562943248e-06
mans O 0 0.00019933228031732142
leucocyte O 0 0.00065745780011639
DNA O 0 2.404835686320439e-05
showed O 0 4.23631354351528e-06
one O 0 1.1258969578875622e-07
normal O 0 3.964441646076011e-07
allele O 0 1.0022147307608975e-06
and O 0 2.094947149089421e-08
one O 0 2.6154321375315703e-08
allele O 0 2.613592755551508e-07
of O 0 7.99250088334702e-09
approximately O 0 8.285359598403375e-08
100 O 0 2.2809990696259774e-07
repeats O 0 1.1205169357708655e-05
. O 0 2.71847329713637e-06

His O 0 2.734505687840283e-05
sperm O 0 4.128198270336725e-05
showed O 0 7.640851436008234e-06
an O 0 8.85648603343725e-08
expanded O 0 2.685910942545888e-07
allele O 0 1.3187511740397895e-06
in O 0 2.7737982577491493e-08
a O 0 1.6319113171903155e-07
tight O 0 6.0348475017235614e-06
range O 0 3.2521720072509197e-07
centering O 0 8.95548168955429e-07
on O 0 2.0162754310604214e-07
a O 0 1.6234112365509645e-07
size O 0 1.26022825952532e-07
of O 0 3.6957235494128327e-08
approximately O 0 2.960591984901839e-07
320 O 0 4.017975243186811e-06
trinucleotide O 0 0.000542709487490356
repeats O 0 7.394299609586596e-05
. O 0 5.5807281569286715e-06

His O 0 7.553455361630768e-05
affected O 0 8.527278623660095e-06
son O 0 2.3347280148300342e-05
has O 0 1.8665184597921325e-07
repeat O 0 1.7689122842057259e-06
sizes O 0 9.09165237317211e-07
of O 0 1.1745005679131282e-07
1040 O 0 5.812229937873781e-05
and O 0 8.383191811844881e-07
540 O 0 2.3113230781746097e-05
. O 0 3.1185575153358513e-06

These O 0 3.435041435295716e-06
data O 0 6.237791012608795e-07
suggest O 0 4.976484433427686e-07
that O 0 2.476378213600583e-08
expansion O 0 1.3471635895712097e-07
occurs O 0 5.8392277679786275e-08
in O 0 1.0498633074007557e-08
two O 0 4.481362836372682e-08
stages O 0 5.262735385258566e-07
, O 0 1.1276114264546777e-08
the O 0 2.9324360717453146e-09
first O 0 2.2093313845061857e-08
during O 0 6.526689588781664e-08
meiosis O 0 6.242676704459882e-07
followed O 0 5.9442065492021356e-08
by O 0 1.0722989607359068e-08
a O 0 6.633619165086202e-08
second O 0 5.118727131048217e-07
mitotic O 0 2.146090628230013e-05
expansion O 0 1.3210862562118564e-05
. O 0 5.843695362273138e-06

We O 0 5.068946848041378e-06
also O 0 3.0893423286215693e-07
show O 0 2.2086706508162024e-07
that O 0 1.2120231929202419e-08
in O 0 1.0274287198797083e-08
all O 0 8.46683878563681e-09
informative O 0 3.130788286398456e-07
carrier O 0 7.798548722348642e-06
father O 0 1.6369644981750753e-06
to O 0 1.2871286969584617e-07
affected O 0 3.0227172942431935e-07
child O 0 5.9437461459310725e-06
transmissions O 0 2.4189790565287694e-05
, O 0 5.2523112969993235e-08
with O 0 2.320443925896143e-08
the O 0 2.4180398128237357e-08
notable O 0 1.379727763151095e-07
exception O 0 6.434676436128939e-08
of O 0 8.396352058070988e-09
the O 0 4.308493117832768e-08
premutation O 0 0.00019528386474121362
carrier O 0 3.953321993321879e-06
, O 0 9.40452604680786e-09
the O 0 5.24928411849146e-09
expansion O 0 1.539212348689034e-07
size O 0 3.882556427470263e-07
decreases O 0 3.565152610462974e-06
. O 0 1.9410090601468255e-07
. O 0 7.0297221554938e-07

The O 0 8.572303158871364e-06
R496H O 0 0.0001684911985648796
mutation O 0 1.4544392797688488e-05
of O 0 9.412102741634953e-08
arylsulfatase O 0 0.00011578699923120439
A O 0 5.807250545331044e-06
does O 0 1.765454044289072e-06
not O 0 1.3371598015510244e-06
cause O 0 0.0001574693014845252
metachromatic B-Disease 1 0.9999412298202515
leukodystrophy I-Disease 1 0.9999693632125854
. O 0 3.6828216252615675e-05

Deficiency B-Disease 1 0.9989417195320129
of I-Disease 0 2.2035801521269605e-06
arylsulfatase I-Disease 0 0.0009977467125281692
A I-Disease 0 1.6790565496194176e-05
( O 0 7.993768349479069e-07
ARSA O 0 0.0007738217245787382
) O 0 1.6889211451598385e-07
enzyme O 0 5.235513071966125e-07
activity O 0 6.542275627907657e-07
causes O 0 3.9187227230286226e-05
metachromatic B-Disease 1 0.99996018409729
leukodystrophy I-Disease 1 0.999997615814209
( O 0 7.847080996725708e-05
MLD B-Disease 1 0.9995865225791931
) O 0 1.0836661203939002e-05
. O 0 4.131464265810791e-06

A O 0 3.36728771799244e-05
number O 0 1.5163623174885288e-06
of O 0 4.17323946066972e-07
ARSA O 1 0.5883634090423584
gene O 0 3.2764575735200197e-05
mutations O 0 1.669400262471754e-05
responsible O 0 8.869347993822885e-07
for O 0 8.415416345997073e-07
MLD B-Disease 1 0.9999773502349854
have O 0 9.485580449108966e-06
been O 0 1.8668795291887363e-06
identified O 0 3.4449490158294793e-06
. O 0 1.5334585441451054e-06

Recently O 0 0.00010668746836017817
, O 0 7.27815290701983e-07
the O 0 1.3128703812981257e-07
R496H O 0 2.4735289116506465e-05
mutation O 0 2.575434564278112e-06
of O 0 8.721324462612756e-08
ARSA O 0 0.016654182225465775
was O 0 1.1472028518255684e-06
proposed O 0 1.3505210461062234e-07
to O 0 3.9595139611492414e-08
be O 0 1.8759010345092975e-08
a O 0 3.0308922305266606e-07
cause O 0 2.623186446726322e-06
of O 0 2.6051640134028275e-07
MLD B-Disease 1 0.9999723434448242
( O 0 2.1617693164444063e-06
Draghia O 0 0.0005939082475379109
et O 0 1.7878797734738328e-05
al O 0 3.3602661915210774e-06
. O 0 2.6185068335848882e-08
, O 0 4.8675548924848044e-08
1997 O 0 4.353563554104767e-07
) O 0 2.9075459906380274e-07
. O 0 5.812514132230717e-07

We O 0 4.38897450294462e-06
have O 0 3.423270982239046e-07
investigated O 0 8.306165568683355e-07
the O 0 4.800414998840097e-08
R496H O 0 0.00014954051584936678
mutation O 0 2.85880946648831e-06
and O 0 4.4073271254774227e-08
found O 0 5.336855224413739e-08
this O 0 1.0868961730636784e-08
mutation O 0 2.0883811657768092e-07
at O 0 5.649896106518781e-09
a O 0 7.422644188181948e-08
relatively O 0 1.8327033046716679e-07
high O 0 1.934227640276731e-07
frequency O 0 8.1856296674232e-07
in O 0 1.7445676903093954e-08
an O 0 2.692126344072676e-08
African O 0 2.428707723822754e-08
American O 0 6.130508722890227e-08
population O 0 4.6370232098524866e-08
( O 0 3.1654941778924695e-08
f O 0 1.3721421510126675e-06
= O 0 9.769531743586413e-07
0 O 0 1.5692620536356117e-07
. O 0 2.064250814726165e-08
09 O 0 2.705629640331608e-07
, O 0 4.314890844625552e-08
n O 0 1.0115463737747632e-06
= O 0 2.55085888056783e-06
61 O 0 1.7191961205753614e-06
subjects O 0 1.1328205573590822e-06
) O 0 5.804636771244986e-07
. O 0 1.1241775155212963e-06

The O 0 1.407705985911889e-05
ARSA O 0 0.001224416308104992
enzyme O 0 8.364054338017013e-06
activity O 0 5.284754251988488e-07
in O 0 8.43566709818333e-08
subjects O 0 5.683111226062465e-07
with O 0 6.268616203897182e-08
and O 0 7.288121395276903e-08
without O 0 7.832072412838897e-08
the O 0 2.3790535763623666e-08
R496H O 0 0.00012973806587979198
mutation O 0 2.038814727711724e-06
was O 0 6.108705008500692e-08
determined O 0 1.2053529019340203e-07
and O 0 1.721170761470603e-08
found O 0 5.168890027107409e-08
to O 0 9.817400581368929e-08
be O 0 1.927995327832832e-07
normal O 0 1.7893661379275727e-06
. O 0 1.7710053725750186e-06

It O 0 9.26722805161262e-06
is O 0 7.581857630611921e-07
therefore O 0 3.779434791795211e-07
concluded O 0 4.0738424900155223e-07
that O 0 1.2887777067760453e-08
the O 0 2.436242496628438e-08
R496H O 0 2.0116469386266544e-05
mutation O 0 9.539007805869915e-07
of O 0 5.925709345433461e-08
ARSA O 0 0.012141025625169277
does O 0 6.638985041718115e-07
not O 0 3.651615188005053e-08
negatively O 0 7.27889641893853e-08
influence O 0 1.52042058942925e-08
the O 0 3.6430840566481493e-09
activity O 0 7.114727917922892e-09
of O 0 4.709791667778518e-09
ARSA O 0 0.014730731025338173
and O 0 9.960064772940314e-08
is O 0 2.3293390327694397e-08
not O 0 2.8459210099640586e-08
a O 0 5.720899025618564e-07
cause O 0 9.441548172617331e-06
of O 0 3.8924986256461125e-06
MLD B-Disease 1 0.9998107552528381

Down O 0 3.07694062939845e-05
- O 0 1.5768871890031733e-05
regulation O 0 6.295906587183708e-07
of O 0 1.1744636196908687e-07
transmembrane O 0 2.2580839868169278e-05
carbonic O 0 7.956057379487902e-05
anhydrases O 0 0.0003301199758425355
in O 0 1.8375811123405583e-05
renal B-Disease 1 0.999983549118042
cell I-Disease 1 0.9999922513961792
carcinoma I-Disease 1 1.0
cell O 1 0.8415346741676331
lines O 0 1.1713260391843505e-05
by O 0 1.7289036691181536e-07
wild O 0 7.974838354130043e-07
- O 0 9.370424231747165e-05
type O 0 5.112598591949791e-05
von B-Disease 0 0.32645922899246216
Hippel I-Disease 1 0.8275483846664429
- I-Disease 0 0.028592202812433243
Lindau I-Disease 0 0.06243833154439926
transgenes O 0 0.0009638943593017757
. O 0 1.5158046153374016e-05

To O 0 1.58615530381212e-05
discover O 0 1.588018494658172e-05
genes O 0 1.9189130853192182e-06
involved O 0 5.028460918765632e-07
in O 0 6.421833518288622e-07
von B-Disease 1 0.8127647638320923
Hippel I-Disease 1 0.995535135269165
- I-Disease 1 0.7449498176574707
Lindau I-Disease 1 0.7866068482398987
( O 0 1.1380277555872453e-06
VHL B-Disease 0 8.375152538064867e-05
) O 0 1.304381669342547e-07
- O 0 7.412142622342799e-06
mediated O 0 4.791562241734937e-05
carcinogenesis O 0 0.004147425293922424
, O 0 2.0548883128412854e-07
we O 0 8.295037190464427e-08
used O 0 1.4864837794448249e-05
renal B-Disease 1 0.9999767541885376
cell I-Disease 1 0.9999912977218628
carcinoma I-Disease 1 1.0
cell O 1 0.921061098575592
lines O 0 4.0472114051226526e-05
stably O 0 7.389857637463138e-05
transfected O 0 0.00020220596343278885
with O 0 2.234603471151786e-07
wild O 0 6.613348091377702e-07
- O 0 7.046811515465379e-05
type O 0 1.1064828868256882e-05
VHL O 0 0.000904074520803988
- O 0 0.00014568702317774296
expressing O 0 3.2566022127866745e-05
transgenes O 0 0.00021833987557329237
. O 0 4.525247277342714e-06

Large O 0 9.721280548546929e-06
- O 0 1.2905957191833295e-05
scale O 0 1.0477966725375154e-06
RNA O 0 8.93068886398396e-07
differential O 0 2.697199533940875e-06
display O 0 2.902559117501369e-07
technology O 0 1.7515503714093938e-07
applied O 0 1.6551838655232132e-07
to O 0 4.788673635403029e-08
these O 0 2.5574394157956704e-08
cell O 0 1.397027062921552e-05
lines O 0 2.8817014481319347e-06
identified O 0 2.432997234791401e-07
several O 0 3.377385127123489e-08
differentially O 0 4.3962636482319795e-06
expressed O 0 3.913966963864368e-07
genes O 0 1.22433561955404e-07
, O 0 1.0353505608406977e-08
including O 0 8.502619941452849e-09
an O 0 4.356802918437097e-08
alpha O 0 1.0459277746122098e-06
carbonic O 0 2.069438596663531e-05
anhydrase O 0 2.932193638116587e-05
gene O 0 1.2603427421709057e-06
, O 0 1.714520152518162e-07
termed O 0 1.2075835002178792e-05
CA12 O 0 0.0016155728371813893
. O 0 5.37431060365634e-06

The O 0 3.703768697960186e-06
deduced O 0 8.697336852492299e-06
protein O 0 7.837674047550536e-07
sequence O 0 2.4678539034539426e-07
was O 0 1.1987923187462002e-07
classified O 0 7.999322093610317e-08
as O 0 1.0604816580439547e-08
a O 0 7.744444019408547e-08
one O 0 7.477949992562571e-08
- O 0 5.192890512262238e-06
pass O 0 1.029985241984832e-06
transmembrane O 0 8.053628334891982e-06
CA O 0 1.1003617146343458e-06
possessing O 0 1.3679779442554718e-07
an O 0 3.371200207880065e-08
apparently O 0 2.4389302666349977e-07
intact O 0 1.5973618872067163e-07
catalytic O 0 1.5367568551027944e-07
domain O 0 4.9949754554745596e-08
in O 0 1.2207419075593862e-08
the O 0 2.478537730610242e-08
extracellular O 0 2.2972265014686855e-06
CA O 0 2.3821197828510776e-05
module O 0 7.616440416313708e-05
. O 0 2.1831397134519648e-06

Reintroduced O 0 0.0007564854458905756
wild O 0 6.319839303614572e-05
- O 0 0.0005742681678384542
type O 0 1.6798045180621557e-05
VHL B-Disease 0 0.0002553134399931878
strongly O 0 3.1286142530007055e-06
inhibited O 0 1.687632902758196e-06
the O 0 5.6416503468881274e-08
overexpression O 0 1.8539683424023679e-06
of O 0 1.1433148650041858e-08
the O 0 5.6440935480850385e-08
CA12 O 0 0.0003308263258077204
gene O 0 3.5430903722044604e-07
in O 0 3.067136589152142e-08
the O 0 3.906620236193703e-07
parental O 1 0.8818852305412292
renal B-Disease 1 0.9999985694885254
cell I-Disease 1 0.9999951124191284
carcinoma I-Disease 1 1.0
cell O 1 0.9933748841285706
lines O 0 0.00034576241159811616
. O 0 8.802468983049039e-06

Similar O 0 0.0003298246010672301
results O 0 4.074392927577719e-05
were O 0 4.5696194206357177e-07
obtained O 0 3.03739994933494e-07
with O 0 2.576552162736334e-07
CA9 O 0 0.09110420942306519
, O 0 9.080183360765659e-08
encoding O 0 2.4573046175646596e-07
another O 0 3.2992744536386454e-07
transmembrane O 0 5.230894657870522e-06
CA O 0 1.0532378382777097e-06
with O 0 2.8089369052963775e-08
an O 0 8.419946340154638e-08
intact O 0 1.3425212728179758e-06
catalytic O 0 1.3173709021430113e-06
domain O 0 2.057701976809767e-06
. O 0 1.3695877214559005e-06

Although O 0 6.627050424867775e-06
both O 0 1.6105352074191615e-07
domains O 0 1.9349175772731542e-07
of O 0 2.0603762251880653e-08
the O 0 3.578391982728135e-08
VHL B-Disease 0 4.357915895525366e-05
protein O 0 1.9732384259896207e-07
contribute O 0 2.478726734977954e-08
to O 0 1.1861820858882766e-08
regulation O 0 5.810508696413308e-08
of O 0 2.3345251065620687e-08
CA12 O 0 0.005320341791957617
expression O 0 1.0116900739376433e-06
, O 0 1.8849787508656846e-08
the O 0 1.2820525974177599e-08
elongin O 0 6.6642910496739205e-06
binding O 0 4.1435563957747945e-07
domain O 0 2.164724435260723e-07
alone O 0 5.154948894414701e-07
could O 0 2.1600844490876625e-07
effectively O 0 1.3031659591433709e-06
regulate O 0 1.2391792552080005e-05
CA9 O 0 0.02667379006743431
expression O 0 2.7538133508642204e-05
. O 0 4.709057975560427e-06

We O 0 1.0528428902034648e-05
mapped O 0 6.590165139641613e-05
CA12 O 0 0.0007633359055034816
and O 0 4.891865046374733e-06
CA9 O 0 0.003480100305750966
loci O 0 1.026974950946169e-05
to O 0 1.288518092223967e-06
chromosome O 0 1.7621034203330055e-05
bands O 0 4.1329976738779806e-06
15q22 O 0 4.339561201049946e-05
and O 0 1.1841837022075197e-06
17q21 O 0 0.0001577225048094988
. O 0 3.851276687782956e-06

2 O 0 4.9328282329952344e-05
respectively O 0 5.951278126303805e-06
, O 0 2.034505541814724e-07
regions O 0 1.278146584127171e-07
prone O 0 2.3526499717263505e-06
to O 0 2.566401917647454e-07
amplification O 0 9.583209248376079e-06
in O 0 2.5182515628330293e-07
some O 0 2.54850220926528e-07
human O 0 9.96882408799138e-06
cancers B-Disease 0 0.21480637788772583
. O 0 9.590851732355077e-06

Additional O 0 1.977387728402391e-05
experiments O 0 1.653285653446801e-05
are O 0 1.1709931158065956e-07
needed O 0 2.8221970183039957e-07
to O 0 4.533634268000242e-08
define O 0 1.4289697958247416e-07
the O 0 1.4328050745859855e-08
role O 0 5.022498683615595e-08
of O 0 3.308733198537084e-08
CA O 0 7.096788613125682e-05
IX O 0 0.0005905476864427328
and O 0 7.325533033508691e-07
CA O 0 8.901562250684947e-05
XII O 0 0.0005435554776340723
enzymes O 0 1.5663958663481026e-07
in O 0 6.054232226659906e-09
the O 0 3.751494226378327e-09
regulation O 0 4.7948148562682036e-08
of O 0 2.05918979645503e-08
pH O 0 1.1248477676417679e-05
in O 0 1.6077720488283376e-08
the O 0 1.015342565580113e-08
extracellular O 0 4.1420037177886115e-07
microenvironment O 0 1.0368434232077561e-05
and O 0 1.7283719344618476e-08
its O 0 2.6890626614317625e-08
potential O 0 1.2283847183880425e-07
impact O 0 5.850408797414275e-07
on O 0 7.671511411899701e-05
cancer B-Disease 1 0.9006883502006531
cell O 0 0.0019143549725413322
growth O 0 6.288025360845495e-06
. O 0 3.1589313493896043e-06

A O 0 6.79878139635548e-05
gene O 0 1.3861978004570119e-05
encoding O 0 2.1313312572601717e-06
a O 0 8.754070677241543e-07
transmembrane O 0 7.123880550352624e-06
protein O 0 3.7360476312642277e-07
is O 0 9.049769289504184e-08
mutated O 0 1.256119958270574e-05
in O 0 2.6965512915921863e-06
patients O 0 0.20952938497066498
with O 0 0.34566083550453186
diabetes B-Disease 1 1.0
mellitus I-Disease 1 0.9999995231628418
and O 1 0.5589965581893921
optic B-Disease 1 0.9999982118606567
atrophy I-Disease 1 0.9999699592590332
( O 0 0.016800589859485626
Wolfram B-Disease 1 0.9999977350234985
syndrome I-Disease 1 0.9999998807907104
) O 0 7.982059287314769e-06
. O 0 5.3636399570677895e-06

Wolfram B-Disease 1 0.9999935626983643
syndrome I-Disease 1 1.0
( O 0 0.048791203647851944
WFS B-Disease 1 0.9986521601676941
; O 0 0.0015666582621634007
OMIM O 1 0.9708045125007629
222300 O 0 0.0007025275845080614
) O 0 4.1207866274817206e-07
is O 0 1.9095303116500872e-07
an O 0 5.231298473518109e-06
autosomal B-Disease 1 0.9998432397842407
recessive I-Disease 1 0.999995231628418
neurodegenerative I-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9999493360519409
defined O 0 1.6023371927076369e-06
by O 0 1.7200900970237853e-07
young O 0 2.8889851364510832e-06
- O 0 0.00030938279815018177
onset O 0 0.000471258390462026
non O 0 2.592348437246983e-06
- O 0 0.0041587334126234055
immune O 0 0.0006441532168537378
insulin B-Disease 0 0.25386950373649597
- I-Disease 1 0.5561213493347168
dependent I-Disease 0 0.04238136485219002
diabetes I-Disease 1 0.999998927116394
mellitus I-Disease 1 0.999994158744812
and O 0 0.0002670702524483204
progressive O 1 0.9907077550888062
optic B-Disease 1 0.9999790191650391
atrophy I-Disease 1 0.9970555305480957
. O 0 4.846085357712582e-05

Linkage O 0 0.00025214802008122206
to O 0 6.420047611754853e-06
markers O 0 1.227550001203781e-05
on O 0 1.7795890698835137e-06
chromosome O 0 0.0005953866639174521
4p O 0 0.11202652752399445
was O 0 1.1353783975209808e-06
confirmed O 0 3.702518256432086e-07
in O 0 3.193194686446077e-08
five O 0 1.997176184431737e-07
families O 0 1.116462499339832e-06
. O 0 1.7486673868916114e-06

On O 0 4.327049282437656e-06
the O 0 1.7640222438330966e-07
basis O 0 7.546770319777352e-08
of O 0 5.074041098396265e-08
meiotic O 0 9.546596993459389e-05
recombinants O 0 0.29035836458206177
and O 0 9.482324821874499e-05
disease O 0 0.007970971055328846
- O 0 0.012637782841920853
associated O 0 2.6495774363866076e-05
haplotypes O 0 0.00019517158216331154
, O 0 1.2677840288688458e-07
the O 0 8.236232673652921e-08
WFS B-Disease 0 0.0003324106219224632
gene O 0 1.16788999093842e-06
was O 0 2.8071221436221094e-07
localized O 0 1.083127585843613e-06
to O 0 3.3945906352528255e-07
a O 0 7.767914212308824e-06
BAC O 0 0.0031751871574670076
/ O 0 4.532277671387419e-05
P1 O 0 3.3203170460183173e-05
contig O 0 9.196803148370236e-06
of O 0 3.3517157049800517e-08
less O 0 1.677392731380678e-07
than O 0 1.4561979355676158e-07
250 O 0 1.2046592701153713e-06
kb O 0 0.000373222166672349
. O 0 3.4256329399795504e-06

Mutations O 1 0.7050003409385681
in O 0 8.57894428918371e-06
a O 0 3.773769321924192e-06
novel O 0 8.807153790257871e-06
gene O 0 1.04434400327591e-06
( O 0 8.85207853684733e-08
WFS1 O 0 1.54138651851099e-05
) O 0 3.038424978285548e-08
encoding O 0 8.099885207002444e-08
a O 0 1.9111536175842048e-07
putative O 0 5.862048510607565e-06
transmembrane O 0 1.8778897583615617e-06
protein O 0 8.798214423677564e-08
were O 0 1.5592576119161095e-08
found O 0 2.4228317130337018e-08
in O 0 8.859186273468822e-09
all O 0 8.226086478657635e-09
affected O 0 5.877218356431513e-08
individuals O 0 7.84340059567512e-09
in O 0 4.0995722372372256e-08
six O 0 8.7656680989312e-06
WFS B-Disease 1 0.5826869010925293
families O 0 7.560427661701397e-07
, O 0 1.4037794926480274e-08
and O 0 1.9171002563211914e-08
these O 0 1.829072715509028e-08
mutations O 0 1.2132707070122706e-06
were O 0 4.112973073233661e-08
associated O 0 1.0396055216688183e-07
with O 0 1.3059660375347448e-07
the O 0 1.982568937819451e-05
disease O 1 0.7486118674278259
phenotype O 1 0.7527228593826294
. O 0 6.220774594112299e-06

WFS1 O 0 0.1698206216096878
appears O 0 8.82814492797479e-05
to O 0 8.16661952285358e-07
function O 0 2.622186059397791e-07
in O 0 9.03783288208615e-08
survival O 0 4.187207196082454e-06
of O 0 6.993947465616657e-08
islet O 0 6.742602272424847e-05
beta O 0 2.996715011249762e-06
- O 0 1.2385671652737074e-05
cells O 0 1.3004545280637103e-06
and O 0 1.5449639079179178e-07
neurons O 0 3.0620449251728132e-06
. O 0 1.764513513080601e-07
. O 0 8.81891082826769e-07

Stable O 0 0.00022494359291158617
interaction O 0 3.4824101931008045e-06
between O 0 2.0536992906272644e-07
the O 0 3.986719221416024e-08
products O 0 4.295061728498695e-08
of O 0 8.969498033195578e-09
the O 0 8.399319284535522e-08
BRCA1 O 0 0.0005351955769583583
and O 0 9.01914609130472e-06
BRCA2 O 0 0.08894374221563339
tumor B-Disease 0 0.00019260782573837787
suppressor O 0 2.8944512450834736e-05
genes O 0 5.277592549646215e-07
in O 0 9.384496735265202e-08
mitotic O 0 1.048662124958355e-05
and O 0 2.4171142740669893e-06
meiotic O 0 0.0013827255461364985
cells O 0 0.0001420923217665404
. O 0 4.164054644206772e-06

BRCA1 O 1 0.9930784106254578
and O 0 0.0002552255755290389
BRCA2 O 1 0.5367968678474426
account O 0 3.2495879622729262e-06
for O 0 1.0522212789965124e-07
most O 0 1.1233250063469313e-07
cases O 0 1.5237976924709074e-07
of O 0 3.4138349036538784e-08
familial O 0 0.0015624640509486198
, O 0 2.6193993107881397e-06
early O 0 4.220074333716184e-05
onset O 1 0.5016331672668457
breast B-Disease 1 0.9971315860748291
and I-Disease 0 0.00016722151485737413
/ I-Disease 1 0.9897528886795044
or I-Disease 1 0.7718612551689148
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999973773956299
and O 0 8.750016178282749e-08
encode O 0 2.0574042025600647e-07
products O 0 4.1373326098437246e-08
that O 0 7.941443946890558e-09
each O 0 8.84174777837643e-09
interact O 0 7.070224228300503e-08
with O 0 1.4144771398605371e-07
hRAD51 O 0 5.2562121709343046e-05
. O 0 2.7308524295222014e-06

Results O 0 0.0005148100899532437
presented O 0 8.479433745378628e-06
here O 0 3.77717896071772e-07
show O 0 6.30461272521643e-07
that O 0 1.2931216986089566e-07
BRCA1 O 0 4.825476571568288e-05
and O 0 2.6420036647323286e-06
BRCA2 O 0 0.08247840404510498
coexist O 0 3.1835807021707296e-05
in O 0 7.826771053487391e-08
a O 0 4.063226413109078e-07
biochemical O 0 6.694574494758854e-06
complex O 0 3.1670131761529774e-07
and O 0 7.893410014503388e-08
colocalize O 0 2.327809670532588e-05
in O 0 8.505737980613048e-08
subnuclear O 0 2.68322564807022e-05
foci O 0 1.8361270122113638e-05
in O 0 1.0893497659481e-07
somatic O 0 1.5180266927927732e-05
cells O 0 2.36614391724288e-06
and O 0 1.4736759368361163e-08
on O 0 3.4671650439577206e-08
the O 0 1.8110695165773905e-08
axial O 0 3.6187927889841376e-06
elements O 0 1.1367181684818206e-07
of O 0 4.461610458861287e-08
developing O 0 1.4609735217163689e-06
synaptonemal O 0 0.0006670384900644422
complexes O 0 2.5098863261519e-05
. O 0 3.1446836601389805e-06

Like O 0 9.032430534716696e-05
BRCA1 O 0 0.01751130260527134
and O 0 7.759384970995598e-06
RAD51 O 0 0.14518791437149048
, O 0 3.032501808775123e-06
BRCA2 O 0 7.613942580064759e-05
relocates O 0 9.259551006834954e-06
to O 0 8.145634069478547e-07
PCNA O 0 0.0002420735254418105
+ O 0 1.3635770983455586e-06
replication O 0 1.2818648542634037e-07
sites O 0 4.8614680281389155e-08
following O 0 9.686973356792805e-08
exposure O 0 4.830495186070038e-07
of O 0 2.1023565111022435e-08
S O 0 0.00030396139482036233
phase O 0 2.1713335627282504e-06
cells O 0 1.161424506790354e-06
to O 0 2.1376098402470234e-07
hydroxyurea O 0 0.00022056742454878986
or O 0 8.431860578639316e-07
UV O 0 0.0020008254796266556
irradiation O 0 0.00013395580754149705
. O 0 5.679075911757536e-06

Thus O 0 6.510536331916228e-05
, O 0 3.1373567708214978e-06
BRCA1 O 0 0.00010757438576547429
and O 0 6.728758989993366e-07
BRCA2 O 0 0.00025762812583707273
participate O 0 6.78575133861159e-08
, O 0 1.9645105098220483e-08
together O 0 4.7938822689275185e-08
, O 0 1.747731737111735e-08
in O 0 1.3540502052933334e-08
a O 0 3.304627966826956e-07
pathway O 0 6.837113915025839e-07
( O 0 8.546964380684585e-08
s O 0 2.9292452381923795e-05
) O 0 2.5572102657633877e-08
associated O 0 2.3265728898991256e-08
with O 0 6.3757519264129314e-09
the O 0 6.457136159099264e-09
activation O 0 6.075750746958875e-08
of O 0 7.164924209490664e-09
double O 0 1.465132868361252e-06
- O 0 3.9947939512785524e-05
strand O 0 1.1674294910335448e-05
break O 0 1.527620042907074e-06
repair O 0 1.596397123648785e-05
and O 0 3.582199497031979e-07
/ O 0 5.914574558119057e-06
or O 0 2.3191766729269148e-07
homologous O 0 3.0918790798750706e-06
recombination O 0 1.2742954822897445e-05
. O 0 5.5675550356681924e-06

Dysfunction O 1 0.6581409573554993
of O 0 1.168007997875975e-06
this O 0 4.4347498828756216e-07
pathway O 0 3.847866082651308e-06
may O 0 1.5373564110632287e-06
be O 0 1.2034308660702209e-08
a O 0 1.0095188684999812e-07
general O 0 1.4499993028493918e-07
phenomenon O 0 4.900101657767664e-07
in O 0 1.064088195334989e-08
the O 0 8.53863468819327e-09
majority O 0 1.6912599676288664e-07
of O 0 1.1163805879732536e-08
cases O 0 2.6688951493269997e-07
of O 0 2.65786667341672e-07
hereditary B-Disease 1 0.9990917444229126
breast I-Disease 1 0.9997531771659851
and I-Disease 0 0.004040782805532217
/ I-Disease 1 0.9946413040161133
or I-Disease 1 0.8657281398773193
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 2.6024449653050397e-06
. O 0 2.7288112960377475e-06

A O 0 0.00013738987036049366
novel O 0 9.943109034793451e-05
Arg362Ser O 0 0.0010181424440816045
mutation O 0 2.064943873847369e-05
in O 0 1.2759008427565277e-07
the O 0 1.0367858038762279e-07
sterol O 0 8.009861630853266e-05
27 O 0 5.745011094404617e-06
- O 0 1.993831574509386e-05
hydroxylase O 0 3.9927948819240555e-05
gene O 0 4.1350926949235145e-07
( O 0 2.4395346187588984e-08
CYP27 O 0 6.900266726006521e-06
) O 0 1.6550695036698926e-08
: O 0 5.943171732525343e-09
its O 0 7.645038380132974e-09
effects O 0 1.245985714604103e-07
on O 0 5.718406725918612e-08
pre O 0 1.466852495468629e-06
- O 0 5.204965987104515e-07
mRNA O 0 1.0905471725664029e-07
splicing O 0 3.8906699728613603e-07
and O 0 2.4907741646984505e-08
enzyme O 0 1.8804654189352732e-07
activity O 0 1.8390885259123024e-07
. O 0 6.495728825939295e-07

A O 0 0.00015802613052073866
novel O 0 9.035756374942139e-05
C O 0 1.3174965715734288e-05
to O 0 1.621291545461645e-07
A O 0 1.6810454326332547e-06
mutation O 0 4.388011802802794e-06
in O 0 2.7392456303232393e-08
the O 0 9.482213414457874e-08
sterol O 0 0.0001670218480285257
27 O 0 7.883275429776404e-06
- O 0 2.7741169105865993e-05
hydroxylase O 0 0.00011128434562124312
gene O 0 3.941618444969208e-07
( O 0 3.176374718805164e-08
CYP27 O 0 1.457506550650578e-05
) O 0 4.8495955695671e-08
was O 0 9.112331866845125e-08
identified O 0 8.720210331603084e-08
by O 0 7.651661526608677e-09
sequencing O 0 1.3983419933083496e-07
amplified O 0 1.1032292604795657e-05
CYP27 O 0 4.1196912206942216e-05
gene O 0 3.7220925719338993e-07
products O 0 1.1910909591961172e-07
from O 0 4.018079380330164e-08
a O 0 2.098151753671118e-06
patient O 0 0.0008663399494253099
with O 0 3.298462615930475e-05
cerebrotendinous B-Disease 1 0.9999682903289795
xanthomatosis I-Disease 1 0.9998914003372192
( O 0 6.945942004676908e-06
CTX B-Disease 0 0.019767634570598602
) O 0 2.9886264201195445e-06
. O 0 2.9471561902028043e-06

The O 0 1.3393496374192182e-05
mutation O 0 9.357744420412928e-05
changed O 0 1.4795672313994146e-06
the O 0 9.678939960622301e-08
adrenodoxin O 0 9.309188499173615e-06
cofactor O 0 3.059668642890756e-06
binding O 0 3.584752334973018e-07
residue O 0 7.166518685153278e-07
362Arg O 0 2.506038299543434e-06
to O 0 1.625003562821803e-07
362Ser O 0 3.4738557133096037e-06
( O 0 3.9649098226846036e-08
CGT O 0 2.0154616322543006e-06
362Arg O 0 3.6150190680928063e-06
to O 0 1.9582766697112675e-07
AGT O 0 0.00017145377933047712
362Ser O 0 2.416371353319846e-05
) O 0 2.793794529054594e-08
, O 0 9.635704678601087e-09
and O 0 8.492846426122469e-09
was O 0 1.4331322972793714e-07
responsible O 0 2.664081364400772e-07
for O 0 2.655358457559487e-06
deficiency O 0 0.023846657946705818
in O 0 5.026610239156071e-08
the O 0 8.528400030627381e-08
sterol O 0 0.0002174038381781429
27 O 0 2.3783493361406727e-06
- O 0 2.5355714114994043e-06
hydroxylase O 0 5.404985586210387e-06
activity O 0 2.307930202505304e-08
, O 0 8.213874025386758e-09
as O 0 9.474598883230101e-09
confirmed O 0 6.640733118956632e-08
by O 0 4.979182843811714e-09
expression O 0 2.3196429665972573e-08
of O 0 4.511420126362964e-09
mutant O 0 3.290627148544445e-07
cDNA O 0 6.111269499342598e-07
into O 0 1.609398907476134e-07
COS O 0 1.3658775060321204e-05
- O 0 2.0099325411138125e-05
1 O 0 1.9069530026172288e-06
cells O 0 4.142238594795344e-06
. O 0 1.2740688362100627e-06

Quantitative O 0 9.211475844494998e-05
analysis O 0 1.6047692042775452e-05
showed O 0 7.027408173598815e-06
that O 0 2.8006022390059115e-08
the O 0 1.555971707034587e-08
expression O 0 1.022434332753619e-07
of O 0 2.2536672972250926e-08
CYP27 O 0 4.514866668614559e-05
gene O 0 2.2722298353983206e-07
mRNA O 0 4.608701686947825e-08
in O 0 1.083135892088194e-08
the O 0 4.316397550496731e-08
patient O 0 2.483003663655836e-05
represented O 0 9.647952765590162e-07
52 O 0 7.135684427339584e-06
. O 0 1.8226459133074968e-06

5 O 0 5.250226240605116e-05
% O 0 1.2406516134433332e-06
of O 0 6.690226683758738e-08
the O 0 1.4969178607771028e-07
normal O 0 1.7517135120215244e-06
level O 0 8.437443170805636e-07
. O 0 2.5446097424719483e-06

As O 0 6.13593647358357e-06
the O 0 4.5860258524044184e-07
mutation O 0 4.858937245444395e-06
occurred O 0 1.8200597651230055e-07
at O 0 1.477390831894354e-08
the O 0 8.495406156328045e-09
penultimate O 0 1.0700514394557104e-06
nucleotide O 0 1.335072141728233e-07
of O 0 1.2040416663694486e-08
exon O 0 1.4185881127559696e-06
6 O 0 1.9047304533614806e-07
( O 0 1.894772694299718e-08
- O 0 3.4196554565824044e-07
2 O 0 6.796761198302192e-08
position O 0 4.084158078399014e-08
of O 0 5.835417038468904e-09
exon O 0 8.085991112238844e-07
6 O 0 3.3315944847345236e-07
- O 0 1.5729871165603981e-06
intron O 0 1.4534437468682881e-05
6 O 0 2.2591940762595186e-07
splice O 0 1.3838697441315162e-06
site O 0 1.1366270769030962e-07
) O 0 5.565199856505387e-09
of O 0 1.258754434019238e-09
the O 0 6.836857302516819e-09
gene O 0 6.674154207075844e-08
, O 0 1.0870287781017396e-08
we O 0 9.43802191955001e-09
hypothesized O 0 2.899399760281085e-07
that O 0 8.091389780418012e-09
the O 0 3.3003818344923275e-08
mutation O 0 6.1896007537143305e-06
may O 0 6.421533385037037e-07
partially O 0 1.4056571444598376e-06
affect O 0 3.405744664064514e-08
the O 0 5.1711452897507115e-09
normal O 0 3.643600265945679e-08
splicing O 0 2.5925365321199934e-07
efficiency O 0 2.3345837973920425e-07
in O 0 3.717462959684781e-08
exon O 0 1.6793885606602998e-06
6 O 0 1.8197992801560758e-07
and O 0 2.5508676060326252e-08
cause O 0 1.9565088393846963e-07
alternative O 0 2.8599663437489653e-07
splicing O 0 3.6308331345935585e-06
elsewhere O 0 5.602568649010209e-07
, O 0 1.599309129574067e-08
which O 0 1.6118866241754404e-08
resulted O 0 2.570972981175146e-07
in O 0 1.5819938425920554e-07
decreased O 0 1.072350460162852e-05
transcript O 0 2.0789255358977243e-05
in O 0 1.446415325290218e-07
the O 0 5.450664275485906e-07
patient O 0 0.0006244682008400559
. O 0 9.641261385695543e-06

Transfection O 0 0.002685884479433298
of O 0 4.371971954242326e-06
constructed O 0 1.5372905181720853e-05
minigenes O 0 0.0001790561364032328
, O 0 1.5745330017580272e-07
with O 0 3.6839210793004895e-08
or O 0 2.8969859400262976e-08
without O 0 2.7031115124032112e-08
the O 0 3.0433955799935575e-08
mutation O 0 3.859568096231669e-07
, O 0 1.0615137213676462e-08
into O 0 4.43897256729997e-08
COS O 0 2.997167393914424e-05
- O 0 6.291697354754433e-05
1 O 0 4.3047967324127967e-07
cells O 0 4.459313913685037e-07
confirmed O 0 9.48849177007105e-08
that O 0 4.0460554906474044e-09
the O 0 6.365897142757149e-09
mutant O 0 1.136821538239019e-06
minigene O 0 7.731795449217316e-06
was O 0 6.403834618140536e-08
responsible O 0 2.343930738391009e-08
for O 0 7.88631826509345e-09
a O 0 1.8577138405362348e-07
mRNA O 0 3.6770418887499545e-07
species O 0 4.6456545277351324e-08
alternatively O 0 3.1053107818479475e-07
spliced O 0 6.029790711181704e-06
at O 0 6.17296080918095e-08
an O 0 5.258195301394153e-08
activated O 0 3.2942484722298104e-06
cryptic O 0 3.854024726024363e-06
5 O 0 6.34325871828878e-08
splice O 0 9.692126923255273e-07
site O 0 1.402452625143269e-07
88 O 0 2.760161805781536e-07
bp O 0 1.6768887007856392e-06
upstream O 0 1.0027447672200651e-07
from O 0 6.356239534710539e-09
the O 0 6.761369686358876e-09
3 O 0 4.910842932304149e-08
end O 0 5.050597451372596e-08
of O 0 4.265564612637718e-08
exon O 0 9.967682672140654e-06
6 O 0 4.342336978879757e-06
. O 0 1.92861466530303e-06

Our O 0 6.176168426463846e-06
data O 0 1.1322698583171587e-06
suggest O 0 3.9766419490661065e-07
that O 0 1.4390112212936401e-08
the O 0 1.433570595565925e-08
C O 0 3.322044790365908e-07
to O 0 2.7992244966412727e-08
A O 0 9.662400088927825e-07
mutation O 0 6.479586431851203e-07
at O 0 1.0903221436819877e-08
the O 0 8.709982957100237e-09
penultimate O 0 1.0091393960465211e-06
nucleotide O 0 9.298066316887343e-08
of O 0 8.052898792243468e-09
exon O 0 5.68704194847669e-07
6 O 0 6.765177573697656e-08
of O 0 2.959141376379648e-09
the O 0 2.6316349988064758e-08
CYP27 O 0 0.0001359960006084293
gene O 0 2.6855215651266917e-07
not O 0 2.1331393540435784e-08
only O 0 7.221935049983585e-08
causes O 0 3.4340814636379946e-06
the O 0 2.381442754995078e-06
deficiency B-Disease 0 0.3265228867530823
in I-Disease 0 5.289105331485189e-08
the I-Disease 0 7.786701416989672e-08
sterol I-Disease 0 0.0002116553660016507
27 I-Disease 0 1.5846136420805124e-06
- I-Disease 0 1.1573997653613333e-06
hydroxylase I-Disease 0 3.186732101312373e-06
activity I-Disease 0 2.2926226250774562e-08
, O 0 6.795696005923446e-09
but O 0 9.215803231654718e-09
also O 0 3.594686504015954e-08
partially O 0 8.374537969757512e-07
leads O 0 2.44869568177819e-07
to O 0 4.746462067828361e-08
alternative O 0 1.2894469136881526e-07
pre O 0 8.508787345817836e-07
- O 0 5.005275625080685e-07
mRNA O 0 9.114661025932946e-08
splicing O 0 1.828302345074917e-07
of O 0 7.101319088320679e-09
the O 0 4.266272668473903e-08
gene O 0 1.690908106866118e-06
. O 0 9.589539331500418e-07

To O 0 5.5855307437013835e-06
our O 0 3.3832077406259486e-07
knowledge O 0 1.0289705443256025e-07
, O 0 1.916683523006668e-08
this O 0 5.219303211845272e-09
is O 0 5.689985371759576e-09
the O 0 7.3019905677540464e-09
first O 0 8.629555026118396e-08
report O 0 1.0785740300889302e-07
regarding O 0 2.980821633968844e-08
effects O 0 4.0561414493822667e-07
on O 0 7.845259375471869e-08
pre O 0 1.3574684771811008e-06
- O 0 5.65709115107893e-07
mRNA O 0 6.919879069755552e-08
splicing O 0 1.5455032098543597e-07
of O 0 7.8929254243576e-09
a O 0 1.0557634055885501e-07
mutation O 0 7.061665314722632e-07
at O 0 1.30619737248594e-08
the O 0 1.2183413389266207e-08
- O 0 2.2753899884264683e-06
2 O 0 1.5547456655440328e-07
position O 0 7.060305762252028e-08
of O 0 6.207872438324102e-09
a O 0 2.2970243662712164e-07
5 O 0 3.527096623656689e-07
splice O 0 1.5197330867522396e-05
site O 0 4.0050440475170035e-06
. O 0 1.0756644996945397e-06

ATM O 0 0.0035689331125468016
germline O 1 0.8109511137008667
mutations O 0 0.1654435396194458
in O 0 1.3168109035177622e-05
classical O 0 0.05321406573057175
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999978542327881
telangiectasia I-Disease 1 0.9999996423721313
patients O 1 0.9995450377464294
in O 0 5.852417643836816e-07
the O 0 3.8987448647276324e-07
Dutch O 0 0.00036421348340809345
population O 0 1.0805646297740168e-06
. O 0 1.224213519890327e-06

Germline O 1 0.9863648414611816
mutations O 1 0.9030608534812927
in O 0 3.917980848200386e-06
the O 0 1.787176699963311e-07
ATM O 0 4.642608473659493e-06
gene O 0 6.418172233679798e-07
are O 0 1.3151217892470868e-08
responsible O 0 8.683960572852811e-08
for O 0 3.7050156720397354e-07
the O 0 0.008849077858030796
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999980926513672
telangiectasia I-Disease 1 0.9999978542327881
( O 0 2.8567423214553855e-05
A B-Disease 1 0.9974251985549927
- I-Disease 1 0.9998382329940796
T I-Disease 1 0.9999791383743286
) O 0 1.8569836583992583e-06
. O 0 1.9200406313757412e-06

In O 0 1.2096606042177882e-05
our O 0 1.6498491959282546e-06
study O 0 7.50665890336677e-07
, O 0 4.7195960917179036e-08
we O 0 1.7564707022188486e-08
have O 0 1.8648952604394253e-08
determined O 0 5.835921257357768e-08
the O 0 1.4494512257101633e-08
ATM O 0 3.371279262864846e-06
mutation O 0 2.117029225701117e-06
spectrum O 0 1.4133486274658935e-06
in O 0 5.294616656215112e-08
19 O 0 3.483392845282651e-07
classical O 0 2.2856859231978888e-06
A B-Disease 1 0.9993575215339661
- I-Disease 1 0.9999940395355225
T I-Disease 1 0.9999998807907104
patients O 1 0.751977264881134
, O 0 4.2582080084230256e-08
including O 0 2.709284885327179e-08
some O 0 3.079557941987332e-08
immigrant O 0 7.329311301873531e-06
populations O 0 8.899038306253715e-08
, O 0 1.3017031008644153e-08
as O 0 6.2707901093972396e-09
well O 0 1.0867302613348784e-08
as O 0 1.257279436117642e-08
12 O 0 2.865704473720143e-08
of O 0 1.3085114325406266e-08
Dutch O 0 1.8357943190494552e-05
ethnic O 0 1.2371496040941565e-06
origin O 0 1.6311923900502734e-06
. O 0 1.3101891909172991e-06

Both O 0 2.338278818569961e-06
the O 0 2.142438688679249e-07
protein O 0 3.257933371969557e-07
truncation O 0 3.705033350343001e-06
test O 0 1.1706999885063851e-06
( O 0 5.7227275362947694e-08
PTT O 0 3.7336969853640767e-06
) O 0 1.4728722241841297e-08
and O 0 5.622966092744264e-09
the O 0 8.685165475696977e-09
restriction O 0 1.4134887749150948e-07
endonuclease O 0 5.009472261008341e-06
fingerprinting O 0 4.914440978609491e-06
( O 0 4.636492434428874e-08
REF O 0 1.1455277672212105e-05
) O 0 4.813964338268306e-09
method O 0 1.6365206079171912e-08
were O 0 8.846234855752755e-09
used O 0 2.135459808982887e-08
and O 0 3.277478555219204e-08
compared O 0 1.7087286607875285e-07
for O 0 3.198898923528759e-09
their O 0 7.456128159333275e-09
detection O 0 1.780334883960677e-07
efficiency O 0 4.134572293423844e-07
, O 0 3.9435732901438314e-08
identifying O 0 1.445928461407675e-07
76 O 0 4.747987532027764e-06
% O 0 3.052074504239499e-08
and O 0 1.7281081454711966e-08
60 O 0 1.1122747878289374e-07
% O 0 1.2629805645758552e-08
of O 0 3.60256446896301e-09
the O 0 1.740022526064422e-07
mutations O 0 1.1757823813240975e-05
, O 0 3.0426474495470757e-07
respectively O 0 1.8765649656415917e-06
. O 0 1.8661781950868317e-06

Most O 0 0.00019523674563970417
patients O 0 0.048356302082538605
were O 0 3.8139808111736784e-07
found O 0 1.2417839911904593e-07
to O 0 7.690745462696214e-08
be O 0 2.3308662377985456e-07
compound O 0 1.2407804206304718e-05
heterozygote O 0 0.0003354885848239064
. O 0 3.7684176277252845e-06

Seventeen O 0 0.0006060205050744116
mutations O 0 0.0029869256541132927
were O 0 1.256769678548153e-06
distinct O 0 5.641230131914199e-07
, O 0 2.6293070831684417e-08
of O 0 7.3910375597563416e-09
which O 0 7.694516312994892e-08
10 O 0 7.985418903899699e-08
were O 0 4.1675555451092805e-08
not O 0 1.836337020222345e-07
reported O 0 5.1780652938759886e-06
previously O 0 2.6425407213537255e-06
. O 0 1.0983183074131375e-06

Mutations O 0 0.18875451385974884
are O 0 1.0745653753474471e-06
small O 0 7.760567655168416e-07
deletions O 0 1.3608200788439717e-05
or O 0 4.564149094221648e-07
point O 0 7.166805175984337e-07
mutations O 0 5.370826784201199e-06
frequently O 0 1.0747468195404508e-06
affecting O 0 1.2528493016361608e-06
splice O 0 3.986772208008915e-05
sites O 0 3.6818566968577215e-06
. O 0 3.3381061257387046e-06

Moreover O 0 0.00021225660748314112
, O 0 2.521580427128356e-06
a O 0 2.7717496777768247e-06
16 O 0 7.432343409163877e-06
. O 0 3.2359221222577617e-06

7 O 0 7.741701847407967e-05
- O 0 5.096213862998411e-05
kb O 0 4.189319952274673e-05
genomic O 0 2.8191889214213006e-06
deletion O 0 3.719517053468735e-06
of O 0 1.0492387403360226e-08
the O 0 1.4237743428680005e-08
3 O 0 4.668046571509876e-08
end O 0 1.536847094030236e-08
of O 0 2.5550783711025815e-09
the O 0 1.274212557689225e-08
gene O 0 9.403327538848316e-08
, O 0 1.677340932815241e-08
most O 0 1.1188918236371137e-08
likely O 0 1.3837534140748176e-07
a O 0 1.695405416057838e-07
result O 0 7.734126228342575e-08
of O 0 7.615653885295615e-09
recombination O 0 3.976766720370506e-07
between O 0 2.6228354599311388e-08
two O 0 2.815336053174633e-08
LINE O 0 4.983071448805276e-07
elements O 0 1.2778578195593582e-07
, O 0 9.49899430224832e-08
was O 0 8.336663768204744e-07
identified O 0 1.3735535731029813e-06
. O 0 9.868763299891725e-07

The O 0 1.7043424804796814e-06
most O 0 3.5854941415891517e-07
frequently O 0 1.3632181889988715e-06
found O 0 3.8980235217422887e-07
mutation O 0 2.9795428417855874e-06
, O 0 9.586305083075786e-08
identified O 0 1.9793563410530624e-07
in O 0 1.4540976422949825e-08
three O 0 3.465988385187302e-08
unrelated O 0 1.714441509648168e-06
Turkish O 0 0.000264596106717363
A B-Disease 1 0.9978827834129333
- I-Disease 1 0.9999125003814697
T I-Disease 1 0.9999959468841553
individuals O 0 1.4840595952136937e-07
, O 0 3.1446365511555996e-08
was O 0 2.513443462248688e-07
previously O 0 2.649057933012955e-07
described O 0 2.5799823788474896e-07
to O 0 2.6157215060607086e-08
be O 0 2.9588944627789715e-08
a O 0 3.446489245106932e-07
Turkish O 0 0.00014866968558635563
A B-Disease 1 0.9887027740478516
- I-Disease 1 0.9996185302734375
T I-Disease 1 0.9999748468399048
founder O 0 0.00042434060014784336
mutation O 0 2.506647797417827e-05
. O 0 2.5778081180760637e-06

The O 0 2.082697847072268e-06
presence O 0 7.818846370355459e-07
of O 0 3.5512488949507315e-08
a O 0 5.34118385075999e-07
founder O 0 4.511359293246642e-05
mutation O 0 4.093598363397177e-06
among O 0 8.209961777083663e-08
relatively O 0 1.841183916440059e-07
small O 0 2.161802470368457e-08
ethnic O 0 8.248400718002813e-08
population O 0 2.8568090115754785e-08
groups O 0 6.847924449715492e-09
in O 0 1.1056243032214752e-08
Western O 0 5.0243862403931416e-08
Europe O 0 9.777820508816149e-08
could O 0 8.68255298769327e-08
indicate O 0 9.370724285417964e-08
a O 0 1.2191927112326084e-07
high O 0 3.207530880899867e-07
carrier O 0 2.5442554942856077e-06
frequency O 0 4.050887980611151e-07
in O 0 2.718955371960874e-08
such O 0 4.318802027114543e-08
communities O 0 5.619730245598475e-07
. O 0 1.4442528026847867e-06

In O 0 8.782659278949723e-05
patients O 0 0.0005573538946919143
of O 0 1.268941502985399e-07
Dutch O 0 5.527413304662332e-05
ethnic O 0 2.6553965426501236e-07
origin O 0 8.810035723172405e-08
, O 0 2.7163167715116288e-08
however O 0 3.6704477679450065e-08
, O 0 1.1424146073579777e-08
no O 0 1.719061160088131e-08
significant O 0 1.5757850135855733e-08
founder O 0 5.55301937765762e-07
effect O 0 2.81900383924949e-07
could O 0 1.801885929353375e-07
be O 0 1.2540992599952006e-07
identified O 0 1.6404918596890639e-06
. O 0 9.788948318600887e-07

The O 0 1.4975324120314326e-05
observed O 0 2.6887277272180654e-05
genetic O 0 8.355723366548773e-06
heterogeneity O 0 8.296147825603839e-06
including O 0 1.9649701243906748e-07
the O 0 5.214937814912446e-08
relative O 0 5.07346101130679e-07
high O 0 1.0596369293125463e-07
percentage O 0 6.77470737286967e-08
of O 0 7.53300444245042e-09
splice O 0 9.60397574090166e-06
- O 0 0.0006733766058459878
site O 0 6.13731162957265e-06
mutations O 0 2.1205250959610566e-06
had O 0 9.271573730984528e-08
no O 0 6.138090924423523e-08
reflection O 0 7.33107526684762e-07
on O 0 3.737579845619621e-07
the O 0 1.0397437790743425e-06
phenotype O 0 0.011862960644066334
. O 0 5.502314252225915e-06

All O 0 3.3330070436932147e-05
patients O 0 0.004555274732410908
manifested O 0 3.466174166533165e-05
classical O 0 1.3641021723742597e-05
A B-Disease 1 0.9375460743904114
- I-Disease 1 0.9982017278671265
T I-Disease 1 0.9998776912689209
and O 0 4.6392571562137164e-07
increased O 0 6.545751602970995e-07
cellular O 0 7.643854587513488e-06
radioresistant O 0 5.030258762417361e-05
DNA O 0 6.881556601001648e-06
synthesis O 0 4.454248937690863e-06
. O 0 2.7502767352416413e-06

Determination O 0 0.00012986009824089706
of O 0 4.381788016871724e-07
the O 0 1.1113417031083372e-07
genomic O 0 1.240720280293317e-06
structure O 0 1.005289718136737e-07
of O 0 5.55304868754547e-09
the O 0 2.101057638981274e-08
COL4A4 O 0 0.00017462506366427988
gene O 0 3.681652742670849e-07
and O 0 3.060597109083574e-08
of O 0 8.088090197588826e-08
novel O 0 0.00018769501184578985
mutations O 0 0.027713606134057045
causing O 0 0.06645328551530838
autosomal B-Disease 1 0.9998981952667236
recessive I-Disease 1 0.9999936819076538
Alport I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999984502792358
. O 0 6.165295781102031e-05

Autosomal B-Disease 1 0.9999834299087524
recessive I-Disease 1 0.9999992847442627
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
is O 0 1.7373875380144455e-05
a O 0 3.5825305531034246e-05
progressive O 0 0.27844953536987305
hematuric B-Disease 1 0.9989905953407288
glomerulonephritis I-Disease 1 0.9999964237213135
characterized O 0 0.0041244602762162685
by O 0 1.207090463140048e-06
glomerular B-Disease 0 0.02660347893834114
basement I-Disease 0 0.04012548178434372
membrane I-Disease 0 0.1638098955154419
abnormalities I-Disease 1 0.9877352118492126
and O 0 6.34203672689182e-07
associated O 0 4.1034533637684945e-07
with O 0 1.7362083326588618e-07
mutations O 0 1.403490205120761e-05
in O 0 4.128889585786055e-08
either O 0 4.198880532158e-08
the O 0 1.986621533944799e-08
COL4A3 O 0 0.0005584887112490833
or O 0 4.134382081133481e-08
the O 0 3.0251538163383884e-08
COL4A4 O 0 0.0004387018270790577
gene O 0 4.0041635429588496e-07
, O 0 1.890714784735792e-08
which O 0 8.550009589214369e-09
encode O 0 7.205148477851253e-08
the O 0 4.594377855937637e-08
alpha3 O 0 5.895394679100718e-06
and O 0 1.199303483190306e-07
alpha4 O 0 7.633586938027292e-05
type O 0 8.610468285041861e-06
IV O 0 0.0017620290163904428
collagen O 0 7.518056372646242e-05
chains O 0 1.0246466445096303e-05
, O 0 4.045325283641432e-07
respectively O 0 2.2405663457902847e-06
. O 0 1.5247484270730638e-06

To O 0 6.970514732529409e-06
date O 0 1.5541793345619226e-06
, O 0 1.5369035111234552e-07
mutation O 0 4.839920393351349e-07
screening O 0 3.1250490906131745e-07
in O 0 2.5304180084617656e-08
the O 0 1.3601720638689585e-08
two O 0 5.0953193664327046e-08
genes O 0 1.7429553622605454e-07
has O 0 9.467611761238004e-08
been O 0 6.923813344883456e-08
hampered O 0 1.9873127712344285e-06
by O 0 5.700906058336841e-08
the O 0 3.3742942662229325e-08
lack O 0 1.1663745169698814e-07
of O 0 5.217425069758974e-08
genomic O 0 5.354348559194477e-06
structure O 0 1.9016625856238534e-06
information O 0 7.055014634715917e-07
. O 0 1.8391182265986572e-06

We O 0 7.880592420406174e-06
report O 0 1.8357712860961328e-06
here O 0 6.835399091187355e-08
the O 0 1.3980160140647513e-08
complete O 0 1.636465327692349e-07
characterization O 0 1.213697714774753e-06
of O 0 1.665357629576647e-08
the O 0 4.336135361882043e-08
48 O 0 4.5686695671065536e-07
exons O 0 4.2459134874661686e-07
of O 0 8.987805166782437e-09
the O 0 2.7428161075704338e-08
COL4A4 O 0 0.00020084247807972133
gene O 0 2.464911403876613e-07
, O 0 1.3180196489770424e-08
a O 0 9.393952637992697e-08
comprehensive O 0 4.22878741801469e-07
gene O 0 2.4027815470617497e-07
screen O 0 1.465778495912673e-06
, O 0 1.3996889869360984e-08
and O 0 7.78043318661048e-09
the O 0 4.929872954306802e-09
subsequent O 0 1.3874203830255283e-07
detection O 0 1.7679970198969386e-07
of O 0 1.0190016830335935e-08
10 O 0 1.001742973016917e-07
novel O 0 2.061758095805999e-06
mutations O 0 4.288662239559926e-06
in O 0 1.7979206745621923e-07
eight O 0 0.000743987038731575
patients O 1 0.9961524605751038
diagnosed O 1 0.9998797178268433
with O 0 0.025518979877233505
autosomal B-Disease 1 0.9999816417694092
recessive I-Disease 1 0.9999959468841553
Alport I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999978542327881
. O 0 7.017378811724484e-05

Furthermore O 0 0.00019403935584705323
, O 0 1.1264312433922896e-06
we O 0 1.0933484873021371e-07
identified O 0 8.048848343378268e-08
a O 0 4.192734692765043e-08
glycine O 0 2.4985163804558397e-07
to O 0 3.5822296240439755e-08
alanine O 0 2.075835823234229e-07
substitution O 0 7.640843335821046e-08
in O 0 1.9771634995890963e-08
the O 0 3.0609594858788114e-08
collagenous O 0 0.00017948946333490312
domain O 0 1.6716406037176057e-07
that O 0 1.945463701247263e-08
is O 0 2.324625469896091e-08
apparently O 0 5.510588039214781e-07
silent O 0 1.4073580132389907e-06
in O 0 1.0311608455992882e-08
the O 0 2.8128614104616645e-08
heterozygous O 0 4.0121776692103595e-06
carriers O 0 4.5753449740004726e-07
, O 0 4.9207820040919614e-08
in O 0 8.52098622772246e-08
11 O 0 1.2355720855339314e-06
. O 0 1.0766989362309687e-06

5 O 0 2.44352086156141e-05
% O 0 3.9378915062115993e-07
of O 0 1.455263021199471e-08
all O 0 1.3252974717659072e-08
control O 0 1.2781846407960984e-06
individuals O 0 4.0257582156755234e-08
, O 0 1.7256676088095446e-08
and O 0 1.593879517258756e-08
in O 0 1.2009293115511355e-08
one O 0 1.513430269994842e-08
control O 0 1.982810005074498e-07
individual O 0 3.4359210587808775e-08
homozygous O 0 4.7593803742529417e-07
for O 0 1.543350691690648e-08
this O 0 4.3704442731495874e-08
glycine O 0 1.5022765182948206e-06
substitution O 0 1.575000055709097e-06
. O 0 1.7497117141829222e-06

There O 0 2.104867235175334e-05
has O 0 1.2423080306689371e-06
been O 0 2.1998164356773486e-07
no O 0 8.24423338485758e-08
previous O 0 7.467203744226936e-08
finding O 0 3.464150921672626e-08
of O 0 4.3992121057101485e-09
a O 0 6.451070078128396e-08
glycine O 0 3.293440045126772e-07
substitution O 0 9.410774026719082e-08
that O 0 3.126073977455235e-08
is O 0 1.5399397312876317e-08
not O 0 1.2613916133830116e-08
associated O 0 1.4751663890422151e-08
with O 0 9.73056124564664e-09
any O 0 4.0270638379524826e-08
obvious O 0 1.5861052816035226e-05
phenotype O 0 0.06467361748218536
in O 0 6.06129503921693e-07
homozygous O 0 6.980910256970674e-05
individuals O 0 6.377207455443568e-07
. O 0 2.3224379219755065e-06

Founder O 0 0.004754114430397749
BRCA1 O 1 0.7291510105133057
and O 0 8.190268999896944e-05
BRCA2 O 1 0.8590970635414124
mutations O 0 0.0002766184916254133
in O 0 9.553209565638099e-07
French O 0 8.137919940054417e-05
Canadian O 0 0.006675396114587784
breast B-Disease 1 0.9998544454574585
and I-Disease 1 0.9990531802177429
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 7.508527778554708e-05
. O 0 8.987601177068427e-06

We O 0 7.1669342105451506e-06
have O 0 6.383955906130723e-07
identified O 0 3.498624323583499e-07
four O 0 1.167488505871006e-07
mutations O 0 6.539449941556086e-07
in O 0 9.762275432478873e-09
each O 0 4.614839177463637e-09
of O 0 1.0545293527286503e-08
the O 0 6.284469691308914e-06
breast B-Disease 1 0.999985933303833
cancer I-Disease 1 0.9998464584350586
- O 1 0.8705130815505981
susceptibility O 1 0.6452483534812927
genes O 0 3.61472598342516e-06
, O 0 3.4661675840652606e-07
BRCA1 O 0 7.996131898835301e-05
and O 0 1.1636074077614467e-06
BRCA2 O 0 0.0008344554807990789
, O 0 1.1130047994356573e-07
in O 0 7.483914998829277e-08
French O 0 3.051104249607306e-05
Canadian O 0 0.008942019194364548
breast B-Disease 1 0.9999102354049683
cancer I-Disease 1 0.9992450475692749
and O 0 0.14453956484794617
breast B-Disease 1 0.9999991655349731
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.6539795979042538e-05
from O 0 7.888516506682208e-07
Quebec O 0 8.41664950712584e-05
. O 0 2.96149710266036e-06

To O 0 2.2804564650868997e-05
identify O 0 1.5118517694645561e-05
founder O 0 2.068574212898966e-05
effects O 0 1.0957678568956908e-05
, O 0 9.157895419775741e-08
we O 0 4.2790510690338124e-08
examined O 0 1.1953563898714492e-06
independently O 0 3.49099536833819e-07
ascertained O 0 1.1429963251430308e-06
French O 0 4.723396614281228e-06
Canadian O 0 0.00016711313219275326
cancer B-Disease 0 0.04020768031477928
families O 0 1.259748785287229e-07
for O 0 7.53300444245042e-09
the O 0 1.9610437718142748e-08
distribution O 0 1.5746973502928086e-08
of O 0 6.406727592889183e-09
these O 0 3.293740746812546e-08
eight O 0 1.1723491297743749e-06
mutations O 0 1.7218646462424658e-05
. O 0 1.2869068086729385e-06

Mutations O 0 0.3689129054546356
were O 0 1.1085795449616853e-05
found O 0 1.0054295671579894e-06
in O 0 1.503028812521734e-07
41 O 0 9.438139159101411e-07
of O 0 6.598563118132006e-08
97 O 0 8.11967493064003e-06
families O 0 2.655948492247262e-06
. O 0 2.0426896298886277e-06

Six O 0 6.264765033847652e-06
of O 0 1.569160446024398e-07
eight O 0 1.1265643706792616e-06
mutations O 0 4.2589049371599685e-06
were O 0 6.323182333289878e-08
observed O 0 1.8174684157656884e-07
at O 0 7.149500191871994e-08
least O 0 2.8882556080134236e-07
twice O 0 2.4321254841197515e-06
. O 0 8.443601586805016e-07

The O 0 2.4983519324450754e-05
BRCA1 O 0 0.02141803503036499
C4446T O 0 0.002482734387740493
mutation O 0 0.0001390873803757131
was O 0 4.5230669343254704e-07
the O 0 3.766509593106093e-08
most O 0 6.972157251539102e-08
common O 0 4.5065633003105177e-07
mutation O 0 1.81549767148681e-05
found O 0 1.4924704316854331e-07
, O 0 1.9826089214802778e-08
followed O 0 8.018631092454598e-08
by O 0 3.806592729915792e-08
the O 0 4.5393323944153963e-07
BRCA2 O 0 0.002501649083569646
8765delAG O 0 0.0005556615651585162
mutation O 0 4.749581421492621e-05
. O 0 4.619263108907035e-06

Together O 0 1.635778789932374e-05
, O 0 5.338820301403757e-07
these O 0 7.576640115303235e-08
mutations O 0 1.213733639815473e-06
were O 0 4.634149775029073e-08
found O 0 4.03771593937563e-08
in O 0 2.56084646821364e-08
28 O 0 1.8915523014584323e-07
of O 0 1.9376276583216168e-08
41 O 0 5.806757599202683e-06
families O 0 1.8131905221707711e-07
identified O 0 1.2277077132694103e-07
to O 0 3.293935435522144e-08
have O 0 1.164010967613649e-07
a O 0 3.819338417088147e-06
mutation O 0 2.7086216505267657e-05
. O 0 2.057450501524727e-06

The O 0 4.353851636551553e-06
odds O 0 1.4117500541033223e-05
of O 0 4.9666837753647997e-08
detection O 0 2.630298467920511e-07
of O 0 9.50910639119229e-09
any O 0 5.977356387631971e-09
of O 0 4.129391495411028e-09
the O 0 3.630129086218403e-08
four O 0 1.175474835690693e-06
BRCA1 O 0 0.0015895458636805415
mutations O 0 1.1226090464333538e-05
was O 0 9.852476523519726e-07
18 O 0 1.6611376167929848e-06
. O 0 1.5511262745349086e-06

7x O 0 0.23876884579658508
greater O 0 1.2393151337164454e-05
if O 0 3.557680372523464e-07
one O 0 5.691605409197109e-08
or O 0 1.967292817539601e-08
more O 0 5.837268091113401e-08
cases O 0 1.929852942339494e-06
of O 0 0.0011793783633038402
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
were O 0 1.315530425927136e-06
also O 0 3.0532658001902746e-07
present O 0 8.690356168017388e-08
in O 0 8.008833418671202e-08
the O 0 1.317268782941028e-07
family O 0 4.051528321724618e-06
. O 0 1.9637932382465806e-06

The O 0 5.747022441937588e-06
odds O 0 2.1437994291773066e-05
of O 0 8.151791064392455e-08
detection O 0 4.132810431656253e-07
of O 0 5.95757398968999e-09
any O 0 4.968187639065036e-09
of O 0 3.901807321682327e-09
the O 0 4.036214562574969e-08
four O 0 3.063055373786483e-06
BRCA2 O 0 0.022586358711123466
mutations O 0 1.2838047950936016e-05
was O 0 1.1346467090334045e-06
5 O 0 1.1945518281208933e-06
. O 0 1.847749899752671e-06

3x O 0 0.013701239600777626
greater O 0 1.845339465944562e-05
if O 0 8.118257710520993e-07
there O 0 1.0770671821092037e-07
were O 0 4.9305526772513986e-08
at O 0 2.235732665667456e-08
least O 0 3.7903781446857465e-08
five O 0 7.833417470237691e-08
cases O 0 3.6694541449833196e-07
of O 0 2.627593403303763e-06
breast B-Disease 1 0.9999946355819702
cancer I-Disease 1 0.9995903372764587
in O 0 8.172229399860953e-07
the O 0 6.308605975391401e-07
family O 0 5.422597041615518e-06
. O 0 1.4200500118022319e-06

Interestingly O 0 0.0006001057918183506
, O 0 7.606546432725736e-07
the O 0 3.1065066963265053e-08
presence O 0 6.523777074107784e-08
of O 0 3.379666324576647e-08
a O 0 0.0012169070541858673
breast B-Disease 1 0.9999771118164062
cancer I-Disease 1 0.9928973913192749
case O 0 2.2414587874663994e-05
< O 0 3.971918886236381e-06
36 O 0 3.9540654483971593e-07
years O 0 9.114052801351136e-08
of O 0 9.152320679106651e-09
age O 0 2.1454361842643266e-07
was O 0 5.781091871881472e-08
strongly O 0 1.3656276109941246e-07
predictive O 0 1.224564556423502e-07
of O 0 3.962503658527794e-09
the O 0 8.363058690008529e-09
presence O 0 1.2572363594642866e-08
of O 0 1.0814880102572033e-09
any O 0 2.447755109713512e-09
of O 0 2.3393380566005817e-09
the O 0 4.2788553145101105e-08
eight O 0 2.1057430785731412e-06
mutations O 0 1.3168234545446467e-05
screened O 0 1.674376289884094e-05
. O 0 4.278681899450021e-06

Carriers O 0 4.3486212234711275e-05
of O 0 1.257708106550126e-07
the O 0 7.490826448020016e-08
same O 0 2.2278750577697792e-07
mutation O 0 1.1623164937191177e-06
, O 0 1.7155890930098394e-08
from O 0 9.18330744781315e-09
different O 0 1.0201625322281416e-08
families O 0 6.787124107177078e-08
, O 0 3.858647446008945e-08
shared O 0 8.817348629008848e-08
similar O 0 4.5366965650828206e-07
haplotypes O 0 3.4815955586964265e-05
, O 0 2.9386358235683474e-08
indicating O 0 8.337420354109781e-08
that O 0 4.471968573227514e-09
the O 0 5.73608938125858e-09
mutant O 0 1.6827473245939473e-06
alleles O 0 3.789330662584689e-07
were O 0 4.636651951273052e-08
likely O 0 8.465357126397066e-08
to O 0 2.4577021306981806e-08
be O 0 3.555301830715507e-08
identical O 0 1.1127665402455023e-06
by O 0 2.710463320454437e-08
descent O 0 8.258048751486058e-07
for O 0 3.5362504036129394e-08
a O 0 1.6087236645034864e-06
mutation O 0 4.690368314186344e-06
in O 0 5.475913411601141e-08
the O 0 1.0681799977874107e-07
founder O 0 1.35733598654042e-05
population O 0 8.024779276638583e-07
. O 0 9.61387854658824e-07

The O 0 2.62852563537308e-06
identification O 0 9.732362968861707e-07
of O 0 1.0593317512075373e-07
common O 0 3.725573378687841e-06
BRCA1 O 0 0.03267792612314224
and O 0 5.532275827135891e-05
BRCA2 O 1 0.6092613935470581
mutations O 0 7.341272521443898e-06
will O 0 6.925794338030755e-08
facilitate O 0 8.754523861398411e-08
carrier O 0 3.0125409011816373e-06
detection O 0 4.85171426589659e-07
in O 0 1.2684407124652353e-07
French O 0 2.487081837898586e-05
Canadian O 0 0.003352849278599024
breast B-Disease 1 0.9999111890792847
cancer I-Disease 1 0.9997714161872864
and O 0 0.30415108799934387
breast B-Disease 1 0.9999992847442627
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 0.00017305831715930253
. O 0 8.116763638099656e-06

Are O 0 8.549573067284655e-06
Dp71 O 0 0.00019850986427627504
and O 0 2.228407083748607e-06
Dp140 O 0 0.0011123651638627052
brain O 0 0.003378654131665826
dystrophin O 0 0.00018817471573129296
isoforms O 0 5.840870471729431e-06
related O 0 7.550757459284796e-07
to O 0 1.1918107247765874e-06
cognitive B-Disease 0 0.01718037948012352
impairment I-Disease 0 0.30631038546562195
in O 0 0.00010269245831295848
Duchenne B-Disease 1 0.9999414682388306
muscular I-Disease 1 0.9999896287918091
dystrophy I-Disease 1 0.9999790191650391
? O 0 0.0016453563002869487

Molecular O 0 0.0010763206519186497
study O 0 2.0762308849953115e-05
and O 0 1.1545796496648109e-06
neuropsychological O 0 9.851937647908926e-05
analysis O 0 6.956508400435268e-07
were O 0 4.9098314747197946e-08
performed O 0 1.9601861822593492e-07
concurrently O 0 3.91304126878822e-07
on O 0 1.0042019766842714e-06
49 O 0 0.00018901161092799157
patients O 0 0.00030315021285787225
with O 0 8.570600039092824e-05
Duchenne B-Disease 1 0.999992847442627
muscular I-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999995231628418
( O 0 0.0005342481308616698
DMD B-Disease 1 0.9999979734420776
) O 0 6.885305197101843e-07
in O 0 6.586114409401489e-08
order O 0 3.92995218589931e-08
to O 0 2.9617289953876025e-08
find O 0 8.64393641109018e-08
a O 0 2.1099293689985643e-07
molecular O 0 2.6475777303858195e-06
explanation O 0 4.619280105089274e-07
for O 0 1.2898326851029651e-08
the O 0 1.267653431114013e-07
cognitive B-Disease 0 0.004505444783717394
impairment I-Disease 0 0.006581881549209356
observed O 0 1.4045957641428686e-06
in O 0 4.767721009102388e-07
most O 0 2.87106213363586e-05
DMD B-Disease 1 0.9999997615814209
patients O 1 0.9997000694274902
. O 0 1.8605840523377992e-05

Complete O 0 3.766165173146874e-05
analysis O 0 2.7344958652975038e-06
of O 0 6.377785410904835e-08
the O 0 9.975597947686765e-08
dystrophin O 0 6.0037906223442405e-05
gene O 0 6.5966622742053e-07
was O 0 1.0296832186895699e-07
performed O 0 8.735941747772813e-08
to O 0 1.542029615109186e-08
define O 0 1.5212624759897153e-07
the O 0 1.553107509266738e-08
localization O 0 2.0495981800650043e-07
of O 0 8.07854405593389e-09
deletions O 0 9.197497661261878e-07
and O 0 6.576825484216897e-08
duplications O 0 8.174973231689364e-07
in O 0 5.388960744312499e-08
relation O 0 8.437437060138109e-08
to O 0 5.5779441510139804e-08
the O 0 9.624797314700118e-08
different O 0 5.879292075405829e-07
DMD B-Disease 1 0.9999048709869385
promoters O 0 0.00021555957209784538
. O 0 6.111600669100881e-06

Qualitative O 0 0.00011189567157998681
analysis O 0 6.011962796037551e-06
of O 0 1.7515118599931156e-07
the O 0 1.926587458456197e-07
Dp71 O 0 6.628624396398664e-05
transcript O 0 2.3228001737152226e-05
and O 0 3.395043179921231e-08
testing O 0 3.570987416878779e-08
for O 0 3.2596469967671737e-09
the O 0 5.10305842027492e-09
specific O 0 7.346414143682978e-09
first O 0 2.3593289100176662e-08
exon O 0 3.1321917504101293e-07
of O 0 1.3691545674987537e-08
Dp140 O 0 5.727111783926375e-06
were O 0 4.40315979233219e-08
also O 0 5.185152929243486e-08
carried O 0 6.155631240289949e-07
out O 0 6.952025159989716e-07
. O 0 1.5722625903435983e-06

Neuropsychological O 0 0.029695503413677216
analysis O 0 8.257712033810094e-05
assessed O 0 2.080162630591076e-05
verbal O 0 1.6937623513513245e-05
and O 0 6.362840281326498e-07
visuospatial O 0 8.079725375864655e-05
intelligence O 0 1.308595756199793e-06
, O 0 7.06345772982786e-08
verbal O 0 1.6366524278055294e-06
memory O 0 6.906771432113601e-06
, O 0 9.316030968875566e-08
and O 0 6.474071057027686e-08
reading O 0 8.159504432114772e-07
skills O 0 1.4057241060072556e-06
. O 0 2.139393473044038e-06

Comparison O 0 5.200212763156742e-05
of O 0 8.359855314665765e-07
molecular O 0 1.0445030966366176e-05
and O 0 7.662426924071042e-07
psychometric O 0 0.0006477490533143282
findings O 0 7.486507092835382e-05
demonstrated O 0 2.2461163098341785e-06
that O 0 5.71103839774878e-08
deletions O 0 1.428520249646681e-06
and O 0 9.8882871668593e-08
duplications O 0 1.273596240025654e-06
that O 0 1.135917386818619e-07
were O 0 5.985789641727024e-08
localized O 0 1.821431283133279e-06
in O 0 7.027577453300182e-08
the O 0 5.0900059278546905e-08
distal O 0 8.448009612038732e-05
part O 0 8.391936034968239e-08
of O 0 5.765342869779033e-09
the O 0 2.5313013907179993e-08
gene O 0 1.914252720780496e-07
seemed O 0 5.961941837995255e-07
to O 0 4.5408171445160406e-08
be O 0 4.002520981316593e-08
preferentially O 0 4.699331839219667e-06
associated O 0 4.623960592198273e-07
with O 0 5.891572527616518e-07
cognitive B-Disease 0 0.008515411987900734
impairment I-Disease 0 0.020922675728797913
. O 0 6.110970844019903e-06

Two O 0 1.600900577614084e-05
altered O 0 3.2740208553150296e-05
Dp71 O 0 8.219169831136242e-05
transcripts O 0 4.517894922173582e-06
and O 0 7.058999784703701e-08
two O 0 4.1074070367130844e-08
deleted O 0 1.2448673487597262e-06
Dp140 O 0 3.6052826999366516e-06
DNA O 0 6.817170401518524e-07
sequences O 0 1.513771650252238e-07
were O 0 1.8252809041996443e-08
found O 0 2.8653655448351856e-08
in O 0 2.3960303963121987e-08
four O 0 7.955650289659388e-07
patients O 0 8.049894677242264e-05
with O 0 2.2757179976906627e-05
severe O 1 0.9999525547027588
cerebral B-Disease 1 0.9999951124191284
dysfunction I-Disease 1 0.9997866749763489
. O 0 3.599935371312313e-05

These O 0 1.0894056686083786e-05
findings O 0 2.0659250367316417e-05
suggest O 0 1.1742400829461985e-06
that O 0 2.597277237725848e-08
some O 0 7.904435328498494e-09
sequences O 0 3.464157671828616e-08
located O 0 2.0687716428824388e-08
in O 0 9.338283923909785e-09
the O 0 8.851415600474866e-09
distal O 0 3.8088212022557855e-05
part O 0 8.421135078151565e-08
of O 0 6.153867193603446e-09
the O 0 1.0408173878317939e-08
gene O 0 5.098430122529862e-08
and O 0 2.0073802176057143e-08
, O 0 2.2669157218047076e-08
in O 0 1.2893801581981279e-08
particular O 0 2.6217652049354e-08
, O 0 5.3546781231261775e-08
some O 0 1.5641373352082155e-07
DMD B-Disease 1 0.9999914169311523
isoforms O 0 1.6746749679441564e-05
expressed O 0 6.613556706724921e-07
in O 0 3.9093404069490134e-08
the O 0 1.3539461463096814e-07
brain O 0 0.038329023867845535
may O 0 6.800547680541058e-07
be O 0 1.8639742194181963e-08
related O 0 3.1832886548954775e-08
to O 0 6.803298191471185e-08
the O 0 3.2725569099056884e-07
cognitive B-Disease 0 0.349486380815506
impairment I-Disease 1 0.8030151724815369
associated O 0 6.398733603418805e-06
with O 0 1.4160715181787964e-05
DMD B-Disease 1 0.999998927116394
. O 0 1.7604437744012102e-05
. O 0 4.119947789149592e-06

I1307K O 0 0.0038162556011229753
APC O 0 0.0004365879576653242
and O 0 3.1373299407277955e-06
hMLH1 O 0 0.0002892069169320166
mutations O 0 2.6027430067188106e-05
in O 0 5.3168701441563826e-08
a O 0 4.5531152181865764e-07
non O 0 4.7368391165036883e-07
- O 0 2.8563719752128236e-05
Jewish O 0 9.85745714388031e-07
family O 0 3.147961535887589e-07
with O 0 2.4995745206979336e-07
hereditary B-Disease 0 0.08303146809339523
non I-Disease 0 0.0003170121053699404
- I-Disease 1 0.9999281167984009
polyposis I-Disease 1 0.999998927116394
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 9.737756045069546e-05

We O 0 8.57060331327375e-06
describe O 0 1.2619263543456327e-05
a O 0 3.999955879407935e-06
French O 0 2.4811242838040926e-05
Canadian O 0 3.106681469944306e-05
hereditary B-Disease 0 0.0665380209684372
non I-Disease 0 0.0008803423843346536
- I-Disease 1 0.9999855756759644
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0003178298065904528
HNPCC B-Disease 1 0.9911308288574219
) O 0 1.0981276545862784e-06
kindred O 0 2.271559242217336e-05
which O 0 1.8427192571834894e-07
carries O 0 1.075278873940988e-06
a O 0 5.876399882254191e-07
novel O 0 2.662283350218786e-06
truncating O 0 3.165640009683557e-05
mutation O 0 1.3503305126505438e-05
in O 0 6.580721105819975e-07
hMLH1 O 0 0.0001252505462616682
. O 0 4.488361355470261e-06

Interestingly O 0 0.0008014033082872629
, O 0 2.3231643808685476e-06
the O 0 2.665354656983254e-07
I1307K O 0 2.387872154940851e-05
APC O 0 2.2836096832179464e-05
polymorphism O 0 0.00011123566218884662
, O 0 1.8287767034053104e-07
associated O 0 8.823102604083033e-08
with O 0 1.1465403737531688e-08
an O 0 6.721050027636011e-08
increased O 0 2.2173412617121357e-06
risk O 0 7.110088972694939e-06
of O 0 0.0004433449648786336
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.557995453069452e-06
is O 0 1.256404971172742e-07
also O 0 1.20796059377426e-07
present O 0 8.388607852793939e-08
in O 0 4.159645783374799e-08
this O 0 9.467485995173774e-08
family O 0 2.3561956368212122e-06
. O 0 1.7958573153009638e-06

The O 0 8.61638272908749e-06
I1307K O 0 0.0003243226674385369
polymorphism O 0 0.0007706959149800241
has O 0 2.3760617295920383e-06
previously O 0 4.1807484763012326e-07
only O 0 1.5506270045761994e-08
been O 0 3.519126323681121e-08
identified O 0 1.065109955789012e-07
in O 0 2.2066698690537123e-08
individuals O 0 7.668141677186213e-09
of O 0 1.7668432050754745e-08
self O 0 0.00027378564118407667
- O 0 0.1762481927871704
reported O 0 0.00030320254154503345
Ashkenazi O 0 1.6109041098388843e-05
Jewish O 0 1.454972334613558e-06
origins O 0 2.5230165192624554e-06
. O 0 2.3296383915294427e-06

In O 0 7.679357622691896e-06
addition O 0 1.1720741213139263e-06
, O 0 9.802843692341412e-08
in O 0 2.4845014934271603e-08
this O 0 3.02624449943778e-08
family O 0 1.8821197045326699e-07
, O 0 2.3865025511327076e-08
there O 0 1.5258356356184777e-08
appears O 0 5.964535034763685e-07
to O 0 5.361198063269512e-08
be O 0 1.9504051707031067e-08
no O 0 4.508471818098769e-08
relationship O 0 4.508815720782877e-08
between O 0 1.649582692664353e-08
the O 0 4.080148130469752e-08
I1307K O 0 2.3764680008753203e-05
polymorphism O 0 8.41568544274196e-06
and O 0 2.135402787928342e-08
the O 0 1.4318597862938987e-08
presence O 0 6.300128774228142e-08
or O 0 4.119112517741996e-08
absence O 0 6.871163122923463e-07
of O 0 1.0654202924342826e-06
cancer B-Disease 1 0.6864292621612549
. O 0 9.303456636189367e-07
. O 0 1.2787918421963695e-06

Identification O 0 1.4861536328680813e-05
of O 0 3.225478906188073e-07
a O 0 2.5987646949943155e-06
novel O 0 1.1845963854284491e-05
mutation O 0 1.7299537375947693e-06
of O 0 1.322537368508847e-08
the O 0 6.869564828093644e-08
CPO O 0 3.18248821713496e-05
gene O 0 2.9861658390473167e-07
in O 0 2.4960815636632105e-08
a O 0 3.671894432955014e-07
Japanese O 0 8.38391588331433e-06
hereditary B-Disease 0 0.0892166793346405
coproporphyria I-Disease 0 0.03431512415409088
family O 0 1.1753205399145372e-05
. O 0 1.7142828028227086e-06

Hereditary B-Disease 1 0.9995399713516235
coproporphyria I-Disease 1 0.9970418810844421
( O 0 0.00041290948865935206
HCP B-Disease 1 0.8080001473426819
) O 0 1.7021203575495747e-06
is O 0 2.7429555871094635e-07
an O 0 2.8900599318149034e-06
autosomal B-Disease 1 0.9939223527908325
dominant I-Disease 1 0.9966046810150146
disease I-Disease 1 0.8873181343078613
characterized O 0 0.00021117560390848666
by O 0 1.6523432577741914e-06
a O 0 0.0005046778242103755
deficiency B-Disease 0 0.01592474989593029
of I-Disease 0 7.553495606771321e-08
coproporphyrinogen I-Disease 0 0.0006889119395054877
oxidase I-Disease 0 1.1026781066902913e-05
( O 0 1.1804949195948211e-07
CPO O 0 1.1633795111265499e-05
) O 0 6.886671854999804e-08
caused O 0 5.363827426663192e-07
by O 0 2.8670712026723777e-08
a O 0 1.0130446526090964e-06
mutation O 0 2.450903821227257e-06
in O 0 4.7401016445292043e-08
the O 0 1.3941023269126163e-07
CPO O 0 0.0008928315946832299
gene O 0 1.54091467265971e-05
. O 0 3.5880466384696774e-06

Only O 0 1.1946341146540362e-05
11 O 0 6.925860361661762e-06
mutations O 0 3.6163467029837193e-06
of O 0 1.8935622847493505e-08
the O 0 4.55752875438975e-08
gene O 0 3.391510006167664e-07
have O 0 1.3211827365466888e-07
been O 0 3.362778215887374e-07
reported O 0 9.623870937502943e-06
in O 0 1.8126473833035561e-06
HCP B-Disease 1 0.9998536109924316
patients O 1 0.9641904234886169
. O 0 8.53443725645775e-06

We O 0 6.280539764702553e-06
report O 0 9.907370213113609e-07
another O 0 4.5371032797447697e-07
mutation O 0 9.676804211267154e-07
in O 0 4.2043943437874987e-08
a O 0 5.680753929482307e-07
Japanese O 0 5.983803021081258e-06
family O 0 4.70359645987628e-06
. O 0 1.629707298889116e-06

Polymerase O 0 0.00102815602440387
chain O 0 0.0003359279944561422
reaction O 0 4.11755136155989e-05
- O 0 1.6176578355953097e-05
single O 0 2.29403030971298e-06
strand O 0 6.4512883000134025e-06
conformational O 0 6.18728699919302e-06
polymorphism O 0 1.1788262781919912e-05
and O 0 4.2872041916552917e-08
direct O 0 7.412966596120896e-08
sequence O 0 1.410242305155407e-07
analyses O 0 4.027571378628636e-07
demonstrated O 0 3.320277244256431e-07
a O 0 1.4966595074383804e-07
C O 0 3.913119712706248e-07
to O 0 6.095844184983434e-08
T O 0 6.306149316515075e-06
substitution O 0 1.0295221386513731e-07
in O 0 3.751624788606023e-08
exon O 0 7.631607559233089e-07
1 O 0 2.2112244479899346e-08
of O 0 3.011726423807204e-09
the O 0 1.8803465451355805e-08
CPO O 0 5.503484771907097e-06
gene O 0 7.622618625191535e-08
at O 0 7.097852527948589e-09
nucleotide O 0 4.7227477040223675e-08
position O 0 8.975628418284032e-08
85 O 0 1.670225628913613e-07
, O 0 1.9587075072990956e-08
which O 0 3.058461572891247e-08
lies O 0 1.0136112393865915e-07
in O 0 9.298169345584029e-09
the O 0 1.0715567988484054e-08
putative O 0 1.192442709907482e-06
presequence O 0 4.788984369952232e-06
for O 0 4.422881261234579e-08
targeting O 0 4.880049004896136e-07
to O 0 6.714438427479763e-07
mitochondria O 0 2.8622129320865497e-05
. O 0 2.9205427836132003e-06

This O 0 8.506493941240478e-06
mutation O 0 1.7890703020384535e-05
changes O 0 1.9104501802758023e-07
the O 0 1.3015070798871875e-08
codon O 0 2.2562443291462841e-07
for O 0 3.50261935011531e-08
glutamine O 0 1.0696351182559738e-06
to O 0 7.641309451855705e-08
a O 0 2.876910230042995e-07
termination O 0 5.920838702877518e-06
codon O 0 1.25465714972961e-06
at O 0 9.367381892388948e-08
amino O 0 3.3218481121366494e-07
acid O 0 1.2245241123309825e-06
position O 0 1.870083451649407e-06
29 O 0 4.805559456144692e-06
. O 0 1.6167781495823874e-06

MaeI O 0 0.0011919202515855432
restriction O 0 2.885180765588302e-05
analysis O 0 2.7751380002882797e-06
showed O 0 2.08013148039754e-06
two O 0 7.342130459164764e-08
other O 0 1.4979853801833087e-08
carriers O 0 3.385531783806073e-07
in O 0 7.250311284678901e-08
the O 0 1.730005294575676e-07
family O 0 3.9616061258129776e-06
. O 0 1.5090107581272605e-06

The O 0 3.3015745430020615e-05
C O 0 0.0006627258262597024
- O 0 0.10630342364311218
T O 1 0.5833550691604614
mutation O 0 4.7201097004290204e-06
is O 0 1.5849002110712718e-08
located O 0 1.4173878959411468e-08
within O 0 8.00517963028824e-09
a O 0 9.957063440424463e-08
recently O 0 1.05719573184615e-06
proposed O 0 2.0526731248082797e-07
putative O 0 1.3826468148181448e-06
alternative O 0 2.1661617211066186e-07
translation O 0 1.1700410595949506e-07
initiation O 0 1.241191966983024e-07
codon O 0 3.856595185425249e-07
( O 0 4.8148667275427215e-08
TIC O 0 4.079116934008198e-06
- O 0 5.914433586440282e-06
1 O 0 1.2274104221887683e-07
) O 0 1.8052617178909713e-08
, O 0 1.1829264678908658e-08
supporting O 0 4.292686384133049e-08
that O 0 6.103208249896852e-08
TIC O 0 2.4829847461660393e-05
- O 0 1.332485226157587e-05
1 O 0 6.579309541621114e-08
is O 0 6.6401986131836566e-09
the O 0 1.0147636508861524e-08
real O 0 2.1999443333697855e-07
TIC O 0 8.723629434825853e-06
rather O 0 1.3133225706951634e-07
than O 0 1.0444909293028104e-07
TIC O 0 4.441856071935035e-05
- O 0 2.5920275220414624e-05
2 O 0 1.9224739844503347e-06
. O 0 5.174424018150603e-07
. O 0 1.5179828096734127e-06

Human B-Disease 0 7.949345308588818e-05
complement I-Disease 0 0.00011401415395084769
factor I-Disease 0 0.0014932851772755384
H I-Disease 1 0.9999970197677612
deficiency I-Disease 1 0.9991704225540161
associated O 0 8.148387860273942e-05
with O 0 0.0911501944065094
hemolytic B-Disease 1 0.9999992847442627
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
. O 0 0.00010905923409154639

This O 0 5.631975454889471e-06
study O 0 3.846105300908675e-06
reports O 0 6.865202522021718e-07
on O 0 2.0969646641333384e-07
six O 0 1.519183342679753e-06
cases O 0 2.800431730065611e-06
of O 0 2.165134446840966e-06
deficiency B-Disease 0 0.46969929337501526
in I-Disease 0 4.012519383422841e-08
the I-Disease 0 1.8848997029863312e-08
human I-Disease 0 3.505406453996329e-08
complement I-Disease 0 8.91063933750047e-08
regulatory I-Disease 0 2.6153057319788786e-07
protein I-Disease 0 2.1300866137607954e-07
Factor I-Disease 0 2.9377315513556823e-07
H I-Disease 0 0.11086245626211166
( O 0 8.810187068775122e-08
FH O 0 0.0002269745455123484
) O 0 2.7835396210207364e-08
in O 0 8.58892690303037e-09
the O 0 7.3348487283908526e-09
context O 0 2.4448914004437938e-08
of O 0 5.583692086474912e-08
an O 0 0.0007585695711895823
acute B-Disease 1 0.9999991655349731
renal I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
. O 0 0.00013310513168107718

Five O 0 8.234147571783978e-06
of O 0 1.667602589350281e-07
the O 0 1.923151131677514e-07
cases O 0 6.27478868864273e-07
were O 0 2.532576957037236e-07
observed O 0 7.370641128545685e-07
in O 0 1.3044586921751034e-07
children O 0 1.3094671658109291e-06
presenting O 0 2.0790801499970257e-05
with O 0 0.2722631096839905
idiopathic O 1 0.9999998807907104
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0012452976079657674
HUS B-Disease 1 0.9997623562812805
) O 0 1.3905419109505601e-05
. O 0 6.8497174652293324e-06

Two O 0 3.763045242521912e-06
of O 0 1.8010938163115497e-07
the O 0 2.1725089993651636e-07
children O 0 2.530790652599535e-06
exhibited O 0 2.237494663859252e-05
a O 0 0.008774586953222752
homozygous O 1 0.9994118213653564
deficiency O 1 0.9782302379608154
characterized O 0 3.1376080187328625e-06
by O 0 2.341700700014826e-08
the O 0 7.692326775554648e-09
absence O 0 6.388377471466811e-08
of O 0 3.7162557475767244e-09
the O 0 1.0182905185729396e-08
150 O 0 5.115339618555481e-08
- O 0 2.312576043550507e-06
kD O 0 1.0519525858398993e-05
form O 0 3.8376338551415756e-08
of O 0 5.418796966694117e-09
Factor O 0 1.6011519221592607e-07
H O 0 0.1140214055776596
and O 0 2.3032072249407065e-08
the O 0 1.1264807753263995e-08
presence O 0 3.3334945470642197e-08
, O 0 1.0644414238925037e-08
upon O 0 1.9414306606790888e-08
immunoblotting O 0 1.7510103589302162e-06
, O 0 4.192244773548737e-09
of O 0 9.810223744466384e-10
the O 0 9.220163299517026e-09
42 O 0 3.35850614874289e-07
- O 0 1.8832521391232149e-06
kD O 0 3.154856676701456e-05
Factor O 0 5.702182761524455e-07
H O 0 0.005560754332691431
- O 0 1.088542262550618e-06
like O 0 7.537347812558437e-08
protein O 0 6.93245496563577e-08
1 O 0 4.092501981745045e-08
( O 0 3.058817199530495e-08
FHL O 0 6.197462425916456e-06
- O 0 1.893679723252717e-06
1 O 0 6.699305288293544e-08
) O 0 1.1149718481817672e-08
and O 0 1.9075367063692283e-08
other O 0 2.397845477730698e-08
FH O 0 0.03179163113236427
- O 0 0.0003681006492115557
related O 0 4.482111251036258e-07
protein O 0 2.535249734592071e-07
( O 0 5.335409980489203e-08
FHR O 0 9.755214705364779e-06
) O 0 1.1381500542029244e-07
bands O 0 1.1478419992272393e-06
. O 0 7.663055043849454e-07

Southern O 0 0.00012532724940683693
blot O 0 0.001224710838869214
and O 0 9.108229050980299e-07
PCR O 0 2.4064827812253498e-05
analysis O 0 3.5589459912444e-07
of O 0 1.3632810436092768e-08
DNA O 0 1.8456333350513887e-07
of O 0 9.01317775969801e-09
one O 0 1.789779275895853e-07
patient O 0 0.0001552676985738799
with O 0 1.4843632015981711e-05
homozygous O 1 0.9377691745758057
deficiency O 0 0.16546833515167236
ruled O 0 6.548217470481177e-07
out O 0 2.4300005563304694e-08
the O 0 5.241080458517899e-09
presence O 0 1.2911397284653958e-08
of O 0 1.3123447883955919e-09
a O 0 4.5589288788505655e-08
large O 0 6.943280084215075e-08
deletion O 0 1.953216042238637e-06
of O 0 1.0728677501958828e-08
the O 0 1.1042843084396736e-07
FH O 0 0.02022586204111576
gene O 0 2.630636970479827e-07
as O 0 1.450103770395117e-08
the O 0 3.239603785232248e-08
underlying O 0 9.342013981950004e-06
defect O 0 0.0001257709227502346
for O 0 5.252417167866952e-07
the O 0 4.418139360495843e-05
deficiency O 1 0.9597426056861877
. O 0 6.824945558037143e-06

The O 0 2.5858819299173774e-06
other O 0 1.5631233907242859e-07
four O 0 3.6987702856094984e-07
children O 0 3.6630629551837046e-07
presented O 0 6.274956376728369e-07
with O 0 4.973527211404871e-06
heterozygous O 1 0.9329036474227905
deficiency O 0 0.06793352216482162
and O 0 1.0634656888441896e-07
exhibited O 0 2.6622349196259165e-06
a O 0 7.137605280149728e-07
normal O 0 5.140148005011724e-07
immunoblotting O 0 1.5217430700431578e-05
pattern O 0 1.701158112155099e-07
of O 0 5.291171056853727e-09
proteins O 0 1.7344417457820782e-08
of O 0 1.360496337809991e-08
the O 0 3.161089807690587e-07
FH O 1 0.9426111578941345
family O 0 1.1875099517055787e-05
. O 0 1.4425679637497524e-06

Factor B-Disease 1 0.9610037207603455
H I-Disease 1 0.9999978542327881
deficiency I-Disease 1 0.9988094568252563
is O 0 7.726376907157828e-07
the O 0 2.5993915642175125e-07
only O 0 5.5150853768282104e-06
complement B-Disease 1 0.9990755319595337
deficiency I-Disease 1 0.9999881982803345
associated O 0 5.749637239205185e-06
with O 0 7.5390244091977365e-06
HUS B-Disease 1 0.9996374845504761
. O 0 2.16682419704739e-05

These O 0 5.3194535212242045e-06
observations O 0 1.2388176401145756e-05
suggest O 0 1.7656172985880403e-06
a O 0 2.6249031748193374e-07
role O 0 2.0671691913776158e-07
for O 0 1.861693590399227e-07
FH O 0 0.4345402121543884
and O 0 2.244189317934797e-06
/ O 0 4.2461524571990594e-05
or O 0 5.110371148475679e-07
FH O 0 0.14510437846183777
receptors O 0 7.255017862917157e-06
in O 0 1.3449005109578138e-07
the O 0 3.450876704391703e-07
pathogenesis O 0 0.0005856248317286372
of O 0 5.064159267931245e-06
idiopathic O 1 0.9999319314956665
HUS B-Disease 1 0.9999860525131226
. O 0 9.288020919484552e-06
. O 0 2.930944447143702e-06

Further O 0 1.364862055197591e-05
evidence O 0 2.5702497623569798e-06
for O 0 7.393917655917903e-08
a O 0 1.91925579429153e-07
major O 0 2.23632824258857e-07
ancient O 0 2.117667463608086e-06
mutation O 0 0.0007278263219632208
underlying O 0 0.17548048496246338
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999996423721313
from O 0 6.317302904790267e-06
linkage O 0 0.00014569328050129116
disequilibrium O 0 0.014288944192230701
studies O 0 3.042977368750144e-06
in O 0 1.125989328443211e-07
the O 0 6.861969836791104e-08
Japanese O 0 2.09328709388501e-06
population O 0 1.7251926465178258e-06
. O 0 3.0839719329378568e-06

The O 0 0.026983849704265594
myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 1.0
( O 1 0.7920049428939819
DM B-Disease 1 0.9999996423721313
) O 0 5.479884202941321e-05
mutation O 0 5.8723886468214914e-05
is O 0 2.032132044860191e-07
an O 0 2.8102266469431925e-07
unstable O 0 0.00013920800120104104
( O 0 2.649489942996297e-07
CTG O 0 3.222010127501562e-05
) O 0 8.131587492243852e-08
n O 0 6.584217544514104e-07
repeat O 0 7.320386430365033e-07
, O 0 2.6397186658755345e-08
present O 0 1.6318701057116414e-08
at O 0 9.445567883403783e-09
a O 0 5.510572975708783e-08
copy O 0 1.3679414223588537e-07
number O 0 3.8903338328566406e-09
of O 0 4.028913203057982e-09
5 O 0 9.547091650574657e-08
- O 0 6.262919214350404e-06
37 O 0 6.12396490851097e-07
repeats O 0 3.3996965953519975e-07
on O 0 3.5661411601495274e-08
normal O 0 4.346270543464925e-08
chromosomes O 0 1.1645994391074055e-07
but O 0 1.7512487460180637e-08
amplified O 0 3.9268545037884905e-07
to O 0 4.947849419068007e-08
50 O 0 9.713060222793501e-08
- O 0 2.8425006348697934e-06
3000 O 0 1.4580435845346074e-06
copies O 0 9.48777426401648e-07
on O 0 4.126452040509321e-06
DM B-Disease 1 0.9999779462814331
chromosomes O 0 0.0002338649646844715
. O 0 7.971804734552279e-06

Previous O 0 0.00018070542137138546
findings O 0 8.484516729367897e-05
in O 0 9.629063697502716e-07
Caucasian O 0 6.131290138000622e-05
populations O 0 3.6065267750018393e-07
of O 0 6.22372553493733e-08
a O 0 0.00015112174150999635
DM B-Disease 1 0.9999997615814209
founder O 0 0.014582824893295765
chromosome O 0 7.473739242414013e-05
raise O 0 5.574098622673773e-07
a O 0 1.592702574271243e-07
question O 0 1.1745028416498826e-07
about O 0 1.6579701167529493e-08
the O 0 8.374551718759449e-09
molecular O 0 3.4307421969970164e-07
events O 0 3.0283462848501586e-08
involved O 0 4.114887630635167e-08
in O 0 2.2093230356290405e-08
the O 0 4.7240447997864976e-08
expansion O 0 8.332861398230307e-06
mutation O 0 4.132830144953914e-05
. O 0 3.8555212995561305e-06

To O 0 8.988656190922484e-06
investigate O 0 1.8610151528264396e-05
whether O 0 1.3455794487526873e-06
a O 0 1.825888830353506e-06
founder O 0 8.49386469781166e-06
chromosome O 0 3.1691599815530935e-06
for O 0 5.06981372438986e-08
the O 0 9.521375545773481e-07
DM B-Disease 1 0.9999998807907104
mutation O 0 0.00670145358890295
exists O 0 2.3472865962048672e-07
in O 0 1.0592020593946927e-08
the O 0 6.301844823752845e-09
Japanese O 0 2.714463391839672e-07
population O 0 5.6179732865757614e-08
, O 0 2.151178257747688e-08
we O 0 2.7078694841975448e-08
genotyped O 0 5.365752713260008e-06
families O 0 3.4109582713881537e-08
using O 0 3.401472881137124e-08
polymorphic O 0 6.629939889535308e-06
markers O 0 2.4125636173266685e-06
near O 0 3.693592134368373e-07
the O 0 6.222088444474139e-08
( O 0 6.271725538908868e-08
CTG O 0 1.2427462024788838e-05
) O 0 5.647948952969273e-08
n O 0 6.890139729875955e-07
repeat O 0 1.275447402804275e-06
region O 0 1.452134625878898e-07
and O 0 1.513384688678343e-07
constructed O 0 1.3074508387944661e-05
haplotypes O 0 0.0001828490785555914
. O 0 4.10824031860102e-06

Six O 0 2.0400912035256624e-05
different O 0 9.265550602322037e-07
haplotypes O 0 7.91632555774413e-05
were O 0 5.401720954978373e-07
found O 0 6.544784127981984e-07
and O 0 2.540819650675985e-06
DM B-Disease 1 0.9999995231628418
alleles O 0 0.00015181225899141282
were O 0 5.943163046140398e-07
always O 0 2.808358885886264e-06
haplotype O 0 0.000665613857563585
A O 0 1.2118900485802442e-05
. O 0 7.0551623139181174e-06

To O 0 8.99535370990634e-06
find O 0 2.1552170892391587e-06
an O 0 1.0787817927848664e-07
origin O 0 4.225288208203892e-08
of O 0 9.86737003216831e-09
the O 0 5.5926669517702976e-08
( O 0 5.542871761576862e-08
CTG O 0 5.5909295042511076e-06
) O 0 3.601095954763878e-08
n O 0 4.265959887561621e-07
repeat O 0 2.138654963346198e-06
mutation O 0 1.1501375638545142e-06
and O 0 2.2411720479453834e-08
to O 0 3.509621393504858e-08
investigate O 0 1.8406026924822072e-07
the O 0 6.8072547598774236e-09
mechanism O 0 1.1526930521199574e-08
of O 0 1.6556654935939719e-09
the O 0 4.152271859680923e-09
expansion O 0 1.5004867748302786e-07
mutation O 0 3.51614147575674e-07
in O 0 6.8636420991197156e-09
the O 0 5.2215436419089656e-09
Japanese O 0 1.407941709885563e-07
population O 0 2.647130337152248e-08
we O 0 8.356935587983116e-09
have O 0 7.580496230730205e-09
studied O 0 7.834971427200799e-08
90 O 0 9.285820112836518e-08
Japanese O 0 2.7882051654160023e-06
DM B-Disease 1 0.9999973773956299
families O 0 1.5934150496832444e-06
comprising O 0 1.43587925549582e-07
190 O 0 9.787146382223e-07
affected O 0 2.8996956302762555e-07
and O 0 1.1652227271952142e-07
130 O 0 2.6369946226623142e-06
unaffected O 0 4.6415047108894214e-05
members O 0 1.0173682767344872e-06
. O 0 2.0688407857960556e-06

The O 0 1.0941763321170583e-05
results O 0 1.3536647202272434e-05
suggest O 0 9.105024219024926e-07
that O 0 1.725098286442517e-08
a O 0 1.2437537577625335e-07
few O 0 1.9992707223082107e-07
common O 0 1.7193340795529366e-07
ancestral O 0 2.5623280635045376e-06
mutations O 0 3.4873655749834143e-06
in O 0 2.9959437597426586e-08
both O 0 3.377977719765113e-08
Caucasian O 0 2.947285338450456e-06
and O 0 7.542611513144948e-08
Japanese O 0 5.6465592024324e-07
populations O 0 7.288274161965091e-08
have O 0 1.0768901326230207e-08
originated O 0 1.2873086596698613e-08
by O 0 2.156443912326722e-09
expansion O 0 1.3091878692250702e-08
of O 0 3.060350639572107e-09
an O 0 2.7872264496409116e-08
ancestral O 0 4.5649238700207206e-07
n O 0 1.0421302931717946e-06
= O 0 5.22584059581277e-07
5 O 0 5.280426762510615e-08
repeat O 0 2.86274143945775e-07
to O 0 7.875770080545408e-08
n O 0 3.3695466754579684e-06
= O 0 1.8425170082991826e-06
19 O 0 3.617045933879126e-07
- O 0 4.7214330152201e-06
37 O 0 2.197856929342379e-06
copies O 0 1.0507507113288739e-06
. O 0 1.167261871160008e-06

These O 0 2.2393232939066365e-06
data O 0 7.188401696112123e-07
support O 0 1.564781939578097e-07
multistep O 0 6.830219717812724e-06
models O 0 8.19376850813569e-07
of O 0 3.795195979705568e-08
triplet O 0 4.4494110625237226e-05
repeat O 0 1.0539361028349958e-06
expansion O 0 1.9115927329949045e-07
that O 0 3.078812227386152e-08
have O 0 1.9986924115755755e-08
been O 0 2.8173019472887972e-08
proposed O 0 5.041300354946543e-08
for O 0 2.7386134249240968e-08
both O 0 4.873481884715147e-07
DM B-Disease 1 0.9999978542327881
and O 0 5.887371298740618e-05
Friedreichs B-Disease 0 0.27286937832832336
ataxia I-Disease 1 0.8476913571357727
. O 0 2.488842483217013e-06
. O 0 2.2701144644088345e-06

The O 0 4.474880825000582e-06
molecular O 0 1.0088824637932703e-05
basis O 0 1.0408152775198687e-06
of O 0 4.847200216318015e-06
C6 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999986886978149
in O 0 3.5738295878218196e-07
the O 0 6.834474675088131e-08
western O 0 6.133948318165494e-07
Cape O 0 2.9614293453050777e-06
, O 0 2.728317269884428e-07
South O 0 1.5965821376084932e-07
Africa O 0 7.068039167279494e-07
. O 0 1.1968586477451026e-06

Deficiency B-Disease 1 0.99817955493927
of I-Disease 0 4.088086882347852e-07
the I-Disease 0 8.633934811541621e-08
sixth I-Disease 0 7.922442932795093e-07
component I-Disease 0 1.2037068586323585e-07
of I-Disease 0 1.049278797182751e-08
human I-Disease 0 6.201235436265051e-08
complement I-Disease 0 4.2158615087828366e-07
( O 0 1.4672552595129673e-07
C6 O 0 0.0004070419818162918
) O 0 7.736264961977213e-08
has O 0 1.1848631231714535e-07
been O 0 1.7646617322952807e-07
reported O 0 8.446742754131265e-07
in O 0 8.702576437258358e-09
a O 0 9.615017404485116e-08
number O 0 1.356666512464244e-08
of O 0 5.0159574271901874e-09
families O 0 3.714641749752445e-08
from O 0 5.5734004078544785e-09
the O 0 2.2768473328937944e-08
western O 0 2.459311190250446e-07
Cape O 0 1.4992695014370838e-06
, O 0 1.1857618886779164e-07
South O 0 1.7608221014597802e-07
Africa O 0 5.283902737573953e-07
. O 0 1.114672954827256e-06

Meningococcal B-Disease 1 0.9999582767486572
disease I-Disease 1 0.999607503414154
is O 0 1.281064123759279e-05
endemic O 0 2.1589490643236786e-05
in O 0 3.961825996157131e-07
the O 0 1.3673231080701953e-07
Cape O 0 1.7967447547562188e-06
and O 0 6.068339075682161e-08
almost O 0 5.6119755953432104e-08
all O 0 9.436257997208486e-09
pedigrees O 0 5.353142000785738e-07
of O 0 1.4803363512783108e-07
total O 0 0.0014783510705456138
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
( O 0 1.8200855720351683e-06
C6Q0 O 0 0.004611220210790634
) O 0 7.85998324204229e-08
have O 0 2.6676630682231917e-08
been O 0 7.183906802765705e-08
ascertained O 0 1.4409564528250485e-06
because O 0 9.855091320787324e-08
of O 0 2.625123443067423e-07
recurrent O 1 0.9978212118148804
disease O 1 0.9696111083030701
. O 0 1.9152426830260083e-05

We O 0 3.949432993977098e-06
have O 0 3.137328121738392e-07
sequenced O 0 9.600116754882038e-07
the O 0 2.5071802411957833e-08
expressed O 0 7.113155930937864e-08
exons O 0 2.854783360817237e-07
of O 0 8.756640745843924e-09
the O 0 5.1659533539805125e-08
C6 O 0 0.0014268812956288457
gene O 0 2.374054446363516e-07
from O 0 1.4641137191517828e-08
selected O 0 6.437524291413865e-08
cases O 0 1.3588150693522039e-07
and O 0 7.442845628702344e-08
have O 0 2.3142651173202466e-07
found O 0 1.2262836435184e-07
three O 0 1.3064331483292335e-07
molecular O 0 4.921040090266615e-05
defects O 0 0.07742734253406525
leading O 0 1.5174588270383538e-06
to O 0 9.026769589581818e-07
total O 0 4.6039502194616944e-05
deficiency O 1 0.7343823313713074
879delG O 0 0.00020409238641150296
, O 0 9.250535981664143e-08
which O 0 1.8427678938337522e-08
is O 0 9.32319110802382e-09
the O 0 2.1349956469407516e-08
common O 0 3.0001240247656824e-07
defect O 0 5.026455983170308e-05
in O 0 7.103110277739688e-08
the O 0 7.022861581162942e-08
Cape O 0 2.2425417682825355e-06
and O 0 2.4017640498641413e-07
hitherto O 0 4.24924110120628e-06
unreported O 0 2.5106505745497998e-06
, O 0 2.8937551022067964e-08
and O 0 1.138818372936612e-08
1195delC O 0 2.5712770366226323e-06
and O 0 5.147668247218462e-08
1936delG O 0 5.804050033475505e-06
, O 0 5.121011881215054e-08
which O 0 3.016562644120313e-08
have O 0 3.282064042764432e-08
been O 0 5.922059642671229e-08
previously O 0 2.8531286488941987e-07
reported O 0 2.720390170907194e-07
in O 0 2.681339417165418e-08
African O 0 3.1297315672418335e-07
- O 0 7.738335261819884e-05
Americans O 0 4.735335551231401e-06
. O 0 1.7970222643270972e-06

We O 0 9.915537702909205e-06
also O 0 7.189381676653284e-07
show O 0 2.774312122255651e-07
that O 0 1.5358596172632133e-08
the O 0 2.235033313979784e-08
879delG O 0 1.5515624909312464e-05
and O 0 8.731192338018445e-07
1195delC O 0 0.15724095702171326
defects O 1 0.9135527014732361
are O 0 9.370527465080158e-08
associated O 0 2.4926166020122764e-07
with O 0 2.2231547802675777e-07
characteristic O 0 0.00019170054292771965
C6 O 1 0.9984036087989807
/ O 0 0.04828934744000435
C7 O 0 0.08951649814844131
region O 0 1.3993334277984104e-06
DNA O 0 1.0487341569387354e-05
marker O 0 2.9170993002480827e-05
haplotypes O 0 0.00010813841072376817
, O 0 5.578252881832668e-08
although O 0 3.663649295049254e-08
small O 0 3.837275031060017e-08
variations O 0 9.657932196205365e-07
were O 0 3.673207800147793e-07
observed O 0 1.9113554117211606e-06
. O 0 8.858596061145363e-07

The O 0 1.4138435290078633e-05
1936delG O 0 0.00042743029189296067
defect O 0 0.00044421348138712347
was O 0 1.1083036497439025e-06
observed O 0 2.1175652875626838e-07
only O 0 1.418983774925664e-08
once O 0 4.1669991901471803e-08
in O 0 1.0884458667703711e-08
the O 0 2.5946283344069343e-08
Cape O 0 1.1573015399335418e-06
, O 0 4.156100885666092e-08
but O 0 3.291053118914533e-08
its O 0 1.1133785449146671e-07
associated O 0 9.518153092358261e-07
haplotype O 0 0.00033428333699703217
could O 0 5.23132086982514e-07
be O 0 1.8905693366377818e-07
deduced O 0 7.407655175484251e-06
. O 0 1.6667645468260162e-06

The O 0 1.698091182333883e-06
data O 0 3.4679595728448476e-07
from O 0 2.2462902649067473e-08
the O 0 1.528550619411817e-08
haplotypes O 0 4.1510549635859206e-05
indicate O 0 5.650108505506068e-07
that O 0 1.857302223129409e-08
these O 0 9.117579580220081e-09
three O 0 1.0216428592002558e-07
molecular O 0 5.8323847042629495e-05
defects O 0 0.02299552410840988
account O 0 1.235183901826531e-07
for O 0 2.78123639674277e-08
the O 0 2.682276090126834e-07
defects O 0 0.20567414164543152
in O 0 5.151341397890974e-08
all O 0 7.345965613581029e-09
the O 0 1.892879808451653e-08
38 O 0 8.098238595266594e-07
unrelated O 0 1.4704967270517955e-06
C6Q0 O 0 0.0038362517952919006
individuals O 0 5.636971422973147e-08
we O 0 1.4268816350693214e-08
have O 0 2.288533273997473e-08
studied O 0 9.341207629631754e-08
from O 0 2.6496762117744765e-08
the O 0 9.770847952950135e-08
Cape O 0 8.495298061461654e-06
. O 0 1.743382313179609e-06

We O 0 1.3791023775411304e-05
have O 0 6.265406682359753e-07
also O 0 1.1899657437197675e-07
observed O 0 1.2022016449009243e-07
the O 0 2.932677922728999e-08
879delG O 0 4.120512676308863e-05
defect O 0 2.106755164277274e-05
in O 0 1.3261274034448434e-07
two O 0 1.1324954130031983e-06
Dutch O 1 0.7917883396148682
C6 B-Disease 1 0.9999946355819702
- I-Disease 1 0.9997325539588928
deficient I-Disease 1 0.999894380569458
kindreds O 0 0.0002314205776201561
, O 0 1.1764713292450324e-07
but O 0 4.880271831098071e-08
the O 0 3.0670896933315817e-08
879delG O 0 2.1816847947775386e-05
defect O 0 1.6003417840693146e-05
in O 0 4.872756775853304e-08
the O 0 2.799961329458256e-08
Cape O 0 1.4924120250725537e-06
probably O 0 3.263238284034742e-07
did O 0 8.209366342271096e-08
not O 0 7.88344589608414e-09
come O 0 1.6868471064412915e-08
from O 0 8.330835576941809e-09
The O 0 3.035077256186014e-08
Netherlands O 0 4.764066943607759e-06
. O 0 2.583971365766047e-07
. O 0 1.4267394590206095e-06

Complement B-Disease 1 0.9927456974983215
C7 I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999991655349731
: O 0 1.708166928438004e-05
seven O 0 1.25472899981105e-06
further O 0 6.377773615895421e-07
molecular O 0 0.00019179123046342283
defects O 0 0.19498281180858612
and O 0 3.292488486295042e-07
their O 0 4.5629045075656904e-07
associated O 0 2.1696280327887507e-06
marker O 0 7.112445018719882e-05
haplotypes O 0 0.0010431837290525436
. O 0 8.264278221759014e-06

Seven O 0 1.9247238014941104e-05
further O 0 1.6563902818234055e-06
molecular O 0 4.408522727317177e-06
bases O 0 1.3670770613316563e-06
of O 0 1.0221403499599546e-05
C7 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999990463256836
are O 0 4.176558832114097e-06
described O 0 7.122408715076745e-05
. O 0 6.065173693059478e-06

All O 0 1.991082399399602e-06
these O 0 2.1074195899473125e-07
new O 0 4.1550993046257645e-07
molecular O 0 4.167730003246106e-05
defects O 0 0.0031510409899055958
involve O 0 2.2894985818311397e-07
single O 0 4.563182756101014e-07
- O 0 3.343656317156274e-06
nucleotide O 0 4.404672040436708e-07
events O 0 4.153604749035367e-08
, O 0 1.604163735180464e-08
deletions O 0 2.7996682661068917e-07
and O 0 2.0084909735373913e-08
substitutions O 0 1.6865824647993577e-07
, O 0 1.447467568027605e-08
some O 0 3.3558593681703996e-09
of O 0 3.365448586478692e-09
which O 0 5.0968356646308166e-08
alter O 0 9.031548984239635e-07
splice O 0 2.192775809817249e-06
sites O 0 1.2317724440435995e-07
, O 0 3.8656676082382546e-08
and O 0 7.382376310260952e-08
others O 0 6.454897629737388e-07
codons O 0 7.5452608143677935e-06
. O 0 2.3821130525902845e-06

They O 0 8.226698810176458e-06
are O 0 2.6156573085245327e-07
distributed O 0 1.3338313920030487e-07
along O 0 5.5498006190646265e-08
the O 0 7.853135031155034e-08
C7 O 0 0.0004044876841362566
gene O 0 6.294987429100729e-07
, O 0 2.938512544403693e-08
but O 0 2.8110809680015336e-08
predominantly O 0 3.9302594956325265e-08
towards O 0 3.3814199440485027e-08
the O 0 3.945988069631312e-08
3 O 0 5.182612312637502e-07
end O 0 1.5420729368997854e-06
. O 0 1.9227802567911567e-06

All O 0 4.635900950233918e-06
were O 0 8.90278840870451e-07
found O 0 2.717939651120105e-07
in O 0 1.0465129918202365e-07
compound O 0 2.843158654286526e-05
heterozygous O 0 7.886374805821106e-05
individuals O 0 8.293026212413679e-07
. O 0 1.2256667787369224e-06

The O 0 3.081207614741288e-05
C6 O 1 0.9741171598434448
/ O 0 0.2500378489494324
C7 O 1 0.9407110214233398
marker O 0 0.0476154126226902
haplotypes O 0 0.048722073435783386
associated O 0 3.4938502722070552e-06
with O 0 3.6875911746392376e-07
most O 0 4.328634531702846e-06
C7 B-Disease 1 0.9997788071632385
defects I-Disease 1 0.9963197708129883
are O 0 2.0330372763055493e-07
tabulated O 0 6.864174793008715e-06
. O 0 4.4026560885868093e-07
. O 0 1.457073381061491e-06

A O 0 0.00012496566341724247
genome O 0 2.1538120563491248e-05
- O 0 2.654967101989314e-05
wide O 0 5.788384669358493e-07
search O 0 5.639766982312722e-07
for O 0 1.1646294950651281e-07
chromosomal O 0 8.535634697182104e-05
loci O 0 3.629337470556493e-06
linked O 0 5.273680926620727e-06
to O 0 2.26598763219954e-06
mental O 1 0.9290990829467773
health O 0 0.0002852597099263221
wellness O 0 0.00033855761284939945
in O 0 1.4878546608088072e-06
relatives O 0 9.891991794575006e-06
at O 0 1.9248481919476035e-07
high O 0 1.5953294223436387e-06
risk O 0 3.0783007787249517e-06
for O 0 1.2645838978642132e-05
bipolar B-Disease 1 0.9999994039535522
affective I-Disease 1 0.9999939203262329
disorder I-Disease 1 0.9994043111801147
among O 0 2.3224680489875027e-07
the O 0 7.16264452194082e-08
Old O 0 1.758619760039437e-06
Order O 0 4.2453385162843915e-07
Amish O 0 2.7895117455045693e-05
. O 0 3.1868021324044093e-06

Bipolar B-Disease 1 0.9999945163726807
affective I-Disease 1 0.9999867677688599
disorder I-Disease 1 0.9999927282333374
( O 0 0.0013822541804984212
BPAD B-Disease 1 0.999971866607666
; O 0 0.013889054767787457
manic B-Disease 1 0.9999399185180664
- I-Disease 1 0.9999836683273315
depressive I-Disease 1 0.9999994039535522
illness I-Disease 1 0.9996022582054138
) O 0 3.020351755367301e-07
is O 0 5.528132618337622e-08
characterized O 0 9.068151030078297e-07
by O 0 4.814903675764981e-08
episodes O 0 4.722180335647863e-07
of O 0 3.9217379566025556e-08
mania B-Disease 0 0.000363424071110785
and O 0 1.0860288739422685e-06
/ O 0 3.1077837775228545e-05
or O 0 3.1073011541593587e-07
hypomania B-Disease 0 0.03604006767272949
interspersed O 0 7.564202405774267e-06
with O 0 1.5018740384675766e-07
periods O 0 1.9616536519606598e-06
of O 0 5.679632977262372e-07
depression B-Disease 0 0.0010840978939086199
. O 0 5.718336069548968e-06

Compelling O 0 0.0007286806358024478
evidence O 0 2.8532467695185915e-05
supports O 0 3.5754867440118687e-06
a O 0 1.0456784593770863e-06
significant O 0 2.8111324468227394e-07
genetic O 0 1.0384912911831634e-06
component O 0 1.5673089137635543e-07
in O 0 3.146016425148446e-08
the O 0 7.125798617835244e-08
susceptibility O 0 0.0003929562517441809
to O 0 2.0912000309181167e-06
develop O 0 6.83618854964152e-05
BPAD B-Disease 1 0.9998863935470581
. O 0 2.4426146410405636e-05

To O 0 2.3029162548482418e-05
date O 0 9.962569492927287e-06
, O 0 3.34011076574825e-07
however O 0 1.6671000935275515e-07
, O 0 6.603611524269581e-08
linkage O 0 1.6181618320842972e-06
studies O 0 2.0568784009356023e-07
have O 0 2.887882999402791e-08
attempted O 0 1.5093288538992056e-06
only O 0 3.0493513492046986e-08
to O 0 3.5582324642291496e-08
identify O 0 4.036969869503082e-07
chromosomal O 0 2.5355269826832227e-05
loci O 0 8.9741530473475e-07
that O 0 1.939203428946712e-07
cause O 0 1.641941139496339e-06
or O 0 4.297839595324149e-08
increase O 0 1.900056929571292e-07
the O 0 5.992632168272394e-08
risk O 0 4.17634112181986e-07
of O 0 7.544899460754095e-08
developing O 0 5.151551249582553e-06
BPAD B-Disease 1 0.9997393488883972
. O 0 8.093142241705209e-06

To O 0 7.842602826713119e-06
determine O 0 2.1862358607904753e-06
whether O 0 3.482060719761648e-07
there O 0 6.031275034956707e-08
could O 0 1.1825907364482191e-07
be O 0 3.663837944145598e-08
protective O 0 6.855924766568933e-06
alleles O 0 6.367253604366852e-07
that O 0 2.774835472507675e-08
prevent O 0 1.1731449234275715e-07
or O 0 6.514228090281904e-08
reduce O 0 8.091668632914661e-07
the O 0 1.0259153526703813e-07
risk O 0 3.5486561955622165e-07
of O 0 1.6374105626937308e-08
developing O 0 2.166319973184727e-06
BPAD B-Disease 1 0.9999765157699585
, O 0 2.36731253266953e-07
similar O 0 4.425598376656126e-08
to O 0 2.1745728773225892e-08
what O 0 2.2082275563661824e-08
is O 0 2.161031709135841e-08
observed O 0 1.0577891629282021e-07
in O 0 8.5038891484146e-08
other O 0 2.0198910988256102e-06
genetic B-Disease 1 0.9999576807022095
disorders I-Disease 1 0.9999978542327881
, O 0 5.768985715803865e-07
we O 0 2.0366213959732704e-07
used O 0 1.365083153359592e-05
mental O 1 0.9307460188865662
health O 0 0.00023395261086989194
wellness O 0 0.00013005750952288508
( O 0 7.006324409530862e-08
absence O 0 1.4576094997664768e-07
of O 0 1.693255491375112e-08
any O 0 3.492904170343536e-06
psychiatric B-Disease 1 0.9999948740005493
disorder I-Disease 1 0.9989370703697205
) O 0 6.967344745589799e-08
as O 0 4.953854570999283e-08
the O 0 8.289296005159486e-08
phenotype O 0 0.004339416511356831
in O 0 5.8116498280469386e-08
our O 0 2.731471759886972e-08
genome O 0 9.515223808875817e-08
- O 0 7.567807074337907e-07
wide O 0 3.807337520811416e-07
linkage O 0 1.9639917354652425e-06
scan O 0 2.5340234060422517e-05
of O 0 1.0083042845110413e-08
several O 0 2.37038886297114e-08
large O 0 6.765074545000971e-08
multigeneration O 0 1.8711107259150594e-05
Old O 0 1.0363048659201013e-06
Order O 0 9.108526199952394e-08
Amish O 0 2.678518512766459e-06
pedigrees O 0 7.326941613428062e-06
exhibiting O 0 1.8674459170142654e-06
an O 0 2.9256784728204366e-07
extremely O 0 6.153503818495665e-06
high O 0 1.945272924785968e-05
incidence O 0 0.0006755804060958326
of O 0 1.3202524087319034e-06
BPAD B-Disease 1 0.9998972415924072
. O 0 2.2447957235272042e-05

We O 0 3.7719053125329083e-06
have O 0 6.206187777024752e-07
found O 0 1.0935611527429501e-07
strong O 0 1.9178177979028987e-07
evidence O 0 1.1207590944195545e-07
for O 0 3.9107202809418595e-08
a O 0 8.968592055680347e-07
locus O 0 6.7737000790657476e-06
on O 0 1.4182282939145807e-06
chromosome O 0 3.997312887804583e-05
4p O 0 0.0004643799038603902
at O 0 2.568899617472198e-07
D4S2949 O 0 4.567206815409008e-06
( O 0 6.772640404051344e-08
maximum O 0 3.9141607999226835e-07
GENEHUNTER O 0 2.599201070552226e-05
- O 0 7.051368356769672e-06
PLUS O 0 9.225979056282085e-07
nonparametric O 0 3.034752808162011e-06
linkage O 0 1.9599165170802735e-06
score O 0 6.883296350679302e-07
= O 0 1.484120502937003e-06
4 O 0 1.5890415738795127e-07
. O 0 4.467759140425187e-08
05 O 0 2.063855163214612e-06
, O 0 1.0692276219970154e-07
P O 0 5.201281965128146e-06
= O 0 6.629646804867662e-07
5 O 0 5.040829265112734e-08
. O 0 8.54769410807421e-09
22 O 0 4.2052121784763585e-08
x O 0 3.431982236179465e-07
10 O 0 3.86217422487789e-08
( O 0 1.1551360756811846e-08
- O 0 1.0473551128598046e-06
4 O 0 1.8119304456831742e-07
) O 0 2.254918562982766e-08
; O 0 3.153219196860846e-08
SIBPAL O 0 4.999487373424927e-06
Pempirical O 0 2.876158305298304e-06
value O 0 2.5514173884744196e-08
< O 0 1.587521012424986e-07
3 O 0 3.279723514992838e-08
x O 0 7.330446578635019e-07
10 O 0 5.053527019072135e-08
( O 0 2.100024154572111e-08
- O 0 1.5045446843942045e-06
5 O 0 9.850882065620681e-08
) O 0 5.83448178659296e-09
) O 0 5.484397824773168e-09
and O 0 2.2755058282086793e-08
suggestive O 0 6.50978336125263e-06
evidence O 0 1.113202259261925e-07
for O 0 1.7444278910261346e-08
a O 0 5.810097718494944e-07
locus O 0 6.280132311076159e-06
on O 0 4.096276825293899e-06
chromosome O 0 0.005251017864793539
4q O 1 0.9994298815727234
at O 0 3.126637864170334e-07
D4S397 O 0 9.289658919442445e-06
( O 0 7.520431921648196e-08
maximum O 0 5.995273681946856e-07
GENEHUNTER O 0 4.1798459278652444e-05
- O 0 5.54360758542316e-06
PLUS O 0 1.3859539649274666e-06
nonparametric O 0 5.904340468987357e-06
linkage O 0 3.897680926456815e-06
score O 0 9.877049933493254e-07
= O 0 1.6655172885293723e-06
3 O 0 1.592031395603044e-07
. O 0 1.564208318427518e-08
29 O 0 2.9507009458029643e-07
, O 0 6.85229082364458e-08
P O 0 3.585070999179152e-06
= O 0 6.410201649487135e-07
2 O 0 7.503825116828011e-08
. O 0 1.8209551200243368e-08
57 O 0 2.3457492659417767e-07
x O 0 1.19028072731453e-06
10 O 0 5.265350822014625e-08
( O 0 1.4490642463727e-08
- O 0 1.0699075119191548e-06
3 O 0 1.4900484757163213e-07
) O 0 3.223381384032109e-08
; O 0 3.7615269121715755e-08
SIBPAL O 0 7.525556611653883e-06
Pempirical O 0 4.085003183718072e-06
value O 0 1.813250527504806e-08
< O 0 1.8643480359514797e-07
1 O 0 4.226730965228853e-08
x O 0 6.144850317468808e-07
10 O 0 3.0554470953347845e-08
( O 0 1.1541450462004832e-08
- O 0 1.8113825035470654e-06
3 O 0 8.21865668854116e-08
) O 0 7.577113159129567e-09
) O 0 5.426916249717806e-09
that O 0 8.77940120602716e-09
are O 0 1.1850514347599983e-08
linked O 0 1.186677536679781e-06
to O 0 5.346470061340369e-06
mental O 1 0.9632434844970703
health O 0 0.0046014185063540936
wellness O 0 0.011161177419126034
. O 0 1.1321983947709668e-05

These O 0 1.4163133528199978e-05
findings O 0 4.24129975726828e-05
are O 0 1.0925083415713743e-07
consistent O 0 3.7801410712745565e-07
with O 0 5.28733039573126e-08
the O 0 6.925292694859309e-08
hypothesis O 0 1.3606244237962528e-06
that O 0 8.871207768379463e-09
certain O 0 9.139046852624233e-09
alleles O 0 2.4606251258774137e-07
could O 0 8.84073969587007e-08
prevent O 0 1.1003191247027644e-07
or O 0 4.3687109041457006e-08
modify O 0 1.5799282664374914e-06
the O 0 1.5430040889441443e-07
clinical O 0 2.013124685618095e-05
manifestations O 0 5.59191585125518e-06
of O 0 1.2942271609972522e-07
BPAD B-Disease 1 0.9999752044677734
and O 0 7.95972539435752e-07
perhaps O 0 6.160487941997417e-07
other O 0 1.2907537438877625e-07
related O 0 1.0992731404257938e-05
affective B-Disease 1 0.9984945058822632
disorders I-Disease 1 0.9991796612739563
. O 0 2.914324613811914e-05

Segregation O 0 0.0036308823619037867
distortion O 0 0.06990137696266174
in O 0 0.004105181433260441
myotonic B-Disease 1 0.9999980926513672
dystrophy I-Disease 1 0.9999992847442627
. O 0 0.00086190365254879

Myotonic B-Disease 1 0.9999992847442627
dystrophy I-Disease 1 1.0
( O 1 0.9989142417907715
DM B-Disease 1 0.9999998807907104
) O 0 4.16661350755021e-05
is O 0 6.972235837565677e-07
an O 0 1.1426672017478268e-06
autosomal B-Disease 1 0.8472055196762085
dominant I-Disease 1 0.8325283527374268
disease I-Disease 0 0.12372506409883499
which O 0 2.7640342636914284e-07
, O 0 4.5018726524403974e-08
in O 0 1.135352700742942e-08
the O 0 1.4730914266181117e-08
typical O 0 6.457409540416847e-07
pedigree O 0 3.603711547839339e-06
, O 0 3.509058998929504e-08
shows O 0 6.442917310778284e-08
a O 0 7.700976567548423e-08
three O 0 1.2483597799928248e-07
generation O 0 3.7423453704832355e-06
anticipation O 0 4.806325250683585e-06
cascade O 0 3.2484287658007815e-05
. O 0 2.8364079298626166e-06

This O 0 1.0564847798377741e-05
results O 0 2.664565181476064e-05
in O 0 8.393603820877615e-06
infertility B-Disease 1 0.9988546371459961
and O 1 0.9400408864021301
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.588702591310721e-05
CDM B-Disease 0 0.00021355823264457285
) O 0 2.1864620691758319e-07
with O 0 5.570108640995386e-08
the O 0 7.186989847696168e-08
disappearance O 0 7.66929497331148e-06
of O 0 2.905358940097358e-07
DM B-Disease 1 0.9999988079071045
in O 0 2.475208248142735e-06
that O 0 5.880284561499138e-07
pedigree O 0 3.863276288029738e-05
. O 0 2.7938667699345388e-06

The O 0 1.4025238215253921e-06
concept O 0 7.413948992507358e-07
of O 0 7.452747041725161e-08
segregation O 0 1.6203299537664861e-06
distortion O 0 4.59428338217549e-05
, O 0 1.531463595938476e-07
where O 0 3.8559178960895224e-08
there O 0 1.7301399424241026e-08
is O 0 2.1519621640209152e-08
preferential O 0 2.071698474992445e-07
transmission O 0 1.0649438308973913e-06
of O 0 9.574515402732686e-09
the O 0 1.911743474636296e-08
larger O 0 1.523544881365524e-07
allele O 0 1.1362470786480117e-06
at O 0 3.473883936067068e-08
the O 0 1.8644938393208577e-07
DM B-Disease 1 0.999997615814209
locus O 0 0.0001259142009075731
, O 0 9.537863832065341e-08
has O 0 4.576885359597327e-08
been O 0 1.1902320906642672e-08
put O 0 3.684567317918663e-08
forward O 0 7.700359816453783e-08
to O 0 4.314109247616216e-08
explain O 0 5.228243367128016e-07
partially O 0 6.043367193342419e-07
the O 0 1.6432519345244145e-08
maintenance O 0 4.7277632120312774e-07
of O 0 1.2601236676346161e-07
DM B-Disease 1 0.999998927116394
in O 0 1.5472788845727337e-06
the O 0 1.9303577403206873e-07
population O 0 6.38311576039996e-07
. O 0 8.578703614148253e-07

In O 0 7.296776402654359e-06
a O 0 2.692360567380092e-06
survey O 0 6.060495252313558e-06
of O 0 3.444189076162729e-07
DM B-Disease 1 0.9999960660934448
in O 0 2.9220468604762573e-06
Northern O 0 1.2624647069969797e-06
Ireland O 0 5.119283059684676e-07
, O 0 1.039952621795237e-07
59 O 0 1.602367774466984e-06
pedigrees O 0 3.7698052892665146e-06
were O 0 5.861768386239419e-07
ascertained O 0 1.1536426427483093e-05
. O 0 2.1774008018837776e-06

Sibships O 0 0.0019111944129690528
where O 0 3.1208753625833197e-06
the O 0 9.647146725910716e-08
status O 0 4.0919399424410585e-08
of O 0 4.117350460575153e-09
all O 0 2.680259125753537e-09
the O 0 6.491775117467569e-09
members O 0 1.5250209983719287e-08
had O 0 1.1332004845598931e-07
been O 0 7.268117485637049e-08
identified O 0 1.4070504050778254e-07
were O 0 2.7561313231672102e-08
examined O 0 5.814843007101445e-07
to O 0 2.1662520666154705e-08
determine O 0 3.4131058868069886e-08
the O 0 1.4450704632906763e-08
transmission O 0 6.100951281950984e-07
of O 0 1.3479150240414128e-08
the O 0 2.8858408995802165e-07
DM B-Disease 1 0.9999901056289673
expansion O 0 2.9609830107801827e-06
from O 0 1.9796922856585297e-07
affected O 0 2.653900423865707e-07
parents O 0 3.2382573067479825e-07
to O 0 1.1563312796170067e-07
their O 0 4.1786077531469346e-07
offspring O 0 2.5037377781700343e-05
. O 0 2.991261453644256e-06

Where O 0 4.657641511585098e-06
the O 0 4.669368820486852e-07
transmitting O 0 1.4096875929681119e-05
parent O 0 3.600846639528754e-06
was O 0 4.600468344051478e-07
male O 0 3.290104359621182e-06
, O 0 3.337200951136765e-07
58 O 0 1.6440424587926827e-05
. O 0 2.0100294477742864e-06

3 O 0 3.968283999711275e-05
% O 0 6.860757935100992e-07
of O 0 1.4092683464639322e-08
the O 0 4.117101326528427e-08
offspring O 0 2.0157497147010872e-06
were O 0 1.3078829397272784e-07
affected O 0 7.542007551819552e-08
, O 0 1.347840417054158e-08
and O 0 1.561367568569949e-08
in O 0 1.765064894243551e-08
the O 0 1.6371888733601736e-08
case O 0 1.584427735679128e-07
of O 0 8.638411763683962e-09
a O 0 5.769260837951151e-07
female O 0 6.529075471917167e-05
transmitting O 0 2.9153581635910086e-05
parent O 0 2.7688829504768364e-06
, O 0 1.3610069515834766e-07
68 O 0 3.953001396439504e-06
. O 0 1.33780520172877e-06

7 O 0 0.0005731135606765747
% O 0 1.748185786709655e-05
were O 0 2.03849958779756e-06
affected O 0 5.6716608014539815e-06
. O 0 3.8777670852141455e-06

Studies O 0 2.78698826150503e-05
on O 0 1.2252893384356867e-06
meiotic O 0 3.214172102161683e-05
drive O 0 1.4433934666158166e-05
in O 0 3.237416194679099e-06
DM B-Disease 1 0.9999985694885254
have O 0 8.428062756138388e-06
shown O 0 9.946478485289845e-07
increased O 0 1.705619041558748e-07
transmission O 0 4.331502623244887e-07
of O 0 7.000003243717856e-09
the O 0 2.5614131260454087e-08
larger O 0 1.463371717136397e-07
allele O 0 1.8268119674758054e-06
at O 0 4.262937736143613e-08
the O 0 2.1038030695308407e-07
DM B-Disease 1 0.9999959468841553
locus O 0 0.00014085797010920942
in O 0 1.004785303848621e-06
non O 0 3.5552250210457714e-06
- O 0 0.17792226374149323
DM O 1 0.9999957084655762
heterozygotes O 0 0.002314311219379306
for O 0 2.7951168704021256e-06
CTGn O 0 0.00041486206464469433
. O 0 8.346500180778094e-06

This O 0 7.680405360588338e-06
study O 0 2.9119712507963413e-06
provides O 0 3.3965528700719005e-07
further O 0 1.198858541329173e-07
evidence O 0 1.7706275912132696e-07
that O 0 2.9281506996881035e-08
the O 0 6.318094847301836e-08
DM B-Disease 1 0.9999614953994751
expansion O 0 2.1548203221755102e-06
tends O 0 2.093748207698809e-06
to O 0 1.5474736869691696e-07
be O 0 2.71398448603577e-07
transmitted O 0 9.309383131039795e-06
preferentially O 0 1.2447791050362866e-05
. O 0 2.266854153276654e-06

Diagnosis O 1 0.9987302422523499
of O 0 0.0003927412908524275
hemochromatosis B-Disease 1 0.9999504089355469
. O 0 0.00022225332213565707

If O 0 0.00044450981658883393
untreated O 1 0.9621982574462891
, O 0 4.040709973196499e-05
hemochromatosis B-Disease 1 0.9999905824661255
can O 0 8.43884699861519e-05
cause O 0 0.0009304179693572223
serious O 1 0.8075620532035828
illness O 1 0.9990137815475464
and O 0 5.2257287279644515e-06
early B-Disease 0 0.00011616741539910436
death I-Disease 0 0.034263480454683304
, O 0 8.941505313941889e-08
but O 0 1.0403076800002964e-07
the O 0 2.877642941712111e-07
disease O 0 9.977949230233207e-05
is O 0 1.223038026409995e-07
still O 0 1.3104365734761814e-06
substantially O 0 6.786574431316694e-06
under O 0 5.419871740741655e-06
- O 1 0.9641827940940857
diagnosed O 1 0.9988740086555481
. O 0 6.9427364906005096e-06

The O 0 1.403497890350991e-06
cornerstone O 0 2.905086830651271e-06
of O 0 5.550361592554509e-08
screening O 0 1.382592813570227e-06
and O 0 1.4160940509100328e-07
case O 0 8.032504865695955e-07
detection O 0 2.815833397562528e-07
is O 0 1.4365951095385299e-08
the O 0 7.496526066574916e-09
measurement O 0 1.306577672721687e-07
of O 0 1.0548189877113145e-08
serum O 0 3.0901103400537977e-06
transferrin O 0 8.010855708562303e-06
saturation O 0 1.8642499526322354e-06
and O 0 3.512447221964976e-08
the O 0 3.7552833731524515e-08
serum O 0 4.254216491972329e-06
ferritin O 0 4.767245991388336e-05
level O 0 7.246612199196534e-07
. O 0 1.0624008837112342e-06

Once O 0 5.105660966364667e-05
the O 0 2.410953584330855e-06
diagnosis O 0 0.009876641444861889
is O 0 2.567814476606145e-07
suspected O 0 3.0162289021973265e-06
, O 0 4.2734274074973655e-07
physicians O 0 1.5610243053743034e-06
must O 0 4.351678484226795e-08
use O 0 7.706310611865774e-08
serum O 0 4.098598310520174e-06
ferritin O 0 4.890649870503694e-05
levels O 0 1.8709221194512793e-07
and O 0 1.2506285429481068e-07
hepatic O 0 0.00015038288256619126
iron O 0 0.0005126500618644059
stores O 0 7.713647391938139e-07
on O 0 1.3273638614919037e-06
liver O 0 0.013970153406262398
biopsy O 1 0.7963083982467651
specimens O 0 4.89039121021051e-06
to O 0 8.784143687989854e-07
assess O 0 0.004123087506741285
patients O 0 0.010215474292635918
for O 0 4.7321254470489293e-08
the O 0 4.7956383752989495e-08
presence O 0 1.4907236334238405e-07
of O 0 1.1136992128513157e-07
iron B-Disease 0 0.035764213651418686
overload I-Disease 0 0.02350127510726452
. O 0 8.034772690734826e-06

Liver O 1 0.9997075200080872
biopsy O 1 0.9984922409057617
is O 0 4.25981897933525e-06
also O 0 2.771979836779792e-07
used O 0 9.844476522857804e-08
to O 0 2.8117781880609982e-08
establish O 0 4.874913273056336e-08
the O 0 1.7409711006166617e-08
presence O 0 1.304321841644196e-07
or O 0 4.0576654924961986e-08
absence O 0 5.598045049737266e-07
of O 0 1.751971296926058e-07
cirrhosis B-Disease 1 0.9413841962814331
, O 0 5.745569069404155e-07
which O 0 1.7466861379489274e-07
can O 0 4.1605753153817204e-07
affect O 0 8.980429811344948e-06
prognosis O 1 0.91246497631073
and O 0 5.811039955005981e-06
management O 0 1.2017415428999811e-05
. O 0 4.79907930639456e-06

A O 0 4.9668236897559837e-05
DNA O 0 4.569291559164412e-05
- O 0 5.4448068112833425e-05
based O 0 4.219353115786362e-07
test O 0 1.9392551564578753e-07
for O 0 1.57940789335953e-08
the O 0 6.801183616289563e-08
HFE O 0 0.0002444837591610849
gene O 0 4.643470674636774e-07
is O 0 1.4586449381681632e-08
commercially O 0 1.1790254461629956e-07
available O 0 2.1796305205157296e-08
, O 0 8.46038084034717e-09
but O 0 4.813037524087349e-09
its O 0 3.7616545434104864e-09
place O 0 1.1952347556132281e-08
in O 0 1.9899662362377057e-08
the O 0 2.0152911872628465e-07
diagnosis O 0 0.3644736409187317
of O 0 1.1155855190736474e-06
hemochromatosis B-Disease 1 0.9999983310699463
is O 0 1.0038428399639088e-06
still O 0 7.538856721112097e-07
being O 0 4.030775926366914e-07
evaluated O 0 6.0333049987093545e-06
. O 0 1.5376922419818584e-06

Currently O 0 1.323874676018022e-05
, O 0 2.3148523098370788e-07
the O 0 1.977442565248566e-08
most O 0 1.2930989612414123e-08
useful O 0 2.2752237427425825e-08
role O 0 2.975970581076126e-08
for O 0 1.0593252497415051e-08
this O 0 2.5663521086016772e-08
test O 0 1.569298007098041e-07
is O 0 1.2179696362579762e-08
in O 0 9.864246308666225e-09
the O 0 9.548545065740655e-09
detection O 0 2.0281494528262556e-07
of O 0 1.326319534200593e-07
hemochromatosis B-Disease 1 0.9999980926513672
in O 0 5.129144824422838e-07
the O 0 6.14305690760375e-08
family O 0 2.2722407777564513e-07
members O 0 1.7074475167078162e-08
of O 0 3.2212977174594926e-08
patients O 0 0.00012164008512627333
with O 0 1.1106084940593064e-07
a O 0 6.693424893455813e-06
proven O 0 4.7530924348393455e-05
case O 0 1.1547415397217264e-06
of O 0 9.81024967927624e-08
the O 0 4.302750312490389e-06
disease O 0 0.0014163871528580785
. O 0 4.4021830944984686e-06

It O 0 2.6495251859159907e-06
is O 0 2.865052124434442e-07
crucial O 0 8.582033501625119e-07
to O 0 6.57642567603034e-06
diagnose O 1 0.9998606443405151
hemochromatosis B-Disease 1 0.9999991655349731
before O 0 0.031525835394859314
hepatic B-Disease 1 0.9995323419570923
cirrhosis I-Disease 1 0.9995536208152771
develops O 0 0.0052319481037557125
because O 0 3.7980857996444684e-06
phlebotomy O 0 0.11025555431842804
therapy O 0 0.0055605326779186726
can O 0 2.100522351611289e-06
avert O 0 0.15134187042713165
serious O 1 0.9999366998672485
chronic O 1 1.0
disease O 1 0.9998695850372314
and O 0 4.006408289569663e-06
can O 0 5.421869673227775e-07
even O 0 9.928237432177411e-08
lead O 0 6.271139341151866e-07
to O 0 2.1610568978758238e-07
normal O 0 6.080127832319704e-07
life O 0 2.6655554847820895e-06
expectancy O 0 3.099591049249284e-05
. O 0 2.993664907080529e-07
. O 0 1.385268092235492e-06

Prevalence O 0 0.020182738080620766
of O 0 8.375552056349989e-07
the O 0 4.6904125383662176e-07
I1307K O 0 4.221817653160542e-05
APC B-Disease 0 7.679196642129682e-06
gene O 0 1.0511596428841585e-06
variant O 0 4.216378329147119e-06
in O 0 5.911192246799146e-08
Israeli O 0 3.1672989280195907e-06
Jews O 0 1.267104750013459e-07
of O 0 8.731840139830638e-09
differing O 0 3.7470698543984327e-07
ethnic O 0 2.7841960559271683e-07
origin O 0 3.011877822700626e-07
and O 0 8.022024644560588e-07
risk O 0 5.479152605403215e-05
for O 0 0.043031275272369385
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0001614318462088704

BACKGROUND O 0 0.0010776390554383397
& O 0 3.872361048706807e-05
AIMS O 0 1.2837582289648708e-05
Israeli O 0 1.4244231351767667e-05
Jews O 0 2.058591661580067e-07
of O 0 1.5093483796135843e-08
European O 0 3.4948425309266895e-07
birth O 0 3.937841938750353e-06
, O 0 6.677210251382348e-08
i O 0 1.4853083030175185e-07
. O 0 1.1329492899392335e-08
e O 0 3.322221431290018e-08
. O 0 5.918748158251219e-09
, O 0 1.385986081459123e-08
Ashkenazim O 0 4.153471309109591e-07
, O 0 1.7323291245929795e-08
have O 0 2.3009590677247616e-08
the O 0 2.143832489309716e-07
highest O 0 0.39453044533729553
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.6834099292755127
of O 0 1.5562943644908955e-07
any O 0 2.563549799106113e-07
Israeli O 0 3.641114744823426e-05
ethnic O 0 2.8082006338081555e-06
group O 0 5.421562491392251e-06
. O 0 1.6133465123857604e-06

The O 0 8.910432370612398e-06
I1307K O 0 0.00020947123994119465
APC B-Disease 0 7.33508204575628e-05
gene O 0 1.1366967555659357e-05
variant O 0 2.8476577426772565e-05
was O 0 1.095345510293555e-06
found O 0 4.0318485616808175e-07
in O 0 3.4488763844819914e-07
6 O 0 7.5849698077945504e-06
. O 0 2.2532822185894474e-06

1 O 0 2.659974961716216e-05
% O 0 6.913914489814488e-07
of O 0 2.9035909676622396e-08
American O 0 1.2977235996913805e-07
Jews O 0 3.9805044593776984e-07
, O 0 6.536905772236423e-08
28 O 0 2.7368858468435064e-07
% O 0 6.865213286744165e-09
of O 0 8.185706334984388e-09
their O 0 1.3954066162114032e-05
familial O 1 0.9999967813491821
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.007837668992578983
, O 0 4.0649590005159553e-07
but O 0 1.2485847378229664e-07
not O 0 3.965809725059444e-08
in O 0 6.86703671703981e-08
non O 0 4.274034779427893e-07
- O 0 8.011840691324323e-05
Jews O 0 4.490767878451152e-06
. O 0 1.7188339143103804e-06

We O 0 1.433779198123375e-05
assessed O 0 7.079027454892639e-06
the O 0 4.2931694110848184e-07
I1307K O 0 0.00015039951540529728
prevalence O 0 3.399352135602385e-05
in O 0 9.592615413112071e-08
Israeli O 0 8.57928807818098e-06
Jews O 0 1.3713139423998655e-07
of O 0 8.771301018839495e-09
differing O 0 2.8464239676395664e-07
ethnic O 0 2.1215959122855566e-07
origin O 0 1.9938460127377766e-07
and O 0 3.11727120561045e-07
risk O 0 1.3230921467766166e-05
for O 0 0.013638907112181187
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00010554294567555189

METHODS O 0 0.00012427712499629706
DNA O 0 8.076890662778169e-05
samples O 0 2.640449565660674e-06
from O 0 1.0975481501418471e-07
500 O 0 1.0238100855985977e-07
unrelated O 0 5.377778506954201e-07
Jews O 0 6.08901089549363e-08
of O 0 8.969207598852336e-09
European O 0 8.959293040788907e-08
or O 0 4.180373380791025e-08
non O 0 8.718896538084664e-08
- O 0 1.3806856259179767e-05
European O 0 1.8967618586884782e-07
origin O 0 4.9692992831751326e-08
, O 0 9.348405605180687e-09
with O 0 1.3230192941193764e-08
or O 0 1.6541701342021042e-08
without O 0 2.7723491058395666e-08
a O 0 1.4727997665886505e-07
personal O 0 1.583947323524626e-06
and O 0 5.4864614185135e-07
/ O 0 2.3605709429830313e-05
or O 0 3.7151092868725755e-08
family O 0 5.856237095258621e-08
history O 0 1.505690860881259e-08
of O 0 1.5899322747259248e-08
neoplasia B-Disease 0 0.005637683905661106
, O 0 3.0768461556363036e-07
were O 0 9.625421881764851e-08
examined O 0 1.1344866379658924e-06
for O 0 1.018840301014734e-08
the O 0 1.8102475962678e-08
I1307K O 0 1.8303191609447822e-05
variant O 0 9.225459507433698e-07
by O 0 7.47039141657524e-09
the O 0 1.5514613593836657e-08
allele O 0 1.1877848464791896e-06
- O 0 7.974921913955768e-07
specific O 0 1.0323577015469709e-07
oligonucleotide O 0 5.7953493524109945e-05
( O 0 2.9258683298394317e-07
ASO O 0 0.00017454252520110458
) O 0 3.1687324053564225e-07
method O 0 1.5662674286431866e-06
. O 0 2.3726108793198364e-06

RESULTS O 0 0.0025501479394733906
In O 0 1.3586276281785103e-06
persons O 0 4.156117654474656e-07
at O 0 1.1542842059952818e-07
average O 0 1.780458433131571e-06
risk O 0 1.045377939590253e-05
for O 0 0.010581865906715393
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.882141406094888e-06
I1307K O 0 0.00013343415048439056
was O 0 4.2981798742403043e-07
found O 0 7.812900548742618e-08
in O 0 8.027935649579376e-08
5 O 0 1.1907700354640838e-06
. O 0 1.122519165619451e-06

0 O 0 6.79127115290612e-05
% O 0 5.030878469369782e-07
of O 0 2.095474727070723e-08
120 O 0 2.3400025384034961e-07
European O 0 2.6017801246780436e-07
and O 0 4.933200443701935e-07
1 O 0 3.0225064620026387e-06
. O 0 2.9311372600204777e-06

6 O 0 5.581903678830713e-05
% O 0 1.3132089407008607e-06
of O 0 5.243003187160866e-08
188 O 0 7.320567760871199e-07
non O 0 6.908325644872093e-07
- O 0 4.207444726489484e-05
European O 0 1.2922356518174638e-06
Jews O 0 1.6429279412477626e-06
( O 0 1.3717638580601488e-07
P O 0 7.241075763886329e-06
= O 0 1.509387857367983e-06
0 O 0 2.986980121022498e-07
. O 0 4.549417198518313e-08
08 O 0 1.2322160500843893e-06
) O 0 3.2895536605792586e-07
. O 0 6.064532840355241e-07

It O 0 1.5809480828465894e-05
occurred O 0 1.0929228665190749e-05
in O 0 1.361531758448109e-06
15 O 0 5.337300081009744e-06
. O 0 3.18723073178262e-06

4 O 0 3.43828032782767e-05
% O 0 9.612392659619218e-07
of O 0 5.2075428413900227e-08
52 O 0 6.545622454723343e-06
Ashkenazi O 0 1.91714680113364e-05
Israelis O 0 1.553801484988071e-05
with O 0 3.7735171645181254e-06
familial O 1 0.9994741082191467
cancer B-Disease 1 0.9997486472129822
( O 0 6.733701525263314e-07
P O 0 7.587146683363244e-05
= O 0 2.906477902797633e-06
0 O 0 3.365983616276935e-07
. O 0 2.4310065072086218e-08
02 O 0 3.6028072258886823e-07
) O 0 6.941158314788254e-09
and O 0 9.13899445009747e-09
was O 0 9.458641159199033e-08
not O 0 2.436544477291136e-08
detected O 0 2.614250718124822e-07
in O 0 2.650252461933178e-08
51 O 0 5.786138785879302e-07
non O 0 1.0543125483764015e-07
- O 0 2.4334849513252266e-06
European O 0 2.7150431947120524e-07
Jews O 0 3.259247876030713e-07
at O 0 4.782439191330923e-07
increased O 0 7.861042104195803e-05
cancer B-Disease 0 0.38328707218170166
risk O 0 3.104567440459505e-05
. O 0 5.4810197980259545e-06

Colorectal B-Disease 1 0.9998003840446472
neoplasia I-Disease 1 0.9946995973587036
occurred O 0 0.0009596448508091271
personally O 0 6.965827924432233e-05
or O 0 3.6783467294299044e-07
in O 0 5.417301451871026e-08
the O 0 4.02787030395757e-08
families O 0 4.998892677576805e-08
of O 0 1.6476770170470445e-08
13 O 0 1.2126756132602168e-07
of O 0 1.5223299953959213e-08
20 O 0 3.095417184795224e-07
Ashkenazi O 0 3.301510560049792e-06
I1307K O 0 9.239897735824343e-06
carriers O 0 6.29382327588246e-07
, O 0 2.262285114795759e-08
8 O 0 3.196814546413407e-08
of O 0 6.769357518976449e-09
whom O 0 6.414898621187604e-07
also O 0 1.1741780525653667e-07
had O 0 1.2911549163163727e-07
a O 0 1.519280488082586e-07
personal O 0 3.1159891022980446e-06
or O 0 1.2474244215354702e-07
family O 0 3.458239916653838e-07
history O 0 1.5408160436436447e-07
of O 0 1.6980962413981615e-07
noncolonic O 0 0.03286122530698776
neoplasia B-Disease 0 0.04492448270320892
. O 0 1.2624125702132005e-05

CONCLUSIONS O 0 0.0005161562003195286
The O 0 2.593624685687246e-06
I1307K O 0 0.0001827622763812542
APC O 0 0.00011138277477584779
variant O 0 0.00029604797600768507
may O 0 1.7373607761328458e-06
represent O 0 8.229370962453686e-08
a O 0 9.171387773676543e-07
susceptibility O 0 0.0027361195534467697
gene O 0 4.683900442614686e-06
for O 0 5.545706699194852e-06
colorectal B-Disease 1 0.9999988079071045
, I-Disease 0 2.054119704553159e-06
or I-Disease 0 6.327103818648538e-08
other I-Disease 0 3.5971421397107406e-08
, I-Disease 0 1.141983034358418e-06
cancers I-Disease 0 0.12956902384757996
in O 0 7.239518140522705e-07
Ashkenazi O 0 0.000539997941814363
Jews O 0 7.244566972985922e-07
, O 0 3.564495187902139e-08
and O 0 8.309875454415305e-08
partially O 0 3.942880994145526e-06
explains O 0 3.9831323306316335e-07
the O 0 1.8057198403198527e-08
higher O 0 3.254201033087156e-07
incidence O 0 0.0022202495019882917
of O 0 0.0005266289226710796
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 6.20680111751426e-06
European O 0 6.598401341761928e-06
Israelis O 0 0.00014448948786593974
. O 0 2.6454954422661103e-06

Systematic O 0 0.0001586100406711921
analysis O 0 1.957193308044225e-05
of O 0 1.2382154181977967e-06
coproporphyrinogen O 0 0.003969354555010796
oxidase O 0 0.000330027483869344
gene O 0 0.0001037122929119505
defects O 0 0.14732728898525238
in O 0 2.7282023893349105e-06
hereditary B-Disease 0 0.22045716643333435
coproporphyria I-Disease 0 0.056636035442352295
and O 0 3.463713028395432e-06
mutation O 0 2.004829002544284e-05
update O 0 5.0470665883040056e-05
. O 0 2.218760755567928e-06

Hereditary B-Disease 1 0.9991368651390076
coproporphyria I-Disease 1 0.9668610095977783
( O 0 5.160159707884304e-05
HC B-Disease 1 0.5109656453132629
) O 0 1.1335500857967418e-06
is O 0 3.2658005011398927e-07
an O 0 1.126289316744078e-05
acute O 1 0.9999455213546753
hepatic B-Disease 1 0.9999868869781494
porphyria I-Disease 1 0.9999892711639404
with O 0 0.013104747049510479
autosomal O 1 0.99397212266922
dominant O 0 0.009387143887579441
inheritance O 0 0.003467034315690398
caused O 0 2.975971256091725e-05
by O 0 1.525365007637447e-07
deficient B-Disease 0 7.195711987151299e-06
activity I-Disease 0 4.7476572007099094e-08
of I-Disease 0 4.146259158233079e-08
coproporphyrinogen I-Disease 0 0.0020541108679026365
III I-Disease 0 0.0028580923099070787
oxidase I-Disease 0 9.671070074546151e-06
( O 0 2.7315923034620937e-07
CPO O 0 1.951761805685237e-05
) O 0 6.071303459975752e-07
. O 0 1.113048824663565e-06

Clinical O 0 0.3817613124847412
manifestations O 0 0.0007549849688075483
of O 0 1.5938999240461271e-06
the O 0 3.5232053051004186e-05
disease O 0 0.08401095867156982
are O 0 1.8921078037692496e-07
characterized O 0 5.685193173121661e-05
by O 0 8.981090104498435e-06
acute O 1 0.9947776794433594
attacks O 0 0.013636269606649876
of O 0 7.060290954541415e-06
neurological B-Disease 1 0.9999802112579346
dysfunction I-Disease 1 0.999671220779419
often O 0 3.132026540697552e-05
precipitated O 0 0.00010981706873280928
by O 0 1.0538943939764067e-07
drugs O 0 1.786178245311021e-07
, O 0 5.218400644935173e-08
fasting O 0 1.1375959729775786e-06
, O 0 1.0061798150218237e-07
cyclical O 0 1.46989632412442e-05
hormonal O 0 0.0010923378868028522
changes O 0 6.079878289710905e-07
, O 0 3.540016564329562e-07
or O 0 1.997387016672292e-06
infectious B-Disease 0 0.26511502265930176
diseases I-Disease 0 0.22085726261138916
. O 0 8.645353773317765e-06

Skin O 1 0.9999748468399048
photosensitivity O 1 0.9999407529830933
may O 0 0.034547027200460434
also O 0 1.7579608311280026e-06
be O 0 2.1455200283071463e-07
present O 0 8.580674943914346e-07
. O 0 2.134585884050466e-06

The O 0 3.755304760488798e-06
seven O 0 1.6804810911708046e-06
exons O 0 5.652233539876761e-06
, O 0 7.773820698275813e-08
the O 0 3.6293815952603836e-08
exon O 0 3.01082627629512e-06
/ O 0 1.357989049211028e-06
intron O 0 4.476468802749878e-06
boundaries O 0 6.844688726914683e-08
and O 0 1.3101545626170719e-08
part O 0 1.3290414102584691e-08
of O 0 6.135092434078615e-09
3 O 0 8.448774480029897e-08
noncoding O 0 9.651109849073691e-07
sequence O 0 2.6062295432893734e-08
of O 0 2.3787256608898133e-09
the O 0 1.7911959915295483e-08
CPO O 0 1.665923628024757e-05
gene O 0 3.3003823318722425e-07
were O 0 3.18325810155784e-08
systematically O 0 2.966954184557835e-07
analyzed O 0 3.3322012882308627e-07
by O 0 1.3259067621618215e-08
an O 0 3.246253044153491e-08
exon O 0 1.323074457104667e-06
- O 0 1.1000731774402084e-06
by O 0 7.206853069874342e-08
- O 0 3.900696810887894e-06
exon O 0 7.758245374134276e-06
denaturing O 0 9.419510024599731e-05
gradient O 0 0.0006596840685233474
gel O 0 0.00020859947835560888
electrophoresis O 0 2.5014085622387938e-05
( O 0 9.295441572021446e-08
DGGE O 0 3.5464950087771285e-06
) O 0 2.158671108531962e-08
strategy O 0 9.538882750348421e-08
followed O 0 8.636948933826716e-08
by O 0 5.171687966765148e-09
direct O 0 1.652971626242561e-08
sequencing O 0 9.398504374757977e-08
in O 0 2.6759543914067763e-08
seven O 0 1.1001658606346609e-07
unrelated O 0 4.0985000850923825e-06
heterozygous O 0 0.0004443784710019827
HC B-Disease 1 0.9937272071838379
patients O 1 0.6748536825180054
from O 0 3.650135909083474e-07
France O 0 8.046366929193027e-06
, O 0 2.688225038127712e-07
Holland O 0 3.917532467312412e-06
, O 0 9.060201477950613e-08
and O 0 1.5744743109280535e-07
Czech O 0 2.9618380722240545e-05
Republic O 0 2.7200294425711036e-06
. O 0 2.1148478026589146e-06

Seven O 0 0.00010250099876429886
novel O 0 0.00011255992285441607
mutations O 0 5.859589873580262e-05
and O 0 1.525139623481664e-07
two O 0 1.0295516972291807e-07
new O 0 4.852029178437078e-07
polymorphisms O 0 1.1398111382732168e-05
were O 0 1.0702208328439156e-06
detected O 0 8.616702871222515e-06
. O 0 2.0932411644025706e-06

Among O 0 1.7739766917657107e-05
these O 0 8.53505298437085e-07
mutations O 0 1.2325602256169077e-05
two O 0 2.212427290260166e-07
are O 0 8.69037251050031e-08
missense O 0 2.3089678506948985e-05
( O 0 6.089813098242303e-08
G197W O 0 3.493017629807582e-06
, O 0 5.908577094260181e-08
W427R O 0 2.6740035536931828e-06
) O 0 1.5108374995520535e-08
, O 0 6.260596041585131e-09
two O 0 9.384313770510744e-09
are O 0 8.692755848471734e-09
nonsense O 0 2.260136625409359e-06
( O 0 4.341597303891831e-08
Q306X O 0 2.34111007557658e-06
, O 0 5.302216266045434e-08
Q385X O 0 2.4430235043837456e-06
) O 0 9.828844405035397e-09
, O 0 4.123103192199551e-09
two O 0 3.864736974890093e-09
are O 0 4.340320547413512e-09
small O 0 3.1662672483889764e-08
deletions O 0 3.2542120607104152e-06
( O 0 9.899797959178613e-08
662de14bp O 0 4.788134901900776e-06
; O 0 9.367900588586053e-08
1168del3bp O 0 1.3056388752374914e-06
removing O 0 1.2821901407278347e-07
a O 0 6.207199731989022e-08
glycine O 0 3.6304066952652647e-07
at O 0 1.5440631884189315e-08
position O 0 9.115877475096568e-08
390 O 0 5.739949529015576e-07
) O 0 2.666894793890151e-08
, O 0 1.0957070806227875e-08
and O 0 1.0235655878432226e-08
one O 0 8.038442800284429e-09
is O 0 5.3551048040390015e-09
a O 0 1.0825765883737404e-07
splicing O 0 5.799994141852949e-06
mutation O 0 2.7316912110109115e-06
( O 0 7.104411281488865e-08
IVS1 O 0 2.6878920834860764e-05
- O 0 5.672510451404378e-05
15c O 0 0.0001287280465476215
- O 0 5.290861736284569e-05
- O 0 0.00012669051648117602
> O 0 7.147535598051036e-06
g O 0 9.195049642585218e-06
) O 0 2.0790089649835863e-08
which O 0 8.303739917892017e-09
creates O 0 7.21964852345991e-08
a O 0 7.545748559323329e-08
new O 0 9.562291580778037e-08
acceptor O 0 6.662160672021855e-07
splice O 0 1.4196223673934583e-05
site O 0 3.524800376908388e-06
. O 0 1.5355379900938715e-06

The O 0 6.413799383153673e-06
pathological O 0 4.379062738735229e-05
significance O 0 9.716726481201476e-07
of O 0 4.55672939381202e-08
the O 0 7.843598837098398e-08
point O 0 4.691808328516345e-07
mutations O 0 1.9638157482404495e-06
G197W O 0 5.6687572396185715e-06
, O 0 1.0701315034111758e-07
W427R O 0 2.6341015200159745e-06
, O 0 2.0849656223731472e-08
and O 0 8.031729947788335e-09
the O 0 9.871737205457976e-09
in O 0 4.554244270593699e-08
- O 0 2.7083993700216524e-05
frame O 0 0.0015131350373849273
deletion O 0 4.738614006782882e-05
390delGly O 0 8.374909157282673e-06
were O 0 5.175341755148111e-08
assessed O 0 8.079224755874748e-08
by O 0 5.5103281937363136e-09
their O 0 6.0712310734345465e-09
respective O 0 3.102361745277449e-08
expression O 0 1.270151130938757e-07
in O 0 1.6150316639595985e-08
a O 0 7.436829463358663e-08
prokaryotic O 0 2.97392318771017e-07
system O 0 3.045062157980283e-08
using O 0 3.7049410650524806e-08
site O 0 9.835205361241606e-08
- O 0 9.852287803369109e-07
directed O 0 2.734193230935489e-06
mutagenesis O 0 6.996271258685738e-05
. O 0 2.948106157418806e-06

These O 0 1.170855830423534e-05
mutations O 0 0.0001540431403554976
resulted O 0 1.265879063794273e-06
in O 0 5.423794391390402e-08
the O 0 2.8474413937829013e-08
absence O 0 4.0130404954652477e-07
or O 0 3.028935324778104e-08
a O 0 3.236401937556366e-07
dramatic O 0 7.607207226101309e-05
decrease O 0 1.0472479516465683e-05
of O 0 9.528390876312187e-08
CPO O 0 0.00013355747796595097
activity O 0 3.0985324883658905e-06
. O 0 1.4559982446371578e-06

The O 0 2.224903482783702e-06
two O 0 6.06263029112597e-07
polymorphisms O 0 6.924995432200376e-06
were O 0 2.0692776558917103e-07
localized O 0 2.5899341835611267e-06
in O 0 1.4286277405517467e-07
noncoding O 0 9.326445251645055e-06
part O 0 6.262545326762847e-08
of O 0 7.961629577835083e-09
the O 0 1.5742919856620574e-08
gene O 0 5.130436164790808e-08
1 O 0 3.809134696552974e-08
) O 0 8.86508466635405e-09
a O 0 2.427221943435143e-07
C O 0 7.028889740468003e-06
/ O 0 2.5919756808434613e-05
G O 0 0.0018776576034724712
polymorphism O 0 3.471728996373713e-05
in O 0 4.5962536887600436e-08
the O 0 2.6867249758311118e-08
promotor O 0 2.9114715289324522e-05
region O 0 9.275287737864346e-08
, O 0 1.3004697763108197e-08
142 O 0 8.115365091043714e-08
bp O 0 1.6775412632341613e-06
upstream O 0 3.371270906882273e-08
from O 0 3.4328733189425975e-09
the O 0 2.317280145547329e-09
transcriptional O 0 6.043251232767943e-08
initiation O 0 5.1838576098361955e-08
site O 0 6.332862767521874e-08
( O 0 1.4855570995564449e-08
- O 0 9.183237921206455e-07
142C O 0 5.835889533045702e-05
/ O 0 8.212306966015603e-06
G O 0 2.9733731935266405e-05
) O 0 2.0006833523211753e-08
, O 0 1.221230938597273e-08
and O 0 1.208509825545434e-08
2 O 0 4.24238386642628e-08
) O 0 5.0288324615621605e-09
a O 0 7.999062745511765e-08
6 O 0 3.945349078549043e-07
bp O 0 6.954153650440276e-05
deletion O 0 1.829356187954545e-05
polymorphism O 0 5.403243449109141e-06
in O 0 3.4762969391977094e-08
the O 0 2.3824773265346266e-08
3 O 0 1.4350551680308854e-07
noncoding O 0 1.317193778049841e-06
part O 0 1.7171146282635164e-08
of O 0 4.844397327730121e-09
the O 0 2.8730930523579445e-08
CPO O 0 1.6348305507563055e-05
gene O 0 3.318802157536993e-07
, O 0 2.3792260606114723e-08
574 O 0 8.479009920847602e-07
bp O 0 8.334322956216056e-06
downstream O 0 8.635087311859024e-08
of O 0 3.390899561139804e-09
the O 0 7.040790173107325e-09
last O 0 8.347222291149592e-08
base O 0 2.339798932382564e-08
of O 0 2.3619706190913803e-09
the O 0 2.351866079663978e-08
normal O 0 3.664069083697541e-07
termination O 0 4.88767773276777e-06
codon O 0 2.0122906789765693e-06
( O 0 3.4069179832840746e-07
+ O 0 1.6561958773309016e-06
574 O 0 6.713709808536805e-06
delATTCTT O 0 3.173941149725579e-05
) O 0 1.536299805593444e-06
. O 0 3.3401918244635453e-06

Five O 0 4.3334777728887275e-05
intragenic O 0 0.00047761001042090356
dimorphisms O 0 0.00033071660436689854
are O 0 3.1144006129579793e-07
now O 0 1.4159509476030507e-07
well O 0 8.323152655975719e-08
characterized O 0 1.3207396705183783e-06
and O 0 5.015022352949927e-08
the O 0 2.588118697133268e-08
high O 0 1.1810038103021725e-07
degree O 0 1.1467442107004899e-07
of O 0 2.1506449954245e-08
allelic O 0 5.189165676711127e-05
heterogeneity O 0 0.00012280227383598685
in O 0 9.678032029114547e-07
HC B-Disease 0 0.2878803610801697
is O 0 1.968170863619889e-06
demonstrated O 0 3.0387204787984956e-06
with O 0 4.30630748837757e-08
seven O 0 6.379404027256896e-08
new O 0 3.577477514227212e-08
different O 0 8.528103556670885e-09
mutations O 0 1.319957476653144e-07
making O 0 1.1225557372540607e-08
a O 0 3.095068734637607e-08
total O 0 1.561352647172498e-08
of O 0 8.351900504521836e-09
nineteen O 0 5.647772013617214e-06
CPO O 0 0.0008261276525445282
gene B-Disease 0 3.043894139409531e-05
defects I-Disease 0 0.08003305643796921
reported O 0 3.6030653518537292e-06
so O 0 1.302478551679087e-07
far O 0 2.584035314612265e-07
. O 0 2.2758753459584113e-07
. O 0 1.3150124686944764e-06

Coincidence O 0 0.00013372045941650867
of O 0 1.2954907333551091e-06
two O 0 6.091456725698663e-07
novel O 0 4.104958406969672e-06
arylsulfatase O 0 6.438753916881979e-05
A O 0 3.432827497817925e-06
alleles O 0 3.6967217056371737e-06
and O 0 4.42477585238521e-07
mutation O 0 1.0157657925446983e-05
459 O 0 3.554909926606342e-05
+ O 0 1.9901479390682653e-05
1G O 0 0.0008949186885729432
> O 0 4.754906967718853e-06
A O 0 3.180333578711725e-07
within O 0 3.123147607198007e-08
a O 0 6.375706220751454e-07
family O 0 3.2146247122000204e-06
with O 0 3.6162914511805866e-06
metachromatic B-Disease 1 0.9999890327453613
leukodystrophy I-Disease 1 0.9999920129776001
: O 0 7.591523853989202e-07
molecular O 0 5.885063956156955e-07
basis O 0 7.404629087659487e-08
of O 0 1.0669968730780965e-07
phenotypic O 0 0.00023448657884728163
heterogeneity O 0 0.0007989761652424932
. O 0 1.7238260625163093e-05

In O 0 9.88097963272594e-06
a O 0 3.7502127270272467e-06
family O 0 1.2639934539038222e-06
with O 0 1.0872760469737841e-07
three O 0 2.9483521757356357e-07
siblings O 0 8.02498652774375e-06
, O 0 2.6789059859311237e-08
one O 0 2.507524499151259e-08
developed O 0 1.249108834144863e-07
classical O 0 9.099502449316788e-07
late O 0 0.00024264544481411576
infantile O 1 0.9984092116355896
metachromatic B-Disease 1 0.9999945163726807
leukodystrophy I-Disease 1 0.9999942779541016
( O 0 1.1904512575711124e-05
MLD B-Disease 1 0.9997324347496033
) O 0 6.928251536919561e-07
, O 0 1.5785050777594734e-07
fatal O 0 0.0038554994389414787
at O 0 1.555239492745386e-07
age O 0 5.08273956256744e-07
5 O 0 1.2828016338062298e-07
years O 0 1.8860798434161552e-07
, O 0 7.045978378528162e-08
with O 0 3.704475091126369e-07
deficient O 0 0.0007708435878157616
arylsulfatase O 0 0.00044243622687645257
A O 0 2.3387603960145498e-06
( O 0 9.705949111094014e-08
ARSA O 0 3.7153524317545816e-05
) O 0 1.9182047950039305e-08
activity O 0 1.1185674608782392e-08
and O 0 2.92739130713926e-08
increased O 0 3.829383103948203e-07
galactosylsulfatide O 0 0.0005983542068861425
( O 0 1.1050098009945941e-06
GS O 1 0.9982427358627319
) O 0 1.1588211918933666e-06
excretion O 0 2.3390361093333922e-05
. O 0 3.917860794899752e-06

The O 0 2.250421630378696e-06
two O 0 3.842816340693389e-07
other O 0 6.792044615622217e-08
siblings O 0 2.095568333970732e-06
, O 0 6.125447526983407e-08
apparently O 0 1.5497598724323325e-06
healthy O 0 1.524131931773809e-07
at O 0 2.6131134589491012e-08
12 O 0 7.404685220535612e-08
( O 0 1.5399104213997816e-08
1 O 0 3.954977501052781e-08
/ O 0 6.515514314742177e-07
2 O 0 9.117025712157556e-08
) O 0 1.1516294584623665e-08
and O 0 1.0758800073062957e-08
15 O 0 4.043218382321356e-08
years O 0 6.389986140220572e-08
, O 0 2.027512557845057e-08
respectively O 0 1.3659415287747834e-07
, O 0 1.42533380653731e-08
and O 0 7.744810126553148e-09
their O 0 1.4896712308143378e-08
father O 0 3.0133942345855758e-06
, O 0 5.254295132317566e-08
apparently O 0 2.0297236460464774e-06
healthy O 0 2.158912622007847e-07
as O 0 1.1642181441118282e-08
well O 0 1.3255932351796673e-08
, O 0 3.120230118724976e-08
presented O 0 1.0235899026156403e-06
ARSA O 0 0.005435912404209375
and O 0 6.104448857513489e-07
GS O 1 0.980958878993988
values O 0 9.740536199842609e-08
within O 0 7.508876187500846e-09
the O 0 1.6547822667689616e-08
range O 0 2.639188210196153e-07
of O 0 1.1011605920430156e-06
MLD B-Disease 1 0.9999959468841553
patients O 1 0.9974753260612488
. O 0 1.3009311260248069e-05

Mutation O 0 0.020512932911515236
screening O 0 0.00012549094390124083
and O 0 1.1730559208444902e-06
sequence O 0 1.2418211099429755e-06
analysis O 0 7.202935989880643e-07
disclosed O 0 1.6592439351370558e-06
the O 0 1.3226937767285563e-08
involvement O 0 1.4517621593768126e-07
of O 0 1.2928030201919682e-08
three O 0 5.236946165609879e-08
different O 0 3.806222537150461e-08
ARSA O 0 0.04155340418219566
mutations O 0 3.693606458909926e-06
being O 0 3.022783090500525e-08
the O 0 9.75099823108394e-09
molecular O 0 2.946466111097834e-07
basis O 0 2.3384471248277805e-08
of O 0 4.911986195565987e-08
intrafamilial O 0 0.0008890840108506382
phenotypic O 0 0.0010409182868897915
heterogeneity O 0 0.0006635182653553784
. O 0 1.1090522093581967e-05

The O 0 1.7235828636330552e-05
late O 0 0.00023270255769602954
infantile O 1 0.9968361854553223
patient O 1 0.9899523854255676
inherited O 0 0.0008882914553396404
from O 0 8.968046927293472e-08
his O 0 5.889128829039691e-07
mother O 0 9.903847058012616e-06
the O 0 3.73025486055667e-08
frequent O 0 2.664439534783014e-06
0 O 0 1.2628283911908511e-06
- O 0 1.5250117940013297e-05
type O 0 3.5767927784036146e-06
mutation O 0 1.638128082959156e-06
459 O 0 3.843058493657736e-06
+ O 0 2.5501194613752887e-06
1G O 0 0.00011092804925283417
> O 0 1.2504453934525372e-06
A O 0 3.974378444127069e-07
, O 0 4.1749867563112275e-08
and O 0 1.3040962976162973e-08
from O 0 1.0544750850272067e-08
his O 0 2.81535278645606e-07
father O 0 8.855032319843303e-06
a O 0 3.3424211665078474e-07
novel O 0 7.977120617397304e-07
, O 0 2.9059510353590667e-08
single O 0 1.2721537245852232e-07
basepair O 0 5.540573965845397e-06
microdeletion O 0 3.763364475162234e-06
of O 0 2.196005333132689e-08
guanine O 0 3.511413240175898e-07
at O 0 3.5769520678741173e-08
nucleotide O 0 2.030396188956729e-07
7 O 0 1.3907121854117577e-07
in O 0 4.8077730241402605e-08
exon O 0 4.761477612191811e-06
1 O 0 4.554761119379691e-07
( O 0 1.9173732823674072e-07
7delG O 0 1.6584732293267734e-05
) O 0 5.311756581249938e-07
. O 0 8.144546086441551e-07

The O 0 8.218237780965865e-06
two O 0 3.956633463531034e-06
clinically O 0 0.0007229876355268061
unaffected O 0 0.0001142763503594324
siblings O 0 1.722578781482298e-05
carried O 0 7.328188758037868e-07
the O 0 1.1992896986612323e-07
maternal O 0 9.461551235290244e-05
mutation O 0 1.1796662874985486e-05
459 O 0 1.4515723705699202e-05
+ O 0 5.324021458363859e-06
1G O 0 0.0002203152107540518
> O 0 3.952575298171723e-06
A O 0 7.934790460240038e-07
and O 0 5.4231737323107154e-08
, O 0 1.7733356116877985e-08
on O 0 5.33272412894803e-08
their O 0 8.464339629199458e-08
paternal O 0 2.9083994377288036e-05
allele O 0 2.4574455892434344e-06
, O 0 1.7823623466028948e-08
a O 0 6.367466198753391e-08
novel O 0 4.3089369228255237e-07
cytosine O 0 5.103674425299687e-07
to O 0 4.652073926081357e-08
thymidine O 0 1.7531357343614218e-06
transition O 0 1.7225525539288356e-07
at O 0 3.5400770315163754e-08
nucleotide O 0 2.4454448066535406e-07
2435 O 0 4.55734789284179e-06
in O 0 3.3168017665730076e-08
exon O 0 1.3804216223434196e-06
8 O 0 1.7000780871967436e-07
, O 0 1.5435745126524125e-08
resulting O 0 6.794363827111738e-08
in O 0 7.701031812246129e-09
substitution O 0 2.4481952465293944e-08
of O 0 1.1369930774662862e-08
alanine O 0 3.3947083011298673e-06
464 O 0 6.693750492559047e-06
by O 0 2.968805006275943e-07
valine O 0 0.00032567139714956284
( O 0 5.115866770211142e-07
A464V O 0 2.9013299354119226e-05
) O 0 7.280881391125149e-07
. O 0 1.7264204643652192e-06

The O 0 2.1945659682387486e-05
fathers O 0 5.946605961071327e-05
genotype O 0 0.000156328096636571
thus O 0 1.6716101072233869e-06
was O 0 1.4957690837036353e-06
7delG O 0 0.00011092032946180552
/ O 0 0.00013929588021710515
A464V O 0 0.000282854336546734
. O 0 1.3923346159572247e-05

Mutation O 0 0.3353625237941742
A464V O 0 0.002252985490486026
was O 0 8.01999067334691e-06
not O 0 1.5356626192897238e-07
found O 0 1.782388778792665e-07
in O 0 1.6398601587752637e-07
18 O 0 6.351706815621583e-06
unrelated O 0 0.0025106295943260193
MLD B-Disease 1 0.999998927116394
patients O 1 0.9814401865005493
and O 0 7.117505447240546e-07
50 O 0 9.189493539452087e-07
controls O 0 1.554615118948277e-05
. O 0 3.2582115636614617e-06

A464V O 0 0.005113908555358648
, O 0 5.075763056083815e-06
although O 0 4.467077587833046e-07
clearly O 0 4.5998365294508403e-07
modifying O 0 2.584124104032526e-06
ARSA O 0 0.002788156969472766
and O 0 2.736632495725644e-06
GS O 1 0.9998784065246582
levels O 0 1.4001449244460673e-06
, O 0 5.023811411319912e-08
apparently O 0 5.167589165466779e-07
bears O 0 2.793667306377756e-07
little O 0 7.19380679470305e-08
significance O 0 9.695217073613094e-08
for O 0 1.0313932818917237e-07
clinical O 0 3.241772355977446e-05
manifestation O 0 8.897218503989279e-05
of O 0 7.661791414648178e-07
MLD B-Disease 1 0.9999328851699829
, O 0 8.033662197703961e-07
mimicking O 0 7.7224513006513e-06
the O 0 4.3718077336052374e-07
frequent O 0 4.243723378749564e-05
ARSA O 0 0.4124816656112671
pseudodeficiency O 0 0.0075657251290977
allele O 0 9.460594446863979e-05
. O 0 5.265268555376679e-06

Our O 0 1.4925580217095558e-05
results O 0 8.294059625768568e-06
demonstrate O 0 1.3340849136511679e-06
that O 0 3.9550002384203253e-08
in O 0 2.6397186658755345e-08
certain O 0 8.268563078672742e-08
genetic O 0 1.7684551494312473e-05
conditions O 0 0.0005174585967324674
MLD B-Disease 1 0.999969482421875
- O 0 0.009346370585262775
like O 0 2.7020655579690356e-06
ARSA O 0 0.11793778091669083
and O 0 1.3293159781824215e-06
GS O 1 0.9978089928627014
values O 0 1.6656252910252078e-07
need O 0 3.821170579954014e-08
not O 0 7.549603608936195e-09
be O 0 1.042090680414276e-08
paralleled O 0 7.541589752690925e-07
by O 0 1.6301612504321383e-06
clinical O 1 0.6876844167709351
disease O 0 0.025090377777814865
, O 0 5.926511903453502e-08
a O 0 1.2150650263720308e-07
finding O 0 1.0860718191452179e-07
with O 0 1.1929257937026705e-07
serious O 0 5.835299816681072e-05
diagnostic O 0 0.0006772690685465932
and O 0 6.143951395642944e-06
prognostic O 0 0.09641622751951218
implications O 0 0.00010400682367617264
. O 0 1.0822336662386078e-05

Moreover O 0 0.00017941195983439684
, O 0 2.2285239538177848e-06
further O 0 1.1710595799740986e-06
ARSA O 0 0.018372097983956337
alleles O 0 1.716550650598947e-05
functionally O 0 6.317821316770278e-06
similar O 0 2.4797489572847553e-07
to O 0 1.5692262422817294e-07
A464V O 0 6.534974818350747e-05
might O 0 9.079357710106706e-07
exist O 0 4.920368823491117e-08
which O 0 1.8638960597172627e-08
, O 0 9.737449069291415e-09
together O 0 1.9371398707335175e-08
with O 0 7.071194829677552e-08
0 O 0 2.1628147806040943e-06
- O 0 0.0004403270431794226
type O 0 6.539712194353342e-05
mutations O 0 7.67126948630903e-06
, O 0 1.0403235961575774e-07
may O 0 1.8663223499970627e-06
cause O 0 3.6014612305734772e-06
pathological O 0 0.0003620743518695235
ARSA O 1 0.8623664975166321
and O 0 1.8723834728007205e-05
GS O 1 0.9999833106994629
levels O 0 7.318291750380013e-07
, O 0 2.9073646601318615e-08
but O 0 5.386987567135293e-08
not O 0 1.0476773582013266e-07
clinical O 0 1.0332976671634242e-05
outbreak O 0 3.7348793284763815e-06
of O 0 1.0440387399057727e-07
the O 0 1.0461758392921183e-05
disease O 0 0.0062312656082212925
. O 0 1.2366282362563652e-06
. O 0 4.806384822586551e-06

Human O 0 0.008779008872807026
MLH1 O 1 0.9997411370277405
deficiency O 1 0.9996548891067505
predisposes O 0 0.1383170336484909
to O 0 8.51462027640082e-05
hematological B-Disease 1 0.9989343285560608
malignancy I-Disease 1 0.9972690939903259
and O 0 0.00015299880760721862
neurofibromatosis B-Disease 1 0.9983645081520081
type I-Disease 0 9.785331349121407e-05
1 I-Disease 0 6.167621450003935e-06
. O 0 3.2440796076116385e-06

Heterozygous O 0 0.002992507303133607
germ O 0 0.0012528342194855213
- O 0 0.004375044256448746
line O 0 5.723740468965843e-05
mutations O 0 1.0044202099379618e-05
in O 0 6.61259775824874e-08
the O 0 9.224547170560982e-08
DNA O 0 6.24954327577143e-06
mismatch O 0 0.00023246905766427517
repair O 0 0.00046742113772779703
genes O 0 1.0728031156759243e-06
lead O 0 3.119086841252283e-06
to O 0 1.240414803760359e-05
hereditary B-Disease 1 0.9993554949760437
nonpolyposis I-Disease 1 0.9999916553497314
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 0.0001364820054732263

The O 0 0.00017632583330851048
disease O 1 0.5865638256072998
susceptibility O 0 0.004077774006873369
of O 0 2.5068220566026866e-07
individuals O 0 4.281594385702192e-07
who O 0 3.858714080706704e-06
constitutionally O 0 1.7425414625904523e-05
lack O 0 3.634099243754463e-07
both O 0 5.191219187850038e-08
wild O 0 2.033372652476828e-07
- O 0 0.000197135959751904
type O 0 5.6021485761448275e-06
alleles O 0 1.6012587593650096e-06
is O 0 2.0978566794838116e-07
unknown O 0 1.569215783092659e-06
. O 0 1.123543029279972e-06

We O 0 9.497501196165103e-06
have O 0 9.84967755357502e-07
identified O 0 5.831113867316162e-07
three O 0 8.03740363153338e-08
offspring O 0 1.0175895113206934e-06
in O 0 5.6090225797333915e-08
a O 0 1.9994542526546866e-05
hereditary B-Disease 1 0.9998620748519897
nonpolyposis I-Disease 1 0.9999986886978149
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0017729256069287658
who O 0 3.12503325403668e-05
developed O 0 8.476506991428323e-06
hematological B-Disease 1 0.9502315521240234
malignancy I-Disease 0 0.2492242008447647
at O 0 1.0314896314866928e-07
a O 0 2.097488618346688e-07
very O 0 1.2416063555065193e-07
early O 0 5.505791591531306e-07
age O 0 4.71951494773748e-07
, O 0 1.582290565238509e-08
and O 0 1.929396375999204e-08
at O 0 1.4714935048232292e-08
least O 0 1.7706691224361748e-08
two O 0 5.275340164700992e-09
of O 0 2.8430549026126073e-09
them O 0 1.7229346838121273e-08
displayed O 0 3.4204839494123007e-07
signs O 0 1.4398424355022144e-06
of O 0 1.4004051251959027e-07
neurofibromatosis B-Disease 1 0.7948629856109619
type I-Disease 0 1.632266321394127e-05
1 I-Disease 0 1.8763322486847755e-06
( O 0 6.504791940642463e-07
NF1 B-Disease 0 0.00041170636541210115
) O 0 1.045146063916036e-06
. O 0 2.5195085981977172e-06

DNA O 0 0.00026156811509281397
sequence O 0 5.444992893899325e-06
analysis O 0 8.692078381500323e-07
and O 0 8.824449082567298e-08
allele O 0 1.32644890982192e-06
- O 0 8.25883603283728e-07
specific O 0 2.2241975372594425e-08
amplification O 0 1.1910403827641858e-06
in O 0 5.346167242237243e-08
two O 0 1.0926229521146524e-07
siblings O 0 1.14869262688444e-05
revealed O 0 2.3951567982294364e-06
a O 0 8.770348358666524e-07
homozygous O 0 7.115504558896646e-05
MLH1 O 0 0.041612375527620316
mutation O 0 9.319501259597018e-06
( O 0 1.1108944875104498e-07
C676T O 0 1.0005931471823715e-05
- O 0 6.232578016351908e-05
- O 0 0.00018005460151471198
> O 0 1.2051156772940885e-05
Arg226Stop O 0 3.3572032407391816e-05
) O 0 3.0939858675083087e-07
. O 0 8.602970638094121e-07

Thus O 0 4.451715722098015e-05
, O 0 9.323013614448428e-07
a O 0 1.4787942745897453e-06
homozygous O 0 1.3499687156581786e-05
germ O 0 2.8161524824099615e-05
- O 0 0.00010995622869813815
line O 0 3.129515243927017e-05
MLH1 O 0 0.08339668810367584
mutation O 0 1.5665480532334186e-05
and O 0 3.9740561419421283e-07
consequent O 0 0.00544067844748497
mismatch O 1 0.9989522695541382
repair O 1 0.9999788999557495
deficiency O 1 0.9999256134033203
results O 0 4.044989691465162e-05
in O 0 5.210225140217517e-07
a O 0 5.085620432510041e-05
mutator O 1 0.9995879530906677
phenotype O 1 0.988817572593689
characterized O 0 0.00016453902935609221
by O 0 1.9812117898254655e-05
leukemia B-Disease 1 0.9996079802513123
and O 0 0.00024085563200060278
/ O 1 0.9898145198822021
or O 0 0.16144342720508575
lymphoma B-Disease 1 1.0
associated O 0 0.00020055733330082148
with O 0 1.4849975741526578e-05
neurofibromatosis B-Disease 1 0.9973152279853821
type I-Disease 0 1.3862401829101145e-05
1 I-Disease 0 7.446636232089077e-07
. O 0 2.7847562478200416e-07
. O 0 1.360784040116414e-06

Missense O 1 0.9781106114387512
mutations O 1 0.7394291758537292
in O 0 3.5090909022983396e-06
the O 0 1.8307694915620232e-07
most O 0 4.1232077307995496e-08
ancient O 0 5.675410008620929e-08
residues O 0 5.401010838568254e-08
of O 0 8.255669037282587e-09
the O 0 6.848920008906134e-08
PAX6 O 0 0.0005408360157161951
paired O 0 4.236309450789122e-06
domain O 0 5.410330459199031e-07
underlie O 0 1.813491167013126e-06
a O 0 5.20734886322316e-07
spectrum O 0 5.540505298995413e-06
of O 0 3.446324967626424e-07
human O 0 0.0005586170009337366
congenital B-Disease 1 0.9999980926513672
eye I-Disease 1 0.9999903440475464
malformations I-Disease 1 0.9999597072601318
. O 0 0.0001050188802764751

Mutations O 0 0.02797785960137844
of O 0 1.5378989246528363e-06
the O 0 9.741239637151011e-07
human O 0 6.154695256554987e-06
PAX6 O 0 0.4797429144382477
gene O 0 0.00024388237216044217
underlie O 0 0.06550870835781097
aniridia B-Disease 1 0.9999940395355225
( O 0 0.0003699366934597492
congenital B-Disease 1 0.9999326467514038
absence I-Disease 0 3.26210938510485e-05
of I-Disease 0 1.174993471408925e-07
the I-Disease 0 6.371542440319899e-07
iris I-Disease 0 0.08939267694950104
) O 0 1.7885028569253336e-07
, O 0 3.144084459449914e-08
a O 0 6.333623332466232e-07
rare O 0 2.0553035938064568e-05
dominant O 0 0.0004111565067432821
malformation B-Disease 1 0.6950739026069641
of I-Disease 0 2.0418295321178448e-07
the I-Disease 0 2.097559672620264e-06
eye I-Disease 0 0.06733730435371399
. O 0 8.562661605537869e-06

The O 0 4.7681214709882624e-06
spectrum O 0 1.4027769793756306e-05
of O 0 4.4948970412406197e-07
PAX6 O 1 0.8220034241676331
mutations O 0 0.011400331743061543
in O 0 1.0752649359346833e-05
aniridia B-Disease 1 0.9999974966049194
patients O 1 0.9471200108528137
is O 0 2.136690682164044e-07
highly O 0 1.8496349696306424e-07
biased O 0 2.0503423456830205e-06
, O 0 7.588094064203688e-08
with O 0 4.3290697249176446e-08
92 O 0 1.749444663801114e-06
% O 0 1.4886827770510536e-08
of O 0 1.911308666890932e-09
all O 0 2.0824499458171886e-08
reported O 0 1.1138091394968797e-05
mutations O 0 1.3357986290429835e-06
leading O 0 2.3354344591552945e-07
to O 0 2.6011500153799716e-07
premature O 0 6.544397183461115e-05
truncation O 0 2.545131337683415e-06
of O 0 3.2753099787896645e-08
the O 0 2.578048530210708e-08
protein O 0 1.0359772772972065e-07
( O 0 1.4545414650513067e-08
nonsense O 0 4.2808065359167813e-07
, O 0 1.8952350799850137e-08
splicing O 0 2.23098766127805e-07
, O 0 2.416951616623919e-08
insertions O 0 5.412559858086752e-07
and O 0 4.1031864128626694e-08
deletions O 0 7.691155019529106e-07
) O 0 2.5904894229711317e-08
and O 0 9.854017157806538e-09
just O 0 3.528805336827645e-08
2 O 0 6.877719016529227e-08
% O 0 1.66337041918041e-08
leading O 0 1.8287307668174435e-08
to O 0 7.180424255182061e-09
substitution O 0 2.807523102887899e-08
of O 0 6.499853544283951e-09
one O 0 3.878103882470896e-08
amino O 0 1.525736053054061e-07
acid O 0 4.356919873771403e-07
by O 0 3.413659399598146e-08
another O 0 4.3151587192369334e-07
( O 0 4.7263975488931464e-07
missense O 0 2.591696465970017e-05
) O 0 5.814326868858188e-07
. O 0 1.1712315881595714e-06

The O 0 3.6325511700852076e-06
extraordinary O 0 8.314825208799448e-06
conservation O 0 5.484217240336875e-07
of O 0 2.0932457545086436e-08
the O 0 5.296050531455876e-08
PAX6 O 0 0.00011563704902073368
protein O 0 2.9739058504674176e-07
at O 0 1.5422854104940598e-08
the O 0 9.209020213063468e-09
amino O 0 8.14667728832319e-08
acid O 0 5.696351195183524e-07
level O 0 5.128557845068826e-08
amongst O 0 1.0917916881680867e-07
vertebrates O 0 6.60532407437131e-07
predicts O 0 1.1386789992684498e-05
that O 0 1.4687377358768572e-07
pathological O 0 0.00017894094344228506
missense O 0 0.047803349792957306
mutations O 0 2.7500971555127762e-05
should O 0 8.933323414339611e-08
in O 0 2.9563445025360124e-08
fact O 0 6.263464769062921e-08
be O 0 2.8203665181081305e-08
common O 0 4.3188105536273724e-08
even O 0 1.0070092315572765e-07
though O 0 5.5949925581444404e-08
they O 0 1.899795520898806e-08
are O 0 7.59644613879118e-09
hardly O 0 2.24388429614919e-07
ever O 0 3.21028210237273e-07
seen O 0 1.8046837340079946e-06
in O 0 1.5396628896269249e-06
aniridia B-Disease 1 0.9999779462814331
patients O 1 0.7241002917289734
. O 0 8.459547643724363e-06

This O 0 2.2263636765273986e-06
indicates O 0 9.764985406945925e-07
that O 0 3.545773452628964e-08
there O 0 1.5252799911991133e-08
is O 0 8.837397480476739e-09
a O 0 7.33850455958418e-08
heavy O 0 1.3830590432917234e-05
ascertainment O 0 0.00022182526299729943
bias O 0 8.779355084698182e-06
in O 0 1.604255572829061e-08
the O 0 9.543265733213957e-09
selection O 0 5.8342848774373124e-08
of O 0 8.257514849674408e-08
patients O 0 0.00021430765627883375
for O 0 5.107754645905516e-07
PAX6 O 1 0.9458786249160767
mutation O 0 5.136388062965125e-05
analysis O 0 2.071994771313257e-07
and O 0 2.953475863876065e-08
that O 0 2.4465242276505705e-08
the O 0 5.050732809763758e-08
missing O 0 5.6882468015828636e-06
PAX6 O 1 0.633720338344574
missense O 0 0.43531787395477295
mutations O 0 0.00028523715445771813
frequently O 0 1.4768021173949819e-05
may O 0 2.1769006707472727e-05
underlie O 0 0.0006582186324521899
phenotypes O 0 0.0011968092294409871
distinct O 0 1.0085025223816046e-06
from O 0 3.099221714819578e-07
textbook O 0 0.0003376477397978306
aniridia B-Disease 1 0.999804675579071
. O 0 2.553220656409394e-05

Here O 0 1.7655349438427947e-05
we O 0 6.606735496461624e-07
present O 0 2.776170333618211e-07
four O 0 2.568926618096157e-07
novel O 0 4.167678071098635e-06
PAX6 O 0 0.11192842572927475
missense O 0 0.06978470832109451
mutations O 0 6.417275290004909e-05
, O 0 1.1344547345970568e-07
two O 0 8.655650418631922e-08
in O 0 1.2248074199305847e-07
association O 0 1.5729540336906211e-07
with O 0 3.281282090483728e-07
atypical O 0 0.21632081270217896
phenotypes O 1 0.5912102460861206
ectopia B-Disease 0 0.0256207175552845
pupillae I-Disease 0 0.005474196746945381
( O 0 5.283656037136097e-07
displaced B-Disease 0 4.516533863352379e-06
pupils I-Disease 0 2.363309249631129e-06
) O 0 5.234045374891139e-07
and O 0 3.6628749512601644e-05
congenital B-Disease 1 0.9999779462814331
nystagmus I-Disease 1 0.9381218552589417
( O 0 1.80116416004239e-07
searching B-Disease 0 7.586725701003161e-07
gaze I-Disease 0 0.00014400533109437674
) O 0 5.8416116388571027e-08
, O 0 2.1779849035397092e-08
and O 0 1.7999806090074344e-08
two O 0 2.9425393677229295e-08
in O 0 8.126936279495567e-08
association O 0 5.577912176590871e-08
with O 0 3.865269704306229e-08
more O 0 2.355754702421109e-07
recognizable O 0 0.0002655316493473947
aniridia B-Disease 1 0.9997226595878601
phenotypes O 0 0.00781251024454832
. O 0 6.309379386948422e-06

Strikingly O 0 0.16103723645210266
, O 0 3.722071824086015e-06
all O 0 1.2055690490342386e-07
four O 0 3.087898789999599e-07
mutations O 0 1.6590888662904035e-06
are O 0 1.0110272619101579e-08
located O 0 2.9120377220692717e-08
within O 0 1.8160921655407947e-08
the O 0 5.837067362790549e-08
PAX6 O 0 0.00033872309722937644
paired O 0 3.1240049338521203e-06
domain O 0 2.9700794357268023e-07
and O 0 4.753982096872278e-08
affect O 0 8.469071133276884e-08
amino O 0 6.579999478617538e-08
acids O 0 2.2333118465667212e-08
which O 0 7.338823326819011e-09
are O 0 1.6493489907176695e-09
highly O 0 1.6943733527341465e-08
conserved O 0 3.933214287599185e-08
in O 0 9.452776339458069e-09
all O 0 3.1521592003258547e-09
known O 0 4.92663261297821e-08
paired O 0 9.123807558353292e-07
domain O 0 3.3226623941118305e-07
proteins O 0 5.189452281229023e-07
. O 0 8.44225667151477e-07

Our O 0 1.0444851795909926e-05
results O 0 4.245615855325013e-06
support O 0 1.8357049214046128e-07
the O 0 8.492088454659097e-08
hypothesis O 0 1.158181476057507e-06
that O 0 1.0087697788208061e-08
the O 0 5.365440980398262e-09
under O 0 4.3497699664385436e-08
- O 0 1.8933654928332544e-06
representation O 0 1.543500189882252e-07
of O 0 4.866626213129166e-08
missense O 0 0.0034080450423061848
mutations O 0 9.404702723259106e-06
is O 0 6.531720941893582e-08
caused O 0 1.3543314025810105e-06
by O 0 8.215631908115029e-08
ascertainment O 0 0.0005252317641861737
bias O 0 0.0002798604255076498
and O 0 3.153099328301323e-07
suggest O 0 4.259195520717185e-07
that O 0 2.017382705332693e-08
a O 0 1.4535672221427376e-07
substantial O 0 9.510358154329879e-07
burden O 0 4.121417987335008e-06
of O 0 1.1722165993433009e-07
PAX6 B-Disease 1 0.9094571471214294
- I-Disease 1 0.9337965250015259
related I-Disease 0 0.0009747977601364255
disease I-Disease 0 0.0012175500160083175
remains O 0 1.1335456520100706e-06
to O 0 1.4719796581630362e-07
be O 0 8.574837551122982e-08
uncovered O 0 5.0855987865361385e-06
. O 0 3.083366948430921e-07
. O 0 1.266840399694047e-06

The O 0 3.830734385701362e-06
chromosomal O 0 0.00014904541603755206
order O 0 2.670147978278692e-07
of O 0 2.5055832963971625e-08
genes O 0 2.013957782764919e-07
controlling O 0 3.365835823387897e-07
the O 0 2.986814706673613e-08
major O 0 1.7896940107675618e-07
histocompatibility O 0 7.866868691053241e-05
complex O 0 6.53787196824851e-07
, O 0 1.0599461575111491e-07
properdin O 0 7.239336355269188e-06
factor O 0 2.719378642268566e-07
B O 0 1.4785713347009732e-06
, O 0 1.6236280941939185e-07
and O 0 6.178230250952765e-06
deficiency B-Disease 0 0.0007438425091095269
of I-Disease 0 5.36778488324785e-09
the I-Disease 0 9.469252049143506e-09
second I-Disease 0 9.44252676049473e-08
component I-Disease 0 7.696718284933013e-08
of I-Disease 0 3.613673982272303e-08
complement I-Disease 0 2.771805156953633e-06
. O 0 2.6713219085650053e-06

The O 0 1.8026282759819878e-06
relationship O 0 1.111623191718536e-06
of O 0 2.7750154174555064e-08
the O 0 4.032459344216477e-08
genes O 0 2.2500321961160807e-07
coding O 0 6.664753300356097e-07
for O 0 8.653371708078339e-08
HLA O 0 9.986211080104113e-05
to O 0 1.2557845252558764e-07
those O 0 2.0551564006154877e-08
coding O 0 3.740946397101652e-07
for O 0 2.714959812522011e-08
properdin O 0 1.4190227375365794e-05
Factor O 0 1.7955920839085593e-07
B O 0 6.891165185152204e-07
allotypes O 0 9.236145160684828e-06
and O 0 1.6247990686224512e-07
for O 0 7.186729362729238e-07
deficiency B-Disease 0 0.00023395953758154064
of I-Disease 0 5.098952815529856e-09
the I-Disease 0 1.0553362628229479e-08
second I-Disease 0 6.815974984419881e-08
component I-Disease 0 3.339005161251407e-08
of I-Disease 0 6.491019721721614e-09
complement I-Disease 0 1.7948849517779308e-07
( O 0 6.208206571045594e-08
C2 O 0 2.7931828299188055e-05
) O 0 2.818688749073317e-08
was O 0 6.960065945804672e-08
studied O 0 5.752230691769e-08
in O 0 2.2225183471391574e-08
families O 0 5.467918740009736e-08
of O 0 9.989039995161875e-08
patients O 0 0.0026617010589689016
with O 0 4.8473702918272465e-05
connective O 1 0.9996832609176636
tissue O 1 0.999951958656311
disorders O 1 0.99950110912323
. O 0 2.526297430449631e-05

Patients O 1 0.9974913597106934
were O 0 2.418211806798354e-06
selected O 0 2.0781534715297312e-07
because O 0 5.625951260412876e-08
they O 0 2.0510171339083172e-08
were O 0 6.171312350033986e-08
heterozygous O 0 4.394259576656623e-06
or O 0 1.9122656169656693e-07
homozygous O 0 3.223540625185706e-05
for O 0 4.7687513870187104e-05
C2 B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999934434890747
. O 0 2.9005774194956757e-05

12 O 0 6.0883605328854173e-05
families O 0 1.5012998346719542e-06
with O 0 9.599771289003911e-08
15 O 0 6.292287366704841e-07
matings O 0 5.6437136663589627e-05
informative O 0 3.711995668709278e-05
for O 0 0.0021646134555339813
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999966621398926
were O 0 4.556699877866777e-06
found O 0 2.4623955141578335e-06
. O 0 2.184572622354608e-06

Of O 0 2.4266948912554653e-06
57 O 0 1.0303831004421227e-05
informative O 0 3.749997858903953e-06
meioses O 0 3.4451855754014105e-05
, O 0 5.0026027764715764e-08
two O 0 1.9251762850558407e-08
crossovers O 0 9.191140293296485e-07
were O 0 4.605134051871573e-08
noted O 0 1.2442259844647197e-07
between O 0 1.4611809717735014e-07
the O 0 0.00010724888124968857
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999902248382568
gene O 0 4.5622167021974747e-07
and O 0 4.686701160494522e-08
the O 0 1.4066613118757232e-07
HLA O 0 0.007460456341505051
- O 0 0.0011773928999900818
B O 0 5.248753950581886e-06
gene O 0 9.705244963242876e-08
, O 0 8.042123411655666e-09
with O 0 1.0251443249842396e-08
a O 0 1.0074530365500323e-07
recombinant O 0 4.083165663359978e-07
fraction O 0 4.3499073854036396e-07
of O 0 9.13816080583274e-08
0 O 0 4.098277258890448e-06
. O 0 2.278936563016032e-06

035 O 1 0.7416987419128418
. O 0 0.0028033307753503323

A O 0 0.0001093960672733374
lod O 0 0.003894284600391984
score O 0 2.3076941033650655e-06
of O 0 4.680670784296126e-08
13 O 0 2.4241219875875686e-07
was O 0 8.164503384477939e-08
calculated O 0 2.217721117858673e-07
for O 0 3.837472561940558e-08
linkage O 0 5.0063885282725096e-05
between O 0 0.002313049975782633
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999967813491821
and O 0 3.0537219117832137e-06
HLA O 0 0.018814831972122192
- O 0 0.000364676263416186
B O 0 1.594816808392352e-06
at O 0 1.0075814849130893e-08
a O 0 3.8304307281578076e-08
maximum O 0 1.267063538534785e-07
likelihood O 0 5.3972517122247154e-08
value O 0 1.8050817507386796e-09
of O 0 7.440439930839204e-10
the O 0 3.7011178566359604e-09
recombinant O 0 1.798608337821861e-07
fraction O 0 1.780667702178107e-07
of O 0 5.4078761024811683e-08
0 O 0 3.0685462206747616e-06
. O 0 1.4954810012568487e-06

04 O 0 0.09493500739336014
. O 0 0.0004345161432866007

18 O 0 0.00020835635950788856
families O 0 4.1461912587692495e-06
with O 0 1.7103002392104827e-07
21 O 0 7.17857744803041e-07
informative O 0 9.796727908906178e-07
matings O 0 1.4289958926383406e-05
for O 0 1.1668296195921357e-07
both O 0 8.915755955740678e-08
properdin O 0 1.045699082169449e-05
Factor O 0 2.9780551358271623e-07
B O 0 1.0025598840002203e-06
allotype O 0 1.0097226549987681e-05
and O 0 5.824539357490721e-07
HLA O 0 0.0005931733176112175
- O 0 0.0008516840171068907
B O 0 9.262571438739542e-06
were O 0 4.3163319674022205e-07
found O 0 6.354362653837597e-07
. O 0 1.2298703495616792e-06

Of O 0 5.455549398902804e-06
72 O 0 1.568905463500414e-05
informative O 0 9.300340934714768e-06
meioses O 0 0.00010048952390206978
, O 0 1.7843053967681044e-07
three O 0 7.273276025898667e-08
recombinants O 0 2.6548254027147777e-05
were O 0 9.125968603029833e-08
found O 0 4.0141269863624984e-08
, O 0 1.0653595339249478e-08
giving O 0 3.494125166980666e-08
a O 0 8.464630241178384e-08
recombinant O 0 4.2533056898719224e-07
fraction O 0 4.586743216350442e-07
of O 0 8.716502009065152e-08
0 O 0 4.009737040178152e-06
. O 0 2.395650199105148e-06

042 O 0 0.028520923107862473
. O 0 0.0004519537906162441

A O 0 4.957520650350489e-05
lod O 0 0.001281730830669403
score O 0 1.4940924302209169e-06
of O 0 5.284366011437669e-08
16 O 0 3.850839789265592e-07
between O 0 1.1078411432663415e-07
HLA O 0 0.00019980761862825602
- O 0 0.00012137430894654244
B O 0 1.8238770280731842e-06
and O 0 5.04584072302805e-08
Factor O 0 7.708794669269992e-08
B O 0 3.506410450881958e-07
allotypes O 0 3.4599756872921716e-06
was O 0 7.004867796922554e-08
calculated O 0 6.815988484731861e-08
at O 0 5.108736100822853e-09
a O 0 3.40848700375318e-08
maximum O 0 2.0126213939875015e-07
likelihood O 0 8.223251057870584e-08
value O 0 3.605135301398832e-09
of O 0 1.0490741608748522e-09
the O 0 6.43887299034418e-09
recombinant O 0 3.3046495673261234e-07
fraction O 0 4.0719703520153416e-07
of O 0 1.0240503200975581e-07
0 O 0 3.59670730176731e-06
. O 0 1.9919959868275328e-06

04 O 0 0.0498754121363163
. O 0 0.00022530333080794662

A O 0 2.407474494248163e-05
crossover O 0 2.230966492788866e-05
was O 0 1.8039661426882958e-06
shown O 0 5.449062996376597e-07
to O 0 4.639827722030532e-08
have O 0 3.393787295635775e-08
occurred O 0 8.52950634566696e-08
between O 0 1.1186058301859703e-08
genes O 0 3.424987937705737e-08
for O 0 7.705028615134779e-09
Factor O 0 5.820368897957451e-08
B O 0 5.17364924235153e-07
and O 0 2.292465808295674e-07
HLA O 0 0.0061781806871294975
- O 0 0.03767680004239082
D O 0 0.01432755310088396
, O 0 5.684911386083513e-08
in O 0 3.3499006235615525e-08
which O 0 2.007403736570268e-07
HLA O 0 0.000831856275908649
- O 0 0.010037001222372055
D O 0 0.0007422853959724307
segregared O 0 1.6717149264877662e-05
with O 0 1.7279904795941547e-07
HLA O 0 0.00019044381042476743
- O 0 1.9531285943230614e-05
A O 0 5.598991720034974e-06
and O 0 1.4409866935238824e-06
B O 0 1.1347580766596366e-05
. O 0 1.8876791045840946e-06

These O 0 1.0658517567208037e-05
studies O 0 2.3207419417303754e-06
suggest O 0 6.226112532203842e-07
that O 0 1.3111770336138306e-08
the O 0 6.918213113493721e-09
genes O 0 2.8543144736659087e-08
for O 0 1.2691963924282845e-08
Factor O 0 2.5973173478632816e-07
B O 0 5.175763362785801e-05
and O 0 0.030288005247712135
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999973773956299
are O 0 3.3817102007560607e-08
located O 0 1.613904743180683e-08
outside O 0 2.7279625669507368e-08
those O 0 7.822484882069602e-09
for O 0 3.1355028795587714e-08
HLA O 0 0.0038685163017362356
, O 0 7.315068728530605e-08
that O 0 1.0925287341478906e-08
the O 0 5.838868499807859e-09
order O 0 7.917925870515319e-09
of O 0 6.220981507709666e-09
genese O 0 1.672344842518214e-05
is O 0 1.258237176671173e-07
HLA O 0 5.890482498216443e-05
- O 0 1.8291921151103452e-05
A O 0 1.3138378562871367e-06
, O 0 8.299341658357662e-08
- O 0 2.3961504211911233e-06
B O 0 1.0092164757224964e-06
, O 0 5.652367462971597e-08
- O 0 6.688007943012053e-06
D O 0 3.2957679650280625e-05
, O 0 2.985441938108124e-08
Factor O 0 7.609472163494502e-08
B O 0 1.771137135619938e-06
allotype O 0 0.00528124812990427
, O 0 0.006513911299407482
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999974966049194
, O 0 1.0607369205217765e-07
that O 0 1.1338832095475482e-08
the O 0 1.6356283438767605e-08
genes O 0 2.205370321917144e-07
coding O 0 4.7386738515342586e-06
for O 0 5.1342380174901336e-05
C2 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999653100967407
and O 0 1.7905406934914936e-07
Factor O 0 2.3236641766288813e-07
B O 0 1.326136498391861e-06
allotypes O 0 9.182596841128543e-06
are O 0 1.4349958554760178e-08
approximately O 0 2.79141882941758e-08
3 O 0 5.526972657321494e-08
- O 0 3.6110393466515234e-06
- O 0 7.078710495989071e-06
5 O 0 1.0476533418568579e-07
centimorgans O 0 1.3941703400632832e-06
from O 0 1.4526617242438533e-08
the O 0 2.0507080478182615e-08
HLA O 0 4.7111785534070805e-05
- O 0 1.5758680092403665e-05
A O 0 2.472787400620291e-06
and O 0 2.6138070552406134e-07
HLA O 0 0.0001988614531001076
- O 0 9.142579074250534e-05
B O 0 1.9505077943904325e-06
loci O 0 1.5077492321324826e-07
, O 0 2.4295973233279256e-08
and O 0 1.7284115472193662e-08
that O 0 1.5994769952953902e-08
the O 0 1.665008397822021e-08
apparent O 0 2.43834733737458e-06
lack O 0 1.0581019438404837e-07
of O 0 2.6793149032755537e-08
recombinants O 0 4.095006443094462e-05
between O 0 2.5343400267274774e-08
the O 0 1.2634383317333686e-08
Factor O 0 8.221134351060755e-08
B O 0 8.892487244338554e-07
gene O 0 1.434208570572082e-06
and O 0 0.0004966137930750847
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999986886978149
gene O 0 3.2571583687968086e-06
suggests O 0 3.4876043741860485e-07
that O 0 6.778324124212531e-09
these O 0 1.4561728489681514e-09
two O 0 1.0388321314280802e-08
genes O 0 5.413727421910153e-08
lie O 0 3.0130038908282586e-07
in O 0 7.408524904661817e-09
close O 0 3.1685747359233574e-08
proximity O 0 7.146569913629719e-08
to O 0 3.611565091432567e-08
one O 0 6.432394172861677e-08
another O 0 8.979872063719085e-07
. O 0 1.471287987442338e-06

Distribution O 0 8.11151767265983e-06
of O 0 4.3045832853749744e-07
emerin O 0 5.760488420492038e-05
and O 0 3.646169375315367e-07
lamins O 0 0.0002822691749315709
in O 0 9.768295683443284e-08
the O 0 1.043350081886274e-07
heart O 0 0.0002489335311111063
and O 0 1.457980829400185e-07
implications O 0 1.3565702374762623e-06
for O 0 6.5277481553494e-07
Emery B-Disease 0 0.08045495301485062
- I-Disease 1 0.9880175590515137
Dreifuss I-Disease 1 0.9999202489852905
muscular I-Disease 1 0.9999332427978516
dystrophy I-Disease 1 0.9999223947525024
. O 0 3.391380232642405e-05

Emerin O 0 0.0040672277100384235
is O 0 2.588252755231224e-06
a O 0 6.52901803732675e-07
nuclear O 0 1.0134193644262268e-06
membrane O 0 1.2543879392978852e-06
protein O 0 1.748656330846643e-07
which O 0 2.3953177219482313e-08
is O 0 1.302127827784716e-08
missing O 0 1.8968721349210682e-07
or O 0 6.286384746090334e-08
defective O 0 2.985377432196401e-05
in O 0 2.9933105452073505e-06
Emery B-Disease 0 0.47840872406959534
- I-Disease 1 0.9993358254432678
Dreifuss I-Disease 1 0.9999783039093018
muscular I-Disease 1 0.999992847442627
dystrophy I-Disease 1 0.999990701675415
( O 0 3.9890761399874464e-05
EDMD B-Disease 1 0.9997825026512146
) O 0 4.592153800331289e-06
. O 0 3.968075816374039e-06

It O 0 4.546187483356334e-06
is O 0 1.536979823413276e-07
one O 0 5.715702755537677e-08
member O 0 1.9456640742987474e-08
of O 0 4.655009711029834e-09
a O 0 2.7975198690910474e-07
family O 0 4.056396960550046e-07
of O 0 4.9943274404995464e-08
lamina O 0 0.0019620454404503107
- O 0 0.011736571788787842
associated O 0 5.732318300033512e-07
proteins O 0 3.1465084759929596e-08
which O 0 1.8066394602556102e-08
includes O 0 1.1310281422538537e-07
LAP1 O 0 7.133842882467434e-05
, O 0 2.0489845553584018e-07
LAP2 O 0 3.550911424099468e-05
and O 0 5.823177957609005e-07
lamin O 0 0.0032523940317332745
B O 0 4.563355469144881e-05
receptor O 0 1.2346225048531778e-05
( O 0 1.2367709132377058e-06
LBR O 0 0.002473954576998949
) O 0 1.6821630879348959e-06
. O 0 1.8478010588296456e-06

A O 0 4.625491419574246e-05
panel O 0 1.115464237955166e-05
of O 0 2.3442440522103425e-07
16 O 0 8.429706213064492e-07
monoclonal O 0 7.537393230450107e-06
antibodies O 0 4.675327090808423e-06
( O 0 1.1966928070705762e-07
mAbs O 0 5.747323939431226e-06
) O 0 2.805997389998538e-08
has O 0 3.843802076630709e-08
been O 0 1.7030890475666638e-08
mapped O 0 2.1209365286267712e-07
to O 0 1.9396576789176834e-08
six O 0 2.884612904097139e-08
specific O 0 5.764638988381421e-09
sites O 0 1.2194665721665388e-08
throughout O 0 8.592728306666686e-09
the O 0 1.0495550206712778e-08
emerin O 0 1.2220440339660854e-06
molecule O 0 9.144402923766393e-08
using O 0 3.78380491383723e-08
phage O 0 1.4090688864598633e-06
- O 0 1.3051123914920026e-06
displayed O 0 2.3662042281102913e-07
peptide O 0 1.1447620806848136e-07
libraries O 0 1.2019719441980214e-08
and O 0 6.636780458535441e-09
has O 0 1.9785968419228084e-08
been O 0 5.5241451413223785e-09
used O 0 1.1896056584248527e-08
to O 0 2.566856416308383e-08
localize O 0 4.913311386189889e-06
emerin O 0 0.0001276646798942238
in O 0 1.199841079824182e-07
human O 0 1.6982129125153733e-07
and O 0 7.496986427213415e-07
rabbit O 0 0.002884022193029523
heart O 0 0.06201982870697975
. O 0 4.508662186708534e-06

Several O 0 1.7002455933834426e-05
mAbs O 0 0.0001629960461286828
against O 0 1.0371115877205739e-06
different O 0 1.5273185738351458e-07
emerin O 0 2.8369295250740834e-05
epitopes O 0 0.00014488793385680765
did O 0 8.031157108234765e-07
not O 0 7.24112112493458e-08
recognize O 0 2.9227169306977885e-07
intercalated O 0 1.2448504094209056e-05
discs O 0 9.724439587444067e-05
in O 0 9.633870945435774e-08
the O 0 9.430053893311197e-08
heart O 0 0.0007931427098810673
, O 0 9.765035002828881e-08
though O 0 7.186647366097532e-08
they O 0 1.7625685799771418e-08
recognized O 0 3.2976004149531946e-08
cardiomyocyte O 0 2.9458467452059267e-06
nuclei O 0 8.640249689051416e-07
strongly O 0 3.8064155205574934e-07
, O 0 1.7062950163904134e-08
both O 0 8.522217598283532e-09
at O 0 6.177339972879281e-09
the O 0 7.002487478757757e-09
rim O 0 5.258837063593091e-07
and O 0 4.341564263654618e-08
in O 0 4.027256039762506e-08
intranuclear O 0 5.425402196124196e-05
spots O 0 3.3391504530300153e-06
or O 0 2.724126204611821e-07
channels O 0 3.87012050850899e-06
. O 0 1.8730195279204054e-06

A O 0 0.00011125093442387879
polyclonal O 0 0.0008138116099871695
rabbit O 0 0.00042993653914891183
antiserum O 0 0.00047213202924467623
against O 0 5.249014066066593e-06
emerin O 0 0.000284853158518672
did O 0 1.086375846170995e-06
recognize O 0 1.606074846449701e-07
both O 0 2.0886673723907734e-08
nuclear O 0 1.1119502829615158e-07
membrane O 0 2.9345844154704537e-07
and O 0 3.713395102522554e-08
intercalated O 0 2.613729975564638e-06
discs O 0 1.5197243556031026e-05
but O 0 3.936952097660651e-08
, O 0 6.232085958401967e-09
after O 0 1.8520172062608253e-08
affinity O 0 4.1962227470548896e-08
purification O 0 2.082180543538925e-07
against O 0 1.924053094626288e-08
a O 0 6.530674312443807e-08
pure O 0 2.1918337722581782e-07
- O 0 3.859913704218343e-06
emerin O 0 1.4925336472515482e-05
band O 0 1.675769993880749e-07
on O 0 2.717068170454695e-08
a O 0 1.203084849521474e-07
western O 0 1.9304607690173725e-07
blot O 0 0.00017961546836886555
, O 0 7.448711158986043e-08
it O 0 3.479513921433863e-08
stained O 0 2.0493984266067855e-05
only O 0 6.719730549775704e-08
the O 0 7.236592125536845e-08
nuclear O 0 3.8356911318260245e-06
membrane O 0 1.8681706933421083e-05
. O 0 3.998914962721756e-06

These O 0 1.0169774213864002e-05
results O 0 7.288089818757726e-06
would O 0 2.661861913111352e-07
not O 0 3.138195481255934e-08
be O 0 1.547548222902151e-08
expected O 0 1.8505807020119391e-07
if O 0 3.252202773751378e-08
immunostaining O 0 3.2590382943453733e-06
at O 0 3.105641965817085e-08
intercalated O 0 2.575766075096908e-06
discs O 0 4.502814408624545e-05
were O 0 8.587521449499036e-08
due O 0 6.250314044109473e-08
to O 0 2.7904127009037438e-08
a O 0 9.877768292199107e-08
product O 0 3.0308079601581994e-08
of O 0 6.30600505147072e-09
the O 0 2.4920382202253677e-08
emerin O 0 3.636655674199574e-05
gene O 0 2.6102372885361547e-07
and O 0 2.552449451798111e-08
, O 0 1.955747030990551e-08
therefore O 0 2.9561753933649015e-08
, O 0 5.883832532305178e-09
cast O 0 1.5902301697678922e-07
some O 0 1.4909845802435484e-08
doubt O 0 1.886921836558031e-07
upon O 0 2.8151855957503358e-08
the O 0 2.1818767237391512e-08
hypothesis O 0 1.7028314687195234e-06
that O 0 8.42815495616378e-07
cardiac B-Disease 1 0.9996222257614136
defects I-Disease 1 0.9987350106239319
in O 0 1.3462929928209633e-05
EDMD B-Disease 1 0.9999967813491821
are O 0 5.429791940514406e-07
caused O 0 2.3254517600435065e-06
by O 0 3.204359799724443e-08
absence O 0 1.5869790104261483e-07
of O 0 2.4894442063327915e-08
emerin O 0 6.20971986791119e-05
from O 0 2.1442436093366268e-07
intercalated O 0 2.0385898096719757e-05
discs O 0 0.00042626538197509944
. O 0 3.523412715367158e-06

Although O 0 5.8919151342706755e-05
emerin O 0 0.0003292327164672315
was O 0 1.024826588036376e-06
abundant O 0 1.8131058254766685e-07
in O 0 3.032600304209154e-08
the O 0 1.2478236222079886e-08
membranes O 0 4.7409878334292443e-07
of O 0 2.356171968642684e-08
cardiomyocyte O 0 7.123556133592501e-05
nuclei O 0 2.4062492229859345e-06
, O 0 4.115389984349349e-08
it O 0 2.4298660861177268e-08
was O 0 9.26399010836576e-08
absent O 0 1.679502474871697e-07
from O 0 1.2369421931168745e-08
many O 0 1.1735081351105237e-08
non O 0 1.4291155991941196e-07
- O 0 0.00010335392289562151
myocyte O 0 0.45525842905044556
cells O 0 6.556674179591937e-06
in O 0 7.239063393171818e-08
the O 0 1.9688904728809575e-07
heart O 0 0.0009389091283082962
. O 0 3.6255078157410026e-06

This O 0 1.2276835832381039e-06
distribution O 0 2.7708696848094405e-07
of O 0 4.237571715748345e-08
emerin O 0 6.45446780254133e-05
was O 0 5.869655979040544e-07
similar O 0 8.000008477893061e-08
to O 0 2.3793031544983023e-08
that O 0 1.9885396440599834e-08
of O 0 2.7841130290084948e-08
lamin O 0 0.0017742823110893369
A O 0 7.356901733146515e-06
, O 0 6.423199039318206e-08
a O 0 1.7504882521279796e-07
candidate O 0 6.308449655989534e-07
gene O 0 1.6186682216812187e-07
for O 0 2.6593264479402023e-08
an O 0 4.0526424527342897e-07
autosomal O 0 0.004932967014610767
form O 0 1.723068180581322e-06
of O 0 6.8586717816288e-07
EDMD B-Disease 1 0.9998724460601807
. O 0 1.455724395782454e-05

In O 0 2.219979251094628e-05
contrast O 0 4.073518721270375e-05
, O 0 1.9132046418235404e-06
lamin O 0 0.09461579471826553
B1 O 0 0.017565466463565826
was O 0 1.0671938071027398e-06
absent O 0 5.034007699578069e-07
from O 0 2.5220485255772473e-08
cardiomyocyte O 0 4.791177161678206e-06
nuclei O 0 1.4687226439491496e-06
, O 0 5.4800196380710986e-08
showing O 0 4.610398605109367e-07
that O 0 1.2496151668983657e-07
lamin O 0 0.03613843396306038
B1 O 0 0.013516982086002827
is O 0 5.6162377859436674e-08
not O 0 8.445419474867322e-09
essential O 0 1.2766574464251335e-08
for O 0 7.193049267328888e-09
localization O 0 1.7377786321048916e-07
of O 0 1.1374985398049375e-08
emerin O 0 9.403842341271229e-06
to O 0 1.0664618343980692e-07
the O 0 9.466673134284065e-08
nuclear O 0 6.277904958551517e-06
lamina O 0 0.0009355853544548154
. O 0 5.5788336794648785e-06

Lamin O 1 0.995342493057251
B1 O 1 0.9953839182853699
is O 0 5.559400506172096e-06
also O 0 3.3772118968045106e-07
almost O 0 1.3967517986657185e-07
completely O 0 4.849544552598672e-07
absent O 0 1.3646100569530972e-06
from O 0 3.664292762550758e-07
skeletal O 0 0.0019902370404452085
muscle O 0 0.001621286734007299
nuclei O 0 0.00016615123604424298
. O 0 4.3658551476255525e-06

In O 0 7.865772204240784e-05
EDMD B-Disease 1 0.998685896396637
, O 0 6.566922365891514e-07
the O 0 3.223092193138655e-08
additional O 0 5.59240014297302e-08
absence O 0 3.2426086704617774e-07
of O 0 8.536586193486073e-08
lamin O 1 0.826747477054596
B1 O 0 0.34572380781173706
from O 0 3.837056112843129e-07
heart O 0 7.012247806414962e-05
and O 0 2.0702606207123608e-07
skeletal O 0 0.0014815967297181487
muscle O 0 0.00015136576257646084
nuclei O 0 7.104476480890298e-06
which O 0 1.8306367621789832e-07
already O 0 4.154738917350187e-07
lack O 0 6.782412356187706e-07
emerin O 0 0.06512317061424255
may O 0 8.099041224340908e-06
offer O 0 2.2970746726969082e-07
an O 0 3.844359142135545e-08
alternative O 0 2.2435976632095844e-07
explanation O 0 2.871381923341687e-07
of O 0 9.005633572201077e-09
why O 0 1.2467964438656054e-07
these O 0 1.777267044644759e-08
tissues O 0 9.57504539655929e-07
are O 0 2.9802933454448066e-08
particularly O 0 5.697850724573073e-07
affected O 0 1.0829456869032583e-06
. O 0 2.7772216526500415e-07
. O 0 1.119345256483939e-06

Genetic O 0 0.001116436324082315
mapping O 0 4.049906783620827e-05
of O 0 5.031282057643693e-07
the O 0 7.465999374289822e-07
copper B-Disease 0 9.146617230726406e-05
toxicosis I-Disease 0 0.003080886323004961
locus O 0 1.1270273716945667e-05
in O 0 3.08538488980048e-07
Bedlington O 0 9.04634998732945e-06
terriers O 0 5.529847840080038e-06
to O 0 2.1283078410760936e-07
dog O 0 1.2194048395031132e-05
chromosome O 0 1.520594105386408e-05
10 O 0 7.974688998046986e-08
, O 0 1.707226182645627e-08
in O 0 1.847409869526473e-08
a O 0 3.1779597975400975e-07
region O 0 3.911287649316364e-07
syntenic O 0 9.840614802669734e-05
to O 0 3.2042200359683193e-07
human O 0 3.336373595175246e-07
chromosome O 0 2.338289050385356e-05
region O 0 1.1145996268169256e-06
2p13 O 0 0.00010111605661222711
- O 0 0.00025701720733195543
p16 O 0 0.0001973727485165
. O 0 4.621986590791494e-06

Abnormal O 1 0.9942646622657776
hepatic B-Disease 1 0.9995463490486145
copper I-Disease 0 0.08763056993484497
accumulation I-Disease 0 0.0001080885122064501
is O 0 5.911597895646992e-07
recognized O 0 1.2360818857359845e-07
as O 0 8.352223090923871e-08
an O 0 1.2955183592566755e-05
inherited B-Disease 1 0.9999986886978149
disorder I-Disease 1 0.9999934434890747
in O 0 6.355902542054537e-07
man O 0 2.94293713523075e-05
, O 0 9.981155102423145e-08
mouse O 0 2.944641892099753e-06
, O 0 1.3029904266659287e-07
rat O 0 3.378426481503993e-05
and O 0 3.3988794712058734e-07
dog O 0 2.6137618988286704e-05
. O 0 3.667687678898801e-06

The O 0 4.006931703770533e-06
major O 0 1.6514295566594228e-06
cause O 0 6.931741609150777e-06
of O 0 3.3877441296681354e-07
hepatic B-Disease 1 0.8029379844665527
copper I-Disease 0 0.018289903178811073
accumulation I-Disease 0 1.0001075679610949e-05
in O 0 1.62985529073012e-07
man O 0 3.2451316656079143e-06
is O 0 4.0026737480047814e-08
a O 0 6.583878757737693e-07
dysfunctional O 0 4.2345265683252364e-05
ATP7B O 0 0.0020349854603409767
gene O 0 4.17404180552694e-06
, O 0 5.681512789124099e-07
causing O 0 0.00011274576536379755
Wilson B-Disease 0 0.039511263370513916
disease I-Disease 0 0.13633014261722565
( O 0 5.770461484644329e-06
WD B-Disease 1 0.5537612438201904
) O 0 1.9997942217742093e-06
. O 0 1.7842726265371311e-06

Mutations O 0 0.26485195755958557
in O 0 3.2285272482113214e-06
the O 0 4.296528004488209e-07
ATP7B O 0 0.0019046746892854571
genes O 0 2.0194136141071795e-06
have O 0 1.4945413795430795e-07
also O 0 1.1034758529149258e-07
been O 0 9.787896715351962e-08
demonstrated O 0 9.641863698561792e-07
in O 0 1.3280661903536384e-07
mouse O 0 9.96500239125453e-06
and O 0 1.222302671521902e-06
rat O 0 0.0010241918498650193
. O 0 4.257527962181484e-06

The O 0 1.1265127795923036e-05
ATP7B O 0 0.0008579145069234073
gene O 0 1.1996369721600786e-05
has O 0 6.722306125084287e-07
been O 0 1.3457049874432414e-07
excluded O 0 1.4611056542435108e-07
in O 0 2.235110052595246e-08
the O 0 1.6254276147265045e-08
much O 0 1.7634201299188135e-07
rarer O 0 9.23836778383702e-05
human O 0 3.819352514256025e-06
copper B-Disease 0 0.07513720542192459
overload I-Disease 1 0.9900535345077515
disease O 0 0.0037108580581843853
non B-Disease 0 9.717115290186484e-07
- I-Disease 0 4.426574378157966e-05
Indian I-Disease 0 4.598209670803044e-06
childhood I-Disease 0 0.0015065897023305297
cirrhosis I-Disease 0 0.48778975009918213
, O 0 5.309918265083979e-07
indicating O 0 8.206005077227019e-06
genetic O 0 1.4321639355330262e-05
heterogeneity O 0 0.00017505986033938825
. O 0 8.423562576354016e-06

By O 0 8.800672731013037e-06
investigating O 0 1.1662777069432195e-05
the O 0 1.2240827800269471e-06
common O 0 2.5905450456775725e-05
autosomal O 1 0.976642370223999
recessive O 1 0.9962816834449768
copper B-Disease 1 0.8663387298583984
toxicosis I-Disease 1 0.9908491373062134
( O 0 7.439537625941739e-07
CT B-Disease 0 0.020492522045969963
) O 0 6.355708848104769e-08
in O 0 5.144713455251804e-08
Bedlington O 0 1.883278673631139e-05
terriers O 0 1.955376319529023e-05
, O 0 1.281671728747824e-07
we O 0 2.6633163230371792e-08
have O 0 1.517891057289944e-08
identified O 0 3.5898768402375936e-08
a O 0 3.9688970332463214e-08
new O 0 1.2909727331589238e-07
locus O 0 2.7181363293493632e-06
involved O 0 5.27526253790711e-07
in O 0 3.024931402251241e-06
progressive O 1 0.9996192455291748
liver B-Disease 1 0.9999998807907104
disease I-Disease 1 0.999987006187439
. O 0 4.130753222852945e-05

We O 0 6.660917279077694e-06
examined O 0 1.829108441597782e-05
whether O 0 4.35069125614973e-07
the O 0 2.352927879201161e-07
WD B-Disease 0 0.07367914915084839
gene O 0 2.789476639009081e-06
ATP7B O 0 7.512624870287254e-05
was O 0 3.81877043764689e-07
also O 0 1.061753067688187e-07
causative O 0 6.598625077458564e-07
for O 0 8.433495679582848e-08
CT B-Disease 0 0.28337475657463074
by O 0 6.452201972706462e-08
investigating O 0 3.486204320779507e-07
the O 0 8.52166834874879e-08
chromosomal O 0 7.524267857661471e-05
co O 0 5.818448698846623e-06
- O 0 3.1885988391877618e-06
localization O 0 8.655218266540032e-07
of O 0 3.214644195281835e-08
ATP7B O 0 0.00010282886069035158
and O 0 1.2878014388206793e-07
C04107 O 0 4.572776560962666e-06
, O 0 1.99247676135883e-08
using O 0 3.22838360489186e-08
fluorescence O 0 1.2254237162778736e-06
in O 0 5.3300805546996344e-08
situ O 0 7.79717265686486e-06
hybridization O 0 2.253630327686551e-06
( O 0 1.9998236666651792e-07
FISH O 0 3.9428104514627194e-07
) O 0 4.5387653813122597e-07
. O 0 1.6064623196143657e-06

C04107 O 0 0.002960857469588518
is O 0 1.6389077472922509e-06
an O 0 2.331555464252233e-07
anonymous O 0 1.8198772977484623e-06
microsatellite O 0 9.230847354047e-05
marker O 0 1.1108686521765776e-05
closely O 0 1.450688387194532e-06
linked O 0 3.14017938762845e-06
to O 0 2.148596649931278e-06
CT B-Disease 1 0.9495351910591125
. O 0 8.8683173089521e-06

However O 0 2.7682926884153858e-05
, O 0 1.1599511253734818e-06
BAC O 0 2.7429807232692838e-05
clones O 0 1.799303163352306e-06
containing O 0 2.6504653760639485e-07
ATP7B O 0 2.4761482563917525e-05
and O 0 1.3860289982403629e-07
C04107 O 0 5.736995262850542e-06
mapped O 0 1.2971399883099366e-06
to O 0 3.781237012390193e-08
the O 0 2.6296682165138918e-08
canine O 0 7.713140803389251e-06
chromosome O 0 1.7219630535691977e-05
regions O 0 2.1638575731230958e-07
CFA22q11 O 0 1.3254917575977743e-05
and O 0 1.838615162341739e-07
CFA10q26 O 0 4.887810064246878e-05
, O 0 9.310168991305545e-08
respectively O 0 1.58461375576735e-07
, O 0 1.150597572774359e-08
demonstrating O 0 2.0086771712612972e-07
that O 0 1.6092546673007746e-07
WD B-Disease 0 0.05827629566192627
cannot O 0 6.104058911660104e-07
be O 0 3.157546402121625e-08
homologous O 0 3.300995956578845e-07
to O 0 1.088478938982007e-06
CT B-Disease 1 0.7683297395706177
. O 0 7.402506525977515e-06

The O 0 1.0517530427023303e-05
copper O 0 1.6154486729647033e-05
transport O 0 1.511751975158404e-06
genes O 0 6.167624064801203e-07
CTR1 O 0 3.8749538362026215e-05
and O 0 4.524287646745506e-07
CTR2 O 0 0.0009158154134638608
were O 0 2.128169853676809e-07
also O 0 9.833348713073065e-08
excluded O 0 9.49019280938046e-08
as O 0 1.707453911592438e-08
candidate O 0 2.197055266606185e-07
genes O 0 9.311483495366701e-08
for O 0 1.0952540208108985e-07
CT B-Disease 1 0.9740071296691895
since O 0 7.774975756547065e-07
they O 0 2.3272518134831444e-08
both O 0 7.971202364842611e-09
mapped O 0 4.618791251687071e-07
to O 0 1.3071610283077462e-07
canine O 0 3.130318145849742e-05
chromosome O 0 0.00014041998656466603
region O 0 3.0953929126553703e-06
CFA11q22 O 0 0.00022701217676512897
. O 0 4.1516909732308704e-06

2 O 0 0.00020410658908076584
- O 0 0.001118766376748681
22 O 0 3.3856249501695856e-05
. O 0 3.6453286611504154e-06

5 O 0 0.0005927659221924841
. O 0 6.506625504698604e-05

A O 0 5.2945262723369524e-05
transcribed O 0 1.800895552150905e-05
sequence O 0 1.7756341321728542e-06
identified O 0 4.1705067133079865e-07
from O 0 7.444305172299437e-09
the O 0 8.530380846138996e-09
C04107 O 0 2.4981402475532377e-06
- O 0 3.073472271353239e-06
containing O 0 3.821462826181232e-07
BAC O 0 1.6342584785888903e-05
was O 0 1.287424424845085e-07
found O 0 2.1126510318936198e-08
to O 0 9.602240780282045e-09
be O 0 8.861822387018492e-09
homologous O 0 6.291086407372859e-08
to O 0 4.712256185257502e-08
a O 0 4.995837912247225e-07
gene O 0 5.548656645260053e-07
expressed O 0 1.756870346980577e-07
from O 0 2.6142652487237683e-08
human O 0 8.950702579113567e-08
chromosome O 0 1.5575829820591025e-05
2p13 O 0 2.7146312277182005e-05
- O 0 1.0533420208957978e-05
p16 O 0 6.77106436342001e-06
, O 0 3.197808595700735e-08
a O 0 5.256199742120771e-08
region O 0 8.228946768440437e-08
devoid O 0 2.2930210263893969e-07
of O 0 7.82376741170765e-09
any O 0 2.8326962109304077e-08
positional O 0 1.1893744158442132e-05
candidate O 0 1.4199080396792851e-05
genes O 0 4.2846072574320715e-06
. O 0 2.6529410206421744e-06

Molecular O 0 0.0003157058672513813
analysis O 0 5.123706614540424e-06
of O 0 1.2100117885438522e-07
the O 0 9.745572526753676e-08
APC B-Disease 0 4.303148671169765e-06
gene O 0 4.6126240249577677e-07
in O 0 5.9113954620215736e-08
205 O 0 1.136351102104527e-06
families O 0 3.803251047429512e-07
: O 0 1.8204207208327716e-07
extended O 0 3.056997002204298e-06
genotype O 0 0.0009693528991192579
- O 0 0.0009997701272368431
phenotype O 0 0.0012077050050720572
correlations O 0 1.7907403844219516e-06
in O 0 2.3255087455709145e-07
FAP B-Disease 0 0.001041500479914248
and O 0 1.2552915222840966e-06
evidence O 0 4.411658949265984e-07
for O 0 2.2214333483816517e-08
the O 0 1.2392989745535488e-08
role O 0 3.606278653478512e-08
of O 0 1.5303680100942074e-08
APC B-Disease 0 2.5942058528016787e-06
amino O 0 2.5247709345421754e-07
acid O 0 6.794803653065173e-07
changes O 0 7.489690005968441e-07
in O 0 0.0002565300674177706
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9962645173072815
. O 0 3.8486374251078814e-05

BACKGROUND O 0 0.013781048357486725
/ O 0 0.0007782903267070651
AIMS O 0 1.8990014723385684e-05
The O 0 2.863964994048729e-07
development O 0 2.488058896688017e-07
of O 0 4.5442309783538803e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 3.0487954063573852e-06
a O 0 2.7151518224854954e-06
variable O 0 2.666931095518521e-06
range O 0 1.215398839349291e-07
of O 0 3.887331700980212e-08
extracolonic O 0 0.001037778565660119
manifestations O 0 0.0005300973425619304
in O 0 0.00014885110431350768
familial B-Disease 1 0.9999971389770508
adenomatous I-Disease 1 0.9999971389770508
polyposis I-Disease 1 0.9999995231628418
( O 0 3.643063246272504e-05
FAP B-Disease 0 0.008369158953428268
) O 0 4.075692174865253e-07
is O 0 4.377352169626647e-08
the O 0 1.2349290479107822e-08
result O 0 3.0675401774260536e-08
of O 0 3.970417328247322e-09
the O 0 4.6156952038245436e-08
dominant O 0 9.765659342519939e-06
inheritance O 0 5.630022496916354e-05
of O 0 1.1578850717341993e-05
adenomatous B-Disease 1 0.9999990463256836
polyposis I-Disease 1 0.9999966621398926
coli I-Disease 1 0.9999269247055054
( O 0 4.862729383603437e-06
APC B-Disease 0 5.453474659589119e-05
) O 0 9.825171218835749e-07
gene O 0 6.810394097556127e-06
mutations O 0 2.1324298359104432e-05
. O 0 1.8937917047878727e-06

In O 0 8.74961642693961e-06
this O 0 3.3380698027940525e-07
study O 0 2.125914164707865e-07
, O 0 1.6024696236627278e-08
direct O 0 1.6635139843401703e-07
mutation O 0 1.1437639386713272e-06
analysis O 0 5.463289909357627e-08
of O 0 6.116491313434835e-09
the O 0 2.3343204702541698e-08
APC B-Disease 0 3.0804681045992766e-06
gene O 0 2.0747236817442172e-07
was O 0 7.316283046066019e-08
performed O 0 7.676076307916446e-08
to O 0 3.462347564209267e-08
determine O 0 5.216728595769382e-07
genotype O 0 0.00031306527671404183
- O 0 0.00033694124431349337
phenotype O 0 0.00041666143806651235
correlations O 0 6.257315590119106e-07
for O 0 3.3556879941443185e-08
nine O 0 3.9877426161183394e-07
extracolonic O 0 0.0001882170618046075
manifestations O 0 4.8095803322212305e-06
and O 0 5.960077587019441e-08
to O 0 7.799722823165212e-08
investigate O 0 1.0190656212216709e-06
the O 0 2.7278568381916557e-07
incidence O 0 8.5753999883309e-05
of O 0 3.494285039096212e-08
APC B-Disease 0 0.0001455230376450345
mutations O 0 1.3739473615714815e-05
in O 0 6.215694270395034e-07
non O 0 2.2823687686468475e-05
- O 1 0.9993508458137512
FAP O 1 0.9999929666519165
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.0002207723882747814

METHODS O 0 3.0608323868364096e-05
The O 0 1.0023046570495353e-06
APC B-Disease 0 1.5584000720991753e-05
gene O 0 2.196396508225007e-06
was O 0 5.645611054205801e-07
analysed O 0 1.3759895409748424e-06
in O 0 7.992581174676161e-08
190 O 0 9.025289386954682e-07
unrelated O 0 3.2042003113019746e-06
FAP B-Disease 0 0.0002304276276845485
and O 0 1.1952708973694826e-06
15 O 0 2.5179158456012374e-06
non O 0 6.888155894557713e-06
- O 1 0.9971357583999634
FAP O 1 0.9999951124191284
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9216978549957275
using O 0 1.4901905842634733e-06
denaturing O 0 0.0014312928542494774
gradient O 0 0.02844354324042797
gel O 0 0.003181787673383951
electrophoresis O 0 2.3680406229686923e-05
, O 0 4.501769623743712e-08
the O 0 9.444324433616202e-09
protein O 0 7.107799149252969e-08
truncation O 0 8.348350775122526e-07
test O 0 4.857385533796332e-07
, O 0 3.805591219929738e-08
and O 0 4.7278128079142334e-08
direct O 0 3.6310021300778317e-07
sequencing O 0 6.646278052357957e-06
. O 0 3.108382088612416e-06

RESULTS O 0 0.0007224555010907352
Chain O 0 2.5251894840039313e-05
terminating O 0 8.588833225076087e-06
signals O 0 1.9399853954382706e-06
were O 0 7.128123513666651e-08
only O 0 4.6597914860058154e-08
identified O 0 5.507971536644618e-07
in O 0 4.3640142166623264e-07
patients O 0 6.483442848548293e-05
belonging O 0 1.5612759796113096e-07
to O 0 7.569995119638406e-08
the O 0 1.4913946699834923e-07
FAP B-Disease 0 0.002547619165852666
group O 0 1.4871998246235307e-05
( O 0 2.3146559158249147e-07
105 O 0 1.558207077323459e-05
patients O 0 0.0031724809668958187
) O 0 9.645901855037664e-07
. O 0 1.7314953311142744e-06

Amino O 0 8.200522279366851e-05
acid O 0 6.0270926041994244e-05
changes O 0 9.661708872954478e-07
were O 0 1.3745662386099866e-07
identified O 0 2.1579327835752338e-07
in O 0 6.793624862666547e-08
four O 0 8.323267138621304e-06
patients O 0 0.0005196448182687163
, O 0 3.1451165227736055e-08
three O 0 1.4163338057926467e-08
of O 0 6.884042669241808e-09
whom O 0 5.0998016831727e-07
belonged O 0 3.973358531084159e-08
to O 0 9.639068210276491e-09
the O 0 1.642474778407177e-08
non O 0 1.532372380097513e-07
- O 0 5.5245578550966457e-05
FAP O 0 0.008577347733080387
group O 0 0.0004869771655648947
of O 0 0.0002822013630066067
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9991232752799988
. O 0 2.7760119337472133e-05

Genotype O 1 0.9971338510513306
- O 1 0.9902856945991516
phenotype O 1 0.9886032342910767
correlations O 0 0.00029977550730109215
identified O 0 8.862846698320936e-06
significant O 0 3.192647000105353e-07
differences O 0 1.0132630450243596e-06
in O 0 7.719417993712341e-08
the O 0 3.08681471494765e-08
nature O 0 9.010361878836193e-08
of O 0 1.3090954986694214e-08
certain O 0 9.840816517225903e-08
extracolonic O 0 0.00037550870911218226
manifestations O 0 6.0344078519847244e-05
in O 0 3.4073673305101693e-06
FAP B-Disease 1 0.9955645799636841
patients O 1 0.9892309308052063
belonging O 0 1.0821631803992204e-06
to O 0 2.1971285946165153e-07
three O 0 8.275337677332573e-07
mutation O 0 1.68944061442744e-05
subgroups O 0 6.6060138124157675e-06
. O 0 2.037075091720908e-06

CONCLUSIONS O 0 0.003741299966350198
Extended O 0 0.0005119232810102403
genotype O 0 0.23717884719371796
- O 0 0.26024720072746277
phenotype O 0 0.2860476076602936
correlations O 0 1.3147504432708956e-05
made O 0 3.868201758905343e-07
in O 0 8.760972036725434e-08
this O 0 8.219221570016089e-08
study O 0 9.525307973490271e-07
may O 0 6.870861284369312e-07
have O 0 1.3147305466532089e-08
the O 0 6.416560172084473e-09
potential O 0 2.2676809763311212e-08
to O 0 1.8315512662070432e-08
determine O 0 4.3098985713641014e-08
the O 0 7.663053303019751e-09
most O 0 9.1629583920394e-09
appropriate O 0 2.3360842149600103e-08
surveillance O 0 4.352978351107595e-07
and O 0 2.322465633142201e-07
prophylactic O 0 0.11810135096311569
treatment O 1 0.8041751384735107
regimens O 0 0.03906302899122238
for O 0 1.7106507357311784e-06
those O 0 2.1760140498372493e-06
patients O 0 0.0014710362302139401
with O 0 3.740204419955262e-06
mutations O 0 0.00015584024367854
associated O 0 4.4861610604129964e-07
with O 0 2.4145009547282825e-07
life O 0 4.8287583922501653e-05
threatening O 0 0.006107870023697615
conditions O 0 0.00031559064518660307
. O 0 6.062362444936298e-06

This O 0 8.687083209224511e-06
study O 0 4.617690592567669e-06
also O 0 2.7556276904761035e-07
provided O 0 9.351619212338846e-08
evidence O 0 7.625512665754286e-08
for O 0 1.7878305058616206e-08
the O 0 8.39035223521023e-08
pathological O 0 3.106403164565563e-05
nature O 0 9.179493076771905e-08
of O 0 1.3394548581402432e-08
amino O 0 1.715944932811908e-07
acid O 0 1.1930866321563371e-06
changes O 0 1.373343820887385e-07
in O 0 6.341541336496448e-08
APC O 0 8.81551477505127e-06
associated O 0 2.555733260578563e-07
with O 0 4.159074862286616e-08
both O 0 1.3733581738506473e-07
FAP B-Disease 0 8.1804180808831e-05
and O 0 4.25857206209912e-06
non O 0 4.9004022002918646e-05
- O 1 0.9997244477272034
FAP O 1 0.9999985694885254
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9998968839645386
. O 0 3.957531589549035e-06
. O 0 4.390644789964426e-06

Inherited B-Disease 1 0.9998905658721924
colorectal I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.999988317489624
and O 1 0.9954694509506226
cancer B-Disease 1 0.999866247177124
risk O 0 1.2078528925485443e-05
of O 0 1.2064190002547548e-07
the O 0 7.412174340970523e-07
APC O 0 0.0004251128702890128
I1307K O 0 0.001572378329001367
polymorphism O 0 0.0005432958714663982
. O 0 1.1487551091704518e-05

Germ O 0 0.003785953624173999
- O 0 0.0005369239370338619
line O 0 5.81193216930842e-06
and O 0 1.7891989045892842e-07
somatic O 0 9.191524441121146e-06
truncating O 0 0.0001123769543482922
mutations O 0 8.273260391433723e-06
of O 0 1.3789274611042401e-08
the O 0 3.66980366095504e-08
APC B-Disease 0 5.515469183592359e-06
gene O 0 1.8952682978579105e-07
are O 0 6.767446603106464e-09
thought O 0 4.394350483494236e-08
to O 0 1.760429171326905e-07
initiate O 0 0.025395922362804413
colorectal B-Disease 1 0.9999997615814209
tumor I-Disease 1 0.9906558394432068
formation O 0 2.1034908058936708e-05
in O 0 3.6298573832027614e-05
familial B-Disease 1 0.9999980926513672
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
and O 0 0.00043839961290359497
sporadic O 1 0.9877287149429321
colorectal O 1 0.9999996423721313
carcinogenesis O 1 0.9991298317909241
, O 0 1.0734103852882981e-05
respectively O 0 1.007613172987476e-05
. O 0 2.7912221867154585e-06

Recently O 0 7.031291897874326e-05
, O 0 8.615919000476424e-07
an O 0 2.4647727059345925e-07
isoleucine O 0 0.0001593495107954368
- O 0 0.000154859313624911
- O 0 0.00017624498286750168
> O 0 6.135462172096595e-06
lysine O 0 1.8650874835657305e-06
polymorphism O 0 2.3311940822168253e-06
at O 0 5.81945904798431e-08
codon O 0 1.165175490314141e-06
1307 O 0 1.306271951762028e-05
( O 0 8.911709414860525e-08
I1307K O 0 1.7211040130860056e-06
) O 0 1.2370083624091421e-08
of O 0 2.662217779558773e-09
the O 0 1.6598463048467238e-08
APC B-Disease 0 3.2037355595093686e-06
gene O 0 2.151096794023033e-07
has O 0 5.216290688281333e-08
been O 0 2.658418551959585e-08
identified O 0 6.152601628173215e-08
in O 0 1.103092373000436e-08
6 O 0 2.624184674004937e-07
% O 0 3.163285100526991e-08
- O 0 1.4123407936494914e-06
7 O 0 5.673445002685185e-07
% O 0 1.7809691499337532e-08
of O 0 7.812822389041685e-09
the O 0 1.2140272076521796e-07
Ashkenazi O 0 4.657208774005994e-05
Jewish O 0 1.1127283414680278e-06
population O 0 7.651780151718413e-07
. O 0 1.7519372477181605e-06

To O 0 2.055840741377324e-05
assess O 0 2.3559738110634498e-05
the O 0 4.5507360368901573e-07
risk O 0 6.522539592879184e-07
of O 0 1.4330400865958381e-08
this O 0 5.037176720179559e-08
common O 0 3.2055402243713615e-07
APC B-Disease 0 1.7077240045182407e-05
allelic O 0 0.00013547451817430556
variant O 0 0.0024395158980041742
in O 0 2.646826942509506e-05
colorectal O 1 0.9999994039535522
carcinogenesis O 1 0.9965096116065979
, O 0 9.760898365129833e-07
we O 0 4.296995115282698e-08
have O 0 2.1372771996652773e-08
analyzed O 0 1.389146717656331e-07
a O 0 5.893213739227576e-08
large O 0 5.078068809893921e-08
cohort O 0 1.2600062291312497e-06
of O 0 3.488811017859916e-08
unselected O 0 0.0003783730498980731
Ashkenazi O 0 3.4553329896880314e-05
Jewish O 0 5.347192200133577e-07
subjects O 0 1.0577705324976705e-06
with O 0 7.731558753221179e-07
adenomatous B-Disease 1 0.9846042990684509
polyps I-Disease 1 0.8262937664985657
and O 0 3.2447910598421004e-06
. O 0 2.2650369828625116e-06
or O 0 0.030797170475125313
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 8.886357250048604e-07
for O 0 3.7884412051880645e-08
the O 0 1.3295286294123798e-07
APC O 0 3.360166374477558e-05
I1307K O 0 0.00012931687524542212
polymorphism O 0 7.925622776383534e-05
. O 0 3.5171883610018995e-06

The O 0 8.202311619243119e-06
APC O 0 9.753341146279126e-05
I1307K O 0 0.00016511330613866448
allele O 0 5.4380820074584335e-05
was O 0 7.654466003259586e-07
identified O 0 2.550637248077692e-07
in O 0 3.0333524136949563e-08
48 O 0 3.502573804325948e-07
( O 0 1.798518667328608e-08
10 O 0 2.7413154413125085e-08
. O 0 1.4719033103460788e-08
1 O 0 4.3756156031804494e-08
% O 0 2.713277424959415e-08
) O 0 2.086509098830902e-08
of O 0 6.485193893013275e-08
476 O 0 0.005910620093345642
patients O 0 0.2698395252227783
. O 0 4.86552698930609e-06

Compared O 0 0.00015639400226064026
with O 0 4.103703474811482e-07
the O 0 9.38632211955337e-08
frequency O 0 1.1688125596265309e-06
in O 0 3.852139585092118e-08
two O 0 3.0279995399951076e-08
separate O 0 1.2121715542434686e-07
population O 0 8.307894461268006e-08
control O 0 4.069132444328716e-07
groups O 0 2.379988650602627e-08
, O 0 1.2975115204483245e-08
the O 0 1.1438666902563455e-08
APC O 0 4.302902198105585e-06
I1307K O 0 6.563872739207e-05
allele O 0 3.4690353913902072e-06
is O 0 2.9560965231212322e-08
associated O 0 2.991706438137953e-08
with O 0 1.1384948095383152e-08
an O 0 1.0452801291194191e-07
estimated O 0 4.2965692159668833e-07
relative O 0 7.692651138313522e-07
risk O 0 2.509314356302639e-07
of O 0 5.649737389035181e-08
1 O 0 1.7263314475712832e-06
. O 0 3.0887108550814446e-06

5 O 0 0.00019927411631215364
- O 0 0.0006534772692248225
1 O 0 1.9687660824274644e-05
. O 0 7.764515430608299e-06

7 O 0 0.000840795983094722
for O 0 0.00015337859804276377
colorectal B-Disease 1 0.999997615814209
neoplasia I-Disease 1 0.9933178424835205
( O 0 5.203499767958419e-06
both O 0 1.5877661780905328e-06
P O 0 0.0005856622010469437
= O 0 1.1076146620325744e-05
. O 0 1.4206742093847424e-07
01 O 0 7.83991072239587e-06
) O 0 3.719562755577499e-07
. O 0 8.583801900385879e-07

Furthermore O 0 0.00019697003881447017
, O 0 1.962136593647301e-06
compared O 0 1.4334495972434524e-06
with O 0 1.4873977249862946e-07
noncarriers O 0 0.00010633919009706005
, O 0 1.6959162962848495e-07
APC O 0 2.525151785448543e-06
I1307K O 0 7.914115485618822e-06
carriers O 0 5.22624475252087e-07
had O 0 1.032302563430676e-07
increased O 0 3.1439526537724305e-08
numbers O 0 2.32627552776421e-08
of O 0 2.254454045669263e-08
adenomas B-Disease 0 0.0019427846418693662
and O 0 0.04524777829647064
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999672174453735
per O 0 0.0009493788820691407
patient O 0 0.06812646239995956
( O 0 8.354443252756028e-07
P O 0 6.941313040442765e-05
= O 0 1.8715802525548497e-06
. O 0 2.3790807546220094e-08
03 O 0 4.024361430765566e-07
) O 0 7.884078279118967e-09
, O 0 3.788077851396565e-09
as O 0 4.4967896073444535e-09
well O 0 7.003182034281963e-09
as O 0 1.0719349852195137e-08
a O 0 3.823416534487478e-07
younger O 0 2.1327758076949976e-05
age O 0 1.119350599765312e-06
at O 0 6.02496925239393e-07
diagnosis O 0 0.02813940867781639
. O 0 3.864443897327874e-06

We O 0 5.449356649478432e-06
conclude O 0 6.6273983065912034e-06
that O 0 1.8058098305573367e-07
the O 0 1.2675423022301402e-07
APC O 0 6.37389712210279e-06
I1307K O 0 2.8379981813486665e-05
variant O 0 1.2358205822238233e-05
leads O 0 1.728393840494391e-06
to O 0 6.075577516639896e-07
increased O 0 1.632331623113714e-05
adenoma B-Disease 1 0.9999179840087891
formation O 0 1.98145767171809e-06
and O 0 6.205779357060237e-08
directly O 0 8.875290546939141e-08
contributes O 0 1.319587283887813e-07
to O 0 5.082089771235587e-08
3 O 0 1.2888764899798844e-07
% O 0 3.392466751961365e-08
- O 0 1.2176674317743164e-06
4 O 0 2.3121297942907404e-07
% O 0 1.3309083612966788e-08
of O 0 3.9840108989608325e-09
all O 0 1.0987461962486123e-07
Ashkenazi O 0 0.005207354668527842
Jewish O 0 0.19437724351882935
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 5.20816320204176e-05

The O 0 7.780830856063403e-06
estimated O 0 5.181523192732129e-06
relative O 0 2.695733883228968e-06
risk O 0 1.251274511560041e-06
for O 0 9.327534655767522e-08
carriers O 0 2.978874817927135e-06
may O 0 8.575627816753695e-07
justify O 0 6.796508387196809e-07
specific O 0 3.8613936936826576e-08
clinical O 0 1.6646629319438944e-06
screening O 0 8.257229637820274e-07
for O 0 3.284430860617249e-08
the O 0 2.716570612903979e-08
360 O 0 2.6117688776139403e-06
, O 0 7.605859053683162e-08
000 O 0 1.477487359125007e-07
Americans O 0 4.2372565900450354e-08
expected O 0 5.8896407750808066e-08
to O 0 2.427128720228211e-08
harbor O 0 1.5149169030337362e-06
this O 0 3.2634741131687406e-08
allele O 0 1.4106864227869664e-06
, O 0 1.944773586615156e-08
and O 0 1.774252567088297e-08
genetic O 0 2.0031811232001928e-07
testing O 0 9.160830671817166e-08
in O 0 9.412260304486608e-09
the O 0 6.728987589355029e-09
setting O 0 2.3283085681669036e-08
of O 0 6.8445031864428074e-09
long O 0 4.684922600972641e-07
- O 0 7.919443305581808e-05
term O 0 4.669801910495153e-06
- O 0 3.7757523386972025e-05
outcome O 0 1.3287418596519274e-06
studies O 0 1.397091580201959e-07
may O 0 1.7397834994881123e-07
impact O 0 3.4359808864792285e-07
significantly O 0 1.5550807802355848e-05
on O 1 0.813495934009552
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.009318165481090546
in O 0 7.697230444136949e-07
this O 0 3.609623604461376e-07
population O 0 1.3693044138562982e-06
. O 0 1.8206967524747597e-06

Localization O 0 0.00014442722022067755
of O 0 1.537350613034505e-06
human O 0 1.8894297681981698e-06
BRCA1 O 0 0.00015132795670069754
and O 0 2.421705005417607e-07
its O 0 2.648201586907817e-07
loss O 0 1.770893686625641e-05
in O 0 8.613949376012897e-08
high O 0 7.697149726482166e-07
- O 0 7.892039866419509e-05
grade O 0 8.041603223318816e-07
, O 0 1.0566982666659896e-07
non B-Disease 0 1.1065990292991046e-06
- I-Disease 1 0.5555672645568848
inherited I-Disease 1 0.9961205124855042
breast I-Disease 1 0.9998760223388672
carcinomas I-Disease 1 0.9999929666519165
. O 0 0.00010486187238711864

Although O 0 1.2860938113590237e-05
the O 0 3.8701466564816656e-07
link O 0 2.2864251150167547e-06
between O 0 2.310247566583712e-07
the O 0 5.917768817198521e-07
BRCA1 O 0 0.223269984126091
tumour B-Disease 1 0.9998998641967773
- O 0 0.0003446429909672588
suppressor O 0 0.00011681391333695501
gene O 0 3.895948793797288e-06
and O 0 1.5126850030355854e-06
hereditary B-Disease 1 0.996829092502594
breast I-Disease 1 0.9999834299087524
and I-Disease 1 0.9998489618301392
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
is O 0 7.495006570934493e-07
established O 0 7.142399738313543e-08
, O 0 1.455529474725381e-08
the O 0 4.780047024866008e-09
role O 0 4.1351707835701745e-08
, O 0 2.6087759508186537e-08
if O 0 1.05179944753786e-08
any O 0 2.6243553996607716e-09
, O 0 5.874357444923817e-09
of O 0 9.831226499557033e-09
BRCA1 O 0 1.61748357641045e-05
in O 0 1.38217203016211e-07
non B-Disease 0 1.4531115084537305e-06
- I-Disease 1 0.5861161351203918
familial I-Disease 1 0.9985437393188477
cancers I-Disease 1 0.9992842078208923
is O 0 3.1311155908042565e-06
unclear O 0 1.8468852431396954e-05
. O 0 4.728800377051812e-06

BRCA1 O 1 0.9994514584541321
mutations O 1 0.8528034687042236
are O 0 1.7463059975852957e-06
rare O 0 8.558661647839472e-06
in O 0 2.0876034341199556e-06
sporadic B-Disease 1 0.7188698053359985
cancers I-Disease 1 0.9988701939582825
, O 0 2.390008546626632e-07
but O 0 2.1637771396854077e-07
loss O 0 1.8755129076453159e-06
of O 0 4.456651936379785e-08
BRCA1 O 0 0.00041715148836374283
resulting O 0 1.9941551272495417e-06
from O 0 1.010459058647939e-07
reduced O 0 1.1213796824449673e-06
expression O 0 4.790842922375305e-07
or O 0 4.139132059322037e-08
incorrect O 0 8.90706814971054e-07
subcellular O 0 3.0215292099455837e-06
localization O 0 1.8863744344344013e-06
is O 0 8.31859736649676e-08
postulated O 0 9.571539294483955e-07
to O 0 2.7328265872483826e-08
be O 0 6.138205499439664e-09
important O 0 7.017274317178135e-09
in O 0 3.901146783391596e-08
non B-Disease 0 1.3605816775452695e-06
- I-Disease 0 0.030921058729290962
familial I-Disease 1 0.9889957904815674
breast I-Disease 1 0.9999876022338867
and I-Disease 1 0.9987215399742126
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999980926513672
. O 0 7.49475002521649e-05

Epigenetic O 0 0.23318172991275787
loss O 0 0.36923155188560486
, O 0 2.2349324808601523e-06
however O 0 4.213695206090051e-07
, O 0 6.314396472362205e-08
has O 0 6.154385800982709e-08
not O 0 1.9296098940912998e-08
received O 0 8.98977958740943e-08
general O 0 1.0998931543326762e-07
acceptance O 0 1.2465305871955934e-06
due O 0 2.874217273074464e-07
to O 0 6.275746500250534e-08
controversy O 0 4.266199766789214e-07
regarding O 0 5.4501970936371436e-08
the O 0 1.553225992267926e-08
subcellular O 0 1.6298472473863512e-06
localization O 0 5.307786636876699e-07
of O 0 1.9549936780549615e-08
BRCA1 O 0 7.797105354256928e-06
proteins O 0 5.5479908667166455e-08
, O 0 4.1497642655485834e-08
reports O 0 3.347192389924203e-08
of O 0 2.9041100635396333e-09
which O 0 2.0865527972091513e-08
have O 0 2.1145053707982697e-08
ranged O 0 2.963936367450515e-07
from O 0 1.3975121504472554e-08
exclusively O 0 5.451839868442221e-08
nuclear O 0 2.3418061800839496e-07
, O 0 1.4638428247337743e-08
to O 0 2.5803901237964055e-08
conditionally O 0 5.514911663340172e-06
nuclear O 0 2.3777998592322547e-07
, O 0 1.3305200496915859e-08
to O 0 1.4732823849783472e-08
the O 0 6.020425757924386e-08
ER O 0 0.0011139180278405547
/ O 0 3.014719368366059e-05
golgi O 0 0.00024227509857155383
, O 0 1.4557521410552e-07
to O 0 8.004450080534298e-08
cytoplasmic O 0 1.4375345926964656e-06
invaginations O 0 4.042944055981934e-06
into O 0 9.622447549872959e-08
the O 0 4.3329940524472477e-08
nucleus O 0 1.8035946141026216e-06
. O 0 1.0683505706765573e-06

In O 0 5.0155094868387096e-06
an O 0 3.0927910188438545e-07
attempt O 0 3.3612470815569395e-06
to O 0 3.502229617424746e-07
resolve O 0 3.2000348255678546e-06
this O 0 5.855600093696012e-08
issue O 0 2.3964628326211823e-07
, O 0 2.664454257228499e-08
we O 0 1.4138453963141728e-08
have O 0 1.704356478171576e-08
comprehensively O 0 5.097315806779079e-06
characterized O 0 2.582301021902822e-06
19 O 0 1.1603772236412624e-06
anti O 0 1.4308178833744023e-05
- O 0 0.0177450068295002
BRCA1 O 0 0.0035667363554239273
antibodies O 0 2.9257249479996972e-05
. O 0 3.599109504648368e-06

These O 0 6.425070296245394e-06
reagents O 0 1.4908537195879035e-05
detect O 0 9.33888804866001e-06
a O 0 4.839735652240051e-07
220 O 0 7.190012638602639e-07
- O 0 6.934782959433505e-06
kD O 0 3.0251389034674503e-05
protein O 0 4.650326559385576e-07
localized O 0 7.011530556155776e-07
in O 0 3.051492569738912e-08
discrete O 0 7.302703011191625e-07
nuclear O 0 7.680438898205466e-07
foci O 0 4.8883489398576785e-06
in O 0 9.039936088584e-08
all O 0 5.7011565246511964e-08
epithelial O 0 0.0017094819340854883
cell O 0 0.005296759773045778
lines O 0 4.778381935466314e-06
, O 0 8.348288815795968e-08
including O 0 4.0083808272584065e-08
those O 0 3.560934658253245e-08
derived O 0 2.522592694731429e-07
from O 0 7.928898071440926e-07
breast B-Disease 1 0.8853927850723267
malignancies I-Disease 1 0.6950979232788086
. O 0 2.575317193986848e-05

Immunohistochemical O 0 0.18988199532032013
staining O 0 0.0052421302534639835
of O 0 3.89806336897891e-06
human O 0 7.093574095051736e-05
breast O 1 0.9971299767494202
specimens O 0 5.860785677214153e-05
also O 0 3.008417934324825e-06
revealed O 0 2.963481892948039e-05
BRCA1 O 0 2.9881228329031728e-05
nuclear O 0 3.2920816011028364e-06
foci O 0 7.206118607427925e-05
in O 0 3.7969377899571555e-06
benign O 1 0.9061163663864136
breast O 1 0.9992306232452393
, O 0 1.7715017747832462e-05
invasive B-Disease 0 0.43510377407073975
lobular I-Disease 1 0.9999886751174927
cancers I-Disease 1 0.9993643164634705
and O 0 2.0997151750634657e-06
low B-Disease 0 2.7330692319083028e-05
- I-Disease 0 0.021962104365229607
grade I-Disease 0 0.000524092058185488
ductal I-Disease 1 0.9989635944366455
carcinomas I-Disease 1 0.9999961853027344
. O 0 8.172067464329302e-05

Conversely O 0 0.0005953451618552208
, O 0 5.597636118181981e-06
BRCA1 O 0 0.00044476939365267754
expression O 0 4.636396170099033e-06
was O 0 1.1970915920755942e-06
reduced O 0 7.446301992786175e-07
or O 0 5.3702251534559764e-08
undetectable O 0 1.3711114661418833e-06
in O 0 3.92116916714258e-08
the O 0 2.5531358360808554e-08
majority O 0 2.1364380131672078e-07
of O 0 6.1485172508923824e-09
high O 0 3.121462839317246e-07
- O 0 6.607394607271999e-05
grade O 0 3.855491740978323e-06
, O 0 2.4979924546641996e-06
ductal B-Disease 1 0.9991668462753296
carcinomas I-Disease 1 0.9999990463256836
, O 0 3.0730036542081507e-06
suggesting O 0 1.6670428522047587e-06
that O 0 2.8573538202181226e-08
absence O 0 1.2910909674701543e-07
of O 0 5.491214949415735e-08
BRCA1 O 0 0.00291874585673213
may O 0 3.158356093990733e-06
contribute O 0 9.86974555416964e-08
to O 0 7.004894087003777e-08
the O 0 1.104061198020645e-07
pathogenesis O 0 7.859576726332307e-06
of O 0 1.059846699291711e-08
a O 0 2.2001772492785676e-07
significant O 0 8.049369881746316e-08
percentage O 0 1.8465330242634082e-07
of O 0 4.916672580179693e-08
sporadic B-Disease 0 0.13417479395866394
breast I-Disease 1 0.9999909400939941
cancers I-Disease 1 0.9995346069335938
. O 0 1.7612968576941057e-06
. O 0 2.272178562634508e-06

